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Rhinosinusitis is a significant health problem which seems to 
mirror the increasing frequency of allergic rhinitis and which 
results in a large financial burden on society (1) . 
The last decade has seen the development of a number of 
guidelines, consensus documents and position papers on the 
epidemiology, diagnosis and treatment of rhinosinusitis and 
nasal polyposis (1-6). In 2005 the first European Position Paper on 
Rhinosinusitis and Nasal Polyps (EP3OS) was published (4, 7). This 
first evidence based position paper was initiated by the European 
Academy of Allergology and Clinical Immunology (EAACI) to 
consider what was known about rhinosinusitis and nasal polyps, 
to offer evidence based recommendations on diagnosis and 
treatment, and to consider how we could make progress with 
research in this area. The paper was endorsed by the European 
Rhinologic Society. Such was the interest in the topic and 
the increasing number of publications that by 2007 we felt it 
necessary to update the document: EP3OS2007 (1, 5). These new 
publications included some important randomized controlled 
trials and filled in some of the gaps in our knowledge, which 
has significantly altered our approach. In particular it has played 
an important role in the understanding of the management of 
ARS and has helped to minimize unnecessary use of radiological 
investigations, overuse of antibiotics, and improve the under 
utilisation of nasal corticosteroids (8). EP3OS2007 has had a 
considerable impact all over the world but as expected with time, 
many people have requested that we revise it, as once again 
a wealth of new data has become available in the intervening 
period.  Indeed one of its most important roles has been in 
the identification of the gaps in the evidence and stimulating 
colleagues to fill these with high quality studies.
The methodology for EPOS2012 has been the same as for the 
other two productions. Leaders in the field were invited to 
critically appraise the literature and write a report on a subject 
assigned to them. All contributions were distributed before 
the meeting in November when the group came together in 
Amsterdam and during the 4 days of the meeting every report 
was discussed in detail. In addition general discussions on 
important dilemmas and controversies took place. Finally the 
management schemes were revised significantly in the light  of  
any new data which was available. Finally we decided to remove 
the “3” out of EPOS2012  title (EPOS212 instead of EP3OS2012) to 
make it more easy to reproduce.
Evidence based medicine is an important method of preparing 
guidelines. In 1998 the Centre for Evidence Based Medicine 
(CEBM) published its levels of evidence, which were designed to 
help clinicians and decision makers to make the most out of the 
available literature. Recently the levels of evidence were revised 
in the light of new concepts and data (Table 1).  Moreover a 
number of other systems which grade the quality of evidence 
and strength of recommendation have been proposed. The 
most important of these is probably the GRADE initiative (9). For 
the EPOS2012 we have chosen to collect the evidence using 
the orginal CEBM format but we plan to update the EPOS2012 
clinical recommendations subsequently, following the approach 
suggested by the GRADE working group. 
 
1. Introduction 
Table 1.2. Strength of recommendation.
A Directly based on category I evidence
B Directly based on category II evidence or extrapolated rec-
ommendation from category I evidence
C Directly based on category III evidence or extrapolated 
recommendation from category I or II evidence
D Directly based on category IV evidence or extrapolated 
recommendation from category I, II or III evidence
Table 1.1. Category of evidence (10).
Ia Evidence from meta-analysis of randomised controlled trials
Ib Evidence from at least one randomised controlled trial
IIa Evidence from at least one controlled study without ran-
domisation
IIb Evidence from at least one other type of quasi-experimental 
study
III Evidence from non-experimental descriptive studies, such 
as comparative studies, correlation studies, and case-control 
studies
IV Evidence from expert committee reports or opinions or clini-
cal experience of respected authorities, or both
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This EPOS 2012 revision is intended to be a state-of-the art 
review for the specialist as well as for the general practitioner: 
•	  to update their knowledge of rhinosinusitis and nasal  
poly-posis; 
•	  to provide an evidence based  review of the diagnostic 
methods; 
•	  to provide an evidence-based review of the available 
treatments;
•	  to propose a stepwise approach to the management of the 
disease;
•	  to propose guidance for definitions and outcome 
measurements in research in different settings.
Overall the document has been made more consistent, some 
chapters are significantly extended and others are added. Last 
but not least contributions from many other part of the world 
have increased our knowledge and understanding.
One of the important new data acquired in the last year is 
that on the prevalence of CRS in Europe. Previously we had 
relied on estimates from the USA pointing at a prevalence of 
14%. Firstly the EPOS epidemiological criteria for CRS from the 
2007 document were validated. We have shown that the EPOS 
symptom-based definition of CRS for epidemiological research 
has a moderate reliability over time, is stable between study 
centres, is not influenced by the presence of allergic rhinitis, 
and is suitable for the assessment of geographic variation in 
prevalence of CRS (11). Secondly, a large epidemiological study 
was performed within the GA(2)LEN network of excellence in 
19 centres in 12 countries, encompassing more than 50.000 
respondents, in which the EPOS criteria were applied to 
estimate variation in the prevalence of Chronic rhinosinusitis for 
Europe. The overall prevalence of CRS was 10.9% with marked 
geographical variation (range 6.9-27.1) (12). There was a strong 
association of asthma with CRS at all ages and  this association 
with asthma was stronger in those reporting both CRS and 
allergic rhinitis (adjusted OR: 11.85). CRS in the absence of nasal 
allergies was positively associated with late-onset asthma (13).
In the EPOS2012 we have made a stricter division between CRS 
with (CRSwNP) and without nasal polyps (CRSsNP) (14). Although 
there is a considerable overlap between these two forms of  
CRS in inflammatory profile, clinical presentation and effect of 
treatment (1, 15-20) there are recent papers pointing to differences 
in  the respective inflammatory profiles (21-26) and treatment 
outcome (27). For that reason management chapters are now 
divided in ARS, CRSsNP and CRSwNP. In addition the chapters 
on acute and chronic  paediatric rhinosinusitis are totally revised 
and all the new evidence is implemented.
 
We sincerely hope that EPOS will continue to act as a stimulus 
for continued high quality clinical management  and research in 
this common but difficult range of inflammatory conditions.
.
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2.1. Introduction
Rhinitis and sinusitis usually coexist and are concurrent in most 
individuals; thus, the correct terminology is now rhinosinusitis. 
Most guidelines and expert panel documents now have adopted 
the term rhinosinusitis instead of sinusitis (1, 2, 6, 28, 29).. The diagnosis 
of rhinosinusitis is made by a wide variety of practitioners, 
including allergologists, otolaryngologists, pulmonologists, 
primary care physicians, paediatricians, and many others. 
Therefore, an accurate, efficient, and accessible definition of 
rhinosinusitis is required. 
Due to the large differences in technical possibilities to diagnose 
and treat rhinosinusitis with or withouw nasal polyps by various 
disciplines, the need to differentiate between subgroups 
varies. On the one hand the epidemiologist wants a workable 
definition that does not impose too many restrictions to study 
larger populations. On the other hand researchers in a clinical 
setting are in need of a set of clearly defined items that describes 
their patient population (phenotypes) accurately and avoids 
the comparison of ‘apples and oranges’ in studies that relate to 
diagnosis and treatment. The taskforce tried to accommodate 
these different needs by offering definitions that can be applied 
in different circumstances. In this way the taskforce hopes 
to improve the comparability of studies, thereby enhancing 
the evidence based diagnosis and treatment of patients with 
rhinosinusitis and nasal polyps. 
2.2. Clinical definition of rhinosinusitis
2.2.1. Clinical definition of rhinosinusitis in adults
Rhinosinusitis  in adults is defined as:
•	 inflammation of the nose and the paranasal sinuses 
characterised by two or more symptoms, one of which should 
be either nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip):
 - ± facial pain/pressure 
 - ± reduction or loss of smell
and either
•	 endoscopic signs of:
 - nasal polyps, and/or
 - mucopurulent discharge primarily from middle meatus 
and/or
 - oedema/mucosal obstruction primarily in middle meatus
and/or
•	 CT changes:
 - mucosal changes within the ostiomeatal complex and/
or sinuses 
2.2.2. Clinical definition of rhinosinusitis in 
children
Paediatric rhinosinusitis is defined as:
inflammation of the nose and the paranasal sinuses characterised 
by two or more symptoms one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/
posterior nasal drip):
 - ± facial pain/pressure
 - ± cough
 -
and either
•	 endoscopic signs of:
 - nasal polyps, and/or
 - mucopurulent discharge primarily from middle meatus 
and/or
 - oedema/mucosal obstruction primarily in middle meatus
and/or
•	 CT changes:
 - mucosal changes within the ostiomeatal complex and/
or sinuses 
2.2.3. Severity of the disease in adult and children*
The disease can be divided into MILD, MODERATE and SEVERE 
based on total severity visual analogue scale (VAS) score (0 10 
cm):
 - MILD    = VAS 0-3
 - MODERATE = VAS >3-7
 - SEVERE    = VAS >7-10 
To evaluate the total severity, the patient is asked to indicate on a 
VAS the answer to the question: 
A VAS > 5  affects the patient QOL 
•	 only validated in adult CRS to date
2. CLASSIFICATION AND DEFINITION OF RHINOSINUSITIS 
How troublesome are your symptoms of rhinosinusitis?
10 cm
Not troublesome   Worst thinkable troublesome
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2.2.4. Duration of the disease in adults and 
children
Acute:
< 12 weeks
complete resolution of symptoms.
Chronic:
≥12 weeks symptoms
without complete resolution of symptoms.
Chronic rhinosinusitis may also be subject to exacerbations
2.2.5. Control of disease
The goal of CRS treatment is to achieve and maintain clinical 
control. Control is defined as a disease state in which the 
patients do not have symptoms or the symptoms are not 
bothersome, if possible combined with a healthy or almost 
healthy mucosa and only the need for local medication. We do 
not know what percentage of patients with CRS actually can 
achieve control of disease and further studies are necessary. We 
here propose an assessment of current clinical control of CRS 
(see Table 2.1.). Further validation of this table is necessary.
2.2.6. Definition of difficult-to-treat rhinosinusitis
Patients who have persistent symptoms of rhinosinusitis despite 
appropriate treatment (recommended medication and surgery). 
Although the majority of CRS patients can obtain control, some 
patients will not do so even with the maximal medical therapy 
and surgery. 
Patients who do not reach an acceptable level of control despite 
adequate surgery, intranasal corticosteroid treatment and up to 2 
short courses of antibiotics or systemic corticosteroids in the last 
year can be considered to have difficult-to-treat rhinosinusitis. 
2.3. Definition for use in epidemiology 
studies/General Practice
For epidemiological studies the definition is based on 
symptomatology without ENT examination or radiology. 
2.3.1. Definition of acute rhinosinusitis
2.3.1.1.  Acute  rhinosinusitis (ARS) in adults 
Acute rhinosinusitis in adults is defined as: 
sudden onset of two or more symptoms, one of which should 
be either nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip):
 - ± facial pain/pressure, 
 - ± reduction or loss of smell
for <12 weeks;
with symptom free intervals if the problem is recurrent,
with validation by telephone or interview.
2.3.1.2. Acute rhinosinusitis in children 
Acute rhinosinusitis in children is defined as:
sudden onset of two or more of the symptoms:
 - nasal blockage/obstruction/congestion 
 - or discoloured nasal discharge
 - or cough (daytime and night-time) 
for < 12 weeks;
with symptom free intervals if the problem is recurrent;
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhea, nasal itching, and itchy watery eyes) should be 
included.
ARS can occur once or more than once in a defined time period. 
This is usually expressed as episodes/year but there must be 
.
Table 2.1. Assessment of current clinical control of CRS.
Assessment of current clinical control of CRS ( in the last month)  
Characteristic Controlled (all of the following) Partly Controlled
(at least one present) 
Uncontrolled 
Nasal blockage Not present or not bothersome Present on most days of the week Three or more features of partly 
controlled CRS
Rhinorrhea/
Postnasal drip 
Little and mucous Mucopurulent on most days of 
the week 
 Facial pain/headachec  Not present or not bothersome Present
Smell  Normal or only slightly impaired Impaired
Sleep disturbance or fatigue  Not impaired Impaired
Nasal endoscopy
(if available) 
Healthy or almost healthy mucosa Diseased mucosa (nasal pol-
yps, mucopurulent secretions, 
inflamed mucosa) 
Systemic medication needed 
to control disease
Not needed Need of a course of antibiotics or 
systemic corticosteroids in the 
last three months
Need of long term antibiotics or 
systemic corticosteroids in the 
last month 
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complete resolution of symptoms between episodes for it to 
constitute genuine recurrent ARS.
We recognise that in general acute rhinosinusitis will usually 
last a maximum of a few weeks. In the literature a number of 
different classifications have been proposed. In the past the 
term ‘subacute’ was sometimes used to fill the gap between 
acute and chronic rhinosinusitis. However the EPOS group 
felt that a separate term to describe patients with prolonged 
acute rhinosinusitis was not necessary because the number 
of patients who have such  a prolonged course is small and 
there are very little data on which to offer  evidence based 
recommendations on how to manage these patients. 
Also in the literature the term ‘acute on chronic’ can be found. 
The EPOS group felt that the term ‘exacerbation of CRS’ was 
more appropriate and also consistent with the term used in 
other respiratory diseases such as asthma.
2.3.1.3. Classification of ARS in adults and children
ARS comprises of viral ARS (common cold) and post-viral 
ARS. In the EPOS 2007 the term non-viral ARS was chosen to 
indicate that most cases of ARS are not bacterial. However this 
term apparently led to confusion and for that reason we have 
decided to choose the term post-viral ARS to express the same 
phenomenon. A small percentage of the patients with post-
viral ARS will have bacterial ARS. 
Common cold/ acute viral rhinosinusits is defined as: duration of 
symptoms for less than 10 days.
Acute post-viral rhinosinusitis is defined as:
increase of symptoms after 5 days or persistent symptoms after 
10 days with less than 12 weeks duration.
Acute bacterial rhinosinusitis (ABRS)
Acute bacterial rhinosinusitis is suggested by the presence of at 
least 3 symptoms/signs of (236, 247): 
 - Discoloured discharge (with unilateral predominance) 
and purulent secretion in cavum nasi, 
 - Severe local pain (with unilateral predominance)
 - Fever (>38ºC)
 - Elevated ESR/CRP  
 - ‘Double sickening’ (i.e. a deterioration after an initial 
milder phase of illness). (for more details see chapter 
3.3.2.1.5)
2.3.2. Definition of Chronic  rhinosinusitis 
2.3.2.1. Definition of Chronic  rhinosinusitis  in adults
Chronic rhinosinusitis (with or without nasal polyps) in adults is 
defined as:
presence of two or more symptoms one of which should 
be either nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip):
 - ± facial pain/pressure;
 - ± reduction or loss of smell;
for ≥12 weeks;
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhea, nasal itching, and itchy watery eyes) should be 
included (see Figure 2.2).
 Post-viral
Rhinosinusitis
ABRS
Common Cold
Figure 2.1. Acute rhinosinusitis can be divided into Common Cold 
and post- viral rhinosinusitis. A small subgroup of the post-viral 
rhinosinusitis is caused by bacteria (ABRS).
Figure 2.2 Definition of ARS
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2.3.2.2. Definition of Chronic  rhinosinusitis in children
Chronic rhinosinusitis (with or without nasal polyps) in children 
is defined as:
presence of two or more symptoms one of which should 
be either nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip):
 - ± facial pain/pressure;
 - ± cough;
for ≥12 weeks;
with validation by telephone or interview.
2.4. Definition for research
For research purposes acute rhinosinusitis is defined as 
above. Bacteriology (antral tap, middle meatal culture) and/or 
radiology (X-ray, CT) are advised, but not obligatory. 
For research purposes chronic rhinosinusitis (CRS) is defined 
as per the clinical definition. For the purpose of a study, the 
differentiation between CRSsNP and CRSwNP must be based on 
endoscopy. 
2.4.1. Definition of chronic rhinosinusitis when 
no earlier sinus surgery has been performed
Chronic rhinosinusitis with nasal polyps (CRSwNP): bilateral, 
endoscopically visualised in middle meatus.
Chronic rhinosinusitis without nasal polyps (CRSsNP): no visible 
polyps in middle meatus, if necessary following decongestant.
This definition accepts that there is a spectrum of disease 
in CRS which includes polypoid change in the sinuses and/
or middle meatus but excludes those with polypoid disease 
presenting in the nasal cavity to avoid overlap.
2.4.2. Definition of chronic rhinosinusitis when 
sinus surgery has been performed
Once surgery has altered the anatomy of the lateral wall, the 
presence of polyps is defined as bilateral pedunculated lesions 
as opposed to cobblestoned mucosa > 6 months after surgery 
on endoscopic examination. Any mucosal disease without overt 
polyps should be regarded as CRS.
2.4.3. Conditions for sub-analysis
The following conditions should be considered for sub-analysis:
1. aspirin sensitivity based on positive oral, bronchial, or 
nasal provocation or an obvious history;
2. asthma / bronchial hyper-reactivity / COPD / 
bronchiectasies based on symptoms, respiratory function 
tests;
3. allergy based on specific serum specific IgE or Skin Prick 
Test (SPT).
4. total IgE in serum (treatment effects may be influenced by 
IgE level)
2.4.4. Exclusion from general studies
Patients with the following diseases should be excluded from 
general studies, but may be the subject of a specific study on 
chronic rhinosinusitis with or without nasal polyps:
1. cystic fibrosis based on positive sweat test or DNA alleles;
2. gross immunodeficiency (congenital or acquired);
3. congenital mucociliary problems (eg. primary ciliary 
dyskinesia (PCD));
4. non-invasive fungal balls and invasive fungal disease;
5. systemic vasculitis and granulomatous diseases;
6. cocaine abuse;
7. neoplasia.
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3.1. Epidemiology and predisposing factors 
of ARS
Summary
ARS is a very common condition that is primarily managed in 
primary care. Prevalence rates vary from 6-15% depending on 
the study parameters, although studies specifying ARS report 
6-12%, with a prevalence of recurrent ARS estimated at 0.035%. 
The primary cause of ARS are viruses with 0.5-2.0% of patients 
developing acute bacterial rhinosinusitis secondary to a viral 
infection. Prevalence of ARS varies with season (higher in the 
winter months) and climatic variations, and increasing with a 
damp environment and air pollution. 
There appears to be overwhelming bodies of evidence to 
support the hypotheses that on-going allergic inflammation and 
cigarette smoke exposure predispose patients to ARS possibly 
via changes to ciliary motility and function. However, the role of 
laryngopharyngeal reflux in ARS is unclear. Chronic concomitant 
disease in children, poor mental health, and anatomical 
variations have been associated with an increased likelihood 
of ARS. Although ciliary function is altered in ARS, there is little 
evidence to support a role for ARS in primary cilia dyskinesia 
progression. 
Further research is required to elucidate the underlying 
mechanisms by which on-going allergy and cigarette smoke 
exposure increases susceptibility to ARS is urgently needed. This 
review found that there is a paucity of studies characterising 
patients with ARS and concomitant diseases. Characterisation 
studies are required to identify possible co-existing or 
predisposing diseases beyond allergy, smoking, and  possibly 
laryngopharyngeal reflux.  
3.1.1. Epidemiology of ARS
ARS is highly prevalent, 
affecting 6-15% of the population.
The incidence of acute sinusitis or rhinosinusitis (ARS) is very 
high, as previously described (8) and as summarised in Table 
3.1.1. It has been estimated that adults suffer two to five 
episodes of viral ARS (or colds) per year and school children may 
suffer seven to ten colds per year (8, 30). Approximately 0.5-2% 
of viral upper respiratory tract infections are complicated by 
bacteria infection (8, 31). In a recent analysis of ENT problems in 
children using data from Dutch general practices participating 
in the Netherlands Information Network of General Practice 
from 2002 to 2008, Uijen et al. (32) reported stable incident rates 
of 18 cases of sinusitis per 1000 children aged 12-17 years per 
year and 2 cases per 1000 children in those aged 0-4 years. In 
children aged 5-11, Uijen et al. observed a decreasing incidence 
from 7 cases per 1000 children in 2002 down to 4/1000 in 2008 
(p<0.001). In contrast, using the data for 240,447 consultations 
for a respiratory tract infection obtained from the EPR system 
Swedestar database, Neumark et al. (33) reported only a 2.5% 
decrease in consultations for sinusitis over the period from 1999 
to 2005. In a small study, Oskarsson and Halldόrsson (34) reported 
an incidence of 3.4 cases per 100 inhabitants per year of acute 
sinusitis across a population derived from three health care 
centres in Iceland. 
In Germany, from July 2000 to June 2001, 6.3 million separate 
diagnoses of ARS were identified resulting in 8.3 million 
prescriptions (30). In a three-year case-control study of the Dutch 
population, van Gageldonk-Lafeber estimated that annually, 
900,000 individual patients consulted their primary care 
physician for acute respiratory tract infection (35).
In the USA, upper respiratory tract infection is the third most 
common reason for a primary care provider consultation, with 
approximately a third of these attributed to ARS (36). Reported 
in 2009 and using data from the US National Health Interview 
Survey for years 1997 through to 2006, Bhattacharyya reported 
a 1-year disease prevalence of 15.2%, although the author 
discusses that this is likely to include both ARS and CRS. USA 
guidelines suggest that rhinosinusitis affects a reported 1 in 7 
adults (37-39). Specifically focusing on ARS, an average of 8.4% of 
the Dutch population reported at least one episode of ARS per 
year in 1999 (8), while during January to March 2002, 9% (23 of 
266 patients) of previously healthy patients presented with ARS 
at a Medical Centre Clinic in San Francisco, USA (40). In the Finnish 
MIKSTRA study conducted during 1998 and 1999, 12% (1601 of 
13740) of patients were diagnosed with acute maxillary sinusitis 
(41). Using the same database, Rautakorpi (42) reported that 12% 
of consultations for infection were attributed to sinusitis. In Asia, 
an estimated 6-10% of patients seen at GP, otolaryngologist, and 
3. Acute Rhinosinusitis
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paediatrician outpatient practices present with ARS (9). 
Recurrent ARS may be considered distinct from ARS and CRS. 
Using data from a medical claims database for 13.1 million 
patients from 2003 to 2008, the point prevalence of recurrent 
ARS has been reported to be 0.035%, and considerably 
lower than that of ARS (43). Whether recurrent ARS should be 
considered a form of acute or CRS requires further discussion. 
A number of studies have described patients attending 
secondary care facilities for acute rhinosinusitis as summarised 
in Table 3.1.2. In North-western Nigeria, 195 of 1661 patients 
seen in a secondary care ENT facility presented with 
rhinosinusitis, of which 16.4% had ARS (44). The proportion of 
patients with acute rhinitis was considerably higher than had 
been previously reported by Ogunleye et al. in 1999 (45). In a 
retrospective review of 90 patients attending a secondary care 
clinic in Ibadan, Nigeria, they reported that only 7% of the 90 
patients were identified as having ARS (45). A prevalence of ARS 
of 1.4% was reported in a 292 patient study of upper respiratory 
tract infections presenting at Siriraj Hospital, Thailand, between 
April and October 2004 (46). This low prevalence may be due to 
the majority of patients with ARS presenting to their primary 
care provider rather than hospital. An increasing prevalence of 
sinusitis has been reported in Turku in south-western Finland, in 
which a 3.14 fold increase in the number of patients presenting 
with acute frontal sinusitis at a secondary care facility was 
observed between 1977-81 (134 patients) and 1982-1986 (421 
patients) (47). While this may be as a result of increasing diagnosis 
Table 3.1.1. Acute Rhinosinusitis (ARS) incidence and prevalence primary care studies.
Author, year, ref. Evidence Type of study
Uijen 2011 (32) Incidence of ARS during 2002 to 2008:
0-4 years: 2/1000 per year in all years
5-14 years: 7/1000 in 2002 reducing to 4/1000 in 2008 (p<0.001
12-17 years: 18/1000 per year in all years. 
Retrospective, population study
Oskarsson 2011 (34) Incidence of ARS is 3.4 cases per 100 inhabitants per year, or 1 in 29.4 
patients visits their GP due to ARS.
Retrospective population study
Wang 2011 (9) 6-10% of patients present at GP, otolaryngologist or paediatric out-
patient practices with ARS
Multi-national questionnaire 
survey
Bhattacharyya  2011 (43) Point prevalence of 0.035% for recurrent ARS during 2003-2008. Retrospective cohort study
Meltzer, Kaliner, Kaliner 2011, 
1997, 1997 (2, 38, 39)
1 in 7 adults affected by rhinosinusitis in USA Guidelines
Neumark 2009 (33) 7.5% of consultations for respiratory tract infections (or 1 in every 13.3) 
were attributable to sinusitis. Expanding to all primary care consulta-
tions, 19.3 consultations/1000 patients were attributable to sinusitis.
Prospective population study
Bhattacharyya 2009 (37, 48) For 1997-2006, 1 year prevalence of sinusitis (all forms) was 15.2% Retrospective cohort study
Fokkens 2007 (8) For 1999, 8.4% of the Dutch population reported at least one episode 
of ARS
Guideline
van Gageldonk-Lafeber 2005 (35) Incidence of acute respiratory tract infection (including ARS) during 
2000-2003 was 54.5 cases /1000 patient-years, or 1 in every 18.3 consul-
tations
Prospective case-control study
Cherry 2005 (36) In the USA, upper respiratory tract infection is third most common 
cause of a primary care consultation, of which a third is attributable to 
ARS.
National Survey
Louie 2005 (40) In US study conducted during January to March 2002, 9% of previously 
healthy patients presented with ARS.
Prospective study
Varonen, Rautakorpi 2004, 
2001 (41, 42)
During 1998-1999, 12% of patients were diagnosed with ARS. 12% of 
consultations for infection (all cause) over this time period were attribut-
able to ARS
Cross-sectional multi-centre 
epidemiological survey
Bachert 2003 (30) Between July 2000 and June 2001 6.3 million separate diagnoses of 
ARS were identified in Germany, resulting in 8.3 million prescription
Review
11
Supplement 23
and willingness to refer to secondary care, Suonpaa and Antila 
(47) suggest that increasing air pollution in the city area of Turku 
may be partly responsible.
3.1.2. Factors associated with ARS
Identifying factors predictive of ARS and/or acute respiratory 
tract infections could aid resource availability.
3.1.2.1. Environmental Exposures
Using a matched case control study design conducted in 
a Dutch population over the period of 2000 to 2003, van 
Gageldonk-Lafeber et al. (50) reported that exposure to an 
individual(s) with respiratory complaints, inside or outside of 
the immediate household was an independent risk factor for 
attending their GP with an acute respiratory tract infection 
(adjusted OR = 1.9 and adjusted OR = 3.7, respectively). In 
contrast, patients with children in secondary education, who 
had dampness or mould at home, or had exposure to passive 
smoking were less likely to visit their GP compared to those 
without children, mould or dampness or passive smoking 
exposure respectively. Increased levels of dampness, but not 
mould, in the home has been associated with sinusitis (51). 
Seasonal trends in occurrences of ARS have been reported. In a 
study of respiratory tract infections, Neumark et al. (33) reported 
seasonal variable in the incidence rate of sinusitis from 1999 
through to 2005, with increased incidence in the first quarter 
of each year. For acute respiratory illnesses in 2000 to 2003, 
van Gageldonk-Lafeber et al. (35) reported similar seasonal 
trends to those of Neumark. Compared to July to September, 
van Gageldonk-Lafeber et al reported that the relative risk of 
acquiring an acute respiratory illness was 2.9 (95% CI: 2.8-
3.0) in January to March, 1.8 (95% CI: 1.7-1.9) in October to 
December and 1.4 (95% CI: 1.3-1.5) in April to June. In an audit 
of complications of ARS, Babar-Craig et al. (52) reported that 
69% of patients were admitted during the winter months of 
November to April. Similar patterns have been reported in acute 
exacerbations of CRS (53) and upper respiratory tract infections (54). 
Climate variations have been reported to induce facial pain 
similar to ARS. Chinook, or föhn, is a weather event in which 
a rapidly moving warm, high-pressurised wind enters into 
a specific location. The pressure changes that occur during 
the Chinook induce facial pain similar to that experienced in 
sinusitis pain. Rudmik et al. (55) report that compared to controls, 
the presence of concha bullosa and spheno ethmoidal cell 
(Onodi cell; p=0.004), and larger maxillary sinus size (right, 
p=0.015; left, p=0.002) are all associated with complaints of 
Chinook headache. 
However, as the Lund-Mackay score was higher in the control 
group, the authors conclude that CRS is unlikely to be associated 
with the Chinook induced facial pain. 
Exposure to air pollution (47, 48, 56), irritants used in the preparation 
of pharmaceutical products (57), during photocopying (58) and 
forest fire smoke (59) have all been associated with an increase in 
the prevalence of symptoms of ARS. 
3.1.2.2. Anatomical factors
Anatomical factors including Haller cells, concha bullosa, septal 
deviation, choanal atresia, nasal polyps and hypoplasia of 
sinuses have all been associated with ARS. In a sinus computed 
tomography study of recurrent ARS versus non rhinosinusitis 
controls, Alkire and Bhattacharyya (60) reported significantly 
higher Lund score (2.25 versus 1.27; p<0.001), higher frequency 
of Haller cells on radiograph (39.9% versus 11.9%; p=0.006) 
and smaller mean infundibular widths (0.591 mm versus 0.823 
mm; p<0.001) compared to controls. They also reported a 
higher frequency of concha bullosa (41.7% versus 28.6%) and 
impinging septal spurs (27.8% versus 19.0%) than controls, 
although neither reached statistically significance. 
Suonpaa and Antila (47) reported an increase in the occurrence 
of nasal polyps in their study of ARS between 1977-1981 and 
1982-1986.
Table 3.1.2. ARS incidence and prevalence in secondary care studies.
Author, year, ref. Evidence Type of study
Iseh 2010 (44) In north western Nigeria, 16.4% of 1661 patients seen in ENT facility had 
ARS
Retrospective case note review
Treebupachatsakul 2006 (46) In Thailand, 1.4% of 292 patients attending Siriraj Hospital between 
April and October 2004 had ARS
Prospective cohort study
 Ogunleye 1999 (45) In Ibadan, Nigeria, 7% of 90 patients attending a secondary care clinic 
had ARS
Retrospective case note review.
Suonpaa 1990 (47) Proportion of patients presenting with acute frontal sinusitis at a sec-
ondary care facility in Turku, South-western Finland increased by 3.14 
fold between years of 1977-1981 and 1982-1986.
Retrospective case note review.
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In patients with recurrent ARS, anatomical 
variations including Haller cells and septal 
deviation, nasal polyps, septal deviation, and 
choanal obstruction by benign adenoid tissue, or 
odontogenic sources of infections should 
be considered.
Odontogenic infections, or infections arising from dental 
sources, causing acute maxillary sinusitis have been reported 
in the literature. Bomeli et al. (61) reported that oroantral fistula 
and periodontal disease plus either a projecting tooth root 
or periapical abscess were significantly identified as sources 
of acute maxillary sinusitis. Furthermore they demonstrated 
that the greater the extent of fluid opacification and mucosal 
thickening, the greater the likelihood of an identifiable dental 
infective source. In a computed tomography (CT) radiological 
study of the maxillary sinus in elderly dentate and edentulous 
patients, Mathew et al. (62) reported an increased prevalence 
of mucosal thickenings (74.3 versus 25.6; p<0.05) and mucous 
cysts (2.1% versus 0) in dentate patients compared to edentate 
controls. 
In a study of 76 children presenting with ARS, Eyigör and Basak 
(63) reported that 16 (21.1%) had septal deviation, and 25 (32.9%) 
had choanal obstruction by benign adenoid tissue. 
3.1.2.3. Allergy
The role of allergy in ARS is the subject of much debate with 
literature both supporting and disputing a role for allergy 
in predisposing for ARS, as summarised in Table 3.1.3. In 
1989, Savolainen (64) reported that 25% of 224 patients with 
acute maxillary sinusitis had allergy, as verified by allergy 
questionnaire, skin testing and nasal smears, with a further 6.5% 
of patients having probable allergy. However, upon comparison 
of those with and without allergy, no differences were found in 
the number of previous episodes of ARS, or bacteriological and 
radiological findings suggesting that the presence of allergy 
maybe incidental. In 1993, Ciprandi et al. (65) demonstrated that 
expression of the inflammatory adhesion molecule, ICAM-1, 
is elevated in patients with AR exposed to allergen challenge. 
As ICAM-1 has been shown to be a receptor molecule for 
rhinovirus, the authors hypothesise that increased expression 
of ICAM-1 maybe responsible for increased susceptibility to 
respiratory infections in patients with allergy (66). More recently 
Melvin et al. (67) demonstrated that patients with AR and 
recurrent episodes of ARS had elevated expression of the toll-
like receptor 9 (TLR9) in the sinonasal epithelium compared 
to patients with only AR, suggesting that TLR9 may be up-
regulated in response to repeated microbial insults. The authors 
theorise that impairment of innate immune gene expression 
may predispose some patients with AR to subsequent 
development of recurrent ARS. In a mouse model of AR, An et 
al. (68) reported that mice with significant mucosal oedema and 
dilate venules due to ovalbumin induced AR (and sensitisation) 
had significantly higher polymorphonuclear neutrophils (PMN) 
and eosinophils following exposure to  
S. pneumoniae than mice with induced AR exposed to saline. 
Furthermore, mice without induced AR, but sensitised to 
ovalbumin and exposed to S. pneumoniae, had significantly 
lower PMN but comparable eosinophils and IL-5 levels to those 
sensitised and with AR, suggesting that an on-going allergic 
response, but not sensitisation, increases the likelihood of S 
pneumoniae sinus infection. Naclerio et al. (69) and Blair et al. (70) 
reported comparable results.
Clinically, ARS has been associated with atopy and AR. In a 
cross-sectional cohort study of 100 children presenting with 
recurrent upper respiratory tract infections compared to 
164 healthy controls, Mbarek et al. (71) reported a significant 
association between allergy and rhinosinusitis (p=0.001), as 
well as recurrent upper respiratory tract infections (p=0.01), 
rhinopharyngitis (p=0.02) and acute otitis media (p=0.01). In 
a comparative case – control study of Israeli air force pilots, 
Ulanovski (72) reported that 33% of pilots with a history of AR 
and 21% of the control group had one or more episodes of ARS 
(p=0.09). Restricting to those pilots aged <26 years of age, the 
resultant findings were 57% and 29% (p<0.001), respectively. 
Stratification of pilots with a history of AR by pilot type showed 
that 54% of transport pilots, 34% of fighter pilot and 13% of 
helicopter pilots has also had one or more episodes of ARS, 
compared to the 28%, 15% and 15% of pilots in the control 
group. The authors theorise that the lower prevalence of ARS 
in the fighter pilot group as compared to the transport pilots 
with a history of AR may be attributable to vasoconstriction 
due to psychological and physiological stress exhibited during 
flight missions. In a retrospective analysis of patients presenting 
with frontal ARS between 1981 and 1990 at a secondary care 
facility in Kuopio, Ruoppi et al. (73) reported that 22 of the 91 
(24%) patients identified had concomitant AR. Schatz et al. (74) 
reported that the odds of developing an episode of ARS was 4.4 
times higher in patients with rhinitis than in healthy controls. 
Symptomatically, Eccles considered the association of sneezing 
in AR and also in ARS to indicate a potential link between the 
two conditions via stimulation of the nasal trigeminal nerves (75). 
Indeed, symptom scores for ‘sneeze’ were higher in children with 
atopy and ARS than those with rhinosinusitis alone (76), while 
ARS has been shown to produce bilaterial large myelinated fibre 
hypersensitivity of the trigeminal nerves compared to healthy 
controls (77). 
Evidence also suggests that AR is associated with impaired 
mucociliary clearance (78). In a prospective study of 125 patients 
with AR, using the saccharine test, Vlastos et al. (78) reported that 
23 patients with AR who were sinusitis prone had a significantly 
greater mucociliary clearance time as compared to 102 control 
patients with AR but not sinusitis prone (12 and 15 minutes, 
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respectively; p=0.02). Further research is required to explore this 
predisposition for rhinosinusitis in AR.
In 2009, Pant et al. (79) undertook a review of allergy in 
rhinosinusitis. In contrast to the above literature, Pant et al 
concluded that insufficient evidence exists to confirm seasonal 
or perennial AR as a significant predisposing factor for ARS. 
However, they do confirm that an association between IgE, mast 
cell, and eosinophil infiltration exists in some subtypes of CRS, 
Table 3.1.3. Evidences in favour and against of allergy being a predisposing factor for Acute Rhinosinusitis (ARS).
Author, year, ref. Evidence in favour Type of study
Lin 2011 (76) Atopic children with ARS have significantly higher levels of dizziness, 
sneeze, snore, itchy or burning eyes, eye congestion, tearing, anxiety, 
dyspnoea and chest tightness; and lower nasal peak inspiratory flow than 
non-atopic children with ARS
Cohort study
Eccles 2011 (75) Sneezing in AR and in ARS is mediated via stimulation of the nasal 
trigeminal nerves
Review article
 Melvin 2010 (67) Elevated levels of toll-like receptor 9 (TLR9) found in patients with AR and 
recurrent episodes of ARS compared to AR only patients
Cohort study
Vlastos  2009 (78) Patients with AR who are sinusitis prone shown to have increased muco-
ciliary clearance time compared to AR patients not sinusitis prone
Cohort study
Ulanovski 2008 (72) Pilots with a history of AR had more episodes of ARS than those who did 
not have a history of AR
Audit,
Mbarek 2008 (71) Significant association between allergy and rhinosinusitis in a study of 
children with recurrent upper respiratory infection compared to health 
controls
Cross-sectional cohort study
Schatz 2008 (74) Patients with AR are 4.4 times more likely to have an episode of ARS than 
healthy controls
Retrospective cohort study
Ciprandi 2006 (66) Children with allergies have more frequent and severe respiratory infec-
tions than children without allergies
Cohort study
An 2007 (68) 
Naclerio 2006 (69) 
Blair 2001 (70)
In mouse models, an on-going local allergic response in the sinuses aug-
ments bacterial sinus infection
In vivo animal studies
Alho 2004 (80) Abnormal nasal airflow and mucociliary clearance rates were more com-
mon in patients with AR than in patients with a history of recurrent ARS 
or health controls
Cohort study
Kirtsreesakul 2004 (81) In mouse models, bacterial sinus infection in mice with an on-going 
local allergic response could be partially inhibited by the H
1
-antagonist 
desloratadine
In vivo animal study
Ciprandi 1999 (82) The antihistamine, terfenadine, down-regulates ICAM-1 expression and 
reduces rhinoconjunctivitis symptoms in children
Randomised, controlled trial
Braun 1997 (83) Adjunct loratadine therapy to standard therapy improved control of some 
symptoms of ARS in patients with concomitant ARS compared to patients 
with AR and ARS given placebo
Randomised, placebo-controlled, 
clinical trial
Ciprandi 1993 (65) Allergic children express the inflammatory adhesion molecule ICAM-1 
which is a receptor for rhinovirus
Cohort study
Ruoppi 1993 (73) 24% of patients attending a secondary care facility for acute frontal sinusi-
tis had concomitant AR
Retrospective cohort study
Savolainen 1989 (64) 25% of 224 patients with ARS had positive allergy skin test and allergy 
symptoms with a further 6.5% having probable allergy
Clinical study
Study, Author, year Evidence against Type of study
Iseh 2010 (44) Only patients with CRS, not ARS, were found to have an allergic compo-
nent to their disease.
Retrospective, cohort study
Pant 2009 (79) Insufficient evidence to confirm involvement of seasonal or perennial 
rhinitis in ARS. IgE, mast cell and eosinophil infiltration exists in some 
subtypes of CRS but not ARS
Review article
Savolainen 1989 (64) No difference in rates of sinus infections or bacterial or radiological find-
ings between allergic and non-allergic patients.
Clinical study
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but not ARS. In contrast to this review, Lin and cols. recently 
reported that children with atopy were more likely to develop 
ARS (76). They reported that atopic children with ARS reported 
significantly higher symptoms (including dizziness, sneeze, 
snore, itchy or burning eyes, eye congestion and tearing) as 
well as significantly higher levels of anxiety, dyspnoea, chest 
tightness, and lower nasal peak inspiratory flow than non-atopic 
children with ARS. Alho (80) reported that during viral ARS (or 
cold), a greater proportion of patients with concomitant AR 
had abnormal nasal airflow, mucociliary clearance and higher 
ipsilaterial paranasal sinus CT scores than patients with a history 
of recurrent ARS or healthy controls. 
3.1.2.4. Ciliary impairment
Ciliary impairment has been demonstrated to be a feature of 
both viral and bacterial rhinosinusitis (8). This includes both the 
loss of cilia and ciliated cells as well as a disruption of normal 
mucociliary flow. Smoking and allergy have been implicated 
in the disruption of cilia function. Indeed impaired mucociliary 
clearance in AR patients predisposes patients to ARS (78). 
Ciliary function is diminished during viral 
and bacterial rhinosinusitis. Exposure to cigarette 
smoke and allergic inflammation has also 
been shown to impair ciliary function, 
although research is required to understand 
these processes further.
Ciliary impairment has also been associated with cigarette 
smoking. In vitro studies have demonstrated that cigarette 
smoke condensate and cigarette smoke extract impairs 
ciliogenesis in a dose-dependent manner (84). Clinical studies 
have also reported that exposure to passive smoking increases 
the levels of matrix metalloproteinase 9 (MMP-9), a gelatinase 
associated with tissue modelling is significantly increased in 
nasal secretions of children (85) exposed to passive smoking. As 
increased production of MMP-9 has been found in the acute 
allergic response in the nose and lungs, the implications for the 
involvement of MMP-9, ciliary function, allergic response, and 
smoking in ARS needs further exploration. 
3.1.2.5. Primary Cilia Dyskinesia
Primary cilia dyskinesia (PCD) is a rare autosomal recessive 
disorder in which cilia are either immotile, or beat in such a 
pattern that there is failure to transport the airway mucous. 
PCD is associated with chronic upper airway symptoms 
including nasal discharge (episodic facial pain and anosmia) and 
bronchiectasis (86), with neonates presenting with continuous 
rhinorrhoea from the first day of life (87-89). Limited information 
is available on the prevalence of PCD. In a Norwegian study 
conducted in 1947 and 1949, prevalence of PCD was estimated 
at 1:40,000 (90). However, this radiological study was likely to 
be an underestimate due to limitations of standard chest 
radiographs in detecting bronchiectasis and that bronchiectasis 
may not have developed in the younger study patients. Using 
data from 1976 – 1990, the prevalence of PCD in Sweden has 
been estimated to range from 1:22,000 to 1:10,000 (91), the 
difference in prevalence due to the likely under-diagnosis of 
the condition. The highest prevalence, 1:4,100, was reported in 
a study of the impact of the Hiroshima and Nagasaki delayed 
atomic bombs (92). The frequency of episodes of ARS in these 
patients groups is not reported.
In a study of 38 bronchiectasis patients, PCD was reported to 
be responsible for 13% of cases, and was more common in 
North African patients than European (93). Barbato et al. (94), for 
the European Respiratory Society Task Force on PCD, report that 
recurrent ARS in PCD patients is rare, although episodes should 
be treated with ‘adequate and prolonged antibiotic(s)’ (95-97). In 
agreement with the ERS Task Force, Bush et al. report that upper 
(and lower) airway infections should be treated aggressively, 
and that lung disease is usually stabilised once treatment is 
initiated. Although evidence exists to suggest that treating 
ARS will prevent recurrence or chronicity (49), whether this can 
applied to the PCD population is unknown. In the absence of 
lower airway infection, the impact of acute or recurrent ARS on 
the progression of PCD related bronchiectatic lung disease is 
unknown. 
3.1.2.6. Smoking
Limited research exists on the impact of smoking on ARS. Using 
data from the 1970 National Health Interview Survey, and after 
excluding families with children with chronic respiratory illness, 
Bonham and Wilson (98) reported that children from households 
with one or more adult cigarette smokers had significantly more 
restricted activity and bed-disability days than did children 
from families with non-smoking adults. This difference was 
found to be due to children from families with active smokers 
having more episodes of acute respiratory illness (including 
ARS). Comparable significant results were found when families 
in which 45 cigarettes or more were consumed per day were 
compared to families with non-smoking adults. The authors 
concluded that higher cigarette consumption was associated 
with increased predisposition for acute respiratory illness. In 
a paediatric characterisation study of 76 patients with acute 
rhinosinusitis aged 4-18 years, Eyigör and Başak (63) reported 
that 51.3% (39 patients) were exposed to second hand smoke 
and 2.6% (2 patients) were active smokers. Based on their 
population, the authors concluded that exposure to primary or 
second hand smoke were predisposing factors for ARS.
In a study characterising the respiratory symptoms of adult 
postal workers in Zagreb, Croatia, the prevalence of sinusitis in 
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active smokers was 53.1% compared to 26.4% in non-smokers, 
although no information was available on whether the sinusitis 
was recurrent acute or chronic in nature (99).  
Active smokers with on-going allergic 
inflammation have an increased susceptibility 
to ARS compared to non-smokers with on-going 
allergic inflammation, suggesting that exposure 
to cigarette smoke and allergic inflammation is 
mediated via different and possibly synergistic 
mechanisms. Research to elucidate these 
mechanisms is needed.
The impact of second-hand tobacco smoke on symptoms of 
rhinosinusitis has also been evaluated in patients with AR (100). 
This study reported that patients with AR exposed to second 
hand smoke had more symptoms consistent with rhinosinusitis 
including facial pain and facial congestion or fullness, and a 
greater proportion had received medication for rhinosinusitis 
including antibiotics for respiratory problems in the previous 
12 weeks compared to disease specific controls. Although the 
authors did not evaluate the occurrences of ARS, the greater 
proportion of patients requiring antibiotics for respiratory 
problems would suggest that patients exposed to second-hand 
tobacco smoke may have had more episodes of ARS or recurrent 
ARS, although the authors do not delineate between antibiotics 
for upper or lower airway respiratory problems. 
Active and passive smoking has been shown to alter the normal 
bacterial flora present in the nasopharyngeal spaces, resulting 
in the colonisation of more potential pathogens than found in 
non-smokers (101). Following smoking cessation, the microbial 
population has been shown to revert back to that found in non-
smokers (102). The impact of smoking cessation programmes on 
the incidence and prevalence of ARS is unknown. 
In vitro and in vivo studies have recently shown to increased 
MMP-9 production in children exposed to passive smokers (85) 
and increased complement activation in human respiratory 
epithelial cells and mice exposed to cigarette smoke extract 
(103). Whether increased MMP-9 production or complement 
activation due to exposure to cigarette smoke predisposes to 
ARS is unknown and requires further investigation. 
3.1.2.7. Laryngopharyngeal reflux
Little is known about the association of ARS and 
laryngopharyngeal reflux. As reviewed by Pacheco-Galván et 
al. (104), epidemiological studies conducted between 1997 and 
2006 have shown significant associations between GERD and 
sinusitis. However, in a recent systematic review, Flook and 
Kumar showed only a poor association between acid reflux, 
nasal symptoms, and ARS (105). 
3.1.2.8. Anxiety and depression
Poor mental health or anxiety and depression have been 
significantly associated with ARS (106). In a study of 47,202 college 
students aged 18 to 24 years, Adams et al. (106) reported that the 
prevalence of acute infectious illness, which included bronchitis, 
ear infection, sinusitis, and strep throat, ranged from 8% to 29%, 
while the prevalence of anxiety and depression ranged were 
12% to 20%, respectively. 
Poor mental health, anxiety, or depression is 
associated with susceptibility to ARS, although the 
underlying mechanisms are unclear.
3.1.2.9. Drug resistance
The most common bacterial pathogens causing acute bacterial 
rhinosinusitis include S. pneumoniae, H. influenzae, S. pyrogenes 
M. Catarrhalis, and S aureus (8). Amoxicillin/clavulanate is the 
principal antibiotic for the treatment of mild ARS. Despite 
resistance to amoxicillin, it is estimated that approximately 80% 
of cases of mild ARS respond to amoxicillin, at a dose of 70-90 
mg/kg/day. Indeed, Principi and Esposito report that most cases 
of H. influenzae and M. catharralis and approximately 15% of S. 
pneumoniae resolve spontaneously (107). 
Amoxicillin is the most commonly used antibiotic 
for mild ARS. However, increasing resistance 
to amoxicillin, particularly in S. pneumoniae 
and H. influenzae infections need to be reviewed 
with caution. Furthermore, changes in bacterial 
pathogenicity in acute bacterial rhinosinusitis 
require consideration for antibiotic therapy.
The introduction of the Pneumococcal conjugate vaccine has 
led to changes in the pathogen profile of ARS. Brook and Gober 
(108) reported a reduction in the incidence of S. pneumoniae from 
44% to 27%, and an increase in the incidence of H. influenzae 
from 37% to 44%, S. pyrogenes from 7% to 12% and S. aureus 
from 4% to 8% with no change in M. catarrhalis (from 13% to 
14%). 
Since the introduction of the Pneumococcal conjugate vaccine 
(PCV7), reductions in the frequency of S. pneumoniae, overall 
resistance and high level bacterial resistance have been coupled 
with indications for increasing levels of β-lactamase-producing 
H. influenza (109). However, evidence of increasing antibiotic 
resistance in non-PCV7 serotypes of S. pneumoniae is emerging 
(110). Rybak (111) reported for the US element of the PROTEKT 
longitudinal global surveillance study on antibiotic resistance, 
that for 2000-2001, S. pneumoniae resistance to beta-lactams, 
macrolides and fluoroquinolone, but not to telithromycin. 
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In 2004, Huang et al. reported that 72.4% S. pneumonia, 60.5% 
H. influenzae, and 58.3% M. catarrhalis resistance to first-line 
antibiotics. Sahm et al. (112) report that 40% of 847 sinus isolates 
were resistant to two or more of the antibiotics tested, and a 
doubling of the resistance to amoxicillin/clavulanate. In 2011, 
Lin et al. (76) report that 70% of isolates of S. pneumoniae and 
71.4% of H. influenzae isolates from 69 children were resistant to 
amoxicillin/clavulanate. 
Changes in bacterial pathogenicity in acute bacterial 
rhinosinusitis require consideration for antibiotic therapy.
Children with chronic disease who develop 
influenza-like symptoms should be monitored 
for bacterial ARS. The impact of chronic 
disease on the likelihood to develop ARS in adults 
is unknown.
3.1.2.10. Concomitant Chronic Disease
Concomitant chronic disease (bronchitis, asthma, cardiovascular 
disease, diabetes mellitus, or malignant cancer) in children 
has been associated with an increased risk of developing ARS 
secondary to influenza. 
Loughlin et al.  (113) reported that the overall incidence rate of 
developing ARS following influenza ranged from 0.9 to 1.3 
in children aged 0 to 14 years. While the incidence of ARS 
subsequent to influenza in healthy children aged 5-14 years was 
1.2 (95% CI: 0.9 – 1.5), this increased to 3.1 (95% CI: 1.5 – 5.8) in 
children with chronic disease (rate ratio: 2.7 (95% CI: 1.5 – 5.4). 
Increased monitoring of children with chronic disease who 
develop influenza maybe necessary.
3.2. Pathophysiology of ARS
Summary
Acute rhinosinusitis is a common disorder and it could be 
divided into acute viral rhinosinusitis and acute bacterial 
rhinosinusitis and is often preceded by a viral rhinitis or 
common cold. This study reviews the inflammatory mechanisms 
underlying viral rhinitis, acute viral rhinosinusitis and acute 
bacterial rhinosinusitis. First of all, the host needs to recognize 
the presence of microorganisms through ‘pattern recognition’, 
initiating the host defense mechanisms through activation of 
multiple signal pathways. Host defense mechanisms consist 
of both cellular immune responses and release of soluble 
chemical factors, which operate in the body through a complex 
interaction with cytokines and other mediators.
3.2.1. Viral ARS (common cold), post-viral ARS, 
and bacterial ARS: a continuum?
ARS could be divided theoretically into viral (common cold), 
post-viral and bacterial ARS (ABRS) and they usually appear in 
this consecutive order. However, viral, post-viral, and bacterial 
ARS show a considerable overlap both in their inflammatory 
mechanism as in their clinical presentation. Viral infection of the 
nose and sinuses induces multiple changes, including post-viral 
inflammation, which increase the risk of bacterial superinfection. 
These changes include epithelial damage and mechanical, 
humoral, and cellular defences.
ARS can be induced by viral and by bacterial 
infections.
 
3.2.2. Microbiology of viral (common cold), post-
viral, and bacterial ARS
•	 Viruses. 
The most common viruses isolated in adult viral rhinitis and 
rhinosinusitis, are rhinoviruses and coronaviruses. Rhinoviruses 
are thought to account for approximately 50% of all colds. 
Other viruses isolated in the common cold are influenza viruses, 
parainfluenza viruses, adenovirus, respiratory syncytial virus 
(RSV), and enterovirus (114).
Acute bacterial rhinosinusitis (ABRS) is 
generally preceded by a viral and or 
post-viral ARS. 
•	 Bacteria. 
The most common bacteria in ABRS are those belonging to 
the ‘infernal trio’ (S. pneumoniae, Haemophilus influenza, and 
M. catarrhalis) and S. aureus. Also other streptococcal species 
and anaerobic bacteria are seen in ABRS (115-117). Payne and 
Benninger performed a meta-analysis of 25 studies concerning 
the microbiology of ABRS, analysing the prevalence of the most 
common bacteria in the middle nasal meatus and the maxillary 
sinus. The maxillary sinuses contained 26% S. pneumoniae, 
28% H. influenza, 6% M. catarrhalis, and 8% S. aureus. These 
findings correlated with those in the middle meatus, being 
respectively 34%, 29%, 11% and 14% (115). In a study comparing 
nasopharyngeal cultures from children pre and post the 
introduction of the Pneumococcal conjugate vaccine, Brook 
and Gober (108) reported a reduction in the incidence of S. 
pneumoniae from 44% to 27%, and an increase in the incidence 
of H. influenzae from 37% to 44%, S. pyrogenes from 7% to 12%, 
and S. aureus from 4% to 8% with no change in M. catarrhalis 
(from 13% to 14%). 
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3.2.3. Inflammatory mechanisms in viral 
(common cold), post-viral, and bacterial ARS
3.2.3.1. Invasion of microorganisms into the host
A variety of physical and biochemical barriers prevent entry 
from infectious agents into the body. First of all, the human 
body contains a variety of physical barriers against entry of 
microorganisms. Most important are the skin and airway 
mucosa. Epithelial cells are the first barrier in contact with 
viruses or bacteria. These release and express mediators and 
receptors to initiate elimination mechanisms. Mucus secretion 
by goblet cells prevents adherence of micro-organisms to 
the epithelial cells, thus preventing their entrance into the 
body. Microorganisms become trapped in the mucus and are 
mechanically removed from the airway by ciliary movements of 
ciliated cells (118).
Second, the human ecosystem performs a selection of potential 
microorganisms. The ecosystem is determined by multiple 
parameters such as temperature, pH, or O
2
 tension. Only 
microorganisms that require an ecosystem that is similar to 
that of the internal environment of the human body are able to 
survive and infect human (118).
•	 Viruses
Viruses are necessary intracellular microorganisms, which 
require host cells for their replication. They attach to host cells, 
using a relatively specific intermolecular interaction between 
their nucleocapsid (in naked viruses) or viral membrane (in 
enveloped viruses) and molecules of the host cell membrane, 
which act as a receptor. This specific intermolecular interaction 
declares the observed specificity between certain types of 
viruses and specific organ systems (119).
Viral infection of the nose and sinuses induces 
multiple changes, which increase the risk of 
bacterial superinfection.
Rhinoviruses, for example, infect airway epithelial cells through 
binding on ICAM-1 receptors on de cell surface (120, 121). This is 
followed by penetration of the virus into the cell and replication 
of the viral RNA (122, 123). The expression of ICAM-1 is upregulated 
by the rhinoviruses itself, via IL-1beta and nuclear factor (NF)-ΚB-
dependent mechanisms, thereby enhancing its own infectivity 
and promoting inflammatory cell infiltration (120, 122, 124). Bianco 
et al. showed that ICAM-1 expression is enhanced by the Th2 
cytokine IL-13 in the atopic airway (125). Whereas in rhinovirus 
infection down regulates ICAM-1 levels on the infected 
cells, decreasing the available cellular binding sites for viral 
attachment and limiting host infectivity (121).
•	 Bacteria.
Bacterial superinfection depends on both host factors and 
bacterial factors (119)..
A normal anatomical, histological and functional state of the 
host tissues usually prevents bacterial infection (119). Factors 
that are shown to be associated with ABRS include pathogens, 
ciliary impairment, allergy (see further), Helicobacter pylori 
and laryngopharyngeal reflux and naso-tracheal intubation or 
presence of a naso-gastric tube (8). Due to viral infection, allergy 
or other factors, multiple changes may occur in the nasal and 
paranasal tissue. Viral infection induces epithelial disruption, 
increases the number of goblet cells and decreases the number 
of ciliated cells (126). Eventually, these changes contribute to the 
obstruction of the sinus ostia in the nasal cavity (127). A transient 
increase in pressure develops in the sinus cavity due to mucus 
accumulation. Quickly followed by development of negative 
pressure in the sinus cavity, due to impaired sinus aeration with 
rapid absorption of the oxygen that is left into the sinus cavity 
(128). Subsequently, this worsens local congestion, promotes 
further mucus retention, impairs normal gas exchange within 
the integrated airspace, decreases both the oxygen and 
pH content, impedes clearance of infectious material and 
inflammatory debris, and increases the risk for second bacterial 
infection (126, 127, 129, 130). All these local changes in the nasal 
and paranasal space form an ideal environment for bacterial 
colonization and growth (131).
ABRS is mainly caused by: Streptococcus 
pneumoniae, Haemophilus influenza, Moraxella 
catarrhalis, and Staphylococcus aureus.
Viral infection of the nasal tissue may also directly increase 
bacterial adhesion to the nasal epithelial cells. Wang et al. 
noticed a significant increased adhesion of S. aureus, 
S. pneumoniae, and H. influenza on rhinovirus-infected cells 
(132). They postulated that the increased expression of host cell 
adhesion molecules in the nasal epithelial cells, after rhinovirus 
infection, may be the mechanism for the increased susceptibility 
to ABRS associated with rhinovirus-induced upper respiratory 
infections (132). 
Other studies confirmed preferential association and 
cooperation between viruses and bacteria, for example 
Influenza A virus and Streptococcal infection, and Human 
Rhinovirus 14 and S. pneumoniae (133). The mechanism of this 
superinfection may be in relation to viral replication, which 
increases bacterial adhesion. 
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A variety of physical and biochemical barriers 
prevent entry from infectious agents into the noses 
and sinuses. 
Next to host factors, also bacterial factors are involved in 
bacterial superinfection. S. pneumoniae and H. influenza are 
pathogenic because of the structure of their capsule, which 
gives them an invasive activity. Other bacteria, for example 
Streptococci, Staphylococci and Gram-negative bacteria, 
produce toxins directed against the defence system, leukocytes 
or epithelial cells, which allows easier invasion and development 
(119).
3.2.3.2. Defence systems of the host, after penetration 
of microorganisms into the body
3.2.3.2.1. General principles
If microorganisms succeed to enter the body, two main 
defensive strategies against the infection come into play. First 
a non-specific phase where the mucus and its contents (for 
example lysozyme, lactoferrin, and defensin) play a major role 
(innate immunity). The second including the immune response 
and inflammatory reaction (addaptive immunity). 
•	 Viruses.
After penetration of the virus into the host cells, defence 
systems of the host are activated. Cells who carry viral 
pathogens inside need to be eliminated, in order to eliminate 
the virus from the body. It is thought that the innate immune 
system is sufficient to clear viral infection from the body (118).
•	 Bacteria.
Also in case of bacterial infection, the host immunity is required 
to eliminate the bacteria from the body. However, activation 
of the adaptive immune system is thought to be required to 
eliminate the bacteria and to clear the associated inflammation 
(134).
3.2.3.2.2. Pattern recognition and Toll-like receptors.
In order to work properly, the immune system must be able 
to recognize microbial patterns and differentiate these from 
molecular structures present on host cells. Specific pathogen 
classes express class specific molecules, the pathogen 
associated molecular patterns (PAMP). Activation of PAMP 
receptors, for example Toll-like receptors (TLR), induces multiple 
signal cascades, involving complement activation, haemostasis, 
phagocytosis, inflammation, and apoptosis, in response to 
pathogens. For example, activation of TLR-dependent signalling 
pathways contributes to activation of the adaptive immune 
response, through the expression of effector molecules such as 
inflammatory cytokines, chemokines, and other co-stimulatory 
molecules (135-137).
In human, ten distinct TLRs have been described. These are 
expressed in various combinations in cells of the immune 
system, as well as in other cell types (138). mRNA of all ten TLRs 
has been described in human nasal airway tissue. Protein 
verification however, is still lacking for most TLRs in the nose (139).  
Corresponding proteins have been documented for TLR-2, TLR-
3, TLR-4 and TLR-5 (140). 
•	 Viruses.
Kunzelmann et al. postulated that TLR-4 is involved in inhibition 
of ion-transport in response to viral respiratory infections. 
They studied the effect of RSV on ion-transport in tracheal 
epithelia in mice and showed that RSV inhibits Na+ transport 
in the epithelia in a few minutes after binding on the apical 
membrane. They also confirmed that this inhibition is mediated 
by protein kinase C (PKC) and toll-like receptor 4 (TLR-4) and 
attributes to the fluid accumulation seen after RSV infection (141). 
Previous, inhibition of epithelial Na+ transport was also seen 
after infection with influenza virus of Para influenza virus (142, 143).
•	 Bacteria.
Bacteria can be recognized by the innate immune system 
through expression of unmethylated CpG motifs in their 
DNA, inducing activation of TLR-9 (144, 145). The TLR-9 pathway is 
known for its ability to induce a Th1 immune response, thereby 
suppressing Th2-driven allergic responses (146, 147).
Mansson et al. showed that CpG administration in the human 
nose, increases nasal airway resistance, nasal nitric oxide 
production and secretion of IL-1beta, IL-6 and IL-8. The later, 
reflects the ability of CpG to induce a pro-inflammatory Th1-like 
immune response (148). 
Another well-known PAMP in bacteria is lipopolysaccharide 
(LPS), which is part of the outer membrane of Gram-negative 
bacteria. LPS induced activation of TLR-4 pathways, causing 
increased transcription of nuclear factor-NF-ΚB genes, which 
regulated genes like those encoding cytokines and chemokines.
(149-151). This enhances the microbicidal activity of phagocytic 
cells and stimulates maturation and migration of dendritic 
cells. These mature dendritic cells show an increased antigen-
presenting capacity and are involved in the activation of the 
adaptive immune response by stimulation of T lymphocytes. 
Thus, the TLR-4 signalling pathway forms a critical link between 
innate and adaptive immune responses (152, 153).
In S. pneumoniae infection, also lipoteichoic acid and 
pneumolysin have been shown to initiate inflammatory 
responses. This occurs through activation of the TLR-2 pathway. 
The TLR-2 pathway is shown to contribute to the adaptive, 
rather than the innate immune responses, by expression of 
co-stimulatory molecules and molecules such as MHC-II which 
are necessary to present bacterial antigens to Th cells. Cytokines 
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that result from the TLR-2 pathway, stimulate a Th1 response, 
which is very important to clear pneumococcal colonization 
(154-157). It has been suggested that pneumolysin can also interact 
with TLR-4, inducing innate immune responses to pneumococci. 
However, Van Rossum et al found no confirmation of a role of 
TLR-4 in the clearance of pneumococcal colonization in their 
murine model (156, 158).
3.2.3.2.3. Soluble chemical factors
3.2.3.2.3.1. Defensin, lysozyme, C-reactive protein and the 
complement system
As mentioned above, the first defensive strategy of the host 
against infection consists of a non-specific phase, where the 
mucus and its contents (for example defensin and lysozyme) 
play a major role. Other important soluble chemical factors 
are acute phase proteins such as C-reactive protein, interferon, 
lactoferrin, sIgA, and the complement system (159). 
•	 Viruses.
Defensin plays an important role in defence against both 
enveloped and non-enveloped viruses. This protein is present 
in immune cells, to assists in the killing of phagocytized 
pathogens. Defensins can bind to the microbial cell membrane, 
forming pore-like membrane defects that allow efflux of 
essential ions and nutrients (159).
Igarashi et al. analysed nasal lavage fluids for proteins and mast 
cell mediators after inoculation with rhinovirus. They found an 
increased secretion of total protein and both plasma proteins 
(albumin and IgG) and glandular proteins (lactoferrin, lysozyme 
and secretory IgA). They also showed that the nasal secretions 
during the initial response to the rhinovirus infection were 
predominantly due to increased vascular permeability (160).
•	 Bacteria.
In bacterial infection both lysozyme and defensin play an 
important role. Lysozyme is present in a number of secretions 
(saliva, tears and mucus) and exerts its defensive function 
by splitting the proteoglycan cell wall of bacteria. C-reactive 
protein (CRP), the best-known acute phase protein, has the 
capacity to react specifically against a part of the pneumococcal 
capsule. However, it also acts against a variety of other bacteria. 
Also the complement system is involved in host defence against 
bacteria, involving both the innate and adaptive immune 
system (118).
3.2.3.2.3.2. Kinins
•	 Viruses.
Bradykinin and lysylbradykinin are significantly elevated in nasal 
lavages of infected and symptomatic volunteers exposed to 
rhinovirus (161, 162). Generation of kinins however, is also confirmed 
in other viral infections. Kinin generation is associated with 
increased neutrophil infiltration and correlates with increased 
production of the proinflammatory cytokine IL-1 (161-163). They 
can stimulate glandular secretion of mucus, increase ciliary 
beat frequency, stimulate sensory nerves endings and elevate 
vascular permeability (164, 165). Bradykinin-induced vascular 
permeability, however, has been reported to be mediated, at 
least in part, by nitric oxide (166). 
•	 Bacteria.
Bradykinin release has also been demonstrated in response 
to bacterial infection. Bacterial proteases can activate the 
‘Hageman factor-kallikrein-kinin’ cascade, leading to production 
of bradykinin. As mentioned above, bradykinin is an important 
factor in the enhancement of vascular permeability and can 
stimulate sensory nerves. Thereby explaining most of the 
inflammatory reaction, including oedema and pain (167). 
Bradykinin generation has also been shown to result in 
activation of NOS, confirming the potential role of NO in this 
pathophysiological process (167)
3.2.3.2.3.3. Nitric oxide (NO)
NO is a gaseous molecule, synthesized by NO synthase 
(NOS), an enzyme that catalyses the oxidation of L-arginine 
to NO and L-citrulline. At least two types of NOS can be 
reported, constitutive NOS (cNOS) and inducible NOS (iNOS) 
(168). cNOS is produced by many cells in the upper and lower 
respiratory system, such as parasympathetic vasodilator 
nerves, endothelial cells and ciliated mucosa cells (169). iNOS is 
described in epithelium, macrophages, fibroblasts, neutrophils, 
endothelium and vascular smooth muscle, and is activated 
by proinflammatory cytokines and endotoxins (168, 170, 171). NO 
is involved in many physiological and pathological processes 
in human, by exerting a role as cellular signalling molecule. 
Its actions in the body include vasoregulation, haemostasis, 
neurotransmission, immune defence, and respiration (168). In the 
respiratory airway, it causes smooth muscle relaxation, affects 
ciliary beat frequency, mucus secretion and plasma exudation, 
and it is involved in neurotransmission, inflammation and cell-
mediated immunity (172). 
•	 Viruses.
NO concentrations are shown to be increased in asthma, allergic 
rhinitis (AR) and viral respiratory infections (168). NO is generated 
in large amounts during infections, because of its antiviral and 
antimicrobial activity and through its upregulation of the ciliary 
motility (173-175).
In patients with rhinosinusitis, on the contrary, the levels of 
nasal NO (nNO) are significantly decreased. These reduced levels 
of nNO are likely because of reduced NO flow into the nasal 
lumen due to mucosal swelling and draining ostia obstruction, 
and removal of NO by reactive oxygen species (168, 176, 177). It is 
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thought that the lack of NO may contribute to the pathogenesis 
of sinusitis. 
•	 Bacteria.
During pneumococcal infection, NO is produced by iNOS 
in human and rodent macrophages. This might contribute 
to the intracellular killing of pneumococci, following their 
phagocytosis (178). 
3.2.3.2.4. Nerve stimulation and neuromediators
Sympathetic nerve stimulation induces vasoconstriction and 
consequent decreases nasal airway resistance. Parasympathetic 
nerve stimulation on the other hand, promotes secretion from 
nasal airway glands and nasal congestion. The nasal mucosa also 
contains nerves of the non-adrenergic, non-cholinergic (NANC)-
system. Neuropeptides from the latter nerves (substance P, 
neurokinin A and K, and calcitonin gene-related peptide) are 
suspected to play a role in vasodilatation, mucus secretion, 
plasma extravasation, neurogenic inflammation, and mast 
cell nerve interactions. However, the magnitude of their role is 
uncertain (179). Further investigations concerning the role of the 
nervous system in ARS are required.
3.2.3.2.5. Cell-mediated immune response
In addition to the non-specific defence consisting of barriers and 
soluble chemical factors, a cell-mediated immune response is 
activated.
3.2.3.2.5.1. Phagocytosis - neutrophils, monocytes and 
macrophages  
The innate immune system operates through phagocytosis 
of the microorganisms. Cells with phagocytic capacity are 
neutrophils, monocytes, and macrophages.
•	 Viruses.
Because of its intracellular nature, cell-mediated immune 
responses are essential to eradicate viral infection. This 
inflammatory cell reaction, consists mainly of neutrophils, 
monocytes, and macrophages. Increased neutrophil counts 
are seen in the nasal mucosa, nasal secretions, and peripheral 
blood, within 24 hours after inoculation. A couple of days later, 
recruitment of monocytes occurs. These monocytes become 
tissue macrophages, after they have crossed the endothelium 
(180). 
•	 Bacteria.
Macrophages and neutrophils are also stimulated in bacterial 
infection. Gabr et al. investigated the immune response to acute 
infection with S. pneumoniae. The naïve host responded by 
activating the innate immune system. Polymorphonuclear cells 
and macrophages were recruited to the site of infection (181)
Neutrophils recruitment occurs due to release of chemotactic 
factors. Pneumolysin, the polysaccharide capsule, and 
lipoteichoic acid, may act as initiating factors for neutrophil 
recruitment during acute infection. Further, also complement 
factor C5a, high-molecular-weight neutrophil chemotactic 
factor, platelet-activating factor, IL-1 and IL-8, and leukotrienes, 
such as leukotriene B
4
, may act as chemoattractants to 
neutrophils, independent of T helper cells (181). 
3.2.3.2.5.2. Antigen presentation - Dendritic cells 
The adaptive immune system becomes activated in specific 
stimulus. Specific antigens are presented to T lymphocytes 
(cytotoxic T cells, as well as T helper cells) by antigen-presenting 
cells, such as monocytes, macrophages, B-lymphocytes, and 
dendritic cells.
In the peripheral blood, two major subtypes of dendritic cells 
are identified, myeloid dendritic cells (MDC), and plasmacytoid 
dendritic cells (PDC) (182). Hartmann et al. demonstrated the 
presence of PDC and MDC in the healthy nasal epithelium and 
in nasal epithelia from patients with different pathological 
conditions (183). 
Antigen-presenting cells need to process the complex protein 
antigens into ‘minimal antigenic peptides’, which are presented 
to T cells on appropriate MHC molecules. Binding of this 
complex (antigenic peptide and MHC molecule) on the antigen-
specific T cell receptor, initiates activation of the adaptive 
immunity (184). 
•	 Viruses.
PDC play a key role in the detection and defence against viruses 
in the nasal epithelium. After recognizing viruses they start 
producing large amounts of IFN-alpha. Hartmann et al. showed 
that the healthy nasal epithelium contains relatively high 
numbers of PDC and MDC. Whereas PDC levels are decreased 
in asymptomatic patients with chronic nasal allergy and 
increased during infectious inflammation. These results indicate 
the importance of PDC against viral invaders, because of the 
presence of high numbers of PDC in the healthy nasal mucosa. 
This also explains why patients with allergy are more susceptible 
to a more severe course of viral infection (183).
•	 Bacteria.
PDC are also able to recognize CpG motifs within microbial 
DNA, resulting in activation of TLR-9 and production of large 
amounts of IFN-alpha and IFN-gamma. Thereby stimulating a 
Th1 response and counteracting a Th2 response (183).
Gabr et al. confirmed the role of macrophages in antigen 
presentation, and in the processing, recognition and 
presentation of the foreign antigens to other immune cells, 
particularly T helper cells (181).
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The adaptive immune system generates an 
adequate immune response to a specific stimulus 
(antigen-presenting cells, T lymphocytes,  
B lymphocytes, and plasma cells).
3.2.3.2.5.3. Specific immunity – T lymphocytes and B 
lymphocytes
The adaptive immunity reacts on antigen presentation through 
formation of immune products (effector T lymphocytes and 
antibodies), which can generate a specific interaction with the 
stimulus.
•	 Viruses.
Interferon is a protein produced and released by infected cells. 
Both IFN-alpha and IFN-gamma have been recovered in nasal 
secretions and lavage fluids at the time of acute viral upper 
respiratory illnesses (185-188). The type I interferon, IFN-alpha, 
induces a antiviral state in surrounding cells, and modulates 
the activity of other immune cells, such as T cells, NK cells, and 
myeloid dendritic cells (183).
Whilst the Th1 related IFN-gamma, a type II interferon, 
stimulates macrophage accumulation and activation, cytokine 
production, NK cells, and antigen specific B cell proliferation (189).
The immediate antiviral response of the host epithelial cells 
induces cytotoxic T lymphocyte recruitment, which is thought 
to be predominantly a Th1 cell mediated response (190). Infected 
cells can be recognized and killed by these CTL lymphocytes, 
through the expression of proteins on their cell surface. Next, 
cell death can also be induced by Natural Killer (NK) cells, 
another type of cytotoxic lymphocytes (118).
•	 Bacteria.
In the defence against bacterial infection also T lymphocytes 
(especially Th1 cells) and antibodies play a major role. T 
lymphocytes recognizing the bacteria can release cytokines, 
which enhance the killing capacity of the phagocytes. They are 
also able to activate the specific immunity, thereby stimulating 
B-lymphocytes to produce specific antibodies.
Epithelial cells are thought to interact directly with T cells and 
to regulate their function. In addition to direct physical contact 
between the T cells and epithelial cells, there are several ligand/
receptor molecules expressed on airway epithelial cells, which 
can bind to respective receptor/ligand complements on T 
cells (190). The mechanisms underlying the capacity of epithelial 
cells to present antigens to and to stimulate T cells are unclear. 
Airway epithelial cells express homologues of B7 cosimulatory 
ligands (191, 192).
Heinecke et al. demonstrated that the proinflammatory 
cytokines TNF-alfa and IFN-gamma or IFN-gamma alone, 
selectively increased B7-H1 and B7-DC, but not B7-H2 and  
B7-H3. The inhibition of B7-H1 and B7-DC resulted in 
enhancement of IFN-gamma expression from T cells. Thus,  
B7-H1 and B7-DC on airway epithelial cells functioned to 
regulate T cell activation by inhibiting T-cell production of IFN-
gamma (190).
Van Rossum et al. showed that mice, deficient in Th cells, did not 
clear pneumococcal colonization during a prolonged follow-up 
period (156). Possibly due to lack of induction of a Th1 response, 
which has previously been shown to play a protective role in 
the host response to pneumococcal disease (193). Further it is 
shown that the Th cell mediated acquired immune response 
is independent of the presence of antibodies. Thus indicating 
that the role of antibodies is limited in the clearance of 
pneumococcal colonization (194, 195).
Antibodies are produces against proteins and polysaccharides 
in the cellular membrane and its possible annexes, such as 
fimbriae and flagellae. Together with complement factor C3, 
the antibodies promote opsonisation and facilitate intracellular 
destruction of bacteria. The host can also generate antibodies 
against proteins in the cell wall or proteins, which inhibit the 
phagocytosis of bacteria. Finally, antibodies may also be formed 
against toxins produced by the bacteria (119).
3.2.3.2.6. Cytokines and other mediators
Multiple mediators and cytokines orchestrate the migration 
and activation of immune effector cells in response to infection. 
These proteins regulate chemotaxis, cellular differentiation and 
activation, by induction of adhesion molecule expression and by 
release of cytokines (180).
•	 Viruses.
Next to IFN-alpha and IFN-gamma, high levels of 
proinflammatory and anti-inflammatory cytokines including 
IL-1beta, IL-6, IL-8, IL-10, and TNF-alpha have been recovered 
in nasal secretions and nasal lavage fluids at the time of acute 
viral upper respiratory illnesses caused by RSV, parainfluenza 
virus, rhinovirus, influenza virus, and infections of unspecified 
aetiology (185-188, 196-199).
IL-1beta has a dual effect. It increases rhinovirus spread via 
ICAM-1 upregulation and initiates the host response to infection 
by enhancing the recruitment of immune effector cells into the 
inflammation site. It also induces the release of proinflammatory 
cytokines such as platelet activating factor and IL-8 (179, 200-202).
IL-6 is a proinflammatory cytokine, which has activating and 
proliferating effects  on lymphocytes. IL-8, on the other hand, is 
a strong chemo-attractant for neutrophils (124, 180).
IL-10 is a regulatory cytokine with anti-inflammatory and Th2 
stimulating properties. It can regulate immune responses by 
either preventing an inflammatory response or by limiting 
excessive ongoing inflammation, though inhibition of 
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production of a wide range of other cytokines. For example, 
Th1-related cytokines (TNF-alpha, IFN-gamma, IL-2, and IL-12), 
proinflammatory cytokine IL-18, and Th2-related cytokine IL-5 
(203).
TNF-alpha is also a Th1-related cytokines. It induces activation 
of the antiviral host immune response through the stimulation 
of functional activities of cytotoxic T lymphocytes, NK cells and 
macrophages, and through the recruitment of inflammatory 
cells to the site of infection. Moreover, together with IL-12, it can 
promote the development of Th1 lymphocytes (203). 
In allergic individuals, experimental rhinovirus infection also 
induces increase of granulocyte colony-stimulating factor 
(G-CSF) in nasal secretions and serum. G-CSF and IL-8 were 
rapidly induced in the nose after viral inoculation, and appeared 
to be related to neutrophil trafficking in the airway. Concerning 
G-CSF, it is suggested that either G-CSF contributes to neutrophil 
recruitment to the airway, or that airway neutrophils are a 
source of G-CSF during viral infection. Increases in nasal G-CSF 
also correlated with increases in blood neutrophils, suggesting 
that G-CSF produced in the nose enters the systemic circulation 
and acts on the bone marrow to increase neutrophilia in the 
blood (204, 205). However, Linden et al. confirmed that G-CSF is only 
elevated in virus-infected patients with concomitant allergic 
rhinitis and not in non-allergic individuals (206). 
•	 Bacteria.
Riechelmann et al. evaluated the nasal biomarker profile in 
acute and chronic rhinosinusitis. They determined cellular 
secretory products (inflammatory cell granule-derived 
proteins), IgE and cytokines in nasal secretions. They found high 
concentrations of IL-2, IL-4, IL-10, IL-12, IL-13, TNFα, and IFNγ 
in patients with ARS, compared to subjects with CRS with or 
without nasal polyps (207). 
Van Rossum et al. studies the role of cytokines in the 
clearance of nasal pneumococcal colonization. First of all, 
they investigated the role of IL-12, a potent inducer of Th1 
type response. IL-12, however, was not found to contribute 
to the clearance of the pneumococcal colonization in this 
study. Neither IL-4, a cytokine important in stimulation of a 
Th2 type response, was found to have a role in the clearance 
of colonization. However, these results do not exclude that 
clearance of colonization is Th1 dependent, since IL-12 is not the 
only inducer of a Th1 response (156, 208, 209).
IFN-gamma is also capable of directing the Th cells towards 
a Th1 response and has previously been shown to play an 
important role in the host defence against pulmonary infection 
with S. pneumoniae (156, 208, 209).
Next to IFN-gamma, also IL-17A has a role in the clearance 
of colonization. IL-17A is released by Th17 cells and induces 
mobilization of neutrophils, through induction of granulopoiesis 
and chemokines. In this pathway also IL-23, produced by 
dendritic cells, is involved (194, 210).
3.2.4. Allergy and ARS
As mentioned above, there exists a pathophysiological link 
between AR and rhinosinusitis (130).
•	 Viruses.
Avila et al. studied the effects of allergic inflammation of the 
nasal mucosa on the severity of rhinovirus colds. They found 
that the severity of cold symptoms was highly similar. However, 
the onset of cold symptoms was significantly delayed and the 
duration of cold symptoms was significantly shorter in the 
allergen group. There was no significant difference between 
the two groups in the increase of total cells and percentage 
of neutrophils in nasal lavage fluid. However, these changes 
paralleled the changes in symptoms, that is, they were delayed 
in the allergen group but of similar magnitude in both groups. 
Also the percentage of eosinophils did not increase in either 
group during cold. Cytokine measurement in nasal lavage 
fluid showed increases in IL-8 and IL-6 concentrations during 
common cold in both groups. Again, those changes were 
delayed in the allergen group but were of similar magnitude to 
those seen in the placebo group (211).
Skoner et al. compared the systemic cellular immune responses 
to experimental rhinovirus challenge in AR and non-AR subjects 
(212). They found that rhinovirus infection induced significant 
acute increases in serum IgE, leucocyte histamine release and 
platelet aggregation, but caused no changes in serum IgE, 
serum IgA, serum IgM, and plasma histamine. This change was 
confined to the AR subjects, but there was no evidence that the 
acute rise in total serum IgE was due to an elevation of a pre-
existing, pollen-specific serum IgE antibody (213). 
Alho et al. studied the cellular and structural changes in the 
nasal mucosa during natural colds in subjects with AR and 
susceptibility to recurrent sinusitis, compared to healthy 
controls. They demonstrated that allergic subjects had 
elevated levels of eosinophils in the acute phase compared 
to the control group. The allergic and sinusitis-prone subjects 
also had elevated levels of epithelial T cells and low levels 
of mast cells in convalescence compared to the control 
group. In convalescence, the allergic subjects also had the 
highest numbers of intraepithelial cytotoxic lymphocytes, 
while such cells were absent in the sinusitis-prone subjects. 
The delayed accumulation of intraepithelial T cells could 
indicate a prolonged inflammatory reaction in the allergic and 
sinusitis-prone subjects, compared to the control subjects. 
They hypothesized that this late response of T cells consists of 
virus-specific T cells. The higher level of cytotoxic lymphocytes 
in allergic subjects during convalescence may be related to the 
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more severe mucosal changes in the paranasal sinuses that have 
previously been shown in subjects with AR during viral colds (214).
•	 Bacteria.
Alho et al. showed that subjects with allergic IgE-mediated 
rhinitis had more severe paranasal sinus changes on CT during 
viral colds, than non-allergic subjects (215). The same investigators 
also found a higher proportion of abnormal nasal airflow and 
mucociliary clearance values in allergic subjects during viral 
colds, compared to healthy controls (216). The latter, leading to 
impaired sinus functioning, could explain how allergy increases 
the risk of bacterial ARS.
Table 3.2.1. Inflammatory cells and mediators in Acute Rhinosinusitis (ARS).
Author, year, 
ref.
Tissue/patients Cells Mediators Technique Conclusions
Melvin  
2010 (67)
Nasal epithelial cells of 
allergic ARS patients
Epithelial cells TLR-9 Flow cytometry TLR-9 is increased in allergic 
ARS patients versus allergic 
patients without ARS
Wang 
2009(132)
Nasal epithelial cells, 
Rhinovirus infection
Epithelial cells Adhesion molecules qPCR, confocal 
microscopy
Adhesion molecules are 
increased after rhinovirus 
infection and facilitate bac-
terial infection
Heinecke 
2008 (190)
Epithelial cells, rhino-
virus infection
Epithelial cells B7-H1 and B7-DC qPCR Flow cytom-
etry,
Induction of B7-H1 and B7-
DC expression on airway epi-
thelial cells after rhinovirus 
infection
Carraro 
2007 (176) 
Children with ARS 
and CRS
Nitric Oxide Exhaled  and nasal 
NO
Nasal NO is decreased in ARS 
and CRS and increases after 
antibiotic treatment
Klemens 
2007 (217) 
Nasal secretion, aller-
gic and viral rhinitis  
IL-1β, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-17, 
ECP, GCSF, GM-CSF
ELISA Increased IL-1β, IL-6, IL-7, IL-
17, IFN-γ, TNF-α, IL-8, G-CSF 
and GM-CSF and elastase in 
viral rhinitis.
Khoury  
2006 (218)
Sinonasal mucosa 
mice,  S. pneumoniae
T cells, eosinophils Nasal lavage Bacte-
rial counts
Increased bacterial counts 
when sensitisation is present
Hartmann 
2006 (183)
Nasal tissue in 
controls, viral rhinitis, 
rhinosinusitis
mDC and pDC CD1a, CD11c, CD14, 
CD16, CD19, CD20, 
CD56, CD80, CD86, 
CD123, and HLA-DR
qPCR, flow cytometry pDC  are higher after upper 
respiratory tract infections. 
pDC and mDC are almost 
absent after treatment with 
glucocorticoids
Passariello 
2006 (133) 
Cell culture epithelial IL-6, IL-8, ICAM-1 ELISA HRV promotes internalisa-
tion of S. aureus due to the 
action of cytokines and 
ICAM-1
Riechelman 
2005 (207)
Nasal secretion / hu-
man ARS
IL-12, IL-4, IL-10, 
IL-13
IHC Differential profile between 
ARS and CRS
Perloff  
2005 (219)
Maxillary mucosa 
rabbits
Infection with 
pseudomonas
No Electron microscopy Presence of biofilm on maxil-
lary sinus mucosa
Van Benten 
2005 (203)
RSV infection in atopic 
vs. non atopic children
IL-2, IL-4,  IL-5, IL-8,  
IL-10, IL-12, IL-18, 
IFN-γ TNF-α
cytometric bead 
array
Reduced nasal IL-10 and 
enhanced TNF-α after rhino-
virus and RSV infection
Yu  
2004  (220)
Mice:  S. Pneumonia 
induced ARS and al-
lergic sensitisation
Eosinophils, 
polymorph-nuclear 
cells
Histology Interference of TH2 cells 
with immune response in 
experimental ARS
Ramadan 
2002 (221)
Virus-induced ARS 
(reovirus)
B cells  T Cells No Histology B and T cells interactions are 
still present after D14 and 
D21 confirming delayed im-
mune response
Rudack  
1998 (222)
Sinus mucosa ARS 
surgical cases
No IL-8, IL-1β,  IL-6, IL-5 ELISA Increase IL-8, IL-1β, IL-6 dur-
ing ARS
RSV, respiratory syncytial virus.
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3.3. Diagnosis and Differential Diagnosis of 
ARS
Summary 
ARS is a common condition that is often self-managed by 
patients without medical care being sought, and will usually 
improve spontaneously or with treatment. When patients do 
consult, this is usually to generalist primary care clinicians. The 
diagnosis is clinical and relies on the presence and duration of 
typical symptoms, particularly nasal blockage, discharge, facial 
pain or pressure and reduction in smell. ARS usually occurs as a 
complication of a viral acute upper respiratory tract infection, 
with persistence of symptoms beyond 10 days or worsening 
of symptoms after 5 days. Persistence of symptoms beyond 
12 weeks signifies chronic rather than acute rhinosinusitis. 
Differentiation from other conditions such as viral URTI, 
allergic rhinitis, oro-dental disease and facial pain syndromes 
should be possible in most cases on clinical grounds, although 
investigations may be needed when diagnostic doubt remains. 
Septic complications are rare but serious, and all primary 
care clinicians should be aware of ‘red flag’ symptoms such as 
periorbital oedema and visual symptoms, which require urgent 
specialist assessment. Although antibiotics are commonly 
prescribed in community practice, ARS the symptoms of 
ARS often relate more to inflammation and disruption of 
sinus drainage mechanisms, and in most cases antibiotics is 
not required. Imaging, haematological and microbiological 
investigations and endoscopy are not routinely required in the 
diagnosis of ARS, but may be needed in particular settings, such 
as research studies or in high-risk patients.
3.3.1. Introduction
Post-viral ARS is a common condition in the 
community, usually following viral URTI.
ARS is a common condition, and is usually self-limiting. Many 
patients will self-manage or use over the counter remedies, so 
will not seek medical care or have a formal diagnosis made. 
When medical care is sought, most patients will consult with 
a primary care physician, although in some health systems 
may directly access specialist services. Although educational 
efforts have been made to familiarize General Practitioners 
(GPs) with the concepts of rhinosinusitis and the diagnostic 
criteria for the diagnosis of ARS (223), ‘sinusitis’ is commonly used 
as a diagnostic label, and as this is frequently considered by 
GPs an acute bacterial rather than inflammatory condition (224), 
antibiotics are extensively prescribed (225, 226).  The dissemination 
of the EP3OS (8)  and other recent guidelines (2, 227) emphasizing 
the inflammatory nature of ARS and providing standardization 
of diagnostic criteria and use of investigations has lead to more 
rational diagnosis and management in some (226, 228) but not all 
(229, 230) settings. In addition to misunderstandings concerning the 
inflammatory nature of ARS (229), concern over the risk of septic 
complications from untreated bacterial disease may be a factor 
in the ongoing high use of antibiotics in ARS. Observational 
evidence indicates, however, that complications are rare (231, 232) 
usually manifest early in the course of the illness with severe 
symptoms (233, 234), and that antibiotic treatment of ARS in general 
practice does not prevent complications (52, 232). Guidelines 
agree that in uncomplicated cases, ARS is diagnosed on clinical 
criteria and supplementary investigations are not required (2). In 
particular patient groups and in those with severe or atypical 
symptoms, additional diagnostic procedures may be needed, 
as discussed below. ARS is frequently an isolated clinical event 
and a self-limiting condition, although may be recurrent in some 
cases. There may be an association with dental disease in some 
(61).
3.3.2. Clinical Diagnosis in Primary Care
ARS is diagnosed by the acute onset of typical 
symptoms that include nasal blockage, discharge, 
facial pain or pressure and reduction in smell.
In primary care setting (and for epidemiological research), ARS is 
defined by symptomatology without detailed ENT examination 
or imaging. ARS is defined in section 2 of this guideline by the 
presence of major and minor symptoms for up to 12 weeks. 
ARS is sub-divided into ‘acute viral rhinosinusitis’ (synonymous 
with the ‘common cold’), in which the duration of symptoms 
is less than 10 days, usually a self-limiting condition that 
frequently does not present to clinicians, and ‘acute post-viral 
rhinosinusitis’, defined by an increase in symptoms after 5 days 
or persistence beyond 10 days (8). 
3.3.2.1. Assessment of ARS symptoms
Most acute viral URTI infections are self-limiting, 
and post-viral ARS should not diagnosed before 10 
days duration of symptoms unless there is a clear 
worsening of symptoms after 5 days.
3.3.2.1.1. Symptoms of ARS
The subjective assessment of ARS is based on the presence and 
severity of symptoms.
•	  Nasal blockage, congestion or stuffiness
•	  Nasal discharge or postnasal drip, often mucopurulent
•	  Facial pain or pressure, headache, and
•	  Reduction/loss of smell
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Besides these local symptoms, distant and systemic symptoms 
may occur.
Distant symptoms are pharyngeal, laryngeal, and tracheal 
irritation causing sore throat, dysphonia, and cough, and 
general symptoms including drowsiness, malaise, and fever. 
There is little reliable evidence of the relative frequency of 
different symptoms in ARS in community practice. Individual 
variations of these general symptom patterns are many (235-239). 
Only a small proportion of patients with purulent rhinosinusitis, 
without coexisting chest disease, complain of cough (236). In 
patients with a suspicion of infection, facial or dental pain 
(especially if unilateral) have been found to be predictors of 
acute maxillary sinusitis, when validated by maxillary antral 
aspiration (236) or paranasal sinus radiographs (237)..The symptoms 
of ARS occur abruptly without a history of recent nasal or 
sinus symptoms. A history of sudden worsening of pre-
existing symptoms suggests an acute exacerbation of chronic 
rhinosinusitis, which should be diagnosed by similar criteria and 
treated in a similar way to ARS.
3.3.2.1.2. Subjective assessment of symptoms: severity
Subjective assessment should address the severity and the 
duration of symptoms. The recommended method of assessing 
severity of symptoms is with the use of a visual analogue scale 
(VAS) recorded by the patient on a 10cm line giving a score on 
a measurable continuum of 1 to 10 (see chapter 2.2.3.). Disease-
specific questionnaires measuring quality of life impairment are 
available (240, 241) but not commonly used in clinical practice; a 
good clinician will, however, informally assess the impact of ARS 
on their patient as part of a full clinical assessment. The VAS can 
be used to assess overall symptom severity and the severity of 
individual symptoms (see below). Asking patients to rate their 
symptoms as absent, mild, moderate or severe, may also assess 
symptom severity. 
3.3.2.1.3. Subjective assessment of symptoms: duration
The sudden onset of symptoms of nasal blockage, obstruction, 
congestion and discharge is usually due to a self limiting viral 
infection, and ARS should not be considered in patients who 
have experience symptoms for less than 5 days unless they are 
unusually severe. Post-viral ARS should not be diagnosed in 
patients with symptoms for less than 10 days unless a marked 
worsening of symptoms occurs after 5 days, and features of 
severe pain and a pyrexia of >38°C are present. Symptoms 
occurring for longer than 12 weeks indicate the presence of 
chronic rhinosinusitis.
3.3.2.1.4. Assessment of specific individual symptoms
3.3.2.1.4.1. Individual symptoms 
Nasal obstruction. Although nasal obstruction can be assessed 
objectively with techniques such as rhinomanometry, nasal 
peak inspiratory flow and acoustic rhinometry, these are rarely 
used in the diagnosis and assessment of ARS, which relies on 
patient report of obstruction and subjective assessment of 
severity, either by VAS score or by assessing obstruction as 
absent, mild, moderate or severe.
3.3.2.1.4.2. Individual symptoms: Nasal discharge 
The presence and severity of nasal discharge (anterior or 
posterior nasal drip) is assessed by subjective report, and graded 
by VAS score or by patient subjective assessment as absent, 
mild, moderate or severe. Patient reported purulence of nasal 
discharge has been recommended as a diagnostic criterion for 
acute bacterial rhinosinusitis (227), and is prioritized by GPs as 
a feature indicating the need for antibiotics (226), with limited 
evidence to support this. Purulent nasal secretions have been 
reported to increase the likelihood ratio of radiological sinus 
opacity (237), and of obtaining a positive bacterial culture (242), 
although purulent rhinorrhoea with a unilateral predominance 
has a positive predictive value (PPV) of only 50%, and pus in the 
nasal cavity a PPV of only 17%, in the prediction of a positive 
bacterial culture of an aspirate of the maxillary sinus (236), so 
cannot be relied upon to accurately identify bacterial infection.
3.3.2.1.4.3. Individual symptoms: Smell abnormalities 
Reduction of smell can be rated by patient subjective report as 
a VAS score or assessed as absent, mild, moderate, or severe. 
Subjective report of olfaction correlates well with objective tests 
(243-245)  and loss of olfaction is commonly associated with ARS. 
3.3.2.1.4.4. Individual symptoms: Facial pain and pressure 
Facial pain and pressure commonly occur in ARS, although may 
also occur transiently in self-limiting viral upper respiratory 
tract infection (URTI). Facial or dental pain, especially when 
unilateral, has been found to be a predictor of acute maxillary 
sinusitis with fluid retention in patients with suspected bacterial 
infection when confirmed by maxillary antral aspiration (236) 
or paranasal sinus radiographs (237). Pain on bending forwards 
and maxillary toothache, particularly when unilateral, are often 
interpreted by GPs as indicative of more severe disease and 
the need for antibiotics (226), with limited supportive evidence. 
Maxillary toothache is reported to increase the likelihood ratio 
of radiological sinus opacity to 2.5 (237), although the PPV of local 
unilateral pain for bacterial infection was only 41% in another 
study (236).  A further study reported that maxillary toothache 
was significantly associated with the presence of a positive 
bacteriological culture, predominantly of S. pneumoniae or 
H. influenzae, obtained by sinus aspiration or lavage (246). The 
severity of pain can be rated subjectively by patients as a VAS 
score or as absent, mild, moderate, or severe.
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Bacterial infection may occur in ARS, but in 
most cases antibiotics have little effect on 
the course of the illness.
3.3.2.1.5. Clinical rules for the prediction of bacterial disease
A number of studies have attempted to provide clinicians with 
combinations of symptoms and signs predicting more severe 
disease, particularly in the prediction of a bacterial infection and 
the likelihood of a response to antibiotics. In a study of primary 
care patients aged 15 years or older with a clinical diagnosis 
of ARS which assessed the likelihood of specific symptoms 
and tests in predicting a fluid level or total opacity of any sinus 
on CT (as a gold standard of sinusitis), Lindbaek (247) reported 
four factors having a high likelihood ratio and independently 
associated with ARS. These were purulent rhinorrhoea, purulent 
secretion in cavum nasi, a raised ESR (>10), and  ‘double 
sickening’ (i.e. a deterioration after an initial milder phase of 
illness). A combination of at least three of these four symptoms 
and signs gave a specificity of 0.81 and a sensitivity of 0.66 for 
ARS. 
Berg (236) reported that 2 or more positive findings (from 
purulent rhinorrhoea with unilateral predominance, local 
pain with unilateral predominance, pus in the nasal cavity 
and bilateral purulent rhinorrhoea) provided 95% sensitivity 
and 77% specificity for ABRS. Williams (237) reported that fewer 
than 2 symptoms (from maxillary toothache, poor response 
to antihistamines or decongestants, purulent nasal secretions, 
abnormal transillumination and coloured nasal discharge) ruled 
out ABRS with a positive predictive value (PPV) of <40%, and 4 
or more symptoms ruled in ABRS (PPV, 81%).
3.3.2.2. Clinical examination
3.3.2.2.1. Anterior rhinoscopy
Although anterior rhinoscopy alone is a very limited 
investigation, it should be performed in primary care setting 
as part of the clinical assessment of suspected ARS. It may 
reveal supportive findings such as nasal inflammation, mucosal 
oedema and purulent nasal discharge, and can sometimes 
reveal previously unsuspected findings such as polyps or 
anatomical abnormalities.
3.3.2.2.2. Temperature
The presence of a fever of  >38°C indicates the presence of 
a more severe illness and the possible need for more active 
treatment, particularly in conjunction with more severe 
symptoms. A fever of >38°C is significantly associated with the 
presence of a positive bacteriologic culture, predominantly  
S. pneumoniae and H. influenzae, obtained by sinus aspiration or 
lavage (246).
3.3.2.2.3. Inspection and palpation of sinuses
Inspection and palpation of the maxillofacial area can reveal 
swelling and tenderness, which are commonly interpreted as 
indicating more severe disease (226) and the need for antibiotics, 
although the sensitivity and specificity of this symptom in the 
identification of ABRS is not established.
3.3.2.2.4. Nasal endoscopy
Nasal endoscopy is not generally available in routine primary 
care settings, and is not required in the clinical diagnosis of ARS, 
although may be required in research settings, and is discussed 
below.
3.3.2.3. Additional Investigations
3.3.2.3.1. Bacteriology
Microbiological investigations are not required for the diagnosis 
of ARS in routine practice, although may be required in 
research settings, or in atypical or recurrent disease. There is 
a reasonable correlation between specimens taken from the 
middle meatus under endoscopic control and sinus taps (248), 
and microbiological sampling may be indicated in more severe, 
recurrent or complicated presentations.
3.3.2.3.2. Imaging
Imaging studies and not required in the diagnosis of ARS in 
routine practice, although may be required to confirm the 
diagnosis in research settings, and are discussed further below.
3.3.2.3.3. C-Reactive Protein (CRP)
CRP is a haematological biomarker (available as rapid assay 
near-patient testing kits) and is raised in bacterial infection. 
Its use has been advocated in respiratory tract infection (247) 
as an aid to targeting bacterial infection and so in limiting 
unnecessary antibiotic use. Recent studies (249, 250) have 
suggested that in ARS, a low or normal CRP may identify 
patients with a low likelihood of positive bacterial infection who 
are unlikely to need or benefit from antibiotics, and CRP guided 
treatment has been associated with a reduction in antibiotic use 
without any impairment of outcomes.  This can be regarded as 
an interesting but preliminary observation, and more research is 
needed before this test can be recommended as routine in the 
diagnosis of ARS and in the targeting of therapy. However, CRP 
levels are significantly correlated with changes in CT scans (251) 
and a raised CRP is predictive of a positive bacterial culture on 
sinus puncture or lavage (246, 252).
3.3.2.3.4. Procalcitonin
Procalcitonin has also been advocated as a potential 
haematological biomarker indicating more severe bacterial 
infection, and investigated as a tool for guiding antibiotic 
prescribing in respiratory tract infections in the community (253). 
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It is available as a near-patient manual assay that can provide 
results in 30 minutes, but with limited performance results (254), 
or as a laboratory test. At present, however, there is no evidence 
of its effectiveness as a biomarker in ARS.
3.3.2.3.5. Erythrocyte Sedimentation Rate (ESR) and plasma 
viscosity
Markers of inflammation such as ESR and plasma viscosity are 
raised in ARS, may reflect disease severity and can indicate the 
need for more aggressive treatment in a similar way to CRP. ERS 
levels are correlated with CT changes in ARS (251) and an ESR of  
>10 is predictive of sinus fluid levels or sinus opacity on CT scans 
(252). A raised ESR is predictive of a positive bacterial culture on 
sinus puncture or lavage (246, 252).
3.3.2.3.6. Nasal Nitric Oxide (NO)
This gaseous metabolite is found in the upper and lower 
respiratory tract and is a sensitive indicator of the presence of 
inflammation and ciliary dysfunction. Measurement of nasal 
NO is relatively simple, requires simple patient co-operation 
by exhaling into the analyser, and is quick and easy to perform 
using chemiluminescence assay equipment. Measurement 
is feasible in routine clinical settings, and as the technology 
improves and cost of measurement apparatus reduces, may 
be practicable as a clinical tool.  Preliminary evidence exists of 
feasibility of using exhaled NO measurement in primary care 
in asthma diagnosis and monitoring (255), but the feasibility of 
use of nasal NO in routine care has not been assessed. Very 
low levels of nasal NO may indicate primary ciliary dyskinesia, 
but may also occur insignificant sinus obstruction (256). Elevated 
levels may suggest the presence of inflammation provided 
ostiomeatal patency is maintained. A recent pilot study (257) has 
suggested that monitoring of nasal NO levels may be useful in 
the diagnosis and management of ARS, but further research is 
needed.
3.3.2.3.7. Other investigations
Detailed tests of nasal airway function such as tests of 
mucociliary function, nasal patency, and olfaction are rarely 
performed in the diagnosis of ARS other than in specific 
research settings.
3.3.2.4. Differential Diagnosis of ARS in clinical practice
The symptoms of ARS are non-specific and may overlap with a 
number of other conditions, which should be differentiated.  
3.3.2.4.1. Viral Upper Respiratory Tract Infection (URTI)
The symptoms of the common cold and of self-limiting viral 
URTIs overlap with those of post-viral ARS. Indeed, most 
episodes of ARS will start as a viral URTI, but with a prolonged 
illness beyond 10 days or with worsening symptoms after 
5 days. Most common colds are associated with rhinovirus 
infection with symptoms peaking by 3 days (258), and the majority 
of patients do not seek medical care. The diagnosis is clinical 
and supportive advice, symptomatic treatment and reassurance 
are generally the only interventions required.
3.3.2.4.2. Allergic rhinitis
Allergic rhinitis (AR) is a common global condition affecting 
10-20% of the adult population (259). Allergic rhinitis is the most 
common form of non-infectious rhinitis and is associated with 
an IgE-mediated immune response against allergens, and is 
often associated with ocular symptoms. Since the nasal mucosa 
is continuous with that of the paranasal sinuses, congestion of 
the ostia may result in sinusitis, which does not exist without 
rhinitis, so AR may be part of an allergic rhinosinusitis with 
similar symptoms to those of ARS (and CRS). Symptoms of AR 
include rhinorrhoea (non-purulent), nasal obstruction, nasal 
itching, and sneezing, which are reversible spontaneously 
or with treatment. AR is subdivided into “intermittent” or 
“persistent” disease. Intermittent rhinitis may occur suddenly 
in response to exposure to a specific allergen, and so cause 
diagnostic confusion between AR and ARS. Seasonal AR is 
related to a wide variety of outdoor allergens such as pollens or 
molds, and sudden exposure to such aeroallergens or to others 
(e.g. cat and dog dander in sensitized individuals) can cause 
acute onset of symptoms. In AR, there will usually be a history 
of similar symptoms in response to similar exposures, often with 
a seasonal pattern. Non-specific irritants such as air pollution 
and viral infection may aggravate symptoms in symptomatic AR 
patients and induce symptoms in asymptomatic patients with 
subclinical nasal inflammation. 
The diagnosis of AR and differentiation from ARS is made 
mainly on the basis of a prior history of allergy and atopy, and 
exposure to an allergen (usually an aeroallergen) to which the 
patient is sensitized. Ocular symptoms are common in AR, in 
particular in patients allergic to outdoor allergens, but not in 
ARS. Mucopurulent rhinorrhoea, pain, nasal obstruction without 
other symptoms and anosmia are uncommon in AR. Diagnostic 
tests for AR are based on the demonstration of allergen-specific 
IgE in the skin (skin tests) or the blood (specific IgE), and may 
be considered to clarify the diagnosis, particularly in those with 
severe or persistent symptoms. 
3.3.2.4.3. Orodontal disease
Patients with orodontal disease may present to primary care 
physicians with ill-defined facial pain, with or without fever and 
toothache. The absence of other ARS-associated symptoms such 
as rhinorrhoea, nasal discharge and smell disturbance will make 
ARS a less likely diagnosis, although in some cases doubt may 
persist. A dental assessment and dental radiography may be 
required to clarify the diagnosis. ARS may occur more frequently 
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and have overlapping symptoms in patients with orodental 
disease (61). 
3.3.2.4.4. Rare diseases
A number of less common conditions may occasionally present 
acutely with similar symptoms to ARS.
3.3.2.4.4.1. Intracranial sepsis 
Intracranial sepsis is uncommon but it is crucial that primary 
care practitioners are aware of the warning signs of complicated 
and severe illness and refer promptly when the diagnosis is 
possible. Symptoms such as periorbital oedema, displaced 
globe, diplopia, ophtalmoplegia, reduced visual acuity, severe 
unilateral or bilateral frontal headache, frontal headache, focal 
neurological signs or meningism point to complications such as 
intracranial sepsis, or an alternative diagnosis and requite urgent 
diagnosis and appropriate management. (See Table 3.3.1).
3.3.2.4.4.2. Facial pain syndromes 
A number of conditions can present acutely with facial pain and 
nasal symptoms, including migraine and cluster headaches. 
The differential diagnosis of facial pain is discussed in section 4. 
Bilateral pressure sensations without other nasal symptoms may 
be caused by tension headaches and mid facial segmental pain. 
3.3.2.4.4.3. Vasculitis 
Autoimmune vasculitides such as Wegener’s granulomatosis 
and Churg-Strauss syndrome or sarcoidosis may involve the 
nose and sinuses and on rare occasions may present acutely. The 
presence of other suggestive symptoms and an atypical clinical 
course can alert the clinician to alternative diagnoses.
3.3.2.4.4.4. Acute invasive fungal rhinosinusitis 
In immunosuppressed patients and in (uncontrolled) diabetics, 
acute invasive fungal rhinosinusitis may present in a similar 
way to ARS, but with severe and rapidly progressive symptoms 
(260, 261). When this diagnosis is suspected, a more aggressive 
diagnostic approach is required as a delay in diagnosis worsens 
the prognosis. 
3.3.2.4.4.5. CSF leak 
Unilateral watery rhinorrhoea is uncommon and should raise 
suspicion of cerebrospinal fluid leakage (262).
3.3.3. Warning signs of complications of ARS
Septic complications of ARS represent a medical emergency 
and require prompt recognition by generalists and immediate 
referral to secondary care for assessment (Table 3.3.1). 
Observational surveys suggest that these complications occur 
rarely but early in the course of the disease, and that outcomes 
are not influenced by the use or non-use of antibiotics in 
primary care (232, 234). 
Septic complications of ARS are uncommon, 
but vital to identify early. They occur early in the 
course of the illness and primary care 
clinicians need to be vigilant for danger signs and 
symptoms, such as high fever, systemic illness, 
periorbital oedema and reduced vision
3.3.4. Enhanced Diagnosis in specialist care
Although uncomplicated ARS is more likely to present to 
primary care physicians, in some health systems patients may 
present acutely to specialists or may be referred early for a 
specialist assessment, usually to a rhinologist or ENT specialist. 
Generally the diagnosis may be made clinically using the same 
clinical criteria outlined above, but sometimes more detailed 
diagnostic investigations may be applied. Immediate referral 
and/or hospitalization are indicated for any of the symptoms 
listed in table 3.1.1.
3.3.4.1. Nasal endoscopy
Nasal endoscopy may be used to visualize nasal and sinus 
anatomy and to provide biopsy and microbiological samples. 
Several microbiology studies (263-267) (Evidence Level IIb) have 
shown a reasonable correlation between specimens taken 
from the middle meatus under endoscopic control and 
proof puncture leading to the possibility of microbiological 
confirmation of both the pathogen and its response to 
therapy (Table 3.3.2). A meta-analysis showed an accuracy 
of 87% with a lower end confidence level of 81.3% for the 
endoscopically directed middle meatal culture when compared 
with maxillary sinus taps in acute maxillary sinus infection 
(248). Some authorities recommend that a clinical diagnosis of 
acute bacterial rhinosinusitis should always be confirmed by 
endoscopy and culture (268), as many patients with clinical or 
Table 3.3.1. Warning symptoms of complications in ARS requiring imme-
diate referral / hospitalization.
Periorbital oedema/erythema
Displaced globe
Double vision
Ophtalmoplegia
Reduced visual acuity
Severe unilateral or bilateral frontal headache
Frontal swelling
Signs of meningitis
neurological signs
Reduced consciousness
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radiological evidence of ARS do not have positive bacterial 
microbiology; since this guideline favours the term ‘acute post-
viral rhinosinusitis’, and favours anti-inflammatory rather than 
anti-infective therapy as first-line management, it is debatable 
how valid this advice is, particularly in settings where access to 
endoscopy is limited. Nasal endoscopy is possible in patients 
of all ages, including children, although does not provide 
additional information in most (269, 270).
3.3.4.2. Imaging
A number of different imaging modalities are possible in the 
diagnosis of ARS.
3.3.4.2.1. CT scanning
CT scanning is the imaging modality of choice to confirm the 
extent of pathology and the anatomy. However, it should not be 
regarded as the primary step in the diagnosis of the condition, 
except where there are unilateral signs and symptoms or other 
sinister signs, but rather corroborates history and endoscopic 
examination after failure of medical therapy. CT may be 
considered in very severe disease, in immuno-compromised 
patients, when there is suspicion of complications. A recent 
study suggests that routine CT scanning in ARS adds little useful 
information (251). The demonstration of the complex sinonasal 
anatomy has however, been regarded as at least as important 
as confirmation of inflammatory change (272-274). Considerable 
ethnic as well as individual differences may be encountered (275). 
Many protocols have been described and interest has recently 
centered on improving definition whilst reducing radiation dose 
(276). Incidental abnormalities have been reported on scanning 
in up to a fifth of the ‘normal’ population (277), although more 
recent data have suggested that healthy normal people should 
not have unexpected abnormal sinus scans (278). In children, in 
whom plain radiographs are technically difficult, sinus scans are 
technically possible and are the imaging investigation of choice 
but similarly are only indicated if complications are suspected or 
if a lack of response to treatment occurs (279).
3.3.4.2.2. Plain sinus X Rays and transillumination
Plain sinus x-rays are insensitive and of limited usefulness 
for the diagnosis of rhinosinusitis due to the number of false 
positive and negative results (280-282). Nevertheless it can be 
useful to prove ARS in research studies. Transillumination was 
advocated in the 1970’s as an inexpensive and efficacious 
screening modality for sinus pathology (283). The insensitivity 
and unspecificity makes it unreliable for the diagnosis of 
rhinosinusitis (284).
3.3.4.2.3. Ultrasound
Sinus ultrasound is insensitive and of limited usefulness for 
the diagnosis of ARS due to the number of false positive and 
negative results. However, the results in well-trained hands are 
comparable to X-ray in the diagnostics of ARS, and so it may be 
a useful investigation in some settings (285-287).
3.3.5. ARS diagnosis specific settings
3.3.5.1. Diagnosis for research
In research settings, a more formal diagnosis may be required. 
In such settings, a variable combination of symptoms, imaging 
findings, examination findings, and bacteriology samples 
(obtained from middle meatus or from sinus puncture) may be 
required for confirmation of the diagnosis as specified in the 
study protocol. The diagnostic criteria used must be specified in 
research studies to allow comparison of results between studies.
3.3.5.2. Diagnosis in the intensive care unit
ARS is common in ICU (with risk factors including naso-gastric 
tubes, mechanical ventilation, failure of defence mechanisms 
and pronged supine posture), and is associated with poor 
outcomes. Sepsis may involve multiple sinuses (288). As a 
consequence, more aggressive diagnostic processes may be 
appropriate to confirm the diagnosis and to guide treatment. CT 
Table 3.3.2. Bacteriology of rhinosinusitis. Correlation of middle meatus versus maxillary sinus. 
Author, year, ref. Number of Samples Type of Rhinosinusitis Technique Concordance
Joniau 2005 (267) 26 ARS Endoscopic swab (MM) vs. maxillary sinus tap 88.5%
Casiano 2001 (266) 29 ARS (intensive care) Endoscopic tissue culture (MM) vs. maxillary sinus 
tap
60.0%
Talbot  2001 (271) 46 ARS Endoscopic swab (MM) vs. maxillary sinus tap 90.6%
Vogan  2000 (265) 16 ARS Endoscopic swab (MM) vs. maxillary sinus tap 93.0%
Gold & Tami 1997 (264) 21 CRS Endoscopic tap (MM) vs. maxillary aspiration during 
ESS
85.7%
Klossek 1996 (263) 65 CRS Endoscopic swab (MM) vs. maxillary aspiration 
during ESS
73.8%
ARS: acute rhinosinusitis; CRS: chronic rhinosinusitis
MM: middle meatus; ESS: endoscopic sinus surgery
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scanning may confirm the diagnosis (289), and sinus puncture is 
safe in skilled hands and can provide important microbiological 
information to confirm the diagnosis and guide therapy (288). 
3.3.5.3. Diagnosis in immunosuppressed patients
Immunosuppressed patients are much more vulnerable  to 
complications of ARS, and a more aggressive diagnostic 
approach is required. Acute invasive fungal rhinosinusitis (290) is a 
serious disease with high mortality and morbidity and requires 
prompt diagnosis and treatment with open or endoscopic sinus 
surgery. 
The diagnosis is histopathological, so early endoscopic 
evaluations indicated, with open biopsy if doubt remains (260, 261).
3.3.6. Recurrent ARS
The differentiation between CRS and recurrent ARS can be 
difficult, but relies on complete resolution of symptoms and 
signs between episodes. Some patients do have recurrent 
episodes of ARS, and may represent a distinct phenotype (291). 
Such patients should be assessed for underlying risk factor, such 
as allergy and anatomical abnormalities (60), with consideration 
of imaging or endoscopic evaluation. Occult immunodeficiency 
may rarely occur in such patients, but routine screening has a 
low yield (292).
3.4. Management of ARS
Summary 
The introduction of evidence-based management of ARS 
has a major impact on the physician’s management of ARS 
patients. It has been proven clearly in many clinical studies 
that ARS resolves without antibiotic treatment in most cases. 
Symptomatic treatment and reassurance is the preferred 
initial management strategy for patients with mild symptoms. 
Intranasal corticosteroids in monotherapy or in adjuvant 
therapy to oral antibiotics are proven to be effective; however, 
in patients with severe ARS, oral corticosteroids can be used 
for short-term relief of headache, facial pain and other acute 
symptoms. Antibiotic therapy should be reserved for patients 
with high fever or severe (unilateral) facial pain. For initial 
treatment, the most narrow-spectrum agent active against 
the likely pathogens should be used. Herbal compounds have 
been commonly used in treatment of ARS, but only a few DBPC 
randomized studies have shown their efficacy. Hence, the 
benefit of herbal compounds in treatment of ARS need to be 
confirmed by more well designed and randomized clinical trials 
in future. 
3.4.1. Introduction
ARS is a common disease that is managed in both primary 
care and specialized clinics, and by general practitioners (GPs), 
Table 3.4.1. Evidence from systemic review or meta-analysis for antibiotics in treatment of Acute Rhinosinusitis (ARS).
Authors, year, ref.  Inclusion criteria Number of Conclusion
Studies Patients/ 
placebo
Falagas, et al. 2009 (298) RCTs 12 4,430 Short-course antibiotic treatment had comparable effectiveness 
to a longer course of therapy
Falagas, et al. 2008 (345) RCTs 17 2,648 Antibiotics should be reserved for carefully selected patients 
with a higher probability for bacterial disease
Burton, et al. 2008 (346) Extracts from the 
Cochrane library
NA NA A small treatment efficacy in patients with uncomplicated ARS
Ahovuo-Saloranta, et al. 
2008 (297)
RCTs 5 631 Antibiotics have a small treatment efficacy in patients with 
uncomplicated ARS. 80%patients improve within two weeks 
without antibiotics
Young, et al. 2008 (295) RCTs 9 2,547 Antibiotics are not justified even if a patient reports symptoms 
for longer than 7-10 days
Williams JW Jr, et al. 
2008 (299)
RCTs 49 13,660 For acute maxillary sinusitis confirmed radio-graphically or by 
aspiration, current evidence is limited but supports the use of 
penicillin for 7 to 14 days
Rosenfeld, et al. 
2007 (347)
DBPC randomized 
trials
13 NA Over 70% of patients with ARS are improved after 7 days, with or 
without antimicrobial therapy
Arroll B. 2005 (348) Review of the Co-
chrane reviews 
4 NA The use of antibiotics for acute purulent rhinitis and acute maxil-
lary sinusitis seems to be discretionary rather than prohibited or 
mandatory, at least for non-severe cases
Stalman, et al. 1997 (349) DBPC randomized 
trials
3 NA The effectiveness of antibiotic treatment in acute maxillary si-
nusitis in a general practice population is not based sufficiently 
on evidence
RCTs: randomized controlled trials; DBPC: double-blind, placebo-controlled; NA: not applicable
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otolaryngologists and paediatricians. Therefore, consensus in 
the management of ARS amongst GPs and different specialists 
who commonly treat ARS is very important. However, it needs to 
be noticed that when analysing studies for scientific evidences 
in the treatment of ARS (no matter of the investigated drug) 
several of them present a mixture of patients with common cold 
and either post-viral or bacterial ARS (i.e. corticosteroids and 
antibiotics in ARS, Williamson IG 2007 (312)). 
ARS resolves without antibiotic treatment in 
most cases. Symptomatic treatment and reassu-
rance is the preferred initial management strategy 
for patients with mild symptoms.
It has been stated clearly in position papers and various meta-
analyses that ARS resolves without antibiotic treatment in most 
cases (8, 293-295). Symptomatic treatment and reassurance is the 
preferred initial management strategy for patients with mild 
symptoms. Antibiotic therapy should be reserved for patients 
with high fever or severe (unilateral) facial pain. For initial 
treatment, the most narrow-spectrum agent active against the 
likely pathogens (Streptococcus pneumoniae and Haemophilus 
influenzae) should be used, rather than a general broad-
spectrum agent (293).
3.4.2. Treatment of ARS with antibiotics
According to data from a National Ambulatory Medical Care 
Survey (NAMCS) in the USA, rhinosinusitis is the fifth most 
common diagnosis for which an antibiotic is prescribed. In 
2002, rhinosinusitis accounted for 9% and 21% of all paediatric 
and adult antibiotic prescriptions respectively (296), although 
the usage of antibiotics in the treatment of mild, moderate 
or uncomplicated ARS has been shown to be not useful by 
most randomized controlled studies (Table 3.4.1) and is not 
recommended by almost all clinical guidelines (8, 293-296). A recent 
multi-nations study in Asia showed that overuse of antibiotics 
is still an alarming problem among GPs, otolaryngologists, and 
paediatricians (9). 
A recent Cochrane study was performed to compare antibiotics 
against placebo, or between antibiotics from different classes in 
the treatment of acute maxillary sinusitis in adults (297). A total of 
59 studies were included in this review; six placebo-controlled 
studies and 53 studies comparing different classes of antibiotics 
or comparing different dosing regimens of the same antibiotic. 
Among them, 5 studies involving 631 patients provided data for 
comparison of antibiotics to placebo, where clinical failure was 
defined as a lack of cure or improvement at 7 to 15 days follow 
up. These studies found a slight statistical difference in favour of 
antibiotics, compared to placebo, with a pooled risk factor (RR) 
of 0.66 (95% confidence interval (CI) 0.44 to 0.98). However, the 
clinical significance of the result is equivocal, also considering 
that cure or improvement rate was high in both the placebo 
group (80%) and the antibiotic group (90%).
Based on six studies, where clinical failure was defined as a 
lack of total cure, there was significant difference in favour of 
antibiotics compared to placebo with a pooled RR of 0.74 (95% 
CI 0.65 to 0.84) at 7 to 15 days follow up. None of the antibiotic 
preparations was superior to another. This study concluded 
that antibiotics have a small treatment effect in patients with 
uncomplicated ARS in a primary care setting with symptoms 
for more than seven days. Eighty percent of patients treated 
without antibiotics improve within two weeks. Clinicians need 
to weigh the small benefits of antibiotic treatment against the 
potential for adverse effects at both the individual and general 
population level (297). 
Although antibiotics for ARS should be reserved for selected 
patients with substantial probability of bacterial disease, 
accurate clinical diagnosis is often difficult to attain. Short-
course antibiotic treatment had comparable effectiveness 
to a longer course of therapy for ARS. Shortened treatment, 
particularly for patients without severe disease and 
complicating factors, might lead to fewer adverse events, better 
patient compliance, lower rates of resistance development and 
fewer costs (298).
In an earlier Cochrane study (299), the authors aimed to examine 
whether antibiotics are indicated for ARS, and if so, which 
antibiotic classes are most effective. Primary outcomes were: 
a) clinical cure, and b) clinical cure or improvement. Secondary 
outcomes were radiographic improvement, relapse rates, and 
dropouts due to adverse effects. 
A total of 49 trials, involving 13,660 participants, were evaluated 
with antibiotic treatment for acute maxillary sinusitis. Compared 
to controls (5 studies), penicillin improved clinical cures (relative 
risk (RR) 1.72; 95% CI 1.00 to 2.96). Treatment with amoxicillin 
did not significantly improve cure rates (RR 2.06; 95% CI 0.65 
to 6.53) but there was significant variability between studies. 
Radiographic outcomes were improved by antibiotic treatment. 
Comparisons between classes of antibiotics (10 studies) showed 
no significant differences between newer non-penicillins 
(cephalosporins, macrolides, minocycline) versus penicillins 
(amoxicillin, penicillin V) with RR for cure 1.07 (95% CI 0.99 to 
1.17); and newer non-penicillins versus amoxicillin-clavulanate 
(RR for cure 1.03; 95% CI 0.96 to 1.11). Compared to amoxicillin-
clavulanate (17 studies), dropouts due to adverse effects were 
significantly lower for cephalosporin antibiotics (RR 0.47; 95% 
CI 0.30 to 0.73). Relapse rates within one month of successful 
therapy were 7.7%. The authors conclude that, for acute 
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maxillary sinusitis confirmed radiographically or by aspiration, 
current evidence is limited but supports the use of penicillin 
or amoxicillin for 7 to 14 days. Clinicians should weigh the 
moderate benefits of antibiotic treatment against the potential 
for adverse effects (299).
Antibiotic therapy should be reserved for 
patients with severe ARS, especially with the 
presence of high fever or severe (unilateral) facial 
pain. Clinicians should weigh the moderate 
benefits of antibiotic treatment against the 
potential for adverse effects.
Comparison between various antibiotics in term of their 
dose and duration, efficacy and side-effect of treatments are 
summarized in three tables, where a total of 42 prospective, 
randomized, double-blind, placebo controlled (n=9, Table 
3.4.2), or comparisons between antibiotics (n=25, Table 3.4.3), 
or comparisons of different dosages (n=5) or durations (n=3) 
of treatment (Table 3.4.4) are listed. In general, a short-course 
treatment, particularly for patients without severe disease and 
complicating factors, might lead to fewer adverse events, better 
patient compliance, lower rate of resistance development and 
fewer costs (298).
Table 3.4.2. Studies on “short-term” antibiotics, compared to placebo, used in the treatment of Acute Rhinosinusitis (ARS). Only studies with a design 
of prospective, randomized, double-blind, and placebo-controlled (Ib) were selected. 
Author, year, ref. Drug Dose / Duration Number of 
patients
Effects Side effects % Level of 
evidence
Outcomes %
Hadley 2010 (350) Moxifloxacin 5 days 73 Clinical success 
rates
78.1 38.2 Ib
Placebo 45 66.7 40.7
Wald 2009 (351) Amoxicillin/
potassium clavu-
lanate
90mg/kg  + 6.4mg/
kg for 14 days
28 Cure 50 Ib
Placebo 28 14
Kristo  2005 (352) Cefuroxime axetil 125mg BD/10 days Complete 
cure, absence 
of prolonged 
symptoms/com-
plications
Differ-
ence of 
6%
Ib
Bucher 2003 (353) Amoxicillin/cla-
vulanic acid
875/125mg BD  /6 
days
252 Time to cure, 
number of days of 
activity restric-
tion, frequency of 
adverse effects
Adjusted 
hazard 
ratio = 
0.99
Ib
Placebo 6 days
Varonen 2003 (354) Antibiotics 
(amoxicillin, 
doxycycline or 
penicillin V)
750 mg, 100mg, 
1500 mg BD/7 days
146 Clinical cure rates 
at test-of-cure 
visit
80 Ib
Placebo BD/7 days 66
Hansen 2000 (355) Penicillin V 133 Pain score, illness 
score, CRP/ESR
71 Ib
Placebo 37
Stalman 1997 (349) Doxycycline Resolution of 
facial pain and 
resumption of 
daily activities
Adjusted 
hazard 
ratio of 
1.17, 1.31
17% Ib
Placebo
Lindbaek 1996 (356) Penicillin V and 
amoxicillin
83 Subjective status, 
difference in clini-
cal severity score
86 Ib
Placebo 44 57
Wald 1986 (357) Amoxicillin 30 Clinical assess-
ment at 3 and 10 
days
67 Ib
Amoxicillin-
clavulanate 
potassium
28 64
Placebo 35 43
BD: twice daily; CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate
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Table 3.4.3. Studies on “short-term” antibiotics, compared to other antibiotics, used in the treatment of ARS. Only studies with a design of prospective, 
randomized, double-blind (Ib) were selected.
Author, year, ref. Drug Dose/Duration Number of 
Patients
Effects Side-Effects % Level of 
Evidence
Outcomes %
Marple, et al. 
2007 (358)
Azithromycin ER Single 2g dose 270 Resolution of > or 
= 3 rhinosinusitis 
symptoms
32.6 23.3 Ib
Levofloxacin 500 mg QD/10 days 261 23.4 15.3
Upchurch, et al. 
2006 (359)
Faropenem medox-
omil
300mg BD/10 days 861 Clinical response 81.8 similar Ib
Cefuroxime axetil 250mg BD/10 days 74.5
Tellier, et al. 
2005 (360)
Telithromycin 800mg OD/5 days Clinical cure and 
bacteriologic eradi-
cation rates
80.9% Similar, mostly 
GIT
Ib
Amoxicillin - clavu-
lanate
500/125mg TDS/10 
days
77.4%
Cefuroxime axetil 250mg BD/10 days
Murray, et al. 
2005 (361)
Azithromycin micro-
sphere
Single 2g dose 256 Clinical efficacy at 
the test-of-cure visit
94.5 lb
Levofloxacin 500mg OD/10 days 251 92.8
Henry, et al. 
2004 (362)
Cefdinir 600mg OD/10 days 123 Clinical and radio-
logic response at 
Test-of-cure visit
83 8 Ib
Levofloxacin 500mg OD/10 days 118 86 1
Gehanno, et al. 
2004 (363)
Pristinamycin 1g bid/4 days 220 Clinical cure rates 91.4 Ib
Cefuroxime axetil 250mg bid/5 days 214 91.1
Ferguson, et al. 
2004 (364)
Telithromycin 800mg OD/5 days 349 Clinical cure rates at 
test-of-cure visit
87.4 lb
Moxifloxacin 400mg OD/10 days 86.9
Buchanan, et al. 
2003 (365)
Telithromycin 800mg OD/5 days 593 Clinical cure rates at 
test-of-cure visit
85.2 lb
Cefuroxime axetil 250mg BD/10 days 82
Luterman, et al. 
2003 (366)
Telithromycin 800mg OD/5 days 434 Clinical cure rates at 
test-of-cure visit
~75 Similar fre-
quency, GIT
Ib
Telithromycin 800mg OD/10 days ~75
Amoxicillin/clavu-
lanic acid
500/125mg TDS/10 
days
~75
Henry, et al. 
2003 (367)
Azithromycin 500mg OD/3 days 312 NA 88.8 Azithromycin 
was better 
tolerated than 
amoxicillin/
clavulanic 
acid
Ib
Azithromycin 500mg OD/6 days 311 NA 89.3
Amoxicillin/clavu-
lanic acid
500/125mg TDS/10 
days
313 NA 84.9
Siegert, et al. 
2003 (368)
Faropenem 
daloxate
300mg BD/7 days 452 Clinical cure rates at 
test-of-cure visit
89 2.2 (diar-
rhoea)
Ib
Cefuroxime axetil 250mg BD/7 days 88.4 2.9
Klossek, et al. 
2003 (369)
Moxifloxacin 400mg OD/7 days 452 Clinical cure rates at 
test-of-cure visit
96.9 16.9 Ib
trovafloxacin 200mg OD/10 days 92.1 22.3
Siegert, et al. 
2000 (370)
Moxifloxacin 400mg OD/10 days 242 Clinical cure rates at 
test-of-cure visit
96.7 5.7 lb
Cefuroxime axetil 250mg BD/10 days 251 90,7 4.4
Burke, et al. 
1999 (371)
Moxifloxacin 400mg OD/10 days 223 Clinical cure rates at 
test-of-cure visit
90 37 lb
Cefuroxime axetil 250mg BD/10 days 234 89 26
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Antibiotics overuse has been reported in some European 
countries (300, 301) to have directly resulted in an increased 
prevalence of antimicrobial resistance in Europe (302, 303). 
Although such data is still unavailable in Asia, a recent survey 
study showed that, even for mild ARS (common cold), medical 
treatments were still recommended by 87% of GPs, 83.9% 
of otolaryngologists, and 70% of paediatricians (9). The top 
three first-line treatments prescribed were antihistamines 
(39.2%), nasal decongestants (33.6%), and antibiotics (29.5%). 
Antibiotics usage was much more often used as the first line 
treatment of moderate (45.9%) and severe (60.3%) ARS. Even 
more alarmingly, 13.6% of the participants used a combination 
of more than two antibiotics classes for treatment of even mild 
ARS. 
The global threat posed by resistant microorganisms has 
Author, year, ref. Drug Dose/Duration Number of 
Patients
Effects Side-Effects % Level of 
Evidence
Outcomes %
Henry, et al. 
1999 (373)
Cefuroxime axetil 250mg BD/10 days 132 Clinical cure rates at 
test-of-cure visit
equal 29 lb
Amoxicillin/clavu-
lanate
500/125mg TDS/10 
days
131 17
Clifford, et al. 
1999 (374)
Ciprofloxacin 500mg BD/10 days, 
placebo 4 days
236 Clinical success ob-
served 6-10 days 
after therapy
84 Ib
221Clarithromycin 500mg BD, 14 days 91
Henry, et al. 
1999 (375)
Sparfloxacin 400mg dose on 
day 1, 200mg OD/9 
days
252 Clinical success ob-
served 6-10 days 
after therapy
83.1 59.7 lb
Clarithromycin 500mg BD/14 days 252 83.4 48.4
Lasko, et al. 
1998 (372)
Levofloxacin 500mg OD/10-14 
days
117 Clinical cure rates at 
test-of-cure visit
93.9 22.5 Ib
Clarithromycin 500mg BD/10-14 
days
221 93.5 39.3
Hayle, et al. 
1996 (376)
Azithromycin 500mg OD/3 days 221 Clinical success at 
the end of therapy 
(D25)
79 33 lb
P h e n o x y m e t h y l -
penicillin
1.3g TDS/10 days 217 76 40.1
Gehanno, et al. 
1996 (377)
Sparfloxacin 200mg OD/5 days 
after 400mg on 
day 1
193 Clinical symptoms 
+ bacteriological or 
radiological data
82.6 2.6 lb
Cefuroxime axetil 250mg BD/8 days 189 83.2 3.8
Von Sydow, et al. 
1995 (378)
Cefpodoxime prox-
etil
117 96 20 lb
Amoxicillin 113 91 16
Kohler, et al. 
1995 (379)
Cefcanel daloxate 300mg BD/10 days 229 Clinical cure or 
improvement
83.3 15.7 lb
Cefaclor 250mg TDS/10 
days
119 89.3 13.4
Unknown author, 
1993 (380)
Loracarbef 400mg BD/10 days 168 Clinical cure or 
improvement
98.2 11.7 Ib
Doxycycline 200mg first dose, 
100mg OD/10 days
164 92.2 10.6
Husfeldt, et al. 
1993 (381)
Ofloxacin 400mg OD/7-14 
days
136 Clinical cure 94.9 11.6 lb
Erythromycin 500mg BD/7-14 
days
144 94.4 19.5
Scheld, et al. 
1986 (382)
Cyclacillin 500mg TDS/10 
days
26 Clinical cure 91 Infrequent 
and similar
lb
Amoxicillin 500mg TDS/10 
days
27 91
Bacampicillin 1200mg BD 22 86.3
OD: once daily; BD: twice daily; TDS; three times daily.
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become an international health issue, a product of careless 
antibiotics abuse. Therefore, for initial treatment, the most 
narrow-spectrum agent active against the likely pathogens 
(Streptococcus pneumoniae and Haemophilus influenzae) 
should be used (293). 
3.4.3. Treatment with intranasal corticosteroids
3.4.3.1. Treatment with intranasal corticosteroids
In the EP3OS 2007 document, intranasal corticosteroids were 
recommended for the treatment of ARS, both in moderate 
(monotherapy) and severe (with oral antibiotics) disease. 
Intranasal corticosteroids are recommended for 
the treatment of ARS, both in moderate (monothe-
rapy) and severe (with oral antibiotics) disease.
Most studies on corticosteroids in ARS have determined the 
effect of topical corticosteroids when used as adjunct therapy to 
antibiotics (Table 3.4.5) (304-309). Recently a double-blind, double-
dummy, placebo-controlled study was published in which 
topical corticosteroid treatment was used as monotherapy and 
compared to antibiotics (310). In this study mometasone furoate 
(MF) was used and compared to both amoxicillin and placebo in 
ARS. MF 200 µg twice daily was significantly superior to placebo 
and amoxicillin in improving the symptom score. Used once 
daily MF was also superior to placebo but not to amoxicillin. This 
is the first study to show that topical corticosteroids when used 
twice daily are effective in treating ARS as monotherapy and is 
more effective than amoxicillin when used twice daily. Data of 
this study are also supported by two other studies with a similar 
design (Table 3.4.5) (311,1367). However, in another study, neither 
antibiotics nor topical corticosteroids alone or in combination 
were effective in altering the symptom severity or the duration 
of bacterial ARS (312). However, this study has included patients 
with 4 days of symptoms, which only satisfy the inclusion criteria 
of common cold but not ARS. 
In a recent Cochrane analysis, the results of four DBPC studies 
with a total of 1945 patients support the use of intranasal 
Table 3.4.4. Studies on “short-term” antibiotics, comparing different duration and dosages, used in the treatment of Acute Rhinosinusitis (ARS). Only 
studies with a design of prospective, randomized, double-blind (Ib) were selected.
Author, year, ref. Drug Dose / Duration Number of 
patients
Effects Side effects % Level of 
evidence
Outcomes %
Poole, et al. 
2006 (383)
Levofloxacin 750mg/5 days 152 Clinical success 91.4 Similar lb
Levofloxacin 500mg/10 days 149 88.6
Gehanno, et al. 
2004 (384)
Cefotiam hexetil 200mg BD/5 days 1018 Clinical cure 
rates
85.5 Similar, 3.36 lb
Cefotiam hexetil 200mg BD/10 days 85.3
Ferguson, et al. 
2002 (385)
Gemifloxacin 320mg OD/5 days 218 Clinical cure 
rates at test-of-
cure visit
Differ-
ence = 
0.44%
Well toler-
ated
lb
Gemifloxacin 320mg OD/7 days 203
Roos, et al. 
2002 (386)
Telithromycin 800mg OD/5 days 123 Clinical cure 
rates at test-of-
cure visit
91.1 Well toler-
ated
lb
Telithromycin 800mg OD/10 days 133 91.0
Murray, et al. 
2000 (387)
Clarithromycin 
ER
122 Clinical cure 
rates at test-of-
cure visit
85 1 lb
Clarithromycin IR 123 79 7
Seggev, et al. 
1998 (388)
Amoxicillin/
clavulanate 
potassium
875/125mg 12 
hourly/14 days
134 Clinical success 
at the end of 
therapy
93 Similar lb
Amoxicillin/
clavulanate 
potassium
500/125mg 8 
hourly/14 days
88
Zeckel, et al. 
1995 (389)
Loracarbef 200mg BD/10 days 106 Favour-
able clinical 
responses
81.1 Similar lb
Loracarbef 400mg BD/10 days 103 81.6
Sorri, et al. 
1981 (390)
Bacampicillin 400mg TDS 25 Clinical assess-
ment
92 lb
Bacampicillin 1200mg BD 22 86.3
OD: once daily; BD: twice daily; TDS; three times daily.
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corticosteroids as a monotherapy or as an adjuvant therapy to 
antibiotics (evidence level Ia) (313). Higher doses of intranasal 
corticosteroids had a stronger effect on improvement or 
complete relief of symptoms; for mometasone furoate 400 µg 
versus 200 µg, (RR 1.10; 95% CI 1.02 to 1.18 versus RR 1.04; 95% 
CI 0.98 to 1.11). No significant adverse events were reported 
and there was no significant difference in the drop-out and 
recurrence rate for the two treatment groups and for groups 
receiving higher doses of intranasal corticosteroids. In the 
future, further randomized clinical studies are needed to study 
the efficacy and appropriate use of antibiotics and intranasal 
corticosteroids as mono- or combined therapy in the treatment 
of ARS with different severities. 
3.4.3.2. Oral corticosteroids adjunct therapy
The result of a recent Cochrane analysis suggests that oral 
Table 3.4.5. Treatment with nasal corticosteroids in Acute Rhinosinusitis (ARS), either in monotherapy or as adjunct therapy to oral antibiotics.
Author, year, ref. Drug Antibiotic Number of 
patients
 Effect X-ray Level of 
evidence
1.   Cochrane database systemic review
Zalmanovici 
2009 (313)
Intranasal corti-
costeroids
No 1,943 
(four 
studies)
Higher doses of intranasal corticos-
teroids (mometasone furoate 400 
mcg versus 200 mcg) had a stronger 
effect on improvement or complete 
relief of symptoms
ARS confirmed 
by radiological 
evidence or by 
nasal endoscopy
Ia
2.  Monotherapy
Keith 2012 (1367) Fluticasone 
furoate
No 737 Significant effect on total  symptoms 
score, nasal congestion/stuffiness, 
and postnasal drip 
Not done 1b
Williamson 
2007 (312)
Budesonide No 240 Neither an antibiotic (amoxicillin) 
nor a topical steroid alone or in com-
bination was effective as a treatment 
for acute sinusitis in the primary care 
setting
Not done Ib
Bachert  2007 (311) Mometasone 
furoate
No 340 Significant improvement in mean 
total symptom score and in all SNOT-
20 items compared with placebo
Not done Ib
Meltzer 2005 (310) Mometasone 
furoate
No 981 Significant effect on total symptoms  
sinus headache. significantly supe-
rior to placebo and amoxicillin
Not done Ib
3. Adjunct therapy with antibiotics
Nayak 2002 (304) Mometasone 
furoate
Amox/clav. 967 Total symptom score (TSS) was im-
proved (nasal congestion, facial pain, 
rhinorrhoea and postnasal drip) 
No statistical 
difference in CT 
outcome
lb
Dolor 2001 (305) Fluticasone 
propionate
Cefuroxime axetil 95 Significant effect. effect measured 
as clinical success depending on pa-
tients self-judgment of symptomatic 
improvement
Not done lb
Meltzer 2000 (306) Mometasone
furoate
Amox/clav 407 Significant effect in congestion, fa-
cial Pain, headache and rhinorrhoea. 
No significant effect in postnasal 
drip
No statistical dif-
ference
in CT outcome
Ib
Barlan 1997 (307) Budesonide Amox/clav 89 (chil-
dren)
Improvement in cough and nasal 
secretion seen at the end of the 
second week of treatment in the 
BUD group
Not done lb
Meltzer 1993 (308) Flunisolide Amox/clav 180 Significant effect: overall score for
global assessment of efficacy was
greater in the group with flunisolide
No effect on x-ray Ib
Qvarnberg
1992 (309)
Budesonide Erythromycin 20 Significant effect on nasal symp-
toms, facial pain and sensitivity; final 
clinical outcome did not differ
Mucosal thicken-
ing =no effect
`lb
CT: Computed Tomography. 
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corticosteroids as an adjunctive therapy to oral antibiotics are 
effective for short-term relief of symptoms (e.g., headache, facial 
pain, nasal decongestion and etc.) in ARS (evidence level Ia) (314). 
Gehanno et al. (315) tried 8 mg methylprednisolone three times 
daily for 5 days as adjunctive therapy to 10 days treatment 
with amoxicillin clavulanate potassium in patients with ARS 
(criteria: symptoms < 10 days, craniofacial pain, purulent nasal 
discharge with purulent drainage from the middle meatus, 
opacities of the sinuses in x-ray or CT scan) in a placebo 
controlled study. No difference was seen in therapeutic outcome 
at day 14 between the groups (n=417) but at day 4 there was a 
significant reduction of headache and facial pain in the steroid 
group (Table 3.4.6). In a multicentre study Klossek et al. (316) 
assessed in a double blind, randomised study in parallel groups 
the efficacy and tolerance to prednisone administered for 3 
days in addition to cefpodoxime in adult patients presenting 
with an ABRS (proven by culture) with severe pain. The 
assessments made during the first 3 days of treatment showed 
a statistically significant difference in favour of the prednisone 
group regarding pain, nasal obstruction and consumption of 
paracetamol (Table 3.4.6). There was no difference between 
the two groups after the end of the antibiotic treatment. The 
tolerance measured throughout the study was comparable 
between the two groups. Pain is significantly relieved during 
treatment with prednisone but after 10 days on antibiotics there 
was no difference between the two groups. 
The long-term use of systemic steroids bears the well-
recognized risk of these drugs. Since evidence on the use of 
corticosteroids in patients with ARS is scarce, high-quality 
trials assessing the efficacy of systemic corticosteroids both 
as an adjuvant and a monotherapy in the primary care setting 
should be initiated to provide a more definite answer on their 
use. These trials should report both short-term (< two weeks) 
and long-term (> two weeks) effects as well as information on 
relapse rates and adverse events (314).
3.4.3.3. Prophylactic treatment of recurrent episodes
In a study by Puhakka et al. (317), fluticasone propionate (FP, 
200 μg four times daily) or placebo were used for 6 days in 199 
subjects with an acute common cold, 24-48 hours after onset 
of symptoms, to study the preventive effects of FP on risk for 
development of ARS. Frequency of sinusitis at day 7 in subjects 
with a positive culture of rhinovirus in nasopharyngeal aspirates, 
based on x-ray, was 18.4% and 34.9% in FP and placebo group 
respectively (p=0.07) thus indicating a non-significant effect of 
FP. Indeed, there is very low evidence for a prophylactic effect 
of nasal corticosteroids in prevention of recurrence of ARS 
episodes.
3.4.4. Other treatments
A large number of trials and Cochrane reviews are performed 
in viral rhinosinusitis. In general the studies are of low quality 
making clear recommendations difficult.
3.4.4.1. Oral antihistamines
There is no indication for the use of antihistamines 
(both intranasal and oral) in the treatment of post 
viral ARS, except in co-existing allergic rhinitis.
Oral antihistamines are frequently prescribed drugs especially 
for mild ARS (9). Antihistamines are standard treatment for 
IgE-mediated allergic diseases such as allergic rhinitis, where 
histamine (released by mast cells and basophils) is one of the 
major effectors of allergic reaction (318, 319). The pathophysiology 
of ARS is felt to be secondary bacterial infection due to the 
impairment of mechanical, humoral and cellular defences 
and epithelial damage caused by viral infection (common 
cold) (8). Antihistamines may be marginally more effective at 
reducing symptoms of runny nose and sneezing at 2 days in 
viral rhinosinusitis (1365). There is no indication for the use of 
antihistamines (both intranasal and oral) in the treatment of 
postviral ARS, except in co-existing allergic rhinitis. 
3.4.4.2. Nasal decongestants
Nasal decongestants are commonly applied in the treatment 
of ARS in order to decrease congestion and in the hope of 
improving better sinus ventilation and drainage, as well as to 
provide symptomatic relief of nasal congestion. Experimental 
trials on the effect of topical decongestants by CT (320) and MRI 
scans (321) on ostial and ostiomeatal complex patency have 
confirmed marked effect on reducing congestion of inferior and 
middle turbinates and infundibular mucosa, but no effect on 
ethmoidal and maxillary sinus mucosa. Experimental studies 
suggest beneficial anti-inflammatory effect of xylometazoline 
and oxymetazoline by decreasing nitric oxide synthetase (322) and 
their anti-oxidant action (323). 
In contrast to previous in vitro trials on the effect of 
decongestants on mucociliary transport, a controlled clinical 
trial (evidence level II) by Inanli et al. suggested improvement 
in mucociliary clearance in vivo, after 2 weeks of oxymetazoline 
application in acute bacterial rhinosinusitis, compared to 
fluticasone, hypertonic saline and saline, but it did not show 
significant improvement compared to the group where no 
topical nasal treatment was given. Also, the clinical course of the 
disease between the groups was not significantly different (324). 
This is in concordance with previous randomized controlled trial 
in adult acute maxillary sinusitis (evidence level Ib), which did 
not prove any significant impact of decongestants when added 
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to a penicillin treatment regime in terms of daily symptoms 
scores of headache and obstruction and sinus x-ray scores (325). 
Therefore, the results of this study suggest that decongestion of 
the sinus ostia is not of primary importance during the course of 
healing of ARS. 
A single dose of a decongestant (oral norephedrine, topical 
oxymetazoline, oral pseudoephedrine, nasal xylometazoline 
may be marginally more effective than placebo at reducing 
congestion at 3 to 10 hours in patients with viral rhinosinusitis(1365).
Decongestant treatment did not prove superior to saline, 
when added to antibiotic and antihistamine treatment in a 
randomized double-blind placebo-controlled trial for acute 
paediatric rhinosinusitis (evidence level Ib) (326). However, 
a double blind, randomized, placebo controlled trial 
demonstrated a significant protective effect of a 14-day course 
of nasal decongestant (combined with topical budesonide after 
7 days) in the prevention of the development of nosocomial 
maxillary sinusitis in mechanically ventilated patients in the 
intensive care unit. (327). Radiologically confirmed maxillary 
sinusitis was observed in 54% of patients in the active treatment 
group and in the 82% of the controls, respectively, while 
infective maxillary sinusitis was observed in 8% and 20% of the 
groups, respectively (327). Clinical experience, however, supports 
the use of the topical application of decongestants to the 
middle meatus in ARS but not by nasal spray or nasal drops 
(Evidence level IV).
Recently, a systematically review (Cochrane analysis) of the 
efficacy of decongestants, antihistamines and nasal irrigation 
in children with clinically diagnosed ARS was reported (328). Of 
the 402 studies found through the electronic searches and 
handsearching, none met all the inclusion criteria (any one of 
these drugs versus placebo or no medication). It concludes that 
no evidence to determine whether the use of antihistamines, 
decongestants or nasal irrigation is efficacious in children with 
ARS.
In another Cochrane review the effectiveness of antihistamine-
decongestant-analgesic combinations in reducing the duration 
and alleviating the symptoms of the common cold in adults 
and children was assessed. The authors included 27 trials (5117 
participants) of randomised controlled trials investigating 
the effectiveness of common cold treatments. Fourteen trials 
studied antihistamine-decongestant combinations. The authors 
conclude that current evidence suggests that antihistamine-
analgesic-decongestant combinations have some general 
benefit in adults and older children (recommendation A). They 
recommend to weighed the benefits against the risk of adverse 
effects. They found is no evidence of effectiveness in young 
children (1363).
3.4.4.3. Nasal or antral irrigation
Nasal irrigation with saline solution has a limited 
effect in adults with ARS.
Nasal irrigation is a procedure that rinses the nasal cavity with 
water, isotonic or hypertonic saline solutions. Other synonyms 
have also been used in the literature such as nasal douche, wash, 
or lavage. A number of randomized controlled trials have tested 
nasal and antral irrigation with isotonic or hypertonic saline in 
the treatment of ARS and CRS. Although saline is considered as 
a control treatment itself, patients in these randomized trials 
were assigned to different modalities of application of saline or 
hypertonic saline, or hypertonic compared to isotonic saline. 
The results between the groups were compared. Most of them 
offer evidence that nasal washouts or irrigations with isotonic 
or hypertonic saline are beneficial in terms of alleviation of 
symptoms. Hypertonic saline is preferred to isotonic saline in 
the treatment of rhinosinusitis by some authors in the USA, 
mostly based on a paper indicating that it significantly improves 
nasal mucociliary clearance measured by saccharine testing in 
healthy volunteers (329).
A randomized trial (Ib) by Adam et al. (330) with two controls 
compared hypertonic nasal saline to isotonic saline and no 
treatment in 119 patients with common cold and ARS (which 
were the majority). Outcome measures were subjective nasal 
symptoms scores (congestion, secretion, headache) at day-3, 
day-8/-10 and the day of symptom resolution. Rhinosinusitis 
patients (98%) were also treated with antibiotics. There was no 
difference between the groups and only 44% of the patients 
would use the hypertonic saline spray again. Thirty-two percent 
noted burning, compared with 13% of the normal saline group. 
Antral irrigation did not offer significant benefit when added 
to standard 10-day antibiotic treatment in (4 antibiotics+ 
decongestants vs. antral washouts; 50 patients per group) ARS, 
demonstrating approximately 5% better cure rate in each group 
for washouts than for decongestants, which was not significant 
(331).
More recently, a review of the Cochrane data from randomised 
controlled trials (3 RCTs with 618 participants) comparing 
topical nasal saline treatment to other interventions in adults 
and children with clinically diagnosed acute URTIs (common 
cold and rhinosinusitis) has been reported. Most results showed 
no difference between nasal saline treatment and control. 
However, there was limited evidence of benefit with nasal saline 
irrigation in adults. One study showed a mean difference of 0.3 
day (out of eight days) for symptom resolution, but this was not 
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significant. Nasal saline irrigation was associated with less time 
off work in one study. Minor discomfort was not uncommon and 
40% of babies did not tolerate nasal saline drops (332).
Another systematic review of literature was performed to 
determine whether nasal douching  is effective in the treatment 
of ARS and in preventing recurrent upper respiratory tract 
infections. The results showed that nasal douching with saline 
solution has a limited effect in adults with ARS (level of evidence 
Ia). It is effective in children with ARS in addition to the standard 
medication (level of evidence Ib) and can prevent recurrent 
infections (level of evidence IIb) (333). 
3.4.4.4. Heated, humidified air 
Heated, humidified air has long been used by sufferers of the 
common cold. The theoretical basis is that steam may help 
congested mucus drain better and heat may destroy the 
cold virus as it does in vitro. Six trials (394 trial participants) 
were included. Three trials in which patient data could be 
pooled found benefits of steam for symptom relief for the 
common cold (odds ratio (OR) 0.31; 95% confidence interval 
(CI) 0.16 to 0.60). However, results on symptom indices were 
equivocal. In conclusion steam inhalation has not shown 
any consistent benefits in the treatment of the common 
cold, hence is not recommended in the routine treatment of 
common cold symptoms until more double-blind, randomized 
trials with a standardised treatment modality are conducted 
(recommendation A(-)) (1364).
3.4.4.5. Physical interventions to interrupt or reduce 
the spread of respiratory viruses in viral rhinosinusitis
A cochrane review was performed to systematically review the 
effectiveness of physical interventions to interrupt or reduce the 
spread of respiratory viruses. The randomized studies suggest 
respiratory virus spread can be prevented by hygienic measures, 
such as handwashing, especially around younger children. The 
incremental effect of adding virucidals or antiseptics to normal 
handwashing to decrease respiratory disease remains uncertain. 
Case-control studies suggested that implementing barriers to 
transmission, isolation, and hygienic measures are effective 
at containing respiratory virus epidemics. There was limited 
evidence that social distancing was effective especially if related 
to the risk of exposure (recommendation A)(1358).
3.4.4.6. Ipratropium bromide
A Cochrane review was performed to determine the effect of 
ipratropium bromide versus placebo or no treatment on severity 
of rhinorrhoea and nasal congestion in children and adults with 
the common cold. Seven trials (2144 participants). Four studies 
(1959 participants) addressed subjective change in severity of 
rhinorrhoea. All studies were consistent in reporting statistically 
significant changes in favour of IB. Nasal congestion was 
reported in four studies and was found to have no significant 
change between the two groups. The authors conclude that 
for people with common cold, the existing evidence, which has 
some limitations, suggests that Ipratropium bromide is likely to 
be effective in ameliorating rhinorrhoea. Ipratropium bromide 
had no effect on nasal congestion and its use was associated 
with more side effects compared to placebo or no treatment 
although these appeared to be well-tolerated and self-limiting 
(recommendation A)(1361).
3.4.4.7. Probiotics
A Cochrane review was performed to assess the effectiveness 
and safety of probiotics for preventing acute URTIs. The authors 
included 14 RCTs, but only available data to meta-analyse could 
be extracted from 10 trials (3451 participants). Probiotics were 
better than placebo in reducing the number of participants 
experiencing episodes of acute URTIs, the rate ratio of episodes 
of acute URTI and reducing antibiotic use (recommendation A)
(1362).
3.4.4.8. Vaccination
Vaccination has no direct effect in treatment of ARS. However, 
routine childhood vaccination has affected frequency and 
bacteriology of acute otitis media (AOM) and acute bacterial 
rhinosinusitis (341). It was found that immunization leads to 
increase of host’s resistance capabilities, decrease of acute 
respiratory disease incidence and changes in structure of 
complications due to infection (342). In another study, a significant 
shift occurred in the causative pathogens of acute maxillary 
sinusitis in children in the 5 years after the introduction of 
vaccination of children with the 7-valent pneumococcal 
vaccine (PCV7) as compared to the previous 5 years. While the 
proportion of S. pneumoniae declined by 18%, the proportion 
of H. influenzae increased by 8% (108). 
3.4.4.9. NSAID’s, Aspirin or acetominophen
In a multicentre, randomized, double-blind, double-dummy, 
placebo-controlled study, 392 patients with URTI received a 
single dose of aspirin 500 or 1,000 mg, acetaminophen 500 or 
1,000 mg, or matching placebo (343). Significant reductions were 
seen in the mean intensity of headache, achiness, and feverish 
discomfort with all active treatments (P < 0.001), but not in sinus 
sensitivity to percussion or sore throat (evidence level Ib). 
A Cochrane review was performed to determine the effects 
and adverse effects of NSAID’s versus placebo and other 
treatments on the signs and symptoms of the common cold. 
The review included nine RCTs, describing 37 comparisons: six 
were NSAID’s versus placebo, and three were NSAID’s versus 
NSAID’s (1064 patients with common cold). NSAID’s did not 
significantly reduce the total symptom score, or duration of 
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colds. However, for outcomes related to the analgesic effects 
of NSAID’s (headache, ear pain, and muscle and joint pain) 
NSAID’s produced significant benefits. There was no evidence 
of increased frequency of adverse effects in the NSAID’s 
treatment groups. The authors recommend NSAID’s for relieving 
discomfort or pain caused by the common cold (1357).
3.4.4.10. Zinc
The Cochrane review Zinc and the common cold included 15 
randomized controlled double-blind trials. It was concluded, 
that zinc would shorten the duration of the episode of common 
cold and also could be used as a prevention so that the risk of 
developing an episode of common cold would be decreased. It 
is too early to give general recommendations for the use of zinc 
as we do not have sufficient knowledge about the optimal dose, 
formulation and duration of treatment. Further research should 
focus on the effect of zinc in patients who are at increased risk of 
developing complications after common cold (recommendation 
C) (1352,1356).
3.4.4.11.   Vitamin C
The role of vitamin C (ascorbic acid) in the prevention 
and treatment of the common cold has been a subject of 
controversy for many years, but is widely sold and used as 
both a preventive and therapeutic agent. A Cochrane study 
was performed encompassing thirty trials involving 11,350 
study participants in the meta-analysis on the relative risk (RR) 
of developing a cold whilst taking prophylactic vitamin C. The 
failure of vitamin C supplementation to reduce the incidence of 
colds in the normal population indicates that routine mega-
dose prophylaxis is not rationally justified for community 
use. But evidence suggests that it could be justified in people 
exposed to brief periods of severe physical exercise or cold 
environments (1366) (Level of evidence Ia, recommendation C).
3.4.4.12. Mucolytics
Mucolytics are used as adjuncts to antibiotic and/or 
decongestant treatment in ARS in order to reduce the viscosity 
of sinus secretion. From a recent survey study in France,  45% 
patients with acute maxillary sinusitis were prescribed with 
mucolytics (228). Although some drugs have been shown to 
have mucolytic effect and were recommended as adjunct 
treatment for ARS,  the benefit of such treatment is not clear 
due to the lack of standardization in pharmacodynamic and 
pharmacokinetic properties of these drugs, and also double-
blinded, placebo-controlled (DBPC) randomized studies to 
prove their efficacy. 
There is an early RCT study (report in Italian) suggests that 
bromhexine is superior to placebo (334). In a recent randomized 
and DBPC study, the use of erdosteine as a mucolytic agent 
in children with ARS does not directly affect the success of 
treatment (335). In future, more standardization of mucolytics and 
larger scale DBPC randomized studies still need to be done in 
order to fully assess the efficacy of mucolytics in the treatment 
of ARS. 
3.4.4.13. Herbal compounds
There are only a few DBPC randomized studies 
performed in order to assess the efficacy of 
herbal compounds in treatment of ARS, which is 
not representative of the full spectrum of herbal 
remedies used in the treatment of ARS. More 
such studies and meta-analysis are needed in 
order to understanding the pharmacodynamic 
and pharmacokinetic properties of the active 
compound from the herbs and their mechanisms 
in treatment of ARS.
Complementary/alternative medicines are extensively used 
in the treatment of both ARS and CRS, but evidence-based 
recommendations are difficult to propose due to the lack of 
randomized controlled trials and methodological problems in 
many clinical studies or trials. To date, there are only a few DBPC 
randomized studies performed in order to assess the efficacy 
of herbal compounds in treatment of ARS (Table 3.4.7), which 
is not representative of the full spectrum of herbal remedies 
used in the treatment of ARS. Also, the active compounds of 
the herbal compounds have not been discovered, purified 
and standardized yet. More such studies and meta-analysis 
are needed in order to understanding the pharmacodynamic 
and pharmacokinetic properties of the active compound from 
the herbs and their mechanisms in treatment of ARS. All this 
information is necessary to allow us to make an evidence-
based recommendation, and thus we are unable to accept 
or reject herbal medicines in the treatment of ARS at present 
(recommendation C).
In a Cochrane study, the effect of pelargonium sidoides 
(P. sidoides) extract in treatment of acute respiratory tract 
infections has been reviewed (336). There was only one study 
in patients with ARS and another one with the common 
cold included in analysis based on the RCT criteria (337, 338). In 
conclusion, P. sidoides may be effective in alleviating symptoms 
of ARS and the common cold in adults, but doubt exists (336)..
In another DBPC, randomized, multi-centre study (evidence 
level Ib), the efficacy of Myrtol standardized (4 capsule of 300 
mg/day for 6±2 days) in the treatment of ARS (n=331) was 
assessed. The results showed a statistically significant difference 
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in the improvement of total sinusitis symptoms score, which had 
changed by 10.5 and 9.2 points for the treatment with Myrtol 
standardized and placebo, respectively (339). A need for antibiotic 
treatment after Myrtol was 23%, compared to 40% for placebo. 
This drug has been recommended for treatment of ARS and 
CRS in the German Society of Oto-Rhino-Laryngology clinical 
guidelines (340).
In another Cochrane study the effectiveness and safety of 
Chinese herbal medicines for the common cold was evaluated. 
Table 3.4.7. Treatment with herbal compounds or homeopathic in ARS (DBPC studies).
Authour, 
year, ref. 
Drug Dose / Duration Number 
of 
patients
Effects Side effects % Level of 
evidence
Outcomes Data
Pfaar,
2012 (392)
Cyclamen euro-
paeum
Spray once daily for 
15 days (adjunct to 
Amoxicillin 500mg/8h, 
8 days)
48 Change in mean 
total
ARS symptom 
scores on Day 7
3.2±2.3
(better improve 
pain and endo-
scopic findings 
on Days 7 and 
15 as compared 
to placebo)
Nasal burn-
ing and mild 
epistaxis
Ib
Placebo (adjunct to 
Amoxicillin 500mg/8h, 
8 days)
51 2.7 ±2.2
Bachert
2009 (337)
EPs 7630, from 
Pelargonium 
sidoides
60 drops, 3 daily, for 22 
days
51 Mean changes in 
sinusitis severity 
score after 7 days
5.5 Well toler-
ated
lb
Placebo matching placebo 52 2.5
Tesche
2008 (393)
Cineole 2 capsules (200 mg), 3 
daily, for 7 days
75 Reduction of 
symptom-sum-
score before and 
after 4 and 7 days 
of treatment
Day 4: 6.7±3.4
Day 7: 11±3.0
Well toler-
ated
lb
Placebo 
(Alternative  herb-
al preparation 
with five different 
components)
Alternative  herbal 
preparation
75 Day 4: 3.6±2.8
Day 7: 8.0±3.0
Zabolotny
2007 (394)
Sinfrontal 22 days 57 (a) Reduction of 
sinusitis severity 
score at Day 7 
(b) Complete 
remission at 
Day 21
(a): 5.8±2.3 
(b): 68.4%
Well toler-
ated in both 
groups
lb
Placebo 
(saline inhalation, 
paracetamol and 
over-the-counter 
medications, but 
not antibiotics, 
were allowed) 
22 days 56 (a): 2.6±1.8 
(b): 8.9%
Friese
2007 (395)
Homeopathic 7 days 72 Reduction of si-
nusitis sum score 
at Day 7
6.2 Well toler-
ated in both 
groups
lb
Placebo 7 days 72 0.7
Kehrl
2004 (396)
Cineole 2 capsules (200 mg), 3 
daily, for 7 days
76 Reduction of si-
nusitis sum score 
at Day 7
12.6 Mild, heart-
burn and 
exanthema
lb
Placebo matching placebo 76 6.4
Gabrielian 
2002 (397)
Andrographis 
paniculata fixed 
combination Kan 
Jang
Andrographis panicu-
lata extract
85 mg and Kan Jang (10 
mg/tab) 4 tab, 3 daily, 
for 5 days
95 Reduction in 
individual mean 
symptom score
0.55 Well toler-
ated
lb
Placebo matching placebo 90 0.20
Federspil
1997 (339)
Myrtol standard-
ized
4 capsule of 300 mg 
daily, for 6±2 days
109 Difference in 
symptoms score 
(the correspond-
ing value) before 
and after treat-
ment
10.5 Similar 
distribution 
of undesired 
events in 
all 3 study 
groups
lb
Essential oil 
(unregistered)
4 capsule of 300 mg 
daily, for 6±2 days
110 10.9
Placebo matching placebo 111 9.2
. 
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Fourteen studies involving 2440 patients were included. The 
methods of all studies were rated of poor quality. Included 
studies used “effective drugs” as controls; however, the efficacy 
of these control drugs was not reported. In six studies, five 
herbal preparations were found to be more effective at 
enhancing recovery than the control; and in the other eight 
studies, five herbal preparations were shown to be equal to the 
control. There was a strong probability of different biases in all of 
the included studies. Chinese herbal medicines may shorten the 
symptomatic phase in patients with the common cold. However, 
because of the lack of high quality clinical trials the authors were 
unable to recommend any kind of Chinese herbal preparation 
for the common cold (1353).
Also a Cochrane study was performed to determine whether 
garlic (allium sativum) was effective for either the prevention 
or treatment of the common cold, when compared to placebo, 
no treatment or other treatments. There was only one relevant 
trial that suggested that garlic may prevent occurrences of the 
common cold, but the authors recommended more studies 
to validate this finding. Claims of effectiveness appear to rely 
largely on poor quality evidence (recommendation C)(1356)..
3.4.4.14. Cromoglycate
In a randomized double-blind study, comparison was made 
between sodium cromoglycate and placebo (saline) given 
as nasal sprays, to control symptoms of post-catarrhal 
hyperreactive rhinosinusitis (344). There was an improvement 
in symptoms in about 50% of the patients in each treatment 
group, but no significant differences between these two 
treatments in rhinopharyngeal symptoms, ultrasonic scanning 
of mucosal thickness in the maxillary sinus, or in the patients’ 
evaluation of rhinitis symptoms (evidence level Ib -).
3.4.4.15. Echinacea
There are 10 RCTs performed on the efficacy on Echinacea 
of wich 5 found that echinacea significantly reduced overall 
symptom score compared with placebo and 5 RCTs found no 
significant difference between groups. The weakness of trial 
methods and differences in interventions make it difficult to 
draw conclusions about effectiveness (recommendation C)(1365).
3.4.4.8.4. Other Studies without evidence
The is no evidence from RCTs or DBPC studies for other 
treatments such as anti-mycotics, bacterial lysates, capsaicin, 
furosemide, proton pump inhibitors, increased fluid intake (1360)  
and anti-leukotrienes in ARS.  
3.5. Complications of ARS
Summary
Orbital, intracranial, and osseous complications of ARS 
represent rare but potentially serious clinical events.  Periorbital 
complications include preseptal cellulitis, orbital cellulitis, 
subperiosteal, and intraorbital abscess and their prompt 
recognition and management (including i.v. antibiotics and 
drainage, as required) is vital in order to avoid long-term 
sequelae. Intracranial complications include epidural or 
subdural abscesses, brain abscess, meningitis, encephalitis, 
and superior sagittal and cavernous sinus thrombosis. They 
may present with non specific signs and symptoms and 
their diagnosis requires a high index of suspicion. Osseous 
complications result from osteomyelitis of the facial skeleton 
associated with the progress of inflammation and may present 
as Potts Puffy tumour or a frontocutaneous fistula.
3.5.1. Introduction
In the pre-antibiotic era, complications of rhinosinusitis 
represented common and dangerous clinical events. Today, 
thanks to more reliable diagnostic methods (CT, MRI), improved 
surgical techniques and the wide range of available antibiotics, 
their incidence and related mortality have dramatically 
decreased. In some cases however, if sinus infection is untreated 
or inadequately treated, complications can still develop (232). 
Complications of rhinosinusitis are classically defined as 
orbital, osseous, and endocranial 2 though rarely some unusual 
complications can develop (Table 3.5.1) (398-402).
3.5.2. Epidemiology of complications
The incidence of ARS complications is approxima-
tely 3 per million of population per year and is not 
reduced by antibiotic prescription
Epidemiological data concerning the complications of 
rhinosinusitis vary widely and there is no consensus on the 
exact prevalence of the different types of complications. 
Moreover, the relationship between ARS or CRS and the various 
complications is not clearly defined in the literature. In patients 
hospitalised with sinusitis, the reported rate of complications 
varies from 3.7%8 to 20% 9, although, by selecting for severe 
sinus disease, these series clearly overestimate the incidence 
of complications. Complications are typically classified as 
orbital (60-75%), intracranial (15-20%) and osseous (5-10%) 
(403).  Overall, sinus disease is the presumed underlying cause of 
about 10% of intracranial suppuration (404, 405), while sinus disease 
is related to 10% (preseptal cellulitis) to 90% (orbital cellulitis/
supberiosteal abscess/intraorbital abscess) periorbital infections 
(406). What is perhaps more clinically relevant is the incidence of 
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complications in patients with acute rhinosinusitis and in the 
population as whole (Table 3.5.1).
Four studies (attempted to) collect nationwide or large-scale 
data: Hansen et al (232), reported 48 ARS complications in 2004 in 
the Netherlands, corresponding to an incidence of 3 per million 
of population per year (or approximately 1 per 12,000 ARS 
episodes in children and 1 per 36,000 episodes of ARS in adults). 
Very similar results were reached by a US study (231) which 
recorded an annual incidence of intracranial complications in 
children between 2.7 and 4.3 per million per year. A French 
study with a 12 million catchment area recorded a yearly 
incidence of 2.5 ARS complications per million of population, 
excluding paediatric patients (414). In almost all studies males 
are significantly more frequently affected than females (231, 232, 
412) and ARS was more often the precipitating factor in children, 
while CRS with or without NP was more  important in adults 
(411, 443). In all studies, the commonest complications were 
orbital appearing at least twice as often as intracranial with 
osseous being the least common (232, 410, 411). There was a clear 
seasonal pattern of complications, mirroring the incidence of 
URTIs and appearing more often during winter months (231).
While orbital complications tend to occur primarily in small 
children, intracranial complications can occur in any age, 
with predilection for the second and third decade of life (232, 
413). It is important to note that both the Dutch study (232) and 
the study by Babar-Craig (52), which was based on returned 
questionnaires by members of the British Rhinology Society 
and probably underestimated the incidence of complications, 
showed that prescribing of antibiotics for ARS does not prevent 
the occurrence of complications. These facts, together with 
the risk of antibiotic resistance and of masking intracranial 
complications argue strongly against the routine use of 
antibiotics in ARS.
The commonest complications of ARS are 
orbital, appearing approximately twice as often 
than intracranial and followed by osseous 
involvement.
Table 3.5.1. Epidemiological data of complications in ARS.
Author,  year, 
ref.
Country Age Disease Patients Incidence of compli-
cations  (per million 
population per year)
Orbital Intra-
cranial
Bone Soft tissue
Piatt 
2011 (231)
USA –National in-
patient database  
(1997, 2000, 2001, 
2003, 2006)
Children ARS 695 2.7 – 4.3
Hansen 
2011 (232)
Netherlands (Na-
tional database 
- 2004)
Adults / 
children
ARS 48 (48/16.3 million=) 
3  (1:12,000  ARS 
episodes - children, 
1:32,000 – adults)
67%
(32)
33%
(16)
Babar-Craig 
2010 (52)
UK – national 
questionnaire
Adults 
and Chil-
dren
ARS 78 N/A 76% 9% 5%
Stoll  
2006 (414)
France (2001-
2003)
Adults 
and ado-
lescents
ARS 43 (30 
in 12 
months)
(30/12 million=) 
2.5 
35%
(15)
37%
(16)
18%
(8)
Oxford 
2005 (407)
USA Children ARS/
CRS
104 N/A 91%
(95)
16%
(17
3%
(3)
Younis 
2002 (408)
USA Adults 
and Chil-
dren
ARS/
CRS
82 N/A 53% 
(43)
46% (38) 3% 
(2)
Ogunleye
2001 (409)
Nigeria adults ARS/
CRS
33 N/A 41%
(13)
5%
(2)
32%
(11)
18%
(6)
Eufinger 
2001 (410)
Germany adults/ 
children
ARS 25 N/A 88%
(22)
20%
(5) 
2 pt. had 
both)
Mortimor 
1997 (411)
South Africa Adults / 
Children
ARS/
CRS
63 N/A 81%
(51) 
13%
(8)
10%
(6)
24%
(15)
N/A, not applicable. 
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3.5.3. Orbital complications of ARS (Table 3.5.2)
3.5.3.1. Classification
The most common complications of rhinosinusitis are orbital, 
and they are associated in order of decreasing frequency with 
the ethmoid, maxillary, frontal and rarely the sphenoid sinus (232, 
410, 414-417). The spread of infection directly via the thin and often 
dehiscent lamina papyracea (416) or by veins (418) occurs with 
relative ease. It is important to note that orbital complications in 
children may occur without pain (419)..
According to Chandler’s classification orbital complications may 
progress in the following steps (403): 
•	 (preseptal cellulitis), 
•	 orbital cellulitis, 
•	 subperiosteal abscess, 
•	 orbital abscess, and 
•	 (cavernous sinus thrombosis)
Although this classification is the most commonly used, it does 
present some problems: The orbital septum is the anterior limit 
of the orbit, hence “preseptal cellulitis” should be classified 
as an eyelid, rather than an orbital infection, as suggested by 
Velasco e Cruz (420) and Voegels (421). Indeed, preseptal cellulitis 
is infrequently associated with sinusitis and its clinical picture, 
its management and its prognosis differentiate it from all 
other orbital infections (422). Orbital involvement (“postseptal 
cellulitis”) presents with swelling, exophthalmos and impaired, 
painful extra-ocular eye movements with diplopia– all (beyond 
swelling) features that do not exist in preseptal cellulitis and 
differentiate it from true orbital involvement (423).
Additionally, cavernous sinus thrombosis as suggested by 
Mortimer already in 1997 (411) is an intracranial complication 
and not necessarily the end stage of orbital infection, while it is 
more often associated with sphenoid (424) rather than ethmoid or 
frontal sinus infection, which are the most common sources of 
infection in orbital cellulitis.
Periorbital or orbital cellulitis may result from direct or vascular 
spread of the sinus infection. As the spread of sinus infection 
through the orbit follows a well-described pattern, the initial 
manifestations are oedema and erythema of the medial 
aspects of the eyelid. Spread of infection from the maxillary or 
frontal sinus produces swelling of the lower or upper eyelid, 
respectively (425). 
The advice of an ophthalmologist should always 
be sought and objective assessment of proptosis 
(exophthalmometer), orbital pressure (tonometer), 
visual acuity, colour vision and eye movements 
should always be clearly documented (411).
3.5.3.2. Preseptal cellulitis
Preseptal cellulitis (inflammation of the eyelid and conjunctiva) 
(426) involves the tissue anterior to the orbital septum and 
is readily seen on CT scan as soft tissue swelling. It occurs 
often as a complication of upper respiratory tract infection, 
dacryocystitis or skin infection and less often sinusitis (427-430) 
and it presents with orbital pain, eyelid oedema, erythema and 
(sometimes) fever. Typically there is no associated proptosis and 
no limitation of eye movement, although this may be difficult to 
Table 3.5.2. Orbital complications of ARS.
Study author, year N Age Type of complications Management
Huang 
2011 (415)
64 Children Subperiosteal/intraorbital abscess 56% (36) Presep-
tal/orbital cellulitis  44% (28)
IV abx only: 53% (34)
Medical and surgical: 47% (30)
Georgakopoulos 
2010 (427)
83 Children Preseptal cellulitis 83% (69)
Orbital cellulitis 12% (10)
Subperiosteal abscess 5%  (4)
Medical only: 95% (79)
Surgical  and medical: 5% (4)
Siedek 
2008  (443)
127 Adults and children Preseptal cellulitis 36% (46) Orbital cellulitis    44% 
(56)
Subperiosteal abscess 6% (8)
Intraorbital abscess 14%  (17) 
(NB: Classification used makes comparisons prob-
lematic)
Medical only:51% (65)
Surgical: 49% (62)
Eviatar 
2008 (436)
52 Children Preseptal cellulitis 92% (48)
Subperiosteal abscess 8% (4)
Medical :  98% (51)
Surgical: 2% (1)
Mekhitarian 2007 
(417)
25 Children Preseptal cellulitis 96% (24)
Subperiosteal abscess  4% (1)
Medical: 92% (23)
Surgical: 8% (2)
Oxford 2006 (441) 43 Children Subperiosteal abscess 100% (43) Medical: 42% (18)
Surgical: 58% (25)
Mortimor 
1997 (411)
51 Adults and children Preseptal cellulitis 55% (28)
Orbital cellulitis  10% (5)
Subperiosteal abscess  33% (17)
Intraorbital abscess  2% (1) 
Not stated
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assess especially in small children (432). Preseptal cellulitis usually 
responds to an oral antibiotic but if not aggressively treated, 
may spread beyond the orbital septum (431). In most cases, 
preseptal cellulitis is a clinical diagnosis and does not mandate a 
CT scan (422).
3.5.3.3. Orbital cellulitis
Unlike preseptal cellulitis, orbital cellulitis, orbital abscess  and 
subperiosteal abscess all occur more often as complications 
of acute rhinosinusitis (427, 429, 432). As the inflammatory changes 
involve the orbit, proptosis develops together with some 
limitation of ocular motion, indicating orbital cellulitis. Typical 
signs are conjunctival oedema (chemosis), a protruding eyeball 
(proptosis), ocular pain and tenderness, as well as restricted and 
painful movement of the extraocular muscles (411, 433, 434).
This complication requires aggressive treatment with 
intravenous antibiotics, as well as the exclusion of subperiosteal 
or intraorbital abscess. 
Any child with proptosis, reduced or painful eye movement 
(ophthalmoplegia), or decreased visual acuity (initially 
manifesting itself with reduced green/red colour discrimination) 
should have a CT scan with i.v. contrast of the sinuses with 
orbital detail to distinguish between orbital cellulitis and 
intraorbital or subperiosteal abscess. If a concomitant 
intracranial complication is suspected or in cases of uncertainty, 
MRI can provide valuable additional information (435-437). All 
three conditions (orbital cellulitis, subperiosteal and intraorbital 
abscess) cause proptosis and limited ocular movement. 
Evidence of an abscess on the CT scan, progressive orbital 
findings or vision (especially colour vision) impairment 
after initial i.v. antibiotic therapy are indications for orbital 
exploration and drainage. Repeated ophthalmologic 
examinations of visual acuity should take place and i.v. antibiotic 
therapy may be converted into oral when the patient has been 
afebrile for 48 hours and the ophthalmological symptoms and 
signs are resolving (438).
3.5.3.4. Subperiosteal and orbital abscess
A Subperiosteal abscess forms between the periorbita and the 
sinuses and is extraconal – i.e. is located outside the ocular 
muscles. The clinical features of a subperiosteal abscess are 
oedema, erythema, chemosis and proptosis of the eyelid 
with limitation of ocular motility and as a consequence 
of extra-ocular muscle paralysis, the globe becomes fixed 
(ophthalmoplegia) and visual acuity diminishes. In most series, 
high fever and raised leucocyte count as well as left turn were 
strongly associated with (subperiosteal or intraorbital) abscess 
formation (439).
An orbital abscess is intraconal (contained within the space 
defined by the ocular muscles) and generally results from 
diagnostic delay or immunosuppression of the patient (440) with a 
frequency of between 13% (416) and 8.3% (437) in paediatric studies 
of orbital complications. 
In case of orbital complications, clinical or 
radiological evidence of an abscess or lack of 
clinical improvement after 24-48 hours of i.v. 
antibiotics are indications for prompt surgical 
exploration and drainage, preferably endoscopic.
Investigations. A CT scan of the sinuses with orbital sequences 
may help to distinguish between cellulitis and orbital or 
subperiosteal abscess. In the case of a subperiosteal abscess 
the CT usually reveals oedema of the medial rectus muscle, 
lateralization of the periorbita, and displacement of the globe 
downward and laterally. When the CT scan shows obliteration 
of the detail of the extraocular muscle and the optic nerve 
by a confluent mass, the orbital cellulitis has progressed to 
an intraorbital abscess, in which there is sometimes air due 
to anaerobic bacteria. The predictive accuracy of a clinical 
diagnosis has been found to be 82% and the accuracy of CT 
91%. MRI may be useful in cases of diagnostic uncertainty or 
when intracranial complications are suspected (408, 441, 442).
Management. Evidence of an abscess on the CT scan or absence 
of clinical improvement after 24-48 hours of i.v. antibiotics 
are indications for orbital exploration and drainage (437). An 
ophthalmologist should check visual acuity from the early 
stages of the illness. Intravenous antibiotic therapy should 
cover aerobic and anaerobic pathogens. It can be converted to 
an oral preparation when the patient has been afebrile for 48 
hours (435). Current consensus states that preseptal and orbital 
cellulitis should be treated with antibiotics while subperiosteal 
and intraorbital abscesses require surgical exploration (which 
Table 3.5.3. Indications for surgical intervention in orbital complications 
of ARS
1.      Evidence of subperiosteal or intraorbital abscess in CT or MRI 
(with potential exceptions stated above).
2.      Reduced visual acuity/reduced colour vision/affected afferent 
pupillary reflex or inability to assess vision.
3.      Progressing or not improving orbital signs (diplopia, oph-
thalmoplegia, proptosis, swelling, chemosis) after 48 hours 
intravenous antibiotics .
4.      Progressing or not improving general condition (fever, infection 
parameters) after  48 hours of  intravenous antibiotics.
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should include not just the drainage of the abscess but also 
of the paranasal sinuses (439). In such cases, the consensus is to 
attempt to drain the abscess endoscopically by opening the 
lamina papyracea and draining the abscess after completing an 
endoscopic ethmoidectomy. External approaches to lateral and 
medial orbital abscesses are also used if necessary (Table 3.5.3).
However, there have been a number of recent studies showing 
good outcomes with i.v. antibiotics in small children with 
subperiosteal abscesses (432, 440, 443). In such cases, and provided 
there is :
•	 clear clinical improvement within 24-48 hours,
•	 no decrease in visual acuity,
•	 small (<0.5-1 ml  in volume) medially located subperiosteal 
abscess, 
•	 no significant systemic involvement, 
•	 patient’s age is less than 2-4 years, 
there can be an argument for withholding surgical drainage (435). 
Prognosis – Follow up. Blindness may result from central retinal 
artery occlusion, optic neuritis, corneal ulceration, or pan-
ophthalmitis. Sepsis not infrequently can spread intracranially as 
well as anteriorly into the orbit (234).
3.5.4. Endocranial complications
Intracranial complications may present with 
non-specific symptoms and signs (high fever, 
headache, lethargy, reduced consciousness) 
or with focal neurologic or increased intracranial 
pressure signs 
These include epidural or subdural abscesses, brain abscess, 
meningitis, cerebritis, and superior sagittal and cavernous sinus 
thrombosis (231, 404, 412, 417, 435, 444).
The clinical presentation of these complications can be non-
specific, being characterized simply by high fever with severe, 
intractable headache, or even be silent (411, 442). The majority 
however, usually presents with more specific signs and 
symptoms that suggest intracranial involvement, such as nausea 
and vomiting, neck stiffness and altered mental state (234, 411, 
412, 440, 445).   Intracranial abscesses are often heralded by signs of 
increased intracranial pressure, meningeal irritation, and focal 
neurologic deficits, including third, sixth or seventh cranial 
nerve palsies (411, 423, 440). Although an intracranial abscess can 
be relatively asymptomatic, subtle affective and behavioural 
changes often occur showing altered neurologic function, 
altered consciousness, gait instability, and severe, progressive 
headache  (431, 446).
Endocranial complications are most often associated with 
frontoethmoidal or sphenoid rhinosinusitis (412). Infections can 
proceed from the paranasal cavities to the endocranial structures 
by two different routes: pathogens, starting can pass through 
the diploic veins to reach the brain; alternatively, they can 
reach the intracranial structures by eroding the sinus bones or 
haematologically (445).
All cerebral complications start as encephalitis, but as necrosis 
and liquefaction of brain tissue progresses, a capsule develops 
resulting in brain abscess. Studies show a high incidence of 
anaerobic organisms or mixed aerobic-anaerobic in patients with 
CNS complications (Table 3.5.4).
A CT scan with contrast is essential for diagnosis as it allows an 
accurate definition of bone involvement. MRI is increasing being 
utilised, being more sensitive than CT (448), as well as have an 
additional value in cavernous sinus thrombosis (412, 445) where an 
MRI may be necessary (450) or in cases with soft tissue involvement. 
Moreover, if meningitis is suspected, a lumbar puncture could 
be useful (445) but only after the exclusion of an abscess using 
imaging. 
High dose long-term i.v. antibiotic therapy followed by burr hole 
drainage, craniotomy or image guided aspiration as needed, 
are usually required for successful treatment (451, 452). Combined 
drainage of the paranasal sinuses (often the frontal sinus) can be 
performed endoscopically (448), albeit is in no way as a substitute 
for the drainage of the intracranial abscess (447). Pathogens 
most commonly involved in the pathogenesis of endocranial 
complications are Streptococcus and Staphylococcus species 
and anaerobes (404, 451).
3.5.5. Cavernous sinus thrombosis
When the veins surrounding the paranasal sinuses are affected, 
further spread can lead to cavernous sinus thrombophlebitis 
causing sepsis and multiple cranial nerve involvement (431). 
Such a complication has been estimated at 9% of intracranial 
complications (444, 445) and is a fortunately rare and dramatic 
complication of ethmoidal or sphenoidal sinusitis (453)..
The main symptoms are bilateral lid drop, exophthalmos, 
ophthalmic nerve neuralgia, retro-ocular headache with deep 
pain behind the orbit, complete ophthalmoplegia, papilloedema 
and signs of meningeal irritation associated with spiking fevers 
and prostration (425). Full blood count may show increased white 
blood cell count with neutrophilia and polymorphotcytosis, while 
lumbar puncture may show non specific meningeal inflammation 
and blood cultures will help to culture the offending organism 
(445).
The cornerstone of diagnosis is MR venogram, demonstrating 
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absence of venous flow in the affected cavernous sinus. 
High-resolution CT scan with contrast can also show filling 
defects. A mortality rate of 30% and a morbidity rate of 60% 
remain in the adult population. No data are available for the 
paediatric population in which the mortality rate for intracranial 
complications is 10% to 20% (454). The use of anticoagulants in 
these patients remains controversial (425) but is probably indicated 
provided imaging shows no evidence of any intracerebral 
haemorrhagic changes (455). Steroids may help to reduce 
inflammation and are likely to be helpful, administered with 
concomitant antibiotics. Drainage of the offending sinus (almost 
always the sphenoid) is indicated.
Table 3.5.4. Endocranial complications in ARS (studies including more than 10 patients).
Author, year, ref. N Complications Mortality /
further defects
Hansen 2011 (232) 16 9 subdural empyema
3 meningitis
2 epidural abscess
2 intracerebral abscess
1 encephalitis
1 superior sagittal sinus thrombosis
Mortality 19%
Morbidity 19%
DelGaudio 2010 (447) 23 8 epidural
10 subdural
2 intracerebral abscesses
3 meningitis
Mortality 4%
Morbidity 12%
Bayonne  2009 (412) 25 Epidural abscesses
Subdural abscesses
Meningitis
Sequelae 16%
Mortality 0%
Germiller  2006 (448) 25 
(mean age 13 y)
13 epidural abscesses
9 subdural abscesses
6 meningitis
2 encephalitis
2 intracerebral abscess
2 cavernous sinus thrombophlebitis
Morbidity 8%
Mortality 4%
Quraishi 2006 (449) 12 
(mean age 14 y)
2 frontal lobe abscess
8 subdural abscess 
1 subdural abscess 1
2 cavernous sinus thrombophlebitis 2
Mortality 8%
Morbidity 16 %
Oxford  2005 (407) 18 
(mean age 12 y)
7 epidural abscess
6 subdural abscess
2 intracerebral abscess
2 meningitis
1 cavernous sinus thrombosis
No mortality
Morbidity 11%
Younis 2002 (408) 39 7 epidural abscess
4 subdural abscess
21 meningitis 
4 intracerebral abscess
1 superior sagittal sinus thrombosis 
Sequelae 10%
No mortality 
Jones 2002 (440) 47 Subdural abscess 38%
Meningitis 2%
Epidural abscess 23%
Intracranial abscess 30%
Mortality 2%
Morbidity 19%
Albu 2001 (444) 16 6 meningitis
6 frontal lobe abscess 
5 epidural abscess
4 subdural abscess
2 cavernous sinus thrombosis
Mortality 6%
Morbidity 25%
Gallagher 1998 (445) 15 Meningitis 18%
Cerebral abscess 14%
Epidural abscess 23%
Mortality 7%
Morbidity 13%
Clayman 1991 (413) 24 Meningitis 29%
Cerebral abscess 46%
Epidural abscess
Subdural abscess 8%
Cavernous sinus thrombosis 8%
Sagittal vein thrombosis 4%
Mortality 4%
Morbidity 33%
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3.5.6. Bone complications
Sinus infection can also extend to the bone producing 
osteomyelitis and eventually involving the brain and nervous 
system. Even if the most frequent intracranial spread is due 
to frontal sinusitis, any sinus infection can lead to such a 
complication (425). The most common osseous complications are 
osteomyelitis of the maxillary (typically in infancy) or frontal 
bones (398). 
As vascular necrosis results from frontal sinus osteitis, an 
osteomyelitis of the anterior or posterior table of the frontal 
sinus is evident. On the anterior wall it presents clinically with 
“doughy” oedema of the skin over the frontal bone producing 
a mass (Pott’s puffy tumour) whereas from the posterior wall 
spread occurs directly or via thrombophlebitis of the valveless 
diploic veins leading to meningitis, peridural abscess or brain 
abscess (425). The infection can proceed anteriorly by breaching. 
In this context, Gallagher (445) reviewed the files of 125 patients 
with complicated rhinosinusitis and found that osteomyelitis 
developed in about 9% of cases. The sinus walls were affected 
in 32% of patients in Ogunleye’s data (409). Lang in 2001 recorded 
10 cases of subdural empyema in adults and children secondary 
to frontal sinus infection: among them four had Pott’s puffy 
tumour and one had periorbital abscess (456). 
Signs and symptoms of intracranial involvement are soft tissue 
oedema (especially of the superior lid), high fever, severe 
headache, meningeal irritation, nausea and vomiting, diplopia, 
photophobia, papillary oedema, coma and focal neurological 
signs. Ocular signs can appear contra laterally. Contrast-
enhanced CT scan confirms the diagnosis. A lumbar puncture, 
though contraindicated if intracranial pressure is elevated, can 
also be useful.
Therapy includes a combination of i.v. broad-spectrum 
antibiotics administration and surgical debridement of 
sequestered bone and drainage (425).
Management of ARS complications is always 
multidisciplinary – the advice of an 
ophthalmologist in cases of orbital involvement 
and of neurologist/neurosurgeon in intracranial 
involvement is mandatory
3.5.7. Unusual complications of rhinosinusitis
3.5.8. Follow-up of complications
It is important to note that some complications may 
occasionally appear simultaneously (for example Potts Puffy 
tumour and intracranial extension, orbital and intracranial 
complications). A follow up of such patients for a minimum of 6 
months is advised, in order to monitor for complete resolution 
of disease as well as exclude disease recurrence or any 
complication of treatment. 
3.6. Paediatric ARS
Summary
ARS in children is a common entity that usually occurs in the 
context of an upper respiratory viral illness.  In the children 
where this illness is not self-limited and extends beyond 
7-10 days, many agree that a bacterial infection is likely.  The 
diagnosis is mostly based on history of symptoms and their 
duration as well as physical findings.  In most cases this is a 
self-limited process but, treatment with antibiotics seems to 
accelerate resolution.  Whether this benefit outweighs the risks 
associated with frequent antibiotic prescriptions remains to 
be clarified.  Intranasal steroids might be useful adjuncts to 
antibiotics in the treatment of ARS and very limited evidence 
in older children suggests that they may be useful as a single 
agent in the treatment.  Ancillary therapy in the form of nasal 
irrigations, antihistamines, decongestants, or mucolytics have 
not been shown to be helpful. 
3.6.1. Definition of ARS in children
ARS is most often viral in aetiology and 
self-limited.
Acute rhinosinusitis in children is defined as the sudden onset 
of two or more of the symptoms (discoloured nasal discharge, 
nasal blockage/obstruction/ congestion, cough at daytime and 
night-time) for less than 12 weeks, with validation by telephone 
or interview. Symptom free intervals may exist if the problem is 
recurrent. 
Table 3.5.5. Unusual complications of ARS.
Study
Author, Year
Complication
Mirza 2001 (398)  
Patel 2003 (399)
Lacrimal gland abscess
Park 2010 (457) Orbital hematoma
Gradoni 2010 (458)
Sethi (459)
Nasal septal abscess
Sibbery 1997 (460) Nasal septal perforation
Wu 2008 (461) Frontocutaneous fistula
Laurens 2008 (462) Clival osteomyelitis with VI nerve 
palsy
Righini 2009 (463) Acute ischemic stroke
Rimal  2006 (464) Septicaemia
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As in adults, common cold / viral ARS is defined as duration 
of symptoms for less than 10 days; post-viral ARS as increase 
of symptoms after 5 days or persistent symptoms after 10 
days; and suggestive of ABRS when are present at least 3 
symptoms/signs among discoloured discharge (with unilateral 
predominance) and purulent secretion in cavum nasi, severe 
local pain (with unilateral predominance), fever (>38ºC), 
elevated ESR/CRP, and double sickening (i.e. a deterioration after 
an initial milder phase of illness) (see also chapter 2).
3.6.2. Paranasal Sinus Development  
Not all sinuses are well developed at birth.  The frontal sinuses 
are indistinguishable from the anterior ethmoid cells and they 
grow slowly after birth so that they are barely seen anatomically 
at 1 year of age. After the fourth year, the frontal sinuses begin 
to enlarge and can usually be demonstrated radiographically 
in around 20-30% of children at age 6 years (465). Their size 
continues to increase into the late teens and more than 85% of 
children will show pneumatized frontal sinuses on CT scanning 
at the age of 12 years (465).  When volume estimates are 
generated from examining 3D reconstructions of CT scans, the 
volume is around 2 ml around age 10 years and reaches adult 
size around age 19 with mean volume after full growth being 
3.46 ml (466).
At birth, the ethmoid and maxillary sinuses are the only sinuses 
that are large enough to be clinically significant as a cause of 
rhinosinusitis.  In one study, more than 90% of subjects showed 
radiographically visible ethmoid sinuses at birth (465).  The 
ethmoid sinuses rapidly increase in size until 7 years of age and 
complete their growth by age 15-16 years with a mean volume 
after full growth averaging 4.51 ml (466). The maxillary sinuses are 
usually pneumatized at birth and the volume in patients at 2 
years of age is around 2 ml (466).  The sinus grows rapidly reaching 
around 10 ml in volume around age 9 years and full growth 
volume by 15 years averaging 14.8 ml.  Much of the growth 
that occurs after the twelfth year is in the inferior direction with 
pneumatisation of the alveolar process after eruption of the 
secondary dentition.  By adulthood, the floor of the maxillary 
sinus is usually 4-5 mm inferior to the floor of the nasal cavity.  
At birth, the size of the sphenoid sinus is small and is little more 
than an evagination of the sphenoethmoidal recess.  By the 
age of 7 years, the sphenoid sinuses have extended posteriorly 
to the level of the sella turcica and over 85% of patients have 
pneumatized sphenoid sinuses visualized on CT scanning by age 
8 years (465). The sphenoid sinuses exhibit a growth spurt between 
6-10 years of age and growth is completed by the age of 15 years 
with the mean volume after full growth averaging 3.47 ml (466). By 
the late teens, most of the sphenoid sinuses have aerated to the 
dorsum sellae and some further enlargement may occur in adults. 
3.6.3. Classification and diagnosis  
The clinical diagnosis of ARS in children is challenging related 
to the overlap of symptoms with other common childhood 
nasal diseases such as viral upper respiratory tract infections 
and allergic rhinitis as well as the challenges related to physical 
examination.  The symptoms are often subtle and the history 
is limited to the observations and subjective evaluation by 
the child’s parent.  Because some younger children might not 
tolerate nasal endoscopy, clinicians are sometimes hindered in 
their physical examination and have to rely on history and or 
imaging studies for appropriate diagnosis.  
Symptom profiles of ARS in children include fever (50-60%), 
rhinorrhoea (71-80%), cough (50-80%), and pain (29-33%) (8).  
In a recent study of 69 children between the ages of 3 and 12 
years, ARS was diagnosed by purulent nasal drainage for more 
than 7 days and abnormal findings in the maxillary sinuses on 
Water’s projection.  In these children, the most troublesome 
symptoms were postnasal drip, nasal obstruction, and cough (76).  
In a mail survey of American general pediatricians, symptoms 
thought to be very important in the diagnosis of ARS included 
prolonged symptom duration, purulent rhinorrhoea, and nasal 
congestion (230). 
In children, ARS most often presents as either a severe 
upper respiratory tract illness with fever >39°C, purulent 
rhinorrhoea and facial pain or, more commonly, as a prolonged 
URTI with chronic cough and nasal discharge.  In a study of 
the relationship between symptoms of acute respiratory 
infection and objective changes within the sinuses utilizing 
MRI scans, 60 children (mean age=5.7 yrs.) were investigated 
who had symptoms for an average of 6 days before scanning 
(467).  Approximately 60% of the children had abnormalities 
in their maxillary and ethmoid sinuses, 35% in the sphenoid 
sinuses, and 18% in the frontal sinuses.  In 26 children with 
major abnormalities, a follow up MRI scan taken 2 weeks later 
showed a significant reduction in the extent of abnormalities 
irrespective of resolution of clinical symptoms. This study 
reinforces the notion that, like in adults, every upper respiratory 
tract infection is essentially an episode of rhinosinusitis with 
common involvement of the paranasal sinuses by the viral 
process.   
Few viral ARS episodes progress to bacterial ARS.
Despite the lack of good studies, most clinicians and 
investigators agree that the diagnosis of bacterial ARS can 
be made after a viral URTI when children have persistent URI 
symptoms for >10 days without improvement (nasal discharge, 
daytime cough worsening at night) or an abrupt increase in 
severity of symptoms after initial improvement of symptoms of 
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a URTI, or a URTI that seems more severe than usual (high fever, 
copious purulent nasal discharge, periorbital oedema and pain) 
(8 , 96, 468).  
In a longitudinal study of 112 children aged 6-35 months, 
623 URTIs were observed over a 3-year period and episodes 
of sinusitis as defined above were documented by the 
investigators (31).  Eight percent of the URIs were complicated 
by sinusitis, with 29% of the episodes diagnosed because 
of an increase in the severity of symptoms before 10 days of 
illness and the remaining diagnosed on the basis of persistent 
symptoms beyond 10 days.  The occurrence of sinusitis in 
the context of URIs was 7% in the 6-11 month age group and 
in children over 24 months, and 10% in children who were 
12-23 months old.  In an older, but similar, study, 159 full 
term infants were followed prospectively for a 3 year period 
and the frequency of URIs and complicating sinusitis were 
evaluated (469). The authors calculated the percentage of children 
experiencing symptoms beyond 2 standard deviations from 
the mean duration of respiratory symptoms (in days) and took 
that as an indicator of ARS.  This value varied with age and 
ranged between 16 and 22 days.  The incidence based on these 
assumptions ranged between 4 and 7.3% and was highest for 
children in their first year of life and in day care.  On average, a 
child younger than 5 years of age has 2 to 7 episodes of URTI per 
year (470, 471), and a child attending day care may have up to 14 
episodes per year (472).  With the incidence rates reported above, 
the number of acute sinusitis episodes in children every year is 
sizeable.
Distinguishing between ARS  and CRS is based on duration of 
illness in both children and adults. ARS is defined by symptoms 
lasting <12 weeks with complete resolution of symptoms.  
Symptoms lasting ≥12 weeks without complete resolution of 
symptoms are consistent with CRS.  A very common clinical 
scenario in children presenting to the otorhinolaryngologist’s 
office is that of CRS with upper respiratory tract infection-
induced acute exacerbations.
3.6.4. Differential diagnosis  
When a child presents with symptoms of ARS as listed above, 
the differential diagnosis must include intranasal foreign body 
and unilateral choanal stenosis.  In these entities, the symptoms 
are usually unilateral and can be relatively easily differentiated 
clinically from ARS by history and physical examination, 
including nasal endoscopy. AR will usually not manifest 
with purulent drainage as part of the clinical presentation. 
Adenoiditis can have a very similar clinical presentation 
including anterior and posterior purulent drainage and cough 
and is very relevant in the differential diagnosis in the paediatric 
age group.  In a study of adenoid size evaluated by MRI in a 
patient cohort with no symptoms related to the adenoids or 
adenoid disease, adenoid size was larger in the paediatric age 
group and declined with advancing age (473).  Peak size was 
between 7 and 10 years of age and largest dimensions were 
in the 4-15 years age group.  In an attempt to differentiate 
between adenoiditis and ARS based on endoscopic findings, 
Marseglia and colleagues performed a cross sectional study of 
287 consecutive children in whom ARS was suspected based on 
symptoms lasting for more than 10 days (270).  Nasal endoscopy 
was performed and the diagnosis of ARS was made if purulent 
discharge was identified in the ostiomeatal or sphenoethmoidal 
areas, and the diagnosis of adenoiditis was made if there was 
purulent drainage over the adenoids.  Based on those criteria, 
rhinosinusitis was confirmed in 89.2% of the patients and 
was isolated in 80.8% and coupled with adenoiditis in 19.2%.  
Adenoiditis alone was confirmed in 7% of the cohort.  Combined 
involvement of the sinuses and adenoids was more frequent 
in younger patients (2-5 years age group) whereas isolated 
rhinosinusitis was more frequent in older children. Although this 
study can be criticized by the manner in which the diagnosis 
was made as one would expect drainage from the sinuses to 
involve the adenoids as it moves posteriorly in the nose, and the 
lack of a more objective measure to diagnose rhinosinusitis such 
as a CT scan, the data supports the high coexistence of infection 
of the adenoids and the paranasal sinuses in the above clinical 
context.  It is also evident that based on clinical presentation 
alone, the differentiation between adenoiditis and ARS in 
children is very difficult. 
3.6.5. Bacteriology  
Wald et al. studied the bacteriology of ARS in 1981 (474). 
They obtained cultures from children with maxillary sinus 
opacification documented by Water’s X-ray by means of sinus 
taps and found that S. pneumoniae, H. influenzae, and 
M. catarrhalis were the organisms most frequently isolated 
from maxillary sinus aspirates in these children.  Several studies 
since then have confirmed that the most common organisms 
responsible for bacterial ARS in children are S. pneumoniae, 
H. influenza, M. catarrhalis, S. pyogenes, and anaerobes (8). Unlike 
the visit rate for acute otitis media in children younger than 18 
years, which has decreased between 1998 and 2007 following 
the introduction of the heptavalent pneumococcal conjugate 
vaccine in the United States, the visit rate for ARS has remained 
stable at 11-14 visits per 1000 children (475).  In a later study, 
Hwang et al performed a retrospective review of all paediatric 
patients requiring intervention for ARS over a seven-year period 
(476). They reported that instead of the common bacteria noted 
above, S. viridans was the major culprit in sinus cultures.  Brook 
et al. found anaerobic bacteria in acute infections as well, 
however, these organisms are most frequently seen in maxillary 
CRS due to odontogenic causes. The predominant anaerobic 
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bacteria were gram-negative bacilli such as Peptostreptococcus 
and Fusobacterium (477, 478).
3.6.6. Diagnostic Workup
A complete physical exam should follow a carefully obtained 
medical and family history.  The nasal exam in children 
should begin with anterior rhinoscopy examining the middle 
meatus, inferior turbinates, mucosal character, and presence 
of purulent drainage.  This is often accomplished easily using 
the largest speculum of an otoscope, or alternatively, a head 
light and nasal speculum.  Topical decongestion may be used 
to improve visualization.  Nasal endoscopy that will allow 
superior visualization of the middle meatus, adenoid bed, and 
nasopharynx is strongly recommended in children who are able 
to tolerate the examination.  An oral cavity exam may reveal 
purulent postnasal drainage, cobblestoning of the posterior 
pharyngeal wall, or tonsillar hypertrophy.
Obtaining a culture is usually not necessary in the context of 
uncomplicated ARS.  Obtaining a culture might be useful in 
patients who have not responded to conventional medical 
treatment within 48-72 hours, in immune-compromised patients, in 
the presence of complications, and if the child presents with severe 
illness and appears toxic (8, 479). Although the golden standard would 
be a maxillary sinus tap, this is a relatively invasive procedure, and 
is difficult to perform in a child in the office.  Middle meatal cultures 
under endoscopic visualization have shown promise in correlating 
with antral cultures. In children, data regarding the usefulness of 
this approach are limited and are mostly based on studies in CRS 
and will be discussed in the relevant chapter.  
While the diagnosis of ARS in the paediatric population is 
generally made on clinical grounds, computed tomography (CT) 
is the imaging modality of choice (279). 
The recommendations of the American Academy of Paediatrics, 
published in 2001, state that CT should be reserved for those 
patients with symptoms persisting after 10 days of appropriate 
therapy and in patients with suspected complications (especially 
in the brain and in the orbit) (96). In children with the clinical 
diagnosis of rhinosinusitis, the most commonly involved sinus is 
the maxillary sinus (99%) followed by the ethmoid sinus (91%) 
(480). MRI of the sinuses, orbits, and brain should be performed 
whenever complications of rhinosinusitis are suspected. 
3.6.7. Medical Treatment of Acute Rhinosinusitis
Most episodes of ARS are self-limited and will 
resolve spontaneously. 
3.6.7.1. Antibiotics 
Antibiotics are the most frequently used therapeutic agents in 
ARS (Table 3.6.1). Published trials in children and adults were 
reviewed in a recent meta-analysis of randomized controlled 
trials evaluating antibiotic treatment for ARS in which 3 of the 17 
evaluated studies were performed in the paediatric age group 
(345). In total, 3291 outpatients (2915 adults and 376 children) 
were treated in the trials included in the meta-analysis.  The 
diagnosis of ARS in the trials was based on clinical criteria in 
most studies and radiologic and other laboratory criteria in 
the rest.  In most studies, inclusion of patients with viral upper 
respiratory tract infections was avoided by enrolling patients 
whose symptoms were of more than 7-10 days duration. The 
results suggest that, compared with placebo, antibiotics were 
associated with a higher rate of cure or improvement within 
7-15 days with the rate of resolution of symptoms being faster 
with antibiotics in most randomized controlled trials.  The 
overall positive effect in favour of antibiotics was significant but 
modest.  No difference in cure was found when a subgroup 
Table 3.6.1.  Antibiotics for Acute Rhinosinusitis (ARS) in children.
Author, study, ref. Intervention / 
disease
Outcome Time to effect Level of 
evidence
Wald 2009 (351) Amox/clav vs. 
Placebo 
in ABRS
Significantly higher 
cure rate on antibiotic 
(50%) vs. placebo (14%) 
(p=0.01).
Faster resolution (NS) with antibiotics (2.26 days) vs. 
placebo (2.6 days)
Ib
Falagas 2008 (345) Antibiotics vs. 
Placebo Metanalysis 
in ABRS
Significant, but mod-
estly, higher cure rate 
(improvement) with 
antibiotics within 7-15 
days
Faster resolution with antibiotics compared to 
placebo
la
Poachanukoon 2008 (481) Cefditoren vs. 
Amox/clav in ARS
Comparable rates of 
improvement for Cefdi-
toren (78.8%) and Amox/
clav (84.7%)
Time to improvement was 3 days in both groups Ib
NS, non-significant
ABRS, acute bacterial rhinosinusitis
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analysis was performed for age.  A more recent randomized, 
placebo-controlled trial not included in the meta-analysis 
evaluated the efficacy of amoxicillin (90 mg/kg) with 
potassium clavulanate (6.4 mg/kg) or placebo in children 
1-10 years of age with a clinical presentation compatible 
with bacterial ARS (persistent symptoms, acutely worsening 
symptoms or severe symptoms) (351).  Symptom scores were 
obtained at multiple time points and the children were 
evaluated at day 14 from onset of treatment and their 
condition rated as cured, improved, or failed.  Twenty eight 
patients in each group completed the study and their 
average age was around 5 years.  Children receiving the 
antibiotic were more likely to be cured (50% vs. 14%, p=0.01) 
and less likely to experience treatment failure (14% vs. 68%, 
p<0.001) than children receiving placebo.  Similar to other 
studies, there were more side effects in the antibiotic treated 
group compared to the placebo treatment (44% vs. 14% of 
children, p=0.014).  In another randomized, controlled study 
in patients 1-15 years of age with clinical and radiographic 
signs and symptoms of ARS, patients received either a 
cephalosporin (cefditoren 8-12 mg/kg daily) or amoxicillin/
clavulanate (80-90 mg/kg amoxicillin daily) for 14 days (481).  
The results show comparable, not statistically different, 
rates of improvement at 14 days: 78.8% for cefditoren and 
84.7% for amoxicillin/clavulanate.  The median time to 
improvement was 3 days in both groups and the rate of 
diarrhoea was significantly higher in the patients treated 
with amoxicillin/clavulanate (18%) compared to those 
treated with cefditoren (4.5%).  
Most of these studies could be criticized for potentially 
including patients with ongoing viral URIs and selecting 
patients on the basis of clinical symptoms and exam only, 
without radiologic documentation.  The results, however, 
suggest that most cases of uncomplicated acute sinusitis 
will improve irrespective of treatment used but will do so 
faster, and will have a higher chance of improvement, if 
given antibiotics.  Based on this evidence, it would seem 
reasonable to recommend only symptomatic treatment 
for uncomplicated episodes of ARS in children.  Antibiotic 
therapy would be reserved to children with complications, 
or concomitant disease that could be exacerbated by ARS 
(asthma, chronic bronchitis).  In some situations, children 
with purulent rhinorrhoea are prevented from staying 
in day-care and thus have created problems for working 
parents.  Whether an acceleration of improvement of the 
symptoms with antibiotics in these children is worth the 
increased risk of antimicrobial resistance remains to be 
determined. (Strength of recommendation: A). 
Antibiotic therapy seems to accelerate resolution 
of ARS in children but whether an acceleration of 
improvement of the symptoms with antibiotics 
in these children is worth the increased risk 
of antimicrobial resistance remains to be 
determined.
When considering antibiotic choices, uncomplicated ARS 
in a child who has not received multiple previous courses 
of antibiotics can still be treated with amoxicillin (40 mg/
kg/day or 80 mg/kg/day).  Other reasonable and safe 
choices are amoxicillin/clavulanate and cephalosporins 
that provide good coverage of typical organisms, especially 
those producing β-lactamase (8).   If hypersensitivity to any 
of the above antimicrobials is suspected, alternative choices 
include trimethoprim/sulfamethoxasole, azithromycin, or 
clarithromycin. Clindamycin is useful if anaerobic organisms 
are suspected but provides no coverage against gram-negative 
organisms.
3.6.7.2. Intranasal Steroids
 
Intranasal steroids might have a beneficial ancil-
lary role in the treatment of ARS.
In a paediatric trial, 89 children with ARS received amoxicillin-
clavulanate and were randomized to receive either budesonide 
or placebo nasal sprays for 3 weeks (307).  There were significant 
improvements in the scores of cough and nasal discharge at 
the end of the second week in the steroid group compared 
to placebo suggesting a benefit of adding intranasal steroids 
to antibiotics in the treatment of ARS.  Several trials in mixed 
adult and paediatric populations (usually 12-14 years and 
older) have demonstrated similar benefits of using an intranasal 
steroid along with an antibiotic for the treatment of ARS (306, 482).  
Therefore there is reasonable evidence to support the addition 
of an intranasal steroid to antibiotics in the treatment of ARS 
(Strength of recommendation: A).  Finally, in a randomized, 
placebo controlled, trial in patients older than 12 years with 
ARS, mometasone 200 mcg twice daily (twice the allergic rhinitis 
dose) was more effective in controlling symptoms than placebo 
and amoxicillin (310). Thus, there is also some evidence that a high 
dose of intranasal steroids in older children might be effective 
as monotherapy for ARS.  However, generalizing to younger 
children is not justified in the absence of more studies.
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3.6.7.3. Ancillary therapy
Ancillary therapies have not been shown to be 
helpful in ARS.
A systematic review of the literature was undertaken to 
evaluate the efficacy of decongestants (oral or intranasal), 
antihistamines, and nasal irrigation in children with clinically 
diagnosed acute sinusitis (328).  Randomized controlled trials 
(RCTs) or quasi-RCTs that evaluated children 0-18 years of age 
with ARS defined as 10-30 days of rhinorrhoea, congestion or 
daytime cough were included.  Of 402 articles reviewed 44 
references were retrieved and were all excluded because they 
did not satisfy the set criteria.  The authors conclude that there 
is no evidence to determine whether the use of the above 
mentioned agents is efficacious in children with ARS.  In a 
more recent publication, erdosteine, a mucolytic agent, was 
investigated in a randomized, placebo controlled trial (335). Eighty 
one patients completed the study and their average age was 
8.5 years and they all had symptoms consistent with ARS.  They 
were randomized to receive either erdosteine or placebo for 
14 days and their symptoms recorded.  Both treatment groups 
had an improvement in symptoms on day 14 but there were 
not statistically significant differences between the active and 
placebo groups. Therefore, there is really no good evidence 
to support the use of ancillary therapies in the treatment of 
ARS in children (Table 3.6.2) (Strength of recommendation: A-, 
negative). 
Table 3.6.2.  Ancillary therapy for Acute Rhinosinusitis (ARS) in children.
author Intervention / 
disease
Outcome Age Group Level of 
evidence
Shaikh 2010 (328) Decongestants, 
antihistamines, 
and nasal irrigation 
Systematic review 
in ARS
No well conducted 
studies to address these 
treatments
Children (<18 yrs.) Ia (-)
Unuvar 2010 (335) Erdosteine vs. 
placebo
No significant difference 
between the groups
Children 
(8.5±3.2 yrs.)
Ib (-)
Barlan  1997 (307) Amox/clav with 
Budesonide or 
Placebo
Significant improve-
ments in cough and 
nasal discharge at the 
end of the second week 
in the steroid group 
(p<0.05)
Children
(Budesonide: 7.3±3.4 yrs.; Amox/clav: 6.6±2.9 yrs.)
Ib
(-), evidence of negative studies
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4.1. Epidemiology and predisposing factors
4.1.1. Summary
The overview of the currently available literature illustrates the 
paucity of accurate information on the epidemiology of CRSsNP 
and CRSwNP, especially in European countries, and highlights 
the need for large-scale epidemiologic research exploring their 
prevalence and incidence. Only by the use of well standardized 
definitions for CRSs and wNP, and well-defined inclusion criteria 
for epidemiologic research, will it be possible to obtain accurate 
epidemiologic data on the natural evolution of these diseases, 
the influence of ethnic background and genetic factors and the 
factors associated with the disease manifestation. 
4.1.2. Introduction
Chronic rhinosinusitis with (CRSwNP) and without nasal polyps 
(CRSsNP) in its many forms, constitutes one of the commonest 
conditions encountered in medicine and may present to a wide 
range of clinicians from primary care to accident and emer-
gency, pulmonologists, allergists, otorhinolaryngologists and 
even intensivists and neurosurgeons when severe complications 
occur (483).
4.1.3. Epidemiology of CRSwNP and CRSsNP.
There is a deficit of epidemiologic studies exploring 
the prevalence and incidence of CRSsNP and 
CRSwNP especially in European countries.
4.1.3.1. CRSsNP. 
The paucity of accurate epidemiologic data on CRS contrasts 
with the more abundant information on microbiology, diagnosis 
and treatment options for these conditions. When reviewing 
the current literature on CRS, it becomes clear that giving an 
accurate estimate of the prevalence of CRS remains speculative, 
because of the heterogeneity of the disorder and the diagnostic 
imprecision often used in publications. In a survey on the 
prevalence of chronic conditions, it was estimated that CRS, 
defined as having ‘sinus trouble’ for more than 3 months in the 
year before the interview, affects 15.5% of the total population 
in the United States (484) ranking this condition second in 
prevalence among all chronic conditions. Subsequently the 
high prevalence of CRS was confirmed by another survey 
suggesting that 16% of the adult US population has CRS (485). 
However, the prevalence of doctor-diagnosed CRS is much 
lower; a prevalence of 2% was found using ICD-9 codes as 
an identifier (486). Corroboration of the definitive diagnosis of 
CRS should be done with nasal endoscopy (487) or CT (488) As 
the diagnosis of CRS has primarily been based on symptoms, 
often excluding dysosmia, this means that the diagnosis of 
CRS is often overestimated (11, 488). The majority of primary 
care physicians do not have the training or equipment to 
perform nasal endoscopy, which also leads to overdiagnosis 
(489). Interestingly, the prevalence rate of CRS was substantially 
higher in females with a female/male ratio of 6/4 (484). 
In Canada, the prevalence of CRS, defined as an affirmative 
answer to the question ‘Has the patient had sinusitis 
diagnosed by a health professional lasting for more than 
6 months?’ ranged from 3.4% in male to 5.7% in female 
subjects (490). The prevalence increased with age, with a mean 
of 2.7% and 6.6% in the age groups of 20-29 and 50 59 years, 
respectively. After the age of 60 years, prevalence levels of CRS 
levelled off to 4.7% (490). In a nationwide survey in Korea, the 
overall prevalence of CRS, defined as the presence of at least 
3 nasal symptoms lasting more than 3 months together with 
the endoscopic finding of nasal polyps and/or mucopurulent 
discharge within the middle meatus, was 1.01% (491), with no 
differences between age groups or gender. By screening a 
non-ENT population, which may be considered representative 
of the general population in Belgium, Gordts et al. (492) reported 
that 6% of subjects suffered from chronic nasal discharge. A 
comparative study in the north of Scotland and the Caribbean 
found that in ORL clinics in both populations there was a 
similar prevalence of CRS (9.6% and 9.3% respectively) (493). 
Recently, a postal questionnaire on the EPOS criteria was 
sent to a random sample of adults aged 15-75 years in 19 
centres in Europe. The Global Allergy and Asthma Network 
of Excellence (GA2LEN) study concluded that the overall 
prevalence of CRS by EP3OS criteria was 10.9% (range 6.9-
27.1) (12). A very recent study in Sao Paulo using personal 
interviews and defining CRS based on the EPOS criteria 
found a prevalence of 5.5% (1368). 
4. Chronic Rhinosinusitis with or without nasal polyps 
(CRSwNP or CRSsNP)
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Recent data have demonstrated that CRS affects 
approximately 5–15% of the general population 
both in Europe and the USA.  The  prevalence of 
doctor-diagnosed CRS was 2-4%.
4.1.3.2. CRSwNP 
Epidemiologic studies rely on nasal endoscopy and/or 
questionnaires to report on the prevalence of nasal polyps. 
Large NP can be visualized by anterior rhinoscopy, whereas 
nasal endoscopy is warranted for the diagnosis of smaller NP. 
Nasal endoscopy is, therefore, a prerequisite for an accurate 
estimate of the prevalence of NP, as not all patients that claim 
to have NP actually have polyps on nasal endoscopy (494). Thus, 
surveys based on questionnaires asking for the presence of 
NP, may provide us with an overestimation of the self-reported 
prevalence of NP. Recently, a French expert panel of ENT 
specialists elaborated a diagnostic questionnaire/algorithm with 
90% sensitivity and specificity (495). In the light of epidemiologic 
research, a distinction needs to be made between clinically 
silent NP or preclinical cases, and symptomatic NP. 
Asymptomatic polyps may transiently be present or persist, 
and hence remain undiagnosed until they are discovered by 
clinical examination. On the other hand, polyps that become 
symptomatic may remain undiagnosed, either because they 
are missed during anterior rhinoscopy and/or because patients 
do not see their doctor for this problem. Indeed, one third of 
patients with CRSwNP do not seek medical advice for their 
sinonasal symptoms (496). Compared to patients with CRSwNP 
not seeking medical attention, those actively seeking medical 
care for CRSwNP had more extensive NP with more reduction of 
peak nasal inspiratory flow and greater impairment of the sense 
of smell (497).
In a population-based study in Skovde, Sweden, Johansson 
et al. (494) reported a prevalence of nasal polyps of 2.7% of the 
total population. In this study, NP were diagnosed by nasal 
endoscopy and were more frequent in men (2.2 to 1), the 
elderly (5% at 60 years of age and older) and asthmatics. In a 
nationwide survey in Korea, the overall prevalence of polyps 
diagnosed by nasal endoscopy was 0.5% of the total population 
(498). Based on a postal questionnaire survey in Finland, Hedman 
et al. (499) found that 4.3% of the adult population answered 
positively to the question as to whether polyps had been found 
in their nose. Using a disease-specific questionnaire, Klossek 
et al. (496) reported a prevalence of NP of 2.1% in France. From 
autopsy studies, a prevalence of 2% has been found using 
anterior rhinoscopy (500). In Denmark after removing whole 
naso-ethmoidal blocks, nasal polyps were found in 5 of 19 
cadavers (501). and in 42% of 31 autopsy samples combining 
endoscopy with endoscopic sinus surgery (502). The median 
age of the cases in the 3 autopsy studies by Larsen and Tos 
ranged from 70 to 79 years. From these cadaver studies, one 
may conclude that a significant number of patients with 
NP do not feel the need to seek medical attention or that 
the diagnosis of NP is often missed by doctors. It has been 
stated that between 0.2% and 1% of people develop NP 
at some stage (503). In a prospective study on the incidence 
of symptomatic NP, Larsen and Tos (504) found an estimated 
incidence of 0.86 and 0.39 patients per thousand per year for 
males and females, respectively. The incidence increased with 
age, reaching peaks of 1.68 and 0.82 patients per thousand 
per year for males and females respectively in the age group 
of 50-59 years. When reviewing data from patient records of 
nearly 5,000 patients from hospitals and allergy clinics in the 
US in 1977, the prevalence of NP was found to be 4.2% (505), 
with a higher prevalence (6.7%) in the asthmatic patients. In 
general, NPs occur in all races and becomes more common 
with age (496, 506-509). The average age of onset is approximately 
42 years, which is 7 years older than the average age of the 
onset of asthma (510-512). NPs are uncommon under the age of 
20 (513) and are more frequently found in men than in women 
(499, 504, 514), except in the studies by Settipane (505) and Klossek 
(496).
Szczeklik et al. (515) studied the natural history of asthma and 
CRS in 16 clinical centres in 10 European countries. Rhinitis 
was the first symptom of the disease. It appeared on average 
at an age of 30 yrs. It was perennial, difficult to treat and led 
to loss of smell in 55% of patients. In an average patient, 2 yrs 
alter commencement of rhinitis, the first symptoms of asthma 
appeared. Intolerance to aspirin and/or other NSAIDs became 
evident 4 yrs later. Nasal polyps were diagnosed at about 
the same time in 60% of subjects. There was a close linear 
association between mean age at onset of rhinitis, asthma, 
NSAID intolerance and nasal polyps (515).
4.1.4. Factors associated with CRSwNP and 
CRSsNP
4.1.4.1. Ciliary impairment 
As may be concluded from the section on anatomy and 
pathophysiology, ciliary function plays an important role in 
the clearance of the sinuses and the prevention of chronic 
inflammation. Secondary ciliary dyskinesia is found in patients 
with CRS, and is probably reversible, although restoration 
takes some time (516). As expected in patients with Kartagener’s 
syndrome and primary ciliary dyskinesia, CRS is a common 
problem and these patients usually have a long history of 
respiratory infections. 
In patients with cystic fibrosis (CF), the inability of the cilia to 
transport the viscous mucus causes ciliary malfunction and 
consequently CRS. NPs are present in about 40% of patients 
with CF (517). These polyps are generally more neutrophilic than 
eosinophilic in nature. 
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4.1.4.2. Allergy 
Review articles on CRS have suggested that atopy predisposes 
to its development (518 , 519). It is tempting to speculate that 
allergic inflammation in the nose predisposes the atopic 
individual to the development of CRS. Both conditions share the 
same trend of increasing prevalence (520, 521) and are frequently 
associated. It has been postulated (522) that swelling of the nasal 
mucosa in allergic rhinitis at the site of the sinus ostia may 
compromise ventilation and even obstruct sinus ostia, leading 
to mucus retention and infection. Furthermore, there has been 
an increase in the body of opinion that regard the mucosa of the 
nasal airway as being in a continuum with the paranasal sinuses 
and hence the term ‘rhinosinusitis’ was introduced (523). However, 
critical analysis of the papers linking atopy as a risk factor to 
CRS reveal that whilst many of the studies suggest a higher 
prevalence of allergy in patients presenting with symptoms 
consistent with rhinosinusitis than would be expected in the 
general population, there may well have been a significant 
selection process, because the doctors involved often had an 
interest in allergy (524-528). 
A number of studies report that markers of atopy are more 
prevalent in populations with CRS. Benninger reported that 
54% of outpatients with CRS had positive skin prick tests (529). 
Among CRS patients undergoing sinus surgery, the prevalence 
of positive skin prick tests ranges from 50% to 84%, of which 
the majority (60%) have multiple sensitivities (64, 530, 531). However, 
the role of allergy in CRS is questioned by other epidemiologic 
studies showing no increase in the incidence of infectious 
CRS during the pollen season in pollen-sensitized patients 
(532). Taken together, epidemiologic data show an increased 
prevalence of allergic rhinitis in patients with CRS, but the role 
of allergy in CRS remains unclear. Notwithstanding the lack 
of hard epidemiologic evidence for a clear causal relationship 
between allergy and CRS, it is clear that failure to address allergy 
as a contributing factor to CRS diminishes the probability of 
success of a surgical intervention (533). Among allergy patients 
undergoing immunotherapy, those who felt most helped by 
immunotherapy were the subjects with a history of recurrent 
rhinosinusitis, and about half of the patients, who had had 
sinus surgery before, believed that the surgery alone was 
not sufficient to completely resolve the recurrent episodes of 
infection (533).
Between 0.5 to 4.5% of subjects with allergic rhinitis have NP 
(505, 534, 535), which compares with the normal population (536). Kern 
found NP in 25.6% of patients with allergy compared to 3.9% in 
a control population (536). On the other hand, the prevalence of 
allergy in patients with NP has been reported as varying from 
10% (537), to 54% (538) and 64% (539). Contrary to reports that have 
implicated atopy as being more prevalent in patients with NP, 
others have failed to show this (513, 535, 539-541). Recently, Bachert 
at al. (542) found an association between levels of both total and 
specific IgE and eosinophilic infiltration in NP. These findings 
were unrelated to skin prick test results. 
Although intradermal test to food allergens are known to 
be unreliable, positive intradermal tests to food allergens 
have been reported in 70 % (543) and 81% (544) of NP patients 
compared to respectively 34% and 11% of controls. Based on 
questionnaires, food allergy was reported by 22% (496) and 31% 
(508) of patients with NP, which was significantly higher than 
in non-NP controls (496). Pang et al. found a higher prevalence 
of positive intradermal food tests (81%) in patients with NP 
compared to 11% in a small control group (545). Further research 
is needed to investigate a possible role for food allergy in the 
initiation and perpetuation of NP.
Considerable overlap between asthma and 
nasal comorbidities confirm a close relationship 
between nasal disease and asthma.
4.1.4.3. Asthma
CRSwNP and asthma are also frequently associated in the 
same patients, but their inter-relationship is poorly understood 
(318). Studies on radiographic abnormalities of the sinuses in 
asthmatic patients have shown a high prevalence of abnormal 
sinus mucosa (545, 546). All patients with steroid-dependant asthma 
had abnormal mucosal changes on CT compared to 88% with 
mild to moderate asthma (547). GA2LEN studied over 52,000 
adults aged 18-75 years and living in 19 centres in 12 countries 
and concluded that there was a strong association of asthma 
with CRS. The association with asthma was stronger in those 
reporting both CRS and allergic rhinitis (13). 
Wheezing and respiratory discomfort are present in 31% and 
42% of patients with CRSwNP, and asthma is reported by 
26% of patients with CRSwNP, compared to 6% of controls (496, 
548).  Alternatively, 7% of asthmatic patients have NP (505), with 
a prevalence of 13% in non-atopic asthma and 5% in atopic 
asthma (513). NP take between 9 and 13 years to develop, but only 
two years in aspirin-induced asthma (515). Ten percent develop 
both polyps and asthma simultaneously and the remainder 
develop polyps first and asthma later (506). Women that have 
nasal polyps are 1.6 times more likely to be asthmatic and 
2.7 times to have allergic rhinitis (509). Asthmatic patients with 
CRSwNP have more nasal symptoms. Alobid et al. (549) showed 
that patients with CRSwNP have an impaired sense of smell, that 
asthma -particularly persistent asthma- has a further impact on 
sense of smell, and that loss of smell may be used as a clinical 
tool to identify the severity of both NP and asthma.
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4.1.4.4. Aspirin sensitivity 
In patients with aspirin sensitivity, 
36-96% have CRSwNP. 
In patients with aspirin sensitivity 36-96% have CRSwNP (513, 534, 
551-555) and up to 96% have radiographic changes affecting their 
paranasal sinuses (556). Patients with aspirin sensitivity, asthma 
and NP are usually non-atopic and the prevalence increases 
over the age of 40 years. The children of patients with asthma, 
NP, and aspirin sensitivity had NP and rhinosinusitis more often 
than the children of controls (557). Concerning hereditary factors, 
HLA A1/B8 has been reported as having a higher incidence in 
patients with asthma and aspirin sensitivity (558) although Klossek 
et al. (496) found no difference between gender in 10,033 patients. 
Zhang et al. (559) found that IgE antibodies to enterotoxins can be 
found in the majority of NP patients who are aspirin sensitive.
4.1.4.5. Immunocompromised state 
Among conditions associated with dysfunction of the immune 
system, congenital immunodeficiencies manifest themselves 
with symptoms early in life. However, dysfunction of the 
immune system may occur later in life and present with CRS. 
In a retrospective review of refractory sinusitis patients, Chee 
et al. (560) found an unexpectedly high incidence of immune 
dysfunction. Of the 60 patients with in vitro T-lymphocyte 
function testing, 55% showed abnormal proliferation in 
response to recall antigens. Low immunoglobulin (Ig), IgA 
and IgM titres were found in 18%, 17%, and 5%, respectively, 
of patients with refractory sinusitis. Common variable 
immunodeficiency was diagnosed in 10% and selective 
IgA deficiency in 6% of patients. Therefore, immunological 
testing should be an integral part of the diagnostic pathway 
of patients with CRS. In a cross-sectional study to assess the 
overall prevalence of otolaryngologic diseases in patients 
with HIV infection, Porter et al. (561) reported that rhinosinusitis 
was present in more than half of the HIV-positive population, 
ranking this condition one of the most prevalent diseases in 
HIV-positive individuals. However, the relevance of these data 
is questioned as there was no difference in sinonasal symptom 
severity between HIV-positive and AIDS patients nor was 
there a correlation between CD4+ cell counts and symptom 
severity. In a more detailed study, Garcia-Rodrigues et al. (562) 
reported a lower incidence of CRS (34%), but with a good 
correlation between low CD4+ cell count and the probability 
of CRS. It should also be mentioned here that atypical 
organisms like Aspergillus spp, Pseudomonas aeruginosa and 
microsporidia are often isolated from affected sinuses and 
that neoplasms such as non-Hodgkin lymphoma and Kaposi’s 
sarcoma, may account for sinonasal problems in patients with 
AIDS (563).
4.1.4.6. Genetic factors. (See also section 4.5)
Although CRSsNP has been observed in family members, no 
genetic abnormality has been identified linked to CRS. However, 
the role of genetic factors in CRS has been implicated in patients 
with cystic fibrosis and primary ciliary dyskinesia (564) and there is 
some evidence in CRSwNP. 
4.1.4.7. Pregnancy and endocrine state 
During pregnancy, nasal congestion occurs in approximately 
one-fifth of women (565). The pathogenesis of this disorder 
remains unexplained, but there have been a number of 
proposed theories. Besides direct hormonal effects of oestrogen, 
progesterone and placental growth hormone on the nasal 
mucosa, indirect hormonal effects such as vascular changes 
may be involved. Whether pregnancy rhinitis predisposes to the 
development of rhinosinusitis, is not clear. In a small prospective 
study, Sobol et al. (566) report that 61% of pregnant women had 
nasal congestion during the first trimester, whereas only 3% 
had sinusitis. In this study, a similar percentage of non-pregnant 
women in the control group developed sinusitis during the 
period of the study. Also in an earlier report, the incidence of 
sinusitis in pregnancy was shown to be quite low, i.e. 1.5% (567). 
In addition, thyroid dysfunction has been implicated in CRS, but 
there is only limited data on the prevalence of CRS in patients 
with hypothyroidism.
4.1.4.8. Local host factors
There is no evidence for a causal correlation 
between nasal anatomic variations in general and 
the incidence of CRS.
Certain anatomic variations such as concha bullosa, nasal 
septal deviation and a displaced uncinate process, have been 
suggested as potential risk factors for developing CRS (568). 
However, some of the studies that have made this assertion 
have equated mucosal thickening on CT with CRS (569) when it 
has been shown that incidental mucosal thickening occurs in 
approximately a third of an asymptomatic population (570). Bolger 
et al. (571) and Nouraei et al. (572) found no correlation between 
CRS and bony anatomic variations in the nose. Holbrook et 
al (573) also found no correlation between sinus opacification, 
anatomical variations and symptom scores. Nonetheless, one 
should mention here that no study has so far investigated 
whether a particular anatomic variation can impair drainage 
of the ostiomeatal complex per se. Whilst some authors have 
postulated that anatomical variations of the paranasal sinuses 
can contribute to ostial obstruction (574) there are several 
studies that show the prevalence of anatomical variations is no 
more common in patients with CRSs or wNP than in a control 
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population (570, 575, 576). 
One area where conjecture remains is the effect of a deviated 
septum. There are a number of studies that show no correlation 
between septal deviation and the prevalence of CRS (498, 577). 
Whilst there is no recognised method of objectively defining 
the extent of a deviated septum, some studies have found 
a deviation of more than 3mm from the midline to be more 
prevalent in rhinosinusitis (578, 579) whilst others have not (575, 
577, 580). In spite of the observation that sinonasal complaints 
often resolve after surgery, this does not necessarily imply that 
anatomic variation is aetiologically involved. CRS of dental origin 
should not be overlooked when considering the aetiology of 
CRS. Obtaining accurate epidemiologic data on the incidence 
of CRS of dental origin is not possible as the literature is limited 
to anecdotal reports though there is some evidence that 
odontogenic sinusitis may be increasing (581).
Taken together, there is no evidence for a causal correlation 
between nasal anatomic variations in general and the incidence 
of CRS.
4.1.4.9. Biofilms (See also section 4.2)
Many pathogenic bacteria colonize the surface of the NPs 
forming biofilms. They are not a primary etiologic agent in 
NP, but a contributor significantly adding more inflammation. 
Clinically, cases of NP with presence of biofilms are correlated 
with severe forms of the disease and worse postoperative 
outcome (550, 582).
Methicillin-resistant Staphylococcus aureus (MRSA) does not 
appear to pose a significant risk of morbidity in our patient 
population. However, ongoing concern regarding the increasing 
prevalence of S. aureus and antimicrobial resistance in chronic 
sinonasal disease highlights the importance of using culture-
directed antimicrobial therapy with the goal of minimizing 
future resistance patterns (583) Bhattacharyya and Kepnes (584)  
analyzed 701 bacterial isolates among 392 culture samples from 
patients with CRS. They concluded that antibiotic resistance 
seems to be emerging for erythromycin at a rate higher than 
for other antibiotics like methicillin, clindamycin, gentamicin, 
tetracycline, sulphamethoxazole, and levofloxacin. Although not 
increasing in prevalence, MRSA maintains a significant presence 
in CRS with associated increased levels of antibiotic resistance. 
Bachert et al. (585) investigated 70 patients and demonstrated 
that mucosal inflammation in nasal polyps orchestrated by 
Th2 cytokines and amplified by S. aureus enterotoxins is 
characterized by an increased eosinophilic inflammation and 
formation of IgE antibodies.
4.1.4.10. Environmental factors (See also section 4.2.)
Cigarette smoking was associated with a higher prevalence 
of CRS in Canada (11) and exposure to secondhand smoke is 
common and significantly independently associated with 
CRS (561), whereas this observation was not confirmed in a 
nationwide survey in Korea (489). GA(2)LEN study demonstrated 
that smoking was associated with having CRS in all parts of 
Europe (GALEN study) (492). Recently, other lifestyle-related 
factors are undoubtedly involved in the chronic inflammatory 
processes of CRSsNP. For instance, low income was associated 
with a higher prevalence of CRSsNP (11). In spite of in vitro 
data on the toxicity of pollutants on respiratory epithelium, 
there exists no convincing evidence for the aetiologic role of 
pollutants and toxins such as ozone in CRSsNP. Koh et al. (562) 
investigated the relationship between CRS and occupation and 
concluded that there were significantly increased prevalence 
ratios of CRS in plant and machinery operators and assemblers, 
elementary occupations, crafts and related trade workers, and 
the unemployed.
The role of environmental factors in the development of 
CRSwNP is unclear. No difference in the prevalence of CRSwNP 
has been found related to the patient’s habitat or pollution at 
work (508). One study found that a significantly smaller proportion 
of the population with polyps were smokers compared to an 
unselected population (15% vs. 35%) (508), whereas this was not 
confirmed by others (496). One study reports on the association 
between the use of a woodstove as a primary source of heating 
and the development of NP (586).
4.1.4.11. Iatrogenic factors 
Among risk factors of CRS, iatrogenic factors should not be 
forgotten as they may be responsible for the failure of sinus 
surgery. The increasing number of sinus mucocoeles seems 
to correlate with the increase in endoscopic sinus surgery 
procedures. Among a group of 42 patients with mucocoeles, 
11 had prior surgery within 2 years prior to presentation (587). 
Another reason for failure after surgery can be the recirculation 
of mucus out of the natural maxillary ostium and back through a 
separate surgically created antrostomy resulting in an increased 
risk of persistent sinus infection (588).
4.1.4.12. Helicobacter pylori and laryngopharyngeal 
reflux 
H. pylori DNA has been detected in between 11% (589) 33% of 
sinus samples from patients with CRSsNP but not from controls 
(590). Flook and Kumar (105) reviewed nineteen papers describing 
varying studies on CRS and acid reflux. There is not enough 
evidence to consider anti-reflux therapy for adult refractory CRS 
and there is no evidence that acid reflux is a significant causal 
factor in CRSsNP.
4.1.4.13. “Osteitis” 
This is considered fully in Section 5b but the study by Telmesani 
and al-Shawarby (591) is noteworthy. They studied 50 patients 
undergoing FESS for the first time and 32 patients undergoing 
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revision surgery. Histopathological examination was performed 
for specimens taken from the bony septa of the ethmoid with 
the overlying mucosa. Bony changes were seen in only 30% of 
primary NP compared to 87.5% in recurrent cases. 
4.2. Inflammatory mechanisms in chronic 
rhinosinusitis with or without polyps 
(CRSwNP or CRSsNP)
4.2.1. Summary: Aetiology and Pathogenesis of 
CRS
Historically, idiopathic CRS was attributed to either the end 
stage of an incompletely treated case of acute RS (CRSsNP) or 
severe atopy (CRSwNP). The limitations of these assessments 
were clear to many but relatively few hypotheses have been 
proposed as alternatives. The first attempt to address aetiology 
and pathogenesis in broad terms was the ‘fungal hypothesis’, 
which attributed all CRS to an excessive host response to 
Alternaria fungi (592, 593). Although most investigators have 
rejected the basic tenets as originally proposed, fungi are still 
believed by many to play a role as a disease modifier in at 
least some forms of CRS. Defects in the eicosanoid pathway, 
most closely associated with aspirin intolerance, have also 
been proposed as a potential cause of CRSwNP in general 
(594, 595). Specifically, increased synthesis of pro-inflammatory 
leukotrienes and decreased synthesis of anti-inflammatory 
prostaglandins (PGE2) have been proposed as a mechanism not 
just for aspirin-sensitive nasal polyps but also aspirin-tolerant 
CRSwNP. While some theoretical evidence supports this line of 
thought in CRSwNP, enthusiasm is muted by the limited clinical 
efficacy of leukotriene pathway inhibitors. The ‘staphylococcal 
superantigen hypothesis’ proposed that exotoxins foster nasal 
polyposis via effects on multiple cell types  (542, 596). The net 
effect is Th2 skewing, Treg inhibition, accentuated eosinophil 
and mast cell activity and heightened tissue damage and 
remodeling. It remains unclear why superantigen effects can be 
demonstrated in only approximately half of CRSwNP patients; 
hence, staphylococcal superantigens are generally seen by 
many as disease modifiers, rather than discrete aetiologic 
agents (594). The ‘immune barrier hypothesis’ proposed that 
defects in the co-ordinated mechanical barrier and/or the innate 
immune response of the sinonasal epithelium manifests as 
CRS (25). These defects theoretically lead to increased microbial 
colonization with a panoply of microbial agents, accentuated 
barrier damage and a compensatory adaptive immune response 
(597). One potential molecular mechanism for this hypothesis 
would include local defects in the STAT 3 pathway, which has 
been identified in some forms of CRS (598). Systemic defects in 
STAT 3 have been identified in Job’s disease, a disorder with 
some striking similarities to CRSwNP (599). The ‘immune barrier 
hypothesis’ does not specifically address the Th subset skewing 
observed in many CRS subtypes, including the Th2 pattern 
and B cell infiltrate observed in Western CRSwNP patients. This 
implies additional, as yet undetermined, mechanisms or defects 
that foster an inappropriate local, adaptive response in the 
sinonasal mucosa. Genes that may be involved in Th2 skewing 
include TSLP, IL-33, IL-25 and genes in the strong B cell response 
include BAFF, CXCL12 and CXCL13 (600-602). An excessive and/or 
inappropriate Th2 adaptive response in this setting may further 
compromise barrier function and diminish innate immunity, 
thereby creating a self-perpetuating cycle of disease. In the 
most severe forms of CRSwNP, new evidence supports the 
generation of local autoantibodies further accentuating tissue 
damage (23). Lastly, biofilms have been suggested as a potential 
entity that can cause CRS (603). It can be speculated that a defect 
in the immune barrier might facilitate formation of biofilms. The 
mechanism of biofilm formation and worsening of CRS remain 
unclear but biofilms on the sinus mucosa have been likened to 
those mediating periodontal disease (604).
Epithelial damage and/or host barrier dysfunction results 
in colonization with S. aureus. Subsequent secretion of 
superantigenic toxins has effects on multiple cell types 
including epithelial cells, lymphocytes, eosinophils, fibroblasts 
and mast cells. Locally, the net effect is to help the organism 
evade the host immune response. The primary host effects are 
a skewing of the inflammatory response in the Th2 direction, 
generation of local polyclonal IgE, promotion of eosinophil 
survival and mast cell degranulation and alteration of 
eicosanoid metabolism. The sum of these local tissue effects is 
believed to foster polyp formation. The capability of S. aureus 
to reside within airway epithelial cells likely only augments this 
process.
CRS can be typically described as a 
dysfunctional host-environment interaction 
at the site of interface, which occurs in the 
nose and paranasal sinuses
The current hypotheses that discuss CRS aetiology and 
pathogenesis are less in conflict than might appear. 
Superantigens for example, have been shown to modulate 
eicosanoid metabolism (605, 606) suggesting a link between 
two of the proposed theories. Furthermore, the presence of 
intracellular S. aureus in epithelial cells from CRSwNP but not 
CRSsNP or controls, suggests defective local immune and/or 
barrier function (607, 608). One mechanism may be the induction 
of M2 macrophages, which have diminished phagocytic 
properties, by enhanced local Th2 immunity induced by 
superantigens (594, 609, 610). It has been suggested that S. aureus 
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biofilms have the ability to skew the cytokine milieu in the Th2 
direction independently of superantigens (603). Lastly, fungi have 
substantial intrinsic protease activities, which may degrade 
tight junctions accentuating host barrier compromise (25, 597). 
The interplay between exogenous agents and host defects 
conceptually links the theories although the relative importance 
and validity of various components remains in flux. 
Host factors that determine susceptibility to CRS depend, in 
part, on genetic variation across key pathways governing the 
immunobiology of the nasal mucosa (25). Cystic fibrosis (CF) is 
the prototypic case of ‘genetic’ CRS wherein dysfunction of 
the CFTR gene triggers defective innate immune and barrier 
functions (611). In the case of CF, simple Mendelian genetics apply 
but a wide variation of sinus disease expression is nevertheless 
observed, despite identical mutations in the CFTR gene (612). 
Consequently even in CF, the most straightforward case of 
genetic CRS, multiple genes are involved in an individual 
patient determining clinical phenotype (613). Early attempts to 
identify additional genetic loci important in CRS have been 
undertaken and this is a work in progress (614). Comprehensive 
genome wide association studies (GWAS) studies have yet to 
been performed in CRS, but multiple studies have been done 
in related chronic inflammatory disorders including asthma (615). 
In terms of aetiology and pathogenesis, these studies as well as 
others, suggest the involvement of not only multiple genetic 
loci but also the importance of environmentally-determined 
epigenetic changes (616-619). Hence, host susceptibility to complex 
diseases such as CRS likely reflects the combined effects of 
variation in not only the DNA base sequence but also the DNA 
methylation and histone modification patterns caused by past 
environmental exposures. Ongoing environmental stresses 
confront the susceptible host, which may lead to development 
of the chronically inflamed state known as CRS. 
The model of CRS, in which interplay between multiple host 
factors and environmental stressors takes centre-stage, makes 
the observed variability in inflammatory tissue infiltrates and 
clinical phenotype readily explicable. At the time of the last 
EPOS review, CRS was divided into CRSsNP, a Th1 disorder, 
and CRSwNP, a Th2 disorder (620). More recent studies have 
demonstrated that this paradigm does not apply worldwide, 
in particular for CRSwNP, as some Asian polyps exhibit Th1, 
Th17 and KCN cytokine profiles (621). A new hypothesis has been 
proposed suggesting that CRSsNP is characterized by fibrosis, 
high levels of TGF-β and increased Treg activity while CRSwNP 
exhibits oedema, low TGF-β levels and low Treg activity (594, 
622). Further studies will be necessary to test the validity of this 
Figure 4.2.1.: Overview of the ‘superantigen hypothesis’ of CRS..
(2061).
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revised proposal. Nevertheless, racial and cultural differences 
across the globe almost assuredly modulate susceptibility 
and response patterns of the host. Variations in the nasal 
bacterial colonization patterns observed worldwide (623) 
indirectly supports this concept and further suggests that 
ongoing environmental stressors likely also vary with culture 
and geography.  
Since the last EPOS document there has been significant 
progress toward understanding the aetiology and 
pathogenesis of CRS. CRS is still described as ‘multifactorial’ 
and there is no clearly delineated single molecular pathway 
that explains the journey from injury to tissue change (20). 
There is however, an emerging consensus that the persistent 
inflammation that defines CRS results from a dysfunctional 
host-environment interaction involving various exogenous 
agents and changes in the sinonasal mucosa. In concert with 
the definition of CRS as an inflammatory disorder, there has 
been movement away from pathogen-driven hypotheses. 
This overall concept is in agreement with the current 
understanding of the aetiology and pathogenesis of chronic 
mucosal inflammatory disorders in general, which describe a 
balance of interactions between the host, commensal flora, 
potential pathogens and exogenous stresses (624).
Figure 4.2.2: Overview of the ‘immune barrier hypothesis’ of CRS.
1: Intrinsic host deficits in nasal epithelium results in reduced production of innate immune anti-microbial molecules. 
2: Local immune deficits permit the colonization and overgrowth of microbial agents. 
3: Intrinsic patterns within microbial agents are capable of activating epithelial cells through pre-programmed pathways. The integrity of the epithe-
lial barrier is disrupted secondary to epithelial activation allowing increased direct stimulation of T and B-cells through antigen or epithelial mediated 
pathways. 
4: These pro-inflammatory factors lead to dysregulation of the local inflammatory microenvironment leading to local pseudofollicle formation and 
site-specific immunoglobulin production. Local antibody mediated effects degranulate eosinophils and basophils releasing cytotoxic and vasoactive 
mediators into the nasal mucosa..
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4.2.2. Introduction
Chronic rhinosinusitis (CRS) is a clinical syndrome characterized 
by persistent symptomatic, inflammation of the mucosa of the 
nose and paranasal sinuses. The inflammation that defines this 
disorder occurs at the interface with the external environment, 
suggesting the still unproven hypothesis that CRS results from 
an inappropriate or excessive immune response to foreign 
agents resulting in persistent mucosal inflammation, cellular 
influx, radiographic changes and clinical disease (25). The 
widespread adoption of the term ‘rhinosinusitis’ in preference 
to ‘sinusitis’ indirectly supports the perspective that foreign 
material brought in through the airway, or perhaps from the 
nasopharynx, acts on the nasal mucosa first, with secondary 
effects-direct and indirect-on the sinus mucosa (14, 594). In a very 
small percentage of cases such as dental or iatrogenic sinusitis, 
this pathway is reversed with processes in the sinus cavity 
leading to secondary nasal inflammation. CRS may also, in rare 
cases, develop secondary to inflammatory processes intrinsic 
to the mucosa in the presumed absence of exogenous stimuli 
(e.g. Wegener’s granulomatosis, sarcoidosis). Lastly, CRS may 
occur in association with distinct host genetic factors (cystic 
fibrosis) or systemic immunodeficiency. In the overwhelming 
majority of CRS cases however, the etiology and pathogenesis 
remains unclear. This section will focus on idiopathic CRS, with 
references to other better-defined inflammatory disorders only 
as they reveal general principles of the immune response of the 
sinonasal mucosa. 
Idiopathic CRS has been typically divided into CRSsNP and 
CRSwNP based on endoscopic findings. In terms of aetiology 
and pathogenesis, CRSsNP is more tightly linked to mechanical 
obstruction of the ostio-meatal complex (OMC) while CRSwNP 
is generally attributed to a more diffuse mucosal response 
(625). A minority of investigators still hold that the distinction 
between the two groups is primarily one of disease-intensity 
and duration (20, 626, 627). The weight of current research however, 
would suggest separate, but likely overlapping inflammatory 
mechanisms and for research purposes this separation facilitates 
data analysis and determination of molecular pathways of 
disease (628). Most investigators, and most lines of research 
however, assume that the inflammation seen in idiopathic 
CRS results primarily from a dysfunctional host-environment 
interaction (25). Identification of the exogenous agents, which 
drive the secondary inflammatory mechanisms, has been a 
major research focus for many years. 
This section will provide an overview of currently proposed 
environmental inflammatory triggers followed by a review of 
the literature concerning the host mucosal response in CRS, 
separating out specific agents and mechanisms based on 
disease phenotype to the extent currently possible. 
4.2.3. Inflammatory triggers
4.2.3.1. Bacteria
Bacteria have an established role in the aetiology of acute 
rhinosinusitis (ARS) and it has long been speculated that 
incompletely treated bacterial ARS leads to the development 
of CRS. While bacteria may well trigger acute infectious 
exacerbations, the role of bacteria in the initial establishment 
of CRS remains unclear. This section will provide an overview 
of evidence for and against bacteria as aetiologic agents in CRS 
with emphasis on recent data. 
The nasal microbiota is complex and multiple methods, with 
varying degrees of sensitivity and specificity, have been utilized 
to determine the bacterial density and composition in health 
and disease (629). Analysis of samples obtained from the vestibule, 
measured using molecular techniques, demonstrate multiple 
bacterial species but a preponderance of the staphylococci 
and corynebacterium (630, 631). An inverse correlation between 
the two families was observed, suggesting an antagonistic 
relationship (632). In addition, the presence of S. epidermidis 
appears to compete with S. aureus (633). The normal microbiota 
of the middle meatus may, of course, be quite different than the 
anterior nostril but these principles likely apply. Healthy sinus 
cavities, studied using conventional techniques only, appear 
to have substantially less bacterial colonization than the nasal 
airway (634). Although not yet tested, more sensitive techniques 
would likely reveal the presence of a significant bacterial load 
in the sinuses, given the documented colonization of the lower 
airway even in healthy individuals (630). Colonizing commensal 
bacteria in the nose and possibly the sinuses may be important 
not only in interfering with the growth of pathogens, but also 
modulating the host immune response (635). This latter effect has 
been studied in the mouse airway. Animals reared in germ-free 
environments and lacking commensals, generated accentuated 
Th2 responses to ovalbumin challenge (636). This effect was 
reversed when the commensals were replaced. In the human 
gut, commensals induce Treg responses (624, 637) but whether 
similar effects occur in the human airway remains unclear. 
Nevertheless, these findings suggest that commensal bacteria, 
interacting through the innate immune system, may play a 
major role in physiologic immune regulation in the upper airway 
(638). 
The nasal and sinus microbiota in CRS has thus far been studied 
primarily only using conventional techniques. Higher rates 
of Staphylococcus epidermidis were seen in controls when 
compared to CRS (639). When ARS and CRS are compared, the 
majority of reports demonstrate increased rates of S. aureus, 
gram negative rods and anaerobes in CRS (3, 640-647). Other 
investigators however, have demonstrated no differences 
between the nasal bacteriology of CRS and normal controls (648, 
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649). In cases of unilateral CRS, similar microbiological floras were 
demonstrated in both diseased and non-diseased sides (650) and 
culture results did not change after clinically successful sinus 
surgery (651). Overall, these studies have challenged the role of 
bacteria in CRS aetiology and pathogenesis, although some 
of the disparities are likely due to variations in methodology 
(3), concomitant allergic rhinitis (652), prior antibiotic treatment 
and source of material for analysis (nasal or sinus). Some 
investigators have discounted any pathologic role for S. 
epidermidis, while others do not. The presence of organisms 
within epithelial cells (653, 654) or in biofilm quora, likely also 
produces variation in the rate of bacterial identification using 
conventional techniques. Application of molecular techniques 
may begin the process of fully defining the nasal microbiota in 
CRS. Recently, a prospective study of samples obtained from 
the middle meatus, using the 16S ribosomal DNA technique, 
revealed a polymicrobial flora in CRS that was distinct from 
controls (655). Results indicated a preponderance of anaerobes 
in CRS. Larger studies using metagenomic techniques (656) are 
likely needed to fully address this issue as the density and 
composition of the microbial community may play a significant 
role in regulating host response (624, 657, 658). Specifically, the lower 
airway microbiota is disordered in asthma and this has been 
proposed to play a role in disease pathogenesis (630). Whether 
effects are seen in CRS remains uncertain. Lastly, it should be 
kept in mind that the vast majority of data has been collected 
on Caucasian patients in western countries and the bacterial 
colonization rates in other races and geographic regions may be 
vastly different in both health and disease (659).
S. aureus is the most common traditional bacterial pathogen 
identified in CRS patients in western countries (660). The 
incidence of staphylococcus is much lower in Asian CRSwNP 
(623) but the presence or absence of bacteria, or any microbial 
agent, does not mandate or eliminate a role in disease 
causation. Host evidence of bacteria specific effects does 
exist for Staphylococcus aureus however, suggesting a role in 
pathogenesis if not aetiology in at least a subset of CRSwNP 
patients. Substantial evidence implicating this organism in 
CRSwNP has accumulated over the last decade, giving rise to 
the “Staphylococcal Superantigen Hypothesis”, which proposes 
that colonizing S. aureus secretes superantigenic toxins (SAgs) 
that amplify local eosinophilic inflammation and foster polyp 
formation (542, 596). In support of this hypothesis, culture studies 
have indicated a high correlation between the presence of 
staphylococcus and nasal polyposis (661). These results were 
supported by the recent demonstration of intracellular S. aureus 
in CRSwNP, but not in CRSsNP or control patients (607, 608). In 
addition, approximately 50% of CRSwNP patients demonstrate 
B and T cells responses in the tissue consistent with prior local 
staphylococcal superantigen exposure (542, 662-666). These include 
specific IgE against SAgs as well as clonal proliferation of 
polyp T cells indicative of local SAg exposure. In addition, SAg 
toxins have been detected in a portion of CRSwNP patients 
but not controls (667). These in vivo findings are immunologic 
‘footprints’ of a staphylococcal superantigen effect, which can 
be demonstrated in approximately 50% of Caucasian nasal 
polyps as well as a lower percentage of Asian polyps. From 
a mechanistic standpoint, in vitro studies indicate that SAg-
induced cytokine release tends to be pro-inflammatory and Th2 
skewed, promoting IL-4 and IL-5 but down regulating TGF-β 
and IL-10 (668-670). SAgs also manipulate eicosanoid metabolism 
in a pro-inflammatory fashion (605, 606), augment granulocyte 
migration and survival (671) and furthermore, another 
staphylococcal toxin (SpA) fosters mast cell degranulation 
(668). Staphylococcus increased cytokine and MMP expression 
in polyp and inferior turbinate organ cultures, presumably 
through a superantigen effect (672). It has also recently been 
suggested that staphylococcal superantigens may induce 
glucocorticoid insufficiency through induction of the β isoform 
of the glucocorticoid receptor (673). Overall, these studies indicate 
that SAgs have the capacity to foster the Th2 cytokine and 
remodeling profile observed in Western nasal polyps. Moreover, 
the demonstration of a local SAg effect correlates with the 
severity of the eosinophilic inflammation (585). Thus far, there is 
no evidence of a role for superantigens in CRSsNP, suggesting a 
distinct aetiology and pathogenesis. 
 
Biofilms and/or intracellular residence of 
bacteria may increase resistance to 
standard therapy
In summary, while staphylococcal superantigens appear 
to amplify and modulate inflammation in nasal polyposis, 
evidence for a direct aetiologic role is lacking (594). The relatively 
common intranasal presence of toxigenic staphylococci 
suggests that unknown host factors likely determine disease 
expression (674). In addition, approximately 50% of Western polyp 
patients studied have no evidence of SAg responses yet have 
a similar phenotypic picture, suggesting that superantigens 
are not necessary for the typical inflammatory response seen 
in CRSwNP. Lastly, cystic fibrosis patients exhibit a high rate 
of staphylococcal colonization and polyp formation yet no 
evidence of a SAg effect and a strikingly distinct histology and 
cytokine profile (25). These considerations lead most investigators 
to view S. aureus as a disease modifier rather than a discrete 
aetiologic agent but these findings are, nevertheless, molecular 
evidence indicating staph specific effects (675, 676). 
Bacterial biofilms have also been implicated in CRS aetiology 
and pathogenesis. Biofilms are highly organized structures 
composed of communities of bacteria encased within a 
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protective extracellular matrix. The formation of bacterial 
biofilms on surfaces such as the sinonasal mucosa reflects a 
universal strategy for survival in conditions less than optimal 
for growth (677, 678). Biofilms serve to protect bacteria from both 
host defenses and antibiotics (679) and are believed to be a 
source of recurrent exacerbations in CRS through the periodic 
release of free-floating bacteria (680). Biofilms are largely absent 
from controls but have been recovered from both CRSsNP and 
CRSwNP patients. Reported rates of biofilms in CRS populations 
vary from 30-100%, likely due to differences in detection 
methodology (681-690). Multiple bacterial species have been 
associated with CRS biofilms including H. influenza, S. aureus, 
S. pneumonia, P. aeruginosa and M. catarrhalis (677, 678, 684, 687, 689). 
The presence of S. aureus and P. aeruginosa biofilms has been 
associated with an unfavorable outcome post surgery (686, 691), 
while the presence of H. influenza biofilms was associated with a 
favorable outcome and milder disease (692). In particular, S. aureus 
has been associated with a particularly poor prognosis (693). It 
has been suggested that S. aureus biofilms foster a Th2 adaptive 
immune response independent of any staph superantigen 
effect (603). In contrast, an earlier report demonstrated a shift 
toward Th1 inflammation in CRS biofilm patients (694). This study 
was not limited to Staphylococcal biofilms, however. In addition, 
the differing results may reflect different patient populations in 
each study, specifically the presence or absence of nasal polyps, 
rather than intrinsic capabilities of the biofilm to skew the host 
response. Very recent studies suggest that disruption of the host 
epithelium may permit biofilm mediated inflammatory effects 
on the sinonasal tissues (695). Overall, it is widely accepted that 
biofilms are a bacterial adaptation facilitating resistance to host 
defenses and antibiotics, helping to foster recalcitrant disease. 
Moreover, it is also possible that biofilm directed therapies will 
prove useful in the management of CRS. However, it remains 
much less clear whether biofilms have any role in the initial 
establishment of CRS (696). 
4.2.3.2. Fungi
The role of fungi in CRS has generated much controversy in the 
last decade (697, 698). The use of sensitive detection techniques 
has indicated that fungi are a ubiquitous intranasal presence, 
identified in close to 100% of both CRS patients and controls 
(592, 699). As opposed to controls however, patients with CRS also 
exhibited eosinophils in the nasal tissues and lumen, with no 
increase in IgE mediated mould allergy (592). These observations 
formed the basis of the “Fungal Hypothesis of CRS”, which 
proposed that an excessive, non-IgE mediated host response 
to common airborne fungi is the primary pathogenic trigger in 
most forms of CRS, both polypoid and non-polypoid, varying 
only in intensity (593, 700, 701). The primary evidence cited to support 
this theory was the relative hyper reactivity of peripheral blood 
mononuclear cells (PBMC) from CRS patients in response to 
stimulation with supra-physiologic doses of Alternaria antigen 
in vitro (702). PBMCs from CRS patients expressed significantly 
higher levels of Th1 and Th2 cytokines upon exposure to 
Alternaria extract and this heightened response was presumed 
to reflect an immunologic sensitization of T cells to Alternaria, 
suggesting it was particularly important in inciting the CRS 
inflammatory response. As further evidence, nasal mucus or 
tissue from CRS patients triggered eosinophil migration (703) 
and a 60-kDa component of the Alternaria fungus was later 
shown to trigger eosinophil de-granulation via PAR receptor 
activation in vitro (704). These data were interpreted to suggest 
that Alternaria served a dual role: first, Alternaria proteins are 
presented to sensitized T cells inducing a cytokine response that 
serves to attract and activate eosinophils. Second, Alternaria 
serves as the target of the eosinophils, triggering de-granulation 
through a surface PAR receptor, with subsequent mucosal 
damage. This effector role for eosinophils against fungi was 
proposed despite the fact that eosinophils do not normally 
participate to a significant degree in the host defense response 
targeting fungal organisms (705). Further challenges to the 
“Fungal Hypothesis” included the observation that the majority 
of patients in these studies (702, 703) had concomitant asthma, 
and the heightened cytokine responses from PBMCs as well as 
the eosinophil migration may reflect priming from this asthma 
rather than CRS (25, 697, 698). Furthermore, attempts to replicate 
the fungal-induced cytokine responses from PBMCs by other 
investigators failed, clearly indicating the absence of a universal 
hyper-responsiveness to fungal antigens in CRS patients (706, 
707). Nevertheless, interest in fungi spawned a series of drug 
trials using topical intranasal anti-fungal agents that initially 
provided mixed support for the overall hypothesis (708-711). An 
extensive, multi-centre, blinded, randomized trial using intra 
nasal amphotericin failed to show any evidence of efficacy, 
however (712). More significantly, a follow up study indicated that 
amphotericin had no significant effect on any pro-inflammatory 
chemokine, cytokine or growth factor in the CRS lavage samples 
(713). Overall, the current literature does not support the routine 
use of topical anti-fungals for CRS (714) and support for the fungal 
hypothesis as originally proposed is scant.
Evidence for a fungal-specific role in the aetiology 
of most CRS cases is lacking
The view of fungi as the universal or even primary antigenic 
stimulus in CRS, has largely faded (715, 716), but this does not 
eliminate fungi as a factor in CRS aetiology or pathogenesis for 
at least three reasons. 
a. Fungi, particularly Alternaria, contain intrinsic proteases 
that can non-specifically activate protease-activated receptors 
(PAR) present on the apical surface of nasal epithelial cells 
with secondary effects on eosinophils and neutrophils (717, 718). 
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Non-specific effects of a protease may be significant, given that 
epithelial-based protease activated receptors (PAR) are known 
to be up-regulated in CRS and this signaling may result in 
significant inflammation in the presence of high levels of fungal 
organisms (25, 719, 720). 
b. Fungi may play a role in the aetiology and pathogenesis of 
allergic fungal rhinosinusitis (AFRS), classically defined as: (25) 
nasal polyposis (14) characteristic thick eosinophilic mucin and 
(594) characteristic CT scan findings (625), type 1 hypersensitivity to 
fungal antigens by serology or skin tests and (626) fungal elements 
in the mucin detected by culture or histology (721, 722). AFRS has 
been proposed to be an immunologically distinct subset of 
CRS (723). In support of this, peripheral blood mononuclear cells 
(PBMCs) from AFRS patients were demonstrated to secrete Th2 
cytokines in response to fungal antigens (724). In addition to this 
systemic sensitization, AFRS patients also demonstrate fungal-
specific IgE in the eosinophilic mucin (725) and the mucosa (726). 
The implications of these observations remain far from clear 
however, as CRSwNP patients with similar, thick eosinophilic 
mucin but without fungal allergy or gross fungi on histology 
clearly exist (290). Significantly, the presence or absence of fungal 
allergy or gross fungi in the eosinophilic mucin had no effect 
on histology, inflammatory cell infiltrate, tissue eosinophilia 
or fungal-specific PMBC proliferation (727-729). A small microarray 
study also showed very few differences in gene expression 
profiles in the absence of fungi in the mucin (730). The similarities 
among the groups irrespective of the presence of fungi or 
fungal allergy have been interpreted by some investigators 
to indicate that allergy to fungus cannot be the primary 
pathophysiologic force driving the inflammation in AFRS (79, 731). 
Further studies will be necessary to resolve the issue (722). 
c. The cell walls of fungi contain the polysaccharide polymer 
chitin, which is recognized by pattern recognition receptor(s) 
in airway epithelial cells triggering innate immune responses 
(732). Chitin induces a local Th2 immune response in vivo mouse 
studies, with mucosal infiltration by eosinophils, basophils 
and Th2 lymphocytes (733). Chitin also induces the enzyme 
acid mammalian chitinase (AMCase), which acts to degrade 
the chitin apparently as a defense mechanism, in turn, down 
regulating the Th2 inflammation (732). AMCase can also be 
elevated in asthmatic inflammation independent of chitin and 
in this setting it actually drives Th2 inflammation (732, 734). In the 
upper airway, epithelial cells also express AMCase and levels 
are significantly higher in nasal polyps (735-738). Similarly, chitin 
stimulates AMCase expression by sinonasal epithelial cells 
in culture (739). While these results are interesting, the clinical 
significance of chitin or AMCase in lower airway disease remains 
uncertain, and any role for AMCase or chitin in the etiology or 
pathogenesis of CRS is even more speculative. 
In summary, while high levels of fungi may theoretically have 
direct immuno-stimulatory effects, with the possible exception 
of AFRS, we lack any consistent in vitro or in vivo evidence 
demonstrating that fungal antigens are the primary targets of 
the mucosal T cell or B cell responses observed in CRS. Therefore, 
despite initial enthusiasm for the fungal hypothesis as the 
basis for all chronic sinus disease, the current state of basic 
science evidence coupled with the failure of clinical trials with 
amphotericin (713), indicates that a central role for fungi in CRS is 
unlikely.
4.2.3.3. Allergens
The potential role of inhaled allergens in the aetiology and 
pathogenesis of CRS is controversial, much of which stems 
from the lack of uniform definitions of both CRS and atopy, 
variability in allergy testing methodologies and potential 
referral bias in patients receiving allergy testing (79, 740). From 
a pathophysiological standpoint, allergic rhinitis (AR) occurs 
through host sensitization to antigenic foreign protein across a 
mucosal barrier via dendritic cells and naive CD4+ lymphocytes, 
with the generation of antigen specific Th2 lymphocytes and 
IgE secreting plasma cells. Subsequent antigenic challenge 
across the mucosa results in cross linking of IgE bound to 
the surface of mast cells and subsequent de-granulation as 
well as the release of additional Th2 cytokines leading to 
recruitment of inflammatory cells including eosinophils. The 
pathogenesis of CRS is much less clear but at least some of 
these mechanisms are operative. Clinically, the symptoms of 
AR also overlap with CRS to a substantial degree (26) but are 
generally less severe than those present in most forms of CRS. 
Studies in CRS indicate that inflammation in the sinus mucosa 
and nasal mucosa are similar in profile if not disease intensity 
establishing the term ‘rhinosinusitis’ (14). Recent studies have 
indicated that nasal challenge with allergen leads to secondary 
maxillary sinus inflammation (741). This is in accordance with 
reports demonstrating CT changes induced in ragweed allergic 
rhinitis (742). Technically speaking then, AR could actually be 
termed allergic rhinosinusitis exhibiting not only nasal, but also 
chronic sinus mucosal inflammation, at least in more severe 
circumstances such as perennial AR, which has a markedly 
more intense inflammatory profile than intermittent AR (743). 
Hence, perennial AR could be included under the CRS definition: 
inflammation of the nasal and sinus mucosa of over 12 weeks 
duration. From this perspective, much of the confusion in regard 
the role of AR in CRS becomes clear. AR can be viewed as just 
one mechanism of sinonasal mucosal inflammation, that is 
comparatively well understood from a molecular perspective, 
sharing the same effector cells, cytokines and inflammatory 
mediators active in many forms of CRS. The contribution of AR 
to the total inflammatory picture in CRS is typically relatively 
mild however, since the presence of allergic rhinitis (as defined 
by positive RAST or skin testing) did not influence symptom 
severity, extent of disease on CT scan or likelihood of surgical 
67
Supplement 23
failure when compared to non-allergic CRS (744-746). Furthermore, 
avoidance and immunotherapy relieved some associated rhinitis 
symptoms but did not reverse sinonasal disease (79). 
In summary then, while more severe, perennial forms of allergic 
rhinitis might technically fulfill the definition of CRS, evidence 
is weak in support of a role for AR in the aetiology of the typical 
case of CRS. The most reasonable conclusion appears to be that 
AR should generally be considered a superimposed problem, 
which contributes in a variable but relatively mild way to the 
sinonasal inflammation seen in most CRS patients. Notable 
potential exceptions may be the patients with severe CRSwNP 
associated with (25) multiple positive skin tests, suggesting a 
generalized barrier failure (14, 23) allergic fungal rhinosinusitis (722) 
as discussed above and (594) patients with local polyclonal IgE 
in the absence of systemic atopy (542, 596). It has been suggested 
that this subgroup of patients manifests a superantigen driven 
local polyclonal IgE response to a diffuse array of environmental 
agents with resultant massive chronic mast cell stimulation (747).  
4.2.3.4. Viruses
The defense against respiratory viruses involves both innate 
and adaptive immunity (748). These protective responses trigger 
sinus inflammation demonstrable on CT scans but the effects 
are presumed to be transient (749) and despite the frequency of 
viral upper respiratory infections (URIs), relatively little attention 
has been paid to any association with CRS. In assessing a role for 
viruses in the aetiology and pathogenesis of CRS, the topic will 
be divided into 3 hypotheses: 
1. viruses are a chronic source of mucosal inflammation,
2. viruses trigger the initial insult that pre-disposes to CRS and 
3. viruses trigger acute exacerbations of CRS (750). 
Evidence that viruses can be a chronic source of sinonasal 
inflammation triggering CRS is relatively scant. Viruses have 
the capacity to incorporate into host DNA and theoretically 
establish latent infections in the upper respiratory mucosa. A 
recent study demonstrated rhinovirus in 21% of epithelial cell 
samples from the inferior turbinates of CRS patients and 0% in 
controls (751). A follow up study testing for a wide array of upper 
respiratory viruses failed to confirm this however, demonstrating 
0% in both patients and controls (750). Taken together, these 
studies do not suggest a significant role for viruses in the 
stimulation of chronic inflammation in CRS. A role for viruses in 
triggering the initial event that predisposes to the development 
of CRS is also lacking. Although this hypothesis has not been 
tested in CRS, early childhood viral infections have been linked 
to the subsequent development of asthma years later (752). The 
mechanism remains unclear but may relate to virally-induced 
durable epigenetic changes in host tissues that manifest as 
disease when challenged later in life (753).  
With regard to exacerbations of airway disease, viral infections 
have been clearly implicated in exacerbations of asthma and 
COPD (754-757). Viral URIs are also presumed to precede most 
episodes of acute bacterial rhinosinusitis. With regard to CRS 
exacerbations, in vivo data is lacking but it has been proposed 
that viral infection in combination with cigarette smoke fosters 
epithelial activation contributing to acute exacerbations of 
CRS (758). These in vitro studies using double stranded RNA plus 
cigarette smoke triggered increased RANTES expression in nasal 
epithelial cells, which should foster an eosinophilic response 
in vivo. In summary, the potential relationship between viral 
infection and CRS is relatively unstudied. Nevertheless, given 
the documented ability of viral upper respiratory infections 
to disrupt the upper airway epithelial barrier (759), it is clearly 
possible they play a role in the aetiology and pathogenesis of 
CRS. 
4.2.3.5. Environmental Toxins
Exposure to toxins such as tobacco smoke, ozone, sulphur 
dioxide, nitrogen dioxide and particulate air pollutants (e.g. 
diesel exhaust fumes) have the potential to trigger damage 
to the epithelium and, in principle, accentuate airway 
inflammation. These agents induce oxidative and nitrosative 
stress with production of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) that have the capacity to cause 
tissue damage (759). The significance of most toxin exposures in 
CRS is unclear, although a number of studies have focussed on 
the effects of tobacco smoke. The prevalence of CRS has been 
reported to be higher in smokers (760, 761) and smokers have a less 
favorable response to surgery (762, 763). The deleterious effects of 
cigarette smoke relevant to CRS include alterations in secretion 
and ciliary beat frequency (764) as well the induction of bacterial 
biofilms (765). Based on in vitro data, it has been proposed that 
cigarette smoke in combination with viral infection contributes 
to acute exacerbations and eosinophilic inflammation in CRS 
patients (758). ROS and RNS from tobacco smoke induces pro-
inflammatory cytokine secretion (765), epithelial apoptosis (766, 767) 
and diminished airway epithelial barrier function (768). Overall, 
data suggest that cigarette smoke likely can contribute to the 
inflammation in CRS in exposed individuals, but evidence for 
a role in the initial establishment of the disorder is lacking. In 
particular, a recent study has suggested that in contrast to the 
lower airways, the pro-inflammatory effects of tobacco smoke 
in the upper airway appear to be down-regulated over time 
(769). Outcome studies have also failed to show a strong negative 
effect from smoking (770). These findings would argue against a 
significant role for tobacco smoke in CRS aetiology. 
4.2.4. Host Inflammatory Pathways in CRS
Sinonasal mucosa serves as the site of interface with inhaled 
irritants, aero-allergens, commensal organisms and pathogens. 
Mucociliary clearance, physical exclusion, and the innate and 
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adaptive immune responses all serve as a barrier, protecting 
host from environment. The major environmental agents thus 
far implicated in CRS were discussed in the preceeding segment 
but their pathophysiologic importance remains unclear. In the 
normal patient, these common entities are cleared without 
tissue damage or the establishment of a chronic process. It 
has been proposed that alterations in the host mucosal innate 
immune response may predispose to the development of CRS 
(25, 597). This hypothesis shifts emphasis away from identifying 
singular environmental or microbial agents and implicates 
host susceptibility as the major factor in CRS pathogenesis. A 
recent expert panel has gone further, proposing the question 
whether all CRS patients may be immunodeficient in some 
fashion (628). If correct, it should be kept in mind that the 
majority of idiopathic CRS patients do not suffer from chronic 
inflammatory pathology outside of the airway. The association 
of asthma and CRS is well established, but the prevalence of 
other chronic inflammatory disorders in the CRS population 
was not found to be significantly above background (771). 
These observations suggest the corollary hypothesis: immune 
abnormalities, if present in CRS, will be mediated by processes 
centred in the airway mucosa. Regardless of the ultimate 
validity of these concepts, the mucosal inflammation in CRS is 
highly variable in character, an observation predictable given 
the broad definition of this entity. Currently, the most widely 
accepted sub types of idiopathic CRS are the forms with and 
without nasal polyps, as the gross finding of ballooned mucosa 
suggests a distinct pathway or pathways in this subset of 
patients. These two groups are themselves heterogeneous, 
however, and incompletely characterized from a standpoint 
of pathogenesis. Distinguishing the molecular pathways that 
characterise or underlie CRS inflammation should be of value 
in determining pathophysiology, further defining sub types of 
CRS and ultimately, guiding new therapeutic approaches (628). 
The following segment will review the current literature on the 
various components of the sinonasal mucosal defense system, 
with emphasis on areas relevant to CRS.
4.2.4.1. Mechanical Barrier
The mechanical barrier of the sinonasal mucosa consists of 
the mucus, motile cilia and respiratory epithelial cells linked 
by adhesion complexes that include apical tight junctions. 
Mucociliary transport is the first line of defense, trapping foreign 
material in the mucus blanket and moving it out of the sinuses 
and nasal cavity towards the nasopharynx. The source of nasal 
secretions includes submucosal glands, goblet cells, epithelial 
cell proteins, lacrimal secretion and vascular transudate.  
Respiratory mucus includes a low viscosity inner sol layer and a 
high viscosity outer gel layer, which rides along the tips of the 
extended cilia. The major protein components of respiratory 
secretions are the mucin glycoproteins with peptide backbones 
and oligosaccharide side chains; these glycoproteins likely play a 
significant role in organizing the mucus, secondarily influencing 
host-microbial interactions (772). In addition, mucins bind surface 
adhesins on microorganisms limiting their ability to access the 
epithelium and facilitating mucociliary transport out of the nasal 
cavity (773). The relevance of this process to CRS is underscored 
by the high prevalence of sinonasal inflammation observed in 
patients with gene defects affecting mucociliary flow such as 
cystic fibrosis (chloride transport) and Kartagener’s syndrome 
(ciliary dyskinesia) (773). Individuals that are heterozygous for 
CFTR mutations are also more likely to suffer from CRS (774). 
Furthermore, in idiopathic CRS there is evidence for ciliary 
dysfunction in explanted epithelial cells (775). Clinically, increased 
mucus viscosity correlates with disease severity in CRS (776) and 
drugs that reduce viscosity have been proposed as therapeutic 
agents (777-779). 
Host defects in the mechanical barrier, 
mucociliary flow and the innate immunity 
(e.g. lactoferrin and S100 proteins) have been 
associated with CRS
Breakdown of the mechanical components of an epithelial barrier 
can play an important role in permitting foreign proteins to 
stimulate an immune response and this has been proposed as a 
major factor in the aetiology of asthma (768). Airway epithelial cells 
are linked by an apical intercellular adhesion complex composed 
of tight junctions, intermediate junctions, desmosomes and 
hemidesmisomes. In CRSwNP, significantly decreased levels of 
the desmosomal proteins DSG2 and DSG3 (780) and tight junction 
proteins claudin and occludin (781) have been reported. Expression 
of the epithelial protein LEKT1 is also significantly decreased 
in CRSwNP (782). This protein, encoded by the gene SPINK5, acts 
as a protease inhibitor involved in regulating the processing of 
the tight junction proteins critical to epithelial barrier function 
in the skin. Interestingly, mutations in SPINK5 are shown to be 
responsible for Netherton syndrome- a rare autosomal recessive 
condition that results in flaky skin, fragile hair and severe 
atopy (783). Lower levels of protease inhibitors like LEKT1 in CRS 
epithelium may result in increased susceptibility to endogenous 
and exogenous protease activity (597). Fungi, bacteria and many 
allergens all possess significant intrinsic protease activity, which, 
in the presence of deficient endogenous protease inhibitors such 
as LEKT1, may render the mechanical barrier more vulnerable 
to protease attack and greater mucosal penetration of foreign 
proteins. Further functional evidence for barrier dysfunction 
in CRS is demonstrated by higher rates of ion permeability in 
cultured epithelial monolayers derived from CRS patients when 
compared with normal controls (784). Increased ion transport has 
been proposed as a mechanism for tissue oedema seen in nasal 
polyps (785, 786). 
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Taken together, these studies suggest that defective mucociliary 
function may play a role in the pathogenesis of CRS broadly, 
while mechanical barrier disruption has been more closely 
linked to CRSwNP. 
4.2.4.2. Epithelial Cells
4.2.4.2.1. Receptors
In addition to the physical barrier, sinonasal epithelial cells 
(ECs) play an active role in both the innate and acquired 
immune response (787, 788). Membrane bound and cytoplasmic 
pattern recognition receptors (PRRs) that recognize pathogen 
associated molecular patterns (PAMPs) have been identified 
on airway epithelial cells (139, 159, 789-791). PAMPs are conserved 
molecular patterns found in parasites, viruses, yeasts, bacteria 
and mycobacteria; recognition by host epithelial cells through 
PRRs results in the release of innate protective agents as 
well as chemokines and cytokines that attract innate cellular 
defenses (e.g. neutrophils). In addition to PAMPs, cells also 
sense cellular damage through damage-associated molecular 
patterns (DAMPs) (159, 792). The combined signal of foreign 
material plus cellular damage triggers an innate response and 
sets in motion, and ultimately helps determine the nature of, 
the adaptive immune response (793). 
Prominent amongst the PRRs are the Toll-like receptors 
(TLRs), currently a family of 10 integral membrane 
glycoproteins that recognize extracellular or intracellular 
PAMPs such as bacterial cell-surface lipopolysaccharides 
(LPS) or unmethylated CpG islands found in pathogen DNA. 
Engagement of the TLRs by a PAMP triggers intracellular 
signaling through adapter proteins like MyD88 or TRIF that 
in turn can effect pro-inflammatory gene expression through 
the activation of nuclear transcription factors such as NF-kB, 
AP-1 and IRF3 (794). Given that TLR2, TLR3, TLR4 and TLR9 in 
particular are expressed on airway epithelium, it is likely they 
play an important role in mediating host inflammation, with 
potential derangements contributing to the development 
of CRS (795).  This hypothesis is supported by the quantitative 
increase in TLR2 mRNA seen in cystic fibrosis polyps and in 
some studies of CRSsNP, (796, 797), as well as reported decreases 
in mucosal TLR2 and TLR9 mRNA in samples from CRSwNP 
(791, 798). These results have not been confirmed at the protein 
level nor is there data demonstrating a functional deficit of 
TLR signaling in CRS patients. Nevertheless, this remains a 
theoretical mechanism that can account for chronic mucosal 
inflammation and merits further exploration. Data regarding 
dysregulation of other PRRs in CRS is sparse, although 
NOD-like receptors (NLRs) are expressed in nasal and sinus 
epithelial cells (799). A single study indicated that levels were 
increased in CRSwNP epithelium and this level was decreased 
after nasal steroid use (800). 
In addition to PRRs, sinonasal epithelial cells also express 
protease-activated receptors (PAR) (720). Although not 
classically considered host defense molecules, these receptors 
are activated by a variety of endogenous and exogenous 
proteases, including those associated with bacteria, fungi and 
allergens (801). Triggering of PAR receptors invokes the NFκβ 
signaling pathway that results in cytokine and chemokine 
production, cellular recruitment and potentially, skewing of 
the both the innate and acquired immune response (794, 802). 
In vitro studies on the nasal epithelium have indicated that 
PAR-2 activation triggers IL-8 release and this response can 
be elicited by Staphylococcus aureus-derived proteases (720, 
803). Other investigators have suggested that fungal proteases 
may act on PAR receptors to drive both a neutrophilic and 
eosinophilic response (718). As mentioned earlier LEKT1 protein, 
a natural anti-protease, is reduced in CRSwNP epithelium 
(782). In addition to protecting tight junctions discussed 
above, this protein should also serve to shield epithelial-
based PAR receptors. In a model of skin disease, a recent 
study demonstrated that the absence of LEKT1 leads to the 
expression of the Th2 skewing molecule TSLP via activation 
of PAR-2 (804). It has been suggested that LEKT deficiency may 
contribute to the pathogenesis of CRS via inappropriate PAR 
stimulation as well (597). This may be of particular significance 
given that CRSsNP and CRSwNP both express higher levels of 
PAR2 in comparison to normal ECs (720). 
4.2.4.2.2. Epithelial Cell Response: Host defense molecules
Epithelial cells secrete a vast arsenal of antimicrobial 
molecules in several classes including enzymes (lysozyme, 
chitinases and peroxidases), opsonins (complement 
and pentraxin-3), permeabilizing proteins (A defensins, 
B defensins and cathelicidins such as LL-37), collectins 
(surfactant protein-A, surfactant protein-D and mannose-
binding lectin) and binding proteins (lactoferrin and mucins) 
(611, 805, 806). Studies of CRS patients have not demonstrated 
a universal trend in the expression of these antimicrobial 
molecules. Levels for complement components, LL-37, 
surfactant protein A (SP-A) and Acid Mammalian Chitinase 
demonstrated increases, presumably compensatory, in 
CRS patients (735, 807-811). Lactoferrin and the S100 group of 
antimicrobials were decreased in CRS, however (686, 812, 813). 
The S100 proteins are products of a multi-gene family 
widely expressed in epithelial cells. In addition to direct 
anti-microbial effects, these have diverse effects on cell 
differentiation and wound healing, linking the mechanical 
barrier and classic anti-microbial properties (814). PLUNC 
(Palate Lung Nasal Epithelial Clone), another secreted 
antimicrobial protein, is decreased in CRSwNP (815). PLUNC is 
secreted by glandular rather than surface epithelium and this 
protein may have particular relevance for CRS as it possesses 
anti-biofilm properties. 
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Sinonasal epithelial cells (ECs) play 
an  active  role in both the innate and 
acquired immune response
Presence of diminished host defense molecules in CRS suggests 
the hypothesis that a primary sinonasal innate immune 
defect may contribute to local microbial proliferation and the 
development of CRS in a subset of patients (597). There is some 
evidence however that Th2 cytokines can cause nasal epithelial 
cells to down regulate the production of innate immune 
molecules such as human beta-defensin 2 and surfactant 
protein A (816). This suggests the alternative hypothesis that an 
inappropriate Th2 effector response at the mucosal surface 
may account for the observed innate immune deficiencies. 
Mechanistic studies to uncover whether diminished EC innate 
immune responses in CRS are constitutive and pre-exist the 
onset of CRS or are inducible responses to Th2 inflammation 
are still incomplete. Nevertheless, innate immune responses 
in ECs can be induced by the T cell cytokine IL-22, which 
works through its receptor IL-22R (817, 818). Binding of IL-22 to 
its receptor activates the transcription factor STAT 3, which 
mediates mucosal host defense and epithelial repair (819, 820). In 
airway ECs, the STAT 3 pathway regulates production of host 
defense molecules including the S100 family (821). Studies in 
the gut and lung indicate that this pathway is critical in the 
regulation of inflammatory responses at the epithelial surface 
in general (822). In CRSwNP, diminished expression of IL-22R has 
been reported (823) and separate studies have indicated that the 
STAT 3 pathway is blunted in CRSwNP (598). Interestingly, STAT 3 
mutations have been indentified in Hyper IgE syndrome (HIES 
or Job’s syndrome), which is associated with eosinophilia, high 
IgE, staph abscesses and recurrent sino-pulmonary infections 
(599). The similarities between CRSwNP and some aspects of Job’s 
syndrome suggest the hypothesis that nasal polyposis may 
result from local (sinonasal) impairment of the STAT 3 pathway 
(598). 
4.2.4.2.3. Epithelial Cell Response: Cytokines and 
Chemokines
Airway epithelial cells produce a variety of inflammatory 
cytokines, typically in response to PRR and PAR receptor 
stimulation (794). A partial list includes IL-1, TNF-α, IFNα/β, 
GM-CSF, eotaxins, RANTES, IP-10, IL-6, IL-8, GRO-α, MDC, SCF, 
TARC, MCP-4, BAFF, osteopontin, IL-25, IL-32, IL-33 and TSLP 
(24, 600, 805, 824-826). In addition to driving pain, swelling, vascular 
dilation and leak and other hallmarks of inflammation, many of 
these cytokines have chemokine properties attracting various 
leukocytes including eosinophils, mast cells, neutrophils, 
dendritic cells and lymphocytes. EC cytokines are also believed 
to play a key role in dendritic cell polarization, shaping the 
nature of the T cell response to antigens (827). 
Given the important role of ECs in mucosal immunity, altered 
nasal EC cytokine release may play a role in CRS pathogenesis. 
The contribution of EC gene expression to the overall mucosal 
cytokine milieu can be difficult to determine. Quantitative 
cytokine studies in CRS have been done on whole tissue 
biopsies for the most part, as the techniques needed to 
analyze isolated nasal EC secretion are more problematic. In 
vivo epithelial scrapings and in vitro EC cultures both have 
limitations: the former is generally limited to mRNA analysis as 
adequate protein samples are difficult to obtain while the latter 
is technically difficult and prone to potential cell culture effects. 
In vitro studies have most commonly demonstrated elevated 
EC cytokine secretion from CRS patients as opposed to normals, 
presumably reflecting their activated state (717, 828-830). Interest 
has centered on potential effects on eosinophils; elevated 
GM-CSF, eotaxins and RANTES from ECs likely contributes to the 
recruitment and survival of these cells in CRSwNP. One study did 
demonstrate decreased IL-8 in cultures from CRSsNP patients 
suggesting that diminished neutrophil recruitment may play a 
role in pathogenesis (831). Recent in vivo studies demonstrated 
elevated EC expression of IL-32 in CRSsNP (832). In CRSwNP, 
elevated secretion of IL-6 (598) and BAFF (600) were observed, and 
this was at least in part from EC activity. BAFF (also called BLys 
or TNFSF13B) triggers B-cell proliferation and class switching, 
and these processes may have particular significance in CRS 
pathophysiology (600). BAFF is secreted by multiple cell types and 
will be discussed more extensively in the section on B cells.
EC cytokines have established effects on multiple cell types, 
including not only effector cells but also dendritic cells. 
Relevant to CRS, in vitro studies indicate that ECs from nasal 
polyps have the capacity to skew dendritic cell polarization in 
the Th2 direction (833). Mechanistically, it has been suggested 
that a subset of EC cytokines (IL-25, IL-33 and TSLP) are key 
determinants of dendritic cell polarization and subsequent T 
cell differentiation in response to mucosal antigens (601, 787, 788, 
834). Specifically, these cytokines have the capacity to skew T 
cell differentiation in the Th2 direction, the pattern observed in 
Western CRSwNP patients. TSLP, in particular, has the ability to 
act directly on dendritic cells, shaping the T cell profile as well as 
directly and indirectly (through mast cells) recruiting eosinophils 
(601, 827). Whether TSLP is relevant to CRS pathogenesis is unclear, 
however a recent paper demonstrated elevated TSLP activity 
using a bioassay of supernatant from nasal polyp explants (835). 
These results were independent of allergic status. Subsequent 
papers have also implicated TSLP in polyposis (836-838). Levels of 
other epithelial cytokines with Th2 properties, such as IL-33, 
have been reported as higher in recalcitrant CRSwNP (839) and 
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Table 4.2.1. Inflammatory cells in Chronic Rhinosinusitis with nasal polyps (IHC; immunohistochemistry; RT-PCR; reverse-transcriptase protein chain 
reaction; ELISA: enzymo-linked immunosorbent assay).
Author, year, ref. Tissue, Patients Cell type Technique Conclusion
Fokkens, 1990 (2062) nasal polyps healthy 
nasal mucosa allergic 
rhinitis nasal mucosa
T lymphocytes B Lym-
phocytes eosinophils
neutrophils dendritic cells
Ig+ cells
IHC
Jankowski, 1996 (1477) nasal polyps
sinonasal mucosa (CRS
eosinophils IHC CRS with NP: more than 10% eosinophils
compared to CRS without NP
Drake-Lee, 1997 (2045) nasal polyps
inferior turbinate
mast cells IHC Greater mast cell degranulation in CRS
with NP compared to healthy inferior
turbinate
Haas, 1997 (856) nasal polyps
healthy nasal mucosa
dendritic cell IHC Dendritic cells are present in NP
Jahnsen, 1997 (2046) nasal polyps endothelial cells flow 
cytometry
RT-PCR
Endothelial cells express VCAM-1, induced
by IL-4 and IL-13, with a role in eosinophils
and T lymphocyte recruitment
Loesel, 2001 (2047) nasal polyps
healthy nasal mucosa
mast cells fluores-
cence
microscopy
Number of mast cells is not different
between controls and CRS with NP
Seong, 2002 (2048) nasal polyps epithelial cells ELISA
RT-PCR
In CRS with NP: inflammatory mediators
may over-express MUC8 mRNA in NP and
downregulate MUC5AC
Sobol, 2002 (862) nasal polyp from cystic
fibrosis (CF)
NP from non-CF
neutrophils IHC There is a neutrophil massive activation in
CF-NP compared to non CF-NP
Wittekindt, 2002 (1007) nasal polyps
healthy nasal mucosa
endothelial cells IHC VPF/VEGF expression was higher in NP
than in healthy nasal mucosa
Shin, 2003 (717) eosinophils from 
healthy volunteers in-
cubated with CRS with 
NP polyp epithelial cell
epithelial cells ELISA Eosinophils in nasal secretions are activated
by GM-CSF, which is produced by nasal
epithelial cells
Chen, 2004 (2049) nasal polyps
healthy nasal mucosa
epithelial cells IHC
RT-PCR
CRS with NP epithelial cells express
increased amounts of LL-37, an
antimicrobial peptide
Claeys, 2004 (863) nasal polyps
sinonasal mucosa (CRS)
healthy nasal mucosa
macrophages real-time
RT-PCR
CRS with NP: MMR has a higher
expression than in CRS without NP and
controls
Watanabe, 2004 (828) nasal polyps epithelial cells IHC Clinical efficacy of glucocorticoids on NP
epithelial GM-CSF production, which
prolongs eosinophil survival.
Gosepath, 2005 (2050) nasal polyps
healthy nasal mucosa
endothelial cells IHC VPF/VEGF are increased in NP compared
to healthy nasal mucosa, suggesting a role
in both the formation of NP and induction
of tissue edema
Kowalski, 2005 (824) nasal polyps epithelial cells, stem
cell factor (SCF)
ELISA
RT-PCR
Epithelial cells release stem cell factor (SCF)
Conley, 2006 (663) nasal polyps
antrochoanal polyp
S. aureus superantigens
of the T-cell receptor
flow cy-
tometry
S .aureus SAg-T-cell interactions in 35% of
CRS with NP lymphocytes
Hao, 2006 (992) nasal polyps
healthy nasal mucosa
T lymphocytes IHC Inverse median ratio of CD4+/CD8+ T
cells as compared to the middle turbinate
Schaefer, 2006 (829) nasal polyps
sinonasal mucosa (CRS)
healthy nasal mucosa
epithelial cells IHC
ELISA
NP endothelial and epithelial cells are the
main source of CC chemokine eotaxin-2
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genetic studies also suggest that variation near the IL-33 gene 
is associated with CRSwNP (840). In regard to IL-25, there is no 
current evidence for elevated expression or activity of this 
cytokine in CRS. Overall, crosstalk between ECs and dendritic 
cells remains an active area of CRS research.
ECs likely play a significant role in mediating not only the 
innate response, but also shaping the subsequent adaptive 
immune response. Whether primary variations in ECs 
responses underlie CRS aetiology and pathogenesis is unclear 
but interfering with EC cytokine expression for therapeutic 
purposes is an area of active research (841, 842). Furthermore, 
in contrast to the up-regulation of antimicrobials in EC, 
corticosteroids down regulate EC cytokine secretion (828, 843, 
844). This bimodal effect of corticosteroids on ECs may be a key 
mechanism accounting for their efficacy in CRS. 
4.2.4.2.4. Epithelial Cell Response: Co-stimulatory 
molecules
In addition to cytokine mediated regulation of T-cells 
mentioned above, airway epithelial cells also express 
homologues of the B7 co-stimulatory family (192). Expression 
of these cell surface ligands, which have the ability to down 
regulate T-cell responses, are increased in CRS patients and 
induced by TNF-α and IFN-γ (191). Induction of B7 molecules also 
occurs via viral infection (190). The clinical significance of this 
down regulation of T-cells and its possible relevance to viral 
exacerbations of CRS remains unclear. 
4.2.4.2.5. Epithelial Cell Response: Inflammatory Enzymes, 
ROS and RNS
Enzymes involved in the generation of reactive oxygen species 
(ROS) are important in multiple epithelial processes including 
mucin production, epithelial repair, innate immunity and 
response to environmental toxins (805). Oxidative enzymes are 
important in the generation of hypothiocyanite, an important 
antimicrobial that selectively kills microorganisms and 
spares host cells; this pathway is defective in cystic fibrosis 
(805). Environmental toxins induce ROS production, which is 
counteracted by various scavenger enzymes and anti-oxidants 
in airway epithelial cells. If these protective mechanisms 
are overwhelmed, pro-inflammatory cytokines are induced; 
additional oxidative stress can lead to cell death (845).
Reactive nitrogen species (RNS) also play a significant role in 
several biologic processes and RNS can also interact with ROS 
in disease causing tissue damage (759). In particular, there has 
been a great deal of interest in a potential role for nitric oxide 
in CRS. Nitric oxide (NO) is produced by nitric oxide synthase 
(NOS) and there are 3 relevant enzymes in the airway: inducible 
NOS (iNOS), and endothelial and neural NOS (eNOS and nNOS), 
which are constitutive. A variety of cells types possess iNOS, 
including epithelial cells and macrophages. Stimuli for induction 
of iNOS include various chemokines, cytokines, allergens, 
viruses, pollutants, hypoxia, bacterial toxins and viruses (805). 
In general, constitutive NO acts as an intracellular messenger 
and neurotransmitter, induced NO mediates inflammatory 
Author, year, ref. Tissue, Patients Cell type Technique Conclusion
Van Zele, 2006 (620) nasal polyps
sinonasal mucosa (CRS)
healthy nasal mucosa
T lymphocytes
plasma cells
eosinophils
neutrophils
IHC CRS with NP: increase in T lymphocytes
numbers and activated T-lymphocytes,
CD4+/CD8+ T cells, and eosinophils than
CRS without NP and controls.
CRS with NP: increased number of neu-
trophils and more MPO compared to
healthy controls but not to CRS without NP
Ramanathan, 2007 (798) nasal polyps
healthy nasal mucosa
epithelial cells flow 
cytometry
RT-PCR
TLR9 is down-regulated in NP epithelial
cells and involved in innate immunity
functions
Sachse 2010 (608) CRSwNP, CRSsNP and 
control tissue
Epithelial cells PNA-FISH; 
EM; ELISA
Staph invasion of  sinonasal epithelial cells 
occurs in CRSwNP
Ayers 2011 (860) AFS, CRSsNP and con-
trol sinus tissue
Dendritic cells IHC Dendritic cells are increased in CRSwNP and 
AFS vs. controls and CRSsNP
Kirsche 2010 (859) CRSwNP, CRSsNP and 
control tissue
Dendritic cells Flow 
cytometry
Low myeloid dendritic cells may be present 
in CRSwNP
Krysko 2011 (609) CRSwNP and control macrophages IHC M2 macrophages increased in CRSwNP; 
phagocytosis impaired
Mjoesberg 2011 (973) Nasal polyps Innate type II lymphocytes flow
cytometry
Innate type II lymphocytes are present in 
high levels in nasal polyps
Payne 2011 (627) Nasal polyps Inflammatory cell types IHC; PCR; 
ELISA
Polyps can be divided in eosinophilic and 
non-eosinophilic (NE). NE polyps demon-
strate glandular hypertrophy and dense 
collagen deposition. 
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and antimicrobial effects and can also regulate apoptosis. 
The sinuses produce very high amounts of NO and it has 
been proposed that this limits bacterial colonization of these 
structures given the proximity of the nasal and oral cavity (846). 
NO also regulates ciliary beat frequency (847) and studies have 
indicated low levels of nasal NO in CRSsNP (848). The lowest levels 
of NO have been reported in CRSwNP, and levels increase with 
treatment (849, 850). These reports have generated a large number 
of studies on the topic of nitric oxide and CRS, but the role of 
nasal NO in health and disease has not been clarified, in part due 
to variations in methodology. No study to date has correlated 
nNO levels with any clinical, molecular or pathological measure 
of sinus mucosal inflammation (851). In terms of aetiology and 
pathogenesis of CRS, it has been suggested that metabolic 
pathways are abnormal in nasal polyposis (852) and that high NO 
levels are important in keeping microbial colonization levels 
low within the paranasal sinuses (853). In particular, high levels of 
NO have inhibitory effects of S. aureus biofilm growth (854) but 
these levels may actually promote growth of other bacteria. The 
clinical relevance also remains unclear since ESS, which has a 
high success rate in most studies, reduces the NO concentration 
in operated sinuses (855). Moreover, a fundamental criticism of 
existing work on the topic is that all studies measure NO in 
the sinus lumen, rather than at the mucosal surface and in the 
respiratory mucus where innate defenses operate (851).
4.2.4.3. Dendritic Cells and Macrophages
Dendritic cells (DCs) activate both innate and adaptive 
immunity via antigen capture, presentation of antigen to 
immature T cells and secretion of soluble inflammatory 
mediators. Crosstalk between epithelial cells and DCs (see 
discussion above) is believed crucial to the determination of any 
subsequent T cell response to mucosal antigen and these cells 
serve as a bridge between the innate and adaptive response (601). 
DCs have been described in the nasal mucosa (856) and a recent 
study indicates that multiple subsets are present (857). Studies 
in CRS have been limited but functional DCs are present in 
polyp mucosa (858). It has been suggested that myeloid dendritic 
cells are decreased in the polyps when compared to CRSsNP 
or control nasal tissues and this accounts for the observed 
Th2 skewing (859). Other investigators demonstrated increased 
DCs in CRSwNP vs. either CRSsNP or control mucosa (860). In this 
study, elevated DC chemoattractants CCL2 and CCL20 were 
present in polyp mucosa suggesting recruitment of immature 
DCs to the sinonasal mucosa. DCs were increased in CRSsNP vs. 
control mucosa but the difference was not significant. Levels of 
Vitamin D3, an immunoregulatory molecule with known effects 
on DCs, were low in CRSwNP suggesting a potential role for 
replacement therapy (833).  More broadly, the key role of DCs in 
the mucosal immune response makes them attractive targets for 
the management of chronic airway inflammation; in particular, 
modulating epithelial/DC crosstalk may have therapeutic value 
(601). 
Macrophages are innate immune cells with diverse roles: 
removal of particulates, primary response to pathogens; tissue 
homeostasis; coordination of the adaptive immune response; 
inflammation; tissue repair (861). The classical macrophage 
activation pathway (M1) is driven by Th1 cytokines that trigger 
a pro-inflammatory response necessary to kill intracellular 
pathogens. The alternative pathway is driven by Th2 cytokines 
in the local milieu leading to M2 macrophages; this process is 
important in the defense against helminthes, humoral immunity 
and tissue repair (861). Macrophages (presumably mostly M1) are 
elevated in the sinonasal mucosa of cystic fibrosis (CF) patients 
in comparison to controls and CRS (862). M2 macrophages, 
which express elevated levels of the macrophage mannose 
receptor (MMR), are present in high levels of CRSwNP patients 
as opposed to CRSsNP, CF and controls (609, 797, 863). Eosinophils, 
via CCL23, may be key to the recruitment of macrophages in 
CRSwNP, which then convert to the M2 type in the Th2 milieu 
(610). These polyp-derived macrophages appear to have an 
impaired ability to phagocytose S. aureus, which may contribute 
to the pathophysiology of CRSwNP (609). In addition, M2 
macrophages derived from nasal polyps secrete high levels of 
CCL18, a cytokine known to be chemotactic for DCs, naïve t cells 
and Th2 cells all of which may contribute to the pathogenesis of 
CRSwNP (832). 
4.2.4.4. Eosinophils
Eosinophils are circulating granulocytes whose function 
at mucosal surfaces is immune defense, primarily against 
multi-cellular parasites. In addition, it has been suggested 
that eosinophils play a significant role in tissue remodeling 
and repair in both health and disease (864). Their presence in 
high numbers in the respiratory mucosa however, has long 
been associated with disease, most prominently asthma and 
allergic rhinitis. Eosinophils are also an important cell type in 
chronic rhinosinusitis, and CRS was at one time considered 
by many to be a purely eosinophilic disease. Eosinophilic 
damage to the sinonasal mucosa was believed to be the 
central pathophysiologic mechanism of CRS and the hallmark 
of the disorder (38, 865). Significantly, the degree of eosinophilia 
in CRS was independent of the concomitant presence of 
allergic rhinitis, suggesting distinct but possibly overlapping 
pathophysiologic processes (744, 866). In addition, the degree of 
tissue eosinophilia in CRS correlates with objective disease 
severity and co-morbid asthma (542, 867-870). The introduction of the 
‘fungal hypothesis’ (see section on fungi) further enhanced the 
role of the eosinophil; toxic mediators released by eosinophils 
targeting fungi were proposed as the common upstream 
pathway for all forms of CRS (592, 699). Variation in the degree of 
tissue eosinophilia in surgical specimens was believed to reflect 
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the presence or absence of allergic rhinitis, prior corticosteroid 
use or simply disease-intensity. It was always clear however, 
that non-eosinophilic forms of nasal polyposis existed, most 
obviously in cases of cystic fibrosis (871) but  this was considered 
an exception. The concept of tissue eosinophilia is relative 
however, and some cases of CRS demonstrated relatively 
minimal eosinophilia and the predominant influx of other 
cell types. Notably, separation of CRS tissue specimens into 
CRSsNP and CRSwNP demonstrated that tissue eosinophilia 
was much higher in the polypoid form (620, 866, 872-874). This close 
association, independent of atopy, suggested that eosinophils 
may be critical to polyp formation but the relationship between 
CRSwNP and mucosal eosinophilia is not maintained in Asian 
polyps (875) as well as a demonstrable minority of Western/
Caucasian polyps (626). While approximately 80% of Caucasian 
polyps are eosinophilic, less than 50% of Asian polyps 
demonstrate tissue eosinophilia above that seen in control 
tissues (875-877). In addition, the majority of CRSsNP worldwide 
appears to be relatively non-eosinophilic, at least in comparison 
to Caucasian polyps. Taken together, these studies indicate that 
eosinophils are not absolutely necessary for nasal polyposis 
or CRS to be present. Although this might appear to diminish 
the importance of these cells in CRS, a recent longitudinal 
study demonstrated that high tissue eosinophilia correlated 
directly with the need for revision surgery (878). A second well 
done prospective study divided patients by polyp status and 
tissue eosinophilia. Results indicated that CRSsNP patients 
with high tissue eosinophilia, while less common, nevertheless 
demonstrated the least improvement of the four groups with 
surgical therapy (879). Consequently, while eosinophils are not 
essential for CRS to exist, they appear to be a biomarker for 
severe, recalcitrant disease, at least in Caucasians, and may still 
be the cell that mediates this relatively poor prognosis (880). 
Eosinophil levels and Th2 cytokine skewing 
are most closely associated with Western 
CRSwNP.
The mechanism of recruitment and activation of eosinophils in 
CRS involves 3 main processes: 
1 the local expression of eosinophil-attracting chemokines by 
the epithelium and other cell types 
2 priming and survival promoting effects of cytokines such as 
GM-CSF and IL-5 and 
3 the expression of adhesion molecules by endothelium 
especially VCAM-1.  
The relevant chemokines are RANTES, Eotaxin 1-3, MCP 1-4, all 
primarily secreted by nasal epithelial cells and all of which work 
through CCR3 (841, 881-891). In allergic inflammation, other cellular 
sources, such as dendritic cells and macrophages, may be the 
most important sources of eotaxin and other CCR3 ligands.  
The regulation of epithelial chemokine expression is complex, 
but the Th2 cytokines IL-4 and IL-13 play a key role working 
through STAT6 and NF-κβ (892, 893). Other stimuli such as chitin 
(see above) may play a role as well (739). In addition, eosinophils 
secrete eotaxin 1-3 as well as RANTES, suggesting a possible 
amplifying effect enhancing local eosinophil recruitment (891, 
894). The relevant cytokines GM-CSF and IL-5 induce increased 
migration, adhesion and survival of eosinophils in nasal polyp 
tissue. GM-CSF was identified first, and is produced in particular, 
by epithelial cells (524, 895-899). IL-5 is also an important priming and 
survival factor for eosinophils in nasal polyps (900-903). Initially, 
IL-5 levels in nasal polyp tissue were believed to correlate 
with atopic status (524) but multiple follow up studies indicated 
that IL-5 status-and hence any effect on eosinophils-was 
independent of systemic allergy (542, 900, 904, 905). The most relevant 
adhesion molecule appears to be VCAM-1, which mediates 
rolling, adhesion and transendothelial migration of eosinophils 
in vitro. Several groups have demonstrated increased expression 
in nasal polyps and levels correlate with the presence of 
eosinophils (883, 906-910). A recent study indicated high VCAM-
1 levels correlated with risk of post surgical recurrence (910). 
P-selectin is an additional adhesion molecule that may also 
play a role in eosinophil accumulation within nasal polyps (911) 
while L-selectin appears to regulate eosinophil accumulation in 
CRSsNP (18, 912).
Asian polyps are less eosinophilic than 
Western CRSwNP, exhibiting a Th1/17 
cytokine skewing
The overall process of eosinophil recruitment, activation and 
survival in CRS, when present, is likely driven primarily by Th2 
cytokines via the mechanisms discussed above. The critical 
upstream cellular sources of these Th2 cytokines in eosinophilic 
CRS remain unclear, but presumably include Th2 helper T-cells. 
In CRSwNP, substantial evidence exists that staphylococcal 
superantigens promote mucosal eosinophilia primarily by 
accentuating local Th2 cytokine release via actions on these 
T-cells, although other mechanisms may also be relevant (542, 621). 
Very recent evidence has further suggested that staphylococcal 
biofilms may play an additional role driving eosinophilia in 
CRS, independent of polyp status or superantigens (603). The 
mechanism for this potential effect is uncertain and further 
studies will be necessary to validate this hypothesis. As 
mentioned earlier, based primarily on in vitro data, the ‘fungal 
hypothesis’ proposed that Alternaria fostered tissue eosinophilia 
via accentuation of Th2 cytokine release from sensitized T-cells 
(593, 702). Two follow up studies failed to confirm these in vitro 
observations however (706, 707) and the weight of evidence does 
not support a major role for fungi in most forms of CRS at this 
time (25, 697, 713, 913). Other factors including IL-33, TSLP, IL-25, PAR 
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receptors, complement proteins, eicosanoids and Stem Cell 
Factor may play an upstream role in CRS tissue eosinophilia but 
evidence is currently very limited (601, 718, 809, 824, 835, 840, 914, 915).
Once present and activated, eosinophils are believed to 
damage the mucosa through degranulation and release of toxic 
mediators with resulting epithelial sloughing and tissue oedema 
(865, 916, 917). In addition to direct toxic effects, eosinophils in nasal 
polyps express CCL23, which acts to recruit macrophages 
and monocytes, whose products may also contribute to the 
inflammation in CRSwNP (610).The mechanism for eosinophil 
de-granulation in CRS is unclear but data from other tissues 
suggests that crosslinking of receptors for IgA is an important 
trigger (918, 919). Effects on eosinophils by IgA can occur even in 
the absence of antigen binding (920). High levels of IgA have been 
identified in nasal polyps suggesting that this immunoglobulin 
may play a key role in vivo (621, 921). Lastly, it has been proposed 
that the epithelial barrier in CRS is already weakened (25, 782), thus 
eosinophilic degranulation should only accentuate the process. 
In addition to the above noted pathologic effects, eosinophils in 
lower airway disease foster fibrotic changes of the sub epithelial 
Table 4.2.2. Inflammatory mediatos (cytokines, chemokines, adhesion molecules, eicosanoids, and matrix metalloproteinases) in Chronic 
Rhinosinusitis without nasal polyps (IHC: immunohistochemistry; RT-PCR: reverse-transcriptase protein chain reaction; ELISA: enzymo-linked immu-
nosorbent assay; CRS; chronic rhinosinusitis without nasal polyps; NP: chronic rhinosinusitis with nasal polyps; FESS: functional endoscopic sinus 
surgery).
Author, year, ref. Tissue, Patients Marker Technique Conclusion
Hamilos, 1993 (526) nasal polyps sinonasal 
mucosa (biopsies
GM-CSF, IL-3 IHC Cellular sources of GM-CSF and IL-3 in NP
remain to be determined
Xaubet, 1994 (899) nasal polyps
sinonasal mucosa
GM-CSF IHC Eosinophil infiltration into the respiratory
mucosa (allergic reaction, CRS with nasal
polyps) is modulated by epithelial cell GM-
CSF
Mullol, 1995 (1643) nasal polyps
sinonasal mucosa
IL-8, GM-CSF, IL-1 ,
IL-6, IL-8, TNF-α
ELISA
RT-PC
Nasal Polyps may represent a more active
inflammatory tissue (more cytokines) than
healthy nasal mucosa
Bartels, 1997 (886) nasal polyps
sinonasal mucosat
CC-chemokines
eotaxin, RANTES
and MCP-3
ELISA Expression of eotaxin and RANTES but no
MCP-3 is elevated in atopic and non-atopic
NP compared to normal mucosa
Bachert, 1997 (900) nasal polyps
sinonasal mucosa
IL-1 , IL-3, IL-4, IL-5, IL-6, IL-8, 
IL-10, TNF-α, GM-CSF,
IL-1RA, RANTES, GRO-α
ELISA IL-5 plays a key role in eosinophil
pathophysiology of nasal polyps and may
be produced by eosinophils.
Ming, 1997 (2063) nasal polyps
healthy sinonasal 
mucosa
allergic rhinitis mucosa
IL-4, IL-5, IFN-γ
mRNA
RT-PCR
Southern 
blot
CRSwNP and allergic rhinitis may differ in 
the
mechanism by which IL-4 and IL-5 are
increased
Simon, 1997 (901) nasal polyps IL-5 ELISA
RT-PCR
IL-5 is an important cytokine that may
delay the death process in NP eosinophils
Bachert, 1998 (904) nasal polyps Th1, Th2 cytokines Elispot Th1 and Th2 type cytokines are
upregulated in NP, irrespective of allergen
skin test results.
Bachert, 2001(542) nasal polyps
sinonasal mucosa
IL-5, IL-4, eotaxin,
LTC4/D4/E4, sCD23,
histamine, ECP,
tryptase, total and
specific IgE for
allergens and
S. aureus enterotoxins
ELISA
Immuno-
CAP
association between increased levels of
total IgE, specific IgE, and eosinophilic
inflammation in NP
Gevaert, 2003 (929) nasal polyps
sinonasal mucosa
Soluble IL-5R RT-PCR antagonistic soluble isoform is upregulated,
the signal transducing transmembrane
isoform is down-regulated in nasal polyps,
mainly in asthma.
Wallwork, 2004 (1708) CRS nasal mucosa
(in vivo & in vitro)
TGFβ-1, NF-kB IHC clarythromycin inhibites TGFβ-1 and NF-kB
only in vitro
Watelet, 2004  (2051) sinonasal mucosa 
(FESS)
MMP-9, TGFβ-1 IHC
ELISA
correlation with the tissue healing quality
Watelet, 2004 (1004) sinonasal mucosa 
(FESS)
TGFβ-1 IHC
ELISA
CRS without NP: increased expression of
TGFβ-1 compared to NP
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Author, year, ref. Tissue, Patients Marker Technique Conclusion
Elhini,2005 (2052) ethmoidal sinus 
mucosa
CCR4+, CCR5+ IHC
real time 
PCR
CRS patients: increase of CCR4+ in atopics
and decrease of CCR5+ in non-atopics
Pérez-Novo, 2005 (1046) sinonasal mucosa COX-2
PGE2
real time 
PCR
ELISA
CRS: COX-2 and PGE2 are more expressed
than in NP
Toppila-Salmi, 2005 
(912)
maxillary sinus mucosa
(surgery)
L-selectin ligands IHC Increased expression in CRS endothelial 
cells
Lane, 2006 (790) ethmoidal mucosa 
(surgery)
TLR2, RANTES,
GM-CSF
real time 
PCR
CRS: increase compared to healthy controls
Lee, 2006 (808) sinonasal mucosa CCL-20 IHC
real time 
PCRS
Increased expression of CCL 20 in CR
Olze, 2006 (890) nasal polyps
turbinate mucosa
eotaxin, eotaxin-2,
and -3
ELISA Eotaxin is expressed in CRS
Pérez-Novo, 2006 (915) nasal mucosa CysLT receptors
EP Receptors
real time 
PCR
CRS: CysLT and EP receptors are more
expressed than in NP
Rudack, 2006 (2053) sinonasal mucosa GRO-α , GCP-2, IL-8,
ENA-78
HPLC + 
bioassay
Expression of GRO- and GCP-2 in CRS
Watelet, 2006 (2054) sinonasal mucosa 
(FESS)
MMP-9 IHC Correlation between MMP-9 expression and
tissue healing quality
Van Zele 2006 (620) CRSsNP; CRSwNP and 
control sinus tissue
Inflammatory cytokines PCR; ELISA CRSwNP is Th2 skewed; CRSsNP is Th1 
skewed
Douglas 2007 (706) PBMC from CRS and 
controls
cytokines PCR Staph SA but not  Alt extracts stimulated 
cytokine response; no difference between 
patients and controls
Ahmed 2008 (1018) Polyp and control 
tissue
Capillary density Confocal 
microscopy
No active angiogenesis in polyps
Kato 2008 (600) CRSwNP, CRS and 
controls
BAFF, IgA, B cells PCR, ELISA, 
IHC
BAFF expression is higher in polyps and 
correlates with IgA and B cells
Lu 2008 (826) CRSwNP, CRSsNP and 
controls
Osteopontin (OPN) ELISA; IHC OPN is unregulated in CRS vs. controls, with 
highest  levels in CRSwNP
Patou 2008 (668) Nasal poly tissue and 
controls
cytokines ELISA; 
tissue 
explants 
SEB staph toxin triggers Th2 skewed 
inflammation; staph protein A triggers mast 
cell degranuation
Ramanathan 2008 (816) SNEC from CRS and 
controls
TLR-9;  beta defensins; spA SNEC cul-
ture; PCR
Th2 cytokines down regulate some SNEC 
antimicrobial factors
Van Bruaene 2008 (984) Sinus tissue from 
CRSwNP, CRSsNP and 
c ontrol
FOX3P; GATA-3; T-bet; RORc; 
cytokines
PCR; ELISA; 
IHC
Low FOX3P and TGFβ, High T-beta and 
GATA-3 in CRSwNP vs. CRSsNP and controls
Zhang 2008 (22) Belgian and Asian 
CRSwNP and control 
tissues
T cell cytokines PCR and 
ELISA
Th2 cytokines elevated in Belgian polyps; 
Th1/Th17 cytokines elevated in Asian 
polyps. Both have decreased FOX3P and 
TGF β vs. control tissue
Allakhverdi 2009 (835) Nasal polyps TSLP Functional 
assay
Elevated TSLP activity in nasal polyps
Ahn 2009 (726) AFS, CRSsNP and con-
trol sinus tissue and  IT
IgE in tissue IHC, ELISA More fungal and non fungal IgE is ex-
pressed in AFS vs. CRSsNP and control  
Cao 2009 (877) Asian CRSwNP, CRSsNP 
and control tissue
Th cytokines; TGF; PCR;ELISA; 
IHC
Asian polyps have Th1, Th17 and Th2 
response patterns; CRSsNP is Th1
Gevaert 2009 (930) CRSwNP and control 
sinus tissue; peripheral 
blood eosiinophils
Soluble and TM IL-5R alpha PCR, Flow, 
ELISA
TM IL-5 alpha is down regulated in polyps 
while SOL-IL-5 alpha is u -regulated
Lalaker 2009 (739) SNEC from CRSwNP 
and controls
AMCase; eotaxin 3 PCR Chitin stimulates AMCase and eotaxin 3
Lee 2009 (1009) Nasal lavage and 
polyps
VEGF PCR; ELISA; 
IHC Flow
VEGF is elevated in CRSwNP tissue and 
lavages
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Author, year, ref. Tissue, Patients Marker Technique Conclusion
Orlandi 2009 (707) PBMC from CRS and 
controls 
Cytokines and fungal spe-
cific IgE
ELISA IL-5 responses to alternaria extract were not 
predictive of CRS
Park 2009 (736) Nasal polyp and IT AMCase; ChT PCR; 
westerns 
and IHC
Polyps have elevated levels of Chitinases
Patou 2009 (949) Nasal polyps and IT Histamine; leuokotrienes; 
PGD2
Tissue 
explants
Enhanced mediator release from Mast cells  
in polyps vs. inferior turbinates
Van Bruaene 2009 (1000) Sinus tissue from CRS 
and controls
TGF-β; TGF-β receptor; col-
lagen
PCR; IHC; 
ELISA
High collagen, TGF, TGF receptor in CRSsNP; 
less collagen, low TGF, TGF receptor in  
CRSwNP
Van Zele 2009 (809) Nasal secretions and 
tissue from CRSwNP 
and controls
C3a; C5a; ECP; MPO; mac-
roglobulin
ELISA; IHC Complement system is activated in CRSwNP
Bachert 2010 (585) Belgian and Asian 
CRSwNP patients 
T cell cytokines; IgE PCR; ELSIA Th2 inflammation, IgE to staph and asthma 
more common in Belgian CRSwNP; Th17 
more common in Asian polyps
Ebbens 2010 (18)  CF, antrochoanal and 
CRSwNP polyps
L-selectin IHC L- selectins ligand are elevated in CF and 
CRSwNP polyps
Lee 2010 (811) Maxillary sinus lavage Anti-microbial lipids Westerns; 
chromatog-
raphy
CRS patients had increased anti-microbial 
lipids
Li 2010  (990) CRSwNP, CRSsNP and 
controls from Asian 
patients
TGF, MMPs, TIMPs; collagen; 
FOX3P
IHC; ELISA; 
PCR
TGF, TIMPs , FOX3P and collagen  lower in 
Asian polyps vs. CRSsNP ; 
Patadia 2010 (602) CRSwNP, CRS and 
controls
B-cell chemokines and their 
receptors
ELISA and 
PCR
BCA-1 and SDF-1alpha elevated in polyps
Perez-Novo 2010 (1052) CRSwNP CRTH2; PGD2 Tissue 
explants
PGD2 from mast cells recruits Th2 cells in 
polyps
Peters 2010 (598) CRS and control tissue IL-6; IL-6r; STAT3 Western; 
ELISA;IHC
IL-6 levels are high in polyps but STAT3 
pathway may be defective
Reh 2010 (839) SNEC culture  CRSwNP IL-33 PCR Increased IL-33 may be associated with 
severe CRSwNP
Schlosser 2010  (810) AFS, CRSwNP and 
control tissue
Complement proteins:  C3, 
C5, C7, factor B
PCR; IHC Complement proteins are increased in 
CRSwNP and AFS vs. controls
Tieu 2010 (813) Tissue and lavages in 
CRS and controls
S100 proteins A7, A8 and A9 ELISA; IHC S100 proteins are decreased in nasal lavages 
and epithelium of CRS patients. 
Van Crombruggen 
2010 (14)
Ethmoid sinus and IT 
from CRS and controls
Various cytokines ELISA Similar mediator profiles seen in ethmoid 
and IT tissue in CRS
Ba 2011 (623) Nasal polyp and 
turbinate
Inflammatory cytokines ELISA Cytokine pattern may correlate with type of 
colonized bacteria
Erbek 2010 (2055) CRSwNP and control 
tissue
ADAM-33 IHC ADAM-33 is elevated in polyps
Foreman 2011 (603) CRS and control sinus 
tissue
SA igE and Th2 cytokines Elisa Presence of staph biofilm skewed Th2 
inflammation independent of SA
Kimura 2011 (838) CRSwNP , AR and NAR 
mucosa 
TSLP PCR; IHC TSLP levels higher in polyps vs. AR and NAR; 
Li 2011 (988) Nasal polyps P63; p73 PCR; IHC Nasal polyps express higher levels of p63, 
possibly important in remodeling
Mansson 2011 (800) CRSwNP and control 
tissue
NOD PCR and IHC NODs mRNA expression is increased in 
polyps 
Mulligan 2011 (833) SNECs from CRSwNP, 
CRSsNP and controls
cytokines Tissue cul-
ture, Flow, 
Polyp SNECs trigger dendritic cell matura-
tion and skew toward Th2 polarization 
independent of antigen exposure
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tissues with the laying down of extracellular proteins (922, 923). 
Eosinophil production of PDGF as well as TGFα and β-1 may alter 
the structure of affected nasal mucosa (924-926). Ultrastructural 
studies on nasal polyps treated with anti-IL-5 will be required 
to more definitively address the role of eosinophils in the 
remodeling of CRS sinonasal tissue (see below).
The association of eosinophilia with refractory disease makes 
this cell a potentially important target in CRS. Eosinophils are 
steroid-responsive (927) and this likely explains at least some of 
the therapeutic effects of glucocorticoids in CRS (27). A large body 
of literature indicates that glucocorticoids can inhibit eosinophil 
recruitment, survival and activation in CRS (880). A recent double-
blind trial using oral corticosteroids demonstrated clinical 
efficacy as well as reduced IL-5 and ECP in nasal secretions 
(928). Targeted therapy using anti-IL-5 in CRSwNP has shown 
promise as well. IL-5 and its receptor are both elevated in 
Caucasian (eosinophilic) nasal polyps (929, 930). Clinical trials using 
anti-IL-5 antibodies demonstrated evidence for reduced polyp 
eosinophilia as well as clinical efficacy (931, 932). 
4.2.4.5. Neutrophils
Neutrophils are circulating immune effector cells with an 
established role in the early phagocytosis and killing of 
extracellular microbes. Recruitment to mucosal sites is 
typically driven by microbial stimulation of PRRs, with release 
of cytokines that trigger endothelial expression of selectins, 
integrin ligands and chemokines. The main chemokine 
fostering neutrophil recruitment in CRS appears to be IL-8, 
in part released by nasal epithelial cells in response to PAR-
2 stimulation (720). The role of the neutrophil in CRS remains 
unclear but the highest sinus tissue levels are seen in CF patients 
(862). For other forms of CRS, differences appear to depend on 
ethnicity as well as the presence or absence of nasal polyps. In 
Caucasians, neutrophilic infiltration can be demonstrated in CRS, 
with slightly lower levels observed in CRSsNP than in CRSwNP 
(620, 873, 874). In concert, studies have shown upregulation of IL-8 
in both CRSwNP and CRSsNP (620, 933-935). Neutrophils did not 
appear to replace eosinophils in CRS mucosa, rather they were 
superimposed on the process; hence the term ‘neutrophilic’ 
rhinosinusitis was not considered completely appropriate for 
CRSsNP (874). Nevertheless, the degree of neutrophilic infiltrate 
was comparable between CRSsNP and CRSwNP as opposed 
to the eosinophilic infiltrate, which was significantly less in 
CRSsNP. As a corollary, it has been suggested that CRSsNP is 
more distinctly a neutrophilic process, while CRSwNP is more 
eosinophilic based on the relative degree of tissue infiltration 
Author, year, ref. Tissue, patients Marker Technique Conclusion
Okano 2011 (2056) Dispersed polyps cytokines ELISA Fungal extracts produced less cytokine 
response than Staph SA
Peterson 2011 (832) CRS and control tissue CCL18 ELISA; West-
erns; IHC
CCL18 increased in CRSwNP; co-localized 
with M2 macrophages
Poposki 2011 (610) Sinus tissue from 
controls, CRSsNP and 
CRSwNP
CCL23 ELISA; 
IHC;PCR
CCL23 is secreted by eosinophils; may 
recruit  Macs and dendritic cells
Roca-Ferrer 2011 (595) Fibroblasts from 
CRSwNP, Samter’s and  
and controls
PGE2; COX-1; COX-2 ELISA; west-
erns
COX and PGE2 levels are reduced in nasal 
polyps with an without ASA intolerance
Rogers 2011(781) CRSwNP and control 
mucosa
Tight junction proteins Confocal 
microscopy
TJ proteins occludin and claudin-1were 
reduced in polyp epithelium
Sejima 2011 (1021) Sinus tissue from 
CRSwNP, CRSsNP and 
c ontrol
Fibrinolytic components ELISA uPA was increased in both CRSwNP and 
CRSsNP vs. controls; Inhibitor (PAI-1)  is over 
expressed in CRSsNP only
Shun 2011(1016) Polyp fibroblasts VEGF; IL-8 Westerns Hypoxia induces Cyr61 which stimulates 
VEGF and IL-8
Tan 2011 (23) CRS and control tissue Anti-nuclear autoantibodies ELISA; West-
erns; IHC
 Anti-nuclear IgA and IgG autoantibodies 
are present in NP
Van Bruaene 2011  
(1001)
Sinus and nasal tis-
sue from early stage 
CRSsNP and controls
TGF-β; inflammatory 
cytokines
ELISA Elevations in TGF-β may pre-date changes 
in inflammatory cytokines; remodeling and 
inflammation may be distinct processes in 
CRS
Wood 2011 (695) Sinus mucosa from CRS 
and controls
Respiratory viruses PCR No evidence for chronic viral infection in 
CRS mucosa
Zhang 2011 (747) AR and nasal polyp 
tissue
Mast cell mediators ELISA  polyclonal IgE in nasal polyps is functional
Keswani 2011 (24) SNEC and tissue from 
CRS and controls
IL-32 PCR; 
ELISA;IHC
Elevated IL-32 may play distinct roles in 
CRSsNP vs. CRSwNP
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(936). Furthermore, in the subpopulation of CRSwNP patients with 
relatively low eosinophilic infiltration, it has been suggested 
that neutrophils may be the major pathologic driver of disease, 
analogous to ‘neutrophilic’ asthma (19). 
In studies of polyps from Chinese patients, neutrophilic and 
eosinophilic infiltration appeared to be less than that seen in 
Caucasian polyps but the degree of eosinophilia was much 
more reduced, hence these polyps were relatively neutrophilic 
(22, 875). A later study on Chinese patients from a different region 
indicated that Asian CRSsNP patients were comparably much 
more neutrophilic than Asian CRSwNP patients (877). In the subset 
of Asian polyps that were non-eosinophilic however, significant 
neutrophilia was observed suggesting distinct underlying 
pathogenic processes within the CRSwNP group (877). Overall, it 
should be kept in mind that Asian polyps may be quite different 
in cellular and cytokine profile throughout the continent.
Traditionally, neutrophils have been considered an acute 
response cell with a relatively short tissue half-life, therefore 
reasons for their accumulation in CRS are not completely clear. 
Recent studies have however, expanded the role of neutrophils 
beyond phagocytocis of extracellular organisms based in part 
on their diverse repertoire of effector molecules, which they 
express upon appropriate stimulation. In particular, neutrophils, 
may play a significant role in the resolution of inflammation 
as well as the pathology of the chronic inflammatory state (937). 
Chronic neutrophilic inflammation is observed in lung disorders 
such as COPD and CF, mediating extensive tissue injury and 
contributing to organ dysfunction. Neutrophil products include 
various proteolytic enzymes, which may alter the protease-
antiprotease balance triggering damage and remodeling. 
The excessive accumulation of neutrophils may be driven by 
the products derived from the breakdown of extracellular 
matrix, namely N-acetyl Pro-Gly-Pro (PGP) (938). PGP is normally 
metabolized but the process is impeded by cigarette smoke, 
with resulting inappropriate neutrophil accumulation in COPD 
(939). In CF lungs, low extracellular chloride levels, driven by 
the CFTR defect, has been proposed to diminish physiologic 
PGP breakdown (939). Whether these processes take place in CF 
polyps or neutrophilic CRS in general is unknown. Interestingly, 
this pathway links smoking with neutrophilic inflammation, 
a process suggested by a separate line of research in CRS (765). 
Nevertheless, they suggest a significant potential role for 
neutrophils in the pathophysiology of CRS and further suggest 
a molecular hypothesis for the negative effect of tobacco smoke 
on treatment outcomes.
4.2.4.6. Mast Cells
Mast cells are resident cells of the sinonasal mucosa with 
physiologic roles in innate immunity and wound healing (940). 
Activation of mast cells results in the release of pre-formed 
granules including histamine, serotonin, proteoglycans and 
serine proteases; in addition, de novo synthesis and secretion of 
various eicosanoids, chemokines and cytokines also takes place. 
Physiologic activation of mast cells in immune defense works 
in part through PPR stimulation (940). In nasal disease states, 
mast cell de-granulation has been most commonly implicated 
in allergic rhinitis via antigen-driven IgE cross-linking. In CRS, 
most interest has centered on a role for mast cells in nasal 
polyposis, in part due to the potential to induce, augment and 
maintain eosinophilic inflammation through IgE-dependent and 
IgE-independent processes (941, 942). In particular, polyp explant 
studies have demonstrated that mast cell de-granulation 
may be triggered directly by protein A (SpA), a staphylococcal 
surface protein (668). Mast cell prostaglandins have been 
implicated in Th2 lymphocyte recruitment and activation in 
nasal polyps (669). These results suggest that mast cells can 
activate Th2 lymphocytes independently of T-cell receptor 
activation, with attendant secretion of Th2 cytokines (943). Stem 
cell factor, secreted by epithelial cells, may be important in the 
recruitment of mast cells in nasal polyps (824). Release of pre-
formed mediators from mast cells should foster tissue oedema 
while serine proteases will effect PAR receptors, degrade 
the extracellular matrix (ECM) and diminish barrier integrity. 
Interestingly, data are mixed as to whether mast cell numbers 
are increased in CRSwNP in comparison to either CRSsNP or 
even control tissues (542, 727, 874, 944-949). Nevertheless, functional 
studies suggest that mast cells in nasal polyps are much more 
active and may display a heightened sensitivity to external 
triggers in vivo (949). Overall however, the relative importance 
of mast cells in the pathogenesis of CRSwNP remains unclear. 
Targeted medications designed to inhibit upstream mast cell 
functions are an area of active research that may help elucidate 
their importance (950). 
4.2.4.2.7. Cells, Plasma Cells and Immunoglobulins
Mucosal immunoglobulin secretion by cells of the B lymphocyte 
lineage is an important part of the adaptive immune response. 
In the nasal mucosa, B cells undergo proliferation, differentiation 
and immunoglobulin class switching to become mature 
plasma cells capable of substantial local antibody secretion. 
In overview, tonic secretion of sIgA works in concert with 
other innate protective factors and mucociliary flow to limit 
mucosal colonization without tissue-damaging inflammation 
(951). In general, this IgA is relatively low affinity, generated via a 
T-independent process, and secreted by extrafollicular B cells.  
In the case of an active breach of the respiratory mucosa, IgA 
secretion increases but it also receives help from IgG and a 
robust inflammatory response ensues. In general, this is high 
affinity IgA, T-dependent and generated by follicular B cells 
and plasma cells. IgM and IgD also play a role. IgD is the least 
understood imunoglobulin but interestingly, it is present in 
significant amounts in the respiratory mucosa (952). Although its 
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precise role is still unclear, IgD exerts protective effects not only 
through antigen binding, but also its capacity to arm basophils 
with IgD highly reactive against respiratory bacteria (953). 
Basophils have recently been discovered to possess the capacity 
to function as antigen presenting cells by migrating back to 
lymphoid organs to initiate Th2 and B cell responses (954). Hence, 
IgD-activated basophils may initiate or enhance innate and 
adaptive responses both systemically and at the mucosa (952).
IgE is mostly closely associated with the pathophysiology of 
allergic rhinitis but it plays several important physiologic roles 
as well including antigen presentation, increased mast cell 
survival, defense against viruses, bacteria, fungi and parasites 
and mucosal homeostasis (729, 940). 
In CRS, polyp homogenates demonstrate high levels of 
immunoglobulins, notably IgA, IgE and IgG, in comparison to 
CRSsNP and control tissues, apparently in response to bacterial 
and fungal antigens (542, 600, 786, 807, 921, 955-957). Levels in polyp 
homogenates do not correlate with levels in serum, suggesting 
that significant immunoglobulin synthesis occurs locally in the 
nasal mucosa (958-960). In parallel with these findings, high levels 
of B cells and plasma cells have been reported in nasal polyps 
in comparison to CRSsNP and control tissue (600, 874, 921). Evidence 
for a dysregulated adaptive B-cell immune response is further 
suggested by the presence of germinal center like follicles in 
nasal polyps (960) and the entire process is likely orchestrated by 
local proliferation and systemic recruitment of B cells (600, 602). 
Elevations of tissue B cells, plasma cells 
and immunoglobulins are associated 
with CRSwNP.
In regard to elevated IgE in nasal polyps, levels have been shown 
to be independent of systemic atopy but they do correlate 
with the presence of IgE to staphylococcal superantigenic 
toxins (542). Approximately 50% of Caucasian CRSwNP and 20% 
of Chinese CRSwNP patients demonstrate local IgE to these 
toxins as well as a concomitant polyclonal IgE response to a 
diverse array of environmental antigens in polyp homogenates 
(542, 621). The presence of IgE to these toxins correlated with not 
only high levels of polyclonal IgE but also high tissue levels of 
ECP (eosinophil cationic protein) and co-morbid asthma (621). 
In regard the mechanism, studies of polyp explants exposed 
to staphylococcal superantigens revealed polyclonal T cell 
activation with a Th2 cytokine polarization (668, 670). In addition 
to pro-eosinophilic effects, this cytokine milieu should favour 
IgE production indirectly by triggering B cell class switching 
towards IgE production (596). Furthermore, staphylococcal protein 
A (SpA) has direct proliferative effects on B cells in vitro, possibly 
further driving the IgE process in nasal polyps (596). Very recent 
studies have demonstrated that the polyclonal IgE in nasal 
polyps is functional and can trigger mast cell de-granulation, 
suggesting a significant role for IgE in the pathophysiology of 
this subset of CRSwNP patients (961). The therapeutic potential 
of anti-IgE for nasal polyposis has been suggested (962) but trials 
have thus far been equivocal (963). 
In regard to elevated IgA in nasal polyps, recent studies 
have implicated BAFF (also called BLyS or TNFSF13B), a 
cytokine of the TNF family favoring B cell proliferation and 
immunoglobulin class switching (600). High levels of BAFF are 
present in nasal polyp tissue in comparison of controls and 
CRSsNP tissue; moreover, the levels of BAFF correlate with 
the number of B cells in the nasal polyp (600). Transgenic BAFF 
mice develop autoimmune disorders (964); further studies in 
polyp homogenates demonstrated IgA and IgG anti-nuclear 
autoantibodies at locally elevated levels in nasal polyp tissue in 
the absence of systemic autoimmunity in some patients with 
CRSwNP (740). The presence of these autoantibodies was detected 
at higher frequency in the most recalcitrant patients who had 
undergone multiple revision surgical procedures, suggesting an 
autoimmune component in the most severe subset of CRSwNP. 
The presence of both abundant class-switched 
immunoglobulins and available antigen is likely to play an 
important role in propagating the inflammatory response 
through antibody-mediated mechanisms (955). As noted in other 
sections of this review, CRSwNP is associated with increased 
infiltration of inflammatory effector cells including eosinophils, 
mast cells, macrophages and neutrophils, which de-granulate 
or phagocytose in response to immune complexes (874, 965). The 
potential impact of IgE and mast cell activation in CRSwNP was 
already noted. Similarly, IgA is an extremely potent trigger of 
eosinophilic degranulation and hence may be a key to local 
mediator release within polyp tissue as well (919). A potential role 
for IgD is CRS is thus far speculative, however the capacity to 
arm basophils is intriguing and this immunoglobulin may play 
a significant upstream role in fostering a Th2 cytokine milieu in 
nasal polyposis.   
4.2.4.8. T Cells and cytokine patterns
Comparatively few studies have examined the topic of T cell 
activity in the nasal mucosa relative to the gut, skin and lower 
airways. In addition, many studies have been performed in vitro, 
and the in vivo factors mediating T cell responses, in particular 
Th polarization across mucosal barriers remains a subject 
of active research. In regard to CRS, the absence of a widely 
accepted animal model compounds the problem; hence, much 
of our understanding of T cell activity in nasal mucosa is based 
on extrapolation. In the immune response of the nose, dendritic 
cells (DCs) act as the initial antigen presenting cells (APCs) 
sampling and then presenting antigens to naïve T lymphocytes 
in draining lymph nodes or local lymph aggregates. Circulating 
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basophils may also enter the tissue and serve along side or 
instead of resident DCs to function as APCs as well (966). Following 
antigen presentation, naïve CD4+ lymphocytes will differentiate 
into one of several T cell lineages, determining the nature of 
the adaptive immune response. The subsets include Th1 and 
Th2 as well as the more recently described Th17 and inducible 
T regulatory cells; each has distinct molecular, cellular and 
functional properties (967, 968). Other subsets have also been 
recently proposed, including Th9 and Th22, and more are likely 
to follow. In vitro studies indicate that for the Th1 subset, the key 
transcription factor is T-bet, the canonical cytokine is IFN-γ and 
the classical cellular infiltrate is macrophage-rich. Th1 responses 
are particularly effective against viruses and intracellular 
bacteria, including mycobacteria. For Th2, the transcription 
factor is GATA-3, the associated cytokines are IL-4, IL-5 and IL-13 
and the cellular response eosinophilic. Th2 protective responses 
are geared against parasites, particularly those too large to 
undergo phagocytosis. For Th17, the transcription factor is RORc 
and the associated cytokine IL-17A and the cellular response 
classically neutrophilic. Extracellular bacteria, particularly 
Staphylococcus aureus (969), are prime targets. T regulatory cells 
are characterized by the transcription factor FOXP3 with the 
purpose of limiting excessive responses by the other lineage 
subsets. These differentiated effector T cells migrate into the 
mucosa where they re-encounter the same antigen, this time 
likely presented by both macrophages and DCs acting as 
APCs. The resultant binding of antigen to the T cell receptor 
(TCR) activates the cell, resulting in a cytokine release pattern 
characteristic for each Th subtype, mediating the appropriate 
effector response. 
The in vivo factors that determine T cell differentiation are 
obviously critical, but currently somewhat speculative in the 
nasal mucosa. In general, the differentiation of naïve CD4+ cells 
into a particular lineage is the integration of multiple signals, 
including T-cell receptor strength, co-stimulatory and innate 
immune signals, and cytokine milieu (967, 968). This process is 
greatly influenced by crosstalk between epithelial cells (ECs) and 
the local DCs (601). ECs, as well as other resident innate cell types 
(mast cells, NK cells, macrophages, basophils, eosinophils), sense 
exogenous, primarily microbial agents via PAR, Toll receptor, 
NLR and other PRR leading to expression of various cytokines 
and chemokines as mentioned in the earlier sections. Cellular 
damage is also detected via DAMPs. Collectively, these resident 
cells are therefore able to sense both damage and danger 
and respond with the appropriate cytokine array, secondarily 
influencing the correct effector T cell response to address 
the particular challenge. In addition to these resident cells 
influencing DC polarization, it has recently been recognized that 
circulating innate lymphoid cells (ILCs) migrate to the site of 
stimulation and also play a role (970). They have been recognized 
separately in a number of tissues and thus have diverse names 
including NK cells, LTi cells, nuocytes, innate T cells, natural 
helper cells and CD34+ hemopoietic progenitor cells (835, 970-973). 
These ILCs are presumably responding to chemokine homing 
signals emanating from resident mucosal cells including ECs and 
are termed innate because they recognize foreign substances 
via PPRs rather than through TCRs or immunoglobulin. Capable 
of responding rapidly, ILCs function in a transitional effector cell 
role, bridging innate and adaptive immunity. Distinct subsets of 
ILCs have been proposed and the lineage relationship is not yet 
clear. Nevertheless upon stimulation, ILCs release cytokines that, 
among other functions, will influence DC polarization. While 
Th1 and Th17 ILCs have been described, in the case of CRSwNP, 
ILCs thus far identified are Th2 skewed, responding to epithelial 
cytokines such as IL-25, IL-33 and TSLP with the production of IL-
4, IL-5 and IL-13 (601, 974). Whether these cells play a role in CRSsNP 
is unclear, but earlier results suggest they may have a prominent 
role in CRSwNP since exceptionally high numbers of ILCs are 
found in nasal polyps (835, 973). No studies have been done on ILCs 
in Asian polyps or CF polyps, which might very well be distinct.
The collective cytokine response from resident cells and 
migrating ILCs is believed to be pivotal in shaping T cell 
differentiation. The typical in vivo T cell effector responses 
are mixed however, and the Th subtypes display some 
heterogeneity as well (975, 976). Nevertheless, the lineage 
subsets tend to be mutually inhibitory resulting in a degree 
of polarization to particular subsets at a site of action (968, 976). 
Under physiologic conditions, the typical adaptive response to 
harmless antigens is immunologic tolerance, with generation 
of Tregs and a baseline controlled Th2 response. Although 
the nasal mucosa has not been studied in vivo, this pattern 
presumably results from appropriate levels of TGF-β, IL-2, 
IL-4 and TSLP secretion influencing DC polarization (834, 968). 
TGF-β fosters Treg differentiation. IL-4 is required for Th2 
differentiation in vitro but evidence suggests this restriction 
may be circumvented in vivo (977, 978). Alternatively, IL-4 may be 
secreted by resident mast cells or basophils. It is not known 
whether circulating innate immune cells play any significant role 
in baseline homeostasis. The net effect is a non-inflammatory 
response, primarily consisting of IgA secretion, which limits 
adherence of microbes to the epithelium (951). 
Homeostasis across mucosal barriers is geared towards 
eliminating microbes and other antigens without tissue-
damaging inflammation (951). When the mucosal barrier is 
breached, an appropriate protective immune response with 
some degree of inflammation must be generated, with ECs and 
other innate immune cells helping to guide the response. In the 
case of a protective Th1 response directed against intracellular 
microbes, ECs and other resident and infiltrating cells including 
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NK cells, trigger IL-12, IL-18 and IFN-γ release, the essential 
cytokines fostering Th1 differentiation. When subsequently 
challenged by antigen, effector Th1 cells secrete large amounts 
of IFN-γ, TNF-α and TNF-β with several key protective effects: 
(25) macrophage activation with enhancement of phagocytic 
properties (14) B cell help and class switching to production 
of IgG subclasses with opsonizing and complement fixing 
capabilities (594) enhanced antigen presentation of macrophages 
and (625) local tissue inflammation and neutrophil activation (979). 
Protective Th2 responses are directed against parasites, and 
cytokines such as TSLP, IL-33 and possibly IL-25 may play 
roles, with the net effect being a milieu favoring a much 
stronger skewing of Th2 T cell differentiation than seen under 
homeostatic conditions (834). Circulating ILCs likely contribute to 
the Th2 cytokine milieu as mentioned above (973). Basophils, mast 
cells and NKT cells (natural killer T cells) are possible sources 
of IL-4, which may be essential for the process as mentioned 
above (977). When subsequently challenged by antigen, Th2 
effector cells secrete large amounts of Th2 cytokines IL-4, 
IL-5 and IL-13, which may drive more TSLP secretion by ECs, 
creating a positive feedback loop (977). The net protective effects 
of these Th2 cytokines includes (25) recruitment, activation 
and survival enhancement of eosinophils, in particular by IL-5 
(14)  immunoglobulin class switching to IgE and IgG4 via IL-4 
and IL-13 (594) increased mucus production via IL-13 and (625) 
alternative macrophage activation by IL-4 and IL-13. IgE and 
IgA are capable of binding parasites, sterically inhibiting their 
ability to invade, but these immunoglobulins do not trigger 
phagocytosis or complement fixation. Mast cell binding to this 
surface IgE triggers de-granulation with release of inflammatory 
mediators and substances toxic to the parasites. Similarly, 
eosinophils may bind IgA with release of granules toxic to the 
parasites as well. Alternatively, high tissue IL-5 levels may also 
foster eosinophil degranulation in the absence of IgA. Mast 
cell and eosinophil degranulation trigger inflammation and 
some degree of tissue damage, which are both inevitable and 
necessary, but have long-term negative consequences. Lastly, 
alternative macrophage activation will trigger expression 
of macrophage mannose receptor (MMR) and secretion of 
cytokines that stimulate collagen synthesis and fibrosis. While 
these granuloma-forming activities may be protective in certain 
settings, they can have significantly negative effects on end-
organ function. 
In the case of a protective response against extracellular 
bacteria and fungi, Th17 responses are preferentially invoked via 
resident cell cytokine responses including IL-1β and IL-6 (968, 980).
As mentioned above, TGF-β alone fosters Treg differentiation; 
however TGF-β together with IL-6 will foster Th17 differentiation 
and the presumed sources of IL-6 are macrophages, DCs and 
ECs (981). Th17 cells produce large amounts of IL-17A, IL-17F and 
IL-22 with several protective effects both directly and indirectly 
including (25) neutrophil recruitment (14) neutrophil activation (594) 
neutrophil proliferation and (625) innate antimicrobial production 
by airway epithelial cells (980).
In addition to the CD4+ helper T cell subsets discussed above, 
CD8+ cytotoxic T cells, natural killer (NK) cells, NKT and memory 
T cells also play significant roles in mucosal immunity. Naive 
CD8+ T cells differentiate and proliferate following exposure 
to antigen presented by DCs. CD4+T cells provide signals that 
amplify the process and may be absolutely essential in the case 
of some antigens. The net result is the generation of cytotoxic 
lymphocytes (CTLs) whose primary function is to eliminate 
intracellular microbes mainly by killing infected cells. Infected 
cells display microbial antigens on the surface together with 
class I MHC molecules, and this complex is recognized by the 
TCR. The infected cells undergo apoptosis from toxic granule 
exposure or via a ligand-receptor mediated process. CTLs 
are frequently localized to the epithelium; the TCRs of these 
lymphocytes often show limited diversity suggesting they 
have a restricted response repertoire and may be focused on 
commonly encountered luminal antigens. NK cells have a similar 
function to CTLs but their receptors are distinct from TCRs and 
they also do not need to undergo differentiation or maturation. 
They recognize stressed/infected cells via differential expression 
of a heterogeneous group of endogenous surface ligands 
rather than foreign antigen; the result is lysis of the stressed 
cell. They also secrete IFN-γ, which activates macrophages and 
fosters Th1 differentiation. NKT cells are a numerically small 
population of lymphocytes that have characteristics of both T 
cells and NK cells. They have TCRs but with limited variability, 
typically against lipid antigens, distinguishing them from typical 
T cells which only recognize protein antigens. They are also a 
source of IFN-γ. Memory lymphocytes are generated alongside 
the differentiation and maturation of the effector CTL and 
Th lineages and are actually the predominant T lymphocyte 
subset in nasal polyps (982)..These memory cells are present in the 
mucosa and respond to subsequent antigen challenge. 
The role of T cells in chronic airway inflammation has been 
a subject of great interest since the discovery of Th1/Th2 
paradigm 25 years ago; consequently most studies have 
focused on the CD4+ lineage subsets (983). Given the chronic 
inflammation that defines CRS, the presence of elevated levels 
of T cells in both CRSsNP and CRSwNP relative to control tissues 
is not surprising (620, 874, 984). It has been proposed however, 
that the various T cell effector lineages orchestrate distinct 
phenotypes of CRS (22, 620, 984). Establishing the predominant T 
effector pattern may therefore help determine pathophysiology, 
guide treatment, or even predict outcome. Early work in this 
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area demonstrated elevations of both Th1 and Th2 cytokines 
in CRS, with higher levels of Th2 cytokines associated with 
atopy (524). Follow up studies failed to confirm this latter finding, 
indicating that Th2 cytokine levels were independent of atopy 
(900). Later studies began the actual process of separating disease 
phenotype and cytokine response. These results indicated that 
in Caucasians, CRSsNP is a skewed Th1 disorder, with relatively 
higher levels of IFN-γ while CRSwNP is a skewed Th2 disorder 
with relatively higher levels of IL-5 (620). In addition, CRSwNP 
had evidence for a relative lack of T regulatory function based 
on decreased FOXP3 expression (984, 985). Studies on Asian CRS 
tissues have yielded some differences and some similarities. 
Decreased Treg function with CRSwNP appears to be similar in 
both Asian and Caucasian polyps (22, 877). CRSsNP in Asians was 
shown to be relatively Th1 biased, similar to Caucasians as well 
(877). Asian CRSwNP patients demonstrated a Th1/Th17 cytokine 
bias, with less IL-5 than Caucasian polyps, consistent with the 
lower eosinophilic and higher neutrophilic tissue infiltration (22, 
875, 877, 986, 987). Other investigators however, showed no differences 
between Asian CRSwNP and Caucasian CRSwNP with regard to 
IL-5 or eosinophilia but this has been interpreted to reflect wide 
variations in environmental and/or genetic factors across the 
continent (988, 989). 
Asian and Western CRSwNP both exhibit low 
TGF-β and diminished Treg activity relative to 
CRSsNP
Recently, comparative expression analyses of the key canonical 
cytokines IFN- γ, IL-5 and IL-17 were performed in both Chinese 
and Belgian polyps. This is the most comprehensive study of its 
kind to date and it confirmed the Th2 bias in Western/Caucasian 
polyps and the Th1/Th17 bias in Chinese polyps (621). The study 
further revealed that a substantial proportion of Chinese polyps 
were negative for all 3 key cytokines, termed therefore KCN 
polyps (key cytokine negative). Most significantly, high IL-5, 
polyclonal IgE with IgE to staphylococcal exotoxins and co-
morbid asthma clustered in both groups (621). A later follow up 
study has associated the inflammatory cytokine pattern with 
bacterial colonization indicating that KCN polyps are associated 
with gram negative bacterial colonization while the smaller Th2 
skewed subset of Chinese polyps is preferentially colonized by 
gram positive organisms (623). While the rate of Staphylococcus 
aureus colonization is much lower even in the IL-5 positive 
Chinese polyps, these results are in relative agreement with 
published findings in Caucasian CRSwNP patients further 
connecting this organism with Th2 cytokine expression (661). 
While these findings are interesting, it remains unclear whether 
the cytokine patterns can predict clinical phenotype or response 
to therapy. Despite differences in levels of inflammatory 
cytokines, low FOX3P expression appears to be characteristic 
of both Asian and Caucasian polyps patients indicating that 
diminished Treg activity may be a key factor in polyp formation 
(22, 984, 990).  
NK, NKT and CD8+ T cells are relatively unstudied in CRS. NK 
cells are present and apparently elevated vs. control tissue in 
both CRSsNP and CRSwNP but any specific role in the disease 
process is unclear (731, 874, 982). Normal nasal mucosa demonstrates 
a ratio of CD4+ to CD8+ cells of approximately 2:1 (535, 991). In nasal 
polyps, relatively more CD8+ T-cells have been demonstrated 
but the implications for pathogenesis remain unclear (877, 982, 
992). Studies on Asian CRSsNP patients also showed a higher 
proportion of CD8+ cells (877). Given the potential role of viruses 
and other intracellular pathogens in CRS in general and acute 
exacerbations in particular, further studies on NK, NKT and CD8+ 
cells may be quite important.
In summary, there is substantial evidence for (25) a down 
regulation of Treg activity in CRSwNP and (14) upregulation of Th 
1, 2 and 17 in various forms of CRS. Current evidence indicates 
that CRSsNP tends to be a relatively Th1 biased disorder in both 
Caucasians and Asians. CRSwNP is Th2 biased in Caucasians 
while Th1/Th17 biased in Asians. CF nasal polyps are likely Th17 
biased but this has not been directly assessed (981). While these 
studies represent data aggregates, individual patient outliers 
are present in each group and it remains to be demonstrated 
whether these outliers are distinct in terms of aetiology and 
clinical behavior. 
4.2.4.9. Remodeling
Tissue remodeling refers to modifications of the normal 
composition and structural organization of tissues, typically in 
response to stress such as chronic inflammation. Characteristic 
patterns of airway remodeling have been associated with 
several chronic inflammatory lower airway disorders including 
cystic fibrosis, pulmonary fibrosis, COPD and asthma (993). 
Remodeling also takes place in the upper airway when 
subjected to chronic inflammation such as seen in allergic 
rhinitis and CRS with changes that include fibrosis, epithelial 
alterations, basement membrane thickening, goblet cell 
hyperplasia, sub-epithelial oedema and inflammatory cell 
infiltrates (985, 994). In general, the histopathologic changes have 
been likened most closely to those observed in asthma (701, 
994). Recent reports indicate that the lower airway epithelium 
and underlying cells function as a unit, termed the epithelial-
mesenchymal unit (EMTU); structural and functional defects 
in the airway epithelium in asthma are proposed to trigger 
persistent epithelial activation with secondary, and ultimately 
irreversible changes in the underlying tissues (768, 995). Studies in 
the upper airway have begun to suggest that similar pathways 
may be operative. Areas of hyperplasia and sloughing are 
apparent in CRSwNP epithelium (988, 996). Other studies suggest 
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that diminished epithelial healing, weaker mechanical 
barrier and diminished innate antimicrobial secretion may be 
characteristic of CRSwNP (25, 782). Increased ion transport and 
higher rates of ion permeability have been observed in nasal 
polyp epithelia supporting this concept (784-786)..Taken together, 
these studies suggest the hypothesis that a permissive, relatively 
vulnerable epithelial barrier in CRS results in secondary changes 
in the underlying mucosal tissues. 
Remodeling of the extracellular matrix (ECM) of the lamina 
propria in CRS patients has been extensively studied and 
somewhat distinct remodeling patterns have been associated 
with subsets of disease. The ECM is a network of collagenous 
and non-collagenous structures that surround cells in the 
airway and affect many aspects of cellular behavior including 
migration, differentiation, survival and proliferation (993). PDGF 
is one factor that has been implicated in lower airway ECM 
remodeling and it may play a role in the upper airway of CRS 
patients with asthma as well (997). In CRS however, the ECM is 
grossly characterized by areas of oedema and fibrosis, with 
the latter dominating in CRSsNP and the former dominating 
in CRSwNP (998). The precise molecular factors mediating this 
differential remodeling pattern are not completely clear, but 
current evidence suggests a key role for the pleotropic cytokine 
TGF-β. Although not all studies agree (859), low levels of TGF-β 
have been demonstrated in CRSwNP and high levels in CRSsNP 
(984). TGF-β modulates ECM deposition in the airway (999) and it 
has been suggested that low levels in CRSwNP contribute to 
decreased tissue repair and collagen formation with secondary 
albumin deposition and tissue oedema, while high levels in 
CRSsNP mediate basement membrane thickening, excessive 
collagen deposition and fibrosis (990, 1000). TGF-β also has an 
established role in Treg differentiation as mentioned earlier. It 
should be noted that low Treg activity and low TGF-β are two 
factors that appear consistent in both Asian and Caucasian 
polyps despite clear differences in inflammation, suggesting a 
key, possibly integrated role in polyp formation (594). In regard 
CRSsNP, a very recent study focused on early stage disease, 
suggested that increased TGF-β is present prior to the onset 
of a significant inflammatory response (1001). Overall, these 
findings give credence to the hypothesis that CRS is primarily a 
remodeling disease, rather than an inflammatory disorder, best 
characterized and possibly best treated based on remodeling 
patterns (594). 
The ECM is dynamic, reflecting the net balance of synthesis 
and degradation that is regulated, in part, by the actions of 
matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) (1002). It has been proposed that 
an imbalance between these factors, mediated by TGF-β, 
triggers the oedema seen in CRSwNP (594). This hypothesis is 
supported by data suggesting differential expression levels 
of MMPs and TIMPs in CRSwNP when compared to CRSsNP 
and control tissue (622, 775, 990, 1003-1005). In addition, extracellular 
matrix metalloproteinase inducer (EMMPRIN) is also elevated 
in CRSwNP as opposed to controls, suggesting high levels of 
ECM degradation in polyps (811). Lastly, a recent ex vivo study 
suggested that S. aureus may promote polyposis by altering 
the MMP/TIMP milieu (672). While these studies suggest a role 
for MMPs and TIMPS in CRS remodeling in general and polyp 
formation in particular, further studies are necessary to elucidate 
a clear molecular pathway of disease pathogenesis. 
Asian and Western CRSwNP exhibit similar remodeling patterns 
of oedema and decreased tissue collagen deposition.
Angiogenic factors have also been associated with upper 
airway remodeling of the lamina propria in CRS, in particular 
CRSwNP, suggesting that angiogenesis may be a driving force 
in polyp formation. Angiogenin, a factor that induces blood 
vessel formation, has been associated with CRSwNP (1006). 
Vascular endothelial growth factor (VEGF), a key protein that 
modulates both angiogenesis and vascular permeability, is 
much more highly expressed in nasal polyp tissue than in 
CRSsNP or control tissues (1007-1009). Expression is seen primarily 
in the epithelium where it is believed to trigger epithelial 
hyperplasia (1009). Endothelial expression of VEGF has been 
hypothesized to mediate the profound oedema seen in CRSwNP 
tissues (1010). The pathophysiological trigger for these angiogenic 
factors is unclear, but relative hypoxia has been demonstrated 
in the maxillary sinuses of CRS patients (1011). Hypoxia is a 
potent inducer of VEGF from nasal fibroblasts in vitro  (1012, 1013), 
likely acting through hypoxia-inducible factor (HIF-1α) (1014). 
This suggested the hypothesis that hypoxia, in part through 
ostiomeatal complex (OMC) occlusion, drives HIF-α expression 
secondarily triggering VEGF, TGF-β, nitric oxide synthetase, 
MMPs and IL-8 (626, 627, 1015, 1016) support of this hypothesis, 
microarray analysis demonstrated substantial up-regulation 
of HIF-α in non-eosinophilic polyps in comparison to control 
tissue (1017). It should be kept in mind however, that VEGF appears 
to upregulated in both eosinophilic and non-eosinophilic 
polyps but not CRSsNP. The latter is a disease more closely 
associated with OMC obstruction and presumably, hypoxia 
(625). The high blood flow to the nose and paranasal sinuses 
would seem to limit actual tissue hypoxia in CRS. Moreover, 
one would anticipate an extremely low polyp recurrence rate 
following aggressive surgery, if hypoxia were the primary driver 
of angiogenesis and subsequent polyp formation. Lastly, and 
perhaps most importantly, carefully performed histologic 
studies have failed to demonstrate that angiogenesis, regardless 
of the inciting agent, is a significant driving force in polyp 
growth (1018). This report suggests that the rate of angiogenesis 
required to meet the needs of the polyp are relatively low and 
can be driven by metabolic or mechanical factors, rather than 
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being an integral part of the pathology as it is in neoplastic 
disease (1019). 
Components of the coagulation cascade have been implicated 
in CRS pathogenesis, primarily in regard to effects on tissue 
remodeling. Airway inflammation is associated with increased 
vascular permeability and leakage of plasma proteins into 
the extravascular space. Thrombin levels are significantly 
increased in the nasal secretions of patients with CRSwNP and 
asthma and it was proposed that this results in increased VEGF 
secretion from epithelial cells via a PAR-1 receptor pathway 
(1020). In addition, fibrinolytic components have been associated 
with CRS. Plasminogen activators such as uPA are elevated in 
CRSwNP tissues compared to controls and CRSsNP (1021). Levels 
of the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) 
were elevated in CRSsNP and this correlated closely with TGF-β 
levels suggesting a mechanistic link (1021). Further studies will be 
necessary to establish the clinical relevance to ECM changes 
seen in CRS.  
Remodeling of the underlying bone has also been observed 
in CRS (1022) and the presence of remodeled osteitic bone has 
been proposed as an explanation for persistent disease (1023, 
1024). The mechanism for this process remains unclear and no 
study has yet recovered microorganisms from the bone of CRS 
patients. Nevertheless, non-infectious inflammatory cytokines 
may drive bone and tissue remodeling in a wide array of 
disorders. In particular, the cytokines osteopontin (OPN) and 
periostin (POSTN) are members of a family of recently described 
tissue remodeling proteins (1025) that may be relevant to CRS. 
OPN has been implicated in both bone remodeling (1026) and 
Th2 airway inflammation (1027) in humans and studies have 
demonstrated particularly high levels in CRSwNP (826). A study 
has also suggested that OPN may modulate ECM deposition 
in CRSwNP, perhaps in relationship to TGF-β (1028). POSTN, also 
called osteoblastic-specific factor 2, has an established role in 
bone formation and is also up-regulated in CRSwNP (1028, 1029). 
In summary, while these cytokines are possible candidates 
mediating the bone remodeling observed in CRS, it remains 
unclear whether this process plays a clinically significant role in 
CRS pathogenesis (1030). 
Mucus secretion with goblet cell and glandular hyperplasia are 
other features of upper airway remodeling in CRS, with changes 
in both the quantity and viscosity of the mucus (1031, 1032). These 
changes are likely mediated by cytokines including TNF-α, IL-8 
and IL-13 (1033). Glandular hyperplasia and hypertrophy have 
been primarily associated with CRSsNP (998, 1034). MUC5AC and 
MUC5B are the main secreted mucins in the human airway, 
with MUC5A being produced primarily by goblet cells (1035). 
Differential expression of mucin genes is observed in CF, CRSsNP, 
CRSwNP and antrochonal polyps (1032, 1035, 1036). These mucins 
ultimately affect viscosity presumably accounting for the thin, 
watery mucus typical of CRSwNP and thick mucus observed in 
CF (1032). It has been suggested that the positive effects of long-
term macrolides for CRS seen in some studies (16) may in part, 
reflect reversal of pathologic increases in mucus viscosity (1037). 
Practically speaking however, there are over 20 mucin genes 
and a wide range of factors likely influences production in the 
individual patient (1038-1040).
4.2.4.10. Eicosanoids and the Arachidonic acid 
pathway
Eicosanoids are signaling molecules with immunologic and 
inflammatory properties generated by oxidative metabolism 
of arachidonic acid (AA) (1041, 1042). Disturbances in this pathway 
have been most closely associated with aspirin-sensitive nasal 
polyposis, but abnormalities have also been suggested to 
potentially underlie aspirin-tolerant CRSwNP as well. There are 
several families of classical eicosanoids with distinct properties: 
(25) leukotrienes (14), prostaglandins (PGD2, PGE2 and PGF2) (594); 
prostacyclin (PGI2); and thromboxane (TXA2) (625). Leukotrienes 
are generated by lipoxygenase (5-LO) activity, while the other 
3 are generated by cyclooxygenase enzyme (Cox-1 and Cox-2) 
activity. Also relevant are the lipoxans, technically termed 
non-classical eicosanoids, which are generated by 12/15 
lipoxygenase (12/15-LO) activity. In general, lipoxans and 
PGE2 have anti-inflammatory effects while the rest are all pro-
inflammatory. 
Leukotriene formation requires 5-LO activity that gives rise 
to the LTA4 precursor; subsequent enzyme activity results in 
the production of LTB4, LTC4, LTD4 and LTE4. The latter three 
are known as the cysteinyl leukotrienes, formerly termed 
slow reacting substance of anaphylaxis (SRSA), and require 
leukotriene C4 synthase activity (LTC4 synthase). Genetic 
polymorphisms in LTC4 synthase have been associated with 
CRSwNP in some studies (1043) and it has been suggested that 
this enzyme may be the engine of aspirin intolerance (1044, 1045). 
The primary sources of leukotrienes in the airway mucosa are 
mast cells and eosinophils, with effects including increased 
vascular permeability, vasodilation, leukocyte chemotaxis, 
broncho-constriction and mucus secretion. Leukotrienes 
have a short tissue half-life, working locally by binding to a 
least 2 receptors: CYSLTR1 and CYSLTR2. CYSLTR1 antagonists 
(e.g. Montelukast and Zafirlukast) have been used for the 
management of AR, asthma and to a lesser extent nasal 
polyposis. Studies in CRS demonstrated levels of cysteinyl 
leukotrienes that were significantly higher in eosinophilic 
polyps compared to control tissue independent of atopy 
(1043). A later study confirmed and extended these findings 
demonstrating the highest levels of cysteinyl leukotrienes 
in aspirin sensitive polyps, followed by CRSwNP, CRSsNP 
and then normal mucosa (915, 1046). Corresponding increases 
were also seen in expression of the enzymes 5-LO and LTC4 
synthase (1046). 
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The action of Cox-1 or Cox-2 enzymes results in the generation 
of prostanoids: prostaglandins, prostacyclin and thromboxane. 
Cox-1 is constitutively expressed while Cox-2 is inducible, the 
latter typically up-regulated in inflamed tissues, while the 
former can be influenced by topical glucocorticoid treatment 
(1047). Subsequent activity of the corresponding synthase 
enzymes produces PGD2 and PGE2 and from the perspective 
of airway disease, these are the most notable prostanoids (1042). 
PGD2 acts via binding to prostanoid receptors triggering pro-
inflammatory effects including chemotaxis, de-granulation and 
enhanced survival of eosinophils (1048-1050) as well as migration 
of Th2 lymphocytes (1051). Increased PGD2 synthase enzyme 
levels were demonstrated in CRSwNP (1052) and differential PGD2 
receptor expression was associated with polyposis (1053). PGE2 
may be more significant from a clinical perspective, as it triggers 
bronchodilation acting via the EP2 prostanoid receptor (1054). In 
addition, PGE2 exhibits an array of primarily anti-inflammatory, 
protective effects by direct inhibition of leukotriene production 
(1055). Interestingly, PGE2 levels, cox-2 levels and PGE2 synthase 
levels are all decreased in nasal polyps (1010, 1046, 1052, 1056). Expression 
of the E-prostanoid receptors may also be altered in CRS (915). 
Studies have suggested that staphylococcal superantigenic 
toxins (SAg) may interact with the PGE2 pathway as well. SAg 
suppresses the PGE2 pathway while PGE2 blunts the pro-
inflammatory effects of SAgs (605, 606). Most significantly, a recent 
study demonstrated that in contrast to normal fibroblasts, polyp 
fibroblasts fail to up-regulate the cox pathway in response to 
inflammatory stimuli (595).
 
Abnormalities of the eicosanoid pathway 
have been associated with CRSwNP, with an 
up-regulation of the pro-inflammatory leukotriene 
pathway and a down-regulation of the primarily 
anti-inflammatory PGE2 pathway
In summary, alterations in the eicosanoid pathways have been 
identified most prominently in CRSwNP, with an up-regulation 
of the pro-inflammatory leukotriene pathway and the down-
regulation of the primarily anti-inflammatory PGE2 pathway. It 
has been suggested that this pro-inflammatory environment, 
perhaps modified by colonized Staphylococcus aureus, may be 
central to the aetiology of nasal polyposis (594).  
4.2.5. Microarray studies 
Microarray studies have been used on CRS tissues, primarily 
nasal polyps, in an effort to (a) understand the pathophysiology; 
(b) explore the mechanism of corticosteroid efficacy; and (c) 
serve as a platform to guide future investigations. The first 
study compared tissue from patients with AR vs. those with AR 
plus nasal polyps. Increased expression of the mammaglobulin 
gene was seen in nasal polyps, in comparison to patients with 
rhinitis alone; other genes associated with neoplastic growth 
were also up-regulated (1057). Another early study compared 
nasal polyps before and after oral glucocorticoid treatment. In 
this study, uteroglobulin- also known as CC10 -demonstrated 
the greatest increase while β-defensin showed the most 
marked down-regulation in response to corticosteroids (1058). 
Uteroglobulin has established diverse anti-inflammatory and 
immunomodulatory properties.
Microarray techniques have also been utilized to directly 
compare nasal polyps to normal control tissues. Relative to 
normal tissue, the most up-regulated genes in polyps included 
statherin,  prolactin-induced protein (PIP), lactoferrin and 
deleted in malignant brain tumor 1 (DMBT1), while the most 
down-regulated gene was uteroglobulin/CC10 (1059). The polyp 
patients were separated into 2 groups: oedematous polyps 
which were highly eosinophilic and glandular polyps which 
were less eosinophilic. Immunohistochemical studies indicated 
that lactoferrin, DMBTI and PIP were increased in the glands of 
only the ‘glandular-type’ polyps, not the oedematous polyps. 
CC10/uteroglobulin was present primarily in the epithelium 
of normal controls and greatly decreased in both forms of 
polyposis. Interestingly, this study did not see significant 
changes in expression of many of the genes commonly 
associated with CRSwNP including IL-4, IL-5 and GM-CSF (3).
Expanded microarrays and bio-informatic analyses were used 
in a larger study comparing 3 groups of patients (10 in each 
group): normal controls, aspirin-sensitive polyps (ASA) and 
aspirin-tolerant polyps (CRSwNP) (1029). This study demonstrated 
substantial agreement between the 2 polyp phenotypes but 
increased expression of periostin and met protoncogene and 
decreased expression of PIP was seen relative to control tissues. 
Periostin is a protein that is highly expressed in the airway 
epithelium of asthma patients believed to play a role in TGF-β 
activation, collagen deposition, fibrosis and remodeling (1060). 
The Met gene (or c-Met) encodes hepatocyte growth factor 
receptor (HGFR), an epithelial membrane receptor known to 
bind hepatocyte growth factor (HGF). HGF and HGFR expression 
are increased in CRSwNP (1061). From a functional perspective, 
this ligand-receptor binding is believed to play a role in wound 
healing and inflammation in lower airway epithelium. In the 
human upper airway, preliminary evidence suggests that 
genetic variation in the c-Met pathway is associated with 
CRSwNP (1062), perhaps through the loss of HGF mediated down 
regulation of the effects of Th2 cytokines (1063). Pip protein, 
whose expression is decreased in the polyp phenotypes, has 
immunologic and water transport functions but no clear 
pathophysiologic role in CRS.
Smaller studies, analyzing more narrow phenotypes have also 
utilized microarray technology. Anand et al., analyzed tissue 
from non-allergic, CRSsNP patients compared to controls and 
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demonstrated increased expression of IL-6, IL-12A, IL-13 and 
TNF-α in disease (1064). Wang et al., compared Asian polyps with 
normal tissue and noted increased expression of IL-17 and 
IL-17R in the CRSwNP patients (1065). Lee et al., compared polyps 
and control mucosa, with results that generally concurred with 
the findings of Stankovic et al. (1066). Orlandi et al., compared 
classic AFS patients and eosinophilic mucin rhinosinusitis 
patients (EMRS) (730). The 2 groups differed only in the ability 
to identify fungi by routine histology or culture and gene 
expression profiles demonstrated marked similarities to each 
other as opposed to dramatic differences to controls. Figueiredo 
et al., compared polyp tissue and surrounding non-polypoid 
tissue from non-atopic patients, with control tissues. Results 
indicated increased IL-5 expression in the polyps and increased 
TGF-β expression in the adjacent inflamed mucosa (1067). A study 
by Bolger et al., demonstrated that systemic glucocorticoids 
decreased expression of several chemokine and leukotriene 
receptor genes (1068). A small study by Payne et al., focused 
on non-eosinphilic polyps, demonstrating significant down 
regulation of IL-4, IL-13 and IFN-γ with up-regulation of IL-6, 
IL-8, SCF (Stem Cell Factor) and hypoxia inducible factor 1α 
(HIF-1α) in polyps versus control tissues (1017). These results 
were interpreted to suggest that NE polyps have a distinct 
pathogenesis. A later study by Wu et al. comparing atopic Asian 
polyps to both normal tissue and AR tissue revealed significantly 
increased expression of CCL20 in the polyp cohort (1069). Lastly, 
a very recent study comparing nasal polyps and control tissue 
demonstrated significantly increased expression of IL-8, MMP10, 
NOS2A and ALOX15 in polyps; decreased expression of ALOX12, 
LTF and DMBT1 was also seen (1070).
The results of these studies reveal substantial differences, 
despite apparent similarities in clinical phenotypes in many 
cases. As a specific example comparing two of the largest 
studies, results from Liu et al.(1059), demonstrated that statherin, 
PIP, lactoferrin and DMBT1 were elevated while uteroglobulin 
was decreased. In contrast, Stankovic et al.(1029), reported that 
statherin, PIP, lactoferrin and DMBT1 were decreased and 
uteroglobulin was unchanged. Variations in patient selection, 
experimental technique, sample size and pre-operative 
treatment account, at least in part, for differences. Despite 
enormous promise, the application of microarray technology 
has thus far failed to result in any major breakthrough in our 
understanding of CRS.
4.3. Diagnosis
4.3.1. Summary
A range of diagnostic tests is available to validate the clinical 
symptoms and signs of rhinosinusitis. However, for the majority 
of patients, the diagnosis is made in primary care based on 
symptoms alone. Objective investigations exist to corroborate 
the diagnosis, notably endoscopy and CT scanning which can be 
semi-quantitatively scored to assist in the stratification of disease 
and its response to therapy. Additional tests may help in the 
differential diagnosis of aetiological and predisposing factors but 
some remain the preserve of tertiary research facilities.
4.3.2. Assessment of rhinosinusitis symptoms
4.3.2.1. Symptoms of rhinosinusitis
Subjective assessment of rhinosinusitis is based on symptoms:
•	  nasal blockage, congestion or stuffiness;
•	  nasal discharge or postnasal drip, often mucopurulent;
•	  facial pain or pressure, headache, and 
•	  reduction/loss of smell.
Besides these local symptoms, there are distant and general 
symptoms. Distant symptoms are pharyngeal, laryngeal and 
tracheal irritation causing sore throat, dysphonia and cough, 
whereas general symptoms include drowsiness, malaise and 
fever. Individual variations of these general symptom patterns 
are many (235-239, 1071). 
Table 4.2.3. Microarray studies.
Author, year, ref. Gene expression
Fritz 2003 (1057) Mammaglobulin elevated in 
polyps
Benson 2004 (1058) Uterogloblin up-regulated, 
β-defensin down-regulated in 
polyps treated with steroids
Liu 2004 (1059) Statherin, PIP, lactoferrin, DMBT1 
increased in polyps; uteroglobin 
decreased in polyps
Stankovic 2008 (1029) Periostin, met protoncogene in-
creased in ASA and CRSwNP; PIP 
decreased in ASA and CRSwNP
Rho 2006 (1061) HGF and HGFR increased in 
CRSwNP
Anand 2006 (1064) IL-6, IL-12A, IL-13, TNF-α in-
creased in CRSsNP
Wang 2006 (1065) IL-17and IL-17R increased in 
polyps
Figueiredo  2007 (1067) IL-5 increased in polyps, TGF-β 
increased in inflamed mucosa
Payne 2008 (1017) IL-4, IL-13, IFN-γ down-regulated 
in polyps; IL-6, IL-8, SCF, HIF-1Χ 
up-regulated in polyps
Wu 2009 (1069) CCL20 increased in polyps
Rostkowska-Nadolska 2011 (1070) IL-8, MMP-10, NOS2A, ALOX15 
increased in polyps; ALOX12, LTF, 
DMBT1 decreased in polyps
ASA, aspirin-sensitive polyps; CRSwNP, chronic rhinosinusitis with nasal 
polyps; DMBT1, deleted in malignant brain tumor protein 1; HIF-1α, 
hypoxia inducible factor 1α;  IFN-γ, interferon-gamma;  PIP, prolactin-
induced protein; SCF, stem cell factor; TGF-β, transforming growth factor 
beta 1; 
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The symptoms are principally the same in acute (ARS) and 
chronic rhinosinusitis with and without nasal polyposis (CRSw/
sNP), but the symptom pattern and intensity may vary. Acute 
forms of infections have usually more distinct and often more 
severe symptoms.
4.3.3. Diagnosis of ARS
Acute rhinosinusitis in adults is defined as a sudden onset of 
two or more symptoms, one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/
posterior nasal drip):
± facial pain/pressure, 
± reduction or loss of smell
for <12 weeks;
This may be supported by endoscopic signs of purulent 
discharge from the middle meatus, oedema/ mucosal 
obstruction primarily in the middle meatus
Imaging is rarely performed except in severe/complicated cases 
4.3.4. Diagnosis of CRS
Chronic rhinosinusitis, with or without nasal polyps in adults is 
defined as:
•	  inflammation of the nose and the paranasal sinuses 
characterised by two or more symptoms, one of which 
should be either nasal blockage/obstruction/congestion or 
nasal discharge (anterior/posterior nasal drip):
•	  ± facial pain/pressure 
•	  ± reduction or loss of smell
for ≥12 weeks
This should be supported by demonstrable disease 
Either endoscopic signs of:
•	  nasal polyps, and/or
•	  mucopurulent discharge primarily from middle meatus 
and/or
•	  oedema/mucosal obstruction primarily in middle meatus
and/or
•	  CT changes:
•	  mucosal changes within the ostiomeatal complex and/or 
sinuses 
Using this symptomatic definition (8), the GA2LEN study  has 
demonstrated significant variation in the prevalence of 
self-reported CRS across Europe, with a mean of 10.9% of 
participants, but a range of 6.9% (Brandenburg, Helsinki) to 27.1 
(Coimbra) (12). As a percentage of EP3OS-defined CRS patients, 
the prevalence of component symptoms of CRS was 83.7% 
blocked nose, 63.6% nasal discharge, 64.7% pain or pressure, 
and 48.5% reduced sense of smell.
It is appropriate that the definition is symptom based, as it is this 
that drives patients to seek medical care for their CRS. However, 
the presence of supporting findings is important to exclude 
differential diagnoses. A recent study of 125 patients with CRS 
based on symptoms found 40% had no radiological evidence 
of disease on CT scan (1072). In a subset of the GA2LEN study (11), 
61.7% of symptom-positive subjects had a positive endoscopy, 
while 38.0% of symptom negative subjects had a positive 
endoscopy. Symptom-based CRS was significantly associated 
with a positive endoscopy (OR 2.62: 95% CI 1.57 – 4.39, p<0.001). 
Symptoms remain the mainstay of 
diagnosis in primary care
In a group of patients meeting the 1997 Rhinosinusitis 
Task Force (RSTF) definition (523) of chronic rhinosinusitis (≥3 
symptoms from a defined list, with severity rating of>5/10) 
were subjected to same-day endoscopy and CT scanning, 
seventeen (22%) of 78 patients had positive endoscopic and CT 
results (1073). There were 20 (26%) of 78 patients with negative 
endoscopic and positive CT results. Six (8%) patients had 
positive endoscopic and negative CT results, and 35 (45%) had 
negative endoscopic and negative CT results. Thus, only 55% 
of symptom-positive CRS had positive supporting findings. The 
lower rates of positive endoscopy in this series may reflect the 
less strict symptom criteria used in the study, including ‘minor’ 
symptoms such as headache, fatigue and cough within the 
definition. The sensitivity of endoscopy was rather low (46%), 
but the positive and negative predictive values indicating the 
proportion of patients with and without disease was better, at 
74% and 64% respectively.
Since this study, new guidelines have been issued by the AAO-
HNS, with diagnostic criteria broadly in line with the EP3OS 
criteria above. Bhattacharya et al repeated the validation study 
in a group of 202 patients, of which 178 met the symptomatic 
criteria. Of the symptom positive group 50.6% had neither 
positive changes on CT nor positi7ve endoscopy, while of the 
symptom negative group, 45.8% had positive CT or endoscopy 
(1074). Therefore, using the findings of disease on either CT or 
endoscopy as the ‘gold standard’, symptoms alone have a 
sensitivity of 89%, specificity of 12%, PPV of 49% and NPV of 
54%. It is notable that 31% of patients failing to meet symptom 
or endoscopic criteria had positive CT scans (LM≥4).
4.3.5. Symptoms reported in CRS
An overlap of symptoms with ARS, those of chronic 
rhinosinusitis are typically of lesser intensity. In addition to 
the diagnostic symptoms listed above, there are several minor 
symptoms including ear pain or pressure, dizziness, halitosis, 
dental pain, distant and general symptoms including nasal, 
pharyngeal, laryngeal and tracheal irritation, dysphonia and 
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cough, drowsiness, malaise and sleep disturbance, presenting in 
numerous combinations (235, 239)..
There is a surprising paucity of epidemiological studies 
reporting symptoms in CRS. Most studies utilise a questionnaire 
asking patients to rate the severity of specific symptoms, thus 
encouraging patients to report only on those listed, and to 
report symptoms that they might not have done so if asked to 
provide a list of symptoms without guidance. Consequently, 
different patterns are reported in the published literature, 
depending on the questionnaire utilised in the study. For 
example, in a study using the ‘Cologne questionnaire’, the most 
commonly reported symptoms of CRS were nasal obstruction 
(92%), postnasal drip (87%) and ‘dry upper respiratory tract 
syndrome’ (68%) (239). Another study asking patients to rate the 
severity of symptoms included in the RSTF diagnostic criteria 
reports nasal obstruction (84%), postnasal drip (82%), and facial 
congestion (79%) as the most prevalent (1075).
Nasal obstruction is one of the most commonly reported 
symptoms of CRS. It consists of 3 main components; 
congestion due to dilation of the venous sinusoids as a result of 
inflammation and oedema, nasal fibrosis and nasal polyposis, 
and may only be partly reversible by topical decongestant.
Nasal discharge may be anterior or posterior, and may vary 
greatly in composition. Patients may report profuse watery 
discharge or thick purulent secretions. Facial pain is perhaps 
one of the most variable symptoms, with reported prevalence in 
patients with CRS ranging from 18 % (1076) – 77.9%  (1075). In a large 
longitudinal study, diagnosis of CRS is associated with a ninefold 
increased risk of reporting chronic headache compared with the 
general population, and symptoms were significantly improved 
after treatment with nasal surgery and nasal corticosteroids (1077). 
Facial pain and it’s differential diagnosis is discussed in more 
detail in section 4d. Olfactory disturbance is common, due to 
physical prevention of odorants reaching the olfactory cleft, and 
oedema in this area. A recent population-based epidemiological 
study found that a history of nasal polyps was a significant risk 
factor for olfactory impairment (OR = 2.33, 95% CI, 1.13–4.59) 
(1078). In a study of 367 patients (1079) with a diagnosis of CRS, 
the presence of polyposis was associated with significantly 
increased risk of hyposmia (OR 2.4, 95% CI 1.3-4.2, P = 0.003) and 
anosmia (OR 13.2, 95% CI 5.7-30.7, P < 0.001) compared with 
non-polyp CRS. The pathophysiology behind these and other 
symptoms found in CRS is discussed elsewhere (75).
Sleep impairment is a significant problem for patients with 
inflammatory disorders of the upper respiratory tract, such 
as CRSsNP and CRSwNP. Nasal congestion is associated with 
sleep-disordered breathing and is thought to be a key cause 
of sleep impairment. Poor sleep can lead to fatigue, daytime 
somnolence, impaired daytime functioning as reflected in lower 
levels of productivity at work or school, and a reduced quality 
of life (483, 1080, 1081). Treatment with intranasal corticosteroids 
has been shown to reduce nasal congestion in inflammatory 
disorders of the upper respiratory tract. There is a growing 
amount of evidence that a reduction in congestion with 
intranasal corticosteroids is associated with improved sleep, 
reduced daytime sleepiness, and enhanced patient quality of life 
(1082).
Serrano et al. (547) showed in a population-based, cross-sectional, 
case-control study that NP patients have a two-fold higher risk 
of suffering sleep disturbance. A quarter of NP patients (24.6 per 
cent) reported a feeling of general discomfort due to their nasal 
condition, during the day as well as the night in most of these 
cases (61.2 per cent). 
4.3.6. Assessment of symptom severity
The severity of the overall symptoms of CRS can be estimated 
using many different grading tools.
•	 recorded as such: no symptom, mild, moderate or severe
•	 recorded as numbers: from 0 to 5 or as many degrees as 
needed;
•	 recorded as VAS score on a line giving a measurable 
continuum (0 – 10 cm).
Both the strength or degree and duration of symptoms should 
be assessed. The duration of the symptoms is evaluated as 
symptomatic or symptom-free moments in given time periods, 
i.e. as hours during the recording period or as day per week.  
“No symptom” can be regarded as a consistent finding in most 
studies.  
A validation study has shown ‘mild disease’ to be defined as 
a VAS score of 0-3 inclusive, moderate as >3-7 inclusive, and 
severe as ≥7. In general, overall quality of life is more likely to be 
affected with scores of 5 or more (1083).
In addition the severity of individual symptoms can be 
measured, including different aspects of quality of life. This is 
done using validated questionnaires, described below.
Endoscopy and CT scanning 
corroborate the  clinical symptoms 
and signs
4.3.7. Examination
4.3.7.1. Anterior rhinoscopy
Anterior rhinoscopy alone is of limited value, but nonetheless, 
remains the first step in examining a patient with these diseases.
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4.3.7.2 Nasal Endoscopy
This may be performed without and with decongestion and 
semi-quantitative scores for polyps, oedema, discharge, 
crusting and scarring (post-operatively) can be obtained 
at baseline and at regular intervals following therapeutic 
interventions eg at 3, 6, 9 and 12 months (5) (table 4.3.1). 
Nasal endoscopy affords significantly better illumination and 
visualization compared to anterior rhinoscopy for examination 
of the middle and superior meati as well as the nasopharynx 
and mucociliary drainage pathways.  Bhattacharyya et 
al. confirmed the added utility of nasal endoscopy in the 
diagnosis of chronic rhinosinusits (1074).. However, in post 
surgical CRS patients, nasal endoscopy does not necessarily 
correlate with symptoms (1084)..
4.3.7.3. Nasal cytology, biopsy and bacteriology
Generally cytology has not proved a useful tool in diagnosis 
of rhinosinusitis although a formal biopsy may be indicated to 
exclude more sinister and severe conditions such as neoplasia 
and the vasculitides. Techniques include lavage with 0.9% 
saline, microsuction, nasal brushes, disposable scrapers with 
a cupped end or small mucosal samples taken with Gerritsma 
forceps. These are largely used for clinical research.
However, a correlation has been shown between the cellular 
content obtained by middle meatal and broncho-alveolar 
lavage in patients with CRS and asthma (1086).
Swabs, aspirates, lavages and biopsies may also be used to 
obtain microbiological samples. Several microbiology studies 
(263-267) (Evidence Level IIb) have shown a reasonable correlation 
between specimens taken from the middle meatus under 
endoscopic control and proof puncture of the maxillary sinus 
or swabs from the ethmoid taken per-operatively leading 
to the possibility of microbiological confirmation of both 
the pathogen and its response to therapy (Table 4.3.2). A 
meta-analysis showed anccuracy of 87% with a lower end 
confidence level of 81.3% for the endoscopically directed 
middle meatal culture when compared with maxillary sinus 
taps in acute maxillary sinus infection (248). 
More sophisticated techniques exist for the detection and 
identification of bacteria including immunohistochemistry 
and the detection and amplification of microbial RNA and 
DNA. Fluorescent in situ hybridization (FISH) and confocal 
microscopy are utilised to demonstrate bacteria in biofilms (582).
4.3.7.4. Sinus Transillumination
This technique was advocated in the 1970’s as an inexpensive 
and efficacious screening modality for sinus pathology. 
However, the insensitivity and unspecificity makes it unreliable 
for the diagnosis of rhinosinusitis (1). More recently with the 
introduction of balloon sinuplastly, transillumination has been 
used for confirmation of proper placement of guide wires.
4.3.7.5. Imaging
The plain sinus x-ray, despite low cost and availability has 
limited usefulness for the diagnosis of rhinosinusitis due to 
underestimation of bony and soft tissue pathology compared 
to computed tomography (CT) and magnetic resonance 
imaging (MRI). 
CT scanning is the modality of choice for the paranasal sinuses 
due to optimal display of air bone and soft tissue. However, it 
should not be regarded as the primary step in the diagnosis 
of the condition, except where there are unilateral signs and 
symptoms or other sinister signs, but rather corroborates 
history and endoscopic examination after failure of medical 
therapy. Much attention has recently been given to the 
radiation exposure associated with CT scans, the use of which 
have increased 20 fold in the last 30 years (1088, 1089). Thus several 
protocols have been developed to decrease radiation exposure 
with comparable or improved resolution (1090, 1091). Cone beam 
technology is becoming increasingly available and is associated 
with lower radiation exposure than conventional imaging. 
A study comparing cone beam CT (CBCT) with multislice CT 
(MSCT) for the sinuses in an anthropomorphic phantom model 
showed the effective dose of CBCT was 30uSv as compared 
with 200uSv and 1400uSv for low dose and standard protocols 
using MSCT (1092).
MRI does not have the radiation risk and has improved soft 
tissue definition over CT scan with an ability to differentiate 
between soft tissue masses and retained/obstructed secretions. 
Thus, MRI compliments CT in the workup of suspected 
neoplastic processes.  Comparison of staging accuracy of 
sinonasal disease between CT and MRI demonstrates close 
correlation between the two modalities (1093). 
It should be noted that incidental abnormalities are found on 
scanning in up to a fifth of the ‘normal’ population (1). Thus, in 
the absence of symptoms, diagnosis of CRS based on radiology 
alone is inappropriate. 
A range of staging systems based on CT scanning have been 
described but the most commonly used is the Lund-Mackay 
system which is based on localization with points given for 
degree of opacification: 0 = normal, 1 = partial opacification, 
2 = total opacification.  These points are then applied to the 
maxillary, anterior ethmoid, posterior ethmoid, sphenoid, 
frontal sinus on each side.  The osteomeatal complex is graded 
as 0 = not occluded, or 2 = occluded deriving a maximum score 
of 12 per side (1094). This scoring system has been validated in 
several studies (1095, 1096).
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Table 4.3.1. Endoscopic appearance scores (1071, 1085).
Characteristic Baseline 3 mo 6 mo 1 y 2 y
Polyp left (0,1,2,3) - - - - -
Polyp, right (0,1,2,3) - - - - -
Oedema, left (0,1,2,) - - - - -
Oedema, right (0,1,2,) - - - - -
Discharge, right (0,1,2) - - - - -
Postoperative scores to be used for outcome assessment only:
Scarring, left (0.1,2) - - - - -
Scarring, right (0.1,2) - - - - -
Crusting, left (0,1,2) - - - - -
Crusting, right (0,1,2) - - - - -
Total points - - - - -
Polyp:
0-Absence of polyps; 
1-polyps in middle meatus only; 
2-polyps beyond middle meatus but not blocking the nose completely; 
3-polyps completely obstructing the nose. 
Oedema: 0-absent; 1-mild; 2-severe.  
Discharge: 0-no discharge; 1-clear, thin discharge; 2-thick, purulent discharge.  
Scarring: 0-absent; 1-mild; 2-severe. 
Crusting: 0-absent; 1-mild; 2-severe. 
Table 4.3.2. Bacteriology of Rhinosinusitis; Correlation of middle meatus versus maxillary sinus.
Author, year, ref. No of Samples Type of Rhinosinusitis Technique Concordance
Gold & Tami, 1997 (264) 21 Chronic Endoscopic tap (MM) v  maxillary 
aspiration during ESS
85.7%
Klossek et al, 1998 (263) 65 Chronic Endoscoic swab (MM) v maxillary 
aspiration during ESS
73.8%
Vogan et al, 2000 (265) 16 Acute Endoscoic swab (MM) v maxillary 
sinus tap
93%
Casiano et al, 2001 (266) 29 Acute (Intensive Care) Endoscopic tissue culture (MM) v 
maxillary sinus tap
60%
Talbot et al, 2001 (271) 46 Acute Endoscopic swab (MM) v maxillary 
sinus tap
90.6%
Ozcan et al , 2002 (1087) 193 Chronic Endoscopic swab (MM) v ethmoid 
swab during ESS
91.6%
Joniau et al 2005 (267) 26 Acute Endoscopic swab (MM) v Maxillary 
sinus tap
88.5%
MM: middle meatus; ESS: endoscopic sinus surgery
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4.3.8. Additional assessment tools
A wide range of other diagnostic tests are 
available to assist with the differential 
diagnosis and to define predisposing and 
aetiological factors but many are only available 
in research departments
4.3.8.1. Mucociliary function
4.3.8.1.1. Nasomucociliary clearance
The use of saccharin, dye or radioactive particles to measure 
mucociliary transit time has been available for nearly thirty years 
(1097-1099). It allows one to recognize early alterations of sinosinusal 
homeostasis. Although a crude measure, it has the advantage 
of considering the entire mucociliary system and is useful if 
normal (< 35 minutes). However, if it is prolonged, it does not 
distinguish between primary or secondary causes of ciliary 
dysfunction.
Nasomucociliary clearance has also been measured using a 
mixture of vegetable charcoal powder and 3% saccharin to 
demonstrate a delay in patients with CRS as compared to 
normal, hypertrophied inferior turbinates and septal deviation 
(1100).
4.3.8.1.2. Ciliary beat frequency
Specific measurements of ciliary activity using a phase contrast 
microscope with photometric cell (1101, 1102) have been used 
in a number of studies to evaluate therapeutic success  (1103, 
1104)  (Evidence Level IIb). The normal range from the inferior 
turbinate is over 8Hz but these techniques are available in 
only a few centres to which those suspected of primary ciliary 
dyskinesia are referred. The final gold standard of ciliary function 
involves culture techniques for 6 weeks (1105).
4.3.8.1.3. Electron microscopy
This may be used to confirm the presence of specific inherited 
disorders of the cilia as in primary ciliary dyskinesia (1106). 
4.3.8.1.4. Nitric oxide
This metabolite found in the upper and lower respiratory tract is 
a sensitive indicator of the presence of inflammation and ciliary 
dysfunction, being high with inflammation and low in ciliary 
dyskinesia It requires little patient co-operation and is quick and 
easy to perform using chemiluminescence, but the availability 
of measuring equipment at present limits its use. The majority of 
nitric oxide is made in the sinuses (chest < 20 ppb, nose 400-900 
ppb, sinuses 20 25 ppm) using an LR 2000 Logan Sinclair nitric 
oxide gas analyser (values may differ with different machines). 
Less than 100ppb from the upper and <10ppb from the lower 
respiratory tract would be highly suspicious of PCD. However, 
whilst very low levels in the nose can indicate primary ciliary 
dyskinesia, they may also be due to significant sinus obstruction 
eg severe nasal polyposis (849). Conversely elevated levels suggest 
nasal inflammation but ostiomeatal patency (849) [Evidence Level 
IIb]. It can be used, as an outcome measure after therapy (16, 1107) 
(Evidence Level IIa) but variable baseline levels limit its value in 
the diagnosis and management of ARS and CRS other than to 
exclude inherited defects in mucociliary clearance. 
4.3.8.2. Nasal airway assessment
4.3.8.2.1. Nasal inspiratory peak flow
This inexpensive, quick and easy test is a useful estimate of 
airflow which can be performed at home as well as in the 
hospital setting. However, it measures both sides together and 
has little direct role in the assessment of chronic rhinosinusitis. 
It could be used to assess gross reduction in nasal polyposis and 
compares well with rhinomanometry (1108, 1109) (Evidence Level 
IIb). However, peak nasal inspiratory flow (PNIF) does appear to 
correlate with nasal obstruction symptoms (1110).  Normative data 
is now available in an adult Caucasian population (1111) and for 
children and adolescents in Brazil and the Netherlands (1112, 1113). 
Expiratory peak flow is less often used as mucus is expelled into 
the mask and the technique may be associated with eustachian 
dysfunction.
There is a relationship between NIPF and oral pulmonary 
expiratory flow (PEF) in that the greater the value of PEF, 
the greater the NIPF (1114). A minimally clinically important 
difference of 20L/min has been shown for NIPF (1115) (Evidence 
Level IIa).
4.3.8.2.2. Rhinomanometry (active anterior and posterior)
The measurement of nasal airway resistance by assessing nasal 
flow at a constant pressure is again of limited usefulness in 
chronic rhinosinusitis and nasal polyposis but can be useful in 
confirming that improvement in nasal congestion is the result 
of reduction in inflammation in the middle meatus rather than 
mechanical obstruction (1103) (Evidence Level IIb). The long term 
mean coefficient of variation (CV) for test-retest over a five 
month period has been shown to be 27% compared to a short-
term CV of 7-17% within one hour which limits its usefulness 
(1116) (Evidence Level IIa).
4.3.8.2.3. Acoustic rhinometry
The distortion of a sound wave by nasal topography allows 
quantification of area at fixed points in the nose from which 
volume may be derived. Standardisation of the technique has 
been recommended (1117) and it is a useful test of nasal patency 
especially in children as little active co-operation is required 
(1118-1120). It can be used to demonstrate subtle changes, both as 
a result of medical and surgical intervention, comparable to or 
better than CT scanning (16, 1109, 1121-1123) (Evidence Level IIa).
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4.3.8.2.4.  Rhinostereometry.
This also measures subtle changes in mucosal swelling, largely 
in the inferior turbinates (1124, 1125) (Evidence Level IIb) and is 
therefore not directly applicable to assessment of chronic 
rhinosinusitis and nasal polyposis.
4.3.8.3. Olfaction
4.3.8.3.1. Threshold Testing
Fluctuations in the sense of smell are associated with chronic 
rhinosinusitis. This may due to a conductive loss secondary to 
obstruction (1110), or to degenerative alterations in the olfactory 
mucosa due to the disease or its treatment eg. repeated 
nasal surgery (1).  Recently, transgenic technology has also 
demonstrated that local inflammation within the olfactory 
epithelium can generate olfactory loss (1126).
The estimation of olfactory thresholds by the presentation of 
serial dilutions of pure odourants such as pm carbinol have been 
used in a number of studies (1104, 1121, 1127-1129) (Evidence Levels IIb, 
III).
4.3.8.3.2. Other quantitative olfactory testing
Scratch and sniff test using patches impregnated with micro-
encapsulated odorants are available (256) and have been utilised 
in studies of both chronic rhinosinusitis and nasal polyposis (1109). 
A cruder screening test, the Zurich Smell Diskette test may also 
be used and has the advantage of pictorial representation of the 
items (1130, 1131). Also on a national footing, the Barcelona Smell 
Test has been developed, comprising 24 odorants and has been 
compared with the Zurich Smell Diskette Test (245). More complex 
tests exist (1132) e.g. ‘Sniff ‘n’ sticks’ which combines threshold, 
discrimination and odour identification and which can be used 
to perform unilateral testing (1133). A combined supra-threshold 
detection and identification test has been devised as a cross-
cultural tool in the European population (1134), the results of 
which are presented in an appendix in EPOS2007 (1) (Evidence 
Level III).
Sources of some commercially available and validated olfactory 
tests are also mentioned in the appendix (1). 
4.3.8.4. Aspirin and other challenges
Objective experiments to differentiate patient groups according 
to severity or aetiology of rhinosinusitis have been done by 
provocation with histamine or metacholine (1135, 1136) which 
test mucosal hyper-reactivity. The tests can differentiate 
sub-populations with statistical significance, but because of 
considerable overlap of results, the tests have not achieved 
the equivalent position as the corresponding tests in asthma 
diagnosis.
Diagnosis of aspirin hypersensitivity is important as it will 
provide the patient with a long list of common drugs that must 
not be taken to avoid the risk of a severe reaction. It diagnoses a 
particular type of asthma and sinonasal disease and allows the 
choice of a specific therapy ie aspirin desensitisation. 
The oral aspirin challenge test was introduced to clinical practice 
in the early 1970s (1137) and since then has been validated (1138-
1140). An inhalation test was introduced in 1977, which is safer 
and faster to perform than the oral one though less sensitive 
(1141-1143). Unlike the oral challenge, it does not produce systemic 
reactions. Nasal challenge was introduced in the 1980s (1144, 
1145) and is recommended for patients with predominantly 
nasal symptoms or those in whom oral or inhaled tests are 
contraindicated because of the asthma severity. A negative 
nasal challenge should be followed by oral challenge. Lysine 
aspirin, the truly soluble form of aspirin must be used for both 
respiratory routes. Test procedures have been reviewed in detail 
(1146) and the sensitivity and specificity of the tests are shown in 
Table  4.3.3. The sensitivity of nasal challenge has been shown 
to be increased by prolonging the detection time from 2 to 3 
hours (1147). The challenges must be performed under medical 
supervision and results measured with symptoms, acoustic 
rhinometry or anterior rhinomanometry and pulmonary 
function.
4.3.9. Laboratory assesments – C-reactive protein 
(CRP)
Known since 1930, C-reactive protein is part of the acute phase 
response proteins. Its principal properties are short half-life  
(6-8 h), rapid response (within 6 hours) and high levels (x500 
normal) after injury. It activates the classical complement 
pathway, leading to bacterial opsonization. Studies have 
shown that the CRP value is useful in the diagnosis of bacterial 
infections (1148). However, among patients suspected of an 
infectious disease, CRP levels up to 100 mg/l are compatible 
with all types of infections (bacterial, viral, fungal, and protozoal) 
(1149).
Sequential CRP measurements will have greater diagnostic 
value than a single measurement and changes of the CRP values 
often reflect the clinical course. When used in general practice 
the diagnostic value of CRP is found to be high in adults with 
pneumonia, sinusitis and tonsillitis. Measurement of CRP is an 
important diagnostic test but the analysis should not stand-
alone but be evaluated together with the patient’s history and 
clinical examination (1150)..
CRP is most reliably used for exclusion of bacterial infection: two 
values less than 10 mg/l and 8 12 hours apart can be taken to 
Table 4.3.3. Diagnosis of aspirin sensitivity.
History ± Challenge sensitivity (%) Specificity (%)
Oral 77 93
Bronchial 77 93
Nasal 73 94
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exclude bacterial infection (1149) and is now available in general 
practice at the point-of-care (249).
A range of other blood tests may be undertaken in specific cases 
as part of the differential diagnosis. This may include full blood 
count including eosinophils, ESR, evaluation of renal, liver and 
thyroid function, humoral immunity markers (immunoglobulins, 
IgG subclasses, IgE and IgG to Aspergillis, specific antibody 
levels to tetanus, haemophilus, pneumococcus) and response to 
immunization if low, cellular immunity markers (T and B cell and 
ratios), HIV, ACE and ANCA (1151).
4.3.10. Validation of subjective symptoms 
assessment
4.3.10.1. Nasal obstruction
Validation of subjective assessment of nasal obstruction or 
stuffiness has been done by studying the relationship between 
subjective and objective evaluation methods for functional 
nasal obstruction. However, the patient’s interpretation of 
nasal blockage has been shown to vary from true mechanical 
obstruction of airflow to the sensation of fullness in the midface  
(1152). Generally the subjective sensation of nasal obstruction and 
rhinomanometric or nasal peak flow evaluations show a good 
intra-individual correlation in a number of studies considering 
normal controls, patients with structural abnormalities, hyper-
reactivity or infective rhinitis (1153-1158). However, there are also 
some studies where this correlation is not seen (1159) or the 
correlation was poor (1160-1162).
The inter-patient variation in subjective scoring suggests that 
every nose is ”individually calibrated”, which makes inter-patient 
comparisons less reliable but still significant (1153, 1155).
Subjective nasal obstruction correlates better with objective 
functional measurements of nasal airflow resistance 
(rinomanometry, peak flow) than with measurements of 
nasal cavity width, such as acoustic rhinometry (1158, 1163). 
Rhinomanometry has been shown to correlate with subjective 
symptom scoring with and without decongestion (1164). In 
healthy individuals there is a poor correlation between acoustic 
rhinometry and subjective nasal obstruction scores, though 
these are better in congested subjects (1165).
Nasal obstruction can also be assessed objectively by tests using 
personal nasal peak flow instruments, inspiratory or expiratory, 
which patients can take home or to their work place and do 
measurements at any desired time intervals.
Subjective assessment of nasal obstruction is a well-validated 
criterion.
4.3.10.2. Nasal discharge
Techniques for objective assessment of nasal discharge are not 
as good as for nasal obstruction: counting the nose blowings 
in a diary card or using a new handkerchief from a counted 
reservoir for each blow and possibly collecting the used 
handkerchieves in plastic bags for weighing have been used in 
acute infective rhinitis (1166) and in “autonomic (previously termed 
vasomotor) rhinitis” (1167).
Validating correlation studies between “objective” discharge 
measures (collecting and measuring amount or weight of nasal 
secretion as drops, by suction, or using hygroscopic paper strips 
etc) and subjective scoring of nasal discharge or postnasal drip 
has not been done.
4.3.10.3. Smell abnormalities
Fluctuations in the sense of smell are associated with chronic 
rhinosinusitis. This may be due to mucosal obstruction of 
the olfactory niche (conductive loss) and/or degenerative 
alterations in the olfactory mucosa due to the disease or its 
treatment eg repeated nasal surgery.
Subjective scoring of olfaction is a commonly used assessment 
method. In validating clinical settings subjective scores have 
been found to correlate significantly to objective olfactory 
threshold and qualitative tests in normal population, 
rhinosinusitis with and without nasal polyps and other disease 
conditions (243-245, 1168-1172).
4.3.10.4. Facial pain and pressure
Facial or dental pain, especially unilateral, have been found to 
be predictors of acute maxillary sinusitis with fluid retention 
in patients with a suspicion of infection, when validated by 
maxillary antral aspiration (236) or paranasal sinus radiographs 
(1173). The importance of facial pain as a cardinal sign of chronic 
rhinosinusitis has also been called into question (See section 
4.4) (1174) where the symptoms are more diffuse and fluctuate 
rendering the clinical correlation of facial pain and pressure 
scorings against objective assessments unconvincing. In a 
study correlating symptoms with CT Lund-Mackay scores, 
patients presenting with facial pain as a primary symptom 
were more likely with a score of 0 or 1 (ie normal) on CT (1175, 
1176). Poor correlation between facial pain localisation and the 
affected paranasal sinus CT pathology in patients with supposed 
infection, both acute and chronic, has been reported (1177). 
However, rhinosinusitis disease specific quality of life studies 
also include facial pain-related parameters, which have been 
validated (1178).
4.3.10. Correlation between patient-reported 
symptoms and objective measures
Several publications have demonstrated the lack of correlation 
between patient rates measures of symptom severity in chronic 
rhinosinusitis and objective measures, such as the radiological 
Lund-Mackay scoring system  (1179-1182). Similarly a recent 
systematic review has demonstrated no correlation between 
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sensation of nasal obstruction and measurements of cross-
sectional airflow using rhinometry (1183). 
The relationship between the biological burden of disease 
and symptoms is complex. Physiological variables can be 
profoundly abnormal in some asymptomatic patients, while 
others may report severe symptoms in the absence of change 
in biological markers of disease – for example a patient may 
present with severe symptoms of CRS in the face of minimal 
disease on cross-sectional imaging, while another may be 
virtually asymptomatic despite pansinusitis on CT. Studies 
in many other medical specialties demonstrate that patient 
reported measures of symptoms are poorly correlated with 
clinical measures. In studies of benign prostatic hypertrophy 
there was only a modest association between urodynamic 
indices of obstruction and obstructive symptoms (1184). Studies 
of asthma and COPD have found little or no correlation 
between subjective dyspnoea and FEV1 (1185). 
It is proposed that patients’ symptoms and quality of life are 
the result of an interaction between many factors, in which 
biological or physiological variables are only a piece of the final 
jigsaw (1186). Disease severity is modified by the interactions 
between many patient factors. For example, studies have 
shown the gender appears to modify symptom severity in 
sinonasal disease, with women reporting higher SNOT-20 (1187) 
scores than men for the same level of disease severity on cross 
sectional imaging. AERD, depression (1188) and ethnicity (1189) 
have also be shown to worsen baseline QOL in CRS. Cultural 
expectations, age, socio-economic status and additional co-
morbidities are amongst other factors that may modify the 
impact of disease.
Clinicians probably overestimate the impact that measurable 
biological variables have on symptoms and functioning. It is 
perhaps not surprising that there should be little correlation 
between a patient-based symptom severity-scoring systems. 
The absence of correlation does not suggest that either 
patient rated or objective scores are invalid, but that they 
are measuring different aspects of the disease process, and 
therefore are useful adjuncts in outcome measurement. 
For the majority of rhinological complaints where reducing 
the impact of symptoms on the quality of life of the patient 
is the primary aim of treatment, patient-rated measures are 
usually more useful in guiding treatment and measuring the 
resulting outcome. Clinician-rated measures may however 
provide more useful feedback to the surgeon in terms of 
technique. There are also occasions when clinician-rated 
measures are important to guide whether treatment is 
likely to be successful; and to confirm if the clinical aim is 
achieved. 
4.4. Facial Pain   
4.4.1. Summary 
The majority of patients who present with facial pain and 
headaches believe they have ‘sinus trouble’. There is an 
increasing awareness that neurological causes are responsible 
for a large proportion of patient’s headache and facial pain. 
The vast majority of patients who present with a symmetrical 
frontal or temporal headache, sometimes with an occipital 
component, have tension type headache. Unilateral, episodic 
headaches are often vascular in origin. Rhinosinusitis rarely 
causes headache, let alone facial pain, except when there is an 
acute bacterial infection when the sinus in question cannot 
drain - and it is usually unilateral and severe. These patients 
usually have a history of a viral upper respiratory infection 
immediately before this and they have pyrexia with unilateral 
nasal obstruction. The vast majority of patients with acute 
rhinosinusitis respond to antibiotics. More than two episodes 
of genuine bacterial rhinosinusitis in one year should be 
investigated for evidence of poor immunity. Patients with 
chronic bacterial rhinosinusitis rarely have any pain unless the 
sinus ostia are blocked and their symptoms are similar to acute 
rhinosinusitis. 
With the advent of nasal endoscopy and computerised 
tomography, along with the finding that many patients’ 
symptoms of headache or facial pain persist after sinus surgery 
it has become apparent that many patient’s symptoms are not 
due to their sinuses. It is also relevant that over 80% of patients 
with purulent secretions visible at nasal endoscopy have no 
headache or facial pain. Even if patients with intermittent 
symptoms of headache or facial pain, and who believe that it 
is due to infection, are asked to attend the clinic when they are 
symptomatic the majority are found not to have any evidence of 
infection and a neurological cause is responsible. 
Over 90% of self-diagnosed and doctor-diagnosed sinus 
headaches meet the International Headache Society criteria 
for migraines and yet 60% receive an antibiotic prescription. 
Over 40% of migraine sufferers had at least one unilateral nasal 
symptom of congestion or rhinorrhoea or ocular lacrimation, 
redness or swelling during an attack, which can confuse the 
picture but these episodes do not last longer than 72 hours.
In cases of headache or facial pain secondary to genuine 
rhinosinusitis, there are usually endoscopic signs of disease, and 
these patients almost invariably have coexisting symptoms of 
nasal obstruction, hyposmia and/or a purulent nasal discharge. 
An interdisciplinary consensus group recently agreed that 
“the majority of sinus headaches can actually be classified as 
migraines” and that “unnecessary diagnostic studies, surgical 
interventions, and medical treatments are often the result of the 
inappropriate diagnosis of sinus headache”. 
Other unilateral, episodic headaches are also vascular in origin, 
96
European Position Paper on Rhinosinusitis and Nasal Polyps 2012.
being hemicrania continua, cluster headache or paroxysmal 
hemicrania – although the latter two comprise more periorbital 
pain than headache. A relatively recently described condition, 
which affects about a third of patients with facial pain seen 
in ENT clinics, is midfacial segment pain. This is a version of 
tension-type headache that affects the midface and its features 
include a symmetrical sensation of pressure or tightness that 
can involve the areas of the nasion, under the bridge of the 
nose, either side of the nose, the peri- or retro-orbital regions, 
or across the cheeks. The symptoms of tension type headache 
often coexist. There may be hyperaesthesia of the skin and 
soft tissues over the affected area. There are no consistent 
exacerbating or relieving factors. There are no nasal symptoms 
(note that approximately 20% of most populations have 
intermittent or persistent allergic rhinitis, which may occur 
incidentally in this condition). The majority of patients with this 
condition respond to low dose amitriptyline, but usually require 
up to 6 weeks of 10 mg (occasionally 20 mg) at night before it 
works. Amitriptyline should then be continued for 6 months 
before stopping it, and the 20% whose symptoms return when 
they stop it need to restart it if the pain returns. 
Patients with facial pain who have no objective evidence of 
sinus disease (endoscopy negative) are very unlikely to be 
helped by nasal medical or surgical treatment. In these patients, 
other diagnoses should be considered and an appropriate 
medical treatment tried.
A comprehensive examination including nasendoscopy is highly 
desirable if medical nasal treatment directed at sinusitis has 
failed in order to confirm or refute the diagnosis of sinusitis. 
4.4.2.Introduction
Otorhinolaryngologists see many patients with facial pain. 
They have the equipment to help diagnose whose facial pain 
is due to paranasal sinus disease or, as important, whose is not. 
This is vital as so many patients and their physicians mistakenly 
attribute their pain as being due to rhinosinusitis, when this 
is not the case. In the group of people who are referred to an 
ORL surgeon with a presumptive diagnosis of rhinosinusitis as 
the cause for their facial pain, only 1 in 8 patients are found to 
have pain attributable to their sinus disease (1076). “Significant 
caution is needed when considering surgery in those patients 
(with facial pain) because of high long-term failure rates and 
the eventual identification of other causes of the pain in many 
cases”  (1190). This does not mean that rhinosinusitis does not 
cause facial pain, rather that caution is needed before making 
the link to this diagnosis.
 Facial pain without any other nasal symptoms is 
unlikely to be due to rhinosinusitis.
4.4.3. Sinogenic facial pain
Before describing the characteristics of facial pain secondary 
to sinusitis it is worthy of note that over 80% of patients with 
purulent secretions visible at nasal endoscopy have no facial 
pain and those that do have it during an acute exacerbation 
(1191) and the majority of patients with nasal polyposis do not 
have pain (1192). Children with chronic rhinosinusitis very rarely 
complain of facial pain, even in the presence of florid purulent 
secretions. Also of note is the fact that a significant proportion 
of patients in several series have persisting facial pain after 
endoscopic sinus surgery (1174, 1193). In other words not only does 
chronic rhinosinusitis not usually cause facial pain but facial 
pain is not synonymous with rhinosinusitis. Interestingly the 
IHS (International Headache Society) classification says “chronic 
rhinosinusitis is not validated as a cause of headache or facial 
pain unless relapsing into an acute stage” (1194).
4.4.3.1. Bacterial rhinosinusitis
Acute bacterial rhinosinusitis usually follows an acute viral 
upper respiratory tract infection and if there is pain it is usually 
unilateral, severe, associated with pyrexia in about 50% and they 
have nasal obstruction. In maxillary sinusitis unilateral facial and 
dental pain are good predictors of true infection and this has 
been validated in studies using maxillary sinus aspiration (236) 
(Evidence Level III). This differs from chronic rhinosinusitis where 
there is a poor correlation between the site of facial pain and 
evidence of sinus pathology (1177, 1195) 
(Evidence Level  III). An increase in the severity of pain on 
bending forward has traditionally been thought to be diagnostic 
of sinusitis but this is non-specific and it can occur in many other 
types of facial pain. 
Coexisting nasal obstruction and/or clear 
rhinorrhoea can occur along with various types 
of vascular facial pain but these are normally 
short lived and rarely last longer than 48 hours.
The key points in the history of sinus related pain are an 
exacerbation of pain during an upper respiratory tract infection, 
an association with rhinological symptoms, worse when flying 
or skiing and a response to antibiotic medical treatment. It is 
important to realise that many types of facial pain are vascular 
in origin and last less than 72 hours so that a patient with this 
type of pain might presume that their pain has responded 
to an antibiotic when it would have resolved within this time 
frame in any event. A good history is vital in arriving at a correct 
diagnosis. There is no diagnostic investigation that can make a 
diagnosis in most neurological causes of facial pain other than 
analysing the patients’ symptom complex in the light of their 
examination and response to treatment. “When patients present 
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with a headache and that they believe to be related to allergies 
and sinus problems, the clinical interview is often orientated by 
them in a way that supports their assumption” (1196).
Normal nasal endoscopy makes it very unlikely 
that a person’s facial pain is due to rhinosinusitis
4.4.3.2. Examination
In acute frontal sinusitis the patient is often pyrexial and 
has tenderness on the medial side of the orbital floor under 
the supraorbital ridge where the frontal sinus is thinnest. 
Endoscopic examination shows marked hyperaemia of the 
nasal mucosa and purulent secretions are often visible. Acute 
sphenoiditis is uncommon and said to cause pain at the vertex 
of the head but pain can be referred to the temporal region 
or whole head. Facial swelling other than that caused by 
periorbital cellulitis, cavernous sinus thrombosis or subgaleal 
infection usually results from dental sepsis (440, 455, 1197) (Evidence 
level III). A normal nasal cavity, showing no evidence of middle 
meatal mucopus or inflammatory changes makes a diagnosis 
of sinogenic pain most unlikely, particularly if the patient is 
currently in pain or has had pain within the past few days. 
If the patient or surgeon are in doubt because the patient 
is asymptomatic on the day they are seen and their nasal 
endoscopy is normal in the clinic, it is often useful to review 
them and repeat the nasendoscopy when they have pain in 
order to clarify the diagnosis.
If a patient complains of constant symmetrical 
facial pain then midfacial segment pain should be 
excluded.
It is extremely rare for patients to have endoscopic evidence 
of inflammation or infection when they return with their pain. 
Even the presence of inflammatory changes or infection does 
not indicate with any certainty that the pain is sinogenic as 
it can occasionally be incidental (1076) (Evidence level III). If it is 
incidental this will become apparent as the patients pain will 
persist after their sinusitis has resolved. 
Nasal endoscopy has better specificity than CT in 
diagnosing whether someone has rhinosinusitis.
4.4.3.3. Investigations
Plain sinus x-rays are very insensitive and non-specific in 
diagnosing chronic sinusitis The interpretation of changes on 
the sinuses with computerised tomography (CT) scans must also 
be treated with caution. Approximately 30% of asymptomatic 
patients will demonstrate mucosal thickening in one or more 
sinuses on CT scanning. The presence of this finding is certainly 
not an indication that pain is sinogenic in origin (277, 570, 1177, 1195, 1198, 
1199) (Evidence level III) However, a clear CT makes it very unlikely 
there is any rhinosinusitis. In one study of 305 patients who met 
the American Academy Taskforce clinical criteria for chronic 
rhinosinusitis, of whom 154 had facial pain, they found that 
60% had normal sinuses thereby questioning the diagnosis and 
selection criteria. More recent guidelines include endoscopic 
findings +/- CT changes to confirm the diagnosis (5, 1175) (Evidence 
level III). Care should be taken in making the diagnosis of 
recurrent acute sinusitis as this is very unusual and patients who 
have two or more bacterial sinus infections within 12 months 
should be investigated for an immune deficiency (560, 1200, 1201).
If a patient complains of recurrent acute 
rhinosinusitis, yet they are clear when you 
see them, ask them to return when they are 
symptomatic. Recurrent bacterial rhinosinusitis is 
rare. Most of these patients with recurrent facial 
pain have a vascular aetiology for their pain
4.4.3.4. Medical treatment
The majority of patients with bacterial sinusitis respond 
to treatment with antibiotics. The common pathogens are 
streptococcus pneumoniae and haemophilus influenzae and 
less commonly S. aureus and M. catarrhalis (296, 1202-1204) (Evidence 
level III), various streptococci, and a minority have anaerobes 
such as bacteroides and anaerobic streptococci. In chronic 
bacterial rhinosinusitis, defined by its persistence over 12 weeks 
(1205), anaerobes (1206) and staphylococci (639) (Evidence level III) are 
more prevalent. 
4.4.3.5. Surgery
Surgery is normally effective in helping many symptoms in 
patients with genuine rhinosinusitis unresponsive to medical 
treatment but specific care is needed when the symptom of 
facial pain is concerned.An analysis of 10 series of endoscopic 
sinus surgery of 1,713 patients showed a mean improvement 
rate of 91%, taking a range of symptoms into account (1207) but 
this series does not specifically address the issue of facial pain. 
Many studies have looked at quality of life, or encompass a 
range of nasal symptoms and pathologies and do not provide a 
sufficient breakdown of the different symptoms to analyze the 
effect of surgery on facial pain (1208-1217). Studies that have looked 
at symptoms of facial pain and pressure in sinusitis show that 
between 56-77% of patients who have facial pain are better 
after sinus surgery (1217, 1218) (Evidence level IIb). However, these 
studies they do not claim very good results in the complete 
resolution of facial pain. One study with a validated outcome 
score showed an improvement in facial pain and headache after 
endoscopic sinus surgery in patients with facial pain caused by 
sinusitis (1219) (Evidence level III). It is important to ensure that 
98
European Position Paper on Rhinosinusitis and Nasal Polyps 2012.
the diagnosis of rhinosinusitis is correct before embarking on 
surgery.
4.4.3.6. Facial pain and CRS with nasal polyps 
(CRSwNP).
Chronic rhinosinusitis with or without clear evidence of a 
bacterial infection is often painless, except during an acute 
exacerbation precipitated by an upper respiratory tract infection 
or induced by barotrauma. CRSwNP patients rarely have facial 
pain, even with opaque sinuses on CT, unless there is an acute 
exacerbation with obstruction of the sinus ostia (1192) (Evidence 
level III).
4.4.3.7. Other diseases of the nose or paranasal 
sinuses that cause facial pain
Although tumours rarely present with facial pain, constant, 
progressive pain, particularly if associated with other suspicious 
symptoms or neurological signs should alert the clinician. A 
thorough examination and appropriate imaging is mandatory to 
exclude the possibility of a tumour. 
Stretching of the arterial tree which, supplies the proximal 
portions of the cranial nerves and the dura within 1 cm of 
any venous sinus induces a headache but can cause facial 
pain.  The supratentorial vessels and dura refer pain to the 
ophthalmic division of the trigeminal nerve.  Infratentorial 
structures refer pain to the distribution of the glossopharyngeal 
nerve and vagus, along with the upper three cervical nerve 
dermatomes. Space-occupying lesions such as meningiomas, 
angiomas and intracerebral metastases can induce facial pain 
by irritation of the trigeminal nerve along its intracerebral 
course.  Syringobulbia, syphilis and multiple sclerosis are rarer 
causes of central lesions, which may cause facial pain.  Raised 
intracranial pressure produces a bursting headache, which is 
worse on coughing or straining and is associated with effortless 
vomiting.  The fundi can show papilloedema in around a third 
of patients.  Lesions in the posterior cranial fossa produce 
occipital and upper neck pain, while supratentorial lesions with 
raised intracranial pressure produce pain at the vertex or over 
the frontal and temporal region. Cerebrovascular accidents can 
cause such pain, but these symptoms may only present when 
the other more distressing signs and symptoms of a stroke are 
resolving. They are particularly severe when part of the thalamus 
has been infracted.
Carcinoma of the maxilla is uncommon.  Patients unfortunately 
often present late when the disease has spread beyond the 
confines of the sinuses.  Unilateral serosanguinous nasal 
discharge and obstruction is the most frequent presentation.  
Less common symptoms are infraorbital paraesthesiae, loose 
teeth or ill-fitting dentures, proptosis, deformity of the cheek, 
epiphora, nasal obstruction or epistaxis.  Pain is usually a late 
feature. Occasionally adenoid cystic carcinoma can present 
with pain in the distribution of the trigeminal ganglion or its 
branches.
4.4.4. Non-sinogenic facial pain
4.4.4.1. General comments on the main categories of 
non-sinogenic facial pain
Only about 1 in 8 patients attending a rhinology clinic have 
pain that is attributable to rhinosinusitis (1076, 1289,1204). (Evidence 
level III). The remainder of patients who have non-sinogenic 
pain have migraine or its variations, tension type headache/
midfacial segment pain, trigeminal-autonomic cephalgias, 
neuropathic pain or other specific neurological conditions. 
Clinical examination and diagnostic tests rarely help to make a 
diagnosis (rare exceptions include an MRI in multiple sclerosis or 
brainstem tumours, and PET scans can shown abnormalities in 
the hypothalamus in cluster headache). In facial pain a diagnosis 
is primarily made on the basis of the history and response 
to treatment. The following broad characteristics are used to 
categorise the main types of facial pain:
4.4.4.2. Migraine, Trigeminal-autonomic cephalgias, 
Cluster headache, Paroxysmal Hemicrania, SUNCT 
syndrome (short lasting unilateral neuralgiform 
headache attacks with conjunctival injection and 
tearing)
Vascular pain of various types can be associated with 
autonomic rhinological symptoms such as nasal congestion 
and rhinorrhoea and this has lead to confusion in arriving at 
Table 4.4.4. Characteristics of migraine without aura (1194).
Migraine without aura
A At least 5 attacks fulfilling B-D 
B Headache lasting 4-72 hours (untreated or unsuccessfully 
treated) 
C Headache has at least two of the following characteristics:
1. Unilateral location 
2. Pulsating quality 
3. Moderate to severe pain intensity 
4. Aggravation by or causing avoidance of routine physical 
activity (eg walking or climbing stairs)
D During headache, at least one of the following
1. Nausea and/or vomiting 
2. Photophobia or phonophobia
E Not attributable to another disorser
Migraine with aura
A At least two attacks fulfilling B
B Migraine aura fulfilling criteria B and C for one of the 
subforms (1.2.1-1.2.6 or migraine without aura, childhood 
periodic syndromes that are commonly precursors of 
migraine, retinal migraine, complications of migraine, prob-
able migraine).
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a correct diagnosis as many patients understandably believe 
that these symptoms are synonymous with rhinosinusitis. The 
prevalence of trigeminal autonomic symptoms is approximately 
27% (1220) (Evidence level III). Other causes of facial pain include 
atypical forms of migraine (1221-1224) cluster headache, paroxysmal 
hemicrania and atypical facial pain.
Migraine has been defined by the IHS (1194) as an episodic 
headache lasting 4-72 hours with certain distinguishing 
features.  The diagnostic criteria for migraine are shown in Table 
4.4.4. These include throbbing head pain in attacks, often with 
a prodromal state and usually preceeded by an aura, which 
frequently contains visual phenomena. Migraine is occasionally 
isolated to the face and a minority can have pain confined to 
the periorbital area, and rarely affect the cheek and nose alone. 
(1225). The pain is typically unilateral but may be bilateral. Nausea, 
vomiting, photophobia and phonophobia often accompany 
the pain. The prevalence of migraine that involves the face 
is approximately 9% of the whole migraine population and 
occasionally it can be isolated to the face (1226, 1227). Patients who 
have migraine that involves the face have more trigemino-
autonomic symptoms than other migraine patients (1226).
The condition has 2 main forms. One type, migraine without 
aura (previously called common migraine) affects almost 75% 
of migraine sufferers. It is characterised by a headache, which 
can be severe and is typically unilateral, sharp, pulsating and 
often accompanied by nausea, photophobia or phonophobia. 
Symptoms last 4 to72 hours. There is no premonition. The 
second type, migraine with aura (previously called classic 
migraine) affects 25% of migraine sufferers. The attacks are 
preceded by neurological symptoms such as visual disturbances 
or numbness. It is three times more common in women 
and there is often a family history. Stress release, diet, the 
premenstrual state and barometric pressure can induce attacks. 
This system of classification is conservative, and it is recognised 
that many patients fall outside these criteria yet have migraine 
(1228). Thus, the diagnostic criteria are highly specific but less 
sensitive. Other conditions have some migrainous features such 
as cluster headache and paroxysmal hemicrania. These however, 
have cohesive groups of symptoms that allow them to be 
categorised separately. However, many patients with facial pain 
do not neatly fit any diagnostic criteria. Some have migrainous 
features such as nausea, an aura, or facial flushing. The proposed 
theories of the cause of migraine have swung between being 
a primarily vascular or neural mechanism. Griggs and Nutt 
suggested migraine may be part of the spectrum of diseases 
known as channelopathies - disorders involving voltage-gated 
channels (1228).  The genetic component of migraine may be 
explained by the identification of migraine genes in familial 
hemiplegic migraine that affect the Ca2+ channei (1229). 
In recent years, neuroimaging of the primary headache 
syndromes, such as migraine and cluster headaches, has begun 
to provide a glimpse of the neuroanatomical and physiological 
basis of these conditions. Functional imaging with positron 
emission tomography and magnetic resonance angiography 
(MRA) have documented activation in the midbrain, pons 
(1230) and hypothalamic grey matter in cluster headache (1231, 
1232). Work by Goadsby and colleagues suggest activation of 
the trigeminal innervation of the cranial circulation due to 
vasoactive peptides such as calcium gene related peptide (1233-
1235).
A primary dysfunction of the mid-brain endogenous anti-
nociceptive system (periaqueductal grey and dorsal raphe 
nucleus and the neural control of cerebral blood flow) 
seems to be responsible (1236). Neuroimaging has reconciled 
previous theories that migraine was solely vascular and they 
now suggest that it is a neurovascular headache and an 
epiphenomenon of trigeminal activation.
It appears that whilst vascular input predominates in migraine 
and myofascial nociception prevails in tension type pain, but 
there is a great deal of overlap. The pioneering work by Olesen 
and colleagues suggests a neurovascular mechanism (1237) 
and this is supported by the finding that approximately 50% 
of patients with tension type headache also have migraine. 
They proposed a vascular-supraspinal-myogenic model that 
integrates the effects of pericranial myofascial afferents, 
activation of peripheral nociceptors from cephalic arteries, and 
convergence on the caudal nucleus of the trigeminal, along 
with qualitative changes in the central nervous system. A recent 
study showed an increase in functional MRI blood oxygen 
dependant levels in the thalamus during migraine attacks with 
allodynia, the experience of ordinarily nonpainful stimuli as 
painful, or hyperaesthesia (1238).
The management of migraine begins with providing 
Table 4.4.3. Treatment options for acute migraine attacks.
Treatment options for acute migraine attacks. 
The Triptans (e.g. Sumatriptan, Naratriptan, Rizatriptan, Zolmatriptan)
Ergotamine or dihydroergotamine 
Aspirin, paracetamol, codeine phosphate, ibuprofen, naproxen, with 
or without metoclopramide.   
Treatment options for preventative therapy. 
Pizotifen (weight gain is a common side-effect and reduces its ac-
ceptability) 
Propranolol 
Amitriptyline 
Sodium valproate 
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information to the patient, the identification and avoidance 
of aggravating factors. Regular sleep, exercise and a diet that 
avoids aggravating factors will help many patients although 
there is no objective data to support this assertion. An 
assessment must be made on the severity based on a frequency 
diary, intensity of pain and degree of disability. Pharmacological 
treatment consists of the management of acute attacks and 
preventative treatment. Current literature suggests preventative 
treatment should be considered if symptoms occur more than 
three times a month with a duration of symptoms more than 48 
hours, and if there is a prolonged aura or failure to reduce acute 
symptoms (1239-1241) (Evidence level III). The options available for 
medication are shown in Table 4.4.3. 
Acute anti-migraine therapy is most likely to be beneficial if 
started early in an attack and prophylactic anti-migrainous 
medication may need to be continued for up to 6 weeks before 
its beneficial effects occur. Treatment can be divided into non-
specific and specific. The former consists of analgesia, such 
as paracetamol, codeine and aspirin, or non-steroidal anti-
inflammatory drugs. An anti-emetic may be added if there is 
associated nausea or vomiting. If headaches are severe, specific 
anti-migrainous medications can be used. These include the 
triptans. Ergotamine has to be carefully prescribed as its overuse 
can cause severe headaches. The 5-HT1B/D receptor agonists, or 
triptans, are shown to be effective after the headache begins as 
long as they are given early (1242) (Evidence level  Ib).
These constrict blood vessels, block neurogenic inflammation 
and neuropeptide release by a neuronal mechanism of action. 
Triptans should be prescribed with caution to patients with 
ischaemic heart disease, a history of myocardial infarction, 
uncontrolled hypertension or cerebrovascular disease. Pizotifen 
is a 5-hydroxytriptamine antagonist that is very effective in the 
prophylaxis of migraine but its side effects include weight gain 
and drowsiness (1243) (Evidence level Ib). Propranolol, a beta-
receptor antagonist, also has some subclass of 5-HT2 effect (1243) 
(Evidence level Ib). Patients with asthma should not be given 
beta-blockers. Topiramate is preferred to sodium valproate as 
a second line drug in the treatment of migraine (1244) (Evidence 
level Ib).
4.4.4.3. Cluster Headache
Cluster headaches are defined as a primary neurovascular 
headache that is both severe and uncommon. It is characterised 
by recurrent, strictly unilateral attacks of headache that typically 
wake the patient and are retro-orbital or centred at the medial 
aspect of the orbit, of great intensity and last up to one hour 
(not in my experience but feel free to change it). The pain is 
also accompanied by ipsilateral signs of autonomic dysfunction 
such as the ipsilateral parasympathetic signs of rhinorrhoea, 
lacrimation, impaired sweating and sympathetic signs of miosis 
and ptosis (1245). The most salient feature is its periodicity, which 
could be circadian or in terms of active or inactive bouts lasting 
6-10 weeks annually, separated by clinical remission when the 
patient is completely pain free for at least 2 weeks between 
attacks. About 15% to 20% of patients suffer from chronic 
CH and have no significant remissions. Treatment includes 
sumatriptan injections, oxygen, and prophylactic treatment 
includes verapamil, gabapentin, and Pizotifen (1246) (Evidence 
level  IIb). 
4.4.4.4. Paroxysmal Hemicrania
Paroxysmal Hemicrania has been described as an excruciating 
unilateral pain, which is usually ocular, and frontotemporal 
with short-lasting (2-45 minutes), frequent attacks (usually 
more than 5 a day). By definition, at least one of the following 
autonomic symptoms should be present; nasal congestion (42%), 
rhinorrhoea (36%), lacrimation (62%), conjuctival injection (36%), 
or rarely ptosis, eyelid oedema, heart rate changes (bradycardia, 
tachycardia and extrasystoles), increased local sweating, salivation 
and facial flushing (1247, 1248). Attacks may occur bilaterally even 
though they are usually more pronounced in the symptomatic 
side. These last between 5 to 45 minutes on each occasion, and 
they recur many times, between 7-22 times daily. Remission varied 
between 3 months to 3 years. Rarely do these headaches develop 
into the chronic form. The ratio is said to be 4:1 for CPH to episodic 
PH (1249).  Overall, the average age of the onset of PH is usually 30-40 
years, but the spectrum range from 6 years old to 81 years old. The 
episodic form tends to have an earlier age onset (1250).
The condition’s complete or rapid response to indomethacin is 
said to differentiate paroxysmal hemicrania from cluster headache 
(1251) (Evidence level III). However, recently the inclusion of this 
‘absolute’ response to make it a criterion has been questioned 
(1252-1254) (Evidence level IV). The majority of patients with PH 
respond to indomethacin within 24 hours. If not, a trial, which 
entails increasing the dose to 75 mg daily after 3 days, followed by 
150 mg daily after another 3 days has been recommended (1255). 
Another study by Antonaci et al., recommended the ‘Indotest’, 
with an intramuscular injection of 50 mg indomethacin, and the 
response is monitored to differentiate paroxysmal hemicrania, 
hemicrania continua (HC) and other headache disorders with 
which they can be confused (1256). They also noted that this test is 
a useful tool in the clinical assessment of unilateral headaches by 
establishing the interval between indomethacin administration 
and the clinical response. 
A need for a persistently high dose may imply a sinister underlying 
pathology (1257). In cases where indomethacin fails to work, other 
drugs that have been sugested, include calcium-channel blockers 
(1253, 1258) naproxen, carbamezapine (1259), and sumatriptan (1260) 
(Evidence level IV). The main features of PH and CH are listed in 
Table 4.4.1.
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4.4.4.5. Hemicrania Continua
Chronic Paroxysmal Hemicrania and Hemicrania Continua 
(HC) are two strictly unilateral headache disorders 
characterised by an absolute response to indomethacin.  
HC, first described by Sjaastad and Spiering, is a unilateral 
headache which is moderately severe without side shift, 
continuous but with fluctuations, with complete resolution 
of pain with indomethacin, and exacerbations that may 
be associated with autonomic features such as conjuctival 
injection, lacrimation, and photophobia to the affected side 
(1261, 1262) (Evidence level IV).
SUNCT (Short-lasting neuralgiform pain with conjunctival 
injection and tearing) SUNCT is one of the rarest idiopathic 
headache syndromes. This is a form of primary headache, 
marked by trigeminal pain, particularly orbital or 
periorbital area, associated with autonomic symptoms, 
in which conjunctival injection and tearing is the most 
prominent feature. Attacks last between 15 to 60 seconds 
and recur between 5-30 times an hour. These attacks may 
be precipitated by chewing movements and ingesting 
certain foods such as citrus fruits. Treatment is difficult with 
lamotrigine, carbamezapine or topiramate (1263) (Evidence 
level IV)
4.4.4.6. Indomethacin-responsive headaches. 
(Episodic and Chronic Paroxysmal Hemicrania, Remit-
ting and Unremitting Hemicrania Continua, and Be-
nign Cough Headache, Benign Exertional Headache, 
and sharp short-lived headache pain syndrome)
Indomethacin-responsive headaches are defined as those 
responding to doses of 25 mg twice daily to 75 mg three times 
daily, usually having an effect in less than 72 hours from the start 
of the effective dose. These rare syndromes include Episodic 
and Chronic Paroxysmal Hemicrania, Remitting and Unremitting 
Hemicrania Continua, and Benign Cough Headache, Benign 
Exertional Headache, and sharp short-lived headache pain 
syndrome. Most of these headaches are provoked by physical 
stimulation, for example exertion, cough, flexion or extension of 
the neck (1263). 
How indomethacin works for these headaches is unclear. 
Currently, it is thought that indomethacin reduces the cerebral 
blood flow (1264), thereby decreasing the load on the presumed 
phlebotic cavernous sinus which chould be the origin of the 
pain in CPH attacks (1236) and is results in a decline in cerebral 
permeability (1265) and cerebrospinal pressure (1266). The anti-
inflammatory effect of indomethacin on these vessels may also 
have a role in aborting pain in CPH (1259) (Evidence level IV).
4.4.4.7. Persistent idiopathic facial pain
This is defined as persistent, unilateral facial pain not associated 
with sensory or physical signs. One study showed that with 
voxel-based morphometry there was a decrease in grey matter 
volume in the left anterior cingulated gyrus and left temporo-
insular region as well as bilateral motor and sensory areas 
projecting to the areas that represent the face (1267) (Evidence 
level IV). 
4.4.4.8. Chronic oro-facial pain
A small proportion of patients go on to have chronic pain 
and a prospective study supports the hypothesis that 
psychological factors such as anxiety, depression, illness 
behaviour, somatic symptoms are markers for chronic 
pain (1268). A multi-disciplinary facial pain clinic supported 
by a clinical psychologist is very helpful in treating these 
patients as it not only stops them from “shopping around” 
but it helps to check that no treatment strategy has been 
overlooked and after that coping mechanisms can be put in 
place. Comprehensive pain programmes have been shown 
to be both therapeutically efficacious and cost-effective in 
an evidence-based review of the subject (1269). Functional 
restoration, often through cognitive behaviour therapy, is 
central to the rehabilitation of most patients with chronic 
pain, almost whatever the cause. Psychological therapies are 
similarly helpful in children and adolescents with chronic pain 
(1270) (Evidence level Ib).
Table 4.4.1. Salient features to differentiate Cluster Headache from 
Paroxysmal Hemicrania.
Parameters Cluster headache Paroxysmal 
hemicrania
Age of onset female 25-50 /5:1 30-40/1:2
Age of onset male 25-50 /5:1 30-40/1:2
Laterality Unilateral Unilateral
Changes sides Sometimes Rarely
Duration 15 mins-2 hours 2-45 mins
Location Occular, fronto-
temporal and 
facial
Occular, frontotempo-
ral, and facial
Wakes subject from 
sleep 
+ +
Waking time Night (50%) Night (30%)
Attack frequency 1 per day, after 
several days
5/day
Remission For days-weeks Unusual
Autonomic (lacrima-
tion, nasal conges-
tion, facial flushing, 
injection of eye)
+ +
Non-narcotic anal-
gesics
Little help Little help
Prophylactic re-
sponse
Indomethacin 
occasional
Pizotifen helps
Indomethacin good
Calcium channel 
blockers some help
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4.4.4.9. “Sinus Headaches”.
Headaches that are due to rhinosinusitis are very uncommon 
and confined to a minority of patients who have acute frontal 
sinusitis or sphenoiditis. The vast majority of people who 
present with a symmetrical frontal or temporal headache, 
sometimes with an occipital component, have tension type 
headache. Unilateral, episodic headaches are often vascular 
in origin. The idea that rhinosinusitis can trigger migraine is 
misplaced as the whole symptom complex is vascular and 
coexisting nasal congestion is due to vasodilation of the nasal 
mucosa that is sometimes part of the vascular event. The use 
of nasal endoscopy and imaging of the paranasal sinuses have 
advanced our appreciation that these patients are suffering 
from a vascular event. 
Over 90% of self-diagnosed and doctor-diagnosed sinus 
headaches meet the International Headache Society criteria 
for migraines and yet 61% receive an antibiotic prescription 
(1271). One study of 100 patients who believed that they suffered 
from sinus headache found that 52% had migraine, 11% 
had chronic migraine associated with medication overuse, 
23% had probable migraine, 1% cluster headache, 1% 
hemicrania continua, 3% secondary to rhinosinusitis, 9% were 
nonclassifiable (1272). Seventy-six percent of migraine subjects 
reported pain in the distribution of the second division of the 
trigeminal nerve (either unilateral or bilateral), 62% experienced 
bilateral forehead and maxillary pain with their headaches and 
the most common associated feature was nasal congestion 
in 56% and rhinorrhoea in 25% (1272). Another study of 1000 
patients with headache has as the diagnostic causes migraine, 
tension-type headache, trigeminal autonomic cephalalgias, 
cranial neuralgias, trauma, drugs but that sinusitis is very, 
very rarely the cause (1273). In another study 46% of migraine 
sufferers attending a tertiary referral centre had at least one 
unilateral nasal symptom of congestion or rhinorrhoea or ocular 
lacrimation, redness or swelling during an attack due to the 
trigeminal-autonomic reflex (1222). Another study found that in 
self-reported sinus headaches 82% of patients had a significant 
response to empiric treatment with triptans (1223) (Evidence level 
IIb). Cady and Schreiber comment that “The concept of sinus 
disease as a common cause of headache is deeply engrained in 
the American public, but there is little evidence to support the 
sinuses as a common cause of disabling headache.” (1274). They 
reported that nearly 90% of participants with self-diagnosed 
or physician-diagnosed sinus headache met the IHS criteria for 
migraine-type headache and responded to triptans. They note 
that during a migrainous episode there is engorgement and 
erythema of the nasal mucosa along with rhinorrhoea and after 
subcutaneous sumatriptan both the symptoms and endoscopic 
signs resolve. Others have found that migraine often affects the 
face and can be misinterpreted as being due to rhinosinusitis, 
particularly as symptoms can last 72 hours and that vascular 
changes in the lining of the nose can also produce nasal 
obstruction through vasodilatation of the vascular turbinate 
tissue (1223, 1275). An interdisciplinary consensus group recently 
agreed that “the majority of sinus headaches can actually be 
classified as migraines” and that “unnecessary diagnostic studies, 
surgical interventions, and medical treatments are often the 
result of the inappropriate diagnosis of sinus headache” (1276). 
(Table 4.4.2.)
Other conditions that are often considered to 
induce headache are not sufficiently validated as 
causes of headache. These include deviation of 
nasal septum, hypertrophy of turbinates, atrophy 
of sinus membranes and mucosal contact
4.4.4.10 Tension type headache
Seventy to eighty percent of the population has headaches 
every year and 50% have at least one a month, 15% once a 
week and 5% daily (1277, 1278). The main quality of the pain is one 
of symmetrical pressure that may be confined to a small area 
just above the nasion or extend across the whole forehead. 
There is often an occipital component. There are often no 
exacerbating or relieving factors although bending forwards 
can sometimes aggravate them, a symptom often incorrectly 
said to mean the patient must have rhinosinusitis. There is often 
some hyperaesthesia of the soft tissues in the area. Patients are 
often taking many analgesics although they say they do little 
to help. Analgesic dependant headache can complicate the 
picture. Withdrawal from analgesics for several weeks alone may 
be sufficient in this group but is rarely tolerated without starting 
other treatment for their headache but this is an option. The 
prevalence of headache increases sharply during the second 
A Frontal headache accompanied by pain in one or more re-
gions of the face, ears or teeth and fulfilling criteria C and D. 
B Clinical, nasal endoscopic, CT and/or MRI imaging and/or 
laboratory evidence of acute or acute-on-chronic rhinosi-
usitis. 
C Headache has at least two of the following characteris-
Headache and facial pain developing simultaneously with 
onset or acute exacerbation of rhinosinusitis. 
D Headache and/or facial pain resolve within 7 days after 
remission or successful treatment of acute or acute-on-
chronic rhinosinusitis
Notes:  
1 Clinical evidence may include purulence in the nasal cavity, 
nasal obstruction, hyposmia/anosmia and/or fever. 
2 Chronic sinusitis is not validated as a cause of headache or 
facial pain unless relapsing into an acute stage.
Table 4.4.2. Headache attributed to rhinosinusitis from so called “sinus 
headaches”.  Diagnostic criteria  Section 11.5. of (1194).
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decade then levels off until the age of 40-50, after which it 
reduces. The ideas from the Copenhagen group on tension-
type headache (1279, 1280) postulate that central sensitisation of 
the trigeminal nucleus from either prolonged nociceptive input 
from a peripheral injury, surgery, inflammation, myofascial 
nociceptive input, along with psychological or neurological 
factors that can reduce supraspinal inhibition can contribute 
to tension-type headache. This concept offers a broader 
perspective and is a more inclusive method of interpreting.
Amitriptyline should be given for six weeks before judging its 
effect, and should be continued for six months if it has helped 
(1281, 1282) (Evidence level Ib). The starting dose is 10 mg, and after 
six weeks if pain is not controlled this can be increased to 20mg 
(and rarely 50mg are needed). Patients need to be warned of 
the sedative effects of even at this low dose, but they can be 
reassured that tolerance usually develops after the first few days. 
It is our practice to inform patients that amitriptyline is also used 
in higher doses for other conditions such depression, but that it 
is not being given for this reason and its effect is unrelated to its 
analgesic properties, that would take effect much more quickly 
and normally require 75mgs. It is often reassuring for patients 
to know that the dose used for depression is some 7 or more 
times the dose used in tension-type headache and that other 
antidepressants do not help this condition. 
4.4.4.11. Midfacial segment pain
Over the last decade, studies on facial pain have shown that 
there is a distinct group of patients who have a form of facial 
neuralgia that has all the characteristics of tension type 
headache with the exception that it affects the midface (1283). 
The criteria that comprise midfacial segment pain is:
•	  A symmetrical sensation of pressure or tightness. Some 
patients may say that their nose feels blocked even though 
they have no nasal airway obstruction. 
•	  Involves the areas of the nasion, under the bridge of the 
nose, either side of the nose, the peri- or retro-orbital 
regions, or across the cheeks. The symptoms of tension type 
headache often coexist.
•	  There may be hyperaesthesia of the skin and soft tissues 
over the affected area. - Nasal endoscopy is normal. 
•	  Computerised tomography of the paranasal sinuses 
is normal (note a third of asymptomatic patients have 
incidental mucosal changes on CT).
•	  There are no consistent exacerbating or relieving factors.
•	  There are no nasal symptoms (note that approximately 20% 
of most populations have intermittent or persistent allergic 
rhinitis, which may occur incidentally in this condition).
The aetiology of this type of pain is uncertain but Olesen’s 
theory, which integrates the effects of myofascial afferents, the 
activation of peripheral nocioceptors and their convergence 
on the caudal nucleus of trigeminal, along with qualitative 
changes in the central nervous system, provides one of the 
best models (1237). Downregulation of central inhibition from 
supraspinal impulses due to psychological stress and emotional 
disturbances may also play a role. A higher proportion of these 
patients have myofascial pain, irritable bowel and fatigue than 
is found in the normal population, although many appear to be 
healthy individuals in all other respects.  
The majority of patients with this condition respond to low 
dose amitriptyline, but usually require up to 6 weeks of 10 mg 
at night and occasionally 20 mg before it works (1076) ((Evidence 
level III). Amitriptyline should then be continued for 6 months 
before stopping it, and in the 20% whose symptoms return 
when they stop it they need to restart it if the pain returns. 
Other antidepressants are not effective; again this is akin to 
tension-type headache. If amitriptyline fails, then relief may be 
obtained from gabapentin or pregabalin. 
4.4.4.12. Analgesic dependant headache 
This entity is all too often unrecognised and mismanaged. 
As has already been mentioned, patients with tension type 
headache or midfacial segment pain often take a great number 
of analgesics in spite of the fact that they have little effect. 
Similarly migraine sufferers can get into a cycle of using an 
excessive amount of analgesics. Drug-induced headache is 
usually described as dull, diffuse, and band-like, and usually 
starts in the early morning. The original headache (migraine or 
tension headache) has often been present for many years and 
the regular intake of drugs often started several years before 
people present. Patients take on average 30 or more tablets per 
week often containing several different substances. The drugs 
most often used are caffeine, ergotalkaloids, paracetamol, and 
pyrazolone derivates. Withdrawal is problematic as patients’ 
symptoms take several weeks to resolve. However, chronic 
headache disappears or decreases by more than 50% in 
two-thirds of the patients. Positive predictors for successful 
treatment are migraine as primary headache, chronic headache 
lasting less than 10 years, and the regular intake of ergotamine. 
It is well worth considering if this might be the patient’s problem 
before adding to it with more tablets!
4.4.5. How surgery can influence pain
It is interesting to note that a proportion of patients who 
mistakenly undergo surgery for non-sinogenic pain experience 
temporary relief from their symptoms, although their pain 
returns within a few weeks and nearly always within 9 
months. It is hypothesised that the reason for a temporary or 
partial reduction in their pain is either the effect of cognitive 
dissonance or the effect of surgical trauma on the afferent 
fibres going to the trigeminal nucleus, which alters its threshold 
for spontaneous activity in the short term.  In about a third of 
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patients surgery does not significantly affect the pain and in 
a third the pain is made far worse (1284). Patients whose pain is 
made worse by surgery may develop a more unpleasant quality 
to the pain such as burning.The criteria for diagnosing chronic 
rhinosinusitis vary, but most studies quote more than three 
nasal symptoms for more than 3 months (490). It is important 
to note that the inclusion of facial pain/pressure “on its own 
does not constitute a suggestive history for rhinosinusitis in 
the absence of another major nasal symptom or sign” (1205). The 
evidence that a vacuum within a blocked sinus can causes 
protracted pain is poor. Transient facial pain in patients with 
other symptoms and signs of rhinosinusitis can occur with 
acute pressure changes when flying, diving or skiing but this 
resolves as the pressure within the sinuses equalises within 
hours through perfusion with the surrounding vasculature. 
Patients who repeatedly suffer these intermittent symptoms 
whilst there is a pressure change are often helped by surgery 
to open the ostia. Persistent blockage of the sinus ostia rarely 
causes continuous pain for example silent sinus syndrome 
that is due to a blocked sinus with resorbtion of its contents 
to the extent that the orbital floor prolapses into the maxillary 
sinus causes no pain (1285). Endoscopic sinus surgery (ESS) has 
been advocated by a few workers for facial pain in the absence 
of endoscopic or CT evidence of sinus disease or anatomical 
variations Cook et al. advocated ESS on patients with facial 
pain, which also occurred ‘independently’ of episodes of 
rhinosinusitis, with no CT evidence of sinus pathology (1286). 
Twelve of the 18 patients who underwent surgery in their 
series had a significant reduction in their pain severity, yet it 
is significant that, “complete elimination of symptoms was 
not accomplished in any patient”. They had no evidence of 
ostiomeatal obstruction. If the cause of their pain was due to 
ostial obstruction then it might be anticipated that surgery 
would cure their symptoms of pain. This was not the case as 
they all had residual pain. Similarly Parsons et al. retrospectively 
described 34 patients with headaches who had contact points 
removed and found that whilst there was a 91% decrease in 
intensity and 84% decrease in frequency, 65% had persisting 
symptoms (1287). One possible reason for a temporary or 
partial reduction in their pain is either the effect of cognitive 
dissonance or the effect of surgical trauma on the afferent 
fibres going to the trigeminal nucleus and this might alter the 
nucleus and its threshold for spontaneous activity for up to 
several months as has been found when patients with midfacial 
segment pain undergo surgery (1174). 
4.4.5.1. Post surgical pain/Neuropathic pain
Neuropathic pain arises as a direct consequence of a lesion or 
disease affecting the somatosensory system (1288). Neuropathic 
pain is often spontaneous or it can be an abnormal response 
to a non-painful stimulus. The pain is often deep, burning, 
gnawing, occasionally stabbing or like an electric shock. It may 
start after a relatively minor injury or surgical procedure. There 
may be an altered sensation in the area affected. Acquadro 
et al. noted that in those patients with preoperative pain 
who underwent endoscopic sinus surgery, 7% developed 
new pain, and 2% reported a worsening of their facial pain 
but none developed de novo pain if they had had no pre-
operative pain (1289). Indeed to date, there has been few 
reported cases of facial pain following ESS in previously pain-
free patients although it may be under-reported (1174, 1284).  This 
fact is surprising given that open sinus surgery, in particular 
the Caldwell-Luc procedure has long been known to cause de 
novo facial pain.  One study noted this complication in 46% 
of all patients who had undergone a Caldwell Luc procedure, 
including some who had no prior facial pain though this may 
be due to direct trauma to the infraorbital nerve (1290). 
Trauma causes pain that is mediated by myelinated A delta 
and unmyelinated C fibres. Prolonged stimulation of these 
can activate N-methyl-D-aspartate (NMDA) and cause central 
sensitisation. An alteration in central processing can then lead 
to an alteration in pain thresholds producing hyperalgesia or 
even lead to spontaneous firing of neurones and may produce 
reverberating circuits. It is also possible that antidromic 
flow in C fibres can cause the release of substance P or that 
efferent sympathetic flow can release noradrenaline; both 
these mechanisms have the potential to sensitise peripheral 
receptors (1291). Trauma can be an initiating factor by either 
altering the fibres within the trigeminal nucleus or by altering 
its somatosensory input, thereby altering nocioceptive fibres 
to or within the caudal nucleus of the trigeminal nerve. These 
mechanisms, by altering the neuroplasticity of the nerves to 
and within the trigeminal nucleus, result in neuropathic pain. 
Amitriptyline has been shown to be effective in relieving 
post-traumatic neuralgia (1292) in doses of 75 mg or 
alternatively gabapentin or pregabalin (1284) (Evidence level 
III). Duloxetine may help, particularly if there is coexisting 
anxiety. These need to be given for 6 to 8 weeks before 
judging if they have helped. A local anaesthetic nerve block 
can sometimes be successful in blocking localised pain 
and having a more prolonged benefit. Lignocaine patches 
over the area can help as can transcutaneous electrical 
nerve stimulation. The management of patients with 
pain unresponsive to medical treatment should involve 
pain coping strategies that involve a pain management 
team and psychologist and cognitive behaviour therapy. 
Physical activity, treated depression and anxiety, as well as 
establishing work or other activities can play an important 
role. Opiates can help but care is needed in prescribing these 
as they can lead to tolerance and dependency, which is a 
further obstacle to recovery. 
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4.4.5.2. Contact points
The theories that implicate contact points within the nose as a 
cause of headache or facial pain originate from McAuliffe who 
described stimulating various points within the nasal cavity and 
paranasal sinuses in five individuals in whom he said that both 
touch and faradic current caused referred pain to areas of the 
face (1293). He illustrated this paper with diagrams that have been 
reproduced in many texts. These findings have been used to 
support the idea that mucosal contact points within the nasal 
cavity can cause referred pain, even though McAuliffe’s studies 
did not describe contact point induced headache or facial pain 
(1294). McAuliffe’s work has recently been repeated in a controlled 
study and was found not to produce the referred pain that he 
described (1295). The prevalence of a contact point has not only 
been found to be the same in an asymptomatic population as 
in a symptomatic population but, when a contact point was 
present in symptomatic patients with unilateral pain, it was 
found in the contralateral side to the pain in 50% (1296). 
Stammberger and Wolf postulated that variations in the 
anatomy of the nasal cavity result in mucus stasis, infection and 
ultimately facial pain (1297). They also stated that mucosal contact 
points might result in the release of the neurotransmitter 
peptide substance P, a recognised neurotransmitter in 
nociceptive fibres but there has been no in vitro or vivo work to 
substantiate this. For contact points to be credible as a cause of 
facial pain or headache they should also be a predictor of facial 
pain in the whole population (1298). Another observation is that 
nowhere else in the body does mucosa-mucosa contact cause 
pain.
Other authors have embraced these concepts to explain how 
pain might be induced by anatomical variants such as a concha 
bullosa (1299-1302), or a pneumatised superior turbinate touching 
the septum (1303). The description of the presence of anatomical 
‘abnormalities’ such as a concha bullosa, a paradoxical middle 
turbinate, a superior turbinate touching the septum, or a large 
ethmoid bulla is a misnomer as these are variations that occur in 
asymptomatic populations. Case-controlled studies examining 
the prevalence of anatomical variations in patients with 
rhinosinusitis and asymptomatic control groups have shown no 
significant differences (277, 570, 571, 576, 578-580, 1177, 1199, 1303-1310). It seems 
probable that the majority of the case series in the literature 
that describe surgery for anatomical variations in patients 
with facial pain that responded to surgery, that is more often 
partial than complete and relatively short lived, result from the 
effect of cognitive dissonance (1311), or from surgery altering 
neuroplasticity within the brainstem sensory nuclear complex 
(1237, 1279, 1280, 1312)..
The IHS classification (1194) has entered mucosal contact point 
headache as a new entry but says the evidence for it is limited. 
“Controlled trials are recommended to validate it, using the 
selection criteria:
A.  Intermittent pain localised to the periorbital or medial 
canthal or temporozygomatic regions fulfilling criteria C and D. 
B.      Linical, nasal endoscopic and/or CT imaging evidence of 
mucosal contact points without acute sinusitis. 
C.     Evidence that the pain can be attributed to mucosal contact 
based on at least one of the following: 
1. pain corresponds to gravitational variations in mucosal 
congestion as the patient moves between upright and 
recumbent positions. 
2. abolition of pain within 5 minutes after diagnostic topical 
application of local anaesthesia to the middle turbinate 
using placebo or other controls. 
D. Pain resolves within 7 days, and does not recur, after surgical 
removal of mucosal contact points (abolition of pain is indicated 
by a score of zero on the visual analogue scale).
At present reports that support the removal of contact 
points are notable by their retrospective nature, the lack 
of any controlled study, ability to explain the prevalence 
of these findings in many asymptomatic people in the 
population (1313) and a failure to meet the criteria in the HIS 
classification (1194).
4.4.6. Specific neurological conditions
4.4.6.1. Trigeminal neuralgia
The characteristic presentation of trigeminal neuralgia 
with paroxysms of severe lanciolating pain induced by a 
specific trigger point is well recognised. In more than one 
third of sufferers the pain occurs in both the maxillary and 
mandibular divisions, while in one fifth it is confined to the 
maxillary division. In a small number of patients only the 
ophthalmic division is affected (3%). Typical trigger points are 
the lips and naso-labial folds, but pain may also be triggered 
by touching the gingivae. A flush may be seen over the face 
but there are no sensory disturbances in primary trigeminal 
neuralgia. Remissions are common but the condition can also 
increase in severity. Younger patients should undergo MR 
imaging to exclude other pathology such as disseminating 
sclerosis that is identified in 2-4% of patients with trigeminal 
neuralgia. Tumours such as posterior fossa meningiomas 
or neuromas are found in 2% of patients presenting with 
trigeminal neuralgia reinforcing the need for imaging to 
exclude such pathology. Carbamazepine remains the first 
line medical treatment, with gabapentin, Lamotrigine (1314) 
(Evidence level IIb) and Topiramate (1315) (Evidence level 
IIb) being employed more frequentlyIn cases refractory 
to medical treatment, referral to specialist centres for 
consideration of other treatment modalities such as micro-
vascular decompression or stereotactic radiotherapy may be 
appropriate.
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4.4.6.2. Post-herpetic Neuralgia
This is pain following a herpes zoster infection, and is defined 
as pain recurring or continuing at the site of shingles after 
the onset of the rash. Up to 50% of elderly patients who have 
had shingles may develop post-herpetic neuralgia, though 
fortunately most recover during the first year. Antiviral 
agents help curtail the pain of acute shingles, and there is 
some evidence that they reduce the risk of subsequent post-
herpetic neuralgia. Various medical treatments may be helpful 
particularly carbamazepine or gabapentin with or without a 
tricyclic antidepressants (1316) (Category of evidence IV).
4.4.6.3. Atypical Facial Pain
This is very much a diagnosis of exclusion and care must be 
taken in reaching this conclusion, even when the patient 
has received previous opinions and no pathology has been 
identified. The history is often vague and inconsistent with 
widespread pain extending from the face onto other areas of 
the head and neck. The pain may move from one part of the 
face to another between different consultations and other 
symptoms such as ‘mucus moving’ in the sinuses are often 
described. A number of patients have such completely fixed 
ideas about their condition that they will not be convinced 
otherwise whatever the weight of evidence to the contrary. 
Pain is often described in dramatic terms in conjunction 
with an excess of other unpleasant life events. Many of these 
patients have a history of other pain syndromes and their 
extensive records show minimal progress despite various 
medications. They have often undergone previous sinus or 
dental surgery and may be resentful about their treatment. 
It is not uncommon for such patients to give a history of 
nasal trauma. Many patients with atypical facial pain exhibit 
significant psychological disturbance or a history of depression 
and are unable to function normally as a result of their pain. 
Some project a pessimistic view of treatment, almost giving 
the impression they do not wish to be rid of the pain that plays 
such a central role in their lives.  A comprehensive examination 
(including nasendoscopy) is essential and imaging such as 
MRI is advisable to exclude pathology before the patient is 
labelled as having atypical pain. The management of such 
patients is challenging and confrontation is nearly always 
counterproductive. A good starting point is to reassure the 
patient that you recognise that they have genuine pain and 
an empathetic consultation with an explanation should 
be conducted. Drug treatment revolves around a gradual 
build-up to the higher analgesic and antidepressant levels 
of amitriptyline (75-100 mgs) at night (1317) (Evidence level  
II). The second line treatment includes gabapentin and 
carbamazepine. Patients should sympathetically be made 
aware that psychological factors may play a role in their 
condition and referral to a clinical psychologist or psychiatrist 
may be helpful (1318) (Evidence level IV). Referral to a pain clinic is 
often appropriate.
4.4.6.4. Myofascial pain
Myofascial pain causes a widespread, poorly defined aching in 
the neck, jaw or ear.  It is five times more common in women 
and worse when the patient is tired or stressed.  Tender points 
may be found in the sternomastoid or trapezius muscles and 
initiating factors include malocclusion or poor deltopectoral 
posture.  This syndrome overlaps to a large degree with 
temporomandibular joint dysfunction.  Reassurance, local heat 
treatment, ultrasound and massage help. 
4.4.6.5. Ophthalmological
Uncorrected optical refractive errors can cause headaches, but 
their importance is exaggerated. Visual acuity is tested ideally 
with a Snellen chart and if there is a refractive problem this 
can be overcome by testing vision through a pinhole. Disease 
involving the optic nerve results in reduced acuity and colour 
vision.  Pain on ocular movement is suggestive of optic neuritis 
or scleritis. It is vital to recognise acute glaucoma, which may 
cause severe orbital pain and headache.  The patient may see 
haloes around lights, and circumcorneal injection can occur 
as well as systemic upset, especially vomiting. This condition 
requires urgent treatment as vision is rapidly lost. Pain is a 
feature of periorbital cellulitis, which may present with lid 
swelling and erythema if it is preseptal and with chemosis, 
proptosis and reduced mobility if it arises posterior to the 
septum.  Orbital pain can also be caused by uveitis, keratitis, 
dry eye syndrome and convergence insufficiency.Orbital 
haemorrhage can cause sudden pain, proptosis, nausea and 
vomiting, along with ecchymosis, reduced mobility and oedema 
of the optic disc.  It may be secondary to an orbital varix, blood 
dyscrasias, hypertension or trauma. 
The term ‘Inflammatory Orbital Pseudotumour’ should not 
be used for disorders whose aetiology is known (polyarteritis 
nodosa and vasculitis).  This condition probably has an 
immunological basis is often a precursor of lymphona and it 
can produce pain, proptosis, reduced mobility, lid swelling and 
injection of the eye.  Some individuals have recurring bouts and 
are pain free, whereas others have pain with upper respiratory 
tract infections and these can mistakenly be held responsible.  
The majority of other causes of proptosis are painless, such 
as hyperthyroidism and tumours of the orbit or of adjacent 
structures.  
4.4.7. Conclusion
The key message in this evidence based review on facial pain 
is that contrary to the preconceptions of many patients and 
their primary care physicians, the majority of patients with 
facial pain or headache do not have rhinosinusitis. It is very 
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important to ensure that the surgeon has the correct diagnosis 
in a patient with facial pain before embarking on any surgical 
treatment. Not only do the vast majority of patients with facial 
pain have a neurological cause, but in the small proportion that 
have paranasal sinus disease, the majority respond to medical 
treatment. We describe the prevalence and characteristics of the 
different causes of facial pain and headache and the symptoms 
and signs that are found in acute and chronic rhinosinusitis in 
order to help differentiate this group from other diagnoses. 
4.5. Genetics of CRS with and without nasal  
polyps  
4.5.1. Summary
Chronic rhinosinusitis (CRS) is a complex disease, with a 
pathophysiology that is likely to be affected by multiple 
genetic and environmental factors. There are several studies 
that linked different chromosomal associations and single 
nucleotides polymorphism to CRS. Although genetic studies 
will probably not answer all questions, it should provide new 
information to redirect basic science studies to disease-related 
pathophysiological pathways. In the future we hope to be 
able to improve diagnostics and treatments for patients with 
CRS using the subclassification of the disease on the basis of 
genetics. Additionally, identification of environmental factors 
that may interact with subject’s genome may also help to avoid 
these risk factors and potentially prevent disease expression.
Chronic rhinosinusitis (CRS) is a complex disease, 
with a pathophysiology that is likely to be affected 
by multiple genetic and environmental factors.
4.5.2. Introduction
Genetic studies to identify genes that could be responsible for 
certain disease can be performed with different techniques. 
These include candidate gene studies, linkage studies, or 
genome-wide association studies (GWAS). However, in genetic 
studies the GWA approach is rapidly replacing the more 
traditional candidate gene studies and microsatellite-based 
linkage mapping studies. The GWA approach would be useful to 
identify causal genes related to complex diseases such as CRS, 
due to its comprehensive and unbiased strategy. This progress 
was made possible by key developments in human genomics 
over the last decade and the completion of human genome 
DNA sequence analysis (HapMap) (1319).  A molecular pathway 
based approach has been recently developed to facilitate 
more powerful analysis of GWA study data sets. In GWAS the 
basic principal is to compare the frequency of a genetic variant 
between cases and controls. Many genetic variants (SNPs) are 
tested (usually 300,000 to 1 million) and therefore adjustment 
for multiple testing is required. For example for NIH catalog of 
GWAS p values of 5x 10-8 or less are required (www.genome.
gov/GWAS) (615). For any gene variant to be considered possibly 
significant for a given disease, it has to be replicated in at least 
two different, independent patient cohorts.
In addition to the direct effect of differences between genotypes 
we must also consider inter-individual and inter-tissue variations 
in gene transcript levels. These differences can be important in 
mediating disease susceptibility and may be caused by either 
genetic or epigenetic variation. Genetic variants influencing 
transcription include large-scale structural changes in the 
genome such as gene duplications and deletions; equally they 
can arise due to polymorphisms in a gene’s regulatory elements. 
4.5.3.Chronic rhinosinusitis with and without 
nasal polyps. (CRSw and CRSsNP)
4.5.3.1. Family and twin studies
 An interesting observation is that chronic rhinosinusitis with 
nasal polyps (CRSwNP) is frequently found to run in families, 
suggesting a hereditary or with shared environmental factor. 
Alexiou et al. (1320) studied 100 patients with NP and 102 controls 
from the general population and showed that 13.3% of the 
patients and none of the controls had a history of polyps in 
the family. In the study by Rugina et al. (508), more than half of 
224 CRSwNP patients (52%) had a positive family history of 
NP. The presence of CRSwNP was considered when NP had 
been diagnosed by an ENT practitioner or the patients had 
undergone sinus surgery for CRSwNP. A lower percentage 
(14%) of familial occurrence of CRSwNP was reported earlier by 
Greisner et al. (1321)  in smaller group (n = 50) of adult patients 
with CRSwNP. Thus, these results strongly suggest the existence 
of a hereditary factor in the pathogenesis of CRSwNP. However, 
studies of monozygotic twins have not shown that both siblings 
always develop polyps, indicating that environmental factors 
are likely to influence the occurrence of NP (1322, 1323). CRSwNPs 
have been described in identical twins, but given the prevalence 
of nasal polyps it might be expected that there would be more 
than a rare report of this finding (1324).
Studies of monozygotic twins have not shown that 
both siblings always develop polyps, indicating 
that environmental factors are likely to influence 
the occurrence of CRSwNP.
4.5.3.2. Linkage analysis and association studies 
Most genetic studies of CRS to date are candidate gene or 
candidate pathway approach studies. The focus in these studies 
has been the role of innate immunity in the pathophysiology 
of CRS. Large-scale genome wide associations studies (GWAS) 
of CRS are still lacking. For GWAS to have sufficient statistical 
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power, larger patient cohorts are needed than that have been 
used up to now. There is one study in CRS using a DNA pool-
based GWA, a technique that was developed to reduce costs 
of GWAS by replacing individual DNA genotyping by pooled 
genomic DNA (1325). The technique uses separate pools of DNA 
from patients and controls and hybridizes these pools on high-
density single nucleotide polymorphisms (SNPs) microarrays to 
determine the allele frequencies in each pool (1326). In this study 
with 210 CRS patients and 189 controls, the authors identified 
600 SNPs from 445 genes that were potentially associated with 
CRS. Authors stated that validation in a bigger cohort is needed 
to separate true positive results from the false positive. 
Several affected genes and enriched SNPs 
have been published for patients with CRS 
with polyposis (CRSwNP) or without polyposis 
(CRSsNP). Three SNPs related to CRSwNP have 
been replicated this far and they are genes IL1A, 
TNF , and AOAH. 
In the near future, due to the decreasing cost of GWAS 
technology, it is expected that large-scale GWAS studies of CRS 
will soon be performed as well.  
Several affected genes and enriched SNPs have been published 
for patients with CRSw and sNP Three SNPs related to CRSwNP 
have been replicated this far. These are for the genes IL1α (1327, 
1328). TNF (1329), and AOAH (1321, 1328). The original study of association 
of IL1α, IL1β and TNF in CRSwNP in a Turkish population was 
published 2007 (1330). Association of IL1A to the development of 
severe CRS was reported in a replication study of 206 patients 
(1328). Patients had had at least one endoscopic sinus surgery and 
their symptoms persisted. Nasal polyps was the initial diagnosis 
in 74,8% of the patients in this study. The TNFA association to 
nasal polyps was replicated in study of 170 CRSwNP patients 
compared to 153 non-polyposis controls (1329).
Several other polymorphisms associated with CRS have 
been published but have not been replicated, including 
polymorphism in IL-22 (1331), and the heterozygote status for 
the alpha-1-antitrypsin (AAT) gene (SERAPINA1) (1332) in severe 
CRSwNP, as well as for the IL-1 receptor-associated kinase 
4 (IRAK4) (1333) and MET gene (1334) in a Canadian population. 
Two SNPs in Toll-like receptor 2 (TLR2) were associated with 
increased risk of CRS in the Korean population (1335) suggesting 
that these SNPs may affect the susceptibility to bacterial 
infections leading to development of CRS. In another study, 
polymorphism of IL-4 (IL-4/-590 C-T), a potential determinant of 
IgE mediated allergic disease, was found to be associated with 
a protective mechanism against NPs in the Korean populations 
(1336). The role of IL-33 pathway in development of pathogenesis 
of NP was studied in 284 NP-patients from Belgium. Thiss 
tudy found two SNPs in the IL-33 ILIRL1 pathway to increase 
susceptibility for NP (840). 
Several other polymorphisms associated with 
CRS have been published but not been 
replicated.
A population based genome-wide screen for CRS among 291 
Hutterites (isolated religious community in US and Canada) 
linked a locus on chromosome 7q to the disease, suggesting 
CFTR (cystic fibrosis transmembrane conductance regulator) 
gene influencing disease susceptibility (1337). Reduced expression 
of several epithelial genes, like S100A7, S100A8 and SPINK5 has 
been reported in CRSwNP and CRSsNP. These finding suggest 
alterations in epithelial barrier function and host defense in CRS 
(782).
A number of genetic association studies found a significant 
correlation between certain HLA (human leukocyte antigen) 
alleles and NP. HLA is the general name of a group of genes in 
the human major histocompatibility complex (MHC) region 
on the human chromosome 6 that encodes the cell-surface 
antigen-presenting proteins. Luxenberger et al. (1338) reported an 
association between HLA-A74 and NPs, whereas Molnar-Gabor 
et al. (1339) reported that subjects carrying HLA-DR7-DQA1*0201 
and HLA-DR7¬DQB1*0202 haplotype had a 2 to 3 times odds 
ratio of developing NP. The risk of developing NP can be as high 
as 5.53 times in subjects with HLA¬DQA1*0201-DQB1*0201 
haplotype (1340). Although several HLA alleles were found to 
be associated with NP, such susceptibility can be influenced 
by ethnicity. In the Mexican Mestizo population, increased 
frequency of the HLA¬DRB1*03 allele and of the HLA-DRB1*04 
allele were found in patients with NP as compared to healthy 
controls (1341). Fruth et al. (1342) studied Glutathione S-Transferases 
(GST) as one of major group of antioxidative active enzymes 
involved in cellular detoxification. The authors analyzed 170 
nasal tissue samples (CRS without nasal polyps=49, CRS with 
nasal polyps=69 and healthy tissue controls of the inferior 
turbinate=52) and concluded that there is no correlation 
between any GST-polymorphism and CRS with and without 
nasal polyps or allergies or asthma or aspirin-intolerance.
4.5.3.3. Multiple gene expressions in nasal polyps
No single gene has been shown to be uniquely 
related to CRS.
The development and persistence of mucosal inflammation in 
NPs have been reported to be associated with numerous genes 
and potential single nucleotide polymorphisms (SNPs). The 
products of these genes determine various disease processes, 
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such as immune modulation or immuno-pathogenesis, 
inflammatory cells (e.g., lymphocytes, eosinophils, neutrophils) 
development, activation, migration and life span, adhesion 
molecule expression, cytokine synthesis, cell-surface receptor 
display, and processes governing fibrosis and epithelial 
remodelling. In the literature, gene expression profiles in nasal 
polyp have been performed by many studies, including the 
major repertoire of disease-related susceptibility genes or 
genotypic markers. With the advance of microassay technique, 
expression profiles of over 10,000 of known and novel genes 
can be detected. A recent study showed that in NP tissues, 192 
genes were upregulated by at least 2-fold, and 156 genes were 
downregulated by at least 50% in NP tissues as compared to 
sphenoid sinuses mucosa (1059). In another study (1065), microarray 
analysis was used to investigate the expression profile of 491 
immune-associated genes in nasal polyps. The results showed 
that 87 genes were differentially expressed in the immune-
associated gene profile of nasal polyps, and 15 genes showed 
differential expression in both NP and controls (turbinate). These 
seemingly conflicting results are likely due to the heterogeneity 
of inflammatory cells within nasal polyps and the differences in 
study designs and analytic approaches. In addition, in most of 
the published studies, the functional significance of aberrant 
gene expression with respective to the pathogenesis of NP 
is yet to be determined. The expression of gene products is 
regulated at multiple levels, such as during transcription, mRNA 
processing, translation, phosphorylation and degradation. 
Although some studies were able to show certain NP associated 
polymorphisms and genotypes, the present data is still 
fragmented. In common with many common human diseases, 
inherited genetic variation appears to be critical but yet still 
largely unexplained. Future studies are needed to identify 
the key genes underlying the development or formation of 
NP and to investigate the interactions between genetic and 
environmental factors that influence the complex traits of 
this disease. Identifying the causal genes and variants in NP is 
important in the path towards improved prevention, diagnosis 
and treatment of NPs. 
A subset of CRSwNp patients has Samter’s triad (ASA) 
characterized by presence of aspirin sensitivity, CRSwNP and 
asthma. Five different genes were reported to be associated in 
this group of 30 patients. The gene most characteristic of the 
ASA phenotype was periostin (POSTN) that was upregulated 
compared to controls. Also the proto-oncogene MET and 
protein phosphate 1 regulatory subunit (PP1R9B) were 
upregulated, whereas prolactin induced protein (PIP) and zinc 
alpha2 glycoprotein (Azgp1) were down-regulated (1029).
A PubMed literature research (Jan1950-July 2010) was 
performed to identify candidate molecular markers associated 
with CRSwNP by Platt et al. (1343). Pathway analysis of molecular 
markers in CRSwNP included 554 genes that had fold change 
more than 3 and False Discovery Rate of less than 0.1 selected 
from the group’s previous genome-wide expression study (1029). 
From these genes 365 were up-regulated and 189 were down-
regulated. The most common affected pathways for these genes 
were: inflammatory response, cellular movement, hematological 
system development and function, immune cell trafficking, 
and respiratory disease pathways. Gene network pathway 
analysis generated from the literature of this data showed tumor 
necrosis factor (TNF) as a central nodal molecule of the highest 
scoring network (p = 1 x 10-41) related to these pathways.  
4.5.3.4. CRS and cystic fibrosis
The role of genetic factors in CRS has been implicated in 
patients with cystic fibrosis (CF) and primary ciliary dyskinesia 
(Kartagener’s syndrome). CF is one of the most frequent 
autosomal recessive disorders of the Caucasian population, 
caused by mutations of the CFTR gene on chromosome 7 
(564). The most common mutation, F508, is found in 70 to 80% 
of all CFTR genes in Northern Europe (1344, 1345). Upper airway 
manifestations of CF patients include CRS and nasal polyps, 
which are found in 25 to 40 % of CF patients above the age of 
5 (1346-1349). Interestingly, Jorissen et al. (1350) reported that F508 
homozygosity represents a risk factor for paranasal sinus disease 
in CF and Wang reported that mutations in the gene responsible 
for CF may be associated with the development of CRS in the 
general population (1351). 
Conclusion
No single gene has been shown to be uniquely related to CRS. 
This is unlikely to change in the future due to a complexity of 
the disease and its pathophysiology. Only when CRS can be 
phenotyped into subgroups with similar pathophysiological 
features could we hope to detect the genes behind these 
subgroups more accurately.
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5.1. Complications of Chronic Rhinosinusitis
Summary
Complications associated with CRSwNP 
and CRSsNP are less dramatic and rarer than 
those that can occur in ARS but may be difficult 
to manage
Complications of CRSwNP & CRSsNP are rare and are largely due to 
effects on the surrounding bone. They include bone erosion and 
expansion due to mucocoeles or polyps, osteitis and metaplastic 
bone formation and occasionally optic neuropathy.
Generally these are far less documented in the literature than 
those associated with acute infection and inflammation. In some 
cases, they may be considered as simply a manifestation of the 
natural history of the condition.
The following may be included:
1. Mucocoele formation 
2. Osteitis 
3. Bone erosion and expansion 
4. Metaplastic bone formation 
5. Optic neuropathy 
 There is no evidence that CRS is associated with neoplastic 
change, either benign or malignant. A few case reports refer to 
orbital, intracranial and osseous complications typical of ARS can 
occur in CRS but are almost always secondary to a superimposed 
acute infective episode.
Complications in CRS generally result from an 
imbalance in the normal process of bone 
resorption, regeneration and remodelling.
5.1.2. Mucocoele formation 
A mucocoele is an epithelial-lined sac completely filling the 
paranasal sinus and capable of expansion as opposed to an 
obstructed sinus which simply contains mucus (1369). Mucocoeles 
are relatively rare and usually uni-locular (92%) and unilateral 
(90%). The exact pathogenesis is unknown though is often 
associated with obstruction of sinus outflow and some form 
of chronic inflammation or infection. Studies of inflammatory 
markers suggest an active process analogous to that seen in 
odontogenic cysts at the mucocoele bone interface (1370). However, 
in one third of cases, no obvious cause for the initiation of this 
process can be found (1371). Where an associated pathology can be 
identified, it is most often chronic rhinosinusitis with or without 
nasal polyposis, cystic fibrosis or allergic/eosinophilic fungal 
rhinosinusitis, in either case with or without surgical intervention. 
The time interval from potential initiating event to clinical 
presentation varies from 22 months to 23 years (1371). Growth is 
generally slow unless an acute bacterial infection produces a 
pyocoele. (Figures 5.1-5.2)
The distribution of mucocoeles within the sinuses is interesting, 
occurring most often in the fronto-ethmoid region (86%). The 
maxillary sinus is least often affected. Consequently the patients 
most often present with orbital symptoms and signs (axial 
proptosis, lateral and inferior displacement of the globe, diplopia). 
5. Special items in CRS
Fig. 5.1. Mucocoele expansion of lateral compartments of frontal sinuses 
associated with nasal polyposis with associated expansion of ethmoids, 
erosion of the lamina papyracea and pseudohyperteliorism . 
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A mucocoele is an epithelial-lined sac 
completely filling the paranasal sinus and 
capable of expansion as opposed to an 
obstructed sinus which simply contains 
mucus which sometimes occurs in CRS, though 
not exclusively and which is managed surgically 
In fronto-ethmoidal mucocoeles, visual acuity is rarely at risk 
unless a pyocoele develops whereas visual loss may be the 
presenting clinical feature with sphenoidal mucocoeles. 
Large  mucocoeles can extend into the anterior cranial 
cavity where they may eventually have a mass effect. Age at 
presentation varies from 23 months to 79 years, though they 
are generally rare in children and affect men and women 
fairly equally. It is not possible to predict who will develop a 
mucocoele.
Diagnosis is confirmed with CT scanning which shows a smooth 
walled lesion filling an expanded sinus, with areas of thinned 
or dehiscent bone, usually between the mucocoele and the 
orbit or anterior cranial fossa (1372). MRI may be used if there is 
doubt about the diagnosis e.g. a carotid aneurysm involving the 
sphenoid. The usual signal characteristics are low T1 and high 
T2 but any permutation can occur depending on the water and 
protein content. 
The histology of the mucocoele lining is also variable, but is 
generally composed of pseudostratified columnar epithelium 
with some squamous metaplasia, goblet cell hyperplasia 
and a cellular infiltrate dependant on the degree and type of 
chronic (and acute) inflammation i.e. neutrophils, eosinophils, 
macrophages, monocytes and plasma cells (1373).
Treatment is by marsupialisation, which can be undertaken 
endoscopically in the majority of cases. No repair of the 
dehiscent bone is required as long as the lining mucosa is 
undisturbed and remodelling of the expanded bone can be 
anticipated with time. A review of the literature shows an 
overall success rate of >90%, particularly in those undergoing 
endoscopic surgery alone. Recurrence is higher in those 
who have undergone previous surgery, have CRS with nasal 
polyposis, fistulas to the upper eyelid and who have had the 
more complex disease, which may require combined external 
and endoscopic surgical approaches. (Table 5.1.1) (1374-1380)..
5.1.3. Osteitis
This process has often been reported in association with CRS 
and might be regarded as part of the pathophysiological 
process rather than a complication. Animal experiments 
in rabbits by Kennedy, Senior and others in the late 1990’s 
suggested that the presence of osteitis acted as a stimulant to 
persistent mucosal inflammation with osteoclastic resorption 
of bone within and adjacent to infected sinuses (1023, 1382). These 
pathological changes in the bone were observed in 92% of 
rabbit models on the infected side and even in 52% on the 
contralateral non-inoculated side suggesting a route of spread 
via the enlarged Haversian canal systems (1383).
Osteitis can be associated with CRS but its role,
 if any, in the pathogenesis of CRS
 remains unclear
Bone remodelling with accompanying neo-osteogenesis 
Fig. 5.2a. Coronal CT showing asymptomatic intracranial extradural 
chronic collection of insipissated mucus in patient with nasal polyposis.
Fig. 5.2b. Coronal MRI (T1 with gadolinium) in same patient.
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has been demonstrated histologically in the ethmoid bone 
of patients with CRS (1384). The extent of bone remodelling 
correlated with severity of disease as evidenced by the Lund-
Mackay CT score. Radionucleotide scintigraphy has been used 
to show increased bone turnover consistent with osteitis in 
CRS as compared to normal controls (1385). Interestingly this was 
greatest in the maxilla and ethmoid whereas clinically it is more 
often observed and problematic in the frontal and sphenoid. A 
prospective study of 121 patients undergoing endoscopic sinus 
surgery for CRS was assessed for radiological and histological 
evidence of osteitis (1022). CT showed neo-osteogenesis in 36% 
whereas osteitis was confirmed histologically in 53%. (Figure 5.4)
A thorough review of the literature by Videler et al. (1030) 
confirmed an association of osteitis with CRS but its role, if any, 
in the pathogenesis of CRS remains unclear. A variety of grading 
systems have been used to classify the osteitis, usually based on 
CT appearances(Table 5.1.2) (1022, 1386, 1387).
An earlier prospective case-control study by Georgalas et al. (1388) 
of 102 patients undergoing CT for CRS were compared with a 
cohort of age and gender matched non-CRS controls using a 
variety of parameters including a Global Osteitis Scoring Scale. 
The severity of osteitis correlated with extent of mucosal disease 
(as assessed by the Lund-Mackay score)(p<0.001), duration of 
symptoms (p<0.01) and previous surgery (p<0.001) but there 
was no correlation between osteitis and symptoms including 
facial pain and headache. There are no studies at present on 
management.
Table 5.1.1. Endoscopic Management of Mucocoeles.
Site Age (yrs) Female:
Male
Previous 
surgery
Follow up Recurrence
n F E S M Range Mean Range Mean
Kennedy et 
al 1989 (1374)
16 9 5 2 - 10-76 44.7 8:10 5 (31%) 2m-42m 17.6m 0%
Moriyama et 
al 1992 (1375)
49 (47pt) - 41 8 - 20-69 46.2 14:33 37 (78%) 2yr-10yr ? ?
Beasley & 
Jones 1995 
(1381) 
34 (25pt) 21 10 1 2 23-76 51 7:18 18 (72%) 6m-3yr 2yr 6% (both had 
previous exter-
nal surgery)
Benninger 
et al 1995 
(1376)
15 - 7 8 - ? ? 10:5 5 (33%) 5m-40m 20m 13%
Lund 1998 
(1377)
20 (ESS) 12 6 2 - 4-89 42.6 10:10 0 7m-61m 34m 0%
28 (Com-
bined ESS & 
external)
28 25-83 59 11:17 9 (42%) 10m-76m 44m 11%
Conboy and 
Jones 2003 
(1378) 
68  (59pts; 
44 ESS 14 
EFE 9 Comb)
42 16 4 6 14-90 56 ? 21 (31%) 3m-10.2yr 6.2yr 13%  (9% post-
ESS; 26% post-
external ops)
Khong et al 
2004 (1379) 
41 (28pts) 32 3 1 5 15-83 52 11:17 At least 
18 (64%)
1-42m 18m 0%
Bockmuhl et 
al 2006 (1380) 
290 (255 pts; 
185 ESS)
148 41 29 72 10-80 52 85:170 168 
(66%)
4-21 yr ? 2%
F: frontal or fronto-ethmoidal. E: ethmoid. S: sphenoid. M: maxilla
Figure 5.3. Coronal CT showing heterogeneous change in left 
antroethmoid region typical of non-invasive eosinophilic fungal 
rhinosinusitis. 
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5.1.4. Bone erosion and expansion
The converse process to bone sclerosis associated with osteitis 
is the bone thinning and erosion seen in the more aggressive 
forms of CRS with nasal polyposis (CRSwNP) (Fig. 5.1.) This 
is distinct from true mucocoele formation and most often 
affects the ethmoids where the lamina papyracea may become 
even thinner than normal and bow into the orbit (1389). This is 
accompanied by expansion of the opacified ethmoid cells and 
is usually a bilateral process, resulting in displacement of the 
orbital contents. Ultimately the lamina becomes dehiscent, most 
often anteriorly, adjacent to the nasolacrimal system and may 
be associated with epiphora. 
Bone erosion and expansion is the converse 
process to osteitis seen in the more aggressive 
forms of CRSwNP
In severe cases a marked pseudohyperteliorism can result. An 
early study looking at plain x-rays of patients with CRSwNP (1390) 
showed that widening of the ethmoids was found in 20% of 
cases and that this correlated with the age at onset of symptoms 
rather than length of symptoms. The skull base may also be af-
fected, simulating a neoplastic process (1391). Both thickening and 
thinning of the walls of the paranasal sinuses can occur in the 
same patient. Foreknowledge of these changes from CT scan-
ning is a pre-requisite to safe surgery. They are particularly mar-
ked in cases of allergic (eosinophilic) fungal rhinosinusitis where 
80% of cases show evidence of bone erosion (1392) (Fig. 5.3).
5.1.5. Osseous metaplasia
Rarely osseous metaplasia can be found in the upper 
aerodigestive tract in response to chronic inflammation with 
or without polyposis and/or previous surgery. New bone 
formation occurs with a well-developed Haversian system and 
bone marrow where one would not expect to encounter it i.e. 
within the lumen of the paranasal sinuses or nasal cavity in 
contradistinction to the osteitis seen in the walls of paranasal 
sinuses. This can achieve impressive proportions, obstructing 
the nose and impacting on the orbit, producing a benign 
looking mass on CT composed of bone hyperdensities and soft-
tissue which may require surgical removal, if only to exclude a 
neoplastic process (1393-1395) (Figure 5.5).
Figure 5.5. Coronal CT showing bilateral osseous metaplasia with 
associated mucosal swelling affecting ethmoids, maxillary sinus and 
expansion of posterior ethmoid cell into right orbital roof with bone 
erosion.
Table 5.1.2. Examples of CT grading systems for severity of osteitis.
Biedlingmaier et al. (1386).
Osteitis is defined as rarefaction and/or demineralization; loss of 
trabeculae; cortical destruction; focal sclerosis; loss of expected 
structures or landmarks
1= normal
2= findings suggestive of osteitis, but polyps make osteitis indeter-
minate
3= interpretation limited due to dental artifact
4 = osteitis
Lee et al. (1022)
Osteitis thickness measurement
Mild:  3 mm
Moderate:  4-5 mm
Severe: >5 mm
Fig. 5.4.  Coronal CT showing unilateral osteitis affecting walls of left 
sphenoid sinus with associated mucosal thickening.
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5.1.6. Optic neuropathy 
Optic neuropathy has been reported in association with CRS 
principally affecting the sphenoid or posterior ethmoid region, 
even without expansion as in a mucocoele but usually in the 
presence of bone erosion between the sinus and orbital apex. 
This may occur with eosinophilic fungal rhinosinusitis (1396). 
Visual improvement can be anticipated when emergency 
decompression is undertaken if the visual loss was partial but 
in patients with pre-operative blindness, recovery is rare (1397). 
Endoscopic approaches are most often recommended usually in 
combination with systemic steroids though no trials have been 
performed due to the rarity and heterogeneous presentation of 
the cases.
5.2 CRS with and without NP in relation to 
the lower airways
5.2.1. Introduction
Due to its strategic position at the entry of the airway, the nose 
plays a crucial role in airway homeostasis. By warming up, 
humidifying and filtering incoming air, the nose is essential in 
the protection and homeostasis of the lower airways (1398). The 
nose and bronchi are linked anatomically, are both lined with a 
pseudo-stratified respiratory epithelium and equipped with an 
arsenal of innate and acquired immune defence mechanisms. 
It is not hard to imagine that nasal conditions causing nasal 
obstruction may become a trigger for lower airway pathology 
in susceptible individuals. In chronic sinus disease with nasal 
polyps (NP), total blockage of nasal breathing may occur, 
hence bypassing nasal functions that may be relevant in 
preventing lower airway disease. It is however evident that 
the nasobronchial interaction is not restricted to bronchial 
repercussions of hampered nasal air conditioning. Nose and 
bronchi seem to communicate via mechanisms such as neural 
reflexes and systemic pathways. Bronchoconstriction following 
exposure of the nose to cold air suggests that neural reflexes 
connect nose and lung (1399). However, Koskela et al. (1400) reported 
on facial cooling rather than nasal cold dry air being responsible 
for bronchoconstriction in COPD. The neural interaction linking 
the release of inflammatory mediators in the bronchi following 
a nasal inflammatory stimulus has recently been shown by 
bronchial release of neural mediators after selective nasal 
allergen provocation (1401). However, the precise neural pathways 
linking nose and bronchi still remain incompletely understood 
(1401). Recently, the systemic nature of the interaction between 
nose and bronchi has received more attention. Indeed, many 
inflammatory diseases of the upper airways show a systemic 
immunologic component involving the blood stream and bone 
marrow (1402). In addition to the systemic and neural interaction, 
genetic factors may as well play a role in the manifestation 
of nasal and/or bronchial disease (1403). In spite of the fact that 
aspiration of nasal contents may take place in neurologically 
impaired individuals, it is not clear whether micro-aspiration 
of nasal contents plays a role in the development or severity of 
bronchial disease (1404). 
5.2.2. Asthma and Chronic Rhinosinusitis 
CRS with/without NP and asthma / COPD are 
diseases that often occur together
Bronchial asthma is considered a comorbid condition of CRS. 
In a recent large-scale European survey, the strong association 
between CRS and asthma was confirmed (13). CRS in the absence 
of nasal allergies was associated with late-onset asthma (13). In 
some centres, around 50% of patients with CRS have clinical 
asthma (1405, 1406). Interestingly, most patients with CRS who do 
not report to have asthma show bronchial hyperresponsiveness 
when given a metacholine challenge test (1405). In the studies 
mentioned above, the differentiation of CRS with/without NP 
was not possible (13) or made (1405, 1406).
Radiologic imaging of the sinuses has demonstrated sinonasal 
inflammatory opacification in the majority of patients with 
severe asthma (1406, 1407). However, these epidemiologic and 
radiologic data should be interpreted with caution as they may 
reflect a large referral bias.
Histopathologic features of CRS and asthma largely overlap. 
Heterogeneous eosinophilic inflammation and features of 
airway remodelling like epithelial shedding and basement 
membrane thickening are found in the mucosa of CRS and 
asthma (1405). Cytokine patterns in sinus tissue of CRS highly 
resemble those of bronchial tissue in asthma (524), explaining the 
presence of eosinophils in both conditions. Therefore, eosinophil 
degranulation proteins may cause damage to the surrounding 
structures and induce symptoms at their location in the airway. 
Finally, lavages from CRS patients show that eosinophils were 
the dominant cell type in both nasal and broncho-alveolar 
lavages in the subgroup of patients with CRS with asthma (1086). 
Beside the similarities in pathophysiology, sinusitis has been 
etiologically linked to bronchial asthma, and vice versa. As is the 
case in allergic airway inflammation, sinusitis and asthma can 
affect and amplify each other via the systemic route, involving 
interleukin IL-5 and the bone marrow. In both CRS and allergic 
asthma, similar pro-inflammatory markers are found in the 
blood. Recently, nasal application of Staphylococcus aureus 
enterotoxin B has been shown to aggravate the allergen-
induced bronchial eosinophilia in a mouse model (1408). However, 
the interaction between both rhinosinusitis and asthma is not 
always clinically present, as Ragab et al. (1086) found no correlation 
between rhinosinusitis and asthma severity. However, patients 
with asthma showed more CT scan abnormalities than non-
asthmatic patients (1409), and CT scan abnormalities in severe 
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asthmatic patients correlated with sputum eosinophilia and 
pulmonary function (1407).
The interaction between chronic upper and lower 
airway inflammation has primarily been studied in 
allergy and not in CRS
Endoscopic sinus surgery (ESS) for CRS aims at alleviating 
sinonasal symptoms but also improves bronchial symptoms 
and reduces medication use for bronchial asthma (1410-1413). 
After a mean follow-up period of 6.5 years, 90% of asthmatic 
patients reported their asthma was better than it had been 
before the ESS, with a reduction of the number of asthma 
attacks and medication use for asthma (1414). Also in children 
with chronic rhinosinusitis and asthma, sinus surgery improves 
the clinical course of asthma, reflected by a reduced number 
of asthma hospitalizations and schooldays missed (1415). Lung 
function in asthma patients with CRS was reported to benefit 
from ESS by some authors (1413, 1416, 1417), but denied by others 
(1410, 1412, 1415). Of note, not all studies show beneficial effects of 
ESS on asthma (1418). The reason for the inconsistency in study 
results between studies relates to the heterogeneity and small 
number of patients included in these studies, and difference 
in outcome parameters studied. Interestingly, the presence 
of lower airway disease may have a negative impact on the 
outcome after ESS. Outcomes after ESS were significantly worse 
in the asthma compared to the non-asthma group (1411, 1417). Poor 
outcomes after ESS have also been reported in patients with 
aspirin-intolerant asthma (1215, 1419, 1420). On the other hand, other 
authors report that asthma does not represent a predictor of 
poor symptomatic outcome after primary (1219, 1421) or revision 
ESS (1409). In a series of 120 patients undergoing ESS, Kennedy (762) 
reports that asthma did not affect the outcome after ESS when 
comparing patients with equally severe sinus disease, except 
for the worst patients, in which asthma did adversely affect the 
outcome. 
Interestingly, Ragab et al. (1422) published the first randomized 
prospective study of surgical compared to medical therapy of 43 
patients with CRS with/without NP and asthma. Medical therapy 
consisted of a 12 weeks course of erythromycin, alkaline nasal 
douches and intranasal corticosteroid preparation, followed by 
intranasal corticosteroid preparation tailored to the patients’ 
clinical course. The surgical treatment group underwent ESS 
followed by a 2-week course of erythromycin, alkaline nasal 
douches and intranasal corticosteroid preparation, 3 months of 
alkaline nasal douches and intranasal corticosteroid, followed 
by intranasal corticosteroid preparation tailored to the patients’ 
clinical course. Both medical as well as surgical treatment 
regimens for CRS were associated with subjective and objective 
improvements in asthma state. Interestingly, improvement in 
upper airway symptoms correlated with improvement in asthma 
symptoms and control. 
The presence of asthma is a negative predictor of 
outcome after ESS for CRS w/s NP
5.2.3. Asthma and Chronic Rhinosinusitis with NP 
Seven percent of asthma patients have NP compared to 
lower percentages in the non-asthma population (505). In 
non-atopic asthma and late onset asthma, NP are diagnosed 
more frequently (10-15%). Alternatively, up to 60 % of 
patients with NP have lower airway involvement, assessed by 
history, pulmonary function and histamine provocation tests 
(1423). Aspirin-induced asthma is a distinct clinical syndrome 
characterized by the triad aspirin sensitivity, asthma and NP 
and has an estimated prevalence of one percent in the general 
population and ten percent among asthmatics (1424). 
Increased nasal colonization by Staphylococcus aureus and 
presence of specific IgE directed against Staphylococcus aureus 
enterotoxins were found in NP patients (661). Interestingly, rates 
of colonization and IgE presence in NP tissue were increased in 
subjects with NP and co-morbid asthma or aspirin sensitivity. 
By their super-antigenic activity, enterotoxins may activate 
inflammatory cells in an antigen-unspecific way. Indeed, nasal 
application of Staphylococcus aureus enterotoxin B is capable of 
aggravating experimental allergic asthma (1408).
No well-conducted trials on the effects of medical therapy for 
NP on asthma have been conducted so far. After ESS for NP in 
patients with concomitant asthma, a significant improvement in 
lung function and a reduction of systemic steroid use was noted, 
whereas this was not the case in aspirin intolerant asthma 
patients (1420). In a small series of patients with NP, endoscopic 
sinus surgery did not affect the asthma state (1425). However, nasal 
breathing and quality of life improved in most patients. 
Data on effects of surgery for NP on asthma mostly point 
towards a beneficial effect of surgery on different parameters 
of asthma. Ehnhage et al. investigated the effects of FESS 
followed by fluticasone proprionate nasal drops 400 μg twice 
daily on nasal and lower airway parameters in 68 asthmatics 
with NP. It was conducted over 21 weeks and the effects of FESS 
on nasal and lower airway parameters were examined. FESS 
significantly improved mean asthma symptom scores and daily 
PEFR and all the nasal parameters measured (1426). Batra et al. (1420) 
reported a significant improvement in lung function (FEV1) and 
a reduction in OCS use after FESS in 17 patients with NP and 
oral corticosteroid dependent asthma. In a series of 13 patients 
with nasal polyposis and asthma, Uri et al. (1425) reported that 
FESS did not improve the asthma state in patients with massive 
nasal polyposis. However, there was a significant decrease 
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in oral corticosteroid and bronchodilator inhaler usage. In a 
subgroup of 35 patients with NP and asthma, Ragab et al. (1427) 
reported that FESS had a subjective and objective tendency for 
asthma improvement. Although the study results are not always 
consistent, overall it would appear that FESS has a positive effect 
on asthma in nasal polyposis. 
5.2.4. Cystic fibrosis and rhinosinusitis
Bilateral NP in children are often a clinical sign of CF (1428). 
Sinonasal inflammation is found in most CF patients, with NP 
being present in 1/3 of CF patients. Rhinosinusitis may often be 
a presenting symptom of the so-called atypical CF patient with 
normal or borderline sweat test result and carrying only one 
mild mutation of the CFTR gene (1428). 
A significant association exists between broncho-alveolar 
lavage and sinus cultures in cystic fibrosis patients (1429). 
Children with CF undergoing sinus surgery may experience 
some improvement of lung function parameters, although this 
change may not be uniform (1430). Large-scale prospective studies 
on the effects of FESS on lower airway function in CF are lacking.
5.2.5. COPD and rhinosinusitis
The upper airways of COPD patients remain less studied 
than in asthma in spite of the fact that a majority of COPD 
patients presenting at an academic unit of respiratory disease 
do experience sinonasal symptoms (1431, 1432). Several pro-
inflammatory mediators have been found in nasal lavages of 
COPD patients (1432) and nasal symptoms corresponded with 
the overall impairment of the quality of life (1431). Recently, a 
high number of patients with bronchiectasis have shown to 
present with rhinosinusitis symptoms, radiologic abnormalities 
on CT scans (1433) and have a reduced smell capacity (1434). The 
impact of upper airway treatment in patients with COPD and 
bronchiectasis still needs to be properly investigated.
5.3. Cystic Fibrosis
5.3.1. Summary
There is increasing evidence that multiple genetic and protein 
expression differences in CF patients may contribute to their 
tendency to develop CRS. Future studies may identify genome- 
and proteome-level therapeutic targets, which may be used 
to prevent or lessen the severity of CRS in CF patients. Topical 
nasal dornase alfa, nasally inhaled or irrigated antibiotics, and 
saline irrigations have all been shown to improve outcomes in 
CF patients with CRS, both as monotherapy or combined with 
ESS. ESS also improves outcomes in CF patients with CRS. Future 
prospective studies are needed to further elucidate the role of 
medical and surgical therapy in CF patients with CRS.
5.3.2. Introduction
Cystic fibrosis (CF) is the most common lethal recessive 
disorder in Caucasians. It is caused by a mutation in the cystic 
fibrosis transmembrane conductance regulator (CTFR) gene 
on chromosome 7, which leads to production of a defective 
chloride channel. This in turn causes improper salt balance and 
thick tenacious secretions in CF patients. Since Bulgarelliet al. 
(1435) and others reported sinusitis in patients with pulmonary 
and pancreatic manifestations of cystic fibrosis, it has been 
recognized that patients with cystic fibrosis are prone to the 
development of early and refractory chronic rhinosinusitis (CRS). 
While mucous stasis and impaired mucociliary transport play a 
significant role, the full range of factors at play in this association 
have yet to be elucidated. Chronic bacterial infections and host 
inflammatory response cause stasis and damage in the sinuses, 
lungs, and gastrointestinal system, and it is thought that high 
mucus viscosity leads to obstruction of sinus ostia, dysfunction 
of ciliary clearance, and recurrent polyposis and paranasal sinus 
infections.
5.3.3. Anatomic, histopathologic, and physiologic 
factors in Cystic Fibrosis patients with Chronic 
Rhinosinusitis 
Histopathologic studies have found several differences in 
expressed proteins found in CF and control patients, particularly 
proteins involved in the various inflammatory pathways. 
Additionally, studies have found altered glandular structure in 
CF patient sinonasal mucosa. Studies have examined anatomic 
differences in CF patients, such as hypoplasia or decreased 
aeration in the sinus cavities of CF patient. The prevalence of 
heterozygous CFTR gene mutations in patients with chronic 
rhinosinusitis has also been examined.
5.3.3.1. Bacteriology/Mycology
The bacteriology and the association between pathogenic 
bacteria found in bronchoalveolar lavages (BAL) and paranasal 
cavity cultures in patients with cystic fibrosis (CF) has recently 
been the subject of investigation (1429). In CF patients who 
underwent functional endonasal endoscopic sinus surgery 
(FESS) culture samples obtained from bronchoalveolar 
lavages and paranasal cavities most frequently demonstrated 
Pseudomonas aeruginosa, Staphylococcus aureus, and 
Streptococcus viridans. Statistical analysis revealed a statistically 
significant association between paranasal cavity cultures and 
lower airway bronchoalveolar lavage cultures for P. aeruginosa 
and S. aureus. Another study reviewed 30 consecutive CF 
patients undergoing ESS for the presence of sinus fungal 
isolates (1436). Thirty-three percent of fungal cultures were 
positive, with two patients newly diagnosed with allergic fungal 
sinusitis. The opportunistic pathogen Pseudomonas aeruginosa 
is a frequent colonizer of the airways of patients suffering from 
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cystic fibrosis (CF). In a study it was observed in several children 
that the paranasal sinuses constitute an important niche for 
the colonizing bacteria in many patients. The paranasal sinuses 
often harbor distinct bacterial subpopulations, and in the early 
colonization phases there seems to be a migration from the 
sinuses to the lower airways, suggesting that independent 
adaptation and evolution take place in the sinuses. Importantly, 
before the onset of chronic lung infection, lineages with 
mutations and antibiotic-resistant clones are part of the sinus 
populations. Thus, the paranasal sinuses potentially constitute 
a protected niche of adapted clones of P. aeruginosa, which can 
intermittently seed the lungs and pave the way for subsequent 
chronic lung infections (1437). It has been suggested that P. 
aeruginosa can adapt or acclimate to the environment in the 
lungs, during growth in anoxic parts of the paranasal sinuses 
(1438).
5.3.3.2. Arachidonic Acid Metabolism
Patients with CF are known to have increased pro-inflammatory 
cytokine, leukotriene, and prostaglandin production. The 
staining patterns of cyclooxygenase 1 and 2 (COX-1 and -2) 
and 12-Lipoxygenase lipoxygenase (12-LO) in the sinonasal 
epithelium and submucosal glands of CF and non-CF 
patients with chronic rhinosinusitis (CRS) demonstrates a 
significant elevation in the staining of columnar epithelium 
and submucosal glands for COX-2 and 12-LO in CF patients 
compared to control CRS patients (1439). No significant differences 
were noted for the staining intensity of COX-1, 5-LO, or 15-LO. 
The upregulation of COX-1 and COX-2 in nasal polyps in patients 
with cystic fibrosis has also been examined (1440). The degree of 
mRNA and protein expression of COX-1 and  
COX-2 in the nasal mucosa of patients with CF was examined 
using RT-PCR and Western blot analysis. COX-1 and COX-2 
Table 5.3.1. CF Histological, immunohistochemical, and immunological markers.
Study Marker Tissue Method Conclusion
Owens et al. 
2008 (1439)
COX-1, COX-2, 
5-LO, 12-LO, and 
15-LO
sinonasal epithelium 
and submucosal 
glands
IHC significant elevation in epithelial COX-2 (cytoplasm) and 12-LO 
(cytoplasm and nucleus) and submucosal glands for COX-2 
(cytoplasm) and 12-LO (cytoplasm) in CF patients compared to 
controls. No difference in COX-1, 5-LO, or 15-LO 
Roca-Ferrer 
2006 et al. 
(1440)
COX-1, COX-2 nasal polyps and 
nasal mucosa
RT-PCR and 
Western blot
COX-1and COX-2 mRNA significantly higher in CF NP versus con-
trol nasal mucosa, COX-1 and COX-2 protein levels significantly 
higher in CF NP versus nasal mucosa and non-CF NP
Schraven et 
al 2011 (1441)
mucous ducts 
and glands
sinus mucosa histology and 
IHC
CF showed dilated glandular ducts, predominance of mucous 
glands, elevated plasma cells and mast cells but not eosinophils
Wu et al 
2001 (1442)
goblet cells 
(GCs), submu-
cosal glands 
and mucin gene 
(MUC) express-
ing cells
sinonasal mucosa histology and 
IHC
significantly increased area of submucosal glands in CRS/CF 
increased glandular MUC5B expression in CRS/CF vs. non-CF CRS
Knipping et 
al.2007 (1443)
glands, goblet 
cells
inferior turbinates 
and nasal polyps
histology and 
IHC
CF tissue with high proportion of goblet cells, abnormal seromu-
cous glands with cystic dilatation. glandular cells with inhomo-
geneous heterogeneous glandular droplets in the supranuclear 
cell portion.
Sobol et al. 
2002 (862)
CD3, CD25, 
CD68, CD20, 
MPO, CD138, 
eotaxin, 
IL-1beta, IL-
2sRalpha, IL-5, 
IFN-gamma, 
IL-8, TGF-beta1, 
and TNF-alpha
sinonasal mucosal 
tissue
IHC NP and CF-NP showed increased numbers/activation of T cells, 
NP patients displayed increase in plasma cells. NP significantly 
higher levels of eosinophils, eotaxin, and eosinophil cationic 
protein (ECP)] compared with CRS, controls and CF-NP. CRS char-
acterized by Th1 polarization with high levels of IFN-gamma and 
TGF-beta, NP showed Th2 polarization/high IL-5 and IgE.
Ebbens et al. 
2010 (18)
CD34, sialylated 
Lewis X Antigen
nasal mucosa IHC CRSwNP patients-decreased CD34+ vessels, increased eosi-
nophils and percentage of vessels expressing [sLe(x)]. Tissue eosi-
nophilia but not % of endothelial sLe(x) increased in NP/aspirin 
intolerance. CF NP similar to simple NP. Antro-choanal polyps-low 
tissue eosinophils and endothelial sLe(x) + vessels.
Woodworth 
et al 2007 
(1444)
surfactant gene 
expression 
(SPA1, A2, and D
sinonasal tissue RT-PCR CF patients significantly increased SPA1, SPA2, and SPD mRNA vs. 
controls. CRS-NP demonstrated elevated SPA1, SPA2, and SPD, 
but lower levels than CF patients. AFS patients non-significant 
increase in SPA1, SPA2, SPD vs. controls.
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mRNA levels were significantly higher in CF nasal polyps versus 
control nasal mucosa, but no significant difference was found 
between CF nasal polyps and non-CF nasal polyps. COX-1 and 
COX-2 protein levels were significantly higher in CF nasal polyps 
versus both nasal mucosa controls and non-CF nasal polyps, 
suggesting that upregulation in the expression of COX-1 and 
COX-2 might be related to the high production of prostanoids 
reported in CF patients.
CF patients with CRS show upregulation in COX, 
MUC/mucin, and surfactant gene expression, as 
well as increased L-selectin mediated lymphocyte 
localization and adhesion. Paranasal sinus 
development is often decreased in CF patients.
5.3.3.3. Mucous Production and Glandular Histology
A study of paediatric CF patients and non-CF patients with CRS 
with polyps who underwent sinus surgery examined surgically 
obtained sinus specimens of each group using conventional 
histology and immunohistochemistry (1441). CF patients showed 
dilated glandular ducts and a predominance of mucous glands 
with a significantly elevated number of plasma cells and mast 
cells, but not eosinophils, compared to non-CF patients. Another 
study examined the histologic and morphometric characteristics 
of paranasal sinus mucosa of paediatric CRS controls and 
paediatric CF patients with CRS (1442). The number of goblet cells 
(GCs) and mucin-expressing cells and the submucosal gland 
(SMG) area was determined, as well as the cellular localization 
and expression of MUC5AC and MUC5B mucins. A significantly 
increased area (4.4-fold) of submucosal glands (SMGs) was 
detected in the sinus mucosa of patients with CRS/CF compared 
with controls. Neither GC hyperplasia nor increased expression 
of MUC5AC was observed in the CRS/CF group, but there was 
a positive trend toward increased glandular MUC5B expression 
in the CRS/CF cohort. Colocalization of MUC5AC and MUC5B 
expression was observed in a subset of GCs. A study examined 
the microscopic ultrastructural mucosal changes in paediatric 
CF patients, comparing the nasal mucosa of patients without 
chronic inflammation as controls and specimens of duodenal 
mucosa of patients with CF (1443). The mucosa of CF patients 
showed seromucous glands displaying abnormal morphological 
structures with wide mucous cells and cystic dilatation under 
a thick layer of respiratory epithelium with a high proportion 
of goblet cells. The glandular cells showed inhomogeneous 
heterogeneous glandular droplets in the supranuclear cell 
portion. The nuclei contained dispersed chromatin as a sign of 
increased activity and the structures of the Golgi apparatus were 
clearly detectable. Alterations in surfactant gene expression 
(SPA1, A2, and D) in various forms of inflammatory CRS, 
including CF, has been examined (1444). Patients with CF showed 
significantly increased SPA1, SPA2, and SPD mRNA when 
compared with controls. Patients with CRS with nasal polyposis 
also demonstrated elevated SPA1, SPA2, and SPD, but lower 
levels than CF patients. Patients with allergic fungal sinusitis 
(AFS) had increased SPA1, SPA2, and SPD, but the increases were 
not significant versus healthy controls.
5.3.3.4. Inflammatory Mediators
The alteration in various inflammatory pathways in CF patients 
has been examined. A study compared the inflammatory-cell 
and cytokine profiles of CRS patients with CF, adults with, 
and control patients with no allergies or sinus disease (862). 
Immunohistochemical analysis found a higher number of 
neutrophils, macrophages, and cells expressing messenger 
RNA for interferon gamma and interleukin-8 in patients with 
CF vs. non-CF patients with CRS or in controls. The number of 
eosinophils and cells expressing messenger RNA for IL-4, IL-5, 
and IL-10 was higher in patients with CRS versus those with CF 
and controls. Subgroups of patients with CRS were identified by 
inflammatory mediator profile in another study (620). Sinonasal 
mucosal tissue from nasal polyp (NP) patients, CF patients with 
nasal polyps (CF-NP), CRSsNP patients and control patients were 
stained for CD3, CD25, CD68, CD20, myeloperoxidase (MPO), 
CD138, eotaxin, interleukin IL-1beta, IL-2sRalpha, IL-5, interferon 
IFN-gamma, IL-8, transforming growth factor TGF-beta1, and 
tumour necrosis factor-alpha. NP and CF-NP patients showed 
increased numbers and activation of T cells, while only NP 
patients displayed an increase in plasma cells. NP patients had 
significantly higher levels of eosinophilic markers (eosinophils, 
eotaxin, and eosinophil cationic protein (ECP)) compared 
with CRS, controls and CF-NP. CRS was characterized by a Th1 
polarization with high levels of IFN-gamma and TGF-beta, 
while NP showed a Th2 polarization with high IL-5 and IgE 
concentrations. NP and CF-NP were discriminated by oedema 
from CRS and controls, with CF-NP displaying a very prominent 
neutrophilic inflammation. The expression of the endothelial 
L-selectin ligand was examined in patients with nasal polyps, 
including CF patients (18). Selectins are a family of glycoproteins 
essential for leukocyte recruitment, and L-selectin is expressed 
by most circulating leukocytes. L-selectins on leukocytes and 
their counter-receptors on endothelial cells (such as CD34) 
have been shown to be involved in leukocyte recruitment in 
chronic rhinosinusitis without nasal polyps. CD34 is a cell-cell 
adhesion molecule also required for T cells to enter lymph 
nodes, and binds to L-selectin. CD34 is expressed on lymph 
node endothelia whereas the L-selectin to which it binds is 
on the T cell. The sialylated Lewis X Antigen (sLe(x)) is another 
reported selectin ligand. Patients with NP showed a decrease in 
the number of CD34+ vessels while the number of eosinophils 
and the percentage of vessels expressing endothelial sulfated 
(sLe(x)) tetrasaccharide epitopes was upregulated in all groups 
of simple NP. Tissue eosinophilia but not the percentage of 
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endothelial sulfated sLe(x) epitopes was also increased in NP 
patients with aspirin intolerance. Results in CF NP patients were 
similar to those observed for simple NP. Antro-choanal polyps 
were characterized by low numbers of tissue eosinophils and 
relatively few vessels expressing endothelial sulfated sLe(x) 
epitopes.
5.3.3.5. Anatomic Variations
Variations in temporal bone pneumatization (TBP) and paranasal 
sinus pneumatization (PSP) in CF patients were assessed by 
computed tomography (1445). Genotype data for patients with 
CF was determined. TBP did not differ between CF, CRS and 
controls. PSP was less developed in the CF group than the CRS 
and control groups. CRS and controls did not differ in PSP. The 
DeltaF508 status correlated with poorer PSP, but greater TBP. PSP 
was impaired in CF, and DeltaF508 homozygosity was related 
to poor PSP. TBP was well preserved in the CF population and 
DeltaF508 homozygosity correlated with greater TBP.
5.3.4. Heterozygous and Homozygous CTFR Mu-
tations and CRS
Evidence suggests that even CFTR-mutation 
heterozygotes may be more likely to experience 
CRS when compared to the normal wild-type CFTR 
population. 
Several studies have examined the prevalence of mutations 
in the cystic fibrosis transmembrane regulator (CFTR) gene 
in the CRS population, and whether heterozygous mutations 
predispose patients to CRS (1446). One study examined the DNA 
of CRS patients and controls for 16 mutations accounting 
for 85% of CF alleles in the general population (1351). Chronic 
rhinosinusitis patients with 1 CF mutation were evaluated 
for a CF diagnosis by sweat chloride testing, nasal potential 
difference measurement, and DNA analysis for additional 
mutations. Of 147 patients with CRS and 123 CRS-free control 
volunteers 11 CRS patients were found to have a CF mutation 
(DeltaF508, n = 9; G542X, n = 1; and N1303K, n = 1). Diagnostic 
testing excluded CF in 10 of these patients and led to CF 
diagnosis in one patient. The proportion of CRS patients who 
were found to have a CF mutation (7%) was significantly higher 
than in the control group (2%). Nine of the 10 CF carriers had 
the CTFR gene polymorphism M470V, and M470V homozygotes 
were significantly overrepresented in the remaining 136 
CRS patients. Another study surveyed 261 obligate CFTR 
heterozygotes and a control group of 201 individuals 
negative for a standard mutation panel for possible CF-related 
conditions such as asthma, bronchiectasis, pneumothorax, 
allergic bronchopulmonary aspergillosis, sinusitis, nasal polyps, 
gallstones, liver cirrhosis, diabetes, pancreatitis, bone fractures, 
and hypertension (1447). There was no difference between 
heterozygotes and controls, with the exception of hypertension 
(carriers 28/261, controls 7/201, p = 0.004), and, in males, nasal 
polyps (carriers 7/126, controls 0/102, p value = 0.0178), and, 
again, hypertension (carriers 17/126, controls 5/102, p value 
= 0.0407). The investigated CF-related conditions were no 
more frequent in CF heterozygotes than in control subjects, 
with the exception of a higher rate of hypertension overall in 
heterozygotes and a higher rate of nasal polyposis in male CF 
heterozygotes. When age-matched carriers and controls were 
compared these differences disappeared, suggesting that age 
differences in the groups with significant differences in nasal 
polyps and hypertension may have contributed. A study in 
an isolated population practicing a communal lifestyle with 
common environmental exposures examined genetic variation 
underlying susceptibility to CRS using linkage analysis (1337). 
Using physical examination, medical interviews, and a review of 
medical records, eight individuals with CRS were identified from 
291 screened. These eight individuals were related to each other 
in a single 60 member, nine-generation pedigree. A genome-
wide screen for loci influencing susceptibility to CRS using 1123 
genome-wide markers was conducted and the largest linkage 
peak was on chromosome 7q31.1-7q32.1, 7q31 and included 
the CFTR locus again indicating that CTFR mutations may be a 
marker for CRS. Genotyping of 38 mutations in the CFTR gene 
did not reveal variation accounting for this linkage signal.
In the paediatric population a study examined 58 white 
children who had chronic rhinosinusitis, none of whom satisfied 
diagnostic criteria for CF, who underwent sweat testing and 
genotyping for CFTR mutations using an assay that detects 
90% of mutations seen in this ethnic group (1448). Of the patients 
tested 12.1% harboured CFTR mutations as compared with the 
expected rate of 3% to 4% in this ethnic group. The mutations 
included DeltaF508, R117H, and I148T. Only 1 child had a 
borderline abnormal sweat test. Two of the patients experienced 
recurrent Pseudomonas aeruginosa rhinosinusitis, and both 
were DeltaF508 heterozygotes. Three other children with no 
detectable CFTR mutation had borderline elevated sweat-test 
results. A related study examined the prevalence of chronic 
rhinosinusitis in known cystic fibrosis carriers (1449). Obligate CF 
carriers (parents of patients with CF) were assessed by a sinus 
disease questionnaire and a subgroup of participants was 
evaluated by a physician for signs and symptoms of CRS. Of 147 
obligate CF carriers 36% had self-reported CRS. Twenty-three CF 
carriers (14 with and 9 without CRS based on self-reporting in 
the questionnaire) were clinically evaluated and of these7 were 
diagnosed as having CRS (all 7 with self-reported CRS), while 
another 6 had allergic rhinitis or recurrent acute rhinosinusitis 
(all 6 with self-reported CRS), and 10 had no evidence of active 
sinus disease (1 with self-reported CRS).
Another study examined 126 cystic fibrosis patients, 90 with 
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typical clinical features and 36 with atypical phenotypes (1450). 
Genetic tests were carried out to determine the genotype of 
CFTR gene. Cytological examination of nasal mucosa was carried 
out in all the patients. In 71.5% of patients with cystic fibrosis, 
infectious chronic non-specific rhinosinusitis was found. Other 
types of rhinosinusitis such as acute infectious, chronic allergic 
and non-allergic with eosinophilia were found in 21.4% of 
patients, whereas in 7.1% of patients no clinical symptoms of 
rhinosinusitis were found. Nasal polyps were found in 18.3% 
of patients with cystic fibrosis: in 21 patients with a typical 
form and in 2 patients with an atypical form. Nasal polyps were 
more frequent in groups with the genotype consisting of both 
“strong” mutations than in the group with unknown or “mild” 
mutations.
Conclusion: There is Level II and III evidence that significant 
immunologic differences exist in the CF population with CRS 
versus non-CF CRS patients. COX-1 and COX-2 are upregulated 
in CF patients with CRS, leading to increased prostaglandin 
levels. Level III data also suggests an increase in mucous gland 
proliferation, surfactant gene expression, and MUC mucin gene 
expression is also seen in CF patients with CRS, and L-selectin 
receptors involved in lymphocyte localization and adhesion 
are also increased in CF patients with CRS. There are conflicting 
level II and III reports on whether CFTR-mutation heterozygotes 
are more likely to experience CRS, but the predominance of 
level II and III data suggests that patients who are heterozygous 
carriers of CF mutations are more predisposed to CRS when 
compared to the normal wild-type CFTR population. Level II and 
III data suggests that the bacteriology of bronchial cultures in 
CF patients often correlates with the bacteriology of sinonasal 
cultures.
There is Level IB evidence to support the use of 
nasally inhaled dornase alfa in CF patients with 
CRS, and level II and III evidence supporting the 
use of nebulized or irrigated topical antibiotics in 
CF patients with CRS.
5.3.5. Medical Therapy in Cystic Fibrosis and 
Chronic Rhinosinusitis
5.3.5.1. Dornase Alfa
Two studies have examined the use of dornase alfa (the 
mucolytic agent Pulmozyme) in CF patients with CRS. One study 
reported on the efficacy of dornase alfa as a postoperative 
adjunct in CF patients with CRS in a double-blind placebo-
controlled trial on 24 patients with cystic fibrosis and chronic 
sinusitis (1451). The patients underwent sinonasal surgery during 
a 3-year period and received once-daily doses of either dornase 
alfa (2.5 mg) or hypotonic saline solution (5 mL of 0.876% 
w/v NaCl solution) beginning 1 month after surgery and for 
a 12-month period. Primary outcomes were nasal-related 
symptoms and nasal endoscopic appearance; secondary 
outcomes were forced expiratory volume in 1 second, nasal 
computed tomography findings, and saccharine clearance test 
results. Patients were evaluated before and after treatment. 
All postoperative outcomes were significantly improved for 
both treatments at 1 month (P<.05); primary outcomes were 
improved at 24 and 48 weeks in the group receiving dornase 
alfa (P<.05), and at 12 weeks in the group receiving placebo. 
Secondary outcomes were better in the dornase alfa group 
(P<.01) than in the placebo group at 12 months except for the 
saccharine clearance test results. In particular, median relative 
difference in forced expiratory volume in 1 second between 
dornase alfa and placebo was significantly improved in the 
dornase alfa group (P<.01). Nasally inhaled dornase alfa was 
superior to hypotonic saline for improving forced expiratory 
volume in 1 second, nasal computed tomography findings, 
and saccharine clearance test results. Another double-blinded 
placebo-controlled crossover trial examined sinonasal inhalation 
of dornase alfa in CF patients (1452). Primary outcome parameters 
were assessed by the Sino-Nasal Outcome Test (SNOT-20) and 
ventilated volume as measured by magnetic resonance imaging. 
Five CF patients were randomized to inhale either dornase alfa 
or 0.9% NaCl for 28 days and, after a wash-out period of 28 days, 
crossed over to the alternative treatment. Normal saline was 
not associated with relevant changes in SNOT-20 scores while 
dornase alfa significantly improved quality of life as measured 
by the SNOT-20. MRI results showed no definite trend.
5.3.5.2. Topical Antimicrobial Therapy in CF Patients 
with CRS
One systematic review examined the evidence for topical 
antimicrobial therapy in CRS, including some data specifically 
looking at cystic fibrosis patients with CRS (1453). A search of the 
MEDLINE, EMBASE, and CINAHL databases; Cochrane Central 
Register of Controlled Trials (3rd Quarter 2007); and Cochrane 
Database of Systemic Reviews (3rd Quarter 2007) databases 
yielded seven controlled trials with five of these double blinded 
and randomized. Only one of the randomized trials showed a 
positive outcome. Overall, there was low-level corroborative 
evidence for the use of topical anti-bacterials. They found 
evidence for the use of nasal irrigation or nebulization rather 
than delivery by nasal spray. For the antibacterial studies, the 
highest level of evidence was for studies that used postsurgical 
patients and culture-directed therapy. Both stable and 
acute exacerbations of CRS appeared to benefit from topical 
antimicrobials. The evidence in the subgroup of cystic fibrosis 
patients with CRS seemed to indicate that topical antibiotics 
should not be first-line management for Cruet were useful in 
patients refractory to topical steroids and oral antibiotics.
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5.3.5.3. Gene Therapy
A single phase II, randomized double blind placebo-
controlled trial of tgAAVCF, an adeno-associated cystic 
fibrosis transmembrane conductance regulator (CFTR) viral 
vector/gene construct, was identified (1454). TgAAVCF was 
given to 23 patients with a dose of 100,000 replication units 
of tgAAVCF administered to one maxillary sinus, while the 
contralateral maxillary sinus received a placebo treatment as 
a control. Neither the primary efficacy endpoint (the rate of 
relapse of recurrent sinusitis) nor secondary endpoints (sinus 
transepithelial potential difference (TEPD), histopathology, 
sinus fluid interleukin IL-8 measurements) achieved statistical 
significance when comparing treated to control sinuses within 
patients. One secondary endpoint, measurements of IL-10 in 
sinus fluid, was significantly increased in the tgAAVCF-treated 
sinus relative to the placebo-treated sinus at day 90 after vector 
instillation. The tgAAVCF administration was well tolerated, 
without adverse respiratory events or enhanced inflammation in 
sinus histopathology and the Phase II trial confirmed the safety 
of tgAAVCF but provided little support of its efficacy in the 
within-patient controlled sinus study.
Conclusion: There is Level IB evidence to support the use of 
nasally inhaled dornase alfa in CF patients with CRS, with 
dornase alfa demonstrating an improvement in nasal-related 
symptoms, nasal endoscopic appearance, FEV1, and CT findings 
vs. inhaled hypo- and isotonic saline. There is level II and III 
evidence supporting the use of nebulized or irrigated topical 
antibiotics as a second-line therapy for CF patients with CRS. 
There is level IB data demonstrating the safety of tgAAVCF, an 
adeno-associated cystic fibrosis transmembrane conductance 
regulator (CFTR) viral vector/gene construct, but no therapeutic 
benefit vs. control vector in reducing frequency of sinusitis, 
decreasing IL-8 levels, or decreasing histopathological evidence 
of inflammation. Further randomized controlled trials on oral 
and topical steroids and antimicrobials in CF patients with CRS 
are needed.
5.3.6. Surgical Therapy in Cystic Fibrosis and 
Chronic Rhinosinusitis
Data on surgical therapy for CF patients
 with CRS is primarily level III but supports the 
safety and efficacy of endoscopic sinus surgery in 
CF patients.
5.3.6.1. ESS in the Adult CF Population
Several retrospective studies and case series have examined 
the efficacy of endoscopic sinus surgery in the CF population, 
but no randomized controlled trials specifically on CF and 
CRS were identified. One prospective, non-randomized study 
examining ESS in CF patients was identified (1455). One study used 
a retrospective medical record review of the extent of nasal 
polyposis endoscopically in a cystic fibrosis population before 
the first surgical intervention and the effect of the severity of 
preoperative polyposis on the need for revision ESS in the CF 
population (1456). Patients with a clinical preoperative diagnosis 
of cystic fibrosis and sinusitis were graded preoperatively 
with the extent of polyps prospectively graded into 3 groups 
before the first surgical intervention [no polyps (grade A), 
mild polyposis (grade B), and extensive polyposis (grade C)]. 
The number of patients needing revision ESS and the mean 
time to revision ESS were compared among the 3 groups: 14 
patients required revision surgery: 3 with mild polyps and 11 
with extensive polyps. Mean time to revision surgery was 39.7 
months for those with grade B and 23.8 months for those with 
grade C and the rate of revision ESS was significantly different 
among the 3 groups. A nested case-control study examined the 
outcomes following endoscopic sinus surgery in adult patients 
with cystic fibrosis compared matched controls without CF (1456). 
Preoperative CT and preoperative/postoperative endoscopic 
findings and changes in two disease-specific quality-of-life 
(QoL) instruments were evaluated both preoperatively and 
postoperatively. Preoperative CT scores and endoscopy 
scores were significantly worse in CF patients. Postoperative 
endoscopy scores were significantly worse for CRS patients with 
CF, although the degree of improvement on endoscopy within 
each group was no different and both groups experienced 
similar improvement in QoL after ESS.
The benefit of endoscopic mega-antrostomy for recalcitrant 
maxillary sinusitis in CRS patients including CF patients was 
examined in a retrospective review of patients who underwent 
endoscopic maxillary mega-antrostomy (EMMA) for recalcitrant 
maxillary sinusitis (1457). Relevant comorbid factors included prior 
Caldwell-Luc or maxillofacial surgery (16/42), cystic fibrosis 
(11/42), asthma (11/42), and IgG deficiency (3/42). Seventy-four 
percent of patients reported complete resolution of symptoms 
while 26% reported partial symptomatic improvement. EMMA 
appeared to be effective and safe for the management of 
recalcitrant maxillary sinus disease, including the CF subset of 
patients.
A prospective trial examined the efficacy of endoscopic 
surgery with serial antimicrobial lavage (ESSAL) in CF patients, 
comparing ESSAL in 32 patients to conventional sinus 
surgery without serial antimicrobial lavage in 19 controls 
(1455). Conventionally treated patients underwent nasal 
polypectomy, ethmoidectomy, antrostomy, or Caldwell-Luc 
operation while the ESSAL approach incorporated preoperative 
rhinosinuscopy and computed tomography, endoscopic 
surgery, a postoperative course of antral antimicrobial lavage, 
and monthly maintenance antimicrobial lavage via brief antral 
catheterization. The main outcome measure was intensity 
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and frequency of sinus surgery after initial presentation. The 
two groups were similar in clinical presentation, including 
the presence of nasal polyposis. The ESSAL group had fewer 
operations per patient, fewer Caldwell-Luc procedures, and a 
decrease in repeated surgery at 1-year and 2-year follow-ups.
CF patients tend to have worse preoperative CT 
and endoscopy scores than non-CF CRS patients, 
but the degree of improvement on endoscopy 
and the improvement in QoL after ESS tends to 
be similar in CF and non-CF patients. ESS with 
serial antimicrobial lavage has been shown to be 
superior to surgery alone in CF patients, and CF 
patients may benefit from mega-antrostomies for 
recalcitrant disease.
Several other retrospective, Level III studies examined the safety 
and efficacy of ESS in the CF population. A retrospective study 
on the effect of ESS on CF with nasal polyposis found that the 
patients had a 50% chance either of their symptoms returning 
to preoperative severity or of undergoing a second endoscopic 
sinus procedure, by 18 to 24 months of postoperative follow-
up (1458). Patients with predominantly infective symptoms of 
mucopurulent rhinorrhoea and pain had a significantly better 
outcome than patients with predominantly nasal blockage. The 
chance of the infective symptom group of patients suffering 
symptom deterioration back to the preoperative state or under-
going a second endoscopic sinus operation was 37% of that of 
the nasal blockage symptom group. A retrospective study on 
functional endoscopic ethmoidectomy (FEE) in patients with CF 
found that symptoms improved or disappeared in 9/12 cases 
between 1 and 3 years of follow-up and in 5/7 cases after 3 years 
of follow-up with a good or mild anatomical result recorded in 
6/12 cases between 1 and 3 years of follow-up and in 5/7 cases 
after 3 years of follow-up. During follow-up, a new surgical 
procedure (limited in 8 patients and complete in 3 patients) was 
often necessary. A retrospective review of complications of ESS 
in patients with demonstrated a complication rate of 11.5%, 
which compared favourably with the non-CF ESS complication 
rates of 0-17% reported in the literature. A related study on the 
effectiveness of sinus surgery in CF patients status post lung 
transplant reviewed ESS in 37 patients with cystic fibrosis after 
lung transplantation and found ESS to be successful in 54% and 
partially successful in 27% of patients (1459). A significant correla-
tion was found between negative sinus aspirates and negative 
BAL and between positive sinus aspirates and positive BAL. Suc-
cessful sinus management led to a significantly lower incidence 
of tracheobronchitis and pneumonia.
5.3.6.2. ESS in the Paediatric CF Population
A retrospective review of paediatric patients with CF treated 
for recurrent sinusitis Duplechain et al. (1460) examined the 
role of ESS in. The charts of 32 children were retrospectively 
reviewed. All children underwent surgery performed by one of 
two physicians. The presence of polyps in the population with 
cystic fibrosis was significant; 86% of patients (12 of 14) in the 
CF group demonstrated polyps at the time of surgery, whereas 
polyps were detected in only 16% of the patients (3 of 18) with 
non-CF CRS. Eighty-nine percent (eight of nine) of intraoperative 
sinus culture samples were culture positive for Pseudomonas 
species in the CF group, while none of the samples taken from 
the group with non-CF showed Pseudomonas organisms. ESS 
was safe, well-tolerated, and effective in the paediatric CF and 
non-CF populations. Another retrospective study examined the 
relationship between CF and ESS (1461). Sixteen paediatric and 1 
adult patients with previously diagnosed CF, documented chro-
nic sinus disease and nasal polyposis that had failed long-term 
maximal medical management underwent ESS. The patients or 
their parents rated the pre- and postoperative severity and fre-
quency of their symptoms associated with chronic sinus disease. 
There was no change in the relative health of patients as measu-
red by the number of hospitalizations but there was a significant 
improvement in the quality of life. There was a marked decline in 
the frequency of nasal obstruction, nasal discharge and postna-
sal drip and a high level of patient satisfaction following FESS.
Conclusion
Data on surgical therapy for CF patients with CRS is primarily 
level III. The available data supports the use of ESS in CF-related 
CRS, and supports its safety and efficacy in retrospective studies. 
The level III data also suggested that the rate of complications 
is similar to non-CF patients, that ESS is safe in paediatric CF 
patients, and that patients with more severe polyposis tended 
to require repeat surgery more frequently. Two level IIA studies 
were identified. One prospective case control study demonstra-
ted that while CF patients tended to have worse preoperative 
CT scores and endoscopy scores and worse postoperative 
endoscopy scores, the degree of improvement on endoscopy 
and the improvement in QoL after ESS tended to be similar 
in CF and non-CF patients. Another level IIA, prospective trial 
demonstrated that endoscopic surgery with serial antimicrobial 
lavage (ESSAL) was superior to surgery alone in CF patients, with 
the ESSAL group having fewer operations per patient, fewer 
Caldwell-Luc procedures, and a decrease in repeated surgery at 
1-year and 2-year follow-ups. Randomized controlled trials are 
lacking.
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5.4  Aspirin exacerbated respiratory disease
5.4.1. Summary
The presence of aspirin sensitivity in a patient with 
rhinosinusitis/asthma is associated with severe and protracted 
eosinophylic airway disease requiring comprehensive 
management of all components of the syndrome. The diagnosis 
of ASA-hypersensitivity initially based on a history should be 
confirmed/excluded with oral, nasal or bronchial provocation 
testing with aspirin. Avoidance of aspirin/non-steroidal anti-
inflammatory drugs (NSAIDs) should be recommended and the 
airway disease management should follow general guidelines, 
with emphasis on adequate dose of topical steroids. If sinus 
surgery is performed the beneficial effects may extend to 
bronchial asthma. Desensitization and maintenance treatment 
with aspirin may be valuable alternative for some patients. 
5.4.2. Introduction
Presence of hypersensitivity to aspirin/NSAID’s in a 
patient with chronic rhinosinusitis heralds severe, 
hyperplastic sinus disease with high polyps recur-
rence after sinus surgery 
The presence of hypersensitivity to aspirin or other NSAIDs in 
a patient with rhinosinusitis and nasal polyposis is associated 
with a particularly persistent and treatment-resistant form of 
the disease, coexisting usually with severe asthma and referred 
to as the “aspirin triad” (1462). Since the chronicity of the upper 
and lower airway inflammation is not related to NSAIDs intake 
or avoidance, and NSAIDs only occasionally may exacerbate 
symptoms the term Aspirin Exacerbate Respiratory Disease 
(AERD) has been recently propose to describe this syndrome 
(1463, 1464). The prevalence of nasal polyposis in aspirin-sensitive 
asthmatics may be as high as 60-70%, as compared to less than 
10 % in the population of aspirin-tolerant asthmatics (1465). The 
unusual severity of the upper airway disease in these patients is 
reflected by high recurrence of nasal polyps, and frequent need 
for endoscopic sinus surgery (1466, 1467). Rhinosinusitis in aspirin 
hypersensitive patients with nasal polyposis is characterized by 
involvement of all sinuses and nasal passages and the thickness 
of hypertrophic mucosa is significantly higher in AERD patients 
as documented with computer tomography (1468).
5.4.3. Pathomechanism of acute ASA-induced 
reactions
In ASA-sensitive patients acute nasal symptoms (sneezing, 
rhinorrhoea and congestion) may be induced by challenge 
with oral or intranasal aspirin but also with other cross-reacting 
NSAIDs .The mechanism of these acute adverse reactions 
has been attributed to inhibition by NSAIDs of an enzyme 
cyclooxygenase-1, with subsequent inflammatory cell activation 
and release of both lipid and non-lipid mediators (1469, 1470). The 
ASA-induced nasal reaction is accompanied by an increase in 
both glandular (lactoferrin, lysozyme) and plasma (albumin) 
proteins in nasal secretions indicating a mixed response, 
involving both glandular and vascular sources (1471). Concomitant 
release of both mast cell (tryptase, histamine) and eosinophil 
(ECP) specific mediators into nasal washes clearly indicate 
activation of both types of cells (1472-1474). Increased concentration 
of cysteinyl leukotrienes in nasal secretion was also observed 
within minutes after ASA-challenge although the cellular source 
of leukotrienes has not been determined (1475). In parallel with 
inflammatory mediator release an influx of leucocytes into nasal 
secretions occurred with significant enrichment in eosinophils 
(1474). 
The mechanisms of hypersensitivity to aspirin/
NSAID’s is not immunological, but is related to 
cyclooxygenase inhibition and involves several 
abnormalities of the arachidonic acid 
metabolism
5.4.4. Pathomechanism of chronic rhinosinusitis 
and nasal polyposis in patients with AERD 
Although the pathogenesis of chronic eosinophilic inflamma-
tion of the airway mucosa and nasal polyposis in ASA-sensitive 
patients, does not seem to be related to intake of aspirin or 
other NSAIDs it has been speculated that the pathomechanism 
underlying rhinosinusitis and nasal polyposis in aspirin-sensitive 
patients may be different from that in aspirin tolerant patients 
(1467, 1476). 
Cells and cytokine profile 
A marked tissue eosinophilia is a prominent feature of rhinosi-
nusitis and nasal polyposis in ASA-hypersensitive patients and 
accordingly significantly more ECP was released from non-
stimulated or stimulated nasal polyp dispersed cells from ASA-
sensitive patients (1477, 1478). An increased number of eosinophils 
in the tissue has been linked to distinctive profile of cytokine 
expression with upregulation of several cytokines related to eo-
sinophil activation and survival ( e.g. IL-5, GMC-SF, RANTES, eo-
taxin) (902, 1479, 1480). It has been suggested that overproduction of 
IL-5 might be a major factor responsible for an increased survival 
of eosinophils in the nasal polyps resulting in increased intensity 
of the eosinophilic inflammation particularly in aspirin-sensitive 
patients (1481). In fact decreased apoptosis was documented in 
polyps from aspirin-sensitive patients, and increased infiltration 
with eosinophils was associated with prominent expression 
of CD45RO+ activated/memory cells and this cellular pattern 
was related to clinical features of rhinosinusitis (1482). Bachert 
at al (542) demonstrated, that IgE-antibodies to Staphylococcal 
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enterotoxins ( SAEs) were present in nasal polyp tissue and their 
concentration correlated with the levels of ECP, eotaxin and IL-5. 
These relations seemed to be particularly evident in ASA-sensi-
tive patients suggesting that an increased expression of IL-5 and 
ECP in polyp tissue from ASA-sensitive patients may be related 
to the presence of SAE that can exert direct effects on eosinophil 
proliferation and survival or may act as a superantigen to trigger 
a T-cell mediated inflammatory reaction (1483-1485).
Not only activated eosinophils but also mast cells are abundant 
in the nasal polyps tissue from ASA-sensitive patients (824, 1486). 
The density of mast cells was correlated with the number of 
polypectomies, implicating an important role for these cells 
in the pathogenesis of nasal polyposis. Stem cell factor (SCF) 
also called c-kit ligand is a multi-potent cytokine generated 
by nasal polyp epithelial cells and critical for differentiation, 
survival, chemotaxis and activation and of human mast cells but 
also involved in eosinophil activation and degranulation. SCF 
expression in nasal polyp epithelial cells in culture correlated 
closely with the density of mast cells in nasal polyp tissue and 
was significantly higher in asthmatic patients with aspirin 
hypersensitivity as compared to aspirin tolerant patients (1483).
In the nasal polyp tissue from AERD patients expression of 
metalloproteinase TIMP-1 was found to be significantly reduced 
and the MMP-9/TIMP-1 ratio was significantly increased in the 
compared with both aspirin tolerant and patients without nasal 
polyps, indicating for the importance of metalloproteinases 
expression in polyps remodelling and inflammatory changes 
(1487). 
Recently, microarray technology was used to examine gene 
expression in nasal polyps of aspirin sensitive patients. It has 
been demonstrated that nasal polyps from AERD patients have 
distinct transcriptional and methylation signatures (1029, 1488, 1489).
Furthermore , using proteomics based approaches several 
proteins that exhibited differential expression between 
ATA and AERD patients were identify , although at present 
pathophysiological and functional significance of these findings 
is not clear yet (1490, 1491). 
5.4.5. Abnormalities in arachidonic acid 
metabolism 
Since Szczeklik et al. (1492) reported an increased susceptibility of 
nasal polyps cells from ASA-sensitive patients to the inhibitory 
action of aspirin , arachidonic aid metabolism abnormalities 
have been considered a distinctive feature of nasal polyps in 
this subpopulation of patients. A significantly lower generation 
of PGE2 by nasal polyps and, nasal polyp epithelial cells as well 
as a decreased expression of COX-2 in nasal polyps of these 
patients were reported (1055, 1493). Low expression of COX-2 mRNA 
in nasal polyps from ASA-sensitive patients was in turn linked to 
a downregulation of NF-ΚB activity and to abnormal regulation 
of COX-2 expression mechanisms at the transcriptional level 
(1494, 1495). Since PGE2 has significant anti-inflammatory activity, 
including inhibitory effect on eosinophil chemotaxis and 
activation, it has been speculated that an intrinsic defect in local 
generation of PGE2 or abnormal balance between PGD2/PGE2 
could contribute to development of more severe eosinophilic 
inflammation in aspirin-sensitive patients (1496). Although a 
significant deficit of PGE2 was demonstrated in polyp tissue of 
ASA-sensitive as compared to ASA-tolerant patients, decreased 
expression of COX-2mRNA seem to be a feature of nasal 
polyposis also in patients without ASA-sensitivity representing 
more general mechanism involved in the growth of nasal polyps 
(595). On the other hand the percentages of neutrophils, mast 
cells, eosinophils, and T cells expressing prostaglandin EP2, but 
not EP1, EP3, or EP4 receptors , were significantly reduced in the 
aspirin-sensitive compared with non aspirin-sensitive patients 
suggesting a potential regulatory abnormality of inflammatory 
cells at the receptor level (1497)..
Cysteinyl leukotrienes have been implicated in the pathogenesis 
of chronic mucosal inflammation in ASA-sensitive patients 
and some studies demonstrated an increased production 
of cysteinyl leukotrienes in nasal polyps of ASA-sensitive 
asthmatics as compared to aspirin tolerant patients in vitro 
(1498, 1499) but these observations could not be reproduced in 
vivo when nasal washes were analysed (1471, 1475). Similarly when 
nasal polyp dispersed cells were cultured basal and stimulated 
release of LTC4 was found to be similar in nasal polyp cells from 
ASA-sensitive and ASA-tolerant patients (902). More recently 
an increased expression of enzymes involved in production 
of leukotrienes (5-LOX and LTC4 synthase) and an increased 
generation of LTC4/D4/E4 in nasal polyp tissue from ASA-
sensitive patients were found (1500-1502). Cysteinyl leukotriene 
production correlated with tissue ECP concentration both in 
ASA-sensitive and ASA-tolerant polyps suggesting that these 
mediators may be linked to tissue eosinophilia rather that to 
aspirin-sensitivity . On the other hand an increased expression 
of leukotriene LT1 receptors was found in the nasal mucosa of 
ASA-sensitive patients, suggesting local hyper-responsiveness 
to leukotrienes in this subpopulation of patients (1496, 1503). More 
recently other arachidonic acid metabolites generated on 
15-LOX pathway have been associated with nasal polyposis in 
AA-sensitive patients. In nasal polyp epithelial cells from ASA-
sensitive but not ASA-tolerant patients aspirin triggers 15-HETE 
generation, suggesting the presence of a specific abnormality 
of 15-LO pathway in these patients (1493). Upregulation of 
15-lipoxygenase and decreased production of the anti-
inflammatory 15-LO metabolite lipoxin A4 found in nasal polyp 
tissue from ASA-sensitive patients further points to a distinctive 
but not yet understood role for 15-LO metabolites in nasal 
polyps.
In summary, presence of hypersensitivity to aspirin or other 
NSAID heralds not only more severe and protracted clinical 
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course of chronic rhinosinusitis/nasal polyps by is also 
associated with distinct pattern of cellular, biochemical and 
molecular markers of inflammation. 
5.4.6. Natural history
A history of chronic rhinosinusitis and or asthma usually 
precedes the development of hypersensitivity to aspirin. In 
some patients the beginning of the disease is associated with 
flu-like infection, which is followed by development of chronic 
intractable rhinosinusitis with nasal polyps and appearance 
of asthma (515) Rhinosinusitis and asthma once developed run 
protracted course which is independent of avoidance of aspirin 
and other NSAIDs (1463). Although patients usually report nasal 
symptoms typical for non-allergic rhinitis, exacerbations of 
symptoms on exposure to both seasonal and perennial inhalant 
allergens are reported by significant proportion of patients (1466). 
Rhinosinusitis in patients with AERD is complicated by mucosal 
hypertrophy and polyps formation : the prevalence of nasal 
polyposis varies from 60% to 90% if diagnosed by rhinoscopy. 
On computer tomography polypoid mucosal hypertrophy 
is present in up to 100 % of patients and is more extensive 
in ASA-sensitive as compared to ASA-tolerant patients with 
nasal polyposis (1468). Nasal polyposis has a high tendency to 
recurrence after surgery ; the recurrence rate in ASA-sensitive 
patients is several times higher even after ESS (1504).
A subgroup of ASA-sensitive patients manifests a reaction 
exclusively in the upper respiratory tract; they do not have 
asthma, but clinical picture of the nasal disease (hyperthrophic 
rhinosinusitis) in these patients is similar to that observed in 
patients with ASA-triad (1505). Although some of these patients 
may evolve with time to a full aspirin triad, their risk of 
developing asthma in the future is not known.
5.4.7. Diagnosis of AERD
Oral challenge with aspirin or nasal / bronchial 
provocation with lysine aspirin are reliable tools 
to confirm/exclude hypersensitivity to aspirin/
NSAID’s
The diagnosis of ASA-hypersensitivity is based on a history of 
adverse reaction precipitated with ASA or other non-steroidal 
anti-inflammatory drug. In asthmatic patients with negative 
history and /or those who have never been exposed to NSAIDs, 
but have additional risk factors (rhinosinusitis, nasal polyposis, 
history of near fatal reactions), the risk of adverse reaction is 
further increased and provocation testing my be required (1506).
Oral challenge is the reference standard for the diagnosis 
of hypersensitivity to aspirin and other NSAIDs and several 
protocols for oral aspirin provocation have been developed 
and described (1507, 1508). Inhalation challenge with lysine-aspirin 
(a soluble form of acetylsalicylic acid ) has been introduced by 
Bianco et al. in 1977 (1509) and in Europe is often used to confirm/
exclude aspirin sensitivity in patients with bronchial asthma. 
Inhalation test is faster and safer to perform than oral challenge 
(the reaction is usually easily reversible by with nebulized 
beta2 agonists) and both tests have similar sensitivity and 
specificity (1510, 1511). Nasal provocation test with lysine aspirin 
is also a possible tool to diagnose hypersensitivity to aspirin 
providing that the clinical symptoms are combined with the 
objective and standardized technique of airflow measurement 
for assessment of the results (1512). The test is rapid and safe and 
can be performed in an outpatients setting even in asthmatic 
patients with low pulmonary function not suitable for bronchial 
provocation. In experienced hands the sensitivity of intranasal 
aspirin provocation is approaching performance of bronchial 
challenge (1512, 1513).
More recently in vitro tests measuring aspirin-specific peripheral 
blood leukocytes activation have been proposed for the 
diagnosis of aspirin sensitivity.
The newly developed in vitro tests (FLOW CAST and ASPITest) 
seem to demonstrated promising performance , but require 
further investigations and validation before becoming routine 
tools for confirming the presence of aspirin hypersensitivity (1477). 
5.4.8. Management of patients with AERD 
Selective COX-2 inhibitors (celecoxib) are 
well tolerated by aspirin sensitive asthmatics 
and are good alternative NSAID’s for patients 
with aspirin triad 
Patient education and careful avoidance of ASA and other 
NSAIDs in sensitive patients seem to be of high importance, 
since aspirin may be a cause of severe asthmatic attack (1510). 
In most patients acetaminophen in low or moderate doses 
(below 1000 mg) can be recommended as an alternative 
antipyretic or analgesic drug. Preferential COX-2 inhibitors 
(nimesulide, meloxicam) are also tolerated by the majority, but 
not all, hypersensitive patients and can be recommended in an 
individual patient after tolerability is proved by oral challenge. 
Selective COX-2 inhibitors (celecoxib) are well tolerated by 
aspirin sensitive asthmatics and could be ideal alternative 
NSAIDs for patients with aspirin triad (1514). 
Antileukotrienes are not more effective 
in  aspirin-sensitive as compared to 
aspirin-tolerant patients  
The presence of aspirin sensitivity in a patient with asthma/
rhinosinusitis heralds severe and protracted disease of the 
respiratory tract, characterized with eosinophilic inflammation 
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and requiring comprehensive management of all components 
of the syndrome . Management of asthma and rhinosinusitis 
in AERD patient should follow general guidelines, but several 
specific measures for AERD should be considered. Standard 
treatment for rhinosinusitis includes high doses of topical 
steroids, antibiotics and occasional bursts of oral corticosteroids 
to control symptoms and slow down nasal polyps recurrence. 
Although antileukotriene drugs may also be effective in in 
AERD patients, they are not more effective than in ASA-tolerant 
(1515, 1516). At certain stage of the disease surgical procedures 
(polypectomy, functional endoscopic sinus surgery or 
ethmoidectomy) are usually needed to relieve symptoms of 
CRS and to remove polypoid tissue from sinuses (1517). Beneficial 
effects of sinus surgery may extend to bronchial asthma (1518), 
although patients with AERD seem to respond less well to 
surgical intervention (1419, 1420, 1519-1521).
Nasal/sinus surgery (polypectomy, functional 
endoscopic sinus surgery or ethmoidectomy) may 
be less effective in patients with AERD 
In order to control asthma symptoms and lower airway 
inflammation inhaled glucocorticosteroids in relevant doses, 
often in combination with long acting beta-2 agonists, are 
recommended but in about 50% of patients chronic treatment 
with oral prednisone may be necessary to control the disease. 
There is some indication that by giving repeated doses of 
ASA after the initial adverse reaction a desensitization can be 
achieved (1522-1526) (Evidence level D).
Desensitization and maintenance treatment 
with aspirin alleviate upper airway symptoms 
and decrease rate of polyp recurrence in some 
patients 
An alternative, but not well documented approach is intranasal 
desensitization and prolonged treatment with soluble lysine 
aspirin, which may reduce recurrence rate for nasal polyps in 
AERD patients (1527-1530)..
5.5. Immunodeficiencies and Chronic 
Rhinosinusitis 
5.5.1. Primary Immunodeficiencies
The association between rhinosinusitis and primary 
immunodeficiencies (PID) can be examined in one of two ways: 
1. Those patients presenting to their primary care physicians 
or otorhinolaryngologists with recurrent acute rhinosinusitis 
(RARS) or chronic rhinosinusitis (CRS) who may have an 
underlying PID contributing to their clinical symptoms or 
2. Patients presenting to immunologists with a variety of 
infections who may have RARS/CRS as one aspect of their 
clinical picture. 
In the first situation, among CRS patients who are referred 
for immune evaluation, up to half may have T lymphocyte 
dysfunction (560), while roughly 20% have decreased IgG, IgA 
or IgM (560, 1531). In addition, nearly 10% have common variable 
immune deficiency (CVID) (560,1532). Among CRS patients who 
underwent FESS and had immune workup, 72% had low 
baseline pneumococcal titres, while 11-67% had an inadequate 
functional response to pneumococcal vaccine (1531,1533) and 
these patients had lower serum IgA (1533). These studies were 
conducted at tertiary institutions, thus it is possible that there is 
significant selection bias. 
In the second situation, when examining patients with 
PIDs, CVID is the most frequent symptomatic primary 
immunodeficiency in North America and Europe, with an 
incidence between 1:25,000 and 1:66,000 (1534). Among CVID 
patients, 36 to 78% present with CRS (1534,1535). In another 
large cohort of multiple forms of PID (1536), the most common 
diagnosis was IgA deficiency (30%), followed by IgG subclass 
deficiency (26%) and hypogammaglobulinemia (23%), with 
CVID being present in 15%. Less common were combined B and 
T cell defects (11%), phagocytic defects (8%) and complement 
defects (3%). RARS was present in 41% of this cohort and CRS in 
40% (1537). In patients with decreased response to pneumococcal 
vaccine, thus a functional antibody deficiency, 77% have 
rhinosinusitis (1538).
5.5.1.1 Diagnosis
The diagnosis of PID can be difficult. Up to 20% of the 
population may have an IgG subclass deficiency but be 
clinically asymptomatic. Up to 90% of IgA deficient patients 
are asymptomatic (1539). Thus a clinically significant diagnosis 
requires both a defect in antibody responsiveness, as well as 
recurrent infections. The diagnostic delay between presentation 
with symptoms and definitive diagnosis ranges from 4.7 to 15 
years (1534, 1536, 1540). Between 53 and 90% of adult and paediatric 
patients with agammaglobulinemia or CVID present with 
CT findings of CRS (1541). These upper airway findings do not 
correlate with pulmonary imaging and most commonly include 
mucosal thickening. Bone sclerosis and polyposis are less 
common (1542).
5.5.1.2 Treatment
 Treatment for IgG deficiency is typically intravenous 
immunoglobulin (IVIG) and/or prophylactic antibiotics. While 
these treatments may improve overall survival and decrease the 
rate of serious life threatening infections, they do not appear 
to prevent radiographic development of CRS (1542) and their 
clinical benefit in CRS is not proven (1534). During clinical follow 
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up of CVID patients, 54 to 63% develop CRS in spite of IVIG (1535, 
1540). Patients with CVID have persistent inflammation in sinus 
mucosa and positive bacterial and viral cultures despite IVIG 
(1541). Those with selective IgA deficiencies have increased IgG 
and IgM and the increase in inflammatory mediators is not as 
significant (1543). Most authors do not recommend IVIG routinely 
for clinically asymptomatic IgG deficiency patients and this 
is typically used in less than 10% of patients (1539). Surgery for 
patients with PID has not been thoroughly studied. Limited 
series examining a variety of patients with immune dysfunction 
contained only a select number of patient with immunoglobulin 
deficiency, thus are inconclusive (1544).
5.5.1.3. Referral
The question of when the otorhinolaryngologist should perform 
an immunologic evaluation or refer to an immunologist for 
a patient with CRS or RARS is not well established. It would 
seem prudent to conduct such an evaluation in children with 
recurrent respiratory tract infections in order to identify PIDs 
as early as possible and initiate treatment that will impact 
overall survival. It would also seem prudent to conduct such 
investigations in adults with multiple system infections, such 
as otitis media, bronchitis or pneumonias or those that fail 
standard medical and surgical treatments for CRS. However, 
widespread immunologic screening in all adult CRS patients 
who respond to routine therapies, would likely uncover 
laboratory abnormalities that are clinically insignificant and do 
not require treatment (1539).
5.5.2. Acquired immunodeficiencies
In contrast to patients with PIDs who typically present 
with viral or bacterial rhinosinusitis, patients with acquired 
immunodeficiencies can develop rhinosinusitis in a variety of 
forms, including non-fungal acute rhinosinusitis (ARS), chronic 
rhinosinusitis (CRS), or fungal forms, most often acute invasive 
fungal rhinosinusitis (AIFRS) or even described more recently, 
fungus balls. Acquired immunodeficiencies that may predispose 
patients to rhinosinusitis include immunosuppression due to 
transplant, diabetes mellitus, medications or malignancies or 
human immunodeficiency virus (HIV). 
Organ transplants: Solid organ transplant patients often 
have hepatic or renal failure prior to transplant and thus are 
immunocompromised from their primary disease state, but 
even after transplant they remain at risk for development of 
rhinosinusitis due to immunosuppressive medications. Prior 
to transplant, Moon (1545) found CRS was present in 28 of 996 
(2.8%) pre-liver transplant patients. Twenty-two of these 
patients had no treatment for CRS prior to transplantation. 
This untreated CRS was associated with aggravated symptoms 
after transplantation, but no increase in infectious or overall 
mortality. Similarly, another study found that preoperative CT 
of patients awaiting organ transplant demonstrated 64% had 
radiographic abnormalities, however 77% of these patients were 
asymptomatic with normal endoscopy, thus routine CT scans 
prior to transplant is not indicated (1546).
One retrospective review of ESS in 7 patients awaiting liver 
transplant reported that operative blood loss was an average 
of 495 mL and 2 cases were stopped due to excessive bleeding. 
Higher blood loss was associated with more severe liver disease. 
Four of seven patients subsequently underwent transplant (1547). 
Thus ESS is feasible in these patients, however it is not without 
risk and the benefits are not established.
Post-transplant acute invasive fungal rhinosinusitis (AIFRS) 
becomes a major concern. Sun (1548) reported an overall mortality 
of 52% in ninety solid organ transplant patients with rhino-
orbital-cerebral zygomycosis. Central nervous system (CNS) 
involvement was present in 56% with isolated CNS involvement 
in only 2%. Sinus disease was most frequent in maxillary sinus 
(80%), followed by ethmoid (65%), sphenoid (45%) and frontal 
sinus (22%). Compared to diabetes mellitus (DM) patients, 
transplant patients had a lower likelihood of orbital and 
sinonasal involvement, but higher likelihood of CNS invasion. 
Lipid formulations of amphotericin B correlated with lower 
mortality in transplant patients.
5.5.2.1. Hematopoietic stem cell transplantation 
(HSCT)
Similar to solid organ transplant, patients undergoing 
hematopoietic stem cell transplantation (HSCT), are at risk 
of developing rhinosinusitis prior to transplant due to their 
underlying malignancy, as well as post-transplant from their 
immunosuppression. A number of studies have looked at pre-
HSCT screening for rhinosinusitis, and have generally concluded 
they are not useful in asymptomatic patients. 
A retrospective review of 100 patients who underwent HSCT 
found that there was no increased risk of developing CRS post-
HSCT for patients with disease on pre-HSCT screening CT, sinus 
symptoms at time of transplant, tobacco use, asthma, allergies, 
low IgG or prior history of CRS. Patients with graft versus host 
disease (GVHD) were 4.3 times more likely to develop CRS post-
HSCT (1549). 
Ortiz (1550) found no evidence of disease on 77% of pre-HSCT 
scans and 61% of post-HSCT scans, thus concluding CT staging 
prior to HSCT is not useful in predicting post-HSCT CRS. This 
was corroborated by Moeller (1551). Prior to HSCT, 71 patients 
underwent evaluation for rhinosinusitis. Sixty-five percent were 
asymptomatic. All patients who required medical or surgical 
treatment had symptoms and positive endoscopy and/or CT. 
Won (1552) evaluated 252 HSCT patients. Nine percent had 
sinusitis prior to HSCT and this increased to nearly 16% 
post-HSCT. Patients with pre-HSCT rhinosinusitis had a high 
occurrence of post-HSCT rhinosinusitis (34 vs. 14%), but again, 
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CT scans alone were not predictive of post-HSCT rhinosinusitis. 
However, in pre-HSCT patients who are clinically symptomatic 
and have CT evidence of CRS, medical or surgical intervention 
for CRS prior to HSCT reduced the rate of post-HSCT CRS. 
Routine CT scans and clinical evaluation in asymptomatic 
patients was not useful. 
When examining clinical symptoms, Arulrajah (1553) found that 
children who are status post HSCT had more severe sinus 
disease on CT associated with symptoms of rhinorrhoea, nasal 
congestion or cough when compared to immunocompetent 
children, however the immunocompetent children still had 
significant symptoms. 
5.5.2.2. Hematologic malignancies
Acute invasive fungal rhinosinusitis (AIFRS) can be a life 
threatening infection in patients with hematologic malignancies 
that requires aggressive medical and surgical intervention. A 
retrospective review of 46 patients with AIFRS found Aspergillus 
was the most common pathogen and AIFRS developed more 
commonly in patients with acute myeloid leukaemia (AML) and 
prolonged neutropenia > 10 days. Bony erosion and extra sinus 
infiltration was found in 33% of patients and 41% patients died 
within 6 weeks (1554). Zappasodi (1555) reported on seven cases of 
AIFS in patients with acute leukaemia with neutropenia. Facial 
pain was the initial symptom in all cases, associated with fever in 
6 of 7. CT demonstrated unilateral involvement, endoscopy and 
biopsy confirmed diagnosis. Resolution required improvement 
in neutropenia, as well as surgical debridement and antifungals. 
There is controversy over the benefits of antifungal prophylaxis 
in these patients (1556). One study found that patients with 
invasive zygomycosis infections were more likely to have sinus 
involvement and be on voriconazole prophylaxis than those 
patients who developed invasive aspergillus infections (1557). 
5.5.2.3. HIV
The prevalence of CRS in HIV infected adults ranges from 
12-14.5% (1558, 1559). The presence of sinusitis was not associated 
with an increased risk of death (1559). In adults with AIDS, there 
is a higher incidence of fever, postnasal discharge and more 
severe CT findings (1558). In a retrospective review of 471 HIV-
infected children, 7.8% had CRS and 6.5% had ARS. Lower CD4 
lymphocytes were seen in children with CRS, while those over 6 
years of age with ARS had higher CD4 counts. Children less than 
6 years old who were taking protease inhibitors presented with 
a higher prevalence of ARS (1560).
5.5.2.4. Diabetes Mellitus (DM)
Uncontrolled DM is among the leading causes of AIFRS in most 
series. AIFRS in DM patients may more commonly involve the 
orbit or sinuses and less commonly involve the CNS when 
compared to transplant patients (1548). Mortality appears to be 
higher in AIFRS associated with DM when compared to that 
associated with hematologic malignancies (1561). 
5.5.2.5. Diagnosis 
The diagnosis of AIFRS depends upon maintaining a high 
clinical suspicion in the immunocompromised patient 
population. Symptoms and radiographic findings can often be 
subtle, as these infections appear to begin in the nasal cavity 
(1562) and prompt biopsy is required to establish the diagnosis. 
Unilateral nasal cavity thickening has been reported as the most 
common finding in AIFRS (1563). The most sensitive imaging study 
for detecting early changes of AIFRS is extrasinus invasion on 
MRI (1564).
5.5.2.6. Treatment and outcomes
A retrospective review of 45 cases of AIFRS included patients 
with hematologic malignancy (28 patients), DM (10 patients), 
solid organ transplant (3 patients), chronic steroid use (3 
patients) and HIV (1 patient). The overall mortality was 18%. 
Twenty five percent of patients with hematologic malignancy 
died and had no recovery of their neutrophil count. Forty 
percent of DM patients died of AIFRS. The mortality rate for 
Mucor was 29% and for Aspergillus it was 11% (1561). AIFRS can 
be treated surgically with endoscopic or open approaches with 
similar outcomes. Overall survival in a retrospective review was 
57% in open surgery group (7 patients) and 47% in endoscopic 
group (19 patients) (260). Ruping (1565) reported on 41 patients 
with invasive zygomycosis, including those with malignancy 
(63%), DM (17%) and solid organ transplant (9.8%). Sites of 
infection included the lungs (58%), soft tissues (19%), sino-
orbital region (19%), and CNS (15%). Overall survival was 51%. 
Antifungal prophylaxis did not prevent development of invasive 
zygomycosis, however, treatment with liposomal amphotericin 
Evidence based recommendations
Statement Grade of Recom-
mendation
Among tertiary CRS patients who undergo im-
mune evaluation, a variety of PIDs are common 
C
Among PID patients, clinical symptoms of CRS 
are found in approximately half
C
PID patients often have CT findings consistent 
with CRS
C
IVIG therapies improve survival and decrease 
serious infections in PID patients, but do not 
provide clinical benefit, prevent radiographic 
development of CRS or decrease bacterial culture 
rate from the sinuses
C
Screening CTs in asymptomatic patients prior to 
solid organ transplant or HSCT are not indicated
C
Successful treatment of AIFRS involves surgery, 
antifungal therapy and reversal of the immune 
compromised state
C
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B was associated with improved response and survival. Early 
detection and reversal of the underlying disease process 
and immunosuppression is as important as the surgical and 
antifungal therapies (1566)..
5.5.2.7. Fungus ball
 In addition to AIFRS, immunocompromised patients can 
develop non-invasive fungus balls that present differently than 
fungus balls in immunocompetent patients (1567). In a retrospec-
tive review of 24 patients, 11 of 24 had some degree of im-
munocompromise. These immunocompromised patients (organ 
transplant or DM) were more likely to have aspergillus and 
non-dilated sinus ostia.
5.6. Allergic fungal rhinosinusitis
5.6.1. Introduction
There is much debate regarding the role of fungi in CRSwNP 
and whether the diagnostic group of AFRS truly represents a 
unique disease. In spite of our limited knowledge regarding 
the pathophysiology of CRSwNP, there is a subset of patients 
as defined by the classic Bent-Kuhn criteria for AFRS who 
demonstrate some phenotypic differences when compared to 
other CRSwNP patients. The original Bent-Kuhn diagnostic criteria 
(721) consist of the following: 
1) Nasal polyposis, 
2) Fungi on staining, 
3) Eosinophilic mucin without fungal invasion into sinus tissue, 
4) Type I hypersensitivity to fungi and 
5) Characteristic radiological findings with soft tissue differential 
densities on CT scanning. 
Although used widely since their inception, many of these 
criteria are not unique to AFRS patients. All CRSwNP patients 
have nasal polyposis by definition, with a large proportion of 
them also demonstrating eosinophilic mucin without fungal 
invasion. Furthermore, as fungal detection techniques improve, 
so does the sensitivity to detect them, with some studies 
demonstrating fungal presence in almost 100% of patients, both 
controls and CRS patients (592, 1568). Consequently it appears that 
type I hypersensitivity and characteristic CT findings are the only 
unique factors in Bent and Kuhn’s criteria for AFRS that allow it be 
distinguished from other forms of sinus disease. Subsequently, 
a number of authors have found other factors particular to 
AFRS. Demographically, AFRS patients are younger, more likely 
to be African American and present with more significant bone 
erosion/expansion than other CRSwNP patients (728,1569,1570). 
While some have reported immunologic differences, with AFRS 
demonstrating increased mean serum total IgE and IgG anti-
Alternaria antibodies when compared to CRSwNP (723), this has not 
been conclusively demonstrated as others report no significant 
differences (727-729, 1571). Many questions remain unanswered: 
Are there any significant underlying immunologic differences 
between AFRS and other forms of CRSwNP? What is the relevance 
of fungi or fungal specific IgE to the pathophysiology of AFRS? Do 
these factors truly play a role in the immunologic response or are 
they simply a defining marker of the disease state?
5.6.2. Medical therapy
Most reports on treatment options for AFRS are combined 
into larger series addressing CRSwNP patients and this issue is 
covered elsewhere in this document. It is therefore difficult to 
discern if there are varying effects in the AFRS population as 
opposed to the entire CRSwNP population. In general, medical 
therapies have been divided into oral and topical steroids, 
oral and topical anti-fungals, leukotriene antagonists and 
immunotherapy. In all but the mildest cases of AFRS, it is felt 
that medical therapy alone without surgical intervention, is not 
effective in the long term, thus most efficacy studies examining 
medical treatments have been performed post operatively.
5.6.2.1. Oral steroids
Oral steroid studies specific to AFRS patients have generally 
been conducted in the postoperative setting where benefit 
has been demonstrated. In a prospective, randomized double-
blinded, placebo-controlled (DBPC) trial in AFRS patients 
examining the effectiveness of postoperative oral steroids, as 
well as the side effects of such treatments, patients received 
oral prednisolone (50 mg qd x 6 weeks, then additional 6 week 
taper) or placebo for two weeks after surgery (1572).  All patients 
received fluticasone nasal spray and oral itraconazole for 12 
weeks. At 12 week follow up, symptoms and endoscopy were 
improved in the oral steroid group. All 12 patients in the steroid 
group suffered from weight gain, 5 developed Cushinoid 
features, 2 developed acne and 1 developed steroid induced 
diabetes mellitus. At 18 months of follow up, patients who 
stopped all treatment, including topical steroids, developed 
recurrent disease. It is unclear if postoperative oral steroids for 
12 weeks had an impact at 18 months.
A number of other non-placebo controlled case series have 
been reported with highly variable dosing protocols and 
durations, but generally reporting a positive effect when using 
postoperative oral steroids (1573-1578)..
5.6.2.2. Topical steroids
It does not appear that prospective studies on the effects 
of topical steroids alone have been conducted in the AFRS 
population. A case controlled study of surgery alone vs. surgery 
plus the combination of postoperative oral and topical steroid 
spray in AFRS patients demonstrated benefits of the combined 
therapy at a minimum of 2 year follow up, as 50% of the no 
steroid group recurred, while only 15% of the combined steroid 
group recurred (1579)..
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5.6.2.3. Subcutaneous Immunotherapy (SCIT)
SCIT may have efficacy in the short term (3-4 years), however, 
its long-term efficacy is unclear. Fortunately, there are a number 
of reports of both high dose and low dose subcutaneous 
immunotherapy that have all demonstrated safety (1580).
A large retrospective, series reported that compliance with 
immunotherapy for all fungal and non-fungal antigens was 
beneficial in preventing recurrence of disease. A 3-4 year 
course of subcutaneous immunotherapy (SCIT) demonstrated 
benefit 12-26 months after discontinuation (1581) and prolonged 
courses of systemic steroids were not used in these patients (1582).
However a subsequent study by the same group on a smaller 
subset of patients with longer term follow up ranging from 46 to 
138 months failed to demonstrate any benefit of SCIT with 60% 
of SCIT patients having normal mucosa or only mild oedema 
on endoscopy, while 100% of non-SCIT patients having normal 
mucosa or mild oedema (1583). This study was not randomized 
and obviously has the potential for bias in selecting treatment 
arms.
5.6.2. 4. Anti-fungal therapy
It is unclear if such therapies have a differing effect in the 
AFRS subset of patients. Limited non-placebo controlled case 
series have reported benefits of systemic anti-fungal therapies 
in patients with AFRS (28, 1584). This is in contrast to a Cochrane 
review of topical and systemic anti-fungal therapies in all CRS 
patients, which failed to demonstrate any benefit (1585).
5.6.2.5. Leukotriene antagonist
One case report of improvement on leukotriene antagonist 
therapy has been reported (1586).
5.6.2.6. Manuka honey
A randomized, single-blind, prospective study of AFRS patients, 
who failed surgery and maximal postoperative medical 
management, used Manuka honey in one nostril. Overall, the 
group failed to demonstrate improvement (1587)..
5.6.2.7. Surgical therapy
Most clinical series describe surgical therapy to remove polyps 
and eosinophilic fungal mucin followed by aggressive medical 
therapies described above. Generally from the literature it 
appears that surgery both alone and in combination with other 
medical treatments leads to improved outcomes.
A retrospective review reported that incomplete removal of all 
fungal and eosinophilic mucin contributed to disease recurrence 
and the need for revision surgery (1588)..
Champagne et al. (1589) demonstrated that in AFRS patients, 
African American patients had higher CT and endoscopy scores, 
but similar SNOT20 scores. At 12 months postoperatively, 
SNOT20 and endoscopy scores improved in all patient groups 
with significantly greater improvement in women. In this series, 
all patients were treated postoperatively with saline irrigations, 
topical nasal steroid spray, oral antibiotics and a one-month 
oral steroid taper. Their maintenance treatment consisted 
of topical nasal steroid spray, nasal saline, montelukast, 
budesonide irrigations and month long bursts of oral steroids 
for exacerbations. Thus it is difficult to isolate the impact of 
surgery alone.
The placebo arm of the Rupa study (1572) was treated with nasal 
steroid spray and oral itraconazole during the postoperative 
period. At 6 weeks, 5 of 12 patients had endoscopic recurrence 
of their disease severe enough to withdraw from the study. At 
12 weeks, 4 of the remaining 7 patients had complete or partial 
relief of symptoms with only 1 of those patients having normal 
endoscopy, thus their recurrence rate at 12 weeks with surgery 
plus nasal steroids and oral intraconazole was 11/12 (92%). The 
recurrence rate in the placebo arm of the Ikram study that did 
not receive oral or topical steroids (1579) was lower at 50% at 2 
years. Overall recurrence rates after surgery has been reported 
from 10% to 100% (1590).
5.7. Paediatric Chronic Rhinosinusitis
5.7.1. Summary
CRS in children is not as well studied as the same entity in 
adults. Multiple factors contribute to the disease including 
bacteriologic and inflammatory factors. The adenoids are a 
prominent contributor to this entity in the pediatric age group. 
The mainstay of therapy is medical with surgical therapy 
reserved for the minority of patients who do not respond to 
medical treatment.
Evidence based recommendations
Statement Grade of Recom-
mendation
AFRS demonstrates immunologic differences 
when compared to CRSwNP
D (conflicting 
reports)
AFRS demonstrates clinical differences when 
compared to CRSwNP
C
Oral steroids lead to short term postoperative 
improvement in symptoms and endoscopy in 
AFRS, but can have significant side effects
A
SCIT improves short term outcomes in AFRS, but 
long term benefits are unclear
C
Anti-fungal therapy improves outcomes in AFRS D
Surgery with postoperative medical therapy 
improves AFRS outcomes
C
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5.7.2. Classification and Diagnosis  
CRS in children is defined similar to adults as an inflammation 
of the nose and the paranasal sinuses characterized by two or 
more symptoms, one of which should be either nasal blockage/
obstruction/congestion or nasal discharge (anterior/posterior 
nasal drip):
± facial pain/pressure, 
± cough;
and either endoscopic signs of disease and/or relevant changes 
on the CT scan of the sinus. 
The clinical diagnosis of CRS in children is challenging related 
to the overlap of symptoms with other common childhood 
nasal diseases such as viral upper respiratory tract infections, 
adenoid hypertrophy/adenoiditis and allergic rhinitis as 
well as the challenges related to physical examination.  The 
EPOS2012 group felt that it was impossible to differentiate 
CRS from adenoid hypertrophy/adenoiditis in young children.  
Furthermore, studies examining the incidence of abnormalities 
in the paranasal sinuses on CT scans obtained for clinical reasons 
not related to CRS in children have shown a percentage of sinus 
radiographic abnormalities ranging from 18% (1591) to 45% (1592) 
with one study actually showing a Lund McKay score average 
of 2.8 in a similar pediatric population without symptoms 
of rhinosinusitis (1593).  It has also been suggested that only a 
Lund-Mackay score over 5 is indicative for CRS in children (1594). 
Adding to the challenge in making the diagnosis is the fact that 
symptoms consistent with the diagnosis of CRS such as purulent 
rhinorrhea and cough are very common in the pediatric age 
group, and the symptoms of CRS are often subtle and the 
history is limited to the observations and subjective evaluation 
by the child’s parent.  Because some younger children might not 
tolerate nasal endoscopy, clinicians are sometimes hindered in 
their physical examination and have to rely on history and or 
imaging studies for appropriate diagnosis. 
Studies examining clinical characteristics of pediatric patients 
with CRS suggest that the four most common clinical symptoms 
are cough, rhinorrhea, nasal congestion, and post nasal drip 
with a slightly higher predominance of chronic cough (527, 1595). 
Tatli et al found that 66% of children undergoing evaluation 
for chronic cough (>4 weeks duration, excluding recent upper 
respiratory tract infections) had CT scan abnormalities in the 
paranasal sinuses which were mild in 14%, moderate in 19%, 
and severe in 33% of the patients (480). In those children, the 
most frequent symptoms reported, other than cough, included 
rhinorrhea, sniffling, and halitosis.
A thorough history of the timing of symptoms is critical to 
attempt to understand the category of disease that best applies 
to each patient.  A very common clinical scenario in children 
presenting to the otorhinolaryngologist’s office is that of chronic 
rhinosinusitis with upper respiratory tract infection-induced 
acute exacerbations.  In this document, we characterize CRS as 
symptoms lasting 12 weeks or longer without symptom free 
periods.  
5.7.3. Prevalence 
 The exact prevalence of chronic rhinosinusitis (CRS) in children 
is difficult to determine as only a small percentage of cases 
present to the physician’s office. Many studies that address 
prevalence have been performed in select populations typically 
in children who have upper respiratory complaints. In one such 
study, CT scans were obtained in 196 children 3-14 years of 
age presenting with chronic rhinorrhoea, nasal congestion and 
cough (1596). Maxillary involvement was noted in 63%, ethmoid 
involvement in 58% and sphenoidal sinus involvement in 29% 
of the children of the youngest age groups. The incidence 
of abnormalities decreased to 10% of the ethmoids, 0% of 
sphenoids, but 65% of the maxillaries being involved in the 
older, 13-14 year old, age group. In a prospective study, all new 
patients (ages 2-18 years) presenting to 2 allergy practices with 
upper respiratory tract symptoms for at least 3 months were 
investigated with a CT scan to determine sinus abnormalities 
(1597). In 91 eligible patients, 63% had chronic sinusitis with 
clinical signs and positive CT findings and 36% had no sinus 
disease. The best association between symptoms and CT scan 
abnormalities was noted when the symptoms of rhinorrhoea, 
cough, and the absence of sneezing were combined. 
Furthermore, age was the single most important risk factor 
associated with chronic sinusitis, with 73% of 2-6 year olds, and 
74% of 6-10 year olds having sinus CT abnormalities as opposed 
to the low incidence of sinus abnormalities detected in only 
38% of children over 10 years of age.
There are few studies that follow the prevalence over time and 
they suggest a decrease in the prevalence of rhinosinusitis after 
age 6-8 years (8 , 1598 , 1599). There is also evidence to suggest that 
children with a family history of atopy or asthma who attend 
daycare in the first year of life have 2.2 times higher odds of 
having doctor-diagnosed sinusitis than children who do not 
attend daycare (1600).
5.7.4. Effects on Quality of life
CRS has a negative impact on quality of life
CRS in children leads to impaired quality of life. In a study of 
children with recurrent and CRS failing medical treatment and 
requiring surgical intervention, Cunningham and colleagues 
administered generic parental and childhood quality of life 
questionnaires (1601). The results showed significant impairment 
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of the quality of life of these children and, surprisingly, 
significantly lower quality of life scores than that of children 
with other common chronic childhood diseases such as asthma, 
attention deficit hyperactivity disorder, juvenile rheumatoid 
arthritis, and epilepsy. The differences were most marked in the 
physical domains of the quality of life questionnaires such as 
bodily pain and limitation in physical activity. The SN-5 survey, a 
disease specific tool was validated as a measure of change over 
time in sinonasal symptoms (1602). It consists of 5 domains, which 
include sinus infection, nasal obstruction, allergy symptoms, 
medication use, emotional distress, and activity limitations, and 
is filled by the parents reflective of the previous 4 weeks. The 
survey’s reproducibility, validity, and responsiveness to change 
was ascertained in a study of 85 children aged 2-12 years 
suffering from sinonasal symptoms for 1 month or longer, and it 
has been shown to correlate with CT scan scores in patients with 
CRS suggesting that it can be used as a substitute for repeated 
CT scans in clinical follow up (1603). There is also limited evidence 
showing improvement of quality of life (using the SN-5 tool) in 
patients with CRS after surgical intervention (adenoidectomy or 
endoscopic sinus surgery) (1604). 
5.7.5. Anatomical factors 
It is not clear whether anatomic abnormalities 
have any contribution to CRS in children
Similar to adults, the ostiomeatal complex (OMC) is believed 
to be the critical anatomic structure in rhinosinusitis and is 
entirely present, though not at full size, in newborns. Changes 
occurring in the anterior ethmoids are known to impair drainage 
through the OMC, resulting in chronic maxillary sinusitis and, 
occasionally, frontal sinusitis. Sivalsi et al studied the anatomical 
variations of the paranasal sinuses in paediatric patients 
with CRS (1605). A pneumatized middle concha was the most 
common anatomic variation, followed by pneumatisation of the 
superior concha, Haller cell, and agger nasi cell. Compared with 
adults, nasal septal deformities tended to be less common. In 
another study, Al-Qudah examined the CT scans of 65 children 
with persistent symptoms of CRS (>3months) after maximal 
medical treatment and identified anatomical abnormalities and 
correlated those to extent of disease in the paranasal sinuses 
(1606). In his population, the most common abnormality was 
an agger nasi cell, followed by concha bullosa, paradoxical 
middle turbinate and Haller’s cell. In addition to listing the 
abnormalities, this study actually performed correlation 
analyses between the anatomical abnormalities and the extent 
of sinusitis and found no significant correlation. The limitation of 
both studies is that they did not include a control group without 
rhinosinusitis making it difficult to assess the importance of 
these changes in the genesis of chronic sinus inflammation. 
Actually, the second study  and studies in adults suggest that 
despite the common occurrence of these anatomical factors, 
they do not seem to correlate with the degree and existence of 
CRS. 
5.7.6. Pathophysiology
5.7.6.1. Bacteriology. 
The pathogens involved in CRS are difficult to identify due 
to low bacterial concentration rates, inconsistent data, and 
because most cultures are obtained at the time of surgery after 
patients have been treated with antibiotic therapy. Muntz and 
Lusk reported bacteriologic findings in 105 children with CRS 
when they obtained cultures from the anterior ethmoid cell at 
the time of endoscopic sinus surgery (1607). The most common 
bacterial species recovered were alpha hemolytic streptococci 
and Staphylococcus aureus, followed by S. pneumoniae, H. 
influenzae, and M. catarrhalis. Anaerobic organisms were 
grown from 6% of specimens. Brook et al also reported that 
the incidence of anaerobic organisms recovered increased 
with chronic infections (477). In 1981, his group obtained 
sinus cultures from 37 of 40 children with CRS and isolated 
anaerobic organisms from all specimens (1608). The most common 
organisms were anaerobic gram-positive cocci, followed by 
other anaerobic organisms including Bacteroides species and 
Fusobacteria. Aerobes were recovered in 38% of these cultures 
and included Streptococci, Staphylococci and few Hemophilus 
species. 
Hsin and colleagues performed maxillary sinus taps for irrigation 
in 165 children with symptoms of CRS for≥12 weeks and 
abnormal radiographs (1609). Of the 295 sinuses tapped, the most 
commonly isolated organisms were α-hemolytic Streptococcus 
(21%), Hemophilus influenza (20%), Streptococcus pneumonia 
(14%), coagulase negative Staphylococcus (13%), and 
Staphylococcus aureus (9%). Anaerobes were identified in 8% of 
the isolates. When examining the susceptibility of the organisms 
over time, an increase rate of resistance of Hemophilus influenza 
to ampicillin was noted. In a study evaluating the effect of 
the introduction of the heptavalent pneumococcal conjugate 
vaccine on the bacteriology of rhinosinusitis in children, McNeil 
and colleagues evaluated all cultures of the paranasal sinuses 
that yielded Streptococcus pneumonia at Texas Children’s 
hospital between 2007 and 2008 (1610). These were all obtained 
from children with the diagnosis of chronic or recurrent 
rhinosinusitis and out of the 24 cultures, 23 were non vaccine 
serotypes, with serotype 19A accounting for 50% of the isolates 
and exhibiting high rates of antimicrobial resistance. 
5.7.6.2. Biofilms 
Biofilms are complex aggregations of bacteria distinguished 
by a protective and adhesive matrix and have recently been 
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implicated in CRS. They form when planktonic bacteria 
adhere and coalesce to various surfaces via glycoconjugate 
moieties and form well organized ecosystems within the 
human host. These ecosystems are well suited for conditions 
of environmental stress and altered oxygen tension, and it is 
thought that 99% of bacteria exist in biofilm form. Biofilms 
are also characterized by surface attachment, structural 
heterogeneity, genetic diversity, complex community 
interactions, and an extracellular matrix of polymeric 
substances, which all contribute to their resistance to antibiotic 
treatment (1611). Intermittently, planktonic bacteria shed from 
the biofilm, migrate, and colonize other surfaces. It is therefore 
hypothesized that biofilms may provide a chronic reservoir for 
bacteria and may be responsible for the resistance to antibiotics 
seen in pediatric patients with CRS. Sanclement and colleagues 
evaluated sinus mucosa obtained at the time of surgery for CRS 
for the presence of biofilms and, in a mixed adult and pediatric 
population, demonstrated the presence of biofilms in 24 out 
of 30 (80%) specimens (1611). Although the existence of biofilms 
is now well documented in adults with rhinosinusitis, more 
research is needed to clearly characterize their contribution to 
the pathophysiology of CRS in children.
5.7.6.3. Role of adenoids 
The adenoids are in close proximity to the paranasal sinuses 
and adenoidectomy has been shown to be effective in resolving 
the symptoms in a proportion of children with CRS (see below). 
In an attempt to explain these findings, Zuliani et al. collected 
adenoid specimens obtained from children with CRS and 
obstructive sleep apnea and examined them for the presence 
of biofilms using electron microscopy (1612). They found that 
a large percentage (88-99%) of the mucosal surface area of 
all the specimens from children with CRS was covered with a 
dense biofilm. This was in contrast with the adenoids obtained 
from patients with sleep apnea where modest percentages (0-
6.5%) of the surface area were found to be covered by biofilm. 
Although the number of specimens in this study was small, the 
work provides a potential explanation for the improvement seen 
with adenoidectomy in antibiotic-resistant CRS. 
In a study comparing middle meatal swabs and adenoid core 
cultures in children with hypertrophied adenoids and chronic 
or recurrent sinusitis, Elwany and colleagues found that the 
bacteria were very similar in both locations and included 
coagulase-negative staphylococci, Staphylococcus aureus, 
Streptococcus pneumonia, Haemophilus influenza and group 
A streptococci (1613). They also found that adenoid core culture 
had a positive predictive value of 91.5 in forecasting the middle 
meatal culture results and a negative predictive value of 84.3, 
suggesting that the bacterial reservoir in the adenoids mirrors 
the bacteriology isolated close to the paranasal sinuses in these 
children. Another line of evidence to support the role of the 
adenoids as a bacterial reservoir in CRS in children comes from 
the observation that bacterial isolation rates from adenoids of 
children undergoing adenoidectomy increased significantly 
according to sinusitis grade on radiographs (1614). This was 
especially true of Hemophilus influenza and Streptococcus 
pneumonia. In contrast, children with nasal discharge who had 
a CT scan of the sinuses and underwent adenoidectomy were 
investigated and the results showed no correlation between 
the size of the adenoids and the severity of disease on CT scan 
as gauged by the Lund McKay score (1615). This suggests that the 
nasal discharge could be due to adenoiditis alone and that the 
bacterial reservoir of the adenoids more than their size was 
important in the relationship between CRS and the adenoids.
There is also some evidence that supports a contribution of the 
adenoids as an immunological organ in children with CRS. One 
study compared immunoglobulin expression in adenoid tissues 
of patients with adenoid hyperplasia compared to those with 
CRS and showed a significantly lower expression of IgA in the 
adenoids of children with CRS with no difference in expression 
of the other immunoglobulins (1616). This could suggest that 
the adenoids of patients with CRS are not able to mount the 
local immune response expected of them. Obviously whether 
this is a primary or secondary occurrence (related to chronic 
infection) cannot be elucidated from this study which only 
evaluated adenoids at one point in time. Shin and colleagues 
examined adenoids obtained from children with and without 
CRS and showed higher levels of tissue-remodeling cytokines, 
transforming growh factor TGF-β1, matrix metalloprotease 
MMP-2, MMP-9, and tissue inhibitor of metalloprotease TIMP-1 
in the CRS patients, again supporting a relationship between the 
adenoids and the status of the sinuses in children with CRS (1617).
In summary, data related to the role of adenoids in CRS is 
emerging but the studies are small and mostly evaluate the 
adenoids after their removal from the site. They do suggest 
a role for the adenoids in patients with CRS, both from a 
bacteriologic and immunologic perspective. Most of these 
studies however, do not really shed light on the relative 
contribution of adenoiditis proper vs CRS in chronic nasal 
symptomatology in children.
5.7.6.4. Cellular Studies
Studies of the cellular response in pediatric CRS indicate that 
eosinophils and CD4+ lymphocytes play a significant role in 
tissue inflammation. Baroody and colleagues found higher 
numbers of eosinophils in the sinus mucosa of older children 
(Median age = 7 years, range: 3-16 years) obtained at the time 
of surgery for CRS as compared to sphenoid sinus mucosal 
specimens of adults with no previous history of sinusitis (1618). 
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The inflammatory reaction in the sinus tissues 
of children with CRS is rich in lymphocytes and 
exhibits less eosinophilia and epithelial disruption 
compared to adults 
Lymphocytes, particularly the CD4+ population, were also 
increased in the sinus mucosa of children with CRS irrespective 
of allergic status (1619). In similar studies performed in younger 
children with CRS (median age= 3.9 yrs) Chan and colleagues 
compared maxillary sinus biopsies from these children to 
archival adult maxillary sinus tissues (1620). The pediatric mucosa 
had more neutrophils, and significantly more lymphocytes, 
while the adult mucosa was richer in eosinophils and major 
basic protein positive cells. They also noted less epithelial 
disruption and thickening of the basement membrane in 
children compared to the adults. In a similar study using 
immunohistochemistry to evaluate different inflammatory 
cells, the same group showed higher numbers of CD8+ cells, 
neutrophils, macrophages, B lymphocytes, and plasma cells 
in younger children with CRS compared to adults (1621). In a 
similar study, Berger and colleagues compared sinus specimens 
obtained from children with CRS to tissues obtained from 
adults (1622). The children were older (mean age=11.6±2.9 years) 
and their tissues had fewer eosinophils and lesser epithelial 
disruption than the adult specimens. There were large numbers 
of T lymphocytes, and extensive fibrosis in the lamina propria 
in half the specimens, findings comparable to the adult 
specimens. In children with nasal polyps, vascular endothelial 
growth factor-expressing cells and intra-polyp blood-vessel 
density were higher in polyp specimens as compared to the 
chronically inflamed tissue of children without nasal polyposis 
(1008). In general these limited studies suggest fewer eosinophils 
and less epithelial disruption in the tissues of children with CRS 
compared to their adult counterparts. 
5.7.7. Comorbid Diseases
5.7.7.1. Allergic Rhinitis 
Allergic rhinitis is a common coexisting disease in pediatric 
patients with CRS. The data about the association between the 
2 diseases in children is variable. In a series of 42 patients with 
CRS refractory to medical treatment on which a RAST test as 
well as a CT scan was available, 40% of the patients were atopic 
and 60% were nonatopic (1623). In the same study, patients with 
a positive RAST test were found to have a significantly higher 
CT score compared to the patients with negative RAST testing. 
While this study supports the relationship of a positive allergy 
test to CRS, the population was mixed children and adults with a 
mean age of 28 years and a range from 2-61 years. In a study of 
100 children with a clinical diagnosis of sinusitis and abnormal 
plain sinus radiographs in Thailand, the authors report a positive 
skin test to common aeroallergens in 53% of the patients again 
suggesting a correlation between the 2 diseases (1624). 
In contrast, a study from Belgium evaluated CT scans from 
allergic children and adults and noted the presence of sinus 
opacification in 61% of allergic children and 58% of adults (1625). 
This data was compared to previous studies of nonallergic 
children and adults showing the incidence of sinusitis 
changes on CT to be similar (64% in children and 57.5% in 
adults) suggesting the lack of an important role of allergy 
in sinus abnormalities on CT scan. In their study of children 
with chronic respiratory symptoms who underwent allergy 
evaluation and CT scanning, Nguyen and colleagues found no 
correlation between atopic status and sinus abnormality and 
the prevalence of sinus disease was essentially similar in the 
atopic patients (63%) versus the nonatopics (75%) (1597). Finally, 
a more recent study showed positive allergy tests in 30% of 
351 Italian children with CRS, a prevalence that was not much 
different than that of allergy in the general population (32%) 
(1626).  When age was examined, the incidence of positive allergy 
testing was significantly higher in children older than 6 years 
as compared to those younger than 3 years of age. Thus the 
causal relationship between allergies and CRS in children is still 
controversial but probably non-existent. 
5.7.7.2. Asthma 
Asthma is another disease that is commonly associated with 
CRS in the pediatric age group. Rachelefsky and colleagues 
reported on treatment outcomes in 48 nonrandomized children 
with moderate to severe asthma and co-morbid CRS (1627). After 
pharmacologic or surgical intervention for sinusitis, 80% of 
these children were able to discontinue asthma medications. 
Furthermore, asthma recurred when sinusitis subsequently 
relapsed. In another study, Tosca and colleagues identified 18 
children, 5-12 yrs of age, with poorly controlled asthma and 
co-morbid CRS (1628). The patients were treated for 14 days with 
antibiotics, intranasal and systemic steroids, and were evaluated 
at baseline, after treatment, and 1 month later. In addition to 
improvement in their nasal symptoms, patients had a significant 
improvement in spirometry, wheezing, and inflammatory 
markers in nasal lavage. These and other studies support 
the concept that clinical control of CRS may be important in 
optimizing the control of difficult-to-treat asthma. However, the 
limitations of most available studies include the lack of good 
controls or randomization to different treatment modalities and 
therefore, the relationship between CRS and asthma in children 
remains largely descriptive.
5.7.7.3. Gastroesophageal Reflux Disease (GERD)
GERD has also been associated with rhinosinusitis in several 
studies. Phipps et al conducted a prospective study of 30 
pediatric patients with chronic rhinosinusitis who underwent 
24-hour pH probe and found that 63% of children with CRS 
had GE reflux (1629). In addition, 79% of children experienced 
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improvement in rhinosinusitis symptoms after medical 
treatment of GERD. In a large case control study at Texas 
Children’s hospital, 1,980 children with gastroesophageal reflux 
disease and 7,920 controls (ages 2-18 yrs) were identified based 
on ICD-9 codes (1630). The number of cases with a concomitant 
diagnosis of sinusitis was significantly higher in the children 
with GERD (4.19%) compared to the control group (1.35%). 
Another retrospective study by Bothwell showed that treatment 
for GERD in patients with CRS (no placebo control) allowed 
many patients to improve and to obviate planned surgical 
procedures (1631). The differential diagnosis between GERD 
and post nasal drip can be difficult. Although some evidence 
supports an association between GERD and CRS, more 
controlled studies are required to strengthen this association 
and validate it and routine anti-reflux treatment of children with 
CRS is not warranted.
5.7.7.4. Immunodeficiency 
Shapiro et al prospectively evaluated the immune function 
of children referred to their offices over a 1-year period with 
recurrent rhinosinusitis despite maximal medical therapy (1632)..
Of 61 patients (2-13 yrs of age), 34 showed some abnormality 
in immune studies with depressed IgG3 levels and poor 
response to pneumococcal antigen 7 being most common. 
Sethi and colleagues reported the following immune deficits 
in 20 patients (ranging from 3 to 51 years) with recurrent/
chronic rhinosinusitis: isolated IgA and IgG1 deficiency, low 
immunoglobulin levels with poor response to pneumococcal 
vaccine, and low immunoglobulin levels with normal vaccine 
responses (1633). Costa Carvalho and colleagues evaluated the 
humoral immune response in 27 children (7-15 years) with 
chronic or recurrent sinusitis (292). One patient had IgA and 
IgG2 deficiency, and another had IgG3 deficiency. Eight and 
12 of 27 patients had IgG2 and IgG3 serum levels below 2.5th 
percentile, respectively and no patient had an abnormal 
response to vaccination. In an open label, pilot, study, Ramesh 
and colleagues treated 6 patients with CRS refractory to medical 
management with IVIG for 1 year and compared their response 
during treatment to the 1 year before therapy (1634). Treatment 
resulted in a decrease in antibiotic intake (183 to 84 days) and 
episodes of sinusitis (9 to 4 per year), and CT scans showed 
significant improvement. Based on the above evidence, it seems 
prudent to evaluate immune function in the child with chronic/
recurrent rhinosinusitis with an immunoglobulin quantitation 
and titers to tetanus and diphtheria as well as pneumococcal 
titers. If responses are abnormal, a repeat set of titers post 
pneumococcal vaccination is appropriate. 
5.7.7.5. Primary Ciliary Dyskinesia 
The normal movement of mucus by mucociliary transport 
toward the natural ostia of the sinuses and eventually to the 
nasopharynx can be disrupted by any ciliary dysfunction or 
mucosal inflammation. The most common cause of ciliary 
dysfunction is primary ciliary dyskinesia (PCD), an autosomal 
recessive disorder involving dysfunction of cilia and present in 
1 of 15,000 of the population (1635). Half the children with PCD 
also have situs inversus, bronchiectasis, and CRS and are known 
as Kartagener’s syndrome. The diagnosis should be suspected 
in a child with atypical asthma, bronchiectasis, chronic wet 
cough and mucus production, rhinosinusitis, chronic and 
severe otitis media (especially with chronic drainage in children 
with ear tubes) (8). Screening tests for PCD include nasal nitric 
oxide (lower levels than controls) and in vivo tests such as the 
saccharin test, which documents slower mucociliary transit time. 
Specific diagnosis requires examination of cilia by light and 
electron microscopy, which is usually available in specialized 
centers. The most commonly described structural abnormality 
involves lack of outer dynein arms, or a combined lack of both 
inner and outer dynein arms (86). Contrary to some thoughts that 
the prolonged inflammation associated with PCD would lead to 
nasal polyposis in adults, a review of 30 children with PCD in one 
center showed none with nasal polyposis despite the fact that 
the children were debilitated by CRS as documented by SNOT-
20 scores (1636).
5.7.7.6. Cystic fibrosis
Cystic fibrosis is a genetic disease with autosomal recessive 
inheritance that affects approximately 1 in 3500 newborns. It 
is caused by a mutation in the CFTR gene on chromosome 7, 
which leads to disruption in cAMP-mediated chloride secretion 
in epithelial cells and exocrine glands. This leads to increased 
viscosity of secretions resulting in bronchiectasis, pancreatic 
insufficiency, CRS and nasal polyposis. The prevalence of chronic 
sinusitis is very high and nasal polyps occur in between 7 and 
50 % of affected patients (1450, 1637). In fact, this is one of the few 
causes of nasal polyposis in children. A lengthier discussion of 
this disorder is presented in the chapter devoted to this entity.
5.7.8. Diagnostic Workup
A complete physical exam should follow a carefully obtained 
medical and family history.  The nasal exam in children should 
begin with anterior rhinoscopy examining the middle meatus, 
inferior turbinates, mucosal character and presence of purulent 
drainage.  This is often feasible in younger children using 
the larger speculum of the otoscope.  Topical decongestion 
may improve visualization but may not always be tolerated 
in younger children.  Nasal endoscopy which will allow 
superior visualization of the middle meatus, adenoid bed 
and nasopharynx is strongly recommended in children who 
are able to tolerate the examination.  An oral cavity exam 
may reveal purulent drainage, cobblestoning of the posterior 
pharyngeal wall, or tonsillar hypertrophy.  The finding of nasal 
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polyps in children is unusual and, if seen on exam, should 
raise the suspicion for cystic fibrosis or allergic fungal sinusitis.  
Although there is no supportive data, nasal polyps might be 
more common in children than previously appreciated as 
evidenced by a report from Taiwan (1008) and anecdotal personal 
communications from Europe.  Obviously, antrochoanal polyps 
occur in children but those are usually unilateral and the rest of 
the sinuses are clear, which would help differentiate that entity 
from CF or bilateral nasal polyposis.  Allergic fungal sinusitis also 
presents with a rather unique clinical picture which includes 
expansile nasal polyps and characteristic CT and MRI findings 
(1638). 
Following the history and physical examination, appropriate 
diagnostic tests should be considered.  Allergy skin testing or 
serologic testing should be considered in children with CRS. 
Immunodeficiency testing should be pursued in children 
with recurrent or chronic disease, poor response to medical 
treatment, history of other infectious diseases (such as recurrent 
pneumonia or otitis media) or when unusual organisms are 
cultured from the sinus contents. 
In patients who have not responded to conventional medical 
treatment, obtaining a culture may be useful in directing 
further therapy.  In children, data regarding the usefulness of 
this approach are limited.  Orobello and colleagues cultured 
the middle meatus at the time of endoscopic sinus surgery 
in children with chronic rhinosinusitis and then obtained 
cultures from the maxillary antrum and the ethmoids during 
the procedure (1639). They reported a strong association between 
cultures of the middle meatus and cultures of the maxillary 
(83%) and ethmoid sinuses (80%).  In a recent study, Hsin and 
colleagues obtained middle meatal cultures and maxillary 
sinus aspirates under general anesthesia from children 
with rhinosinusitis unresponsive to medical treatment (1640). 
Endoscopic sampling provided a sensitivity of 75%, a specificity 
of 88.9%, a positive predictive value of 96%, a negative 
predictive value of 50%, and an accuracy of 50%, making it a 
little less favorable compared to results from adult studies.  In a 
more recent study by the same group, the correlation between 
maxillary sinus taps and middle meatal cultures improved 
when the middle meatal sample was obtained by suction 
aspiration (correlation 87%) as opposed to swabs (correlation 
66%) (1609).  We reserve this technique for the older children who 
have a complicated course and who are likely to tolerate rigid 
endoscopy in the office setting.  If general anesthesia is needed, 
one should revert to the gold standard, which is obtaining 
a culture from the maxillary sinus itself by antral puncture, 
a technique that also allows the potential benefit of sinus 
irrigation.
Interdisciplinary consultations are useful in evaluating the 
pediatric patient with medically refractory disease. Consultants 
may include those in the disciplines of allergy-immunology, 
infectious disease, pulmonary or genetics to aid in further 
workup.  
Not any CT scan abnormality indicates relevant 
clinical CRS in children
While the diagnosis of chronic rhinosinusitis in the pediatric 
population is generally made on clinical grounds, computed 
tomography (CT) is the imaging modality of choice (279). Findings 
on plain radiographs have been shown not to correlate well 
with those from CT scans in the context of chronic/recurrent 
sinus disease (281). In a prospective study where children with 
chronic sinus symptoms were imaged using both modalities, 
the findings on plain radiographs did not correlate with those 
on CT scans in 75% of the 70 patients studied (281). About 45% 
of the patients had normal findings on plain radiographs of 
at least one sinus with an abnormality of that sinus shown on 
CT scan, and almost 35% of the patients had an abnormality 
of at least one sinus on plain radiographs but that sinus was 
normal on CT scan.  Thus, the most useful modality for the 
diagnosis of rhinosinusitis in children is the CT scan.  A recent 
study compared CT scans obtained in 66 patients (mean age 8 
years) satisfying the clinical criteria of CRS to those obtained in 
a group of 192 control children (mean age 9 years) for non-
sinusitis reasons (1594). The scans were graded using the Lund-
Mackay system and the analysis showed that adopting a Lund 
cutoff score for diseased vs nondiseased patients of 5 offers 
a sensitivity and specificity of 86% and 85% respectively in 
making an appropriate diagnosis.  Lund scores of 2 or less, have 
an excellent negative predictive value, whereas scores of 5 or 
more have an excellent positive predictive value. 
In uncomplicated CRS, scanning is reserved to evaluate for 
residual disease and anatomic abnormalities after maximal 
medical therapy.  Abnormalities in the CT scan are assessed in 
the context of their severity and correlation with the clinical 
picture and guide the plan for further management which 
might include surgical intervention.  In children with the clinical 
diagnosis of rhinosinusitis, the most commonly involved sinus is 
the maxillary sinus (99%) followed by the ethmoid sinus (91%) 
(1595). Magnetic resonance (MR) imaging of the sinuses, orbits, 
and brain should be performed whenever complications of 
rhinosinusitis are suspected.    
Adenoidectomy is successful in improving CRS 
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in 50% of operated children. Whether this is due 
to the fact that the symptoms were related to 
adenoiditis per se or to the elimination of the 
contribution of the adenoids to sinus disease
 is not clear
CT scans provide an anatomic road map for surgical treatment 
and are also useful for identifying areas of bony erosion or 
attenuation (1641).  Two examples of sinonasal diseases with 
characteristic radiologic appearances are allergic fungal 
sinusitis (AFS) and cystic fibrosis.  In AFS, expansile disease may 
attenuate the bony skull base or orbital wall on CT.  In addition, 
a speckled pattern of high attenuation (“starry sky”) on both soft 
tissue and bone window settings correlates with the presence 
of thick allergic mucin and associated calcifications that may be 
noted intra-operatively.  MRI T1 images show low signal in areas 
of fungal mucin, and T2 images show central signal void in areas 
of fungal mucin with high signal in peripheral inflamed mucosa 
(1638).  In patients with cystic fibrosis, CT scans characteristically 
demonstrate pan-opacification of the sinuses and medial 
displacement of the lateral nasal wall, which may obstruct the 
nasal passages (1642)..
Finally, it has to be emphasized that the physical exam and 
history alone do not help in differentiating between adenoiditis 
and CRS, especially in the younger child.  As detailed above a 
high Lund-Mackay score on the CT scan (>5) might be more 
suggestive of CRS than adenoiditis but further studies are clearly 
required to help distinguish these 2 entities.
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In this chapter a differentiation is made between CRSsNP 
and CRSwNP. Readers have to realize that often in studies no 
clear difference is made between these two patients groups. 
Sometimes for this reason studies are discussed in both the 
parts on CRSsNP as the parts of CRSwNP. 
6.1.  Treatment of CRSsNP with
corticosteroids
6.1.1. Introduction
The introduction of topically administered glucocorticoids 
has improved the treatment of upper (rhinitis, nasal polyps) 
and lower (asthma) airway inflammatory disease. The clinical 
efficacy of glucocorticoids may depend in part on their ability 
to reduce airway eosinophil infiltration by preventing their 
increased viability and activation. Both topical and systemic 
glucocorticoids may affect the eosinophil function by both 
directly reducing eosinophil viability and activation (899, 1643-1645) 
or indirectly reducing the secretion of chemotactic cytokines by 
nasal mucosa and polyp epithelial cells (1646-1649). The biological 
action of glucocorticoids is mediated through activation of 
intracellular glucocorticoid receptors (GR) (1650, 1651) expressed 
in many tissues and cells (1652). Two human isoforms of GR have 
been identified, GRα and GRβ, which originate from the same 
gene by alternative splicing of the GR primary transcript (1653). 
Upon hormone binding, GRα enhances anti-inflammatory or 
6.  Management, reasons for failure of medical and 
surgical therapy in Chronic Rhinosinusitis
Figure 6.1.1
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represses pro-inflammatory gene transcription, and exerts most 
of the anti-inflammatory effects of glucocorticoids through 
protein-protein interactions between GR and transcription 
factors, such as AP-1 and NF-κB. The GRβ isoform does not 
bind steroids but may interfere with the GR function. There 
may be several mechanisms accounting for the resistance to 
the anti-inflammatory effects of glucocorticoids, including an 
overexpression of GRβ or a down-expression of GRα. Increased 
expression of GRβ has been reported in patients with nasal 
polyps (1654, 1655) while down-regulation of GR levels after 
treatment with glucocorticoids (1656, 1657) has also been postulated 
to be one of the possible explanations for the secondary 
glucocorticoid resistance phenomenon.
The ability of the drug to reach the appropriate anatomic 
region on the para-nasal system has been the subject of much 
research in the past 5 years. While systemic delivery is available, 
effective topical therapy relies on several factors. Delivery 
technique, surgical state of the sinus cavity, delivery device and 
fluid dynamics (volume, pressure, position) have a significant 
impact on the delivery of topical therapies to the sinus mucosa. 
Distribution of topical solution to the unoperated sinuses is 
Table 6.1.1. Study characteristics of included publications on INCS in CRSsNP.
Study Study 
type
Participants (di-
agnostic criteria)
Number 
of partici-
pants 
Age 
(Mean)
Type of 
steroid
Steroid dose Sinus 
Surgery 
Status
Delivery 
method of 
steroid
Duration 
of treat-
ment 
(weeks)
Compari-
son 
Hansen 
2010 
(1823)
RCT CRSsNP (by 
symptoms, 
endoscopy and 
MRI
20 47,9 fluticasone 
propionate
400 mcg bid with 
sinus 
surgery
with 
Optinose 
device
12 placebo
Jorissen 
2009 
(1674)
RCT mixed CRS (by 
symptoms, en-
doscopy, CT)
99 47.4 mometa-
sone 
furoate
200 mcg bid with 
sinus 
surgery
spray 24 placebo
Furukido 
2005 
(1669)
RCT CRSsNP (by 
AAO-HNS)
25 53.7 betam-
ethasone
2ml solution 
(0.4 mg/ml) 
weekly  
without 
sinus 
surgery
through 
YAMIK 
nasal 
catheter
4 placebo
Dijkstra 
2004 
(1668)
RCT mixed CRS (by 
symptoms and 
CT)
162 41 fluticasone 
propionate
Arm1. 
400µg bid             
Arm2.800µg 
bid 
with 
sinus 
surgery
spray 52 placebo
Lund 
2004 
(1671)
RCT CRSsNP (by 
symptoms)
167 40.6 budeso-
nide
128 mcg bid without 
sinus 
surgery
spray 20 placebo
Giger 
2003 
(1676)
RCT allergic rhinitis 
or CRSsNP (by 
symptoms)
112 32.3 beclom-
ethasone 
dipropion-
ate
200 mcg bid without 
sinus 
surgery
spray 12 beclom-
etha-
sone 
dipro-
pionate 
400mcg 
od
Lavigne 
2002 
(1670)
RCT CRSsNP (by 
symptoms)
26 46 budeso-
nide
2ml solution 
(256 mcg) 
od  
with 
sinus 
surgery
through 
maxil-
lary sinus 
catheter
3 placebo
Parikh 
2001 
(1672)
RCT CRSsNP (by 
symptoms, 
endoscopy and 
CT)
29 46.6 fluticasone 
propionate
200 mcg bid mixed spray 16 placebo
Qvarn-
berg 
1992 (309)
RCT CRSsNP (by 
symptoms)
40 45.4 budeso-
nide
200mcg bid without 
sinus 
surgery
aerosol 12 placebo
Cuenant 
1986 
(1675)
RCT CRSsNP (by 
symptoms, 
endoscopy, 
radiograph and 
ventilometry)
60 39 tixocortol 
pivalate
5 ml 
solution of 
50mg 
without 
sinus 
surgery
through 
maxillary 
sinus cath-
eter (plus 
neomycin)
11/7 neomy-
cin only
Sykes 
1986 
(1673)
RCT CRSsNP (by 
symptoms)
50 not 
stated
dexam-
ethasone
20 mcg 
daily
without 
sinus 
surgery
spray 2 placebo
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limited (1658) and in the setting of CRS with mucosal oedema it 
is probably only in the order of <2% of total irrigation volume 
(1659). Nebulization is also ineffective with <3% sinus penetration 
(1660). A fundamentally held belief amongst those treating CRS 
patients is that Endoscopic sinus surgery  (ESS) improves the 
delivery of topical medications to the sino-nasal mucosa (1661, 
1662), yet only recent evidence exists to support this claim (1658, 1663). 
Endoscopic sinus surgery is essential to effectively allow topical 
distribution to the sinuses. The frontal and sphenoid sinus are 
essentially inaccessible prior to surgery (1658) and an ostial size 
of 4mm+ is required to even begin penetration to the maxillary 
sinus (1658).  For delivery, nebulizers poorly penetrate the sinuses 
even after maximal ESS (1664) and large volume squeeze bottles 
or passive flow devices appear to have the best efficacy post 
ESS (1658, 1661, 1662, 1664). Pre-surgery, the distribution to the sinuses 
is extremely limited regardless of device (1658, 1659, 1663) and sprays 
are the least effective of all (1658).  Post-surgery distribution 
is superior with high volume positive pressure devices (1658, 
1659, 1663). Simple low volume sprays and drops have very poor 
distribution and should be considered a nasal cavity treatment 
only, especially prior to ESS (1658).  Although multiple devices 
and head positions have been trialled, less than 50% of most 
low volume applications will reach even the middle meatus 
(1665). There is limited data on the exact volume required to allow 
complete distribution.  Higher volumes do appear to penetrate 
both maxillary and frontal sinus with good coverage starting 
at about 100ml (1666). The frontal and sphenoid sinuses are not 
accessed well by pressurized spray when compared to high 
volume devices such as squeeze bottles or neti pots (1658). Higher 
volume and positive pressure irrigation is likely to result in the 
best distribution from current research. 
The anti-inflammatory effect of corticosteroids could, 
Table 6.1.2. Summary of outcomes from included studies of INCS on CRSsNP (studies with positive symptom outcomes are shaded. No study had 
placebeo favoured over INCS).
Study Type of 
steroid
Steroid dose Delivery 
method of 
steroid
Compari-
son 
Patients report 
outcome measures 
(PROM) (scoring 
system and scale)
Summary PROM 
results
Endoscopic 
outcomes  (scor-
ing system and 
scale)
Summary 
endoscopic 
results
Hansen 
2010 (1823)
fluticasone 
propion-
ate
400 mcg bid with 
Optinose 
device
placebo symptom scores 
(3 symptoms; 0-3) 
total symptom VAS 
RSOM-3
favour steroid over 
placebo for com-
bined symptom-
score and nasal 
RSOM subscale
endoscopy 
scores (Lund-
Kennedy;0-2)
favours 
steroid
Jorissen 
2009 (1674)
mometa-
sone 
furoate
200 mcg bid spray placebo symptom VAS (5 
symptoms)
no difference  
(p=0.09)
1.endo-
scopic score (8 
variables;0-2) 
2.post-hoc 
combination 
endoscopic 
score (3 vari-
ables;0-2)
1.no dif-
ference 
(p=0.34) 
2.favor 
steroid 
(p=0.02)
Furukido 
2005 (1669)
betam-
ethasone
2ml solution 
(0.4 mg/ml) 
weekly  
through 
YAMIK 
nasal 
catheter
placebo symptom scores (4 
symptoms;0-3)
comparison not 
reported
nil nil
Dijkstra 
2004 (1668)
fluticasone 
propion-
ate
Arm1. 
400µg bid             
Arm2.800µg 
bid 
spray placebo symptom VAS (6 
symptoms)
not reported at the 
endpoint
polyp recur-
rence
no differ-
ence (p-
value not 
shown)
Lund 
2004 (1671)
budeso-
nide
128 mcg bid spray placebo 1. symptom scores 
(4 symptoms;0-3) 
2. overall efficacy 
(0-4) 3. disease-
specific quality of 
life (chronic sinusitis 
survey) 4. general 
health quality of life 
(SF-36)
1. favours steroid 
over placebo for 
all symptoms 
except facial pain 
and evening sense 
of smell 2. favour 
steroid  (p=0.015) 
3. no difference 4. 
favor steroid (p-
value not shown)
nil nil
Giger 
2003 (1676)
beclom-
ethasone 
dipropion-
ate
200 mcg bid spray beclom-
etha-
sone 
dipro-
pionate 
400mcg 
od
symptom scores (8 
symptoms;0-3)
no difference be-
tween 2 regimes 
(p-value not 
shown)
nil nil
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theoretically, be expected to benefit all forms of rhinosinusitis.  
Considering the abundance of publications on the use of 
corticosteroids in CRSsNP and CRSwNP, we present the findings 
from level 1 studies. Where no level 1 study exists, a summary of 
available evidence is presented. Data is presented separately on 
CRSsNP and CRSwNP along with local and systemic use.
6.1.2. Local corticosteroid (INCS) in CRSsNP 
The use of local intranasal corticosteroid (INCS) has been widely 
published for many years and the following summary is based 
on a systematic search and summary of level 1 or randomized 
controlled trials for the evidence of benefit for symptoms in 
treating CRSsNP with INCS. However, not all studies demonstrate 
a benefit and a subgroup analysis is performed to help elucidate 
the reasons for some authors findings benefit over others.
6.1.2.1. Inclusion criteria and exclusion criteria Local 
corticosteroid (INCS) in CRSsNP
Inclusion criteria
Participants in the trials have to be defined as having chronic 
rhinosinusitis (CRS) by either:
•	 European Position Paper on Rhinosinusitis and Nasal Polyps 
2007 (8); 
•	 or Rhinosinusitis Task Force Report (523) and its revision (1667); 
•	 or having chronic sino-nasal symptoms for longer than 12 
weeks.
 -  Trials which included participants of any age, who 
had any co-morbidity including asthma and aspirin 
sensitivity, were either allergic or non-allergic, and 
were followed for any duration.
 -  Trials which included participants with CRS both with 
and without polyps if the majority of participants were 
without polyps. If possible, we only extracted data for 
participants with CRS without polyps.
Exclusion criteria
•	  Patients defined by the study authors as having acute or 
recurrent-acute sinusitis.
•	  Patients defined by the study authors as having CRS with 
polyps or nasal polyposis.
•	  Patients had CRS both with and without polyps and the 
majority of participants had polyps.
6.1.2.2. Types of interventions Local corticosteroid 
(INCS) in CRSsNP
•	  Any dose of topical steroid versus placebo.
•	  Any dose of topical steroid versus no treatment.
•	  Any dose of topical steroid versus alternative topical steroid.
Fig. 6.1.2 a en b
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6.1.2.3. Flow chart
A total of 666 references from the searches: 541 of these were 
removed in first-level screening (i.e. removal of duplicates and 
clearly irrelevant references), leaving 125 references for further 
consideration. We subsequently found one additional trial from 
a manual search guided by the identified references. A flow 
chart of study retrieval and selection is provided as Figure 6.1.1. 
6.1.2.5. Included studies
Ten studies with a total of 590 patients met the inclusion criteria. 
The characteristics of included studies are listed as Table 6.1.1. 
6.1.2.6. Summary of data
There were 11 included studies. Nine trials (80%) compared 
topical steroid against placebo (Hansen 2010; Dijkstra 2004; 
Furukido 2005; Jorissen 2009; Lavigne 2002; Lund 2004; Parikh 
2001; Qvarnberg 1992; Sykes 1986) (309, 1668-1674, 1823).
One trial (10%) (1675) with 112 patients compared two treatment 
regimes of steroid administration without comparing to 
placebo. One (10%) trial (1676) with 60 patients compared topical 
steroid with antibiotic against antibiotic alone. We found no 
trials comparing topical steroid versus alternative topical steroid.
Five included studies were sponsored by pharmaceutical 
companies. Two were fully and three were partly supported as 
follows: Dijkstra 2004 (1668) (GlaxoSmithKline (GSK), Jorrisen 2009 
(1674) (Schering-Plough Corp), Hansen 2010 (1823) (Optinose UK ltd), 
Lund 2004 (1671) (AstraZeneca and R&D Lund) and Lavigne 2002 
(1670) (AstraZeneca Canada Inc and Fon de Recherche en Sante 
du Quebec). Medications were supplied by pharmaceutical 
companies in three studies: Parikh 2001 (1672) (Glaxo Wellcome 
Research), Sykes 1986 (1673) (Boehringer Ingelheim), Qvarnberg 
1992 (309) (Suomen Astra OY). Furukido 2005 (1669) was not 
funded by pharmaceutical companies. Two studies did not 
state how they were funded (Cuenant 1986; Giger 2003) (1675, 
1676). A summary of outcomes is provided in Table 6.1.2. with the 
majority demonstrating a benefit to the use of INCS.
6.1.3.1. Meta-analysis
Of the eight studies comparing INCS to placebo, Five studies 
(Furukido 2005; Jorissen 2009; Lavigne 2002; Lund 2004; Parikh 
2001); (1669-1672, 1674) and could be combined in the meta-analysis. 
Pooled data analyses of symptom scores and proportion of 
responding patients demonstrated significant benefit in the 
topical steroid group. The pooled results significantly favoured 
the topical steroid group (combined standardised mean 
difference (SMD -0.37; 95% confidence interval (CI) -0.60 to -0.13, 
p=0.002; five trials, 286 patients) The I2 was 12%, suggesting no 
heterogeneity (x2 = 4.57, degrees of freedom (df ) = 4, p=0.33).  
This was true for both SMD and responder analysis (Figure 
6.1.2a & 6.1.2b). The four studies that did not provide data for 
meta-analysis were (309, 1673, 1677, 1823) and only Dijkstra 2004 did not 
favour INCS.
           
Endoscopic scores were report in only 2 studies (Jorissen 2009 
and Parikh 2001) (1672, 1674) and did not reach significant outcome 
on meta-analysis.  Three studies used non-validated radiologic 
outcomes (Furukido 2005, Qvarnberg 1992, Sykes 1986) (309, 1669, 
1673)  and these all had no benefit favouring INCS but could not 
be combined for meta-analysis.
The standardised mean difference (SMD) and 95% CIs for 
continuous data such as post-intervention scores or change in 
symptom scores. The risk ratio (RR) and 95% CI of responsiveness 
was used at a specific time point for dichotomous data such 
as number of patients responding to treatment or number of 
patients having positive radiographs. The intervention effects 
were pooled when trials were sufficiently homogeneous. A 
fixed-effect model was used and assumed that each study was 
estimating the same quantity.
6.1.3.2. Subgroup analysis 
Subgroup analysis was performed as follows.
•	 Topical delivery method
 -  Nasal (drops, sprays, nebulisers) versus sinus (direct 
cannulation, irrigation post-surgery) delivery method.
Low volume (defined as any simple spray volume approximating 
< 1 ml) versus large volume (defined as any significant volume 
> 60 ml - representing a simple irrigation syringe or smallest 
commercial irrigation device. We pre-defined low and large 
volume based on previous studies showing how the volume 
applied affects sinus delivery (1666). Low pressure (including spray, 
nebulisers, instilled solution through a tube and non-pressure 
irrigation) versus high pressure (including positive pressure 
irrigation).
•	  Surgical status
 -  Patients with prior sinus surgery versus those without 
sinus surgery.
•	  Corticosteroid type
 -  Modern corticosteroids (mometasone, fluticasone, 
ciclesonide) v first-generation corticosteroids 
(budesonide, beclomethasone, betamethasone, 
triamcinolone, dexamethasone)
Differences between the two subgroups for fixed-effect analyses 
were based on the inverse-variance method in the case of 
continuous data and the Mantel-Haenszel method in the case of 
dichotomous data.
There was a benefit on subgroup analysis for INCS delivery 
method. This was significant when sinus delivery methods (SMD 
-1.32; 95% CI -2.26 to -0.38) were compared to nasal delivery 
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methods (SMD -0.30; 95% -0.55 to -0.06) (p=0.04). Similar 
findings were seen in responders as well as SMD analysis (Figure 
6.1.3.a and 6.1.3.b). There were no studies using nasal drops and 
thus no comparison is made. No high volume and high pressure 
topical delivery techniques (i.e. irrigation or atomizer) were 
described.
When the surgical state of the patients was assessed on 
subgroup, only patients with prior surgery for CRSsNP had 
symptom improvement (SMD-0.54 CI -1.03, -0.06)) but there was 
no improvement for those patients without surgery (SMD -0.10, 
-0.90, 0.71). The comparative assessment between subgroups 
did not reach significance (p=0.23). This was true for responders 
as well as SMD (Figures 6.1.4.a and 6.1.4.b).
Figure 6.1.3. a en b
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Finally, by corticosteroid type, there were 3 studies using 
modern corticosteroids (1674, 1668,1672) compared to 7 with older 
first-generation corticosteroid types. Only symptom scores were 
available for comparison with no significant difference between 
subgroups (p=0.75).  Although, it may appear that the early 
generation INCS perform better than modern on the forest plot 
(Figure 6.1.5.a and 6.1.5.b) this difference is not significant and 
there are no data from modern INCS to use in the proportion of 
responders analysis.
Figure 6.1.4. a en b
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6.1.4. Side-effects of local corticosteroid chronic 
rhinosinusitis without nasal polyps 
Epistaxis, dry nose, nasal burning and nasal irritation are 
considered to be drug-related events. It is acknowledged that 
rare adverse events are possibly not detected in randomised 
controlled trials (RCTs). However, they were extremely low and 
there was no difference in adverse events between the study 
groups and control groups in any trial. Post-market adverse 
events for intranasal steroid sprays are very low. Minor adverse 
events from nasal steroid are well tolerated by patients. The 
amount of benefit clearly outweighs the risk. The reported 
adverse events from the included studies are summarized in 
Table 6.1.3.
6.1.5. Systemic corticosteroid chronic 
rhinosinusitis without nasal polyps
6.1.5.1. Introduction 
There is limited data showing efficacy of oral corticosteroids 
in chronic rhinosinusitis without nasal polyps. A systematic 
review was performed by Lai et al (1678) in 2011. They found 27 
clinical human publications on systemic corticosteroid use. 
Only 1 of these was a prospective trial (case series - level 4 
evidence) and no RCTs or controlled cohorts. The remaining 
publications were 2 retrospective case series and 24 reviews or 
treatment guidelines.  All studies used systemic corticosteroid 
in conjunction with antibiotics and INCS. Improved subjective 
and objective outcomes were seen in the 3 studies for CRSsNP 
(49, 1679, 1680). In Tosca et al. the study population was children with 
asthma (49). Subramamian et al. had both CRSwNP and CRSsNP 
and noted that the CRSsNP had better outcomes (1679). Lal et 
al. noted that the CRSsNP had symptom resolution of 54.9% 
compared to 51% for the total CRS group (1680).
6.1.5.2. Side-effects of systemic corticosteroid chronic 
rhinosinusitis without nasal polyps 
The side effect profile of corticosteroid use is likely to be similar 
between CRSsNP and CRSwNP, however, given the relative 
lack of clinical data (not data against) to support systemic 
corticosteroid use this risk-benefit ratio may be greater. 
Please refer to the description of side-effects of systemic 
corticosteroids from the section on CRSwNP.
6.1.5.3. Evidence based recommendations
There is good evidence that INCS benefit CRSsNP. However, not 
all author demonstrate this finding. The surgical state of the 
sinuses treated (i.e. whether the sinuses have been opened and 
the ability of topical INCS to penetrate into the sinus cavity) 
appears to have a significant influence on response. The delivery 
device may be significant but there were not enough studies to 
come to a conclusion other than technique that deliver more 
effectively to sinuses are probably more beneficial. 
Table 6.1.3. Reported adverse events in the included studies on INCS for CRSsNP (*low and ** high dose INCS compared, NR = not reported).
Study ID Steroid 
group n(%)
Placebo group 
n(%)
Description of events reported Remarks
Jorissen 
2009  (1674)
29 (63) 28 (62) Headache, sinusitis, cold 1. Most common headache 
2. Few drug-related events 
3. Rare serious events
Furukido 
2005 (1669)
NR NR NR NR
Dijkstra 
2004 (1668)
 NR  NR  Epistaxis Epistaxis: not higher in steroids group
Lund 
2004 (1671)
39 (48) 46 (53) Respiratory infection, headache, 
blood-tinged secretion, viral infection, 
pharyngitis, sinusitis, flu-like, pain, 
rhinitis, external ear infection
1. Most events are mild or moderate  
2. Regarding serious events, none were 
considered to be due to study medication  
3. No difference of steroids with placebo   
4. No increased incidence of infection
Giger 
2003 (1676)
26* (47)  
32** (56)
Epistaxis, dry nose, nasal burning, 
nasal itching, sinusitis, pharyngitis, 
otitis, change of taste, eczema, nausea/
diarrhoea, nasal irritation, common cold
1. Mild 61.6% moderate 4% severe; 3.8%  
2. Most common epistaxis  
3. No candidiasis   
4. No difference between od and bid   
5. No change in morning serum cortisol level
Lavigne 
2002 (1670)
 NR  NR Tube fell out, epistaxis, diabetes with 
glycaemia, tube infection, asthma
No sinus irritation from steroid instillation
Parikh 2001 (1672) NR NR NR NR
Qvarnberg 
1992 (309)
NR NR NR NR
Cuenant 
1986 (1675)
NR NR NR NR
Sykes 
1986 (1673)
NR NR NR NR
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Figure 6.1.5. a en b
Evidence based recommendations corticosteroids in CRSsNP.
Statement Level of evidence Grade of recommendation
Local
INCS improve symptoms and patient reported outcomes in CRSsNP 1a A
Delivery of INCS directly to sinuses brings about a greater effect 1a A
Patients with prior sinus surgery have a positive effect of INCS compared to 
those without surgery
2a B
INCS is associated with only minor side-effects 2a B
Modern INCS do not have greater clinical efficacy (although potentially fewer 
sider-effects) compared to first-generation INCS
1a A
Systemic
Systemic corticosteroids benefit CRSsNP 4 C
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6.2. Treatment of CRSsNP with antibiotics
6.2.1. Short-term treatment with antibiotics in 
CRSsNP
No placebo controlled trials exists in short-term 
systemic antibiotic treatment of CRSsNP
6.2.1.1. Summary of data
In this review short-term treatment with antibiotics is defined as 
treatment duration shorter than 4 weeks. There are no placebo-
controlled trials available. However three randomised studies 
were identified, two double-blind and one open comparing 
the effect of 2 different antibiotics. In a multicentre, open 
parallel randomised clinical trial 206 adults with exacerbation 
of CRS were randomised to either amoxicillin/clavulanic acid 
(875 mg/125 mg b.i.d) or cefuroxime axetil (500 mg b.i.d). 
Clinical response rate was similar 95 and 88 % respectively. 
Bacteriological cure rate was 65 and 68 % respectively. Clinical 
relapse was significantly higher in the cefuroxime group, 8% 
compared to 0 % in amoxicillin/clavulanic acid group (1681). In 
a double-blind study 251 CRS patients were randomised to 
either ciprofloxacin or amoxicillin/clavulanic acid. Clinical cure 
and bacteriological eradication rate was similar in both groups 
at approximately 60 % and 90 %. However, at 40 days after 
treatment cure rate was significantly higher in the ciprofloxacin 
group and there were more gastrointestinal side effects in the 
amoxicillin/clavulanic group (1682). In the study by Huck et al 
comparing cefaclor with amoxicillin only 15 patients with CRS 
were included, too few to allow statistical analysis (1683).
6.2.1.2. Conclusion
In conclusion, no placebo-controlled studies are available. 
The 2 studies could not show any difference in short-term 
outcome comparing different antibiotics. Short-term treatment 
in CRSsNP is probably only relevant in exacerbations with 
a positive culture. The present level of evidence is level II. 
Recommendation B.
6.2.2. Long-term treatment with antibiotics 
in CRSsNP
6.2.2.1. Introduction to long-term treatment with 
systemic antibiotics in CRS
There has been an increasing interest in the use of macrolides in 
airway inflammatory disease since the publication of long-term, 
low-dose erythromycin treatment of diffuse panbronchiolitis 
(DPB). The treatment changed the 10 years survival rate from 
25% to over 90 % and simultaneously cleared the CRS (1684, 
1685). Interesting to note is that the effect is seen at lower doses 
than used to treat infection and that the onset is slow and 
there is effect in the absence of common pathogens or in the 
presence of non-sensitive pathogens. Combined with the well-
documented anti-inflammatory effects of macrolides in vitro it 
has led to the concept of macrolides being immune-modulatory 
rather than anti-bacterial.  
6.2.2.2. Evidence for effect of long-term treatment 
with macrolides in the lower airways
From the literature it is evident that the pulmonary physicians 
have been much more successful than the ENT community to 
initiate Randomised Controlled Trials. In order to understand the 
potential of macrolide antibiotics to modify the inflammatory 
response in the airway it is therefore prudent to summarize 
present evidence from the lower airway.
The remarkable effect in diffuse panbronchiolitis patients 
have already been mentioned (1684, 1686). In CF no less than eight 
RCTs have showed a beneficiary effect using clarithromycin, 
Table 6.2.1. “Short Term” Antibiotics in CRSsNP.
Study Drug Number Time/Dose Effect on symptoms Evidence 
Huck 1993 (1683). ceflaclor vs. amoxi-
cillin 
56 acute rhinosinusitis 25 recur-
rent rhinosinusitis 15 chronic  
maxillary sinusitis
2x 500mg 
3x500mg 
for 10 days 
clinical improvement: acute rhinosi-
nusitis 86% recurrent rhinosinusitis 
56% chronic maxillary sinusitis no 
statistics 
1b (-)*
Legent 1994 
(1682)
ciprofloxacin vs. 
amoxicillin clavu-
lanate 
251 9 days nasal discharge disappeared: cipro-
floxacin 60% amoxicillin clavulanate 
56% clinical cure: ciproloxacin 59% 
amoxicillin clavulanate 51 clinical 
cure: ciproloxacin 59% amoxicillin 
clavulanate 51% bacterological eradi-
cation: ciprofloxacin 91% amoxicillin 
clavulanate 89% 
1b (-)
Namyslowski  
2002 (1681)
amoxicillin clavu-
lanate vs. cefuro-
xime axetil 
206 875/125mg 
for 14 days 
500mg for 
14 days 
clinical cured: amoxicillin clavulanate 
5% cefuroxime axetil 88% bacterial 
eradication: amoxicillin clavulanate 
65% cefuroxime axetil 68% clinical 
relapse: amoxicillin clavulanate 0/ 98 
cefuroxime axetil 7/89 
1b (-)
* 1b (-): a level 1b study showing no difference between treatments
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(one) or azithromycin, (seven). There are undisputed effects on 
inflammatory markers, such as IL-8, IL-4, interferon-gamma and 
TNF-α as well as reducing the rate of exacerbations and reducing 
decline in lung function (1687-1689). Although not all studies have 
shown an overall improvement in quality of life it is now a 
recommended adjunctive treatment in CF. 
In asthma, RCT studies using macrolides have shown to reduce 
airway hyperresponsiveness and to reduce inflammatory 
mediators in bronchoalvelar lavage such as IL-5, TNF-alpha and 
IL-12 (1690-1692). More surprisingly roxithromycin therapy reduced 
markers for eosinophilic activity in aspirin sensitive asthmatics 
(1693). A subgroup responding well to macrolides are the asthma 
patients with positive PCR for Chlamydophila pneumoniae or 
Mycoplasma pneumonia (1690)..
Until recently in COPD there were two small (n<100) RCTs 
showing no effect on health status and exacerbation rate (1694, 
1695). However recently  a large RCT in COPD (n=1577) using 
azithromycin for one year, showed a significant effect on time to 
exacerbation and number of exacerbation as well as improved 
functioning (1696)..
In non-CF bronchiectasis, 3 RCTS have shown reduction in 
bronchial inflammation and sputum volume, individual studies 
have also demonstrated pulmonary function improvement and 
reduction in metacholine induced hyper responsiveness (1697-1699).
To sum up, the anti-inflammatory effects of macrolides in the 
lower airways is clearly demonstrated, especially in a neutrophilic 
inflammatory- infectious disease, such as CF. One has to bear in 
mind that a reduced dose was not always used and an added 
anti-bacterial effect is likely. In asthmatics PCR identification 
of Chlamydophila or Mycoplasma seems to be one way to 
identify the responsive phenotype. The case with COPD where 
2 small studies showed little or no effect, whereas a large RCT 
showed effect, is an important reminder that a power analysis 
is paramount. A similar sized RCT in a defined CRS population 
would be of great consequence in constituting the care of CRS 
patients in the future.
6.2.2.3. Long-term treatment with systemic antibiotics 
in CRSsNP
In CRSsNP there is some evidence to use long-
term, low-dose macrolide antibiotics for 12 weeks. 
Selecting patients with normal serum IgE could 
improve response rate.
In this review long-term treatment with antibiotics is defined 
as treatment duration longer than 4 weeks. Although antibiotic 
treatment is one of the mainstays of CRS treatment the number 
of placebo controlled trials are limited to two studies. 
There are a number of open studies using macrolide antibiotics 
in varying doses, most often about half the daily dose compared 
to treating acute infections. All studies show a response rate 
(reduction in symptoms) that varies between 60 and 80 %. 
Most studies also show a reduction of inflammatory markers 
and some an increased ciliary beat frequency indicating less 
sticky secretions (1700-1706). One study compared surgery with 12 
weeks of erythromycin. Both treatment modalities improved 
symptoms significantly, except for nasal volume, which was 
better in the surgery group (16).
A recent review, June 2011, from the Cochrane Collaboration 
titled: Systemic antibiotics for chronic rhinosinusitis without 
nasal polyps (1707) identified only one prospective randomised 
placebo controlled trial (1708). Recently and not included in the 
Cochrane review, another randomized controlled study has 
been published (1709). These two studies represent the only 
placebo controlled randomised trials available in CRS. The 
studies investigated the effect of a macrolide antibiotic on the 
signs, symptoms and quality of life in patients suffering from 
chronic rhinosinusitis. In both studies the treatment period 
was 12 weeks. However, whereas the study of Wallwork and 
co-workers showed a clinical effect of roxithromycin with 
significant improvements in SNOT-20 score, nasal endoscopy, 
saccharine transit time, and IL-8 levels in lavage fluid, the study 
by Videler and co-workers showed that azithromycin lacked 
Table 6.2.2. Placebo controlled RCTs in long-term treatment with antibiotics in chronic rhinosinusitis without polyps (1708) and in a mixed population 
CRS (1709).
Study Drug N= Time/dose Effect symptoms Level of evidence
Wallwork 2006 (1708) Roxithromycin 64 12 weeks/150 mg 
daily
Significant effect on SNOT-20 
score, nasal endoscopy, saccharine 
transit time, and IL-8 levels. CRSsNP 
population. Improved or cured in 
treatment group was 67% vs 22% 
in placebo group. In a subgroup 
with normal IgE levels 93% were 
improved or cured in the treatment 
group. 
1b
Videler 2011 (1709) Azithromycin pla-
cebo controlled
60 12 weeks/500 mg 
week
No significant effect. Response rate 
was 44% in treatment group vs 
22% in placebo group. 
Ib (-)
* 1b (-): a level 1b study showing no difference between treatments
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efficacy.  In the Wallwork study the response rate overall in the 
treatment group was 67%, compared to 22% in the placebo 
group whereas in the Videler study it was 44% for azithromycin 
and 28% for placebo.
Both studies are about the same size 64 vs. 60 patients with 
CRS included. The inclusion criteria are however different. In the 
Wallwork study the patients were without polyps, whereas, the 
Videler study included patients both with and without nasal 
polyps, in fact a minimum CT score was required (CT scan score 
≥5 at worst side according to Mackay-Lund), which suggest a 
polyposis or hyperplastic sinusitis. In the Wallwork study it was 
noted that a sub-population of patients with normal IgE levels 
had a higher response rate to the macrolide treatment than 
patients with elevated IgE, where most of the non-responders 
were found. Although not analysed, it is possible that the study 
population in the Videler study comprised of a higher number 
of patients with elevated IgE making them less suitable for 
macrolide treatment as previously described by Suzuki (1710). 
Higher CT scores are also positively related to elevated IgE 
levels and eosinophilia (1711). The discrepancy between these two 
studies highlights the need for matching the right patient with 
the right treatment. When considering long-term macrolide 
treatment, a serum IgE is helpful in trying to identify likely 
responders.
A retrospective analysis compared a mixed CRS population 
(both with and without polyps) treated with long-term 
macrolide, azithromycin or clarithromycin or trimethroprim-
sulfamethoxazole. 76 patients were included, 53% had asthma 
and all had undergone sinus surgery. Severe nasal polyposis 
patients were excluded. The mean length of treatment was 189 
and 232 day respectively. The response rate was 78% with no 
difference between the 2 treatment groups. Follow up for 4.7 
months in mean after cessation of treatment showed that the 
improvement was sustained in 68% of patients. Interesting to 
note, smokers were less likely to respond and there were more 
allergic patients in the responding group (1712).
6.2.2.4. Conclusion
The majority of studies have used macrolide antibiotics. A 
number of open studies using macrolides have shown a 
response rate of 60-80%. One placebo controlled study using 
a roxithromycin showed efficacy in patients without polyps. 
The other placebo controlled azithromycin study had a mixed 
population of patients with or without polyps and although 
there were more responders in the treatment group it did not 
reach significance. Further larger placebo controlled studies in 
a defined CRS population are warranted. Concerning the open 
studies one has to be cautious, especially since an intervention 
is more likely to occur when the patient is suffering from an 
exacerbation, and as in any cyclic disease an improvement will 
eventually occur regardless of action taken. Thus, in a study 
lacking a placebo group, the risk of over-estimating efficacy of 
the intervention is high. 
For now, long-term antibiotic treatment should be reserved 
for patients where nasal corticosteroids and saline irrigation 
has failed to reduce symptoms to an acceptable level. Data 
suggests that the population with high serum IgE are less likely 
to respond to macrolide treatment and the ones with normal IgE 
more likely to do so (1713). Future phenotyping may also include 
PCR for Chlamydiophilia and Mycoplasma although this has not 
been explored in CRS. 
Other choices such as long-term treatment with doxycycline or 
trimethroprim-sulfamethoxazole could turn out to be promising 
alternatives and further studies are warranted.
Level of evidence for macrolides in all patients with CRSsNP is 
Ib, and strength of recommendation C, because the two double 
blind placebo controlled studies are contradictory; indication 
exist for better efficacy in CRSsNP patients with normal IgE the 
recommendation A. No RCTs exist for other antibiotics.
6.2.2.5. Adverse events of antibiotic therapy of CRS
6.2.2.5.1. Effects on bacterial resistance.
 A concern with long-term antibacterial treatment is the 
emergence of resistant bacterial strains. Especially when using 
a low dose not attaining minimal inhibitory concentrations. 
Data from primary care have shown that increased macrolide 
prescription in group A streptococci tonsillitis leads to a 
subsequent increase in resistance, which can reach alarmingly 
high levels (1714, 1715). However in a tertiary setting, data is sketchy. 
The study by Videler at al. using azithromycin for 12 weeks, 
found 3 of 50 cultures with macrolide resistant strains before 
treatment, and after treatment 4 of 43 cultures with resistant 
strains (1709). An emerging concern in cystic fibrosis patients is 
the increasing incidence of infection with the highly pathogenic 
Mycobacterium abscessus in azithromycin treated patients. The 
effect is probably due to azithromycin inhibition of autophagic 
and phagosomal degradation (1716-1718). This has not been 
reported in CRS patients.  In a placebo randomised, double-
blind trial, studying the effect of exposure of oral streptococcal 
flora of healthy volunteers to azithromycin and clarithromycin, 
definitive proof that antibiotic use is the single most important 
driver of antibiotic-resistance was demonstrated. Physicians 
prescribing antibiotics should take into account these striking 
ecologic side-effects of antibiotics (1719). 
6.2.2.5.2. Other side effects 
Well-known side effects of antibiotics includes; gastrointestinal 
upset, skin rash reversible elevation of liver enzymes. In the 
study by Videler et al including 78 patients, the investigators 
found 1 case of muscle ache in the azithroprim group and 2 
cases of mild skin rash in the clarithromycin treated patients 
and no adverse effects in the trimethroprim-sulfamethoxazole 
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group. The study comparing doxycycline treatment for 20 days 
with methylprednisolone and placebo reported no difference in 
adverse events in the different groups. However, rare side effects 
are not picked up in small clinical trials, but rather in national 
records on side effects. Hearing impairment due to macrolide 
treatment is a rare side effect but was recorded in a recent large 
trial in COPD (1696).
6.2.2.5.3. Conclusions on adverse events of antibiotic 
therapy of CRS
The safety of long-term antibiotic therapy, either azithromycin, 
clarithromycin or roxithromycin is recognised in patients with 
CRS, but also due to it’s established long-term use in cystic 
fibrosis. As for doxycycline there is longstanding experience for 
long-term use in acne and rosacea patients.  Trimethroprim-
sulfamethoxazole has been used long-term in both the 
paediatric and adult population for treatment of infectious 
prone patients with certain immune deficiencies as well as 
urinary tract infections. Drawing on the experience from other 
areas than CRS, long-term treatment with the mentioned 
antibiotics is relatively safe.  Although one has to bear in 
mind the interaction between macrolides and drugs such as 
dicumarol, antiepileptic drugs, terphenadine, methotrexate and 
antidepressant drugs. 
To monitor the risk of the development of resistant bacterial 
strains, nasal swabs with culture every 3 months during 
treatment is advisable.
6.2.3. Treatment with topical antibiotics in 
CRSsNP 
6.2.3.1. Summary of the data
There are three placebo-controlled studies with topical 
antibiotics and a number of open labelled studies. They open 
labelled studies show benefit in either signs and or symptoms 
ranging from 40 to 80% response rate (1455, 1720-1725). A number 
of different topical solutions have been used with different 
treatment periods. Any general conclusions from these studies 
are difficult to draw.
There are 3 placebo-controlled trials with topical 
antibiotics in CRS. None of them showed any ad-
ditive effect compared to saline.
However the three placebo-controlled studies are all negative. 
A study from 1986 where dexamethasone, neomycine  
and tramazoline were compared with dexamethasone 
without neomycine and a placebo group with vehicle alone 
showed no additive effect of neomycin both the group with 
dexamethasone alone and with the addition of neomycin 
were superior to placebo (1673). Another placebo controlled trial 
by Desrosiers et al. investigated 20 patients in a randomized, 
double-blind trial of tobramycin-saline solution or saline-only, 
administered thrice daily by means of a nebulizer for 4 weeks, 
followed by a 4-week observation period. Both patient groups 
experienced improvement in signs and symptoms but the 
addition of tobramycin appears of no benefit (1726). 
Thirdly a study by Videler et al investigated the effect of nasal 
irrigation with bacitracin/colimycin or placebo in a randomised, 
double blind, cross-over study in 14 patients with recalcitrant 
CRS in spite of surgery.  Both groups improved and there was 
no difference in SF-36 and endoscopic appearance (1727). Chiu et 
al showed in a rabbit model with Pseudomonas sinus infection 
that increasing concentrations of topical tobramycin resulted in 
the eradication of viable bacteria within the lumen of the sinus 
but did not eradicate Pseudomonas attached to the mucosa 
(1728).
6.2.3.2. Conclusion concerning the use of topical 
antibiotics in CRS
There is low level of evidence for the efficacy of topical 
antibacterial therapy in seven uncontrolled trials. However 
3 placebo controlled trials failed to show any additive effect 
of topical antibiotics as compared to saline alone. Topical 
antibacterial therapy cannot be recommended in the treatment 
of CRS. Level of evidence Ib, grade of recommendation A.
Table 6.2.3. Placebo controlled RCTs in topical treatment with antibiotics in chronic rhinosinusitis without polyps 
Study Drug   N Time/dose Effect symptoms Level of evidence
Sykes 1986 
(1673)
Dexamethasone  (D)  neomycine (N) 
tramazoline (T) vs DT vs propellant 
alone
50 4x daily for 2 weeks NDT 14/20 improved DT 12/20 
improved
Placebo
2/20 improved
1b (no effect of 
added antibiotic)
Desrosiers 
2001 (1726)
Tobramycin double blind placebo 
controlled
20 80 mg x3 daily/4 
weeks
Significant improvement in both 
groups in symptoms QoL and 
endoscopy
Ib (no effect of 
antibiotic)
Videler 
2008 (1727)
Bacitracin/colimycin topical spray with 
systemic levofloxacin double-blind, 
randomized, placebo-controlled, 
cross-over
14 bacitracin/colimycin 
(830/640 μg/ml) x 2 
daily / 8 weeks
Improvement in both groups, no 
significant difference in symptom 
score and SF-36
1b (no effect of 
antibiotic)
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6.2.3.3. Adverse events of topical antibiotic spray
Not all studies mention side effects but the most common side 
effects seems to be intra-nasal stinging, burning sensation, 
moderate pain, throat irritation, cough and dry skin. Topical 
antibiotics not being registered as drugs makes reports on side 
effects sketchy.
6.3. Other medical management in CRSsNP 
6.3.1. Summary 
This chapter deals with medical therapies of CRSsNP in adults 
except antibiotics and glucocorticoids. For medical treatment of 
acute rhinosinusitis and in paediatric rhinosinusitis, please refer 
to the according chapters. No RCT for the treatment of CRSsNP 
in adults were identified for antihistamines, mucolytics and 
expectorants, homeopathic remedies, proton pump inhibitors, 
surfactants including baby shampoo or nasal decongestants. 
These treatment modalities are not recommended. No benefit 
was found in randomized controlled trials or systemic reviews 
for antimycotics, herbal medicines, or probiotics, which are 
also not recommended for the treatment of CRSsNP in adults. 
Based on the results of 1 RCT, bacterial lysate treatment may 
be considered as an adjunct to standard medical treatment in 
adults with CRSsNP. One Cochrane review and 2 RCTs indicate a 
beneficial effect of nasal douches in CRSsNP in adults.
6.3.2. Antimycotics
One trial with nasal amphotericin B treatment was explicitly 
performed in 64 CRS-patients without polyps (711). Following 
inclusion, patients were randomized to either 20mg/day 
amphotericin B or a yellowish solution without amphotericin 
administered in 500 ml saline solution with a pulsatile irrigator. 
If the type of therapy was concealed to the investigators is 
not reported. Main outcome parameter was the sum score 
of the Rhinosinusitis Outcome Measures 31 questionnaire. 
Secondary endpoints included a nasal endoscopy score and 
pre- and post-treatment fungal cultures. Symptom scores were 
significantly lower in the amphotericin treated patients after 
2 weeks treatment (p=0.018), but not after 4 weeks treatment 
(p=0.091). Endoscopy scores and fungal culture rates did not 
significantly differ between groups. Based on current data, 
nasal amphotericin B treatment in CRSsNP is not recommended 
(grade of recommendation A).
 
6.3.3. Bacterial Lysates
Bacterial lysates enhance Th1-skewed immune responses and 
dendritic cell maturation via activation of toll like receptors (1729, 
1730). Several trials on the preventive effect of immunostimulants 
including bacterial lysates on recurrent respiratory infections 
mainly in children were identified, however, only 1 bacterial 
lysate trial particularly assessed the effect on chronic 
rhinosinusitis in adults. In a multicentre randomized double-
blind study, 284 patients with chronic purulent sinusitis were 
treated with the oral bacterial lysate Broncho Vaxom (OM-85 
BV) or placebo in addition to standard therapy (antibiotics, 
mucolytics, inhalants). Treatment lasted for three ten-day 
periods in three consecutive months. At the start and during 
the therapy as well as after six months, symptoms were 
assessed on the basis of a scoring system and the X-rays of 
the nasal sinuses evaluated. During the course of therapy and 
the follow-up period, improvement of the major symptoms 
headache, purulent nasal discharge, cough, and expectoration 
was statistically significant in the immunostimulant group 
as compared with the placebo group, objective evidence 
being provided by the X-ray examinations and the number of 
reinfections during the period of observation (1731). Based on the 
results of 1 RCT, oral OM-85 BV treatment may be considered as 
an adjunct to standard medical treatment in adults with CRSsNP 
(grade of recommendation A).
6.3.4. Herbal medicines and homeopathic drugs
Phytotherapy is the use of plants or herbs to treat diseases. A 
huge range of preparations, most of them not yet subjected to 
clinical trials and some with unknown ingredients, are marketed 
over the counter in Europe. Homeopathy is a system of 
therapeutics founded by Samuel Hahnemann (1755-1843), based on 
the Law of Similars where “like cures like”. Diseases are treated 
by highly diluted substances that cause, in healthy persons, 
symptoms like those of the disease to be treated. Herbal and 
homeopathic drug use is subjected to great regional differences. 
Alternative treatment modalities are used by 15-50% of 
rhinosinusitis patients (1732-1734). 
Guo and co-authors reviewed randomized clinical trials (RCTs) 
testing a herbal preparation, as sole or adjunctive treatment, 
administered systemically or topically, against a control 
intervention (placebo or no treatment), in patients with acute 
or chronic rhinosinusitis (1735). The authors found no evidence 
that any herbal medicines are beneficial in the treatment of 
CRSsNP. Alcoholic extracts of pelargonii radix are marketed since 
decades as a treatment for upper and lower respiratory tract 
infections. In a recent Cochrane report on P. sidoides extracts 
and tablets, no trials on CRSsNP fulfilled the inclusion criteria 
(336)..
No RCT on homeopathic treatment of CRSsNP could be 
identified. Based on current data, herbal medicines and 
homeopathic remedies are not recommended for the treatment 
of CRSsNP (grade of evidence D).
6.3.5. Nasal irrigation
Isotonic or hypertonic saline solutions delivered by bottle, 
spray, pump or nebuliser are frequently used in the treatment 
of sinus disease, mainly as a supplement to other therapies. 
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Sinus penetration of irrigation fluids differs in patients with 
and without previous sinus surgery (1663) and depends on the 
application mode (1661,1662). 
Nasal saline irrigations were judged beneficial in the treatment 
of the symptoms of chronic rhinosinusitis when used as the sole 
modality of treatment in a Cochrane report (1736). However, in this 
evaluation children were also included and no clear separation 
between CRSwNP and CRSsNP was reported. Moreover, it 
remained unclear, if patients had undergone previous sinus 
surgery.
In a community based, randomized, controled trial, Pynnonen 
and co-workers compared isotonic nasal saline spray and 
isotonic nasal saline douches in 127 adult patients with CRS 
without recent sinus surgery. Outcome parameters included 
change in symptom severity measured by mean 20-Item 
Sino-Nasal Outcome Test (SNOT-20) score; change in symptom 
frequency measured with a global question; and change in 
medication use. Outcomes were measured at 2, 4, and 8 weeks 
after randomization. All outcome parameters were significantly 
better in the nasal douches group than in the nasal spray group 
(1737).
The value of nasal douching following sinus surgery was 
assessed in an intra-individual, single blinded randomised 
controlled trial. Nasal douches were used by 22 patients 
following sinus surgery in one side of the nasal cavity, three 
times per day for 6 weeks. The opposite nasal cavity was not 
irrigated. Presence of adhesions, polyps, crusting, discharge or 
oedema was assessed 3 weeks and 3 months postoperatively. 
At 3 weeks, nasal saline douching improved the presence 
of discharge and oedema, but had no effect on adhesions 
or crusting. At 3 months, no significant differences between 
douched and non-douched nasal cavities were observed (1738).
Thorough cleaning of irrigation devices is required to prevent 
bacterial contamination, however, no sinus infection due to 
irrigation device contamination has yet been reported (1739-1741). 
Based on current data, nasal douches are recommended for 
CRSsNP in adults without recent sinus surgery and in the post 
sinus surgery setting (grade of recommendation A).
6.3.6. Additions to nasal irrigation
Sodium hypochlorite (NaOCl) is a well-known bleaching and 
desinfecting agent that has been found to be effective against 
several organisms including S. aureus and P. aeruginosa. Nasal 
irrigation with 0.05% NaOCl solution in saline was significantly 
more effective than saline alone in the treatment of S. aureus 
positive CRS patients in a study where patients used saline 
irrigation for 3 months and afterwards saline irrigation with 
0.05% NaOCl solution (1742) (Level of evidence IIb). Xylitol has 
been shown to effect ASL ionic composition in vitro and to 
reduce nasal bacterial carriage, otitis media, and dental caries 
in vivo. Xylitol in water is a well-tolerated agent for sinonasal 
irrigation. Xylitol irrigations result in greater improvement 
of symptoms of chronic rhinosinusitis as compared to saline 
irrigation (1743) (level of evidence 1b).
Biofilms are considered to play a pathophysiological role in CRS. 
Data on the impact of biofilms on sinus surgery outcomes are 
conflicting (693, 1744). Surfactants reduce water surface tension and 
may help to dissolve biofilms (1745). No RCT of surfactants in the 
treatment of CRSsNP was identified. Baby shampoo contains 
several surface active agents. Nasal irrigations containing 
Johnson’s Baby Shampoo were tested in a non-randomized, 
open-label trial in 15 CRS patients for 4 weeks. Concomitant 
medications included antibiotics and oral prednisolone. 
Subjective improvement was observed in 46% of the patients 
(1746) (level of evidence III). 
Current data do support the use of xylitol (recommendation 
A) or sodium hypochlorite nasal irrigations (grade of 
recommendations B) but not irrigations containing baby 
shampoo in CRS patients (grade of recommendation D).
6.3.7. Probiotics
Probiotics are living microorganisms that benefit the health 
of the host by conditioning the intestinal microenvironment. 
Supplementation with probiotics may alter intestinal microflora 
and promote Th1 responses by activating interferon gamma, 
interleukins 12 and 18. In a randomized, double-blinded, 
placebo-controlled trial, 77 patients with chronic rhinosinusitis 
received either oral probiotic Lactobacillus rhamnosus R0011 
strain (500 million active cells/tablet twice daily, n=39) or oral 
placebo (n =38) for 4 weeks. The main study endpoint was the 
change in the SNOT-20 score. Secondary outcome parameters 
included a symptom frequency score and a medication score. 
No significant differences were found between the probiotic 
and the placebo group in their changes in SNOT-20 scores 
from baseline to 4 weeks (p=0.79) or from baseline to 8 weeks 
(p=0.23) (1747). Current data do not support probiotic treatment in 
CRSsNP (grade of recommendation A).
6.3.8. Proton Pump inhibitors
Extraesophageal reflux has been supposed a possible cause 
of CRS (1748), however clinical data on the frequency of extra-
oesophageal reflux in patients with rhinosinusitis do not 
support this link (1749, 1750). No RCT on proton pump inhibitors 
in the treatment of CRSsNP in adults was identified. In one 
uncontrolled trial in 11 adult CRS patients with abnormal pH-
monitoring, omeprazole 20mg daily for 12 weeks led to modest 
symptom improvement (1751).
Proton pump inhibitors frequently cause gastrointestinal 
symptoms and increase the risk to acquire pneumonia in 
children and respiratory infection in adults (1752, 1753). Current data 
do not provide sufficient evidence for proton pump inhibitor 
treatment for CRSsNP in adults (grade of recommendation D).
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6.4. Evidence based surgery for CRSsNP
6.4.1. Summary
Although trials providing high level evidence are missing, 
a number of large, well organised prospective studies has 
shown that endoscopic sinus surgery (ESS) is safe and effective 
in managing patients with CRS without NP when medical 
treatment has failed. ESS is more likely to be effective in 
managing nasal obstruction and facial pain than postnasal drip 
or Hyposmia and is associated in significant improvements 
in generic as well as disease specific quality of life outcomes.  
Middle meatal antrostomy as opposed to simple uncinectomy 
and (targeted) partial removal of the middle turbinate may 
be associated with improved endoscopic and radiological 
outcomes but not subjective improvements. 
6.4.2. Introduction
Surgery is an imprecise art, and surgeons have traditionally had 
to make decisions with limited facts: Unfortunately, a look at 
the past will reveal a surgical landscape virtually “littered “ with 
procedures and interventions that have now been abandoned 
and are deemed useless and even harmful. Evidence-based 
surgery emphasizes the need to evaluate adequately the 
efficacy of surgical interventions before accepting them 
as standard. Essential for evidence-based surgery is a clear 
definition of the disease and standardized outcome measures.
6.4.3. Evidence based surgical treatment of 
rhinosinusitis
Evidence based medicine does not always have to be based 
on randomized controlled trials (RCT). In surgery (just as in 
parachuting (1754)) it is often not ethical or possible to do RCTs; 
however, the fact remains that we need to evaluate the available 
evidence to prevent us from giving our patients ineffective or 
even harmful treatments. Evaluation of the available evidence 
is not always easy: There are a number of potential biases 
in all types of medical research (expectancy bias/patients 
expectations from treatment, variations between patients/
selection bias, co-intervention and timing bias, publication bias 
and withdrawal bias). Surgical studies introduce additional types 
of bias, including the lack of patient blinding to the surgical 
intervention and performance bias (procedures or interventions 
are not executed in a uniform way – any one surgeon may do 
the same procedure in a different way from day to day, and that 
is even more true between different surgeons). Despite these 
difficulties, studies are being performed, and sinus surgeons 
should critically evaluate published evidence and adjust their 
practices accordingly. We will attempt in this article to assess 
evidence on surgery for CRSsNP or CRSwNP, taking into account 
however, that many studies included patients with CRS with and 
without nasal polyps.
6.4.4. Functional endoscopic sinus surgery in 
CRSsNP
Large prospective studies and case series have 
shown that endoscopic sinus surgery is effective 
and safe for the management of patients of CRS 
without NP who have failed medical treatment
6.4.4.1. Randomised controlled trials
The “holy grail” of evidence-based medicine is the Randomised 
Controlled trial (RCT). However, the search for such studies is 
not always successful, and in the meanwhile, surgeons have 
to practice with the (best) available evidence. The Cochrane 
collaboration re-assessed and revised in 2009 (1755) the evidence 
for surgery in CRS: they screened 2323 studies and found 6 
randomised control trials:  Using strict methodological quality 
inclusion criteria they excluded 3 of these studies and examined 
the three remaining RCTs: the first one, a University of London 
thesis written by Fairley in 1993 (1153) compared 12 patients with 
CRS undergoing endoscopic middle meatal antrostomy with 
17 patients who undergoing conventional intranasal inferior 
meatal antrostomy. The study found symptom improvement 
in both groups but no differences between groups; one year 
follow-up data were available for 11 patients and 9 patients 
respectively, a sample size the author acknowledges as being 
too small to exclude a type II error. The second study from 
1997 (1756) assessed patients with isolated maxillary sinusitis and 
compared symptom improvement after ESS and after saline 
rinses among patients randomized before antibiotics were 
Table 6.4.1.  Randomised controlled studies comparing surgery with medical treatment in Chronic Rhinosinusitis without Nasal Polyps.
Author N Follow up Inclusion criteria Non ESS group ESS group Outcome
Hartog 
1997 (1756)
89 (77) 12-52 wks Rhinorhea /obstruc-
tion/headache and 
radiological evidence 
of maxillary opacifi-
cation
Sinus irrigation + Loracarbef 
po 10 days
Sinus irrigation+ 
loracarbef po 10 
days + ESS
No difference in overall 
cure rates, ESS group 
improved more in post-
naasal discharge and 
hyposmia
Ragab 
2004 (16)
90 (78) 52 wks 2 major or one 
major and 2 minor 
symptoms and CT 
evidence of CRS
3 months of erythromycin + 
nasal steroid + nasal douche
ESS+nasal steroid 
+ nasal douche
No difference in 
total symptom scores, 
greater improvement in 
nasal volume in surgical 
group
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administered. The third study by Ragab et al. from 2004 (16) was 
the most relevant of the three as it randomized 90 patients with 
CRS with and without NP in medical (long term antibiotics) 
or surgical (ESS) management and assessed both objective 
(endoscopic scores, nitric oxide, PNIF and saccharine clearance 
time) and patient reported outcomes (symptoms VAS, SF36 
and SNOT 20 scores). It found that both treatments significantly 
improved almost all the subjective and objective parameters of 
CRS (P <.01), with no significant difference being found between 
the medical and surgical groups, except for the total nasal 
volume, in which the surgical treatment demonstrated greater 
changes. The effect of surgery was the same in both CRS groups 
(with and without NP). However, the surgical group received 
only 2 weeks of erythromycin after surgery while the medical 
group received 3 months of erythromycin after randomization. 
However, there was no placebo group, which somewhat reduces 
the importance of findings.
The Cochrane collaboration, using data from these 212 patients, 
stated that “(ESS) has not been demonstrated to confer 
additional benefit to that obtained by medical treatment with 
or without antral irrigation in relieving the symptoms of chronic 
rhinosinusitis”. However, our impression is that there was simply 
insufficient evidence for any comment about the value of ESS 
compared with medical treatment based on these three studies. 
The first study included in the Cochrane review (1153)  did not 
compare ESS with medical treatment, and the other two studies 
(16, 1756) did not analyse ESS results among patients who failed 
medical treatment, including antibiotic therapy. Indeed, current 
thinking precludes that sinus surgery must be always preceded 
and/or followed by various forms of medical treatment. This, 
together with the fact that surgery is often suggested for 
patients who fail medical therapy render comparisons of 
medical treatment with surgery difficult (Table 6.4.1). 
6.4.4.2. Case series, case-control and cohort studies
RCTs in surgery are notoriously difficult to organise and (as in 
the case of truly blind “sham” studies), potentially unethical. 
If these are not available, it is appropriate to assess the 
available evidence, even if it is grade 2 or 3. Indeed, it seems 
counterintuitive to ignore high quality evidence collected from 
thousands of patients purely on the grounds that they did not 
form part of a randomised controlled trial.
In 2000 the Clinical Effectiveness Unit of the Royal College of 
Surgeons of England conducted a National Comparative Audit 
of the Surgery for Nasal Polyposis and Chronic Rhinosinusitis 
covering the work of 298 consultants working in 87 hospital 
sites in England and Wales (1757). Patients undergoing sinus 
surgery were prospectively enrolled and followed up in this 
observational study at 3, 12 and 36 months post-operatively 
using the SNOT-22 as the main outcome measure. Two thirds 
(2176) of the 3128 patients participating in this study had CRS 
with nasal polyps. CRS patients with nasal polyps suffered more 
frequently from concomitant asthma and ASA-intolerance, 
had more previous sinonasal surgery, their mean CT score 
was higher and their mean SNOT-22 symptom score was 
slightly lower than that of CRS patients without polyps. All 
forms of sinus surgery were included though the majority 
were performed endoscopically. Overall there was a high 
level of satisfaction with the surgery and clinically significant 
improvement in the SNOT-22 scores was demonstrated at 3, 
12 and 36 months (1757) (Figure 6.4.1.). Patients with chronic 
rhinosinusitis without polyps benefited less from surgery than 
polyp patients; surgery was indicated in 3.6% of patients at 12 
months and 11.8% at 36 months. Major complications were 
very uncommon. Five year follow up results from almost half of 
the patients of this audit were published in 2009 (1758): Nineteen 
percent of patients surveyed eventually underwent revision 
surgery during these five years, including 15% of patients with 
CRS without NP. The mean SNOT-22 score for all patients was 
28.2, very similar to the results observed at 36 months (27.7), 
and represents a consistent 14-point improvement over the 
baseline score. Scores were better for polyp patients (mean = 
26.2) than patients with CRS alone (mean = 33.3). (Evidence level 
IIc)
Long term revision rates in patients with CRSsNP 
have been shown to be above 10% 
(and as high as 15-20%)
6.4.4.3. Symptom-specific outcomes
A recent review by Chester et al (1759), screened 289 studies 
including only studies with 20 or more patients who used 
symptom severity scores to analyse at least 3 CRS symptoms 
(facial pressure, nasal obstruction, postnasal discharge, 
hyposmia and headache). They eventually included 21 studies 
and 2070 patients with CRS with or without NP a mean of 13 
months after ESS: All symptoms improved compared with 
their preoperative scores by an overall Effect Size of 1.19 (95% 
confidence interval, 0.96 to 1.41). Nasal obstruction (Effect 
Size, 1.73) improved the most, with facial pain (ES, 1.13) and 
postnasal discharge (ES, 1.19) demonstrating moderate 
improvements. Hyposmia (ES, 0.97) and headache (ES, 0.98) 
improved the least (Evidence level IV).
6.4.4.4. Quality of life outcomes
6.4.4.4.1. Generic QOL
A number of studies have shown improvement in generic 
QOL outcome measures after surgery: Among others, a study 
published in 2010 (1760) included three hundred thirty-six patients 
assessed with Short Form 36 Health Survey (SF-36) four months 
after surgery: the SF36 scores that were significantly decreased 
before surgery improved and came very close to normal 
levels. Another study that used the SF-36 in 150 patients after 
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a mean follow-up of 3 years showed statistically significant 
improvements in QOL scores postoperatively. Importantly, the 
scores improved to the point of reaching general population 
levels.
6.4.4.4.2. Disease specific QOL
A variety of disease – specific instruments have been used 
to assess QOL changes after ESS: These included the Chronic 
Sinusitis Survey and the Rhinosinusitis Disability Index (1760, 1761), 
SNOT 20  (1757, 1762), SNOT 22 (1758) RSOM 31 (1763). In all of these 
studies, evidence of improvement of generic and disease 
specific QOL with surgery was shown. Deal and Kountakis 
(1762) using SNOT 20 showed that patients with nasal polyps 
have worse nasal QOL compared to CRS without NP patients 
while the English National Comparative Audit using SNOT 22 
showed the opposite. However, both studies confirmed that 
the improvement in QOL after surgery was more pronounced 
in patients with nasal polyps compared to CRS patients without 
polyps (1758) (Evidence level IIc).
6.4.4.5. Conclusion
It is fair to say that trials providing high level evidence of the 
efficacy of ESS for CRS are missing, as only a small percentage 
of the studies are RCTs, and those who are have inconsistent 
inclusion criteria, outcome measures and types of interventions 
making generalisations difficult.  Additionally, intervention bias 
(the variability in surgical techniques and in experience between 
different surgeons) should not be underestimated.  Having 
said that, there is a significant amount of well designed level 
II-level III evidence collected from tens of thousands of patients, 
that endoscopic sinus surgery is safe and is associated with 
improvements in symptoms scores (especially nasal obstruction 
and discharge), disease specific and generic QOL as well as 
objective measures.
6.4.5. Functional endoscopic sinus surgery versus 
conventional surgery
There have been no studies comparing open ethmoidectomy/
sphenoethmoidectomy with endoscopic sinus surgery for CRS.
Lund (1764) examined retrospectively long term outcomes of 
inferior and middle meatal antrostomy and showed better 
outcomes in the endoscopic middle meatal antrostomy group.  
Penttila compared in a RCT ESS and Caldwell Luc and showed 
marked improvement in 50.7% of the C-L group and in 76.7% 
of the FESS group at one year (1765). Venkatachalam compared 
in a RCT conventional surgery with ESS and found that ESS was 
associated with greater rates of complete relief of symptoms 
(76% versus 60%) and better overall outcomes (2064).
Conclusion
Functional endoscopic surgery is superior to conventional 
procedures including polypectomy, Caldwell-Luc, inferior 
meatal antrostomy and antral irrigations, but superiority to 
conventional sphenoethmoidectomy is not yet proven.
6.4.6. ESS modifications / extent of surgery
While there is some evidence that more extensive 
surgery (larger middle meatal antrostomy, 
widening of the frontal recess, more extensive 
sphenoithmoidectomy) may be associated with 
better objective outcomes, it is suggested to tailor 
the extent of surgery to the extent of disease.
Extent of surgery may vary from mere uncinectomy to radical 
sphenoethmoidectomy with middle turbinate resection. 
In several studies, the extent of sinus surgery on various 
outcome parameters was investigated in CRS patients, not 
differentiating between CRS with and without polyps. In a 
prospective trial, 65 CRS patients with and without polyps were 
randomized to undergo limited endonasal functional surgery 
(uncinectomy) and a more extensive functional procedure 
including sphenoethmoidectomy and wide opening of the 
frontal recess. Disease extent was similar in both treatment 
arms. Outcome parameters included symptom scores, 
rhinoscopy scores and nasal saccharin transport time (1766). 
Outcome parameters revealed no relevant differences after 
3, 6 and 12 months, however, recall rates lower than 60% 
limit the usefulness of this study . Jankowski and co-authors 
retrospectively compared a case series of 37 CRS patients 
with extensive nasal polyps treated with FESS with a historical 
group of 36 patients with similar disease extent treated with 
radical sphenoethmoidectomy and middle turbinate resection 
(1767). Outcome parameters assessed 5 years following surgery 
included a mailed questionnaire on nasal symptoms, the 
number of patients with revision surgery, and nasal endoscopy 
scores at a follow up visit. Recall was below 80% and differed 
significantly between the two groups. The radical surgical 
procedure yielded better symptom scores, less recurrences, and 
better endoscopic scores at the follow up visit (Evidence level 
IV).
In a randomized trial, 1,106 matched CRS patients with and 
without polyps, who underwent similar functional endonasal 
sinus surgery with (509 patients) or without (597 patients) 
partial middle turbinate resection (1768). Partial middle turbinate 
resection was associated with less adhesion formation and 
less revision. Complications specific to partial middle turbinate 
resection were not observed (Evidence level Ib). In a study by 
Marchioni et al, 22 patients with middle turbinate resection and 
34 patients with turbinate preservation were followed for three 
years. Patients without middle turbinate resection were shown 
to have earlier relapse of polyposis as judged by endoscopy 
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examination (1769). A recent non randomised prospective study 
compared patients on which 2/3 of the medial turbinate 
were removed (on medical reasons) with those where it was 
preserved (1770). It is interesting to note that patients with MT 
resection were more likely to have asthma , aspirin intolerance, 
nasal polyposis, and prior sinus surgery, and higher baseline 
disease burden. Although there were no differences in generic 
or disease specific QOL measures, patients undergoing MT 
resection were more likely to show improvements in mean 
endoscopy and olfaction.
The patency rate after large middle meatal antrostomy and 
undisturbed maxillary ostium in endoscopic sinus surgery for 
CRS without nasal polyps was compared in a recent (2011) study: 
thirty patients with CRS without NP underwent randomized 
endoscopic sinus surgery (1771). A large middle meatal 
antrostomy was performed on one side, whereas on the other 
side an uncinectomy preserving the natural maxillary ostium 
was done. The patency rates of the middle meatal antrostomy 
were significantly higher and the radiological Lund-McKay score 
was lower 9 months after surgery when compared to the side 
with the undisturbed maxillary ostium. This difference however 
did not translate to improved subjective outcomes (Evidence 
level Ib). 
6.4.6.1. Balloon catheter 
In a recent Cochrane review (2065) as well as in an  evidence 
– based review published in 2011 (1772), Batra et al. assessed 
the evidence available for new ballon catheter systems for 
sinus surgery in CRS: There have not been any prospective 
comparative studies comparing it to standard FESS techniques. 
The one retrospective comparative study referred to patients 
with recurrent acute or mild CRS and the patients elected 
themselves the way of treatments, while follow up was 3 
months, precluding any meaningful conclusions. On the other 
hand, a number of prospective multicentre studies assessing the 
balloon catheter systems have been published, which confirm 
a good safety profile (albeit not complication – free (1773)), but 
have unclear inclusion criteria, making their results difficult 
to generalise. Overall, the place of these systems in the sinus 
surgeon’s armamentarium remains unclear (Evidence level IV).
Conclusion
Although not fully evidence based, the extent of surgery is 
frequently tailored to the extent of disease, which may appear 
as a reasonable approach. In primary paranasal sinus surgery, 
surgical conservatism is recommended. The decision to preserve 
or resect the middle turbinate can be left to the discretion of 
the surgeon based on its disease status. There is not enough 
data to support the use of balloon catheters as an alternative to 
standard endoscopic sinus surgery techniques.
6.4.8. Revision sinus surgery
Approximately 20% of operated patients respond 
unsatisfactorily to sinus surgery with concomitant medical 
therapy and eventually require a secondary surgical procedure 
(1758). Middle turbinate lateralisation, adhesions and scar 
formation in the middle meatus, an incompletely resected 
uncinate process, and retained ethmoid cells are frequent 
findings in patients undergoing revision surgery (1778). Previous 
revision surgery, extensive polyps, bronchial asthma, ASA-
intolerance and cystic fibrosis are predictors of revision surgery 
(1762, 1775, 1779). Inflammatory involvement of underlying bone may 
also be of significance (1388). Technical issues of sinus revision 
surgery have be reported by Cohen and Kennedy (1780) and 
Javer more recently (1781). A more extensive surgical procedure 
and also external approaches may be indicated (1767, 1782). 
Success rates of revision endoscopic sinus surgery have been 
reported to range between 50 and 70% (762, 1783). Complication 
rates of revision surgery are higher when compared with 
initial surgery and approximate 1%, but may be as high as 
7% (1784, 1785), McMains and Kountakis also reported the results 
of 59 CRS patients with nasal polyps after revision surgery 
(1779). Consistent with the results of the National Comparative 
Audit (1757) and the comparative study by Deal and co-workers 
(1762), CRS patients without polyps had higher SNOT scores 
preoperatively (more severe symptoms), less previous surgeries, 
and a lower CT score preoperatively than CRS patients with 
polyps. However, the improvement of outcome parameters 
after revision surgery was significant and comparable with the 
improvement in CRS patients without polyps, greater even 
after 5 years (1758) in the case of the English National Audit study. 
The same was found in, a recent comparative study (1786) that, 
Figure 6.4.1 SNOT-22 scores in the National Comparative Audit in CRS 
patients with and without nasal polyps (adapted from Hopkins, 2006 
(1757).
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using Rhinosinusitis Disability Index (RSDI) and Chronic Sinusitis 
Survey (CSS) showed that the improvement in QOL is the same 
in patients undergoing revision or primary surgery, although 
the endoscopic improvement was CRS without NP patients 
undergoing revision surgery.
Schlosser (1787) and Ferguson (1788) looked at patients who 
underwent multiple failed procedures: such patients often 
harbour subtle humoral immunodeficiencies, systemic 
granulomatous or eosinophilic syndromes. There are a handful 
of observational studies suggesting that patients with aspirin 
exacerbated respiratory disease may benefit from aspirin 
desensitization, while dealing with allergy with antihistamines 
and desensitisation, as well as long term, culture driven 
antibiotics and an intensive program of nasal lavage may 
improve outcome.
 
Conclusion
Revision endonasal sinus surgery is only indicated, if medical 
treatment is not sufficiently effective. Substantial symptomatic 
improvement is generally observed in both, CRS with and 
without polyps, though the improvement maybe somewhat less 
than after primary surgery. Complication rates and particularly 
the risk of disease recurrence are higher than after primary 
surgery. Some patients still suffer from CRS symptoms after 
several extensive surgical procedures. CT scans frequently show 
mucosal alterations adjacent to osteitic bony margins in an 
extensively operated sinus system. As a rule, revision surgery 
is not indicated in these patients but radical surgery can be an 
option (1782). 
6.5. Treatment with corticosteroids in
CRSwNP 
6.5.1. Introduction
In this chapter a differentiation is made between CRSsNP 
and CRSwNP. Readers have to realize that often in studies no 
clear difference is made between these two patients groups. 
Sometimes for this reason studies are discussed in both the 
parts on CRSsNP as the parts of CRSwNP.
In studies on the treatment of CRSwNP, it is of value to look 
separately at the effect on rhinitis symptoms associated with 
polyposis and the effect on the size of nasal polyps per se.  
There are many symptom aspects of CRSwNP and we have also 
included an objective measure of nasal obstruction, nasal peak 
inspiratory flow (PNIF), as this was the most commonly reported 
objective measure behind endoscopy. 
6.5.2. Local corticosteroid (INCS) in chronic 
rhinosinusitis with nasal polyps 
Considering the number of studies in the literature, only 
RCTs will be referred to in this summary.  INCS for CRSwNP 
encompasses range of different treatment regimes.  These have 
been carefully described in the Table of study characteristics 
(Table 6.5.1.).
6.5.2.1. Inclusion criteria and exclusion criteria
Inclusion criteria
Patients with benign nasal polyps diagnosed clinically with 
either:
•	  endoscopic evidence of nasal polyps; or/and
•	  radiological evidence of nasal polyps
Exclusion criteria
•	  Antrochoanal polyps (benign polyps originating from the 
mucosa of the maxillary sinus).
•	  Malignant polyps.
•	 Cystic fibrosis.
•	  Primary ciliary dyskinesia
6.5.2.2. Types of interventions  
•	  Topical steroids versus no intervention.
•	  Topical steroids versus placebo.
•	 Topical and oral steroids versus oral steroids only
6.5.2.3. Flow chart
A total of 873 references were retrieved: three more records 
were identified from references of retrieved studies. 735 of 
these were removed in first-level screening (i.e. removal of 
duplicates and clearly irrelevant references), leaving 141 
references for further consideration. Title and abstracts were 
screened and 93 studies were subsequently removed. Forty-
eight full texts were assessed for eligibility. Three papers were 
abstracts of presentations at academic meetings of included 
studies. One paper pooled data from two included studies 
for reanalysis. Three non-randomized studies and neither two 
studies comparing topical steroid to neither placebo nor no 
intervention were excluded. Thirty-nine studies were included. 
A flow chart of study retrieval and selection is provided in Figure 
6.5.1.
6.5.2.4. Included studies
There were 3,532 participants totally in 38 included studies. The 
mean age of patients was 48.2 years. The percentage of men 
was 66.6. The characteristics of included studies are listed as 
Table 6.5.1. 
6.5.2.5. Summary of data
Thirtyfour trials (92%) compared topical steroid against placebo 
(Aukema 2005; Bross-Soriano 2004; Chalton 1985; Dingsor 1985; 
Djikstra 2004; Drettner 1982; Ehnhage 2009; Filiaci 2000; Hartwig 
1988; Holmberg 1997; Holmstrom 1999; Holopainen 1982; 
Jankowski 2001; Jankowski 2009; Johansen 1993; Johansson 
2002; Jorissen 2009; Keith 2000; Lang 1983; Lildholdt 1995; Lund 
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1998; Mastalerz 1997; Mygind 1975; Olsson 2010; Passali 2003; 
Penttila 2000; Rowe-Jones 2005; Ruhno1990; Small 2005; Stjarne 
2006; Stjarne 2006b; Stjarne 2009; Tos 1998; Vlckova 2009) (1109, 
1172, 1426, 1668, 1674, 1789-1816). Among these, eight trials also compared 
low dose to high dose of topical steroid (Djikstra 2004; Filiaci 
2000; Jankowski 2001; Lildholdt 1995; Penttila 2000; Small 2005; 
Stjarne 2006; Tos 1998) (1668, 1794, 1804, 1808, 1810, 1813, 1815-1817) and three 
trials also compared two steroid agents, fluticasone propionate 
and beclomethasone dipropionate (Bross-Soriano 2004; 
Holmberg 1997; Lund 1998) (1109, 1790, 1796).
Three trials (8%) compared topical steroid against no 
intervention (El Naggar 1995; Jurkiewicz 2004; Karlsson 1982) 
(1818-1820).
Twenty (55%) included studies were fully or partially sponsored 
by pharmaceutical companies; Glaxo (Aukema 2005; Djikstra 
2004; Ehnhage 2009; Holmberg 1997; Keith 2000; Lund 1998; 
Mastalerz 1997; Mygind 1975; Olsson 2010; Penttila 2000; 
Rowe-Jones 2005) (1109, 1172, 1426, 1668, 1789, 1796, 1802, 1805, 1806, 1808, 1821). Astra 
(Johansen 1993; Johansson 2002; Ruhno1990; Tos 1998) (1800, 1801, 
1809, 1813) and Schering Plough (Jorissen 2009; Small 2005; Stjarne 
2006; Stjarne 2006b; Stjarne 2009) (1674, 1810-1812, 1816)..
The steroid agents used were differed across the studies:
1. Fluticasone propionate was studied in 15 trials (Aukema 
2005; Bross-Soriano 2004; Djikstra 2004; Ehnhage 2009; 
Holmberg 1997; Holmstrom 1999; Jankowski 2009; 
Jurkiewicz 2004; Keith 2000; Lund 1998; Mastalerz 1997; 
Olsson 2010; Penttila 2000; Rowe-Jones 2005; Vlckova 2009) 
(1109, 1172, 1426, 1668, 1789, 1790, 1796, 1797, 1799, 1802, 1805, 1808, 1814, 1819, 1821).
2. Beclomethasone dipropionate was studied in 7 trials (Bross-
Soriano 2004; El Naggar 1995; Holmberg 1997; Lund 1998; 
Karlsson 1982; Lang 1983; Mygind 1975) (1109, 1790, 1796, 1803, 1806, 
1818, 1820).
3. Betamethasone sodium phospate was studied in 1 trial 
(Chalton 1985) (1791)..
4. Mometasone furoate was studied in 6 trials (Jorissen 2009; 
Passali 2003; Small 2005; Stjarne 2006; Stjarne 2006b; 
Stjarne 2009) (1674, 1807, 1810-1812, 1816, 1822-1825).
5. Flunisolide was studied in 2 trials (Dingsor 1985; Drettner 
1982) (1792, 1793).
6. Budesonide was studied in 9 trials (Filiaci 2000; Hartwig 
1988; Holopainen 1982; Jankowski 2001; Johansen 1993; 
Johansson 2002; Lildholdt 1995; Ruhno1990; Tos 1998) (1794, 
1795, 1798, 1800, 1801, 1804, 1809, 1813, 1815).
Table 6.4.3. Factors associated with outcome after endoscopic sinus surgery.
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Kennedy, 1992 (762) verbal rating, endoscopy 120 u2 - - yes no no - no
Chambers 1997 (1421) questionnaire, endoscopy 182 12 u1 - - - no no no
Gliklich, 1997 (1774) SF-36, CSS, endoscopy 108 6 m3 no no no4 - no no
Marks, 1997 (1775) improvement score 93 12 u no yes5 - no no no - -
Marks, 1997 (1775) endoscopy score 93 12 m no no - yes no no - -
Wang, 2002 (1776) CSS 230 6 m - - yes yes - - - -
Wang, 2002 (1776) endoscopy score 230 6 m - yes - - - -
Kim, 2005 (1777) endoscopy score 98 12 m no no - no no yes - -
Smith, 2005 (1761) endoscopy score 119 12 m - no yes 0.09 no no no yes 
Smith, 2005 (1761) CSS/RSDI 119 12 m - no yes no no no no yes 
Smith, 2010 (1189) CSS /RSDI 302 12 yes no no no
1 stratified for disease severity
2 univariate
3 multivariate
4 high preoperative CSS score was associated with worse outcome
5 less symptomatic improvement in females (p=0.008)
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A summary of outcomes is provided in Table 6.5.3. with the 
majority demonstrating a benefit to the use of INCS.
6.5.2.6. Meta-analysis
When compared to placebo, pooled data analyses of symptoms, 
polyp size, polyp recurrence and nasal airflow demonstrated 
significant benefit in the topical steroid group. Although these 
outcomes were reported in various ways across studies such 
as the final value, the change of value after intervention and 
the proportion of responders, all meta-analyses show the same 
results favouring topical steroid. Although 32, 29 and 22 studies 
reported symptoms, polyp size and nasal airflow, data from only 
9, 13 and 9 studies respectively can be pooled for meta-analysis. 
Most studies do not provide numeric data of the outcomes or 
do not show any of standard deviation, standard error, 95%CI, 
range nor interquartile range. Data from only one study was 
analyzed for change in CT scan (1789), and quality of life (1172). 
No difference from placebo was found in these 2 outcomes. 
Olfactory outcomes are mentioned in 22 studies (1426, 1797, 1800, 
1802, 1804, 1808, 1810-1814, 1816, 1818) and with mixed benefit to INCS. More 
studies may be helpful to make conclusions for these three 
outcomes.
6.5.2.6.1. Symptom improvement (score or responders)
Data addressing the change in combined symptom scores 
was available from seven studies (1674, 1794, 1798, 1801, 1805, 1806, 1814) and 
could be combined in the meta-analysis. The pooled results 
significantly favoured the topical steroid group (SMD -0.46; 
95% CI -0.65 to -0.27), p<0.00001; seven trials, 445 patients) 
(Figure 6.5.2.A). Data addressing the proportion of responders 
in symptoms was available from four studies (1794, 1796, 1806, 1808). The 
pooled results significantly favoured the topical steroid group 
(RR (Non-event) 0.59; 95% CI 0.46 to 0.78), p=0.0001 (Figure 
6.5.2.B).
6.5.2.6.2. Polyp size (score, change or responders on 
endoscopy)
Data addressing the final value of polyp score at the endpoint 
was available from three studies (Dingsor 1985; Hartwig 
1988; Johansson 2002) (1792, 1795, 1801) and could be combined in 
the meta-analysis. The pooled results significantly favoured 
the topical steroid group (SMD -0.49; 95% CI -0.77 to -0.21), 
p=0.0007 (Figure 6.5.3.A).  Data addressing the change in polyp 
score was available from three studies (1806, 1814, 1815).
and could be combined in the meta-analysis. The pooled results 
significantly favoured the topical steroid group (SMD -0.73; 95% 
CI -1.00 to -0.46), p<0.00001 (Figure 6.5.3.B).  Data addressing 
the proportion of responders in polyp size was available 
from eight studies (1791, 1797, 1798, 1802, 1803, 1808, 1811, 1814) and could be 
combined in the meta-analysis. The pooled results significantly 
favoured the topical steroid group (RR (Non-event) 0.74; 95% CI 
0.67 to 0.81), p<0.00001. (Figure 6.5.3.C)
6.5.2.6.3. Nasal breathing (score, change or responders on 
Peak Nasal Inspiratory Flow (PNIF))
Data addressing the peak nasal inspiratory flow was available 
from seven studies (1789, 1798, 1799, 1801, 1805, 1809, 1814) and could be 
combined in the meta-analysis. The pooled results significantly 
favoured the topical steroid group (MD 22.04; 95% CI 13.29 to 
30.80), p<0.00001 (Figure 6.5.4a).  Data addressing the change 
in nasal airflow was available from three studies (Ehnhage 
2009; Holmstrom 1999; Ruhno1990) (1797, 1809, 1818) and could be 
combined in the meta-analysis. The pooled results significantly 
favoured the topical steroid group (SMD -0.57; 95% CI -0.85 to 
-0.29), p=0.0001 (Figure 6.5.4b). Data addressing the proportion 
of responders in nasal airflow was available from two studies 
(Chalton 1985; Ruhno1990) (1791, 1809) which significantly favoured 
the topical steroid group (RR (Non-event) 0.55; 95% CI 0.33 to 
0.89), p=0.02 (Figure 6.5.4.c.).
The standardised mean difference (SMD) and 95% CIs for 
continuous data such as post-intervention scores or change in 
symptom scores. The risk ratio (RR) and 95% CI of responsiveness 
was used at a specific time point for dichotomous data such as 
number of patients responding to treatment. The intervention 
effects were pooled when trials were sufficiently homogeneous. 
The SDs were imputed from p values for Lund 1998 after 
assuming parametric data. A fixed-effect model was used and 
assumed that each study was estimating the same quantity. 
6.5.2.7. Subgroup analysis 
Subgroup analysis was performed as follows.
•	  Surgical status
•	  Patients with prior sinus surgery versus those without sinus 
surgery.
•	  Topical delivery method
•	  Nasal drops versus nasal sprays versus sinus (direct cannula-
tion, irrigation post-surgery) delivery method.
•	  Corticosteroid type 
•	  Modern corticosteroids (mometasone, fluticasone, cicleso-
nide) versus first-generation corticosteroids (budesonide, 
beclomethasone, betamethasone, triamcinolone, dexamet-
hasone)
Differences between the two subgroups for fixed-effect analyses 
were based on the inverse-variance method in the case of 
continuous data and the Mantel-Haenszel method in the case of 
dichotomous data.
The 38 included studies were diverse, both clinically and 
methodologically. Variability included sinus surgery status, topical 
delivery methods, polyp severity, steroid agent used and regimes. 
Subgroup analyses were performed to investigate heterogeneity. 
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Table 6.5.1. Characteristics of included studies on INCS for CRScNP.
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 100 mcg (ages 
6-11y) 
 200 mcg 
(ages 12-17y)        
arm1. od arm2. 
bid
without 
sinus 
surgery
spray 16 placebo
Olsson 2010 
(1172)
RCT CRSwNP (by 
endoscopy)
68 51.6 fluticasone 
propionate
400mcg bid with sinus 
surgery
nasal 
drop
10 placebo
Ehnhage 2009 
(1426)
RCT CRSwNP (by 
endoscopy)
68 51.6 fluticasone 
propionate
400 mcg bid with sinus 
surgery
nasal 
drop
10 placebo
Jankowski 
2009 (1799)
RCT CRSwNP (by 
endoscopy)
242 51 fluticasone 
propionate
200mcg bid without 
sinus 
surgery
spray 4 placebo
Jorissen 2009 
(1674)
RCT mixed CRS (by 
endoscopy)
99 47.4 mometasone 
furoate
200 mcg bid with sinus 
surgery
spray 24 placebo
Stjarne 2009 
(1812)
RCT CRSwNP (by 
endoscopy)
159 48.5 mometasone 
furoate
200 mcg od with sinus 
surgery
spray 24 placebo
Vlckova 2009 
(1814)
RCT CRSwNP, small 
to medium size 
(by endoscopy)
109 47.9 Fluticasone 
propionate
400mcg bid mixed spray 12 placebo
Stjarne 2006 
(1816)
RCT CRSwNP (by 
endoscopy)
310 48.6 mometasone 
furoate
arm 1. 200 
mcg od                  
arm 2. 200 
mcg bid
without 
sinus 
surgery
spray 16 placebo
Stjarne 2006b 
(1811)
RCT CRSwNP (by 
endoscopy)
298 53 mometasone 
furoate
200 mcg od mixed spray 16 placebo
Aukema 2005 
(1109)
RCT CRSwNP (by 
endoscopy and 
CT)
54 44 fluticasone 
propionate
400 mcg od mixed nasal 
drop
12 placebo
Rowe-Jones 
2005 (1821)
RCT CRSwNP (by 
endoscopy)
109 41 fluticasone 
propionate
200 mcg bid with sinus 
surgery
spray 260 placebo
Small 2005 
(1810)
RCT CRSwNP (by 
endoscopy)
354 47.5 mometasone 
furoate
arm 1. 200 
mcg od                  
arm 2. 200 
mcg bid
without 
sinus 
surgery
spray 16 placebo
Bross-Soriano 
2004 (1109)
RCT CRSwNP (NS) 142 40.4 Arm1.flutica-
sone propion-
ate   Arm2. be-
clomethasone 
dipropionate
arm1. FP 
400 mcg od     
arm2. Beclo 
600 mcg od
with sinus 
surgery
spray (af-
ter saline 
lavage)
72 saline 
lavage 
only
Dijkstra 2004 
(1668)
RCT mixed CRS (by 
endoscopy and 
CT)
162 41 fluticasone 
propionate
arm1. 
400µg bid             
arm2.800µg 
bid 
with sinus 
surgery
spray 52 placebo
Jurkiewickz 
2004 (1819)
RCT CRSwNP (NS) 86 NS fluticasone 
propionate
400mcg bid with sinus 
surgery
spray 52 no treat-
ment
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Passali 2003 
(1807)
RCT CRSwNP, 
medium to 
large size (by 
endoscopy)
73 37.3 mometasone 
furoate
400mcg od with sinus 
surgery
spray 52 (at 
least)
1.pla-
cebo 
2.intra-
nasal 
furosem-
ide
Johansson 
2002 (1801)
RCT CRSwNP (by 
endoscopy)
98 56 budesonide 128 mcg bid without 
sinus 
surgery
spray 2 placebo
Jankowski 
2001 (1804)
RCT CRSwNP (by 
endoscopy)
183 44 budesonide arm1. 128mcg 
od arm2. 
128mcg bid 
arm3. 256mcg 
od
without 
sinus 
surgery
spray 8 placebo
Filiaci 2000 
(1794)
RCT CRSwNP (by 
endoscopy and 
MRI)
157 47.9 budesonide arm 1.  140mcg 
bid arm 2. 
280mcg od arm 
3. 140mcg od
without 
sinus 
surgery
turbu-
haler
8 placebo
Keith 2000 
(1802)
RCT CRSwNP, small 
to medium size 
(by endoscopy)
104 48 fluticasone 
propionate
400 mcg od mixed nasal 
drop
12 placebo
Pentilla 2000 
(1808)
RCT CRSwNP, small 
to medium size 
(by endoscopy)
142 51 fluticasone 
propionate
arm 1. 400 
mcg bid arm 2. 
400mcg od   
mixed nasal 
drop
12 placebo
Holmstrom 
1999 (1797)
RCT CRSwNP, small 
to medium size 
(by endoscopy)
104 NS fluticasone 
propionate
400 mcg od without 
sinus 
surgery
nasal 
drop
12 placebo
Lund 1998 
(1796)
RCT CRSwNP (by 
endoscopy and 
CT)
29 49.3 1.fluticasone 
propionate  
2.beclometh-
asone dipropi-
onate
arm 1. FP 400 
mcg bid arm 2. 
Beclo 400 mcg 
bid
mixed spray 12 placebo
Tos 1998 (1813) RCT CRSwNP, 
medium to 
large size (by 
endoscopy)
138 NS budesonide arm1. spray64 
mcg bid     
arm2. turbu-
haler 100 mcg 
per nominal 
dose/170 mcg 
per delivered 
dose bid
with sinus 
surgery
spray or 
turbu-
haler
6 placebo
Holmberg 
1997 (1790)
RCT CRSwNP (by 
endoscopy)
55 54 arm1. 
fluticasone 
propionate         
arm 2. be-
clomethasone 
dipropionate
arm1. FP200 
mcg bid arm2. 
Beclo200 mcg 
bid
with sinus 
surgery
spray 26 placebo
Mastalerz 
1997 (1805)
RCT 
cross-
over
mixed CRS, 
with aspirin 
sensitivity (NS)
15 44.7 fluticasone 
propionate
400mcg od without 
sinus 
surgery
spray 4 placebo
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El Naggar 
1995 (1818)
RCT CRSwNP (by 
endoscopy)
29 51.5 beclometh-
asone dipropi-
onate
100mcg bid in 
one nostril 
with sinus 
surgery
spray 6 no treat-
ment 
in the 
other 
nostril
Lidlholdt 1995 
(1804)
RCT CRSwNP (by 
rhinoscopy)
126 51 budesonide arm1. 200 mcg  
arm2. 400 mcg 
bid
without 
sinus 
surgery
turbu-
haler
4 placebo
Johansen1993 
(1800)
RCT CRSwNP, small 
to medium size 
eosinophilic 
polyps (by 
pathology)
91 52 budesonide 200mcg bid without 
sinus 
surgery
spray 
and 
aerosol
12 placebo
Ruhno1990 
(1809)
RCT CRSwNP (NS) 36 46.6 budesonide 400mcg bid with sinus 
surgery
spray 4 placebo
Hartwig 1988 
(1795)
RCT CRSwNP (by 
endoscopy)
73 54.2 budesonide 200 mcg bid with sinus 
surgery
aerosol 24 placebo
Chalton 1985 
(1791)
RCT CRSwNP (by 
endoscopy)
30 42 betametha-
sone
100mcg bid without 
sinus 
surgery
nasal 
drop
4 placebo
Dingsor 1985 
(1792)
RCT CRSwNP (by 
rhinoscopy)
41 49 flunisolide 100mcg bid with sinus 
surgery
spray 52 placebo
Land 1983 
(1803)
RCT CRSwNP, small 
to medium size 
(by endoscopy)
32 42 beclometh-
asone dipropi-
onate
400 mcg bid without 
sinus 
surgery
spray 104 placebo
Drettner 1982 
(1793)
RCT CRSwNP (NS) 25 43.8 flunisolide 100mcg bid with sinus 
surgery
spray 12 placebo
Holopainen 
1982 (1798)
RCT CRSwNP, small 
to medium size 
(by rhinoscopy)
19 42 budesonide 200 mcg bid with sinus 
surgery
spray 16 placebo
Karlsson 1982 
(1820)
RCT CRSwNP, me-
dium to large 
size (NS)
40 49 beclometh-
asone dipropi-
onate
400mcg od 
for1month then 
200mcg od
with sinus 
surgery
intrana-
sal
30 no treat-
ment
Mygind 1975 
(1172)
RCT CRSwNP, me-
dium to large 
size (NS)
35 51 beclometh-
asone dipropi-
onate
100mcg qid mixed aerosol 3 placebo
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Table 6.5.2. Outcome summary of studies using INCS for Chronic Rhinosinusitis with nasal polyps (No study had placebo favoured over INCS).
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Chur 2010 
(1822)
mometa-
sone 
furoate
100 mcg 
(ages 
6-11y) 
200 mcg 
(ages 
12-17y)        
Arm1. od 
Arm2. 
bid
spray placebo symptom scores 
(2 symp-
toms;0-4)
favour steroid 
bid (-40%) over 
od (-30%) and 
placebo (-28%)
polyp size 
reduction (NS)
favour steroid 
bid (-34%) over 
od (-26%) and 
placebo (-24%)
Olsson 
2010 (1172)
flutica-
sone pro-
pionate
400mcg 
bid
nasal 
drop
placebo general health 
quality of life 
(SF36;1-5)
favour steroid for 
mental compo-
nent (p=0.01) but 
not physical com-
ponent (p=0.08)
nil nil
Ehnhage 
2009 (1426)
flutica-
sone pro-
pionate
400 mcg 
bid
nasal 
drop
placebo nasal and 
asthma symp-
tom scores (5 
symptoms;0-3)
no difference  
(p>0.05)
polyp score 
(0-3)
no difference 
(p-value not 
shown)
Jankowski 
2009 (1799)
flutica-
sone pro-
pionate
200mcg 
bid
spray placebo symptom scores 
1. overall score 
(Likert;0-3) 
2.VAS (3 symp-
toms)
1.favour steroid 
(p=0.0001) 
2.favour steroid 
(p-value not 
shown)
polyp grade 
(0-3)
favour steroid 
(p<0.01 for 
right nostrils, 
p<0.001 for left 
nostrils)
Jorissen 
2009 (1674)
mometa-
sone 
furoate
200 mcg 
bid
spray placebo symptom VAS (5 
symptoms)
no difference  
(p=0.09)
1.endo-
scopic score (8 
variables;0-2) 
2.post-hoc 
combination 
endoscopic 
score (3 vari-
ables;0-2)
1.no differ-
ence (p=0.34) 
2.favour steroid 
(p=0.02)
Stjarne 
2009 (1812)
mometa-
sone 
furoate
200 mcg 
od
spray placebo symptom scores 
(3 symp-
toms;0-3)
1. favour steroid 
for rhinoorhea 
(p=0.04) 2. no 
difference for con-
gestion and sense 
of smell (p-value 
not shown)
polyp relapse 1. 
percentage of 
patients 2. time 
to relapse
1. favour steroid 
(33%)  over 
placebo (44%) 
2. favour steroid 
(175 days)  over 
placebo (125 
days)
Vlckova 
2009 (1814)
Flutica-
sone pro-
pionate
400mcg 
bid
spray placebo symptom scores 
(7 symp-
toms;0-3)
favour steroid 
over placebo 
(p<0.001) 
polyp score 
(0-3) 1. change 
in polyp score 
2. proportion of 
responders
1. favour steroid 
over placebo 
(p<0.001) 2. 
favour steroid 
(57%) over 
placebo (9%)
(p<0.001)
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Stjarne 
2006 (1816)
mometa-
sone 
furoate
Arm 
1. 200 
mcg od         
Arm 2. 
200 mcg 
bid
spray placebo symptom 
scores (4 
symp-
toms;0-3)
1.favour steroid 
od over placebo 
for obstruction 
and rhinoorhea 
(p<0.05 both). 
No difference 
for post nasal 
drip and loss of 
smell.2.favour 
steroid bid 
over placebo 
for obstruction 
(p<0.01), rhinor-
rhea (p<0.01) 
and post nasal 
drip (p<0.05). No 
difference for loss 
of smell. 
polyp score 
(0-3)
favour steroid 
bid over placebo 
(p=0.04). No dif-
ference between 
steroid od and 
placebo.
Stjarne 
2006b (1811)
mometa-
sone 
furoate
200 mcg 
od
spray placebo symptom 
scores (3 
symp-
toms;0-3)
favour steroid  
over placebo 
(p<0.005) 
polyp score 
(0-3)
favour steroid 
in proportion of 
responders (41%)  
over placebo (27%), 
p=0.003
Aukema 
2005 (1109)
flutica-
sone pro-
pionate
400 mcg 
od
nasal 
drop
placebo symptom 
VAS (6 
symptoms)
favour steroid  
over placebo 
for obstruction 
(p=0.0001), rhin-
orrhea (p=0.003), 
mucus in throat 
(p=0.03) and loss 
of smell (p=0.04). 
No difference for 
facial pain (p-
value not shown) 
and headache 
(p=0.76).
polyp volume 
estimated by 
the investigator 
(NS)
favour steroid  over 
placebo (p=0.038) 
Rowe-
Jones 2005  
(1821)
flutica-
sone pro-
pionate
200 mcg 
bid
spray placebo symptom 
VAS (6 
symptoms)
no difference 
(p=0.23 for "How 
do you feel over-
all" VAS, p=0.39 
for toatal VAS)
endoscopic 
score (Lund 
Kennedy)
1. favour steroid 
over placebo 
for polyp score 
(p=0.02) 2. no dif-
ference for  edema 
score (p=0.56) and 
discharge score 
(p=0.29)
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Small 2005 
(1810)
mometa-
sone 
furoate
arm 1. 200 
mcg od                  
arm 2. 200 
mcg bid
spray pla-
cebo
symptom scores 
(4 symptoms;0-3)
1.favour steroid 
od over placebo 
for obstruction 
(p<0.001), rhinor-
rhea (p<0.05) , 
post nasal drip 
(p<0.001) and loss 
of smell (p<0.01). 
2.favour steroid 
bid over placebo 
for obstruction 
(p<0.001), 
rhinoorhea 
(p<0.001)  , 
post nasal drip 
(p<0.01) and loss 
of smell (p<0.05)
polyp score 
(0-3)
favour steroid 
over placebo 
(p<0.001 for od 
and p=0.01 for 
bid ) 
Bross-
Soriano 
2004  
arm1.flu-
ticasone 
propion-
ate   Arm2. 
beclom-
ethasone 
dipropion-
ate
arm1. FP 
400 mcg od     
arm2. Beclo 
600 mcg od
spray 
(after 
saline 
lavage)
saline 
lavage 
only
nil nil polyp recur-
rence
favour steroid 
(fluticasone 
14.8% and 
beclometha-
sone (25.9%) 
over placebo 
(44.4%) 
Dijkstra 
2004 (1668)
flutica-
sone pro-
pionate
arm1. 
400µg  bid  
Arm2.800µg 
bid 
spray pla-
cebo
symptom VAS (6 
symptoms)
NR polyp recur-
rence
no difference 
(p-value not 
shown)
Jurkiewickz 
2004 (1819)
flutica-
sone pro-
pionate
400mcg bid spray no 
treat-
ment
symptom scores 
(5 symp-
toms;0-10)
favour steroid 
over placebo 
(p<0.01) 
 endoscopy 
(presence of 
polyps)
favour steroid  
over placebo 
(p<0.01) 
Passali 
2003 (1807)
mometa-
sone 
furoate
400mcg od spray 1.pla-
cebo 
2.in-
tra-
nasal 
furo-
sem-
ide
nil nil polyp recur-
rence
favour steroid 
(24.2%)  over 
placebo (30%, 
p-value not 
shown) 
Johansson 
2002 (1801)
budeso-
nide
128 mcg bid spray pla-
cebo
symptom VAS (1 
symptom)
favour steroid 
over placebo 
(p=0.0017) 
polyp score 
(Lildholdt;0-3)
no difference 
(p=0.12)
Jankowski 
2001 (1804)
budeso-
nide
arm1. 
128mcg 
od arm2. 
128mcg 
bid arm3. 
256mcg od
spray pla-
cebo
1. symptom 
scores (4 symp-
toms;0-3) 2. 
overall efficacy 
(0-4)
1. favour steroid 
(all doses)  over 
placebo (p<0.01) 
2.  favour steroid 
(all doses)  over 
placebo (p<0.001)
polyp score 
(0-3)
favour steroid 
(all doses) 
than placebo 
(p<0.01) 
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Filiaci 2000 
(1794)
budeso-
nide
arm 1.  
140mcg bid    
Arm 2. 
280mcg od       
Arm 3. 
140mcg od
turbu-
haler
pla-
cebo
1. symptom 
scores (3 
symp-
toms;0-3) 2. 
overall ef-
ficacy (0-4)
1. favour steroid 
(all doses) over 
placebo (p<0.01) 
2.  favour steroid 
(for 140mcg bid 
and 280mcg od)  
over placebo (p-
value not shown).
polyp score 
(0-3)
favour ster-
oid (140mcg 
bid;p<0.014 
and 280mcg 
od;p=0.009)  over 
placebo. No differ-
ence for 140mcg 
od and placebo (p-
value not shown).
Keith 2000 
(1802)
flutica-
sone pro-
pionate
400 mcg od nasal 
drop
pla-
cebo
symptom 
scores 
(4 symp-
toms;0-3)
no difference  (p-
value not shown)
polyp score 
(0-3)
no difference  (p-
value not shown)
Pentilla 
2000 (1808)
flutica-
sone pro-
pionate
arm 1. 400 
mcg bid                 
arm 2. 
400mcg od   
nasal 
drop
pla-
cebo
symptom 
scores 
(3 symp-
toms;0-3)
1. favour steroid 
bid over pla-
cebo for rhinitis 
(p<0.001) and 
nasal blockage 
(p<0.05) but not 
sense of smell (p-
value not shown) 
2. favour steroid 
od for rhinitis 
(p<0.05) but not 
nasal blockage 
and sense of 
smell (p-value not 
shown).
polyp score 
(0-3)
favour steroid bid 
in proportion of 
responders (41%) 
over placebo (15%) 
(p<0.01). No dif-
ference for steroid 
od (24%) and 
placebo (p-value 
not shown).
Holmstrom 
1999 (1797)
flutica-
sone pro-
pionate
400 mcg od nasal 
drop
pla-
cebo
nil nil polyp score 
(0-3)
no difference  (p-
value not shown)
Lund 1998 
(1796)
1.flutica-
sone pro-
pionate  
2.beclom-
ethasone 
dipropion-
ate
arm 1. FP 
400 mcg bid  
arm 2. Beclo 
400 mcg bid
spray pla-
cebo
symptom 
scores 
(4 symp-
toms;0-4)
favour both ster-
oids over placebo 
for nasal blockage 
(p-value not 
shown). No differ-
ence for rhinitis 
and sense of 
smell. Facial pain 
and headache not 
reported.
polyp score 
(0-3)
favour fluticasone 
over placebo 
(p=0.02). No dif-
ference between  
beclomethasone 
dipropionate and 
placebo (p-value 
not shown)
Tos 1998 
(1813)
budeso-
nide
arm1. 
spray64 mcg 
bid arm2. 
turbuhaler 
100 mcg 
per nominal 
dose/170 
mcg per 
delivered 
dose bid
spray or 
turbu-
haler
pla-
cebo
1. symptom 
scores (3 
symp-
toms;0-3) 
2.sense of 
smell 3. over-
all efficacy 
(0-4)
1.favour steroid 
over placebo 
(both spray 
and turbuhaler, 
p<0.001) 2. favour 
steroid over pla-
cebo (both spray 
and turbuhaler, 
p=0.001 3.favour 
steroid over pla-
cebo (p=0.001 for 
spray and p=0.01 
for turbuhaler) 
1. polyp score 
(0-3) 2. number 
of polyps (0-4)
1.favour steroid 
over placebo (both 
spray and turbu-
haler, p<0.001) 2. 
no difference from 
placebo
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Table 6.5.2. continued.
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Holmberg 
1997 (1790)
arm1. flu-
ticasone 
propi-
onate         
Arm 2. 
beclom-
ethasone 
dipropion-
ate
arm1. 
FP200 mcg 
bid arm2. 
Beclo200 
mcg bid
spray pla-
cebo
symptom 
scores (5 symp-
toms;0-3)
favour flutica-
sone (86%) over 
placebo (0%) in 
the percentage 
of days with an 
overall scores of 
zero (p<0.05). 
No difference 
between bedo-
methasone (19%) 
and placebo.
nil nil
Mastalerz 
1997 (1805)
flutica-
sone pro-
pionate
400mcg od spray pla-
cebo
symptom 
scores (4 symp-
toms;0-3)
favour steroid 
over placebo 
(p<0.05) 
nil nil
El Naggar
1995 (1818) 
beclom-
ethasone 
dipropion-
ate
100mcg 
bid in one 
nostril 
spray no 
treat-
ment 
in the 
other 
nostril
nil nil nil nil
Lidlholdt 
1995 (1804)
budeso-
nide
arm1. 200 
mcg bid  
arm2. 400 
mcg bid
turbu-
haler
pla-
cebo
symptom 
scores (3 symp-
toms;0-3)
favour steroid 
over placebo 
(p<0.001 for both 
doses) 
polyp score 
(0-3)
favour steroid 
over placebo 
(p<0.001 for 
200 mcg bid 
and <0.05 for 
400 mcg bid) ) 
Johansen 
1993 (1800)
budeso-
nide
200mcg bid spray 
and 
aerosol
pla-
cebo
1. symptom 
scores (3 symp-
toms;0-3) 2. 
sense of smell 
(0-3)
1.favour steroid 
over placebo  for 
both spray and 
aerosol (p-value 
not given)  2. no 
difference (p-
value not given)
polyp score 
(0-3)
favour steroid 
over placebo 
(p<0.01  for 
both spray and 
aerosol) 
Hartwig 1988  
(1795)
budeso-
nide
200 mcg bid aerosol pla-
cebo
symptom 
scores (1 symp-
toms;0-3)
no difference  (p-
value not shown)
polyp score 
(0-3)
favour steroid 
over placebo 
(p-value not 
shown)
Chalton 1985 
(1791)
betam-
ethasone
100mcg bid nasal 
drop
pla-
cebo
nil nil disappearnce 
of nasal polyps
favour steroid 
over placebo 
(p<0.05)
Dingsor 1985 
(1792)
flunisolide 100mcg bid spray pla-
cebo
symptom 
scores (3 symp-
toms;0-2)
favour steroid 
over placebo 
(p<0.05) for 
obstruction. No 
difference for 
rhinorrhea and 
sneezing.
1.polyp 
number (NS) 2. 
polyp size (NS)
favour steroid 
over placebo 
1.p<0.05and 
2.p<0.03
Land 1983 
(1803)
beclom-
ethasone 
dipropion-
ate
400 mcg bid spray pla-
cebo
symptom 
scores (3 
symptoms;NS)
no difference  (p-
value not shown)
Polyp size (NS) no difference  
(p-value not 
shown)
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6.5.2.7.1. Effect of prior surgery
Patients with sinus surgery responded to topical steroid greater 
than patients without sinus surgery in polyp size reduction 
(Figure 6.5.5.). However improvement in symptoms and 
nasal airflow was not statistically different between the two 
subgroups (Figure 6.5.6.). It is difficult to make a complete 
assessment as not all studies could be pooled for meta-analysis. 
A summary of studies that showed a benefit with INCS by the 
surgical status of their patient population is shown in Table 6.5.3.
6.5.2.7.2. Effect of delivery of spray v drops
Nasal aerosols and turbuhaler were found more effective than 
nasal spray in symptom control (Figure 6.5.7.) but there was 
no difference in polyp size reduction and nasal airway across 
various types of topical delivery methods. Similar to assessing 
the surgical state, a complete assessment is difficult as not all 
studies could be pooled for meta-analysis. A summary of studies 
that showed a benefit with INCS by spray or drop is shown in 
Table 6.5.4. No study reported on direct sinus delivery methods 
or high volume, high pressure delivery in patient with prior 
sinus surgery.
6.5.2.7.3. Effect of modern corticosteroid v first generation
There does not appear to be a significant benefit of modern 
corticosteroid against first-generation for the final symptom 
score (Figure 6.5.8.a) or for responder with polyp reduction 
(Figure 6.5.8.b).
6.5.2.8. Side-effects of local corticosteroid chronic 
rhinosinusitis with nasal polyps 
The most common events were epistaxis and nasal irritation 
including itching, sneeze, dry nose and rhinitis. Adverse events 
reported were possibly ambiguous. Rhinitis symptoms could 
be disease-related. It is acknowledge that rare adverse events 
are possibly not detected in randomised controlled trials (RCTs). 
However, they were extremely low and there was no difference 
in adverse events between the study groups and control groups 
in any trial. Post-market adverse events for intranasal steroid 
sprays are very low. However, we have not specifically sought 
adverse event data from non-RCT studies. Minor adverse events 
from nasal steroids are commonly tolerated by patients. The 
amount of benefit clearly outweighs the risk. The reported 
adverse events from the included studies are summarized in 
Table 6.5.5.
Reported epistaxis may be attributable to local effects 
of the INCS on septal mucosa and exacerbated by poor 
technique (1826) with significance preponderance of the side 
Table 6.5.2. continued.
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Drettner 1982 
(1793)
flunisolide 100mcg bid spray pla-
cebo
symptom 
scores (3 
symp-
toms;0-3)
favour steroid 
over placebo 
(p<0.05)
Polyp size (NS) no difference  (p-
value not shown)
Holopainen 
1982 (1798)
budeso-
nide
200 mcg bid spray pla-
cebo
symptom 
scores (4 
symp-
toms;0-3)
no difference  (p-
value not shown)
1.polyp 
number (NS) 2. 
polyp size (0-3)
favour steroid over 
placebo for polyp 
number and size (p-
value not shown)
Karlsson 1982 
(1820)
bedo-
meth-
asone 
dipropio-
nate
400mcg od 
for1month 
then 
200mcg od
intrana-
sal
no 
treat-
ment
nil nil polyp score 
(0-3)
favour steroid over 
placebo (p=0.003)
Mygind 1975 
(1172)
bedo-
meth-
asone 
dipropio- 
nate
100mcg qid aerosol pla-
cebo
1.symptom 
scores (3 
symp-
toms;0-3) 
2. change 
in symp-
toms 
(-3)-(+3)
1. favour steroid 
over placebo (p-
value not shown) 
2.no difference 
(p>0.1)
polyp size (NS) no difference 
(p>0.1)
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of epistaxis to handedness. Some have attributed epistaxis 
to the vasoconstrictor activity (1827) of the corticosteroid 
molecules, and postulated this as a mechanism for the very 
rare occurrence of nasal septal perforation (1828).  However, it 
should be remembered that minor nose bleeds are common in 
the population, occurring in 16.5% of 2197 women aged 50-64 
years over a one year study (1829) and that spontaneous nasal 
perforation occurs within the community at a low rate (1830). 
Nasal biopsy studies do not show any detrimental structural 
effects within the nasal mucosa with long-term administration 
of intranasal corticosteroids and atrophy does not occur as 
the mucosa is a single layer of epithelium compared to keratin 
producing multi-layered skin where atrophy is reported (1831-
1838). Much attention has focused on the systemic safety of 
intranasal application. The systemic bioavailability of intranasal 
corticosteroids varies from <1% to up to 40-50% and influences 
the risk of systemic adverse effects (1828, 1839). Potential adverse 
events related to the administration of intranasal corticosteroids 
are effects on growth, ocular effects, effects on bone, and on 
the hypothalamic-pituitary-adrenal axis (1840). Because the dose 
delivered topically is small, this is not a major consideration, and 
extensive studies have not identified significant effects on the 
hypothalamic-pituitary-adrenal axis with continued treatment. 
A small effect on growth has been reported in one study in 
children receiving a standard dosage over 1 year. However, 
this has not been found in prospective studies with the 
intranasal corticosteroids that have low systemic bioavailability 
and therefore the judicious choice of intranasal formulation, 
particularly if there is concurrent corticosteroid inhalation for 
asthma, is prudent (1841). In summary, intranasal corticosteroids 
are highly effective; nevertheless, they are not completely 
devoid of systemic effects. Thus, care has to be taken, especially 
in children, when long-term treatments are prescribed. However 
the systemic effects of nasal corticosteroids are negligible 
compared to inhaled corticosteroids. 
6.5.3. Systemic corticosteroid chronic 
rhinosinusitis with nasal polyps
Traditionally systemic steroids have been used in patients based 
on the significant effect on NP supported by open studies where 
a single injection of 14 mg betametasone have been compared 
with snare polypectomy surgery (1085, 1842). In these studies effects 
are seen on nasal polyp size, nasal symptom score and nasal 
expiratory peak flow but it is difficult to differentiate the effect 
of systemic steroids from that of local treatment since both 
treatments were used at the same time. The control groups 
Figure 6.5.2. CRScNP INCS for symptoms.
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underwent surgery during the study period. 
Since then a Cochrane review published in 2007 and its update 
in October 2010 has identified 3 level 1 studies (166 patients) 
to support the use of systemic corticosteroids in CRS with nasal 
polyps.  The characteristics of these 3 included studies including 
the addition of 3 additional studies are described in Table 6.5.6.  
Martinez-Anton 2008 (1843) and Benitez 2006 (1169) both contain 
the same data on the randomized component of these trials 
with oral corticosteroid (author correspondence).. The two 
other trials include a RCT in the allergic fungal sinusitis subtype 
of CRSwNP (1572) and a recent study of pre-treatment with and 
without systemic corticosteroid before ongoing INCS (1844).  There 
is definite intermediate effect that occurs with both symptoms 
and polyp size (Table 6.5.7.). However, given the inherent short 
period that this therapy is applied in a chronic condition, the 
treatment effects are short lived.
A combined oral followed by INCS protocol was described 
by Benitez et al.(1169) who performed a randomized placebo 
controlled study with prednisone for two weeks (30 mg 4 
days followed by a 2-day reduction of 5 mg). After two weeks 
on prednisone or placebo, the prednisone group continued 
for ten weeks on intranasal BUD. After two weeks treatment 
Figure 6.5.3. CRScNP INCS for polyp reduction.
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a significant polyp reduction was seen, several symptoms 
improved and anterior rhinomanometry improved compared 
to the placebo group. After 12 weeks a significant reduction of 
CT-changes were seen in the steroid treated group. 
6.5.3.1. Side-effects of systemic corticosteroid chronic 
rhinosinusitis with nasal polyps 
The anti-inflammatory effects of corticosteroids cannot be 
separated from their metabolic effects as all cells use the same 
glucocorticoid receptor; therefore when corticosteroids are 
prescribed measures should be taken to minimize their side 
effects. Clearly, the chance of significant side effects increases 
with the dose and duration of treatment and so the minimum 
dose necessary to control the disease should be given. Patients 
on systemic corticosteroid therapy should be aware of impact 
on bone mineral density and regular calcium+vitamin D 
supplements are recommended. A bone density study every 
two years is commonly performed. There are changes to fat 
metabolism, catabolic muscle effects and appetite changes 
such that careful diet, exercise and weight management should 
be instituted. Additionally, the impact on glucose tolerance, 
early cataract formation and the pituitary-hypothalmic axis 
suppression need to be assessed and the patient educated on 
the impact of these.
6.5.4. Evidence based recommendations
There is good evidence that both INCS and systemic 
corticosteroids are effective for the management of CRSwNP. 
However, considering the evolving understanding of CRSwNP 
Figure 6.5.4. CRScNP INCS for nasal airflow. 
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Figure 6.5.5. CRScNP INCS influence of surgery for polyp reduction.
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Figure 6.5.6. CRScNP INCS for symptoms by surgery..
Table 6.5.3. Summary of outcomes comparing INCS versus placebo.
 CRSwNP Favours INCS No effect 
or favours 
placebo
Without 
sinus 
surgery
Chalton 1985, Chur 2010, Filiaci 2000, 
Jankowski 2001, Jankowski 2009, 
Johansen 1993, Johansson 2002, 
Lildholdt 1995, Small 2005, Stjarne 
2006, Stjarne 2006b (n=11)
Holmstrom 
1999, Lang 
1983, Mas-
talerz 1997 
(n=3)
Mixed 
Populations
Aukema 2005, Keith 2000, Lund 
1998, Mygind 1975, Ruhno1990, 
Vlckova 2009 (n=6)
Penttila 
2000 (n=1)
Prior sinus 
surgery
Bross-Soriano 2004, Dingsor 1985, 
Drettner 1982, Hartwig 1988, Holm-
berg 1997, Jurkiewicz 2004, Karlsson 
1982, Olsson 2010, Passali 2003, 
Rowe-Jones 2005, Stjarne 2009, Tos 
1998 (n=12)
Dijkstra 
2004, El 
Naggar 
1995, Ehn-
hage 2009, 
Holopainen 
1982, Joris-
sen 2009 
(n=5)
Table 6.5.4 Study outcome comparing Drops v Sprays.
 CRSwNP Favours INCS No effect 
or favours 
placebo
Drops Aukema 2005, Pentilla 2000, Charlton 
1985 (n=3)
Olsson 
2010, Ehn-
hage 2009, 
Keith 2000, 
Holmstrom 
1999 (n=4)
Sprays Chur 2010, Jankowski 2009, Stjarne 
2009, Vlckova 2009, , Stjarne 2006, 
Stjarne 2006b, Small 2005, Bross-So-
riano 2004, Jurkiewickz 2004, Passiali 
2003, Johansson 2002, Jankowksi 
2001, Filiaci 2000, Lund 1998, Tos 
1998, Holmberg 1997, Mastalerz 
1997, Lidlholdt 1995, Johansen 1993, 
Dingsor 1985, Drettner 1982, Karls-
son 1982, Mygind 1975 (n=23)
Jorissen 
2009, Rowe-
Jones2005, 
Dijkstra 
2004, 
Hartwig 
1998, 
Lang 1982, 
Holopainen 
1982 (n=6)
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Figure 6.5.7. CRScNP INCS for symptoms by delivery. 
Figure 6.5.8. CRScNP INCS for symptoms for modern INCS..
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Table 6.5.5. Adverse events reported from included  studies of INCS  for CRSwNP.
Study Steroid group 
n(%)
Placebo 
group n(%)
Description of events reported Remarks
Chur 2010 
(1822)
there was no difference in 24h urinary free 
cortisol change in all groups.
Ehnhage 
2009 (1426)
22(73) 18(47) 70%mild23%moderate7%serious severity
Jankowski 
2009  (1799)
the incidence of AEs was similar in all groups.
Jorissen 
2009 (1674)
10(63) 16(62) headache, sinusitis, cold rare serious events
Stjarne 
2009 (1812)
11(14) 9(11) epistaxis, dyspepsia, obstruction, headache, 
sneezing, nausea, nasal congestion, rhinor-
rhea, skin irritation
Most AE are mild or moderate
Vlckova 
2009 (1814)
13(24) 11(20) epistaxis no serious AE.Morning plasma cortisol was 
not changed.
Stjarne 
2006 (1816)
54(53) 54(51) respiratory infection, headache, epistaxis most AE are mild or moderate.
Stjarne 
2006b (1811)
93(61) 68(47) epistaxis most AE are mild or moderate.All epistaxis 
were mild.
Small 2005 
(1810)
56(49) 64(55) epistaxis and headache most AE are mild or moderate and unrelated 
to study treatment.
Djikstra 
2004 (1668)
the incidence of epistaxis was not higher in 
the steroid group.
Jankowski 
2001 (1804)
16(33) 5(11) blood tinged nasal secretion, headache, 
bronchospasm
most events are mild or moderate.
Filiaci 2000 
(1794)
viral infection, abdominal pain, bronchitis, 
respiratory infection
80% are mild to moderate.
Keith 2000 
(1802)
12(23) 9(17) epistaxis, headache, viral respiratory infection no serious events.No difference between 
groups in serum cortisol level.
Penttila 
2000 (1808)
21(45) 27(57) respiratory infection, epistaxis no serious events. no difference in incidence 
of events between groups.
Holmstrom 
1999 (1797)
14(14) 18(18) epistaxis, throat irritation, nose dryness there was no change in morning serum 
cortisol and no difference between treatment 
groups in the overall frequency of adverse 
events.
Lund 1998 
(1796)
7(70) 3(33) asthma, respiratory infection, headache no serious events
Tos 1998 
(1813)
respiratory infection, nasal mucosal blood, 
rhinitis, bronchospasm, headache
no serious events
Lildholdt 
1995 (1804)
epistaxis, dryness no serious events
Johansen 
1993 (1800)
dry nose, headache, epistaxis no differences between treatment groups.
Ruhno1990 
(1809)
6(33.3) 5(27.8) headache, epistaxis, dizziness no serious events
Hartwig 
1988 (1795)
9(25) 1(3) nose bleed, nasal irritation
Dingsor 
1985 (1792)
6(30) 10(48) itching, sore throat, sneeze, blood traces, 
nausea
no patients had abnormal plasma cortisol.
Drettner 
1982 (1793)
4(36) 7(64) nasal irritation, blood stain mucus, nasal crust, 
eye irritation, cataract, pharynx irritation
Holopainen 
1982 (1798)
transient nasal stinging and slight throat 
irritation.
mean morning plasma cortisol was not dif-
ferent between before and 4 months after 
treatment in both groups. Local SE were mild 
in both groups.
Mygind 
1975 (1172)
8(44) 0(0) nasal infection
178
European Position Paper on Rhinosinusitis and Nasal Polyps 2012
Table 6.5.6.  Characteristics of included studies for systemic corticosteroid use in CRS with nasal polyps.
Study Study 
type
Participants 
(diagnostic 
criteria)
number 
of par-
ticipants 
age 
(Mean)
Type of 
steroid
Steroid 
dose
Sinus Sur-
gery Status
Delivery 
method 
of steroid
Dura-
tion of 
treatment 
(weeks)
Comparison 
Vaidyanathan 
2011 (1844)
RCT CRSwNP 
(moderate 
to large)
58 49/52 pred-
nisolone
25mg 
daily 
23% in ac-
tive and 30% 
in placebo
oral 2 placebo
Rupa 2010 
(2066)
RCT AFS 24 32/35 pred-
nisolone
50mg 
daily for 
6 weeks 
then 
tapered 
over 6 
weeks
100% prior 
surgery 
oral 12 placebo
Van Zele 
2010 (928)  
RCT CRSwNP, 
recurrent af-
ter surgery 
or massive 
polyps (en-
doscopy)
47 53.2 methyl-
pred-
nisolone
32 mg 
daily for 5 
days fol-
lowed by 
a reduc-
ing dose 
to 16 mg 
daily for 
5 days 
and 8 mg 
daily for 
10 days
NS oral 20/7 1.antibio- 
tics group 
2. placebo 
group
Martinez-
Anton 2008/
Benitez 2006 
(1843, 1169)
RCT CRSwNP, 
medium 
to large 
size (by 
endoscopy 
and CT)
32 54.2 prednisone 30mg 
daily for 4 
days then 
5mg ta-
per every 
2 days
without 
surgery
oral 2 no 
treatment
Alobid 2006 
(2067)
RCT CRSwNP 
(endoscopy 
and CT)
78 50 prednisone 30 mg 
daily for 
4 days 
followed 
by a dose 
reducing 
by 5mg 
every 2 
days
15.4% of 
patients had 
previous 
sinus 
surgery
oral 10/7 no 
treatment
Hissaria 2006  
(2068)
RCT CRSwNP 
(endoscopy)
41 48.5 prednisone 50 mg 
daily 
51.2%  of 
patients had 
previous 
sinus 
surgery
oral 2 placebo
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Table 6.5.7.  Summary of outcomes from included studies of oral corticosteroid for CRS with NP.
Study Type of 
steroid
Steroid dose Delivery 
method 
of ster-
oid
Compari-
son 
Patients report 
outcome meas-
ures (PROM) 
(scoring system 
and scale)
Summary 
PROM results
Endoscopic 
outcomes  
(scoring 
system and 
scale)
Summary endo-
scopic results
Vai-
dyanathan 
2011 (1844)
pred-
nisolone
25mg daily for 
2weeks
oral placebo total Nasal 
symptom score 
(VAS) and 
mRQLQ
mean dif-
ference 0.15 
(0.02 to 0.40) 
p=0.001 favors 
steroid
polyp score 
(0-6)
 mean difference 
favors steroid 
1.8 (–2.4 to –1.2) 
p<0.001
Rupa 2010 
(2066)
pred-
nisolone
50mg daily for 
6 weeks then 
tapered over 6 
weeks
oral placebo 
(all pa-
tients on 
INCS)
symptom score 
(8 questions)
steroid group 
had complete 
resolution of 
symptoms 
(p<0.0001)
kupferberg 
score
steroid group 
had complete 
resolution 
(p<0.0001)
Van Zele 
2010 (928)
meth-
ylpred-
nisolone
32mg daily for 5 
days followed by 
a reducing dose 
to 16 mg daily for 
5 days and 8 mg 
daily for 10 days
oral placebo 
(addition-
al arm of 
doxycy-
cline)
symptom score 
(4symptoms)
improvement 
at 4wks then 
slow decline to 
no difference 
at 12 weeks for 
all symptoms
polyp score 
(0-4)
improvement up 
to 8wks then no 
difference at 12 
weeks 
Martinez-
Anton 
2008/Be-
nitez 2006 
(1843, 1169)
pred-
nisone
30mg daily for 4 
days then 5mg 
taper every 2 
days (2weeks)
oral no treat-
ment 
symptom scores 
(2 symp-
toms;0-3)
favor steroid 
over placebo 
(p<0.01)
nil nil
Alobid 
2006 (2067)
pred-
nisone
30 mg daily for 4 
days followed by 
a dose reducing 
by 5mg every 2 
days
oral no treat-
ment
1. symptom 
score (2symp-
toms;0-3) 
2. quality of life 
(SF-36)
1. favor steroid 
(p<0.05) 
2. favor steroid 
(p<0.05)
polyp score 
(0-3)
favor steroid 
(p<0.05)
Hissaria 
2006 (2068)
pred-
nisone
50 mg daily oral placebo 1. symptom 
score (RSOM-
31;6 nasal 
symptoms;1-5)  
2.quality of life 
(total RSOM-
31; 31symp-
toms;1-5)
1. favor steroid 
(p<0.005) 
2. favor steroid 
(p<0.05)
polyp score 
(percentage 
reduction 
in polyp 
size) on: 
1.endoscopy 
& 2. MRI
1. favor steroid 
(p<0.005)
2. favor steroid 
(p<0.05)
Statement Grade of 
Recom-
mendation
Level of 
evi-
dence
Local
INCS improve symptoms and patient re-
ported outcomes in CRSwNP
A 1a
Delivery of INCS post surgery brings about a 
greater effect
A 1a
Objective measures of nasal breathing 
improve with INCS use in CRSwNP
A 1a
INCS is associated with only minor side-
effects
B 2b
Modern INCS do not have greater clinical 
efficacy (although potentially fewer sider-
effects) compared to first-generation INCS
A 1a
Systemic
Systemic corticosteroids benefit CRSwNP but 
the effects are time limited post therapy
A 1a
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and the chronicity of this condition (not from lack of treatment 
but natural history) many treatments will need to ongoing 
similar to local corticosteroid therapy in asthma. Thus the 
short-lived benefits of systemic corticosteroid therapy need to 
be balanced with the long-term potential side-effects.  Local 
therapy appears to be effective but the ability to effectively 
deliver INCS to the paranasal sinuses may greatly influence the 
treatment response.
6.6. Treatment CRSwNP with antibiotics 
Systemic doxycycline treatment for 3 weeks reduce 
polyp size and post-nasal discharge but not other 
symptoms compared to placebo in CRSwP.
6.6.1. Short-term treatment with antibiotics in 
CRSwNP
Short-term treatment with antibiotics in chronic rhinosinusitis 
with polyps
Two recent placebo controlled studies are available. It is the 
theory of endotoxin producing staphylococci as disease 
modifiers in CRSwNP that has prompted the interest. A placebo-
controlled study by van Zele and co-workers, compared the 
effect of methylprednisolone in a 3 week course (32 mg for 1 w, 
16 mg for 1 week and finally 8 mg for 1 week) with doxycycline 
(100 mg except for the first day of 200 mg) for 20 days with 
placebo. 
Another placebo controlled study was performed by Schalek 
and co-authors (1845) 23 patients undergoing FESS, who tested 
positive for S. Aureus enterotoxin producing strains were 
randomized to oral anti-staphylococcal antibiotics (quinolone, 
amoxicillin/clavulanate or co-trimoxazole) for 3 weeks, or 
placebo. Both groups were compared pre-operatively and at 
3 and 6 months using endoscopic score and SNOT-22. Slightly 
better results were found in the antibiotic group but it did not 
reach significance. Inflammatory markers were measured in 
both nasal secretions and blood, polyp size was estimated and 
symptoms were registered. Methylprednisolone had a short but 
dramatic effect on polyp size and symptoms. Doxycycline had a 
significant but small effect on polyp size compared to placebo, 
which was present for the length of the study, 12 weeks. 
Doxycycline showed a significant effect on postnasal discharge 
leaving other symptoms unchanged. Analysis of nasal secretions 
revealed that doxycycline reduced metallomatrix protein-9 
(MMP-9) as well as myeoloperoxidase (MPO) and eosinophilic 
cationic protein (ECP).  However quality of life measurements 
are lacking and one cannot deduce from the results whether 
the effect of doxycycline improved quality of life in the study 
population (928).
Conclusion
One RCT have shown that doxycycline for 3 weeks had a small 
effect on polyp size and post-nasal discharge but not other 
symptoms compared to placebo. The second study, where 
sample size was low, showed a trend towards effect (Level of 
evidence 1b) (Recommendation C).
6.6.2. Long-term treatment with antibiotics in 
CRSwNP
There are few studies where the study population has been 
properly defined into groups with, or without polyps. However 
one can identify at least 3 open studies where effect on polyp 
size is mentioned. 
In an uncontrolled trial twenty patients with CRS and nasal 
polyps were treated for at least 3 months with clarithromycin 
400 mg/day. In the group whose polyps were reduced in size, 
the IL-8 levels decreased and were initially significantly higher 
before macrolide treatment than those in the group whose 
polyps showed no change (1846). In another uncontrolled trial 40 
patients altogether were treated with either roxithromycin 150 
mg alone or in combination with an antihistamine (azelastine) 
for at least 8 weeks. Smaller polyps were more likely to shrink 
and this happened in about half of the patients (1702). A small, 
n=12, open study, using Roxithromycin 150 mg x1, also showed 
a reduction in IL-8 and improved aeration on CT (1704).
Conclusion
A few open studies have shown some effect on polyp size and 
patient symptoms. The effect seems to be moderate but may 
be more long lasting than systemic steroids, however quality 
of life data are missing and the clinical benefit for the patient is 
not fully investigated to date. Further studies are necessary to 
Table 6.6.1. Placebo controlled RCTs in short-term treatment with antibi-
otics in CRSwNP. 
Study Drug  N Time/dose Effect symp-
toms
Level of 
evidence
Schalek 
2009 
(1845)
anti 
staph 
anti-
biotic 
placebo 
control-
led
23 3 weeks no signifi-
cant effect 
at 3 and 6 
months, 
endoscopy, 
SNOT-22
1b (-)
Van 
Zele 
2010 
(928)
doxy-
cycline 
placebo 
control-
led
47 3 weeks/ 
100 mg 
day
reduction of 
polyp size 
and postna-
sal secretion, 
reduction 
of pro-in-
flammatory 
markers
Ib
1b(-): 1b study with negative effect.
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evaluate this treatment option (Level of evidence III. Strength of 
recommendation C).
6.6.3. Treatment with topical antibiotics in 
CRSwNP 
There are no data on the effect of topical antibitoics in CRSwNP.
6.6.4. Adverse events of antibiotic therapy of CRS
6.6.4.1. Effects on bacterial resistance.
A concern with long-term antibacterial treatment is the 
emergence of resistant bacterial strains. Especially when using 
a low dose not attaining minimal inhibitory concentrations. 
Data from primary care have shown that increased macrolide 
prescription in group A streptococci tonsillitis leads to a 
subsequent increase in resistance, which can reach alarmingly 
high levels (1714, 1715). However in a tertiary setting, data is sketchy. 
The study by Videler at al. using azithromycin for 12 weeks, 
found 3 of 50 cultures with macrolide resistant strains before 
treatment, and after treatment 4 of 43 cultures with resistant 
strains (1709). An emerging concern in cystic fibrosis patients is 
the increasing incidence of infection with the highly pathogenic 
Mycobacterium abscessus in azithromycin treated patients. The 
effect is probably due to azithromycin inhibition of autophagic 
and phagosomal degradation (1716-1718). This has not been 
reported in CRS patients.
6.6.4.2. Other side effects 
Well-known side effects of antibiotics includes: gastrointestinal 
upset, skin rash reversible elevation of liver enzymes. In the 
study by Videler et al. including 78 patients, the investigators 
found 1 case of muscle ache in the azithroprim group and 2 
cases of mild skin rash in the clarithromycin treated patients 
and no adverse effects in the trimethroprim-sulfamethoxazole 
group. The study comparing doxycycline treatment for 20 days 
with methylprednisolone and placebo reported no difference in 
adverse events in the different groups. However, rare side effects 
are not picked up in small clinical trials, but rather in national 
records on side effects. Hearing impairment due to macrolide 
treatment is a rare side effect but was recorded in a recent large 
trial in COPD (1696).
6.6.4.3. Conclusions on adverse events of antibiotic 
therapy of CRS
The safety of long-term antibiotic therapy, either azithromycin, 
clarithromycin or roxithromycin is recognised in patients with 
CRS, but also due to it’s established long-term use in cystic 
fibrosis. As for doxycycline there is longstanding experience 
for long-term use in acne and rosacea patients. Trimethroprim-
sulfamethoxazole has been used long-term in both the pediatric 
and adult population for treatment of infectious prone patients 
with certain immune deficiencies as well as urinary tract 
infections. Drawing on the experience from other areas than 
CRS, long-term treatment with the mentioned antibiotics is 
relatively safe.  Although one has to bear in mind the interaction 
between macrolides and drugs such as dicumarol, antiepileptic 
drugs, terphenadine, methotrexate and antidepressant drugs. 
To monitor the risk of the development of resistant bacterial 
strains, nasal swabs with culture every 3 months during 
treatment is advisable.
6.7. Other medical management in CRSwNP 
6.7.1. Summary 
Current data yield insufficient evidence to recommend anti-IgE, 
anti-IL5, antihistamines in non-allergic patients, antimycotics, 
immunosuppressants, furosemide, leukotriene antagonists, 
aspirin desensitisation, capsaicin and various other medical 
treatments for treatment of CRSwNP. 
6.7.2. Introduction
In the EP3OS 2007 publication (8), non-antibiotic and non-
steroidal medical treatment of acute rhinosinusitis, CRSsNP and 
CRSwNP were discussed in one chapter. Due to differences in 
aetiology and pathophysiology, but also treatment principles, 
the authors decided to consider CRSwNP and CRSsNP in 
adults in separate chapters. Criteria to include publications in 
the current analysis were more restrictive, mainly focused on 
randomized controlled trials (RCT) and studies published after 
2007. As a consequence, not all publications cited in the former 
version of EPOS were included. An analysis of publications on 
anti-IgE and anti-IL-5 antibodies was included. Moreover, a 
more in depth analysis of included publications was performed. 
The part on antihistamines was revised. The part on topical 
amphotericin B treatment was replaced due to the availability 
of a recent comprehensive Cochrane analysis. Tables were 
restricted to RCT, when at least two trials were available. A 
column was added indicating if patients with or without 
previous sinus surgery were included. For each substance group, 
most relevant adverse effects and levels of recommendation are 
provided.
6.7.3. Anti-IgE
In several investigations, total IgE-levels in nasal secretions, 
nasal polyp homogenisates and blood serum were higher in 
CRS-patients with nasal polyps than in controls. Omalizumab(R), 
a recombinant DNA-derived humanized IgG1k monoclonal 
antibody that selectively binds to human IgE, reduces serum 
and tissue IgE-levels. Omalizumab(R) is approved for patients 
with moderate-to-severe or severe allergic asthma. Two 
anecdotal reports (1847, 1848), 1 pilot study in 8 patients (1849) and 1 
case series (1850) showed beneficial effects of omalizumab(R) in 
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CRS patients with nasal polyps. Pinto and co-workers conducted 
a randomized, double-blind, placebo-controlled trial of anti-
IgE for chronic rhinosinusitis in 14 patients (12/14 with nasal 
polyps) with severe CRS refractory to standard treatment 
including sinus surgery (963). Pretreatment serum total IgE-levels 
between 30 - 700 IU/ml were required for inclusion. All patients 
received omalizumab(R) 0.016 mg/kg per IU total serum IgE/
mL subcutaneously or placebo injections all 4 weeks for 6 
months on top og other medical treatment. The main outcome 
parameter was pre- and post-treatment sinus opacification in 
coronal CT scans. The median change of sinus opacification in 
omalizumab(R) treated patients was 11.9% vs. 5.9% in placebo 
treated patients (p<0.391). No significant differences were also 
found in various secondary outcome parameters including 
SNOT-20 scores, olfactory test scores, endoscopy scores, 
eosinophils in nasal lavage, and peak nasal inspiratory flow 
values. This study is underpowered due to recruitment problems 
following FDA warnings on anaphylactic AE to omalizumab.
Omalizumab may cause anaphylaxis in approximately 1 
patient per 1,000 (1851). Omalizumab may increase the risk of 
cardiovascular events, thrombocytopenia or cancer (1852). Based 
on current data, omalizumab is not recommended for the 
treatment of CRS with nasal polyps (grade of recommendation: 
C). Mainly data on patients with previous sinus surgery are 
available.
6.7.4. Anti-IL-5
IL-5 is a key activator in eosinophil growth, recruitment and 
activation. High amounts of IL-5 were detected in polyp 
homogenisates, nasal secretions and blood serum of patients 
with NP. Mepolizumab (Glaxo Smith Kline) and reslizumab 
(Schering-Plough) are humanized anti–IL-5 mAb that reduce 
the number of eosinophils in blood and tissues (1853, 1854). 
Both antibodies currently undergo Phase II and III trials. In 
2004, orphan designation (EU/3/04/213) was granted by the 
European Commission for mepolizumab for the treatment of 
hypereosinophilic syndrome. Two clinical trials with anti-IL-5 
antibodies in CRS patients with nasal polyps were identified. 
In a double-blind, placebo-controlled, randomized, 2-center 
phase I/II trial, 24 subjects with bilateral nasal polyps were 
randomized to receive a single intravenous infusion of 
reslizumab 3mg/kg or 1mg/kg or placebo (i.e. 8 patients per 
treatment arm). The post-injection observation period was 
36 weeks. Adverse events did not significantly differ between 
treatment groups. No pharmacokinetic data and no detailed 
data on drop outs are provided. Main outcome measure for 
efficacy was an endoscopic nasal polyp score repeatedly 
evaluated for each nostril. Secondary efficacy parameters 
included peak nasal inspiratory airflow and nasal symptom 
scores. At no individual time point, a significant difference in 
the symptom scores or in the nasal peak inspiratory flow values 
was observed in both treatment groups compared with those in 
the placebo group. The total nasal polyp score was significantly 
decreased in the 1mg/kg group at week 12 compared with 
baseline values, however apparently not with the values of the 
control group. No dose response relation was observed. Blood 
eosinophil counts dropped significantly in both active groups, 
followed by a steep increase above baseline values 8-19 weeks 
post injection suggesting a rebound hypereosinophilia. Patients 
with nasal secretion IL-5 levels >40pg/ml were more likely to 
reveal a reduction of at least 1 polyp score on an 8 point scale 
when treated with anti-IL-5 (931). 
In a further randomized, double-blind, placebo-controlled study, 
CRS-patients with nasal polyps received 2 single intravenous 
injections (28 days apart) of 750 mg of mepolizumab (20 
subjects) or placebo (10 subjects). Post-injection observation 
period was 48 weeks. The primary end point was the reduction 
in an endoscopic nasal polyp score on an 8 point scale at 8 
weeks after the first dosing (4 weeks after the second dose). 
Secondary outcome parameter included sinus opacification in 
CT scans, peak nasal inspiratory flow and symptom scores. Last 
observation carried forward imputation was used to handle 
missing data. Number and severity of adverse events did not 
differ between treatment groups. In the treatment group, nasal 
polyp scores improved 1.30±1.72 (SD) score points while it 
remained unchanged (0.00±0.94) in the control group, resulting 
in a treatment difference of 1.30±1.51 score points (p=0.028, 
Mann-Whitney U test). Moreover, significantly less sinus 
opacification was observed in the treatment arm (932).
The results of these clinical trials suggest that anti-IL-5 
antibodies could play a role in the treatment of selected 
CRS-patients with nasal polyps. In a recent reslizumab 
study in asthma patients, nasopharyngitis, fatigue, and 
pharyngolaryngeal pain were common adverse events (1855). No 
data on patients without previous sinus surgery are available.
6.7.5. Antihistamines
One randomized placebo-controlled trial on antihistamines 
in CRS-patients with nasal polyps was identified. Forty-five 
surgically treated patients with residual or recurrent nasal 
polyps received either cetirizine 20mg b.i.d. (n=23) or placebo 
(n=22) for three months. Inhaled steroids for asthma treatment 
up to 800 µg per day were allowed as concomitant medication. 
Endoscopic polyp size, nasal symptom score at follow up visits 
and a nasal symptom daily diary cards served as outcome 
parameters. No primary study endpoint was defined and no 
power calculations are provided. In each group, 18 patients 
finished the study regularly, an IT analysis was performed. The 
method of missing value handling is not reported. Adverse 
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events were equally distributed among treatment arms. The 
number and size of polyps remained unchanged during the 
study period. Nasal symptom scores at follow up visits did not 
significantly differ between the two treatment arms. In the daily 
diary cards, significantly less days with a symptom score <= 1 
were observed for nasal hypersecretion (weeks 1 to 4, 5 to 8 and 
9 to 12), sneezing (weeks 1 to 4 and 5 to 8) and nasal obstruction 
(weeks 9 to 12). However, daily dairy scores above >1 were 
rare for nasal hypersecretion and sneezing in the whole study 
population. No adjustment for multiple testing is reported (1856).
Cetirizine is a safe antihistamine. Adverse effects include 
drowsiness; dry mouth and tiredness. Based on current data, 
cetirizine is not recommended for the treatment of CRS with 
nasal polyps (grade of recommendation: D). In patients with 
concomitant nasal allergies, antihistamines may be indicated. 
(grade of recommendation: C) No data on patients without 
previous sinus surgery are available.
6.7.6. Antimycotics
Eosinophilic rhinosinusitis is a non-invasive, chronic 
eosinophilic sinus inflammation frequently associated with 
nasal polyps. Viscid sinus secretions with eosinophil decay 
products, termed eosinophilic mucus by Bent and Kuhn (721), 
are characteristic for this condition. If fungal elements are 
detected by histology, fungal culture or molecular methods, 
the term eosinophilic fungal rhinosinusitis is appropriate. 
Eosinophilic fungal rhinosinusitis may be further divided in 
allergic fungal rhinosinusitis (AFRS) with a positive diagnostic 
test for IgE mediated allergy to the fungal elements detected 
within the sinus. It is considered an IgE mediated mucosal 
hypersensitivity directed against fungal antigens deposited on 
sinus mucosa (1857). If Type I allergy tests to moulds are negative, 
but eosinophilic mucus with fungal elements is found, the 
term non-allergic fungal eosinophilic rhinosinusitis is used (2069). 
Eosinophilic mucus may also occur in the absence of fungal 
elements and is categorized as non-fungal eosinophilic mucus 
rhinosinusitis.
Based on fungal detection and the presence of allergic mucus 
in almost all patients with chronic rhinosinusitis, Ponikau 
and coauthors proposed that CRS is generally caused by 
a dysregulated, but IgE independent immune response to 
fungal elements present on the mucosal surface (592, 702). As a 
consequence, reduction of fungus load should influence disease 
severity in all subtypes of CRS. This hypothesis led to a series 
of investigations, which did rather serve to proof this concept 
than to treat fungal disease. In these studies, patients complying 
with the AAO-HNS or EPOS definitions of CRS were included (8, 
1205), irrespective of the presence of eosinophilic mucus and/or 
fungus detection.
6.7.6.1. Topical amphotericin B 
In most trials with antifungals in CRS, amphotericin B was 
applied topically, either as a nasal spray or as a nasal irrigation. 
The majority of patients included in these trials suffered from 
CRS with polyps. However, not in all trials, the presence of nasal 
polyps was explicitly reported. Topical amphotericin B trials 
were extensively discussed in the last EPOS version. Since then, 
topical amphotericin B treatment was reviewed in 2 review 
articles and 1 Cochrane analysis. The authors conclude that the 
use of topical amphotericin B in patients with CRS with polyps is 
not justified (1585, 1858, 1859).
Amphotericin B is not systemically available after oral intake. 
Adverse events after topical nasal application include local 
irritation and rarely unpleasant smell sensations. Based on 
current data, topical amphotericin B is not recommended for the 
treatment of CRS with nasal polyps (grade of recommendation: 
A).
One report on topical nasal treatment with another antifungal 
was identified. In an uncontrolled study, 16 patients with 
previously treated allergic fungal sinusitis and worsening clinical 
symptoms received nasal fluconazole spray in addition to 
systemic steroids and/or systemic itraconazole. Stable disease or 
improvement was observed in 12/16 patients (1860).
6.7.6.2. Systemic antifungal treatments
There is 1 controlled study and few reports of uncontrolled 
studies of postoperative systemic antifungal treatment in 
patients with confirmed fungal rhinosinusitis. 
Kennedy and co-authors prospectively compared oral 
terbinafine with placebo in fungus positive and fungus negative 
CRS patients. Treatment with terbinafine failed to improve 
Table 6.7.1. Anti-IL-5 in CRSwNP. 
author drug study design active (n) control (n) number of 
patients post 
sinus surgery
effect evidence 
level
Gevaert et al. 
2006 (931)
reslizumab 1 i.v 
injection; 1mg/kg or 
3mg/kg
randomized, double 
blind, placebo controlled
16 8 all negative 2
Gevaert et al. 
2011 (932)
mepolizumab 2 i.v. 
injections 750mg
randomized, double 
blind, placebo controlled
20 10 all positive 2
* Ib (-): Ib study with a negative outcome.
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symptoms or radiographic appearance of chronic rhinosinusitis 
even when nasal irrigation samples were positive for fungus on 
culture (1861).
Seiberling and co-authors performed a retrospective chart 
review of 23 patients with AFRS and non-allergic eosinophilic 
fungal sinusitis, who had failed maximal medical and surgical 
therapy. Patients with recurrent disease received itraconazole 
at a dose of 100mg b.i.d. for a minimum period of 6 months. 
Three patients had to stop treatment due to hepatic side effects, 
4 patients did not respond and 16 patients showed a varying 
degree of symptom improvement including a decrease in the 
use of oral steroids and fungal mucus/polyps on endoscopy (1584).
Rains and Mineck performed a chart review of 139 patients with 
allergic fungal rhinosinusitis and reported a benefit of high-
dose systemic itraconazole treatment in patients with recurrent 
disease (1862). Chan and co-authors treated 32 patients with 
fungal eosinophilic chronic rhinosinusitis who did not respond 
to surgery, oral cortisone and nasal amphotericin B spray with 
oral itraconazole for at least 3 months. Twelve patients has 
improved endoscopic findings following treatment, 15 showed 
no difference, and 5 were worse. Serum total IgE levels were 
not affected (1863). Rupa and co-workers treated 12 patients 
with fungus positive eosinophilic rhinosinusitis following sinus 
surgery with nasal steroids and oral itraconazole 200 mg daily 
for 12 weeks. All patients but one patient relapsed within the 
study period (1572).
Long-term itraconazole treatment has considerable adverse 
effects including nausea and fatigue. The main problem is 
hepatic toxicity with increased serum alanine tranferase levels 
in 4% of patients. Congestive heart failure is an infrequent side 
effect of itraconazole treatment. Itraconazole interacts with 
various other drugs. Drug interactions may increase the risk of 
congestive heart failure.
Based on current data, systemic antifungal treatment is 
not recommended in CRS with nasal polyps (grade of 
recommendation A).
6.7.7. Furosemide
Aerosolized furosemide was used in the treatment of acute 
asthma attacks (1864). Several mechanisms including induction of 
relaxant prostaglandins, blockade of mediator production from 
inflammatory cells, and regulation of ion exchange in the airway 
epithelium were proposed to explain its anti-asthmatic activity 
(1865).
In a controlled, open label study, 64 CRS-patients with nasal 
polyps received furosemide nasal spray (200 µg daily) following 
endonasal sinus surgery. A control group of 40 patients received 
no treatment. The mode of randomization is not detailed. After 
6 years, 4 patients in the furosemide group and 12 patients in 
the control group had experienced recurrent disease (p<0.01).
Drop out handling is not detailed in the report (1866). In 2003, 
Passali and co-workers published long term results of topical 
furosemide treatment in 170 CRS patients with nasal polyps 
following endonasal surgery. From 1991 to 1997, patients 
were randomly assigned to furosemide or control treatment. It 
appears that patients included in the 2000 report were included 
also in this evaluation. Furosemide was 1:1 diluted 2 mL isotonic 
sodium chloride solution administered as nasal spray (100µg 
per nostril and day). One-month treatment alternated with 
1 month without treatment. The intervals without treatment 
were then gradually extended. In the control group, no specific 
treatment was given. In 1998, control treatment was stopped 
and mometasone was given instead. Patients received 2 puffs 
mometasone spray per day per nostril with the same monthly 
interruptions used in the furosemide group. No adverse 
events were registered. Seventeen (17.5%) of 97 patients in 
the furosemide group, 12 (30.0%) of 40 patients in the control 
group, and 8 (24.2%) of 33 patients in the mometasone group 
experienced nasal polyposis relapses (p>0.2) (1807).
Mode of randomization, number of screened patients, drop 
out rate and missing data handling are not reported. As 
a consequence, the value of these two trials is difficult to 
interpret. In a randomised trial, 40 CRS-patients with nasal 
polyps were randomly allocated to treatment either with oral 
methylprednisolone (1 mg/kg/day) or inhalation of 6.6 mmol/l 
furosemide solution/10 min through a jet nebulizer (20 mg/
day furosemide) for 7 days prior to endonasal sinus surgery. 
The mode of randomization is not detailed. Twelve patients 
had undergone previous sinus surgeries (‘recurrences’). Study 
endpoints were a nasal symptom score and an endoscopic 
polyp score assessed before and after treatment. Serum 
potassium levels and blood pressure were monitored before 
and during 1 h after each inhalation in the furosemide group. No 
systemic diuretic effects were observed. Total symptom scores 
changed from 15.50±3.44 (mean ± SD) to 9.55±3.55 in the 
methylprednisolone group and from 15.60±3.91 to 9.80±3.69 
in the furosemide group (both p<0.01). Nasal polyp scores 
changed from 2.38±0.67 to 1.95±0.78 in the methylprednisolone 
group and from 2.23±0.89 to 1.68±0.89 in the furosemide group 
(both p<0.01) (1867).
The bioavailability of furosemide after oral intake is 
approximately 60%. Data on nasal uptake are not available. 
Main side effects of oral furosemide are water and electrolyte 
imbalances. Based on current data, (postoperative) long-term 
nasal furosemide treatment is not recommended (grade of 
recommendation D). Further studies are needed to assess the 
possible benefit of preoperative short term, high dose nasal 
furosemide treatment.
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6.7.8. Immunosuppressants
In glucocorticoid-dependent asthma, immunosuppressants 
including methotrexate may aid to reduce the steroid dose 
(1868). There are two anecdotal reports that nasal polyps may 
substantially improve, if methotrexate is given in steroid-
dependent asthma or malignant conditions with concomitant 
nasal polyps (2070,2071). Based on current data, the use of 
immunosuppressants is not recommended in CRS with nasal 
polyps (grade of recommendation D). 
6.7.9. Leukotriene antagonists
Ragab and co-authors evaluated the efficacy and tolerability 
of montelukast as an add-on therapy in the treatment of 
nasal polyposis in association with asthma. In 44 adult CRS-
patients with nasal polyposis (24 with AERD) refractory to 
medical therapy with long-term intranasal corticosteroids; oral 
montelukast (10 mg/day) was given for three months as an 
add-on therapy to intranasal and inhaled corticosteroids. Main 
outcome parameter was a clinical score based on the results of 
clinical symptoms, examination, acoustic rhinometry, and peak 
nasal inspiratory flow. The majority of patients experienced 
clinical improvement. Improvement of nasal polyp score was 
significant, irrespective if the patients suffered from AERD or not 
(1515). 
In a single-blind, randomized, placebo-controlled cross over 
trial, 24 patients with asthma and post-FESS CRS with nasal 
polyps were enrolled. One group started with a 4-week placebo 
phase and continued with 6 weeks of montelukast treatment 
(10 mg/day) while the other group started with montelukast 
treatment for 6 weeks and continued with placebo for 4 weeks. 
Statistical analysis did not account for the special problems of 
cross-over designs and the data presentation is not appropriate 
for this type of trial design. During montelukast treatment, the 
mean scores decreased from 1.8 to 0.6 for nasal blockage, from 
1.5 to 0.6 for rhinorrhoea, and from 0.6 to 0.25 for itching. In a 
similar manner, the quality of smell improved from 2.0 to 0.3 and 
the total symptom score improved from 5.9 to 1.75 (p<.001). 
No significant changes in symptoms were observed during the 
placebo period. Significant improvements were also noted in 
nasal endoscopy scores. Various proinflammatory biomarkers in 
nasal lavages revealed significant improvements (1869). 
In an uncontrolled, open label study 26 CRS-patients with 
nasal polyps without AERD received 10 mg montelukast 
daily for 3 months on top on long-term nasal steroid therapy. 
Symptom scores were assessed before and after the 3-month 
treatment interval in 24 patients, who finished the study 
regularly. The symptoms improved in 17 patients (71%) and 
remained the same or worsened in 7 patients (29%). Patients 
with concomitant nasal allergy responded better than patients 
without allergy (1870).
In an uncontrolled open label study, 26 patients with nasal 
polyps received oral zafirlukast 10 mg bid or zileuton 600 
mg qid on top of systemic steroid therapy. Nasal symptom 
scores were assessed before and after a treatment period of 
7 months. Concomitant asthma was present in 14 patients, 
2 patients suffered from AERD. Overall, 26 of the 36 patients 
(72%) experienced improvement in their symptomatology 
after starting antileukotriene therapy. No patient experienced 
a worsening of symptoms. The remaining 10 patients (28%) 
experienced no change (1871).
In an uncontrolled open label study, 20 patients with nasal 
polyps and bronchial asthma received oral montelukast 10 mg/
day on top of nasal and inhaled steroid therapy for 1 year. Study 
endpoints included nasal polyp scores and sinus opacification 
on pre- and post treatment CT scans. Nasal allergy was present 
in 11 patients and 8 were judged to suffer from AERD on the 
basis of their history. Nasal polyp and CT scores improved 
significantly during treatment (1872).
Table 6.7.2. Systemic antifungal treatment in CRSwNP.    
author drug study design active 
drug (n)
control (n) number of 
patients post 
sinus surgery
effect evidence 
level
Kennedy 2005 
(1861)
terbinafine 625 mg/
day
randomized, double 
blind, placebo controlled
25 28 none with 
sinus sur-
gery within 
3 months 
before trial 
entry
negative Ib(-)#
Rupa 2010 (1572) itraconazole 200mg 
daily + oral pred-
nisolone (active) vs. 
Itraconazole alone 
(control)
randomized, double 
blind, controlled
12 12 all negative* Ib(-)#
*All patients but 1 in the itraconazole only group had disease recurrences within the observation period.
# Ib (-): Ib study with a negative outcome.
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Following endoscopic sinus surgery, Mostafa and co-
workers randomly assigned 40 patients with nasal polyps 
without asthma either to 10 mg montelukast daily or 400 µg 
beclomethasone nasal spray daily for 1 year. Study endpoints 
included disease relapse and nasal symptom scores. No 
differences in disease relapse frequency were noted. Nasal 
beclomethasone was superior to montelukast controlling 
nasal obstruction, rhinorrhoea, sense of smell and sneezing. 
The onset of montelukast action was prolonged, with the 
maximum therapeutic effect seen after 6 months of treatment 
(1873). In a randomized, placebo-controlled trial, 20 patients with 
nasal polyps were treated with montelukast 10 mg/day and 10 
patients received placebo treatment for 4 weeks. Nasal polyp 
scores, eosinophila cationic protein levels in nasal secretions and 
HRQL employing a modified Juniper score were assessed before 
and after treatment. No significant changes in polyp scores 
and nasal ECP levels were observed. In some HRQL parameters, 
better scores were observed in the treatment group (1874) In a 
randomized, controlled trial without allocation concealment, 
38 consecutive adult patients with bilateral nasal polyps were 
treated with oral prednisolone for 14 days and budenoside 
nasal spray for 8 weeks (n=18). Twenty subjects received similar 
treatment with additional oral montelukast 10 mg/day for 8 
weeks. Concomitant nasal allergy was more frequent among 
montelukast treated patients. Outcome measures included 
nasal symptom scores and the SF-36 HRQL questionnaire. When 
compared with subjects treated with steroid alone, subjects 
treated with montelukast showed a significant reduction in 
symptom scores at eight weeks with respect to headache, facial 
pain, and sneezing. However, montelukast therapy did not 
have a significant effect on the overall symptom score or on 
symptoms of nasal blockage, hyposmia, or nasal discharge (1875). 
Adverse effects of leukotriene antagonists include skin rash, 
mood or behavior changes, tremors or shaking and occasional 
worsening of sinus symptoms and asthma. Current data do 
not support anti-leukotriene therapy in CRS-patients with 
polyps. Leukotriene antagonists are not recommended for the 
treatment of CRSwNP (Grade of recommendation A). 
6.7.10. Aspirin desensitisation
Aspirin-exacerbated respiratory disease (AERD) is characterized 
by chronic rhinosinusitis with nasal polyps, bronchial asthma 
and hypersensitivity to inhibitors of cyclooxygenase-1 (Cox-1) 
including aspirin and other non-steroidal anti-inflammatory 
drugs (1525). The diagnosis is mainly based on patient history and 
aspirin provocation tests (1506). In AERD patients, aspirin may 
induce a period lasting 24 to 72 hours, in which patients are 
refractory to repeated aspirin challenges and experience clinical 
improvement (1876). Based on this observation, several oral and 
nasal aspirin desensitisation protocols were developed. Most 
widely used is the Scripps-clinics oral aspirin desensitisation 
protocol, in which, following a stepwise dose increase, 625 mg 
aspirin is orally administered twice daily (1525). 
Several case series suggest albeit weak clinical benefit from oral 
aspirin desensitisation (1526, 1877), but no randomized placebo-
controlled trial on oral aspirin desensitisation in patients with 
AERD could be identified. In a cross-over trial, 25 AERD patients 
were treated with oral aspirin in 3 different dosages or with 
placebo for 3 months, separated by a 1 month wash out phase. 
Symptom scores and concomitant medication use in the two 
trial phases were compared with 1-sided t-test. The mode of 
randomization is not detailed in the publication. In the aspirin 
phase, less nasal symptoms and less nasal steroid use was 
observed. Lower respiratory tract symptoms, values of FEV1, 
and the use of anti-asthmatic medications including prednisone 
were not better during ASA treatment (1825).
In one clinical trial, 14 patients who reacted positively in an 
aspirin provocation test were alternately allocated to take 100 
mg aspirin or 300 mg aspirin daily and were followed for at least 
1 year. After 1 year of aspirin therapy, all patients of the 100mg 
group (100%; 95%CI, 59–100%) had developed recurrent nasal 
polyps. No patient of the 300mg group showed recurrent nasal 
polyps in endoscopic examination (0%; 95% CI, 0–41%) (1878).
Nasal administration of lysine-aspirin reduces the risk of severe 
hypersensitivity reactions and the frequency of gastrointestinal 
side effects associated with oral aspirin desensitisation. Some 
retrospective studies reported clinical benefit from nasal 
lysine-aspirin treatment (1824, 1529). In a randomized, double-blind 
placebo-controlled cross over trial, AERD patients with positive 
nasal lysine-aspirin challenge received either 16mg nasal lysine 
aspirin or placebo every 48 hrs. for 6 months. Of 22 patients 
entering the trial, 11 were eligible for analysis. Multivariate 
analysis of measured parameters did not reveal a significant 
clinical benefit to patients receiving topical lysine-aspirin 
compared with placebo (1528). 
Oral aspirin desensitisation is associated with the risk of severe 
hypersensitivity reactions and gastrointestinal side effects. 
Based on current data, the benefit of oral or nasal aspirin 
desensitisation in patients AERD remains elusive. Aspirin 
desensitisation is currently not recommended outside clinical 
trials (grade of recommendation D).
6.7.11. Capsaicin
Two case series and 1 RCT on nasal capsaicin treatment 
following sinus surgery were identified (1879-1881). In the RCT, 29 
patients capsaicin soaked cotton pellets were brought into the 
middle meatus of both nostrils for 20 min once a week for 5 
weeks. An age and gender matched control group of 22 patients 
were treated with the capsaicin vehicle alone (70% ethanol). 
Nasal symptom scores and a nasal endoscopy score were the 
main outcome parameters. Patients treated with capsaicin 
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showed a significant smaller staging of their nasal polyposis 
compared with the control group (p<0.001) (1879) (grade of 
recommendation: C).
6.7.12. Various other medical treatments
Single studies and anecdotal reports on various topical and 
systemic treatments do not allow to recommend their use in 
CRSwNP including nasal decongestants (1882), mucolytics (1883), 
postoperative saline douches (1738) or spray (1884), manuka honey 
(1587), proton pump inhibitors or phytopreparations (no data 
available for CRSwNP). 
6.8. Evidence based Surgery for CRSwNP 
6.8.1. Introduction 
Nasal polyps affect approximately 20% of patients with CRS. 
From a clinical, radiological and histological perspective the 
mucosal inflammatory response is more florid in CRS patients 
with nasal polyps than in those without, and the rate of relapse 
after surgery for nasal polyps tends to be higher (1885).
Surgical intervention in the treatment of nasal polyps is 
considered in patients who fail to improve after a trial of 
maximal medical treatment. Functional endoscopic sinus 
surgery involves the clearance of polyps and polypoid mucosa 
and opening of the sinus ostia. The removal of inflammatory 
tissue and reduction of the load of antigens inciting that 
inflammation, as well as the improvement of sinus ventilation 
and mucociliary clearance, are the probable mechanisms 
whereby FESS improves symptoms in nasal polyposis. 
The optimal surgical management of nasal polyps has not yet 
been established. There are a number of factors contributing to 
the difficulty in gathering clinical data on which to base surgical 
management. A number of studies fail to distinguish between 
CRS with and without polyps. However in those studies that 
do, the distinction made on clinical grounds preoperatively 
(whether polyps are visible in the middle meatus) is itself 
imperfect. Many cases in which no polyps can be observed have 
impressively polypoid mucosa within the sinuses at the time 
of operation. There are very few RCT’s which compare medical 
and surgical treatment with the extent of surgical resection 
required to optimize outcomes, hence this is largely unknown.  
Functional endoscopic sinus surgery describes an approach and 
not a standardized operation. The efficacy of procedures may 
well be dependent on their extent and so the specific details of 
the procedures performed need be considered carefully when 
assessing the reported efficacy.
The outcome post polyp surgery is influenced by whether 
the polyps are idiopathic or related to an underlying mucosal 
condition such as aspirin exacerbated respiratory disease, 
cystic fibrosis or primary ciliary dyskinaesia. However in both 
idiopathic and secondary nasal polyps, the long-term efficacy of 
surgery is almost certainly influenced by the regimen of medical 
treatment prescribed postoperatively and the subsequent 
compliance with this regimen.
In this chapter the evidence for efficacy of surgery will be 
reviewed, and compared to medical treatment alone. This is 
not an easy comparison to make as it is generally agreed that 
surgery is only indicated when medical therapy has failed. The 
issue of extent of surgery will be addressed, and the impact of 
underlying conditions and medical treatment have on surgical 
outcome will be summarized.  Surgery for nasal polyps has been 
associated with a high rate of revision, and the role of second 
line procedures such as endoscopic modified Lothrop procedure 
will be discussed.
6.8.2. Efficacy of surgery for nasal polyposis
Endoscopic sinus surgery for nasal polyposis has 
been generally reported to be a safe and effective 
procedure.
A number of series have demonstrated that sinus surgery in 
Table 6.7.3. Leukotrine antagonists in CRSwNP.  
Author Drug Study design Active 
drug (n)
Control (n) Effect Evidence 
level
Schaper 
2011 (1869)
montelukast (10 mg/day) randomized, placebo controlled cross over 24 24 positive Ib
Stewart 
2008 (1875)
montelukast (10 mg/day)2) randomized, unblinded 20 182 negative Ib(-)*
Pauli 
2007 (1874)
montelukast (10 mg/day) randomized, double blind, placebo controlled 20 10 negative Ib(-)
Mostafa 
2005 (1873)
montelukast (10 mg/day) randomized, double blind 20 201 negative Ib(-)
* Ib (-): Ib study with a negative outcome.
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patients with nasal polyps can result in a prolonged reduction 
of nasal symptoms and an improvement in quality of life. 
Dalziel et al. evaluated 33 articles published between 1978 and 
2001 (1886). The review included three studies comparing FESS 
with Caldwell–Luc or other endonasal procedures (n=240), 
three nonrandomized studies comparing different surgical 
approaches (n=2,699) and 27 case series (n=8,208). Seven 
studies included only patients with polyps and 26 had CRS had 
with and without polyps. Patients judged their symptoms to 
be ‘improved’ or ‘greatly improved’ in 75 to 95% of cases. The 
percentage of overall complications was low (1.4% for FESS 
compared and 0.8% for traditional procedures). The implications 
of this review are that FESS is safe and effective treatment for 
the great majority of patients.
Two-thirds (2176) of the 3,128 patients included in the National 
Comparative Audit had CRS with nasal polyps (1757). In this 
prospective cohort study, a significant improvement in SNOT-22 
scores was demonstrated at 3, 12 and 36 months with CRSwNP 
patients were found to benefit more from surgery than those 
with CRSsNP. Revision surgery was indicated in 3.6% of patients 
at 12 months and 11.8% at 36 months (1757).
6.8.3. Efficacy of surgery for nasal polyps 
compared to CRSsNP
The efficacy of FESS in patients with
 CRSwNP is at least as great as in patients 
with CRSsNP
There is some evidence that a significantly higher rate of 
recurrent surgery is required in patients with nasal polyposis 
than those without polyps (1887). Despite the increased rates of 
revision, patients with polyps may have more improvement 
following sinus surgery than CRSsNP patients (1757). In one large 
series, FESS was performed in 251 patients with medically 
refractory CRS (86 with polyps and 165 without), and the 
patients followed for at least 12 months. Symptom scores 
improved significantly in both groups (p<0.001). There were 
no significant differences between the groups except in 
oropharyngeal symptoms, which were improved more in the 
non-polyp patients (1888)..
In another series, 43 patients with polyps were compared with 
76 patients without polyps before and after ESS. Mean follow-up 
was 1.5 years. Patients were analysed prospectively based on CT 
scans, endoscopy, quality-of-life (QOL) assessment and visual 
analog symptom scales. Despite significantly worse objective 
scores, patients with polyps surprisingly reported significantly 
better QOL scores and less facial pain or headache both pre- and 
postoperatively (1885).
6.8.4. Efficacy of surgery for nasal polyps 
compared to medical therapy
The efficacy of FESS is equivalent to the efficacy 
of medical therapy (which includes systemic 
corticosterioid treatment) in CRSwNP patients 
randomized to receive one or other treatment.
As surgery for nasal polyposis is usually not considered until 
medical therapy has failed to provide adequate symptom relief, 
a clinically relevant comparison of the relative efficacies of 
medical and surgical treatment is difficult to make because the 
patient populations in whom these treatment modalities are 
indicated are different.
However, if untreated patients are randomized into either a 
medical treatment or surgical arm comparisons of the relative 
efficacies of these approaches can be made.  In a randomized 
controlled trial comparing the effect of medical and surgical 
treatment of CRS on quality of life, 90 patients were evaluated 
before and after 6 and 12 months of follow up after either 
medical or surgical therapy (15). Both medical and surgical 
treatment of CRS significantly improved almost all the domains 
of SNOT 20 and SF-36 (p < 0.05), with no significant difference 
being found between the medical and surgical groups (p > 
0.05). The presence of nasal polyps did not adversely affect the 
outcome observed after either medical or surgical treatment.
Another study included 109 patients with nasal polyps (1889). 
A total of 53 patients were randomly allocated to receive 
oral prednisone for 2 weeks and 56 patients were allocated 
to undergo ESS. All patients were administered intranasal 
budesonide for 12 months. Patients were evaluated for nasal 
symptoms, polyp size and quality of life. At 6 and 12 months, 
a significant improvement in all SF-36 domains was observed 
after both medical and surgical treatment, reaching the levels 
seen in the general population. Nasal symptoms and polyp size 
improved after both medical and surgical treatment at 6 and 12 
months. These results suggest that both medical and surgical 
treatment can lead to similar effects in improving quality of life.
Although these studies provide an interesting insight into the 
relative efficacies of medical and surgical therapy in unselected 
patients, neither reflects currently accepted practice guidelines 
in which surgery is performed in medically refractory patients.
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6.8.5. Extent of treatment 
The extent of surgery required to optimize outco-
mes in CRSwNP patients has not been established. 
Some reports suggest that outcomes may be 
improved after more extensive procedures.
A wide range of surgical procedures are undertaken to treat CRS 
and currently the vast majority of these are being performed 
endonasally. Although treatment by polypectomy alone 
effectively relieves symptoms of nasal blockage, it is associated 
with high recurrence rates (1887, 1890). In 1997, Jankowski et al. 
prospectively compared patient satisfaction and recurrence 
rate of nasal polyps in a group of patients with severe nasal 
polyposis, 39 of whom had radical ethmoidectomy (nasalisation) 
and 37 of whom underwent functional ethmoidectomy 
performed by two different surgeons (reducing comparability 
between the groups) (1767). It was found that the nasalisation 
group had a significantly lower recurrence rate of 22.7% versus 
58.3% in the functional ethmoidectomy group. The overall 
functional benefit was also reported to be significantly higher 
in the nasalisation group, suggesting that treatment of nasal 
polyposis with complete ethmoidectomy leads to better long-
term results than incomplete ethmoidectomy. 
In a more recent study a retrospective review of revision rates 
and complications in 149 patients who underwent extensive 
FESS was performed (1891). A comparison was made with patients 
from the UK National Comparative Audit who underwent polyp 
surgery limited to the anterior ethmoid cavity. At 36 months 
after surgery, five patients from the extensive surgery group 
had undergone a revision procedure, which was significantly 
less than the National Audit figure (4.0 vs. 12.3%, P = 0.006). The 
peri-operative adverse complication rate was similar (7.4 vs. 
6.6%). There was a large improvement in SNOT-22 scores from 
the pre-operative period (mean 39) to the post-operative period 
(mean 8) in the extensive surgery group. This study provides 
some evidence that extensive sinus surgery performed by an 
experienced rhinologist can lead to a lower revision rate without 
compromising patient safety. 
6.8.5.1. Surgery of the frontal recess
Mucosal thickening of the frontal recess easily leads to 
obstruction of the frontal sinus outflow tract. At the time 
of initial development of endoscopic surgery there was a 
reluctance to perform frontal recess dissection because of the 
ease with which the recess may stenose with postoperative 
scarring. However in recent years understanding of the anatomy 
of this region and instruments for its dissection have improved, 
and impressive patency rates have been reported. A recent 
review of the evidence of clinical efficacy of frontal sinus 
procedures for CRS found a generally high rate of success but 
some of the series were small and the follow up relatively short 
term (1892). The review did not differentiate between CRS with 
and without polyps. Chan et al reported results from a group 
of 58 patients with eosinophilic CRS (most of whom presented 
clinically with nasal polyps) after frontal sinusotomy (Draf IIa) 
with an average follow-up of 61.6 months.  A very high patency 
rate of 85% was achieved (although this was slightly lower 
than the 90% patency rate in non-eosinophilic CRS patients). 
This series demonstrates that frontal sinusotomy performed by 
experienced surgeons can produce excellent long-term patency 
rates (1893). Friedman reported a slightly lower patency rate of 
71.1% after a similarly long period of follow up in a group of 152 
patients in whom frontal sinusotomy (Draf IIa) was performed 
(1894). Many of these patients had nasal polyps, and recurrent 
polyps or scarring were the two most common causes of 
obstruction of the frontal sinus in this series. 
6.8.5.2. Approaches to the maxillary sinus
In an effort to clear polypoid mucosa as completely as 
possible from the maxillary sinus, anterior antrotomies have 
been performed to allow access of powered instruments. The 
efficacy of this manoeuvre on the outcome after FESS has been 
the subject of a small number of studies. One such trial has 
compared the results of performing a canine fossa puncture 
with clearance of polyps via a middle meatal antrostomy (1895). No 
benefit of the canine fossa procedure over conventional middle 
meatal antrostomy was seen after 12 months follow up, however 
the number in both groups is small. The authors concluded that 
although canine fossa puncture is a useful method for removing 
severe mucosal disease that cannot be reached through the 
MMA, it does not guarantee a better subjective or objective 
surgical outcome in patients with nasal polyposis. However, case 
control studies have found that patients who had a canine fossa 
puncture had a better outcome than those with similar disease 
severity who did not (1896, 1897). 
Another approach to chronically diseased maxillary antra has 
been to lower the medial antral wall to the level of the hard 
palate. This procedure necessitates at least partial removal of the 
inferior turbinate and has been termed a mega-antrotomy. Cho 
and Hwang reported on a series of 28 patients who underwent 
42 mega-antrostomies for recalcitrant maxillary sinusitis (1457). All 
patients had previous maxillary sinus surgery (mean number of 
procedures 2.3). At the time of the most recent postoperative 
examination, 74% of patients reported complete resolution 
of symptoms while 26% reported partial symptomatic 
improvement. There were no complications and the revision 
rate was 0%.
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6.8.6. Perioperative medical care
Prolonged postoperative medical treatment with 
topical corticosteroid sprays would appear to 
improve outcomes post FESS for CRSwNP
Although many studies have demonstrated the effectiveness of 
sinus surgery for patients who have nasal polyposis, it should 
not be thought of as the only treatment but rather as a modality 
used to manage patients to remove the disease burden 
and increase the efficacy of post-operative medical therapy. 
Surgically removed polyps have a high tendency for recurrence 
without aggressive postoperative medical management.
However, surgical management can be used to decrease the 
amount of inflammation so that the medical treatment may 
become more effective and the rate of recurrence may be 
reduced. In one study, 109 patients (77 of whom had nasal 
polyps) were randomized to receive postoperative fluticasone 
spray beginning six weeks after FESS. The change in the overall 
visual analogue score was significantly better in the fluticasone 
group at 5 years and significantly more prednisolone rescue 
medication courses were prescribed in the placebo group (1821)..
There is evidence that administration of systemic steroids 
in the postoperative period for patients who have polyps 
may have a significant impact on their postoperative course. 
In a randomized placebo controlled study, those patients 
who received a course of perioperative prednisone (for five 
preoperative and 9 post operative days) had significantly 
healthier looking cavities at 6 month follow up than those 
patients who received the placebo (1898). There was however no 
impact of perioperative prednisone on symptom scores.
6.8.7. Efficacy of revision surgery for nasal polyps
Revision surgery may be performed with 
good outcomes for recurrent nasal polyposis. 
Recalcitrant frontal sinus disease can be treated 
with good success rates and relatively little 
morbidity by performing the endoscopic modified 
Lothrop procedure.
Even after meticulous removal of polyps and polypoid 
mucosa, the opening of all sinus ostia to their anatomical 
limits and optimal postoperative medical care, some patients 
will present with recurrent disease. The frontal recess is the 
most common site of recurrence, probably because it is so 
easily stenosed postoperatively with scarring and recurrent 
inflammation.  
Many studies have examined the prognostic factors affecting 
the success of endoscopic sinus surgery (ESS), and a history 
of previous ESS is often found to be a factor contributing to 
a poor surgical outcome.  However this is not uniformly the 
case. In a recently reported study, the postoperative results 
between primary (101 cases) and revision (24 cases) FESS for 
chronic rhinosinusitis with nasal polyposis were compared using 
the SNOT-20 and nasal endoscopy scores at 6 and 12 months 
(1895). Postoperatively the subjective and objective surgical 
outcomes of the 2 groups did not differ statistically. Also the 
need for additional medications during the follow-up period 
and the proportion of patients who required additional surgical 
intervention due to surgical failure was similar in both groups.
The extent of revision surgery is largely guided by postoperative 
CT scan results. If persisting sinus cells or septations are causing 
ongoing obstruction or stenosis of sinus ostia, then these 
require removal.  However, in cases of severe nasal polyposis it 
is not uncommon for the frontal recess to have been completely 
cleared of cells, but for the soft tissue or neo-osteogenesis to 
have narrowed or occluded the recess. The implication is that 
the frontal recess needs to be enlarged beyond its anatomical 
limits. During the endoscopic modified Lothrop procedure 
the floor of the frontal sinuses and the intersinus septum are 
removed, creating a large common ostium (1899). A very recently 
published series of 122 consecutive patients undergoing an 
endoscopic modified Lothrop procedure, reported a frontal 
patency rate of 90%(1900). A meta-analysis of the 612 cases of 
endoscopic modified Lothrop procedures has been reported 
recently (1901). Nearly 30% of these patients had nasal polyposis. 
In those patients with available data, patency was achieved in 
95.9% and improvement of symptoms in 82.2%. The overall 
failure rate (requirement of further surgery) was 13.9%. The 
reported complication was low. This meta-analysis suggests 
that the endoscopic modified Lothrop procedure is a very good 
option if the frontal sinusitis persists after frontal sinusotomy 
has been performed. It would appear to offer a success rate 
similar to frontal sinus obliteration procedures but with much 
less morbidity.
6.8.8. Complications of surgical treatment of 
nasal polyps
The frequency of occurrence of severe orbital or 
skull base complications is very low in recently 
reported series
A number of significant complications have been reported after 
FESS for nasal polyps. Fortunately the frequency of occurrence 
of severe complications would appear to be reducing with 
time, and the risk of major orbital, intracranial or vascular injury 
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occurring is now very low. 
A systematic review of safety and efficacy of FESS for removal 
of polyps by Dalziel et al. in 2006 reviewed three randomized 
control trials, four nonrandomized comparative studies and 
35 case series studies (1902). Major complications ranged from 
0% to 1.5% and minor complications from 1.1% to 20.8%. 
Infection was reported in 16% of FESS procedures and 28% 
of conventional procedures. Disease recurrence ranged from 
4% to 60% with a median of 20% across all studies reviewed. 
Recurrence following revision surgery ranged from 3% to 42% 
with a median of 6%.
The National Audit in England and Wales assessed the rate of 
complications of surgery for polyposis and chronic rhinosinusitis 
(1903). A total of 3123 patients were included in the study of 
which 2176 (69.1%) had nasal polyps. Nearly 40% of patients 
underwent a simple polypectomy ± antral washout and the 
majority of operations were performed endoscopically. 
The microdebrider was used in 16.5% of operations. Major 
complications were observed in 0.4% of cases, minor 
complications in 6.6%. Statistical significance was found 
in complication rates between grades of polyposis, use of 
microdebrider, increasing Lund-Mackay score, increasing 
American Society of Anesthesiology score and patients with 
previous sinonasal surgery.
A retrospective study by Ecevit et al. compared the rate of 
microdebrider complications between 90 cases (177 sides) 
of chronic sinusitis with polyps to 49 cases (98 sides) of 
chronic sinusitis without polyps (1904). The minor and major 
complication rate for the group with nasal polyps was 11.8 and 
0.5% respectively. Only one major complication was reported, 
a cerebrospinal fistula which was repaired intra-operatively. 
The complication rate for chronic sinusitis without polyps was 
4%. The difference between complication rates of the two 
groups was statistically significant (p=0.0001)
A retrospective medical record review by Devars du Mayne 
et al. assessed outcomes of patients with nasal polyps 
undergoing either radical ethmoidectomy (n=77) or 
polypectomy (n=50) (1905). No severe complications were 
observed in either group although few complications were 
seen in the polypectomy group (8% vs 18.3%). Seven patients 
from the radical ethmoidectomy group required further 
surgery (four for polyp recurrence, two for ethmoidofrontal 
mucocoele and one for nasofrontal duct stenosis) and four 
from the polypectomy group required further surgery, all for 
polyp recurrence.
A retrospective case note review was performed by Bajaj et al. 
assessing the results of FESS as day-case surgery (1906). Of the 
105 procedures, 62.8% had both CRS and NP. The only reported 
complication of the study was bleeding, seen in 7 patients. Five 
patients had primary haemorrhage and were packed in theatre 
and 2 had reactionary bleeding, 1 of which required packing.
6.9.  Influence of concomitant diseases 
on outcome of treatment in Chronic 
Rhinosinusitis with and without NP including 
reasons for failure of medical and surgical 
therapy 
6.9.1. Summary
Many factors potentially outcome of treatment in CRS with and 
without nasal polyps. Extent of the disease, asthma, AERD, CF 
and biofilm formation have been proven to have a negative 
influence. For some factors, like allergy, smoking and ,  type of 
inflammation, studies contradict each other. 
Gender does not seem to influence the results of treatment 
of CRS. Patients with higher age and fatigue may have a more 
pronounced improvement after FESS.
6.9.2. Sinus surgery in the elderly 
In general no difference is found in symptomatology and QoL 
of CRS in the elderly (1187, 1907, 1908). In a study comparing the 
objective endoscopic findings and subjective improvements 
in symptoms among the groups 6 months after the functional 
endoscopic sinus surgery (FESS) in  three groups according to 
patient age: 20 paediatric (5-18 yr), 20 adult (19-65 yr), and 20 
geriatric patients (over 65 yr.) no statistical differences in polyp 
extent or Lund-Mackay score were found before FESS between 
the three age groups  and the subjective surgical outcome did 
not differ statistically between the groups, with the exception of 
olfactory disturbance. On the other hand the objective surgical 
outcome based on the endoscopic findings was worst in the 
paediatric group (45%), whereas the geriatric group showed 
the best results (90%). The differences in objective outcome 
among the three groups were significant, and patient age 
was a predictive variable for surgical result based on multiple 
logistic regression analysis (1907). Also in the study of Sil et al. 
increasing age was significantly positively correlated with the 
objective signs improvement in endoscopic polyp scores and in 
nasal mucociliary clearance times, but not in symptomatology 
(1909). This better objective outcome in the elderly could not be 
substantiated by Reh, however his elderly group comprised of 
only 18 patients (1908). Analysis of recurrences was accomplished 
in a retrospective study on 192 patients operated for CRSwNP. 
No association of recurrence with age, gender, purulent nasal 
discharge, facial pain, anosmia, post nasal dripping, headache, 
nasal allergy, and asthma were observed (1910). 
In a retrospective case control study, FESS outcome in 46 CRS 
patients > 65 years were compared with 522 CRS patients 
who were 18¬64 years old (1911). In the elder patient group, 
complications occurred significantly more frequently than in 
the younger patients group. In particular orbital complications 
were frequently observed in the elder patient group (level III). 
Jiang and Su retrospectively compared complication rates of 
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171 CRS patients older than 65 years with 837 adult patients 
and 104 patients younger than 16 years. They found that the 
geriatric group experienced a disproportionately larger share 
of operative complications. Outcomes were similar in all three 
groups (1912). A study evaluated outcome of sinus surgery in 180 
patients older than 65 yrs. compared to 180 adults (15-65 yrs.), 
both groups with CRS.  Diabetes mellitus was shown to be risk 
factor for complications, not so much the patients’ age (1913).
Conclusion: CRS is a common condition in the elderly. Reported 
symptomatology before and after surgery does not differ from 
a younger patient population and postoperative objective signs 
seem to improve more in the elderly. However, higher surgical 
complication rates were found in 2 reports. Moreover, general 
anaesthesia bears higher risks and the capacity to recover 
from a severe surgical complication such as a CSF leak may be 
impaired. 
6.9.3. Gender
In most studies women with CRS report higher levels of 
symptoms despite less extensive disease and this is likely to 
be due to a systematic difference in response style (1187, 1914, 1915). 
In a prospective study of 514 adult patients who presented 
with chronic rhinosinusitis with and without nasal polyposis 
facial pain and headache were more prevalent among women, 
while nasal obstruction was more prevalent among men. This is 
partly explained by the fact that CRSsNP was the more common 
diagnosis among women, while CRSwNP was the more common 
diagnosis among men. There was no statistically significant 
difference in the improvement of the other presenting 
symptoms, comparing the gender (1915). Most other studies also 
show comparable improvement of FESS between men and 
women (1909, 1910, 1915).
6.9.4. Extent of disease at baseline 
Patients presenting with extensive disease suggested by 
C.T scan staging are at higher risk for the development of 
recurrences after endonasal surgery for nasal polyps (1910). CT 
scan scores and polyp scores were the strongest predictors of 
the need for postoperative systemic medication (1909). 
6.9.5. Primary versus revision surgery
The symptomatic relief that revision FESS can provide for 
patients with refractory chronic rhinosinusitis is similar to that 
following a primary FESS (1785, 1918). However, in one study patients 
undergoing primary surgery were 2 times more likely to improve 
compared with patients undergoing revision surgery (1189).
6.9.6. Type of inflammation
The influence of the type of inflammation on treatment is 
contradictory.
The efficacy of macrolides appears to be less in patients with 
CRSwNP, severe findings on CT scans, asthma, low IgE and 
polyps with increased eosinophil infiltration (1708, 1713). 
There is a significant positive correlation between sinus CT stage 
and peripheral eosinophil levels. Eighty-nine percent of the 
abnormal eosinophil counts (>550 cells/microL) were associated 
with CT scores higher than 12. Total IgE did not correlate with CT 
stage of disease (1919)..
Patients with a total peripheral eosinophil count of 520/microl 
or more or mucosal eosinophilia were more likely to experience 
recurrence of CRS after surgery in two studies (878, 1920). However 
in another study CRS patients with higher levels of eosinophils 
were less likely to suffer from post-operative recurrent sinonasal 
disease when treated post-operatively with nasal corticosteroids 
(27)..
6.9.7. Asthma 
Bronchial asthma is frequently associated with CRS with and 
without polyps and may have influence on sinus surgery 
outcomes. Prevalence of asthma is shown to be much higher 
in patients with CRS than in normal population. A study of 
145 consecutive adult CRS patients evaluated the prevalence 
of asthma with CRS. The study showed 23,4% prevalence of 
asthma compared to the 5% in adult general population. These 
patients had also significantly higher prevalence of polyps 
(22%, p=0.004), olfactory dysfunction (6%, p=0.001) and nasal 
congestion (60%, p=0.037). There was no difference between 
CRS patients with or without asthma in the proportion of 
patients needing primary sinus surgery , but patients with 
asthma did require significantly more revision sinus surgeries 
(mean 2.9 vs 1.5)  p=0.0003 (1921).
More severe sinus disease in CRS patients with concomitant 
asthma has been reported (746, 762, 1922, 1923). Clinically, CRS patients 
with polyps and asthma have higher CT-scores, more severe 
nasal obstruction and hyposmia, and more severe asthma, 
while CRS patients without polyps and asthma experience 
more severe headache and postnasal discharge (746, 1922-1924). The 
incidence of self reported rhinosinusitis in asthma patients was 
recently evaluated employing the data of two major asthma 
trials (1925). Self reported rhinosinusitis was associated with 
bronchial asthma in 70% of the 2500 study participants. Asthma 
patients with concomitant rhinosinusitis had more asthma 
exacerbations, worse asthma symptoms, worse cough, and 
worse sleep quality. Investigations of concomitant asthma on 
sinus surgery outcomes in CRS patients with or without nasal 
polyps yielded inconsistent results (1417). Concomitant asthma 
was associated with worse postoperative endoscopy findings 
in two retrospective analyses (1761, 1775), but had no independent 
influence on other outcome parameters (level IV). Consistently, 
symptom scores improved significantly in both asthmatics 
and non-asthmatics postoperatively, but asthmatics exhibited 
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significantly worse postoperative endoscopic. Asthma with and 
without aspirin intolerance was shown to be a determinant of 
recurrence after FESS in patients with CRSsNP and CRSwNP (878, 
1521, 1923), but not in all studies (1910, 1926).
6.9.7.1. Asthma in CRSsNP 
There is a strong association of asthma with CRS (adjusted OR: 
3.47; 95% CI: 3.20-3.76) at all ages (1927). Concomitant asthma 
is frequent in CRSsNP patients (122). Asthma was shown to be a 
determinant of recurrence after FESS in patients with CRSsNP (878, 
1923), but not in all studies (1926).
6.9.7.2. Asthma in CRSwNP 
Asthma is more prevalent in white patients with CRSwNP than 
in patients with CRSsNP, however the same does not seem to 
hold for chinese polyps (585, 621). Asthma with and without aspirin 
intolerance was shown to be a determinant of recurrence after 
FESS especially in patients with CRSwNP (878, 1521, 1923), but not in all 
studies (1910, 1926).
6.9.7.3. Effect of treatment on bronchial asthma 
The question, how sinus surgery and medical CRS treatment 
may alter the course of bronchial asthma, was reviewed by Lund 
(1928) and Scadding (1929). The authors describe the somewhat 
intricate base of evidence and conclude that the weight 
of evidence suggests a beneficial effect. Studies published 
thereafter support this view (1416, 1924, 1930, 1931). In a case series 
study, 50 CRS patients with concomitant asthma were included 
(1924). Ragab and co-workers report a prospective evaluation of 
a subgroup of 43 asthma patients joining a randomised trial 
comparing the effects of sinus surgery and medical treatment in 
CRS patients with and without polyps (1423). Outcome parameters 
included asthma symptoms, control, forced expiratory volume 
in one second (FEV1), peak flow, exhaled nitric oxide, medication 
use and hospitalisation at 6 and 12 months from the start 
of the study. Overall asthma control improved significantly 
following both treatment modalities, but was better maintained 
after medical therapy, where improvement could also be 
demonstrated in the subgroup with nasal polyps. Medical 
treatment was superior to surgery with respect to a decrease in 
exhaled nitric oxide and increase in FEV1 in the polyp patients. 
Two patients noted worsening of asthma postoperatively. 
Treatment of chronic rhinosinusitis, medical or surgical, benefits 
concomitant asthma; that associated with nasal polyposis 
benefits more from medical therapy (level Ib). Haruna and 
coworkers also showed that asthma was negative factor in the 
treatment with macrolides (1713).
Palmer and coworkers retrospectively reviewed the charts of a 
subgroup of 15 CRS patients with steroid dependent asthma 
selected from a group of 75 consecutive CRS patients with 
asthma who underwent endoscopic sinus surgery (1932). Outcome 
parameters included the number of days and total dose of oral 
prednisone and antibiotics in the year before and after sinus 
surgery. Fourteen of the 15 patients meeting study criteria 
decreased their postoperative prednisone requirement by total 
number of days Antibiotic use also decreased (p < 0.045), with 
an average use of antibiotic nine weeks preoperatively versus 
seven weeks postoperatively (Evidence level IV).
Conclusion
Apparently, various confounders not yet sufficiently defined 
influence the effects of surgical CRS treatment on concomitant 
asthma. In studies published in recent years, predominantly 
positive effects of surgical CRS treatment on concomitant 
asthma severity were reported However, the level of evidence is 
low (122). 
6.9.8. Aspirin exacerbated disease (AERD)
The majority of CRS patients with AERD have diffuse, extensive 
rhinosinusitis (762). AERD patients usually present with more 
severe asthma (1519). AERD is rather consistently found to 
adversely affect sinus surgery outcomes (1419, 1420, 1504, 1517, 1933, 
1934). The asthmatic complaints of aspirin intolerant and aspirin 
tolerant patients improved significantly after ESS but CT scan 
improved more in the aspirin tolerant patients than in the 
aspirin patients (1519). Although FESS helped both groups of 
patients, AERD patients had statistically significant better results 
compared with aspirin tolerant patients in asthma severity 
scores and decreased need for ICS (1518). The olfactory recovery 
after FESS for nasal polyposis is significantly affected by the 
concomitant presence of AERD (1520). Patients with AERD were 
significantly more likely to have a recurrence and undergo a 
second surgery following recurrence (risk-odds ratio, 2.7; 95% 
confidence interval, 1.5 to 3.2; p < 0.01) than were patients 
without asthma or with only asthma from the triad (1521).
Conclusion
CRS patients with AERD tend to suffer from more extensive sinus 
disease. They benefit from sinus surgery, but to a lesser extent 
than patients without AERD. They are more prone to disease 
recurrence and more frequently undergo revision surgery than 
aspirin tolerant CRS patients. 
6.9.9. Allergy and atopy 
In most studies, the diagnosis of allergy was based solely on 
the presence of a positive skin prick test and/or serum specific 
IgE determinations. This indicates atopy, but may not suffice 
to diagnose allergic rhinitis (AR), particularly persistent AR (1933). 
Consistently, the reported incidence of atopy in CRS patients 
ranges between 50 and 80%, which is higher than in the general 
population. The risk-ratio of chronic sinusitis in the AR group in 
a large cohort was shown to be 4.5 (1935). CRS in atopic patients 
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appears to be more severe (530, 1623, 1936-1940). Atopy was equally 
frequently associated with CRS with and without polyps (1941). 
Reports on potential negative effects of allergy on outcomes 
of surgery are various. There are a number of studies indicating 
a negative outcome of atopy (1775, 1887, 1900).  But also quit some 
studies did not interference with atopy In recent studies allergy 
did not seem to be a determinant of treatment failure (1926, 1942-
1944).
 
6.9.10. Cystic fibrosis 
In cystic fibrosis (CF), CRS with and without nasal polyps is 
observed (1945). The inflammatory profile of CRS in CF patients 
differs from CRS in patients without CF (18, 1482, 1945). Persistent 
colonisation with Pseudomonas aeruginosa is a common 
finding. The paranasal sinuses often harbor distinct bacterial 
subpopulations, and in the early colonization phases there 
seems to be a migration from the sinuses to the lower airways, 
suggesting that independent adaptation and evolution take 
place in the sinuses. The paranasal sinuses potentially constitute 
a protected niche of adapted clones of P. aeruginosa, which can 
intermittently seed the lungs and pave the way for subsequent 
chronic lung infections (1437).
 In 37 patients with cystic fibrosis after lung transplantation, 
sinus surgery was performed and repeated sinus aspirates and 
broncho-alveolar lavages were obtained for microbiological 
examinations. Sinus surgery was successful (three or less 
Pseudomonas aeruginosa positive aspirates) in 54% and 
partially successful (4 or 5 positive aspirates) in 27% of patients 
(1459). A significant correlation of bacterial growth in sinus 
aspirates and broncho-alveolar lavages was observed (p < 
0,0001). Successful sinus management led to a lower incidence 
of tracheobronchitis and pneumonia (p = 0,009) and a trend 
toward a lower incidence (p = 0,23) of bronchiolitis obliterans 
syndrome (Evidence level IV). FESS with subsequent monthly 
antimicrobial antral lavages (n=32) was compared with a historic 
control group receiving conventional sinus surgery without 
postoperative lavages (n=19). The group treated with FESS and 
antral lavages had fewer operations per patient, and a decrease 
in repeated surgery at 1 year (10% vs. 47%) and 2 year follow up 
(22% vs 72%) (Evidence level IV). Not all studies report positive 
effects of sinus surgery on the lower airways (1946).
In general improvement after FESS is significant but quit often 
recurrences are seen (1947, 1948). While baseline measures of 
disease severity are worse in the CF population, objective and 
QoL improvements for adult patients with comorbid CF are 
comparable to patients without CF (1456).  
Conclusion
CF patients frequently suffer from severe CRS, in particular 
with diffuse polyps refractory to medical treatment. Due to a 
tendency to recur, repeated sinus surgery is often needed to 
achieve symptomatic relief. In CF patients, the paranasal sinuses 
may serve as a source for Pseudomonas aeruginosa induced 
lung infections. Consequent local antibiotic lavages help to 
prevent recurrent CRS and lung infection. 
6.9.11. Immune dysfunction
Immune deficiency states are frequently associated with 
CRS include HIV-infection, bone marrow transplantation and 
humoral immunodeficiencies. 
6.9.11.1. HIV-positive/AIDS patients
The first line treatment of sinusitis in HIV-positive patients 
is medical, in refractory cases targeted to the identified 
organisms. Surgical treatment is reserved for patients who 
do not respond to targeted medical treatment. Sabini and 
co-authors retrospectively reviewed their experience with 
performing endoscopic sinus surgery in 16 acquired immune 
deficiency (AIDS) patients (563). At an average follow-up time of 
16 months, 14 of the endoscopic sinus surgery patients reported 
improvement from their preoperative condition (Evidence 
level IV). In a retrospective case series study, 106 HIV+ patients 
who underwent sinus surgery between 1987 and 1998 were 
evaluated (1949). Between 1987 and 1991, 36 patients were treated 
with minimal invasive sinus surgery just addressing the involved 
sinus with only 20% clinical improvement. Since 1992, the 
authors treated their HIV+ patients with more extensive surgery 
including sphenoethmoidectomy, middle meatal antrostomy 
and drainage of the frontal recess, which resulted in a clinical 
improvement rate of 75%, irrespective of the CD4 counts 
(Evidence level IV). In two case series, Murphy and co-workers 
observed the clinical outcome of 30 HIV-positive CRS patients 
refractory to medical treatment (1950). Outcome parameters 
included olfactory tests, symptom scores, and a quality of well-
being assessment. Symptom and well-being scores improved 
significantly following endoscopic sinus surgery, whereas 
olfactory thresholds did not improve significantly (Evidence 
level IV). Patients with AIDS may develop acute invasive fungal 
sinusitis. If detected early, combined surgical and antifungal 
treatment may be beneficial (1951, 1952). 
6.9.11.2. Bone marrow transplant
Bone marrow transplantation (BMT) is a frequent cause of 
acquired immune deficiency. Allogeneic BMT is associated 
with acute and chronic CRS in approximately 40% (1953). Sinus 
microbiology was investigated in 18 BMT patients who 
developed sinusitis evaluating 41 microbiological specimens 
obtained by antral puncture and nasal swabs from the middle 
meatus (1954).  Agents most commonly isolated were gram-
negative bacteria including Pseudomonas aeruginosa and 
Searratia marescens. Gram-positive bacteria were isolated in 
27%. Various fungi were isolated in 16% of the specimens. 
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Microbiological results of antral punctures and nasal swabs were 
consistent in 5 of 41 specimens. Kennedy and co-workers report 
on 29 bone marrow transplant recipients with documented 
invasive fungal infections of the sinuses and paranasal tissues 
(1.7% of 1,692 bone marrow transplants performed). All 
patients received medical management, such as amphotericin, 
rifampin, and colony-stimulating factors, in addition to surgical 
intervention (1955). Surgical management ranged from minimally 
invasive procedures to extensive resections including medial 
maxillectomies. The mortality rate from the initial fungal 
infection was 62%. Twenty-seven percent resolved the initial 
infections but subsequently died of other causes. Prognosis 
was poor when cranial and orbital involvement and/or bony 
erosion occurred. Extensive surgery was not superior to 
endoscopic functional surgery (Evidence level IV). Sinus surgery 
was performed in 28 of 311 bone marrow trans-plant patients 
retrospectively evaluated (1956). No fungal sinusitis was observed. 
An aggressive surgical approach yielded a high mortality 
rate whereas limited surgical approaches with intensive 
postoperative care proved appropriate (Evidence level IV). 
6.9.11.3. Non-acquired immunodeficiencies 
Patients with humoral immunodeficiencies including 
common variable immunodeficiency, ataxia telangiectasia, 
or X-linked agammaglobulinaemia are at increased risk to 
develop CRS (1543, 1957-1959). Chee and co-workers selected 79 
out of 316 patients with CRS with and without polyps, who 
suffered from severe CRS refractory to medical treatment 
(560). Fifty-seven patients had undergone one or more 
previous sinus surgeries. Approximately 30% of the 79 
included patients suffered from decreased T-cell function 
and approximately 20% had some form of immunoglobulin 
deficiency. Common variable immunodeficiency was 
diagnosed in 10%. Accordingly, in a high number of patients 
with long lasting rhinosinusitis, humoral deficiencies were 
identified, particularly of the IgG3-subclass (1633, 1960). Also 
Carr et al. showed that patients with medically refractory 
CRS may have a high prevalence of lower serum IgA levels, 
low pre-immunization anti-pneumococcal titres and specific 
antibody deficiency (1533).
However, in unselected patients with sinus fungus ball, 
CRS with and without polyps, humoral deficiencies were 
not more frequent than in the general population (1961). 
Recently, the relevance of isolated immunoglobulin or IgG 
subclass deficiencies has been challenged and vaccine 
response to protein and capsular polysaccharides has been 
suggested superior to assess humoral immune function in 
CRS patients (1962 , 1963 , 1964 , 1965). Surgical outcome in patients 
with immunodeficiencies seems comparable to other CRS 
patients (1544, 1966). 
Conclusion
In the small series available in HIV-positive patients, patients 
with bone marrow transplantation and patients with non-
acquired immunodeficiencies endoscopic sinus surgery seems 
to be effective. In bone marrow transplantation patients with 
(fungal) infections extensive surgery was not superior to FESS. 
In non-acquired immunodeficiencies surgical outcomes are 
comparable to other CRS patients.
6.9.12. Fatigue
Fatigue is a common symptom in patients with CRS (75) and 
is associated with severity scores approximating those of 
facial pressure, headache, and nasal discharge. In a meta-
analysis measuring the effect of FESS on fatigue, significant 
improvement in fatigue was noted equalling the improvement 
of pooled major CRS criteria (1967). In a study with subgroup 
analysis of 11 independent studies measured the response of 
fatigue following FESS in various groups, patients with more 
severe fatigue showed more pronounced improvement than 
patients with less severe fatigue (1968). Preoperative fatigue 
severity was less in patients with CRS and nasal polyposis than 
in patients with CRS only; however, preoperative fatigue was 
more severe in patients with fibromyalgia or depression.
6.9.13. Fibromyalgia
Patients with CRS and comorbid fibromyalgia showed similar 
improvements in QoL after FESS when compared with patients 
without fibromyalgia when controlling for age, gender, and 
disease severity (1969).
6.9.14. Biofilm
Bacterial biofilm formation was shown to be significantly 
associated with positive culture results, prior sinus surgeries, and 
nasal steroid use in the month prior to sample collection but not 
significantly associated with polyps, allergy, Samter’s triad, sleep 
apnea, smoking status, age, or gender (1970). 
Different biofilm species are associated with different disease 
phenotypes. H. influenzae biofilms are typically found in patients 
with mild disease, whereas S. aureus is associated with a more 
severe, surgically recalcitrant pattern (692). Patients with biofilms 
have more severe disease preoperatively and persistence of 
postoperative symptoms, ongoing mucosal inflammation, and 
infections (686, 693, 1923, 1971). Asthma and biofilm-forming bacteria 
were shown to be independently associated with revision sinus 
surgeries for chronic rhinosinusitis (1923).
6.9.15. Smoking
The effect of smoking on outcome of FESS is unclear. Most 
studies show no effect of smoking on FESS outcomes (770, 1972-1974). 
Although one of the studies suggest that increased smoking  
may contribute to worse post-operative endoscopy scores (770).
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Another study showed that while smoking did not influence 
preoperative symptoms, smokers had worse postoperative 
outcomes (763).
6.9.16. Occupational exposure
It is known that airway exposure to occupational agents can 
give rise to occupational airway disease (1975). It was recently 
shown that exposure at work also appears to be a risk factor for 
the occurrence of CRS and for its recurrence or persistence, as 
evidenced by the need for revision surgery (1976).
6.9.17. Gastro-oesophageal reflux
Chambers et al (1421) showed in one hundred eighty-two patients 
that only gastro-oesophageal reflux disease was statistically 
significant as a predictor of poor symptomatic outcome. 
However, a number of other studies have failed to replicate this 
finding and it is likely that gastro-oesophageal reflux can mimic 
the symptoms of CRS rather that contribute to it (1788).
6.9.18. Osteitis
In a recent retrospective study the grade of osteitis was directly 
correlated with the number of revision surgeries, with an almost 
linear response. However, from the nature of the study it could 
not be clear if that was a cause-effect or a secondary association 
(1388). A study assessing the correlation between postoperative 
outcome and osteitis showed similar results, adding to the 
evidence for a link (1778) (Evidence level IV).
6.10. Management of  Paediatric Chronic 
Rhinosinusitis
6.10.1. Summary
CRS in children is not as well studied as the same entity in 
adults.  Multiple factors contribute to the disease including 
bacteriologic and inflammatory factors.  The adenoids are 
a prominent contributor to this entity in the paediatric age 
group.  The mainstay of therapy is medical with surgical therapy 
reserved for the minority of patients who do not respond to 
medical treatment.
 
6.10.2. Medical treatment of chronic 
rhinosinusitis in children
6.10.2.1. antibiotics
There is no good evidence in the literature to support the use of 
antibiotics in CRS in children.  Otten and colleagues investigated 
141 children between the ages of 3 and 10 years with CRS as 
defined by purulent nasal drainage lasting at least 3 months, 
signs of purulent rhinitis on rhinoscopy, and unilateral or 
bilateral abnormalities of the maxillary sinus on plain films (1977).  
The patients were assigned non-selectively to receive one of the 
following 4 treatments for 10 days: saline nose drops (placebo), 
xylometazoline 0.5% nose drops with amoxicillin 250 mg PO TID, 
drainage of the maxillary sinus under anaesthesia and irrigation 
via indwelling catheter for at least 5 days, and a combination 
of drainage and irrigation with xylometazoline and amoxicillin.  
They followed the patients for up to 26 weeks after treatment 
and show no significant differences in cure rate among the 
treatments based on history, physical exam or maxillary 
sinus films.  In the total group, the cure rate was around 69%.  
Although this study did not show a significant difference 
between the treatments, it suffers from some methodological 
limitations including lack of randomization or blinding, and that 
the placebo group actually received saline drops which might 
have been helpful in and of themselves. Further, this study 
does not assess the state of the ethmoid sinuses and used plain 
X-rays as the objective diagnostic modality.  In a later study, 
the same group performed a randomized, double-blind study 
of cefaclor (20 mg/kg/day) vs placebo in 79 healthy children 
between the ages of 2 and 12 years with chronic sinusitis 
defined essentially as in the first study (1978).  All patients had 
a tap and washout and were then randomized to cefaclor or 
placebo PO for 1 week and were followed at 6 weeks.  After 6 
weeks, there was no significant difference in resolution rate 
between the children on cefaclor (64.8%) and those on placebo 
(52.5%).  Among the limitations of this study which could have 
influenced the outcome is that all children had an initial tap 
and washout which could have helped the whole group even 
before enrolment, making the antibiotic irrelevant, and plain 
radiographs were used to evaluate the sinuses.  
Despite the lack of good evidence to support the use of 
antibiotics for any length of time in children with CRS, in 
practice, these children are often treated with the same 
antibiotics listed in the section on acute rhinosinusitis but 
typically for longer periods of time that vary between 3 and 
6 weeks.  Because of the lack of data to support this practice, 
its usefulness must be weighed against the increasing risks 
of inducing antimicrobial resistance.  It is also difficult to 
ascertain whether what is actually being treated is CRS or acute 
exacerbations on top of pre-existing chronic disease.  The exact 
type of antibiotics used is usually dependent on local resistance 
patterns which might be different in different countries.  Further, 
it is advisable to always treat with as narrow a spectrum of 
antibiotics as will likely cover the bacteria that are prevalent in a 
specific geographic locale.
In sum, available data does not justify the use of short-term 
oral antibiotics for the treatment of CRS in children (Strength 
of recommendation: B). There might a place for longer-term 
antibiotics for the treatment of CRS in children (equivalent to 
CRS in adults) (Strength of recommendation: D).
Intravenous antibiotic therapy for CRS resistant to maximal 
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medical treatment has been studied as an alternative to 
endoscopic sinus surgery.  In a retrospective analysis of 70 
children aged 10 months to 15 years with CRS, Don et al found 
that 89% had complete resolution of symptoms after maxillary 
sinus irrigation and selective adenoidectomy followed by one 
to 4 weeks of culture-directed intravenous antibiotics (1979).  
Cefuroxime IV was most frequently used followed by ampicillin-
sulbactam, ticarcillin clavulanate and vancomycin.  Despite 
the good success rate, the therapy was not without adverse 
effects which included superficial thrombophlebtitis (9%), 
dislodgment of wire during placement necessitating venotomy 
(1%), and antibiotic related complications such as serum 
sickness, pseudomembranous colitis, and drug fevers.  A similar 
retrospective study evaluated 22 children with CRS refractory 
to medical therapy and with an age range between 1.25 to14.5 
years (1980).  They all underwent adenoidectomy, maxillary 
sinus aspiration and irrigation and placement of intravenous 
catheters and then culture-directed IV antibiotic therapy until 
resolution of symptoms (mean duration of therapy was 5 
weeks).  All patients achieved control of symptoms at the end 
of IV therapy and 89% demonstrated long term amelioration of 
CRS symptoms (>12 months after cessation of IV therapy).  The 
retrospective design, lack of randomization, and lack of placebo 
arms limit the value of the above studies.  Furthermore, it is hard 
to assign benefit to intravenous antibiotic therapy when other 
interventions were utilized such as irrigation/aspiration of the 
sinus and adenoidectomy.  Therefore available data does not 
justify the use of intravenous antibiotics alone for the treatment 
of CRS in children (Strength of recommendation: C).   
6.10.2.2. Corticosteroids  
There are no randomized controlled trials evaluating the effect 
of intranasal corticosteroids in children with CRS.  However the 
combination of proven efficacy of intranasal corticosteroids in 
CRS with and without nasal polyps in adults (see chapter 6.1 and 
6.5) and proven efficacy and safety of intranasal corticosteroids 
in allergic rhinitis in children makes intranasal corticosteroid the 
first line of treatment in CRS (1981 , 1982 , 1983).  A recent randomized, 
placebo-controlled, double blind trial was conducted in children 
with CRS with signs and symptoms of more than 3 months 
duration and CT abnormalities (1984).  Children were all treated 
with amoxicillin/clavulanate for 30 days and randomized to 
receive methylprednisolone or placebo PO for first 15 days of 
treatment (1mg/kg/day (max 40 mg) for 10 days, 0.75 mg/kg/
day for 2 days, 0.5 mg/kg/day for 2 days, and 0.25 mg/kg/day for 
1 day).  The average age of the children was 8 years and the total 
CT score was between 11-12 (maximal score=24) suggesting 
mild-moderate disease.  When comparing post treatment 
outcomes to baseline, there were significant improvements 
in all parameters (symptoms and CT scores) in both groups 
suggesting that antibiotics alone and antibiotics and steroids 
together both improved outcomes compared to baseline.  
Furthermore, there was a significant additional effect of oral 
steroids over placebo in cough, CT scan, nasal obstruction, 
postnasal drainage and total symptom scores.  The strength of 
the evidence for the efficacy of antibiotics alone is unfortunately 
diminished by the absence of a placebo group, but the 
superiority of the combination of antibiotics and steroids over 
antibiotics alone is clearly supported by this trial. 
Nasal corticosteroid treatment is a first line treatment in 
CRS with and without nasal polyps in children (Strength of 
recommendation: D).   
6.10.2.3. Ancillary treatments 
Nasal irrigations and decongestants have been thought to 
help in decreasing the frequency of rhinosinusitis episodes.  
Michel et al in 2005 performed a randomized, prospective, 
double-blind, controlled study looking at the effect of a 14-day 
treatment (1-2 sprays) with either isotonic saline solution or a 
nasal decongestant in children 2-6 years of age (1985).  Outcomes 
evaluated included the degree of mucosal inflammation and 
nasal patency.  They found that both groups experienced 
improvement in outcomes measured with no significant 
differences between the groups.  There were no side effects 
observed with the saline spray.  The decongestant group used 
120% more drug than prescribed, demonstrating the potential 
for these medications to be overused.  No cases of rhinitis 
medicamentosa were reported.
A recent Cochrane review analysed randomized controlled 
trials in which saline was evaluated in comparison with either 
no treatment, a placebo, as an adjunct to other treatments, 
or against other treatments (1736). A total of 8 trials satisfied 
inclusion criteria of which 3 were conducted in children.  The 
studies included a broad range of delivery techniques, tonicity 
of saline used, and comparator treatments.  Overall there 
was evidence that saline is beneficial in the treatment of the 
symptoms of CRS when used as the sole modality of treatment.  
Evidence also exists in favor of saline as a treatment adjunct 
and saline was not as effective as an intranasal steroid.  Various 
forms of administration of saline were well tolerated.  In a more 
recent trial, Wei and colleagues enrolled 40 children with CRS 
in a randomized, prospective, double-blind study comparing 
once daily irrigation with saline or saline/gentamicin for 6 weeks 
(1986).  There were statistically significant improvements in quality 
of life scores after 3 weeks and a reduction of CT scores after 6 
weeks in both groups with no significant difference between 
the groups, suggesting that the addition of gentamycin to saline 
irrigations provided no additional benefit.   
Clinicians have certainly tried other treatments for CRS including 
antihistamines and leukotriene modifiers, especially in light of 
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their effectiveness in treating allergic rhinitis.  However no data 
exists about their potential efficacy and thus usefulness in the 
context of CRS in children. We reserve the use of these agents 
for children with documented allergic rhinitis.
6.10.3. Surgical treatment of chronic 
rhinosinusitis in children
Adenoidectomy is successful in improving CRS 
symptoms in 50% of operated children.  Whether 
this is due to the fact that the symptoms were 
related to adenoiditis per se or to the elimination 
of the contribution of the adenoids to sinus 
disease is not clear
Surgical intervention for rhinosinusitis is usually considered for 
patients with CRS who have failed maximal medical therapy.  
This is hard to define but usually includes a course of antibiotics 
and intranasal and/or systemic steroids and differs widely 
between practitioners and practice locations.  Adenoidectomy 
with or without antral irrigation and balloon sinus dilation, 
and functional endoscopic sinus surgery (FESS) are the most 
commonly used modalities.
6.10.3.1 Adenoidectomy with/without sinus irrigation 
and balloon dilation 
The rationale behind removal of the adenoids in patients 
with CRS stems from the hypothesis that the adenoids are a 
nasopharyngeal bacterial reservoir (as detailed earlier) and 
the possibility that many of the symptoms might be related 
to adenoiditis proper.  The benefit of adenoidectomy alone 
in the treatment of children with CRS was recently evaluated 
by a meta-analysis (1987).  The review included 9 studies that 
met the inclusion criteria.  Mean sample size was 46 subjects 
with a mean age of 5.8 years (range 4.4-6.9 years).  All studies 
showed that sinusitis symptoms or outcomes improved in half 
or more patients after adenoidectomy.  Eight of nine studies 
were sufficiently similar to undergo meta-analysis and, in 
these, the summary estimate of the proportion of patients 
who significantly improved after adenoidectomy was 69.3%.  
Ramadan and Tiu reported on the failures of adenoidectomy 
over a ten year period and found that children younger than 7 
years of age and those with asthma were more likely to fail after 
adenoidectomy and go on to require salvage FESS (1988).
Maxillary antral irrigation is frequently performed in conjunction 
with adenoidectomy.  To evaluate the efficacy of this added 
intervention, Ramadan and colleagues analysed 60 children 
who underwent adenoidectomy for CRS (symptoms and 
positive scans despite prolonged medical treatment), 32 of 
which also had a sinus wash and culture via the middle meatus 
(1989).  All children received post-operative antibiotics for 2 weeks 
and outcomes were assessed at least 12 months postoperatively. 
Patients who underwent adenoidectomy alone had a 61% 
success rate at 12 months compared to children who underwent 
adenoidectomy with a sinus wash who had a higher success 
rate of 88%.  Children with a high Lund-Mackay CT score and 
asthma had better success with adenoidectomy with a wash 
compared to adenoidectomy alone.  In a similar retrospective 
study, Criddle and colleagues reviewed the records of 23 
children who had adenoidectomy with a sinus wash for CRS 
(persistent symptoms in all and a positive scan in 7/23) followed 
by a course of post-op oral antibiotics (average duration 5.8 
weeks) (1990).  If there was no improvement after the procedure 
Table 6.10.1.  Effect of antibiotics+steroids in CRSwNP. 
Author Intervention Age Range Outcome Category of 
Evidence
Ozturk 2011 
(1984)
Amoxicillin/Clavulanate PO x 30 days and methyl-
prednisolone or placebo PO x 15 days
6-17 years CT scan and symptom scores im-
proved in all with superiority of the 
combination treatment
Ib
Adappa 2006 
(1980)
Intravenous antibiotics (5 weeks)+maxillary irrigation 
and adenoidectomy
1-14 years 89% long term improvement in 
CRS symptoms (>12 months after 
therapy)
III
Don 2001 (1979) Intravenous antibiotics+maxillary irrigation and 
adenoidectomy
10 mos-15 
years
89% complete resolution of symp-
toms
III
Otten 1994 
(1978)
Tap and washout followed by randomization to 
cefaclor or placebo PO for 1 week
2-12 years No difference in resolution rate at 6 
weeks
Ib(-)*
Otten 1988 
(1977)
saline nose drops (placebo), xylometazoline 0.5% 
nose drops with amoxicillin 250 mg PO TID, drainage 
of the maxillary sinus under anesthesia and irrigation, 
and a combination of drainage and irrigation with 
xylometazoline and amoxicillin for 10 days
3-10 years No difference in cure rate between 
groups at 6 or 26 weeks
IIa(-)**
* Ib (-): Ib study with a negative outcome.
**  IIa(-): IIa study with a negative outcome.
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on oral antibiotics, intravenous antibiotics were utilized in 
a small proportion of the children.  Long-term resolution 
rate was reported in 78% of the 18 patients who did not 
need intravenous antibiotics.  This data suggests that antral 
irrigation adds to the efficacy of adenoidectomy and also 
suggests that a prolonged course of IV antibiotics (as reported 
above) might not be necessary to obtain a good result.
Balloon sinuplasty was approved by the FDA for use in 
children in the United States in 2006, and a preliminary study 
in children has shown the procedure to be safe and feasible 
(1991).  In this study, the cannulation success rate was 91% 
and the majority of the sinuses addressed were maxillaries.  
The most common cause of failure of cannulation with the 
balloon catheter was the presence of a hypoplastic maxillary 
sinus.  Most surgeons now use the illuminated catheter to 
confirm cannulation of the sinus thus avoiding fluoroscopy 
and its inherent risks.  In a recent nonrandomized, prospective 
evaluation of children with CRS failing maximal medical 
therapy, balloon catheter sinuplasty and adenoidectomy 
were compared (1992).  Outcomes were assessed at 1 year 
after surgery and were based on SN-5 scores and the need 
for revision surgery.  Twenty four/30 patients (80%) who 
underwent balloon sinuplasty showed improvement in their 
symptoms compared to 10/19 (52.6%) of the patients who 
underwent adenoidectomy (p<0.05).  As some of the balloon 
patients also underwent irrigation, it is hard to discern the 
effect of dilation vs irrigation from this study.  In sum, most of 
the available surgical data support adenoidectomy with sinus 
irrigation as a first step in the management of the child with 
CRS refractory to maximal medical management.  Whether or 
not balloon maxillary sinuplasty imparts additional benefit 
to irrigation alone, in combination with adenoidectomy, 
cannot be established with available data to date (Strength of 
recommendation: C).
6.10.3.2. Functional Endoscopic Sinus Surgery (FESS) 
A meta-analysis of FESS results in the paediatric population 
has shown that this surgical modality is effective in reducing 
symptoms with an 88% success rate and a low complication rate 
(1993).  Initial concerns about possible adverse effects of FESS on 
facial growth have been allayed by a long term follow up study 
by Bothwell and colleagues that showed no impact of FESS 
on qualitative and quantitative parameters of paediatric facial 
growth, evaluated up to 10 years postoperatively (1994).  Many 
advocate a limited approach to FESS in children consisting 
of removal of any obvious obstruction (such as polyps and 
concha bullosa), as well as anterior bulla ethmoidectomy and 
maxillary antrostomy.  This approach typically yields significant 
improvements in nasal obstruction (91%), rhinorrhoea (90%), 
PND (90%), headache (97%), hyposmia (89%) and chronic cough 
(96%) (1995).
Whereas second look procedures were common after FESS to 
clean the cavities, the advent of absorbable packing has made 
it possible to avoid a second look procedure.  Walner et al found 
comparable rates of revision sinus surgery in children with 
and without a second look procedure suggesting that it may 
not be necessary (1996).  Ramadan and colleagues observed that 
the use of corticosteroids during initial FESS might obviate a 
second look procedure (1997).  Younis in a review of available data 
suggested that a second look is not necessary in most children 
after FESS (1998). 
 
There are few reports on the causes of failure of ESS in children.  
The most comprehensive describes 23 of 176 (13%) children 
who failed FESS and required revision (1991).  The most common 
findings in these patients were adhesions (57%) and maxillary 
sinus ostium stenosis or missed maxillary sinus ostium (52%).  
In 39% of the cases, disease recurred in the operated sinuses, 
whereas in 26% of the cases, surgery was needed because of 
Table 6.10.2.  Surgical Treatment of Pediatric CRS.
Author Intervention Age Outcome Category of 
Evidence
Hebert  
(1993)
Meta-analysis of 8 published FESS studies 
(n=832) and author’s unpublished data 
(n=50) 
11 mos-18 
years
88.7% positive outcome with an average of 3.7 
years of combined follow up
Ia
Brietzke 
(1987)
Meta-analysis of 9 adenoidectomy studies 4.4-6.9 years 69% improvement rate Ia
Ramadan 
(1989)
Adenoidectomy (n=28) vs Adenoidectomy 
with maxillary wash (n=32)
Average= 6.3 
yrs, Range= 
3-13 yrs
Success rate at 12 months postop: Adenoidec-
tomy= 61% Adenoidectomy + wash= 88%
III
Criddle  
(1990)
Adenoidectomy + wash and postop antibi-
otics (n=23)
Average= 2.3 
yrs Range= 6 
mos-6 yrs
78% long term improvement in patients who 
did not receive IV antibiotics (n=18)
III
Ramadan 
(1992)
Adenoidectomy (n=19) Adenoidectomy 
with  Balloon maxillary sinuplasty + irriga-
tion (as necessary) (n=30)
Average= 6.6 
yrs  Range= 
2-11 yrs
80% improvement after 12 months for balloon 
vs 53% for adenoidectomy alone (p<0.05)
III
200
European Position Paper on Rhinosinusitis and Nasal Polyps 2012
disease present in sinuses that were not originally operated.  
In another report, a retrospective review of children with CRS 
having undergone ESS yielded 39.6% who continued to have 
mucopurulent nasal drainage for more than 3 months after 
surgery (1999).  Sinonasal polyposis, history of allergic rhinitis, and 
male gender were significantly more frequently observed in the 
group that continued to have problems after ESS.
In summary, the most supported surgical approach to the child 
with CRS who has failed maximal medical therapy probably 
consists of an initial attempt at an adenoidectomy with a 
maxillary sinus wash plus/minus balloon dilation followed by 
FESS in case of recurrence of symptoms.  An exception to this 
statement are children with cystic fibrosis, nasal polyposis, 
antrochoanal polyposis, or AFS where FESS to decrease disease 
burden is the initial favoured surgical option.  Unfortunately, 
most of the data supporting this recommendation are not 
based on randomized prospective studies.  It is therefore 
clear that prospective, randomised, controlled clinical trials 
should be undertaken.  In these trials, severity of disease on CT 
scans and symptom questionnaire should ideally be matched 
preoperatively and the following interventions would be 
compared: adenoidectomy alone, adenoidectomy with a wash, 
adenoidectomy with a wash and balloon maxillary sinuplasty, 
and endoscopic sinus surgery.  An additional arm that includes 
medical therapy might also be included.
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7.1. Quality of Life measurements in the 
diagnosis and outcome measurement of CRS 
with and without NP
7.1.1. Introduction
There is now growing acceptance that patients’ views are 
essential in the delivery of high quality care. In addition to 
enquiries regarding overall severity of CRS symptoms using 
the VAS, individual symptom severity may be recorded, either 
using a VAS, or using validated symptom-based questionnaires. 
Patient Reported Outcome Measures (PROMs) are measures 
of health-related quality of life (HRQOL) that are self-rated 
and reported directly by patient. They usually refer to a single 
time point or clearly defined preceding period, thus ‘outcome’ 
measure in this setting is a misnomer.  The impact of chronic 
disease or medical care can be determined by comparing 
repeated measures of patient’s self reported health status. As 
symptoms drive a patient to seek medical care, measurement of 
the impact of these symptoms will better reflect the efficacy of 
treatment from the patient’s perspective than a clinician-rated 
outcome.
Quality of life is measured using one of a growing number of 
‘instruments’; typically these are questionnaires, but in some 
cases visual scales or grading systems can be used. These allow 
quantitative assessment of otherwise subjective results. The 
questionnaires usually require the patient to rate the impact of 
their disease across a number of specified ‘domains’ or areas of 
interest. Individual questions are scored according to severity or 
impact of disease, and then scores are combined to produce an 
overall score. Some PROMs have been developed for particular 
conditions or treatments (disease-specific) while others are 
designed for use in all patient groups or healthy individuals 
and measure the patient’s perception of their general health 
(generic measures).
Generic PROMS allow comparison between conditions or 
treatments, and therefore can be used to determine the impact 
of different diseases on patient groups, the relative cost utility of 
different interventions and to inform commissioning decisions. 
However, they are often lack sensitivity to detect small but 
important changes in disease specific QOL. There are now 
several different rhinosinusitis-specific instruments available, 
differing in terms of aims of use, number of items, setting and 
ease of use. In addition, the choice of instrument will depend 
upon the aim of outcome measurement.
HRQOL is defined across two main domains; psychosocial and 
physical functioning, and the impact that disease has on this 
as rated by the patient. Therefore an instrument that measures 
HRQOL should include items pertaining to both domains. In 
addition, there are a number of validated questionnaires that 
include only physical functioning as defined by disease specific 
symptoms only, without a psychosocial domain, and some 
measuring cost-effectiveness. These have been included for 
completeness.
7.1.2. Assessment of Instruments
All instruments must have a published psychometric validation 
in the appropriate setting (e.g. for inclusion under ARS 
instruments, the instrument must be validated in a group of 
patients with ARS) to be considered for inclusion – several 
questionnaires were excluded on this basis. Further quality 
assessment was undertaken using the scoring system described 
by van Oene (2000) et al. in a systematic review of outcome 
tools undertaken in 2007. This excellent scoring system 
comprehensively captures aspects of instrument validity, 
including construction of the questionnaire, description of the 
items and domains, feasibility and respondent burden, size of 
validation study and reliability in terms of internal consistency, 
test-retest reliability, content, convergent and discriminant 
validity, responsiveness, and calculation of the minimally 
important difference.
The time to complete an instrument will determine it’s practical 
applications, and the times presented were taken from the 
validation papers where published, and by trialling the tools 
directly.
Finally, the number of published studies utilising each 
instrument (excluding those reporting the validation of the 
instrument), and the number of validated translations are 
presented. If an instrument is to be translated, it must be done 
in both a forward and backward direction to ensure the original 
7.  Burden of Rhinosinusitis 
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meaning of the items is retained, and then must be revalidated 
to ensure it has the same psychometric properties.
7.1.3. Results
The identified outcome instruments and key properties are 
summarised in Table 7.1.
There are several validated tools available for use in CRS in the 
adult population.
The predominant differences between the tools are the number 
of items. There is a direct relationship between the number 
of items and the respondent burden, and this should be 
considered when selecting an instrument for use. 2 instruments 
(SNOT-20 and SNOT-22) including general HRQOL items rate 
highly in terms of psychometric quality, and have a significant 
volume of published studies where the tools have been used, 
to provide comparative data. However, the SNOT-20 lacks items 
pertaining to nasal obstruction and reduced sense of smell, and 
as they are essential for the diagnosis of CRS, we do not feel the 
SNOT-20 to have adequate content validity to recommend use. 
The CSS contains only disease specific items but is widely used 
in the literature. 
There are fewer tools available for adult ARS, and for both 
paediatric CRS and ARS.
Although there are many generic HRQOL instruments, the 
SF-36 has been extensively used both in rhinosinusitis and 
other chronic diseases, and provides a wealth of normative and 
comparative data. The short form 36 (SF-36) is a multipurpose, 
36-item survey that measures eight domains of health: physical 
functioning, role limitations due to physical health, bodily pain, 
general health perceptions, vitality, social functioning, role 
limitations due to emotional problems, and mental health.  It 
has been widely used in many medical conditions and over 5000 
publications, with normative values available for the general 
population (SF website). It has been used to measure both the 
impact of CRS on quality of life, and to assess the outcome of 
treatment (15, 2001).
Health related quality of life can be measured 
using a large number of disease-specific or global 
patient-rated outcome measures
7.1.4. Impact of ARS on quality of life
While the socio-economic burden of acute rhinosinusitis has 
been measured in terms of medical consultation, medication 
usage and absenteeism, there is a relative paucity in the litera-
ture regarding the impact of acute sinusitis on quality of life. As 
episodes are by definition short-lived, impairment in quality of 
life should also be transient, returning to baseline levels after 
recovery. In addition, due to variation in the definition used in 
studies, most groups described in clinical trials are a heteroge-
neous group of patient with a viral ‘common cold’ and acute 
bacterial sinusitis.
There is one disease-specific patient rated outcome measure 
validated for use in ARS. Using the SNOT-16 (2022) in a group 
of 166 patients, the mean scores declined steadily from 1.71 
(SD 0.5 at onset of illness) to 1.13 (SD0.54) at day 3, 0.74 (SD 
0.5) at day 7 and falling to 0.49 (SD0.44) by day 10. In terms of 
comparison with CRS, and normal patients one study reports the 
use of the SF-36, with significant differences between all groups 
(p<0.001), with patients with ARS having poorer HRQOL (mean 
score 60.8) than healthy individuals (51.8), but less reduction 
than those with CRS (75.5) (2025). In terms of specific symptoms, a 
recent survey based study in France asked physicians to report 
symptom frequency and severity prospectively on patients 
with a diagnosis of acute maxillary sinusitis (228). The most 
common presenting signs and symptoms were moderate-to-
severe nasal obstruction (80.4%), pain on sinus palpitation 
(76.8%), facial pain (74.5%), rhinorrhoea (70.4%), and headache 
(63.6%). Symptoms were indicated as having a moderate to very 
significant effect on quality of life areas including activities of 
daily living (71.6% of patients), leisure (63.1%), and professional/
school activities (59.2%). In a prospective randomized, double-
blind, placebo-controlled trial (311), comparing the effect of 
antibiotics and topical steroids, the most severe symptoms 
were post-nasal discharge, need to blow nose, runny nose 
and waking up tired, using the SNOT-20 to assess symptom 
severity (which therefore does not capture nasal obstruction or 
anosmia). This study demonstrated significant improvement in 
health related quality of life from baseline to the end of the trial 
period at day 15, with mometasone producing a significantly 
greater improvement in the SNOT-20 mean total score than that 
seen with placebo (p = 0.047).
A number of disease-specific and global 
patient-rated outcome measures have been 
used to demonstrate significant impairment in 
HRQOL in both ARS and CRS
Table 7.1. Recommended outcome tools based on current literature.
Adult CRS – SNOT22 or RSOM-31
Adult ARS – SNOT-16
Paediatric CRS – SN-5
Paediatric ARS – S5
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Table 7.2.  Summary of outcome instruments and their key properties. 
Instrument HRQOL 
content
Items / 
Domains
Psychometric 
Quality score
MID Normal Completion 
time (min)
No of 
Studies
Validated 
translations
Notes
Adult Chronic Rhinosinusitis instruments
RSOM-31 (2002) + 31 / 7 15/18 + rating 20 5
SNOT-16 (2004) + 16 / 1 7/17 +rating 5 5 French (2003)
SNOT-20 (20) + 20 / 1 13/17 +rating 5 - 10 83 Japanese (2005), 
Piccirillo (1178), 
Chinese (2006), 
Portuguese 
(2007), 
German (2008)
RSDI (240) + 20 / 1 7/18 10.35 5 16 Turkish (2009)
RhinoQOL 
(2011)
+ 17 / 3 14/18 5 – 10 1 French (2010)
SNOT-22 (2013) + 22 / 1 13/17 8.9 7 5 20 Danish (2012), 
Czech (2014), 
Chinese (2015), 
Swedish (2016), 
Portuguese
CSS (2018) - 6 / 2 9/16 9.75 5 29 Norwegian 
(2017), 
Chinese (2019) 
duration based
FNQ (2020) - 12 / 1 9/17 <5 3 -
SNAQ-11 (2021) - 11 / 1 2/17 5 3 -
Adult Acute Rhinosinuitis Instruments
SNOT-16 (2022) + 16 / 1 13 / 17 5 3 -
MSSUI (2023) - 5 / 1 8/17 + rating >10 2 - Complex 
web-based 
scoring 
system
Paediatric chronic rhinosinusitis
SN-5 (1602) + 5 / 5 8/17 <5 4 -
Paediatric acute rhinosinusitis
S-5 (2024) - 5 / 1 10/18 <5 2 -
Adult generic quality of life instrument
SF-36 (43) + 36 / 8 10 – 
12.5
5 – 10 48* >120 validated 
translations
HRQOL content + includes general HRQOL / psychosocial functioning items in addition to disease-specific symptoms, -  includes only disease specific 
symptoms.
Psychometric quality score as rated by van Oene et al. (2000). Denominator varies, as some criteria are not applicable in every case.
No. of studies – published studies up to Sept 12th 2011 utilising the outcome instrument, excluding those related to its validation. 
Validated translation – published translations where the outcome instrument has been revalidated in the new language.
*publications of use in rhinosinusitis only.
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7.1.5. Impact of CRS on quality of life
Using the SF-36, chronic rhinosinusitis has been shown to have 
a negative impact on several aspects of quality of life, and has 
a greater impact on social functioning the chronic heart failure, 
angina or back pain (2001). Published studies report scores below 
the normal population in 5 – 7 of the SF-36 domains (2001, 2026, 
2027). The SNOT-22 was shown to have a median value of 7 in 
healthy volunteers, compared to a mean pre-operative SNOT-22 
score of 42.0 (95% CI = 41.2-42.7) in a cohort of 3,128 patients 
undergoing surgery for CRS (2028). Several studies have shown 
that CRSwNP tend to report better QOL than those with CRSsNP 
despite worse CT and endoscopy scores (1885).
Improvement following both medical and 
surgical intervention has been demonstrated 
in CRS using PROMS
Quality of life measures may also be used to evaluate changes 
over time following either medical or surgical intervention. In 
the large cohort study above, the mean SNOT-22 score for all 
patients was 28.2 (standard deviation [SD] = 22.4) at 5 years after 
surgery (1758). This was remarkably similar to the results observed 
at 3 months (25.5), 12 months (27.7), and 36 months (27.7), and 
represents a 14-point improvement over the baseline score (ES 
0.8SD).
Chester et al. (2029) undertook a systematic review of the literature 
reporting symptomatic outcome following FESS. The meta-
analysis of 21 of 289 identified FESS studies was conducted 
for each symptom separately with the standardized difference 
between the preoperative and postoperative severity scores as 
the effect size (ES). ESS symptom outcomes were reported using 
various symptom scoring systems and more than 18 survey 
instruments. A total of 2070 patients with CRS were studied a 
mean of 13.9 months after ESS. All symptoms demonstrated 
improvement compared with their respective preoperative 
severity scores by an overall ES of 1.19 (95% confidence interval, 
0.96 to 1.41; I (2) = 81.7%) using the random-effects model. 
Nasal obstruction (ES, 1.73) improved the most, with facial pain 
(ES, 1.13) and postnasal discharge (ES, 1.19) demonstrating 
moderate improvements. Hyposmia (ES, 0.97) and headache (ES, 
0.98) improved the least. When individual symptom scores were 
pooled by meta-analysis, most major CRS symptoms improved 
to a similar degree following surgery, with an overall effect size 
of 1.19 (95% confidence interval, 0.96-1.41; I (2) = 82%). Fatigue 
and bodily pain were more severe than general population 
normative values and improved following ESS by an effect 
size of approximately 0.5 SD, a change usually regarded as a 
minimally important clinical difference.
The impact on different treatment modalities is considered in 
more detail in each relevant section.
7.2. Direct Costs 
7.2.1. Direct costs of chronic rhinosinusitis
Chronic rhinosinusitis (CRS) (with and without polyps) is a 
frequent pathology with a high impact on quality of life. The 
research concerning the socioeconomic impact of the disease is 
limited. Ray et al estimated, already in 1999 the total direct cost 
in the US at 5,78 billion dollars per year (2030).
In US the total cost of treating a patient with CRS 
was $2609 per year; in Europe the direct costs of a 
patient treated in a university hospital for severe 
chronic rhinosinusitis was $1861/year
In 2002, Murphy et al (2031) examined the direct costs of a patient 
with a diagnosis of CRS. These patients seemed to make 43% 
more outpatient and 25% more urgent care visits than a patient 
without CRS. CRS patients filed 43% more subscriptions, but had 
fewer hospital stays. The total cost of treating a patient with CRS 
was $2609 per year; this is 6% more than the average adult.
In Europe only one study was found, in the Netherlands, 
executed by van Agthoven et al. Here the direct costs of a 
patient treated in a university hospital for severe chronic 
rhinosinusitis was $1861/year (2032).
In addition to these findings, also mentioned in EPOS2007, 
a search was made through recent English literature 
2007-December 2011. The studies discussed are all carried 
out by N. Bhattacharyya and his team. The studies are well 
performed and concern a big amount of data, but are limited to 
USA patients. There are no recent studies carried out in Europe. 
In March 2009 Bhattacharyya (2033) published the assessment of 
the additional disease burden of nasal polyps in CRS. A series of 
patients were recruited from their centre. Patients were included 
according to the Rhinosinusitis symptom inventory (Task force 
on Rhinosinusitis criteria) and by findings with nasal endoscopy 
and on CT (Lund MacKay score). Three groups were composed: 
one with CRS without nasal polyps (CRSsNP), a second group 
with CRS with nasal polyps (CRSwNP) and a third with CRS with 
recurrent nasal polyps after surgery. 
The groups with and without nasal polyps show a clear 
difference in symptom phenotype, but this did not translate into 
a difference in expenditures for physician’s visits and medication 
costs between the first 2 groups. There was no statistically 
significant difference. However there was a difference in total 
medication costs for the last group with recurrent polyps after 
surgery with a higher cost for this group of $ 865.50 compared 
to the $ 569.60 for group 1 and $ 564.50 for group 2.
In July 2009 a contemporary assessment of the disease burden 
of sinusitis from Bhattacharyya (37) was published. Here data 
were extracted from the National Health interview survey over 
a 10-year period of 1997-2006. One year disease prevalences 
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show that one quarter (22.7%) of patients with CRS visited 
an emergency department, one third (33.6%) saw a medical 
specialist, more than half (55.8%) spent $500 or more per year 
on health care. Health care spending was significantly greater 
in sinusitis than that of other chronic diseases as ulcer disease, 
acute asthma and hay fever.
National health care costs in the US remain very high for CRS, at 
an estimated 8.6 billion dollar per year (2034).
Factors contributing to a high economic impact of this 
condition are: the high disease prevalence (10 to 14% of the 
population would be affected), it is a chronic condition with no 
universal cure, there are frequent exacerbations of symptoms 
prompting acute treatments in addition to the chronic ones 
already in place, there is a high quality of life-impact, a generally 
incomplete symptom control leading patients to seek additional 
therapies to achieve relief and it is difficult to accurately 
diagnose  the condition without radiologic or diagnostic 
procedures (2035).
The highest costs were made by the group with 
recurrent polyps after surgery
In 2011 Bhattacharyya (2034) calculated the incremental health 
care utilization and expenditure for CRS in the United States. 
Patient data were extracted from the Medical Expenditure 
Panel Survey. With the incremental expenditure methodology, 
expenditures are measured attributable particular to CRS, there 
is adjusted for differences in variables that are having an impact 
on expenditures, like age, gender, insurance status etc. For the 
expenditures next components are taken into consideration: 
office-based health care expenditures, prescription expenditures 
and patients’ self-expenditures for prescription medications.
For utilization of health care, data show that CRS patients 
incurred ±3, 5 additional office visits and 5,5 additional 
prescription fills compared to patients without CRS. This extra 
utilization of healthcare evokes higher expenditures; a CRS 
patient would have a substantial incremental increase of 
total health care expenditure of $772 (±$300) consisting of 
$346(±$130) for office-based expenditures, $397(±$88) for 
prescription expenditures and $90(±$24) for self-expenditures.
Bhattacharyya et al. (2035) reported the costs pre- and postope-
rative to Endoscopic Sinus Surgery (ESS). Data come from the 
Market Scan Commercial Claims and Encounters Database from 
2003 to 2008. Numerous studies have shown the effectiveness 
of surgery in improving quality of life in CRS patients, but the 
effect of surgery on expenditures was not clarified. Patients were 
included if 2 CRS-related diagnoses were retrieved, confirmed by 
either CT-scan or endoscopy. Likely this might cause a selection 
of more severe cases. Patients with nasal polyps were excluded 
from this study. All sinus-related health care utilization costs 
were rolled up in the study (medication, operation costs, office 
visits, diagnostic assessment with radiology and endoscopy).
Results show that in the year prior to ESS costs run op to $2,449 
($2,341-$2,556) with a clear increase in the last 6 months before 
surgery; the first semester accounts for $361 and the last se-
mester for $1,965. This is due to an augmentation in office visits, 
diagnostic investigations and medication use.  The augmenta-
tion in prescription medication is for the greatest part due to a 
higher antibiotic use; from $75 in the first to $225 in the second 
semester. 
The ESS-procedure and the 45-day post procedure period count 
for $7,726 ($7,554 – $7,898).
In the first year following ESS, costs drop by $885 to an average 
of $1,564 per year. In the second year post procedure they drop 
an additional $446 to $1,118 per year. This decrease was mostly 
due to a lower amount of doctor visits, there was only a minor 
change in the costs of anti-inflammatory medication. Important 
to mention is that the costs in the 4th semester postoperative 
remain higher than in the first semester preoperative, possibly 
inflammation does not return to premorbid levels.
Health care spending was significantly 
greater in sinusitis than in other chronic 
diseases such as ulcer disease, acute asthma 
and hay fever
From above studies we see that the direct costs of CRS are quite 
high (average $772), also compared to other chronic diseases. In 
the year prior to surgery the disease burden augments and also 
causes a strong increase in costs ($2,449/patient/year). 
Endoscopic sinus surgery is expensive ($7,726 for procedure and 
45-day follow-up), but causes a drop of costs in the 2 years post 
operative (average $1,564 in year 1, average $1,118 in year 2). 
The important clinical difference in CRS with and without polyps 
only causes a difference in medication costs for the group with 
recurrence of polyps after surgery; probably this group has a 
higher disease severity.
Endoscopic sinus surgery is expensive, 
but causes  a drop in costs for 
the 2 post-operative years
Above data is all from the same principal investigator, which 
shows that there is little interest in the economic burden of CRS. 
There were no recent European data available, although many 
important questions remain unanswered, like: What would be 
the personal costs and the health insurance costs in European 
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countries with different health care systems than in the US? 
Which link is there between disease severity and costs?
7.2.2. Direct costs of acute rhinosinusitis
Besides the pathology of chronic rhinosinusitis, also acute 
rhinosinusitis can be an economic burden. Anand estimated 
in 2004 that there are approximately 20 million cases of acute 
bacterial rhinosinusitis yearly in the United States (2036).
One in 3,000 adults would suffer from a recurrent acute 
rhinosinusitis (43). This entity was in the study of Bhattacharyya 
defined as at least 4 claims of sinusitis in 12 months, with 
antibiotic prescription; this with a relative paucity of symptoms 
at baseline between episodes.  Considering this definition, there 
might be an overlap with the diagnosis of CRS. 
This patient group has an average of 5,6 health care visits/year, 
9,4 prescriptions filled (40% antibiotic). Only 20% of patients 
had either a nasal endoscopy or CT scan annually. This probably 
means that only a small part sees an ENT-specialist for his 
complaints.
The total direct health care cost of recurrent acute rhinosinusitis 
would be an average of $1,091/year: $210 to antibiotics, $452 
to other sinus-related prescriptions (relatively large cost due to 
leukotriene inhibitors who are not generically available), $47 to 
imaging and $382 to other visit costs.
Patients with recurrent acute rhinosinusitis 
have an average direct health care cost 
of $1,091/year in average (US)
A study in Taiwan showed that acute nasopharyngitis and acute 
upper respiratory tract infections were the 2 diseases with the 
highest number of outpatient department visits (2037). The drug 
expenditure for acute respiratory infections accounted for 6% of 
total drug expenditure. Only 42,8% of drugs for these illnesses 
was described as suitable for patients’ self-care.
Sinusitis cannot only cause direct costs on it’s own, but 
especially as comorbidity with asthma it is known to augment 
disease burden. Bhattacharyya et al. studied in 2009 the 
additional disease burden from hay fever and sinusitis 
accompanying asthma (2038). This showed that there were more 
emergency room visits from patients with asthma and sinusitis, 
than of those with only asthma or a comorbidity of hay fever. 
The total health care visits and the household healthcare 
expenditures are higher for this group of patients.
Total health care costs and the household 
healthcare expenditures are higher for patients 
with sinusitis and asthma
The above studies show that also acute sinusitis is an important 
pathology to consider economically. Because of the high 
prevalence, the risk of recurrence and the augmentation of 
disease burden to chronic conditions as asthma. Literature does 
not give an answer to the question how much one episode of 
acute sinusitis would cost; this can be an objective for future 
investigations.
7.3. Indirect Medical Costs
The studies of direct medical costs demonstrate a tremendous 
social economic burden of Rhinosinusitis.  However, the total 
costs of rhinosinusitis are far greater when the indirect costs are 
considered.  With 85% of patients with Rhinosinusitis of working 
age (between 18-65 years old) (485), indirect costs such as missed 
workdays (absenteeism) and decreased productivity at work 
(presenteeism) significantly add to the economic burden of 
disease. 
Rhinosinusitis is one of the top ten most costly 
health conditions to US employers
Goetzel et al. (2039) attempted to quantify the indirect costs of 
rhinosinusitis.  Their 2003 study resulted in rhinosinusitis being 
named one of the top ten most costly health conditions to US 
employers.  A large multi-employer database was used to track 
insurance claims through employee health insurance, absentee 
days, and short-term disability claims.  Episodes of illness were 
linked to missed workdays and disability claims, accurately cor-
relating absenteeism to a given disease.   In a large sample size 
(375,000), total healthcare payments per employee per year for 
sinusitis (acute and chronic) were found to be $60.17, 46% of 
which came from the cost of absenteeism and disability. These 
figures approximate the cost to employers, disregarding the cost 
incurred by other parties, and therefore tremendously underes-
timate the entire economic burden of the disease.
Indirect costs account for 40% of the total 
costs of rhinosinusitis
In his 2003 study, Bhattacharyya used patient-completed 
surveys from 322 patients to estimate the direct and indirect 
costs of chronic rhinosinusitis (2040). Patients completed a survey 
assessing symptoms of disease, detailing medication use, 
and quantifying missed worked days attributable to CRS.  The 
conclusions of the report included that the cost of treating CRS 
per patient totalled $1,539 per year with forty percent of these 
costs due to the indirect costs of missed work; the mean number 
of missed workdays in this sample of 322 patients was 4.8 days 
(95% CI, 3.4-6.1).  The author of the study followed this up in 
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a 2009 report using data from the National Health Interview 
Survey between 1997 and 2006 encompassing nearly 315,000 
individuals and reported that patients with sinusitis missed on 
average 5.7 days of work per year (37).
A major component of the indirect costs
 result from absenteeism and 
presenteeism
The cost burden of absenteeism is enormous, and yet it is only 
the beginning.  The general health status of patients with CRS is 
poor relative to the normal US population (2001). This decreased 
quality of life not only leads to absenteeism, but also contributes 
to the idea of “presenteeism” or decreased productivity when at 
work.  Ray et al. estimated by the 1994 National Health Interview 
Survey, that missed worked days due to sinusitis was 12.5 
million and restricted activity days was 58.7 million days (2030).  
Economic loss due to presenteeism cannot be easily quantified 
as it varies from individual to individual, but clearly increases the 
cost burden of the disease.   
Recently Stankiewicz et al. reported on the rates of absenteeism 
and presenteeism in a population of 71 patients undergoing 
surgical intervention for chronic rhinosinusitis.  Prior to surgery, 
they report a 6.5% rate of absenteeism (i.e., 6.5% of work time 
missed) and 36.2% rate of presenteeism (reduction of on-job 
effectiveness).  When combined the rate of absenteeism and 
presenteeism yielded a 38% work productivity loss in the study 
population, but no dollar value was placed on this figure (2041). 
Supporting this, Stull et al. reported that nasal congestion alone 
resulted in poor sleep, increased fatigue, and daytime sleepiness 
contributing to decreased work productivity (2042). 
Patients with rhinosinusitis miss on average 
6 days of work annually due to the disease.
Although incidence rates may be similar to that reported in the 
U.S. direct and indirect costs would vary widely based upon 
medical costs, per-capita income and life expectancy.  Although 
in the U.S., chronic rhinosinusitis is estimated to cost as much 
as $5.78 billion annually in the U.S.2, extrapolation of figures 
from other studies suggests the possibility of a substantially 
larger cost.  Decreased quality of life in patients suffering from 
rhinosinusitis results in an average of 4.8 -5.7 missed workdays 
translating into $600 of decreased productivity annually per 
patient (2031), contributing to the cost burden of the disease 
not incorporated into the $5.78 billion.  Whatever the precise 
cost, it is clear that socioeconomic burden of the disease is great 
and the disease has significant quality of life implications.  As 
such it is therefore imperative that we continue to understand 
the pathophysiology of the disease and to devise cost effective 
strategies to provide relief to patients.   
Absenteeism and presenteeism for “the Common cold” is also 
substantial. In a 2002 study, Bramely et al reported each cold 
experienced by a working adult caused an average of 8.7 lost 
work hours (2.8 absenteeism hours; 5.9 hours of on-the-job 
loss/presenteeism), and 1.2 work hours were lost because of 
attending to children under the age of 13 who were suffering 
from colds. The study concludes that the economic cost of lost 
productivity due to the common cold approaches $25 billion, 
of which $16.6 billion is attributed to on-the-job productivity 
loss, $8 billion is attributed to absenteeism, and $230 million is 
attributed to caregiver absenteeism (2043). A more recent study 
in Sweden by Hellgren et al evaluated the productivity loosed 
due to the common cold and allergic rhinitis and estimated the 
economic burden in Sweden alone was €2.7 billion annually. 
Of the total costs, absenteeism (44%) was the dominant factor, 
followed by presenteeism (37%) and caregiver absenteeism 
(19%) (2044)..
There are no data on ARS, research is urgently needed.
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8.1. Introduction 
The following schemes for diagnosis and treatment are the result 
a critical evaluation of the available evidence. The tables give the 
level of evidence for studies with a positive outcome and well  
powered studies with negative outcoume. For example Ib (-) 
in this tables means a well designed (Ib) study with a negative 
outcome. The grade of recommendation for the available therapy 
is given.  
Under relevance it is indicated whether the group of authors think 
this treatment to be of relevance in the indicated disease. 
Since the preparation of the EP3OS2007 document an increasing 
amount of evidence on the pathophysiology, diagnosis and 
treatment has been published. 
However, in compiling the tables on the various forms of 
therapy, it may be that despite well powered level Ib trials, no 
8.  Evidence based schemes for diagnostic and treatment
Table 8.1. Treatment evidence and recommendations for adults with acute rhinosinusitis.
Therapy Level Grade of recommendation Relevance
antibiotic Ia A yes in ABRS
topical steroid Ia A yes mainly in post viral ARS
addition of topical steroid to antibiotic Ia A yes in ABRS
Addition of oral steroid to antibiotic Ia A yes in ABRS
saline irrigation Ia A yes
antihistamine analgesic-decongestion  combination Ia A yes in viral ARS
ipratropium bromide Ia A in viral ARS
probiotics Ia A to prevent viral ARS
zinc Ia C no
vitamine C Ia C no
echinacea Ia C no
herbal medicine ( pelargonium sidoides, Myrtol) Ib A yes, in viral and postviral ARS
aspirin / NSAID’s Ib A yes, in viral and postviral ARS
acetaminophen (paracetamol) Ib A yes, in viral and postviral ARS
oral antihistamine added in allergic patients Ib (1 study) B no
steam inhalation Ia(-)$ A(-)** no
cromoglycate Ib(-)* A(-) no
decongestion no data for single use D no
mucolytics no data D no
*1b (-): 1b study with negative outcome
$ Ia(-)  Ia level of evidence that treatment is not effective.
**A(-): grade A recommendation not to use
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significant benefit has been demonstrated. Equally results may 
be equivocal or apparently positive results are undermined by 
the small number of trials conducted and/or the small number 
of participants in the trial(s). In these cases, after detailed 
discussion, the EPOS group decided in most cases, that there 
was no evidence at present to  recommend use of the treatment 
in question. Alternatively for some treatments no trials have 
been conducted, even though the treatment is commonly used 
in which case a pragmatic approach has been adopted in the 
recommendations.
8.2. Evidence based management for adults 
with acute rhinosinusitis 
8.2.1. Definitions
8.2.1.1. Acute rhinosinusitis in adults is defined as: 
sudden onset of two or more symptoms, one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip):
± facial pain/pressure, 
± reduction or loss of smell
for <12 weeks;
with symptom free intervals if the problem is recurrent,
with validation by telephone or interview.
questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhea, nasal itching, and itchy watery eyes) should be 
included. ARS can occur once or more than once in a defined 
time period. This is usually expressed as episodes/year but there 
must be complete resolution of symptoms between episodes 
for it to constitute genuine recurrent ARS.
8.2.1.2. Common cold/acute viral rhinosinusits is 
defined as duration of symptoms for less than 10 days.
8.2.1.3. Acute post-viral rhinosinusitis is defined as:
increase of symptoms after 5 days or persistent symptoms after 
10 days with less than 12 weeks duration.
8.2.1.4. Acute bacterial rhinosinusitis (ABRS)
Acute bacterial rhinosinusitis is suggested by the presence of at 
least 3 symptoms/signs of (247).
•	 Discoloured discharge (with unilateral predominance) and 
purulent secretion in cavum nasi, 
•	 Severe local pain (with unilateral predominance)
•	 Fever (>38ºC)
•	 Elevated ESR/CRP  
•	 ‘Double sickening’ (i.e. a deterioration after an initial milder 
phase of illness).
Figure 8.1. Management scheme for primary care for adults with acute rhinosinusitis.
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8.2.2. Evidence based management for adults 
with acute rhinosinusitis for primary care
8.2.2.1. Diagnosis
Symptom based, no need for radiology.
Not recommended: plain x-ray.
Symptoms
sudden onset of two or more symptoms one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip):
± facial pain/pressure;
± reduction/loss of smell;
Signs (if applicable)
•	nasal	examination	(swelling,	redness,	pus);
•	oral	examination:	posterior	discharge;
exclude dental infection.
8.2.2.1. Treatment
For treatment evidence and recommendations for acute 
rhinosinusitis see Table 8.1 Initial treatment depending on the 
severity of the disease (See Figure 8.1):
•	  Mild (viral, common cold): start with symptomatic relief 
(analgetics, saline irrigation, decongestants, herbal 
compounds);
•	  Moderate (postviral): additional topical steroids
•	  Severe (including bacterial): additional topical steroids, 
consider antibiotics
8.3 Evidence based management for children 
with acute rhinosinusitis for primary care
8.3.1. Definitions
8.3.1.1 Acute rhinosinusitis in children 
Acute rhinosinusitis in children is defined as:
sudden onset of two or more of the symptoms:
•	 nasal blockage/obstruction/congestion 
•	 or discoloured nasal discharge
•	 or cough (daytime and night-time) 
for < 12 weeks;
with symptom free intervals if the problem is recurrent; with 
validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhea, nasal itching, and itchy watery eyes) should be 
included. ARS can occur once or more than once in a defined 
time period. This is usually expressed as episodes/year but there 
must be complete resolution of symptoms between episodes 
for it to constitute genuine recurrent ARS.
8.3.1.2. Common cold/ acute viral rhinosinusits is 
defined as: duration of symptoms for less than 10 days.
8.3.1.3. Acute post-viral rhinosinusitis is defined as: 
increase of symptoms after 5 days or persistent symptoms 
after 10 days with less than 12 weeks duration.
8.3.1.4. Acute bacterial rhinosinusitis (ABRS)
Acute bacterial rhinosinusitis is suggested by the presence of at 
least 3 symptoms/signs of (247).
•	 Discoloured discharge (with unilateral predominance) and 
purulent secretion in cavum nasi, 
•	 Severe local pain (with unilateral predominance)
•	 Fever (>38ºC)
•	 Elevated ESR/CRP  
•	 ‘Double sickening’ (i.e. a deterioration after an initial milder 
phase of illness).
Table 8.2. Treatment evidence and recommendations for children with 
acute rhinosinusitis.
Therapy Level Grade of 
recommen-
dation
Relevance
antibiotic Ia A yes in ABRS
topical steroid Ia A yes mainly in 
post viral ARS 
studies only 
done in children 
12 years and 
older
addition of topical 
steroid to antibiotic
Ia A yes in ABRS  
mucolytics (er-
dosteine)
1b (-)* A(-)** no
saline irrigation IV D yes
oral antihistamine IV D no
decongestion IV D no
*1b (-): 1b study with negative outcome
**A(-): grade A recommendation not to use
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8.3.2. Evidence based management for children 
with acute rhinosinusitis in primary care
8.3.2.1. Diagnosis
Symptoms
sudden onset of two or more symptoms one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge
(anterior/posterior nasal drip):
± facial pain/pressure;
± cough
Signs (if applicable)
•	 nasal	examination	(swelling,	redness,	pus);
•	 oral	examination:	posterior	discharge;
exclude dental infection.
Not recommended: plain x-ray.
CT-Scan is also not recommended unless additional problems 
such as:
•	 very	severe	diseases,
•	 immunocompromised	patients;
•	 signs	of	complications.
8.3.2.2. Treatment
For treatment evidence and recommendations for children with 
acute rhinosinusitis see Table 8.2
Initial treatment depending on the severity of the disease: see 
Figure 8.2.
Figure 8.2. Management scheme for children with acute rhinosinusitis.
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8.4  Evidence based management for adults 
and children with acute rhinosinusitis for 
ENT specialists
8.4.1. Diagnosis
Symptoms
sudden onset of two or more symptoms one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip):
± facial pain/pressure;
± reduction/loss of smell;
Signs
•	 nasal	examination	(swelling,	redness,	pus);
•	 oral	examination:	posterior	discharge;
•	 exclude	dental	infection.
ENT-examination including nasal endoscopy.
Not recommended: plain x-ray.
CT-Scan is also not recommended unless additional problems 
such as:
•	 very	severe	diseases,
•	 immunocompromised	patients;
•	 signs	of	complications.
8.4.2. Treatment
For Treatment evidence and recommendations for acute 
rhinosinusitis. See Table 8.1. and Table 8.2
Initial treatment depending on the severity of the disease:
See Figure 8.3. 
Figure 8.3. Management scheme for ENT specialists for adults and children with acute rhinosinusitis.
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Table 8.3. Treatment evidence and recommendations for adults with 
chronic rhinosinusitis without nasal polyps * %.
Therapy Level Grade of 
recommen-
dation
Relevance
steroid – topical Ia A yes 
nasal saline irrigation Ia A yes 
bacterial Lysates (OM-
85 BV)
Ib A unclear 
oral antibiotic therapy 
short term < 4 weeks 
II B during exacer-
bations
oral antibiotic 
therapy long term ≥12 
weeks** 
Ib C yes , especially 
if IgE is not 
elevated
steroid – oral IV C unclear
mucolytics III C no 
proton pump 
inhibitors 
III D no 
decongestant oral / 
topical 
no data 
on single 
use 
D no 
allergen avoidance in 
allergic patients 
IV D yes 
oral antihistamine 
added in allergic 
patients 
no data D no 
herbal en probiotics no data D no 
immunotherapy no data D no 
probiotics Ib (-) A(-) no
antimycotics – topical Ib (-) A(-) no 
antimycotics - 
systemic 
no data A(-) no 
antibiotics – topical Ib (-) A(-)$ no 
* Some of these studies also included patients with CRS with nasal 
polyps
% Acute exacerbations of CRS should be treated like acute rhinosinusitis
# Ib (-): Ib study with a negative outcome
 $ A(-): grade A recommendation not to use
** Level of evidence for macrolides in all patients with CRSsNP is Ib, and 
strength of recommendation C, because the two double blind placebo 
controlled studies are contradictory; indication exist for better efficacy in 
CRSsNP patients with normal IgE the recommendation A. No RCTs exist 
for other antibiotics.
Table 8.4 Treatment evidence and recommendations postoperative 
treatment for adults with chronic rhinosinusitis without nasal polyps *.
Therapy Level Grade of 
recommen-
dation
Relevance
steroid – topical Ia A yes 
nasal saline irrigation Ia A yes 
nasal saline irrigation 
with xylitol 
Ib A yes
oral antibiotic therapy 
short term < 4 weeks 
II B during exacer-
bations
nasal saline irrigation 
with sodium 
hypochlorite
IIb B yes
oral antibiotic 
therapy long term ≥12 
weeks** 
Ib C yes , especially 
if IgE is not 
elevated
nasal saline irrigation 
with babyshampoo
III C no
steroid – oral IV C unclear
antibiotics – topical Ib (-) # A(-) $ no 
* Some of these studies also included patients with CRS with nasal 
polyps
# Ib (-): Ib study with a negative outcome
 $ A(-): grade A recommendation not to use
** Level of evidence for macrolides in all patients with CRSsNP is Ib, and 
strength of recommendation C, because the two double blind placebo 
controlled studies are contradictory; indication exist for better efficacy in 
CRSsNP patients with normal IgE the recommendation A. No RCTs exist 
for other antibiotics.
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8.5 Evidence based management for adults 
with Chronic Rhinosinusitis 
8.5.1. Definitions
8.5.1.1. Chronic Rhinosinusitis (with or without NP) in 
adults is defined as:
presence of two or more symptoms one of which should be  
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip):
± Facial pain/pressure;
± reduction or loss of smell;
for ≥12 weeks;
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhea, nasal itching, and itchy watery eyes) should be 
included.
Chronic Rhinosinusitis with nasal polyps (CRSwNP): Chronic 
rhinosinusitis as defined above and bilateral, endoscopically 
visualised polyps in middle meatus.
Chronic Rhinosinusitis without nasal polyps (CRSsNP): Chronic 
Rhinosinusitis as defined above and no visible polyps in middle 
meatus, if necessary following decongestant.
This definition accepts that there is a spectrum of disease in CRS 
which includes polypoid change in the sinuses and/or middle 
meatus but excludes those with polypoid disease presenting in 
the nasal cavity to avoid overlap.
Figure 8.4. Management scheme for adults with CRS with or without NP for primary care and non-ENT specialists.
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8.5.2. Evidence based management for adults 
with CRS with or without NP for primary care and 
non-ENT specialists
8.5.2.1. Diagnosis
Symptoms present equal or longer than 12 weeks
two or more symptoms one of which should be either nasal  
blockage/obstruction/congestion or nasal discharge (anterior/
posterior nasal drip):
± facial pain/pressure, 
± reduction or loss of smell;
Signs (if applicable)
•	nasal	examination	
•	oral	examination:	posterior	discharge;
exclude dental infection.
Additional diagnostic information
•	 questions	on	allergy	should	be	added	and,	if	positive,	
allergy testing should be performed.
Not recommended: plain x-ray or CT-scan 
8.5.2.2. Treatment
For treatment evidence and recommendations for chronic 
rhinosinusitis see Table 8.3 and 8.5.
Initial treatment depending on the availability of an endoscope 
and severity of disease: See Figure 8.4.
Acute exacerbations of CRS should be treated like acute 
rhinosinusitis.
8.5.3. Evidence based management for adults 
with CRS without NP for ENT specialists
8.5.3.1. Diagnosis
Symptoms present longer than 12 weeks
Two or more symptoms one of which should be either nasal  
blockage/obstruction/congestion or nasal discharge (anterior/
posterior nasal drip):
± facial pain/pressure, 
± reduction or loss of smell;
Signs
•	  ENT examination, endoscopy;
•	  review primary care physician’s diagnosis and treatment;
•	  questionnaire for allergy and if positive, allergy testing if it 
has not already been done.
Figure 8.5. Management scheme for adults with CRS without NP for ENT specialists.
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Table 8.5. Treatment evidence and recommendations for adults with chronic rhinosinusitis with nasal polyps *.
Therapy Level Grade of recommendation Relevance
topical steroids Ia A yes 
oral steroids Ia A yes 
oral antibiotics short term <4 weeks 1b and 1b(-) C% yes, small effect 
oral antibiotic long term ≥ 12 weeks III C yes, especially if IgE is not elevated, small effect
capsaicin II C no
proton pump inhibitors  II C no 
aspirin desensitisation II C unclear
furosemide III D no
immunosuppressants IV D no 
nasal saline irrigation Ib, no data in single use D yes for symptomatic relief 
topical antibiotics no data D no 
anti-Il5 no data D unclear
phytotherapy no data D no 
decongestant topical / oral no data in single use D no 
mucolytics no data D no 
oral antihistamine in allergic patients no data D no
antimycotics – topical  Ia (-) ** A(-) no 
antimycotics – systemic Ib (-)# A(-) $ no 
anti leukotrienes Ib (-) A(-) no
anti-IgE Ib (-) A(-) no
* Some of these studies also included patients with CRS with nasal polyps
% short term antibiotics shows one positive and one negative study. Therefore recommendation C.
# Ib (-): Ib study with a negative outcome
** Ia(-): Ia level of evidence that treatment is not effective. 
$: A(-):  grade A recommendation not to use
Table 8.6. Treatment evidence and recommendations postoperative treatment in adults with chronic rhinosinusitis with nasal polyps*.
Therapy Level Grade of recommendation Relevance
topical steroids Ia A yes
oral steroids Ia A yes
oral antibiotics short term <4 weeks Ib A yes, small effect 
anti-Il-5 Ib A yes
oral antibiotics long term > 12 weeks Ib C** yes, only when IgE is not increased
oral antihistamines in allergic patients Ib C unclear
furosemide III D no
nasal saline irrigation no data D unclear
anti leukotrienes Ib(-)# A(-)$ no
anti-IgE% Ib(-) C unclear
* Some of these studies also included patients with CRS with nasal polyps. 
** Level of evidence for macrolides in all patients with CRSsNP is Ib, and strength of recommendation C, because the two double blind placebo 
controlled studies are contradictory; indication exist for better efficacy in CRSsNP patients with normal IgE the recommendation A. No RCTs exist for 
other antibiotics.
# Ib (-): Ib study with a negative outcome.
$ A(-):  grade A recommendation not to use
% Because positive level III evidence and positive unpublished 1b evidence recommendation is C
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8.5.3.2. Treatment 
For treatment evidence and recommendations for CRSsNP see 
Table 8.3 and 8.4.
Treatment should be based on severity of symptoms
•	 Decide on severity of symptomatology using VAS and 
endoscope. See Figure 8.5.
Acute exacerbations of CRS should be treated like acute 
rhinosinusitis.   
8.5.4. Evidence based management for adults 
with CRS with NP for ENT specialists
8.5.4.1. Diagnosis
Symptoms present longer than 12 weeks
Two or more symptoms one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/
posterior nasal drip):
± facial pain/pressure, 
± reduction or loss of smell;
Signs
•	  ENT examination, endoscopy;
•	  review primary care physician’s diagnosis and treatment;
•	  questionnaire for allergy and if positive, allergy testing if it 
has not already been done.
Figure 8.6. Management scheme for adults with CRS with NP for ENT specialists.
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8.5.4.2. Treatment 
For treatment evidence and recommendations for CRSwNP see 
Table 8.5 and 8.6.
Treatment should be based on severity of symptoms
•	  Decide on severity of symptomatology using VAS and 
endoscope. See Figure 8.6.
8.6. Evidence based management for 
children with Chronic Rhinosinusitis 
8.6.1. Definitions
8.6.1.1. Chronic Rhinosinusitis (with or without NP) in 
children is defined as:
presence of two or more symptoms one of which should be  
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip):
± facial pain/pressure;
± cough;
for ≥12 weeks;
with validation by telephone or interview.
Questions on allergic symptoms (i.e. sneezing, watery 
rhinorrhea, nasal itching, and itchy watery eyes) should be 
included.
Chronic rhinosinusitis with nasal polyps (CRSwNP): Chronic 
rhinosinusitis as defined above and bilateral, endoscopically 
visualised polyps in middle meatus.
Figure 8.7.  Management scheme for young children with chronic rhinosinusitis.
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Chronic Rhinosinusitis without nasal polyps (CRSsNP): Chronic 
Rhinosinusitis as defined above and no visible polyps in middle 
meatus, if necessary following decongestant.
This definition accepts that there is a spectrum of disease in CRS 
which includes polypoid change in the sinuses and/or middle 
meatus but excludes those with polypoid disease presenting in 
the nasal cavity to avoid overlap.
8.6.2. Evidence based management for children 
with Chronic Rhinosinusitis 
8.6.2.1.  Diagnosis
Symptoms present equal or longer than 12 weeks
two or more symptoms one of which should be either nasal  
blockage/obstruction/congestion or nasal discharge (anterior/
posterior nasal drip):
± facial pain/pressure;
± cough;
Additional diagnostic information
•	  questions on allergy should be added and, if positive, 
allergy testing should be performed.
ENT examination, endoscopy if available;
Not recommended: plain x-ray or CT-scan (unless surgery is  
considered)
8.6.2.2. Treatment
For treatment evidence and recommendations for Chronic 
Rhinosinusitis in children see Table 8.7.
This management scheme is for young children. Older children 
(in the age that adenoids are not considered important) can be 
treated as adults. See Figure 8.7.
Acute exacerbations of CRS should be treated like acute 
rhinosinusitis.   
Treatment should be based on severity of symptoms.
Table 8.7. Treatment evidence and recommendations for children with chronic rhinosinusitis. 
Therapy Level Grade of recommendation Relevance
nasal saline irrigation Ia A yes
therapy for gastro-oesophageal reflux III C no
topical corticosteroid IV D yes
oral antibiotic long term no data D unclear
oral antibiotic short term <4 weeks Ib(-)# A(-)* no
intravenous antibiotics III(-)## C(-) ** no
# Ib (-): Ib study with a negative outcome
*A(-): grade A recommendation not to use
##III(-): level III study with a negative outcome
**C(-): grade C recommendation not to use
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9.1. Introduction
The search strategies for all the (subchapters) include many pages. 
For that reason it was chosen to only have them online. You can 
find them at www.rhinologyjournal.com.
While our understanding of CRS has increased considerably, this 
only serves to outline areas that will require further exploration 
and clinical trials for validation of observations and hypotheses.
9.2. Classification and Definitions
Much of the problems which have beset our understanding 
of rhinosinusitis, particularly chronic forms is the difficulty of 
defining populations for study. Thus there remains the need for 
clear and widely accepted guidelines on the design of clinical 
trials which indicate: 
•	  how to define the study population
•	  choice of outcome measurements
•	  choice of instruments to evaluate QoL.
It may also be advantageous to introduce some form of additional 
aetiological qualification to our classification systems which might 
be based on ICD coding.  
There is also a need for the development of better objective 
staging systems that correlate with patient symptoms and QoL.
  
9.3. Acute rhinosinusitis 
In acute rhinosinusitis, we need:
 
•	  To know what factors determine whether ARS patients in the 
community consult with a doctor, pharmacist or self-manage 
without professional support
•	  To demonstrate the prevalence of ARS in low, middle 
and high income countries and consider whether any 
predisposing factors differ dependant on income.
•	  To develop a validated disease-specific QoL questionnaire 
specific to acute rhinosinusitis.
•	  To establish if early use of therapies in viral URTI prevent 
bacterial ARS, particularly in those with recurrent ARS or at 
risk of complications.
•	  To confirm if there are combinations of symptoms and signs 
that predict acute bacterial rhinosinusitis in Primary and 
Secondary Care.
•	 To show if the relative frequency of different symptoms 
and signs in ARS predict a differential response to different 
therapies, such as topical steroids and antibiotics?
•	  To determine what constitutes a clinically important response 
to antibiotics in ARS eg change in purulence of nasal 
discharge.
•	  To determine biomarkers (eg CRP, procalcitonoin) that can 
predict acute bacterial rhinosinusitis or a clinically important 
response to antibiotics in ARS?
•	  To confirm whether topical nasal steroids can be the first-line 
treatment for ARS in Primary Care and consider whether there 
are clinically important differences between different topical 
nasal steroid molecules and dosing regimes
•	  To show whether the provision of educational and 
information materials for patients improve outcomes of ARS 
and reduce non-essential antibiotic use?
•	  To demonstrate whether professional education and efficient 
dissemination of evidence-based guidelines to clinicians 
improve outcomes of ARS and reduce non-essential antibiotic 
use?
•	  To show if the clinical and economic outcomes of ARS differ 
depending on which health professionals (e.g. rhinologists, 
ENT specialists, GPs, pharmacists?) manage patients.
•	  Large epidemiological data collection on the true incidence 
of complications in ARS, determining the role of Primary 
Care physicians in the detection and/or prevention of 
complications and whether complications of ARS relate to 
access to medical care?
•	  A large prospective study on the role of antibiotics in the 
prevention of acute complications. 
•	  A randomised trial of drainage versus intravenous antibiotics 
for small abscesses in young children (orbital and intracranial)
•	  Large population studies characterizing co-morbidities in 
patients with ARS, compared to matched controls to identify 
significant co-morbidities or risk factors. 
•	  Studies to establish how allergic rhinitis increases the 
predisposition for rhinosinusitis and specifically if it increases 
the likelihood of S. pneumoniae sinus infection.
•	  Assuming this is confirmed, studies to establish whether 
regular antihistamines and/or leukotriene receptor 
antagonists are effective in reducing ARS episodes in patients 
with allergic rhinitis.
9. Research needs and search strategies 
222
European Position Paper on Rhinosinusitis and Nasal Polyps 2012
•	  To determine how exposure to cigarette smoke increases 
the predisposition for ARS, to establish whether exposure 
to cigarette smoke (active or passive) augments the 
predisposition for ARS in patients with allergic rhinitis 
and to show whether smoking cessation improves the 
frequency of ARS compared to active smokers. 
•	  To establish the prevalence of ARS in the Primary Ciliary 
Dyskinesia population, to determine whether aggressive 
treatment of ARS in patients with PCD prevents recurrence 
of ARS or development of CRS and to establish if aggressive 
treatment of ARS affects the progression of PCD-related 
bronchiectatic lung disease. 
 
9.4. Chronic rhinosinusitis with or without NP
In chronic rhinosinusitis we need:
•	  To consider if the prevalence of and predisposing factors for 
CRSsNP and CRSwNP differs in low, middle and high income 
countries
•	  To determine the relative frequency and prognostic sig-
nificance of different symptoms and signs in CRSsNP and 
CRSwNP in Primary Care. 
•	  To refine severity staging and its impact on QoL, using both 
subjective and objective measures
•	  For endotyping and phenotyping, to define the minimal 
criteria for measuring sinus inflammation. eg sampling 
procedures and expression of data should be unified (ng of 
cytokine per ml, mg of tissue or protein content) so that a 
meta-analysis may be done. 
•	  To refine the inclusion criteria of non-ENT control groups.
•	 To consider response to standard treatments for endoty-
ping.
•	  A long-term study on the natural history of osteitis. 
•	  A randomised trial comparing different treatment options 
for patients with CRS with significant osteitis.
•	  A trial to show if the purulence of nasal discharge is truly 
an indicator of bacterial infection and can be used as a 
clinically important response to antibiotics in CRS?
•	  To establish what, if any, childhood events increase chances 
of developing CRSwNP. 
•	 To establish how smoking increases the risk of CRS and 
whether the risk is reduced by smoking cessation. 
•	  To show if recognition of and appropriate treatment 
of allergic rhinitis reduce the incidence of CRSsNP and 
CRSwNP?
•	  To investigate the impact of psychological problems such 
as depression, stress exposure and anxiety on subjective 
severity scores and to consider the impact of neurological 
co-morbidities like chronic fatigue, post-traumatic stress 
disorder, neurological hyposmia, and measures of other 
neural-based disorders that play a role in non-allergic rhini-
tis, which may have an impact on rhinosinusitis scores.
•	  To consider neural aspects of facial pain, headache, smell 
disorders and hypersecretion. 
•	  To consider the role of gastro-oesophageal reflux. 
With respect to inflammatory mechanisms in CRSwNP and 
CRSsNP, we should consider if it is possible to:  
•	  Develop a classification of CRS of phenotypes/endotypes 
based on “hypothesis-free” cluster analyses.
•	  Understand the regulation of TGF-ß and related molecules 
in remodeling processes.
•	  Understand the T regulatory cell deficit and the role of T 
effector cells in nasal polyp disease.
•	  Understand the role of dendritic cells in CRS.
•	  Understand the links between inflammation and remode-
ling.
•	  Understand the impact of the microbiome on inflammation
•	  Understand epigenetic regulation of upper airway disease.
•	  Understand the pathogenesis of ‘allergic’ fungal rhinosinusi-
tis and AERD.
•	  Understand the link between CRSwNP and lower airway 
disease.
Nasal epithelial remodelling is a part of this natural defence 
mechanism, including migration, proliferation, and 
differentiation of epithelial cells, as well as the interactions 
between epithelial cells and stromal cells. To date, it is not 
possible to distinguish between a cause and an effect with 
regard to epithelium remodelling, nor are there clear roles for 
the many factors involved in nasal infectious and inflammatory 
diseases, due to a lack of intrinsic information about nasal 
epithelial cell responses. Most reported data are derived from 
lower airway studies or animal models. Therefore, research 
based on human nasal epithelial stem/progenitor cells can 
offer new light on pathophysiology of nasal airway disease 
from a different, more specific perspective. It will also allow 
molecular studies of human nasal epithelial cell interactions, 
differentiation, and repair, as well as responses to both 
environmental agents and to potential anti-inflammatory 
treatments.
•	  Further research is needed on the impact of bacterial, 
fungal or other microbial colonization/infection, with clear 
definition of such impact and we need some standardized 
methodology for research. For example should measures of 
minimal undetectable colonization, like PCR, or molecular 
cultivating techniques or hardly detectable immune 
response to colonizer be taken into account and if so, 
when? 
•	  If infection is characterized by invasion, as well as by 
immune response to the micro-organism, we need to 
.
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define how this invasion is established at both a local and 
systemic level.
•	  Nearly all of the currently conducted human research is 
performed in patients who already have established disease 
or controls who do not. While this is useful in identifying 
unique contributors to the pathophysiology of CRS and 
subsequent treatments, it does not identify the actual cause 
of the disease. Currently available animal models are either 
allergic models or genetically manipulated animals that 
artificially generate an inflammatory response and again, 
do not answer the cause of the disease. There is thus a need 
for innovative experimental models in CRS.
•	  We should also focus on the differences between CRSwNP 
in western patients and elsewhere in the world. We need to 
identify  key cytokines which mediate Th2 skewing across 
the epithelial barrier: TSLP vs. IL-25 vs. IL-33 vs.? The second 
key issue is the identity of the key effector cell(s): mast cells 
vs. esoinophils vs. neutrophils vs. ?
•	  There are variations in local anatomic immune response 
that are not related to airflow and environmental ex-
posures. Research is needed into variations in immune 
response of the ethmoid/middle meatus for example, as 
this is different from the mucosal response of the septum or 
inferior turbinate.
•	  In the assessment of rhinosinusitis symptoms and examina-
tion in chronic rhinosinusitis, we need better tools for the 
diagnosis and  differential diagnosis of facial pain.
•	  We need to understand the environmental factors that 
alter gene expression which may predispose to CRS. This 
may allow us to begin recognizing disease-causing agents 
versus disease-modifiers or exacerbating agents and in turn 
may allow us to alter behavior or implement therapies that 
can counteract any genetic predispositions and reverse/ 
moderate epigenetic pre-disposition.
 
9.5. CRSwNP and CRSsNP in relation to the 
lower airways 
To better understand the relationship of the upper and lower 
airways, we need:
•	  To conduct research on the basic physiology of the nose, 
including humidification and heat exchange and its effect 
on pulmonary function.
•	  To establish whether treatment of CRS affects outcomes of 
co-morbid lower airways disease (eg asthma, COPD).
•	  To undertake further RCTs studying the effects of surgery 
and medical treatment on the lower airways (lung function/
QoL/symptoms) in CRSwNP and concomittant asthma.
9.6. Paediatric Chronic Rhinosinusitis
There is an urgent need to:
•	  Develop tools/tests in the context of clinical trials to 
differentiate the role of chronic adenoiditis from that 
of chronic rhinosinusitis in children with chronic nasal 
complaints.
•	  Establish the relevance of CT abnormalities in children with 
chronic nasal symptoms.
•	  Investigate immune mechanisms by better evaluating 
tissues obtained at the time of surgery for CRS through well 
organized, multi-centre collaborations.
•	  Undertake a multicentre randomized, placebo controlled, 
double- blind study evaluating the effect of oral antibiotics 
in paediatric CRS.
•	  Elucidate best surgical interventions by designing and 
executing prospective, randomized, multi-centre, controlled 
clinical trials.  Severity of disease on CT scans and symptom 
questionnaire should ideally be matched pre-operatively 
and the following interventions could be compared: 
adenoidectomy alone, adenoidectomy with a wash-out, 
adenoidectomy with a wash-out and balloon maxillary 
sinuplasty, and endoscopic sinus surgery.  An additional 
arm that includes medical therapy should also be included.
 
9.7. Management of CRSwNP and CRSsNP
We need to:
•	  Improve professional education and efficient dissemination 
of evidence-based guidelines to optimise outcomes and 
reduce referral rates to secondary care.
•	  Develop therapeutic approaches based on endotypes of 
disease such as IL-5 and SE-IgE positive polyps.
•	  Demonstrate whether the relative frequency of different 
symptoms and signs in CRSwNP and CRSsNP predict a 
differential response to different therapies, such as topical 
steroids and antibiotics.
•	  Conduct multicentre trials on endoscopic versus open 
management of complications of CRS, both intracranial and 
orbital.
•	  Conduct a large prospective placebo controlled study 
of long-term antibiotic treatment in a well-defined CRS 
population, exploring effects on the patient’s quality of life, 
immune system, microbiota of the airway as well as the 
health economic impact.
•	  Seek better local therapies for immunomodulation.
•	  Conduct an RCT on oral steroids versus surgery on the long 
term outcomes of CRSwNP.
•	  Conduct an RCT studying the effects of oral corticosteroids 
on olfactory function in CRSwNP.
•	  Conduct multicentre RCTs on surgery versus no treatment 
for patients with CRSwNP to establish the natural course of 
disease. 
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•	  Conduct RCTs on minimal versus more extensive endosco-
pic sinus surgery.
•	  Investigate the effect of early surgical intervention on 
CRSwNP to see if it alters the course of the disease.
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9. SEARCH STRATEGIES 
For all  searches apart from what is indicated below a search has been done in the Cochrane 
library. Also all searches have been discussed in the working group and suggestions for missing 
articles are done.  
9.1 Search strategies of chapter 3 
9.1.1. Search strategy of 3.1. Epidemiology and predisposing factors of ARS 
 
 
Pubmed search 
[Acute rhinosinusitis or Acute sinusitis] AND prevalence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 493) 
Additional records 
identified through other 
sources 
(n= ) 
 
Records after duplicates removed 
(n = 399) 
Records screened 
(n = 399) 
Records excluded 
(n= 348) 
Full text articles 
assessed for 
eligibility 
(n= 51) 
Full text articles excluded 
(n=32) 
Chronic disease only 2 
Review 13 
Not prevalence study 9 
Clinical management 8 
Studies included 
(n=19) 
JOAQUIM MULLOL I …, 1/10/12 7:57 AM
Met opmaak: Lettertype:Myriad Pro, 12 pt
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Pubmed search 
[Acute rhinosinusitis or Acute sinusitis] AND Smoking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 32) 
Additional records 
identified through other 
sources 
(n= 4) 
 
Records after duplicates removed 
(n = 31) 
Records screened 
(n = 31) 
Records excluded 
(n=17) 
Full text articles 
assessed for 
eligibility 
(n=12) 
Full text articles excluded 
(n= 3) 
Lower respiratory tract 
infections: 1 
Occupational 
rhinosinusitis: 2 
Studies included 
(n= 9) 
 3 
 
Pubmed search 
[Acute rhinosinusitis or Acute sinusitis] AND Allergy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 405) 
Additional records 
identified through other 
sources 
(n= ) 
 
Records after duplicates removed 
(n = 312) 
Records screened 
(n = 312) 
Records excluded 
(n= 263) 
Full text articles 
assessed for 
eligibility 
(n= 49) 
Full text articles excluded 
(n=30) 
Chronic disease only = 1 
Review = 20 
Clinical measures = 2 
Not prevalence study = 3 
Clinical management = 2 Studies included 
(n=19) 
 4 
 
Pubmed search 
[Acute rhinosinusitis or Acute sinusitis] AND dyskinesia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 18) 
Additional records 
identified through other 
sources 
(n=11) 
 
Records after duplicates removed 
(n =27) 
Records screened 
(n = 27) 
Records excluded 
(n= 15) 
Full text articles 
assessed for 
eligibility 
(n= 12) 
Full text articles excluded 
(n= 1) 
Clinical trial 1 
 
Studies included 
(n= 11) 
 5 
 
Pubmed search 
 
[Acute rhinosinusitis or Acute sinusitis] AND environment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 63) 
Additional records 
identified through other 
sources 
(n= 6) 
 
Records after duplicates removed 
(n = 69) 
Records screened 
(n = 69) 
Records excluded 
(n= 49) 
Full text articles 
assessed for 
eligibility 
(n= 20) 
Full text articles excluded 
(n=7) 
Review articles 4 
Complications of acute 
rhinosinusitis 1 
Prevalence 1 
Otitis media only 1 Studies included 
(n=13) 
 6 
9.1.2. Search strategy of 3.2. Pathophysiology of ARS. 
 
1. Acute sinusitis      =>     3230 results 
acute sinusitis + filter 2 (English, 1/1/2006-31/12/2011) =>       602 results 
ð possibly relevant publications based on title and abstracts   =>         46 results 
 
2. Acute rhinosinusitis       => 592 results 
acute rhinosinustis + filter 2 (English, 1/1/2006-31/12/2011) => 269 results 
ð possibly relevant publications based on title and abstracts  * =>     3 results 
 
* only publications that were not in the search on ‘acute sinusitis’ 
 
3. Viral rhinitis        => 615 results 
viral rhinitis + filter (English)     => 528 results 
ð possibly relevant publications based on title and abstracts  ** =>   66 results 
 
** only publications that were not in the search on ‘acute sinusitis’ of ‘acute rhinosinusitis’ 
JOAQUIM MULLOL I …, 1/10/12 7:57 AM
Met opmaak: Lettertype:Myriad Pro, 12 pt
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9.1.3. Search strategy of 3.3. Diagnosis and Differential Diagnosis of ARS.  
Searches 
The primary Pubmed search used the terms ‘sinusitis’, ‘rhinosinusitis’, ‘diagnosis’ and acute, 
2007-current, limited to human and English language yielded 453 results. The abstracts were 
assessed for relevance. The searches were repeated limiting the searches to rhinosinusitis and 
sinusitis, and all searches were repeated in Embase.  All papers that had possible relevance were 
obtained. 12 additional relevant references were found and accessed from papers scanned in this 
search.  
Only 24 of these papers contained original research relevant to the diagnosis of ARS; the search 
also identified 37 review papers (!), 8 sets of guidelines (!) including 1 pediatric guideline, 
numerous case series/case reports, 4 editorials. 35 papers were concerned with pediatric ARS, 8 
papers with complications of ARS, 7 with fungal ARS. From the assessment of the abstracts, 
the majority of papers were not relevant to the diagnosis of ARS (either they were not focused 
on ARS or were not focused on diagnosis). The remaining papers were assessed in detail. A 
total of   
 
Review articles 
Many of the review articles were accessed. The recommendations for diagnosis were generally 
consistent with EPOS criteria, with ARS defined clinically by the sudden onset of 2 or more 
symptoms of nasal blockage/congestion/obstruction or nasal discharge, plus facial pain/pressure 
and/or reduction or loss of smell, and duration of symptoms of less than 12 weeks. Most review 
papers distinguished between the ‘common cold’ or acute viral RS and ARS in a similar way to the 
EPOS criteria, emphasizing that most acute viral RS was self-limiting. Consistent recommendations 
that imaging or invasive diagnostic processes were not needed in uncomplicated ARS were made. 
Many review articles emphasized the inflammatory basis to ARS and propagated messages from 
EPOS on effective treatment with anti-inflammatory medication. Most guidelines propagate similar 
messages, although the Dutch College of GPs guideline does not distinguish between ATS and 
CRS, which may be a source of confusion to GPs. Attempts were made to distinguish between 
‘bacterial’ and ‘viral’ ARS in some reviews, with consequent recommendations on treatment and 
investigation, although these were based on opinion rather than strong evidence. The differentiation 
of definitions for clinical, research and epidemiological/GP purposes appears to be unique to EPOS, 
as does the term ‘acute non-viral RS’. A number of papers presented case series of complications of 
ARS or of acute fungal RS, rare but serous conditions of interest to specialists. 
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JOAQUIM MULLOL I …, 1/10/12 7:57 AM
Met opmaak: Lettertype:Myriad Pro, 12 pt
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9.1.4. Search strategy of 3.4. Management of ARS. 
 
Data included in this chapter were based on the electronic searches and hand-searching 
through PubMed. 
 
• The primary key words are “acute rhinosinusitis” or “acute sinusitis”. 
 
• The second key words are “randomized controlled trials” or “double-blinded placebo-
controlled studies”.  
 
• Data obtained from above two steps are analyzed separately by comparing each drug (e.g., 
antibiotics, intranasal or systemic steroids, and other type of medications which are 
recommended in clinical management of acute rhinosinusitis) versus placebo or no 
medication. 
 
• In addition, hand-searching with above criteria are made in order to check if any missing data 
from above searching criteria. 
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9.1.5. Search strategy of 3.5. Complications of ARS 
Search details 
 
(("sinusitis"[MeSH Terms] OR "sinusitis"[All Fields]) AND ("complications"[Subheading] OR 
"complications"[All Fields])) AND ("humans"[MeSH Terms] AND English[lang] AND 
"2006/10/06"[PDat] : "2011/10/04"[PDat]) 
 
1084 entries + Klossek 
 
after going through all the abstracts –  
71 selected as relevant 
 
 
9.1.2. Search strategy of 3.6. Paediatric ARS. 
 
 
Search 1: PubMed 
Keywords: Acute sinusitis and symptoms 
Limits: Past 3 years, English language, All infants-23 months and All 0-18 years 
Result: 75 articles 
After careful review of the abstracts, selected 7 relevant articles to review in detail 
 
Search 2: PubMed 
Keywords: Adenoiditis 
Limits: Any date, English language, All infants-23 months and All 0-18 years 
Result 41 articles 
After careful review of the abstracts, selected 16 relevant articles to review in detail 
 
Search 3: PubMed 
Keywords: Sinusitis and Children 
Limits: Past 5 years, English language, All infants-23 months and All 0-18 years 
Results: 499 
After careful review of the abstracts selected 96 relevant articles 
After elimination of reviews, irrelevant articles, and articles related to complications, cystic 
fibrosis, and chronic rhinosinusitis, was left with 14 articles for careful review. 
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9.2 Search strategies of chapter 4 
9.2.1. Search strategy of 4.1. Epidemiology and predisposing factors of chronic rhinosinusitis 
MEDLINE® was searched using “nasal polyposis”, “polyps”, “ chronic rhinosinustis”, “polyps”, 
“predisposing factors” and “epidemiology” as keywords. The Cochrane database of systematic 
reviews was also searched and in addition, we used a personal archive of references relating to 
our clinical experience. Only a few publications have been published since 2007 in this area. 
  
9.2.2. Search strategy of 4.2. Inflammatory mechanisms in chronic rhinosinusitis with or without 
nasal polyposis    
Both Pub Med and OVID were searched for the following: 
 Chronic rhinosinusitis; Nasal polyposis; asthma;  biofilms; TSLP; superantigens;  all known 
investigators in the CRS field. A further detailed search was undertaken from 2007 to date of the 
following journals:Oto-HNS; Laryngoscope; AJRA; Rhinology; Current Opinion in 
Otolaryngology;  IFAR; JACI; Allergy: Nature Immunology; Nature Reviews in Immunology; Ann 
Review of Immunology 
 
9.2.3.  Search Strategy 4.3 Assessment of rhinosinusitis symptoms and examination in chronic 
rhinosinusitis 
Ovid Medline search 1980-2011 for : CRS/nasal polyps and diagnosis, imaging, subjective 
symptoms, signs, investigations, nasomucociliary clearance, ciliary beat frequency, nitric oxide, 
electron microscopy, nasal airway, nasal inspiratory peak flow, acoustic rhinometry,  
rhinomanometry, olfactory tests, aspirin challenge, C-reactive protein. 
4.1. Epidemiology and predisposing factors of chronic 
rhinosinusitis 
4.2.  
4.3 Assessment of rhinosinusitis symptoms and examination 
in chronic rhinosinusitis 
4.4. Diagnosis and  differential diagnosis of facial pain    
4.5. Genetics of Chronic Rhinosinusitis with and without 
nasal polyps 
 
 
9.2.4.  Search strategy of 4.4. Diagnosis and  differential diagnosis of facial pain    
(1) Pubmed 2007-12 (English language):  
Facial pain 2,920 
Sinusitis 3,532 
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Facial pain and sinusitis 29 
Facial migraine 816 
Cluster headache 2,805 
SUNCT 248 
Paroxysmal hemicrania 340. 
(2) EPOS 2007 related articles: 38. 
(3) Searcher’s database on Facial pain, Sinusitis, Facial migraine, Cluster headache, SUNCT, 
Paroxysmal hemicranias 644. 
Pooled (1), (2) and (3): 9,680 
Abstracts for all papers screened. Exclusions included case reports. Few randomized controlled 
trials (three), one systematic reviews or meta-analysis, many small case series and observational 
retrospective studies. Full text screened in 917 papers.  
 
9.2.5.  Search strategy of 4.5. Genetics of Chronic Rhinosinusitis with and without nasal polyps 
Pubmed: 2007- 6th Sep 2011, English language, 5 yrs back 
Embase: same criteria, no new publications to include: results was 113 compared to 118 from 
Pubmed 
Search words:   1. chronic rhinosinusitis: 2235 
  2. genetics: 410301 
  3. combine #1 AND #2: 118 
Result was 118 articles. After reviewing abstracts, 38 was pulled up as PDFs. From these for the 
review was included 18 articles that used genomic techniques from patients with CRS.  
Exclusion criteria were: 
 1) Techniques: I concentrated on studies of genes and genomics. I excluded expression studies 
including measurements of mRNA: 11 articles.  Also animal studies or cell culture on epithelial 
cells were excluded: 1 article 
2) Reviews if there was nothing new: 3 articles 
3) Negative results: 3 articles 
4) Non relevant: 2 articles  
 
 
 
9.3 Search strategies of chapter 5 Special items in Chronic Rhinosinusitis 
9.3.1. Search Strategy of 5.1. Complications of Chronic Rhinosinusitis including late 
complications like mucoceles 
 12 
Ovid Medline search 1980-2011 for: CRS/nasal polyps and complications, imaging, osteitis, 
sclerosis, bone erosion, bone expansion, mucocoeles, metaplastic bone, bone metaplasia, optic 
atrophy  
 
 
9.3.2. Search Strategy of 5.2. Chronic Rhinosinusitis with or without nasal polyps in relation to 
the lower airways  
The Cochrane Library (2000-10), MEDLINE (1990-2010), EMBASE (1990-2010) were 
searched as well as rhinosinusitis guidelines and websites including BSACI and NHS. The search 
terms were “chronic (rhino)sinsutis and asthma/COPD/CF”, “nasal polyps and asthma/COPD/CF”,  
in combination with the terms “treatment, management, advances”. We largely selected 
publications in the past 5 years, but did not exclude commonly referenced and highly regarded older 
publications. We also searched the reference lists of articles identified by this search strategy and 
from papers in our possession and selected those we judged relevant.  
 
9.3.3. Search Strategy of 5.3. Cystic fibrosis 
The Pubmed database was searched using the search terms "Cystic Fibrosis Sinusitis". This 
identified 29 English language articles related to physiological/anatomical/immunological 
differences in CF patients with CRS, medical therapy for CRS in CF patients, and surgical therapy 
in CF patients with CRS which were included in this analysis. 
 
9.3.4. Search Strategy of 5.4 Aspirin exacerbated respiratory disease 
Ovid Medline search 1980-2011 for: aspirin/NSAIDs hypersensitivity, aspirin triad,  aspirin 
exacerbated respiratory disease  and  CRS/nasal polyps  ; plus follow-up of reference lists for 
other relevant publications 
 
9.3.5. Search Strategy of 5.5. Immunodeficiencies  and Chronic Rhinosinusitis 
 
Pubmed search terms since 2001: immunodeficiency or immunosuppression or HIV or transplant 
or diabetes mellitus or immunocompromised AND sinusitis or rhinosinusitis 
Excluded: Review articles  
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9.3.6. Search Strategy of 5.6. Allergic fungal rhinosinusitis  
Pubmed search terms since 2001: Allergic fungal sinusitis or allergic fungal rhinosinusitis 
Excluded: Review articles or articles that combined all forms of CRS or CRSwNP and unable to 
isolate AFRS 
 
9.3.7. Search Strategy of 5.7. Paediatric Chronic Rhinosinusitis 
Search 1: PubMed 
Keywords: Adenoiditis 
Limits: Any date, English language, All infants-23 months and All 0-18 years 
Result 41 articles 
After careful review of the abstracts, selected 16 relevant articles to review in detail 
Search 2: PubMed 
Keywords: Sinusitis and Children 
Limits: Past 5 years, English language, All infants-23 months and All 0-18 years 
Results: 499 
After careful review of the abstracts selected 96 relevant articles 
After elimination of reviews, irrelevant articles, and articles related to complications, cystic 
fibrosis, and acute rhinosinusitis, was left with 42 articles for careful review 
 
 
 
9.4. Search strategies of chapter 6. Management, reasons for failure of medical and 
surgical therapy in Chronic Rhinosinusitis 
9.4.1.  Search Strategy of 6.1. Treatment of Chronic Rhinosinusitis without nasal polyps with 
corticosteroids  
The following databases from their inception to July 2010 were searched for published, 
unpublished and ongoing trials: the Cochrane Ear, Nose and Throat Disorders Group Trials 
Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 
2010, Issue 3); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB 
Abstracts; Web of Science; BIOSIS Previews; CNKI; ISRCTN; ClinicalTrials.gov; ICTRP and Google. 
The pubmed search was: #1 "Paranasal Sinus Diseases"[Mesh:NoExp] 
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#2 “SINUSITIS” [Mesh] OR “RHINITIS” [Mesh] OR sinusiti* [ti] OR rhinosinusiti* [ti] OR 
rhiniti* [ti] OR nasosinusiti* [ti] OR pansinusiti* [ti] OR ethmoiditis [ti] OR antritis [ti] OR 
sphenoiditis [ti] OR ((sinus* [ti] OR sinonasal [ti] OR endonasal [ti] OR paranasal [ti] or nose [ti] 
or nasal [ti] or rhinosinus* [ti]) AND (inflammation [ti] OR inflamed [ti] OR pain* [ti] OR ache [ti] 
OR aching [ti] OR infect* [ti] OR pressure [ti] OR purulen* [ti] OR obstruct* [ti] OR block* [ti] 
OR drainage [ti] OR discharge* [ti] OR symptom* [ti] OR disease* [ti])) 
#3 #2 OR #1 
#4 “CHRONIC DISEASE” [Mesh] OR “RECURRENCE” [Mesh] OR chronic* [tiab] OR persist* 
[tiab] OR recur* [tiab] OR reoccur* [tiab] 
#5 #3 AND #4 
#6 “STEROIDS” [Mesh] OR “GLUCOCORTICOIDS” [Mesh] OR steroid* [tiab] OR 
corticosteroid* [tiab] OR glucocorticoid* [tiab] OR corticoid* [tiab] OR beclomethason* [tiab] OR 
beclamet [tiab] OR beclocort [tiab] OR beclometasone [tiab] OR becotide [tiab] OR betamethason* 
[tiab] OR betametasone [tiab] OR betadexamethasone [tiab] OR flubenisolone [tiab] OR 
hydrocortison* [tiab] OR cortisol [tiab] OR celesto* [tiab] OR dexamethason* [tiab] OR 
dexamethason* [tiab] OR hexadecadrol [tiab] OR decadron [tiab] OR dexasone [tiab] OR hexadrol 
[tiab] OR budesonid* [tiab] OR horacort [tiab] OR pulmicort [tiab] OR rhinocort [tiab] OR 
methylfluorprednisolone [tiab] OR flunisolid* [tiab] OR nasalide [tiab] OR millicorten [tiab] OR 
oradexon [tiab] OR fluticason* [tiab] OR flonase [tiab] OR flounce [tiab] OR mometason* [tiab] 
OR nasonex [tiab] OR triamclinolon* [tiab] OR nasacort [tiab] OR tri next nasal [tiab] OR 
aristocort [tiab] OR volon [tiab] #7 "ANTI-INFLAMMATORY AGENTS" [Mesh] NOT "ANTI-
INFLAMMATORY AGENTS, NON-STEROIDAL" [Mesh] 
#8 #6 OR #7 
#9 #5 AND #8 
#10 “ADMINISTRATION, TOPICAL” [Mesh] OR “NEBULIZERS AND VAPORIZERS” [Mesh] 
OR “ADMINISTRATION, INTRANASAL” [Mesh] OR spray* [tiab] OR aerosol [tiab] OR 
powder [tiab] OR inhal* [tiab] OR solution [tiab] OR turbuhaler [tiab] OR intranasal* [tiab] OR 
intra-nasal [tiab] OR topical* [tiab] 
#11 #9 AND #10 
The full search strategy can be found on the website of Rhinology as Appendix 1. 
 
9.4.2.  Search Strategy of 6.2. Treatment of Chronic Rhinosinusitis without nasal polyps with 
antibiotics 
Sinusitis, chronic sinusitis, treatment outcome, anti-bacterial agents, antibiotics, randomized 
controlled trials. Search performed in PubMed, EMBASE and Cochrane library databases 1/1-
2006 to 1/12 -2011 supplemented with the references from EPOS2007. 
 
9.4.3.  Search Strategy of 6.3. Other medical management for Chronic Rhinosinusitis without 
nasal polyps 
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(("Sinusitis/drug therapy"[Majr] OR "Nasal Polyps/drug therapy"[Mesh])   
NOT "Glucocorticoids"[Majr]) NOT "Anti-Bacterial Agents"[Majr] AND   
(Clinical Trial[ptyp] AND English[lang]). Divided by studies in patients with CRSsNP and studies in 
patients with CRSwNP. 
9.4.4. Search Strategy of 6.4 and 6.8. Evidence based surgery management for Chronic 
Rhinosinusitis with or without nasal polyps 
(("nasal polyps"[MeSH Terms] OR ("nasal"[All Fields] AND "polyps"[All Fields]) OR "nasal 
polyps"[All Fields]) OR (chronic[All Fields] AND rhinosinusitis[All Fields]) AND English[lang]) 
AND (("endoscopy"[MeSH Terms] OR "endoscopy"[All Fields] OR "endoscopic"[All Fields]) 
AND ("paranasal sinuses"[MeSH Terms] OR ("paranasal"[All Fields] AND "sinuses"[All Fields]) 
OR "paranasal sinuses"[All Fields] OR "sinus"[All Fields]) AND ("surgery"[Subheading] OR 
"surgery"[All Fields] OR "surgical procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] 
AND "procedures"[All Fields] AND "operative"[All Fields]) OR "operative surgical 
procedures"[All Fields] OR "surgery"[All Fields] OR "general surgery"[MeSH Terms] OR 
("general"[All Fields] AND "surgery"[All Fields]) OR "general surgery"[All Fields])) AND 
English[lang] 
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9.4.5.  Search Strategy of  6.5. Treatment of Chronic Rhinosinusitis with nasal polyps  with 
corticosteroids 
The following databases from their inception to November 2010 for published; unpublished; 
and ongoing trials were searched: the Cochrane Ear, Nose and Throat Disorders Group Trials 
Register; the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 
Issue 4, 2010); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB 
Abstracts; Web of Science; BIOSIS Previews; CNKI; ISCTRN; ClinicalTrials.gov; ICTRP; and Google. 
The pubmed search was:  
#21 #19 OR #20 
#20 polyp* or papilloma* 
#19 polyps[mh] 
#18 rhinopolyp* 
#17 Nasal Polyps[mh] 
#16 #1 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 
#15 triamclinolon* OR nasacort OR tri next nasal OR aristocort OR volon 
#14 fluticason* OR flonase OR flounce OR mometason* OR nasonex 
#13 flunisolid* OR nasalide OR millicorten OR oradexon 
#12 budesonid* OR horacort OR pulmicort OR rhinocort OR methylfluorprednisolone 
#11 dexamethason* OR dexamethason* OR hexadecadrol OR decadron OR dexasone OR hexadrol 
#10 hydrocortison* OR cortisol OR celesto* 
#9 betamethason* OR betametasone OR betadexamethasone OR flubenisolone 
#8 beclomethason* OR beclamet OR beclocort OR beclometasone OR becotide 
#7 steroid* OR corticosteroid* OR glucocorticoid* OR corticoid* 
#6 ADRENAL CORTEX HORMONES[mh] 
#5 Glucocorticoids[mh] 
#4 #2 NOT #3 
#3 Anti-Inflammatory Agents, Non-Steroidal[mh] 
#2 Anti-Inflammatory Agents[mh] 
#1 Steroids[mh] 
The full search strategy can be found on the website of Rhinology as Appendix 2 
 
9.4.6.  Search Strategy of  6.6. Treatment Chronic Rhinosinusitis with nasal polyps with antibiotics 
Chronic sinusitis, nasal polyps, paranasal sinus disease, treatment outcome, anti-bacterial 
agents, antibiotics, randomized controlled trials. Search performed in PubMed, EMBASE and 
Chochrane library databases 1/1-2006 to 1/12 -2011 supplemented with the references from 
EPOS2007. 
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9.4.7.  Search Strategy of  6.7. Other medical management for Chronic Rhinosinusitis with nasal 
polyps 
(("Sinusitis/drug therapy"[Majr] OR "Nasal Polyps/drug therapy"[Mesh])   
NOT "Glucocorticoids"[Majr]) NOT "Anti-Bacterial Agents"[Majr] AND   
(Clinical Trial[ptyp] AND English[lang]). Divided by studies in patients with CRSsNP and studies in 
patients with CRSwNP. 
 
9.4.8.  Search Strategy of  6.8. Evidence based surgery management for Chronic Rhinosinusitis 
without or with nasal polyps including evidence tables complications of treatment:  See: 9.4.4. 
Search Strategy of 6.4 and 6.8. Evidence based surgery management for Chronic Rhinosinusitis 
with or without nasal polyps 
 
 9.4.9.  Search Strategy of 6.9. Influence of concomitant diseases on outcome of treatment in 
Chronic Rhinosinusitis with and without nasal polyps including reasons for failure of medical and 
surgical therapy 
A literature search in Pubmed and EMBASE was undertaken using the search: (((((((((paranasal 
sinus) OR nasal polyps OR sinusit*) AND (therapy OR treatment OR surgery)) AND (outcome OR 
predict* OR respond* OR risk) AND (Humans[Mesh] AND English[lang] AND "last 5 years"[PDat])) 
OR ("search"[All Fields] AND (((paranasal sinus) OR nasal polyps OR sinusit*) AND (therapy OR 
treatment OR surgery)) OR "paranasal sinus diseases/drug therapy"[MeSH Terms] OR "paranasal 
sinus diseases/surgery"[All Fields] OR "paranasal sinus diseases/therapy"[All Fields] OR "nasal 
polyps/complications"[All Fields] OR "nasal polyps/drug therapy"[All Fields] OR "nasal 
polyps/surgery"[All Fields] OR "nasal polyps/therapy"[All Fields] OR "sinusitis/drug therapy"[All 
Fields] OR "sinusitis/complications"[All Fields] OR ("sinusitis/surgery"[All Fields] OR 
"sinusitis/therapy"[All Fields]) OR ("rhinosinusitis/asthma"[All Fields] OR "rhinosinusitis/asthma 
syndrome"[All Fields] OR "rhinosinusitis asthma"[All Fields] OR "rhinosinusitis asthma aspirin"[All 
Fields] OR "rhinosinusitis asthma syndrome"[All Fields] OR "rhinosinusitis disability"[All Fields] OR 
"rhinosinusitis disease"[All Fields] OR "rhinosinusitis endoscopic surgery"[All Fields] OR 
"rhinosinusitis outcome measure"[All Fields] OR "rhinosinusitis outcome measure 31"[All Fields] 
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OR "rhinosinusitis outcomes"[All Fields] OR "rhinosinusitis therapy"[All Fields] OR "rhinosinusitis 
treatment"[All Fields]) AND ("humans"[MeSH Terms] AND English[lang] AND "2007/01/29"[PDat] 
: "2012/01/27"[PDat]) AND (Humans[Mesh] AND English[lang] AND "last 5 years"[PDat])) AND 
(Humans[Mesh] AND English[lang] AND "last 5 years"[PDat])) NOT acute NOT Transsph* NOT 
Skull base NOT carc* NOT Adenocarc* NOT Cystic fibrosis NOT Genetics NOT septoplasty NOT 
Intracr* NOT Cellulit* NOT otit* NOT Fractur* NOT Neurob* NOT Implant NOT papill* NOT 
mening* NOT mucoc* AND (Humans[Mesh] AND English[lang] AND "last 5 years"[PDat])) NOT 
case report AND (Humans[Mesh] AND English[lang] AND "last 5 years"[PDat])) NOT fung* AND 
(Humans[Mesh] AND English[lang] AND "last 5 years"[PDat])) NOT epist* NOT silent NOT graft* 
NOT tumor NOT tumour NOT osteot* AND (Humans[Mesh] AND English[lang] AND "last 5 
years"[PDat])) AND ("humans"[MeSH Terms] AND English[lang] AND "2007/01/30"[PDat] : 
"2012/01/28"[PDat]) 
898 papers 
Based on abstract: 91 relevant 
Fulll text search: 91 papers 
Complemented by hand search based on EPOS2007 and references found in the 91 selected 
papers. 
Full text search 156 papers 
Included: 118 papers. 
 
9.4.9.  Search Strategy of 6.10. Management of Chronic Paediatric Rhinosinusitis 
Search 1: PubMed 
Keywords: Adenoiditis 
Limits: Any date, English language, All infants-23 months and All 0-18 years 
Result 41 articles 
After careful review of the abstracts, selected 16 relevant articles to review in detail 
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Search 2: PubMed 
Keywords: Sinusitis and Children 
Limits: Past 5 years, English language, All infants-23 months and All 0-18 years 
Results: 499 
After careful review of the abstracts selected 96 relevant articles 
After elimination of reviews, irrelevant articles, and articles related to complications, cystic 
fibrosis, and acute rhinosinusitis, was left with 42 articles for careful review. 
 
9.5. Search strategies of chapter 7. Burden of Rhinosinusitis  
 
9.5.1.  Search Strategy of 7.1. Quality of Life measurements in the diagnosis and outcome 
measurement of CRS with and without NP 
 
A literature search in Pubmed and EMBASE was undertaken using the search terms; 
(sinusitis or rhinosinusitis or nasal polyposis) and (outcome or quality of life or instrument or 
questionnaire). No limits were placed on publication language, or date, as this search had not 
been performed for the 2007 EP3OS document. 
The aim was to identify all disease-specific HRQOL pertaining to rhinosinusitis (either acute or 
chronic), validated in either the adult or paediatric group. Tools relating to allergic rhinitis were 
not considered for the purpose of this document. 
This identified 3152 records that were screened, identifying 92 records whose abstracts were 
read relating to disease specific outcome instruments. Reference lists were cross-referenced. The 
databases www.proqolid.org and http://phi.uhce.ox.ac.uk/perl/phig/phidb_search.pl were also 
searched, but currently have limited records of disease-specific tools in rhinosinusitis. 
 
Generic PROMs have not been assessed for the purpose of this review, but the SF-36 has been 
used extensively to compare the impact of CRS on HRQOL. In addition, there is an ENT specific 
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outcome tool (the GBI), which was excluded, as it does not capture baseline measurements, and 
an organ specific tool (the general nasal patient inventory), as it was not disease specific. 
 
 
9.5.2.  Search Strategy of  7.2. Direct Costs of Rhinosinusitis 
Pubmed:  
Limits Activated: Humans, English, Publication in last 5 years 
Search terms: economic burden, chronic rhinosinusitis, chronic sinusitis, costs, acute 
rhinosinusitis, acute sinusitis, common cold, rhinitis, nasal polyps. + combinations of these 
search terms. 
Economic +rhinosinusitis 
Resulted in 14 papers 
3 publications were chosen after screening of abstracts 
Costs + rhinosinusitis 
Resulted in 20 papers 
2 publications were chosen after screening of abstracts 
Economic + acute sinusitis 
Resulted in 18 papers 
3 publications were chosen after screening of abstracts 
Nasal polyps + costs 
Resulted in 9 papers 
1 publication was selected 
Common cold + economic/ economic + costs/ economic + rhinitis 
yielded no useful publications on the subject 
0 publications selected 
2 Articles were selected based on citations in other already selected publications. 
This resulted in a final selection of 11 publications. 
 
9.5.3.  Search Strategy of  7.3 Indirect Costs of  Rhinosinusitis  
All searches were limited to the last 5 years and English 
 
Pubmed was searched for  
 22 
(1) Sinusitis, rhinosinusitis, cost 
Resulted in 16 papers 
5 were chosen after screening the abstracts 
 
(2) Presenteeism and sinusitis or rhinosinusitis 
 yielded no documents 
(3) Absenteeism and sinusitis or rhinosinusitis 
 Resulted in 6 papers 
 3 was chosen after screening abstracts 
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